-- phpMyAdmin SQL Dump
-- version 4.7.7
-- https://www.phpmyadmin.net/
--
-- Host: localhost
-- Generation Time: Feb 19, 2018 at 12:51 PM
-- Server version: 5.7.21-log
-- PHP Version: 7.1.6

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
SET AUTOCOMMIT = 0;
START TRANSACTION;
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `krisp`
--

-- --------------------------------------------------------

--
-- Table structure for table `b_blogs`
--

CREATE TABLE `b_blogs` (
  `id` int(11) NOT NULL,
  `email` char(50) DEFAULT NULL,
  `summary` longtext,
  `summary2` longtext,
  `authors` longtext,
  `photo2` tinytext,
  `bioafricaSATuRN` int(11) DEFAULT NULL,
  `title` char(200) DEFAULT NULL,
  `date` date DEFAULT NULL,
  `image` char(100) DEFAULT NULL,
  `keywords` longtext,
  `topdescription` longtext,
  `video` longtext,
  `pubid` int(11) DEFAULT NULL,
  `imagefront` char(100) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_blogs`
--

INSERT INTO `b_blogs` (`id`, `email`, `summary`, `summary2`, `authors`, `photo2`, `bioafricaSATuRN`, `title`, `date`, `image`, `keywords`, `topdescription`, `video`, `pubid`, `imagefront`) VALUES
(1, NULL, '<p>Botswana hosted a successful HIV / TB workshop, which included 219 participants from the SADC region and from across the globe.  These included  junior and senior clinicians, researchers (on drug resistance), government health officials and workers, and also students who are currently involved in the study of HIV and TB drug resistance. ', '<p>This also included 37 invited senior presenters from the WHO, Stanford, UFS, Brazil, and the Africa Centre, to name a few. <b><i> \'If you want to go fast go alone, if you want to go far, go together. We need to go far, very fast\' </b></i> -  this modified African proverb set the course for SATuRN and its partners in reaffirming the possibilities and heights that can be reached through combining individual efforts to create a solid network. </p>\r<p>The SADC region in Africa is home to 4 % of the global population; unfortunately, it is also home to 40 % of the people living with HIV/AIDS in the world. One of the goals of governments in this region is to reach a sustainable, equitable and socio-economic development that will lead to the alleviation of poverty. However,  the rate at which the epidemic of HIV/AIDS has spread has seen most of these objectives delayed, if not halted. Over the past two decades, most governments in the SADC region have unanimously recognised the need for and the significance of providing Anti-retro rivals (ARVs) to patients infected with HIV/AIDS. This progressive approach has led to a rising number of people initiated on Anti-retroviral Treatment (ART). Unfortunately, this achievement could soon be compromised by the lingering ghost called drug resistance. It is true that all viruses, through defaulting/failing treatment, develop resistance to particular drugs. HIV is no exception in this; a rising number of patients on ART are failing treatment. Rising concerns about the ever increasing failure rate and determination to lay this ghost to rest led the Southern African Resistance Network (SATuRN) to host its 6th Workshop on HIV/TB drug resistance in Gabarone, Botswana.</p>\r<p>After the success of the workshops held at the University of Western Cape in 2008 and at the University of the Free State in 2009 and 2010, the Botswana workshop followed the same successful format. It covered presentations of Anti-Retroviral treatment (ART) programmes and clinical cases management. The workshop also expanded to cover TB resistance. The general consensus, as was echoed by Dr Refeletsoe Lebelonyane,* the Director of the Health Ministry of Botswana, was that HIV drug resistance and TB resistance should be talked about on the same platform. Dr. Lebelonyane also ended by saying <b><i>\'...how we cope with these challenges will determine our success in future\' </b></i>. The achievements and success of the workshop were also accompanied by the launch of an open access HIV/TB Drug Resistance and Clinical Management Case Book designed to help clinicians to better understand resistance and virus mutations. This was also coupled by a SATuRN/Life Technologies Genotype Manual for laboratory use.</p>\r<p>The Southern African Resistance Network (SATuRN) has been a champion in the campaign for promoting collaborative efforts between virologists, researchers, clinicians, medical personnel and policy makers in the SADC region and across the globe. SATuRN currently includes 24 research partners in Southern Africa and has collected over 3,200 resistance genotypes linked to treatment and clinical information. To collect, curate, interpret, and disseminate sequence and drug resistance data, SATuRN has installed the two best HIV drug resistance databases in the world (the Stanford HIV Drug Resistance Database and RegaDB clinical Management and Drug Resistance Database) in South Africa and Botswana. </p>\r<p>This workshop was sponsored by the Botswana Ministry of Health in collaboration with Africa Centre for Health and Population Studies, The South African Medical Research Council (MRC),The Southern African Treatment and Resistance Network (SATuRN) in collaboration with Life Technologies, the European Commission (EC), the Canadian International Development Agency (IDRC), the Wellcome Trust and the US PEPFAR/CDC.</p>\r', 'Tulio de Oliveira, Lungani Ndwandwe', 'id8HIVDRWorkshop.png', 3, 'Botswana hosted a successful HIV and TB workshop', '2011-12-01', 'imgworkshop2011c.png', 'Botswana, hosted, successful, HIV , TB, drug resistance, workshop', 'Botswana hosted a successful HIV and TB workshop. A blog by Lungani Ndwandwe and Tulio de Oliveira on the SATuRN workshop, 2011', NULL, NULL, NULL),
(7, NULL, 'Dr Allison Russell from USAID Southern Africa\'s Regional HIV/AIDS Program (RHAP) will be attending the annual SATuRN workshop and will share her thoughts here as a guest blogger of <a href=\"http://www.hivsharespace.net\">SHARE</a>', 'Submitted by SHARE Administrator on 2 November 2011<br>\rThe Southern African Treatment Resistance Network (SATuRN) will be hosting the Sixth Southern African HIV & TB Drug Resistance and Treatment Monitoring Workshop from 7 to 8 November 2011 in Gaborone. Dr Allison Russell from USAID Southern Africa\'s Regional HIV/AIDS Program (RHAP) will be attending the workshop and will share her thoughts here as a guest blogger.<br><br>\rLinks to the Blogs at SHARE:<br>\r<a href=\"http://www.hivsharespace.net/node/430\"> Opening of the SATuRN 6th Southern African HIV/TB Drug Resistance Workshop</a><br>\r<a href=\"http://www.hivsharespace.net/node/441\">SATuRN Conference Day 2</a><br>\r\r<br>Event website:<br>\r<a href=\"http://www.bioafrica.net/saturn/\">6th Southern African HIV/TB Drug Resistance Workshop Website</a><br>', 'Alisson Russell', '', 3, 'Blogging from the Field: SATuRN Workshop in Gaborone', '2011-11-02', 'imgshare.png', 'Alisson Russell, share, blog, SATuRN, workshop, treatment, resistance, network, africa', 'SHARE blog and coverage of the SATuRN Workshop in Gaborone. A blog by Alisson Russell ', NULL, NULL, NULL),
(3, NULL, '<p><a href=\"#paper\">A recent paper in Emerging Infectious Diseases </a>has provided full details of the national anti-TB drug resistance survey in Swaziland performed in 2009-2010. The results are quite alarming and there is detailed information within the report that should challenge us to rethink current strategies for diagnosis and treatment of drug-resistant TB not only in Swaziland but elsewhere in Southern Africa.</p>\r', '<p><b>TB in Swaziland</b></p>\r<p>The Kingdom of Swaziland is a small country (population 1,185,000) with the highest incidence rates of TB in the world. The estimated annual incidence of TB disease in 2010 was 1,287 per 100,000 giving an estimated 15,000 cases per year. Approximately 80% of TB cases are HIV-infected. </p>\r<p></p>\r<p>Case detection rates and cure rates are below targets set by the World Health Organization. Case detection rate in 2010 was 66% (target 70%) and the cure rate for new smear positive cases in 2009 was only 51% (target 85%). In 2010 there were 326 confirmed cases of multidrug-resistant TB (MDR-TB), but only 2% of new cases and 35% of previously treated cases were tested for drug resistance. There is one laboratory performing culture and first-line drug susceptibility testing (DST), and second-line DST is performed outside the country. </p>\r<p></p>\r<p><b>The survey</b></p>\r<p>A nationwide cross-sectional survey was performed, enrolling 840 smear positive cases >14 years old from TB diagnostic centres. The cases were defined either as new cases (no previous TB treatment or anti-TB drugs for <1 month duration) or previously treated cases (anti-TB drugs for >1 month duration). The survey achieved excellent coverage, with about 84% of potentially eligible individuals screened for the survey. DST for first-line drugs (rifampicin, isoniazid, ethambutol, and streptomycin) was performed on all culture positive samples. DST for second-line drugs (amikacin, capreomycin, ofloxacin, 4-aminosalicylic acid (PAS), and ethionamide) was performed on isolates resistant to rifampicin and/or isoniazid. In addition, pyrazinamide susceptibility was tested for isolates resistant to any first-line drug and moxifloxacin susceptibility was tested for isolates resistant to ofloxacin. DST results were available for 633 patients (75% of those enrolled). </p>\r<p></p>\r<p><b>Key findings</b></p><b>\r<p> - The proportion with MDR was 7.7% (27/352) in new cases and 33.8% (95/281) in previously treated cases</p>\r<p> - 68.9% (84/122) of MDR isolates were resistant to pyrazinamide</p>\r<p> - 47.5% (58/122) of MDR isolates were resistant to ethionamide </p>\r<p> - 9.0% (11/122) of MDR isolates were resistant to either ofloxacin or a second-line injectable (pre-XDR)</p>\r<p> -  0.8% (1/122) of MDR strains were resistant to both ofloxacin and a second-line injectable (XDR)</p></b>\r<p><b>Context</b></p>\r<p>The prevalence of MDR-TB in this survey was considerably higher than in the previous national survey performed in 1995. It is also considerably higher than reported from other Southern Africa countries. Botswana is the only country in Southern Africa to have performed regular national drug resistance surveys. As can be seen in the figures below, in the last Botswana survey in 2008 the prevalence of MDR in both new cases and previously treated cases had increased from previous surveys but not to the extent described now in Swaziland.</p>\n<img src=\"imagesBIO/blog3img.png\"><br>\n\n<p><b>Implications for diagnosis and treatment of MDR-TB</b></p>\r<p>This survey highlights the pressing need for improved diagnostic strategies for drug resistance. In this regard, it is encouraging that several initiatives to assist with TB control are in place within the country, e.g. <a href=\"#expand\">the EXPAND-TB project</a> and < a href=\"#MSF\"> Medecins sans Frontieres</a>. According to the <a href=\"#who\">WHO monitoring of Xpert MTB/RIF roll-out</a>, Swaziland has procured 20 GeneXpert modules and 5,100 Xpert MTB/RIF cartridges with <a href=\"#expansion\">plans for further expansion of this technology</a>. </p>\r<p><b>Implications for use of Xpert MTB/RIF</b></p>\r<p>There are interesting details within this paper that could help to inform the use of Xpert MTB/RIF and which highlight some limitations of the technology. The detection of rifampicin resistance is considered a good proxy for the presence of MDR and this is supported by the evidence in this survey: the proportion of RIF-resistant strains that were also resistant to INH was 93.8% (122/130) so rifampicin mono-resistance was rare. </p>\r<p>On the other hand, the proportion of strains that were INH-resistant but not RIF-resistant was quite high (52 isolates, 8.2% of total). The implication of this is that if Xpert detects no rifampicin resistance and no other DST is performed, undetected INH resistance will potentially lead to poor outcomes and the emergence of MDR strains on standard first-line therapy.</p>\r<p><b>Implications for standardised drug regimens for MDR-TB</b></p>\r<p>In terms of drug regimens for MDR-TB, the findings of high levels ethionamide resistance in the MDR strains should be of huge concern not only in Swaziland but throughout Southern Africa. Ethionamide resistance may partly arise due to cross-resistance from inhA mutations selected by isoniazid. Ethionamide is considered a key element of the standardised MDR treatment regimen yet this data would suggest that in half of all cases, it is likely to be an ineffective component of the regimen. WHO guidelines suggest that a standardised MDR regimen should consist of a fluoroquinolone, an injectable, ethionamide, and either cycloserine/terizidone or PAS. This data would suggest that ethionamide cannot be relied upon as an active drug and it might be necessary to include both cycloserine/terizidone and PAS in a standardised regimen. It seems that this is indeed the recommendation in the <a href=#swazi\">Swaziland national guidelines</a> but <a href=\"#ZA\">South African guidelines</a> are more in parallel with the WHO guidance. There is an urgent need in South Africa for up-to-date representative data to inform treatment guidelines. </p>\r<p>Although pyrazinamide is not considered an active drug in an MDR treatment regimen, it is recommended as a component of a standardised regimen to take advantage of its activity in an acidic environment (as in chronically inflamed lung tissue sometimes seen in MDR-TB cases). One also has to question this rationale if the drug will be ineffective in almost two-thirds of cases. </p>\r<p></p>\r<p><b>Conclusion</p></b>\r<p>This paper is very important and highlights the importance of surveillance for drug resistance. Better surveillance systems are required in many countries and there is a need to assimilate all the data to inform drug-resistant TB control strategies in the region.  </p>\r<p></p>\r<p><b>References and links</p></b>\r<p><a name=\"paper\"></a><a href=\"http://dx.doi.org/10.3201/eid1801.110850\">Sanchez-Padilla E et al. High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010. Emerg Infect Dis 2012; 18(1): 29-37. </a></p>\n<p><a name=\"expand\"></a><a href=\"http://www.who.int/tb/publications/factsheet_expand_tb.pdf\">The EXPAND-TB project</a></p>\n<p><a name=\"msf\"></a><a href=\"http://www.msf.org.za/countries/swaziland\">Medecins sans Frontieres in Swaziland</a>. </p>\r<p><a name=\"who\"></a> <a href=\"http://www.who.int/tb/laboratory/mtbrifrollout/en/index.html\">The WHO monitoring of Xpert MTB/RIF roll-out</a>.</p>\r<p><a name=\"expansion\"></a><a href=\"http://www.stoptb.org/wg/gli/assets/documents/map/2/Pdf_files/SWZ.pdf\">Swaziland has procured 20 GeneXpert modules and 5,100 Xpert MTB/RIF cartridges with plans for further expansion of this technology</a>. </p>\r<p><a name=\"Swazi\"></a><a href=\"http://www.tbonline.info/archive/document/10/\">The Swaziland TB national guidelines</a></p>\n<p><a name=\"ZA\"></a><a href=\"http://www.tbonline.info/archive/document/8/\">South TB African guidelines</a>.</p>\n<br>\n\r\r\n\r', 'Richard Lessells', '', 3, 'Drug-resistant tuberculosis in Swaziland: a concern for us all', '2012-01-24', 'blog3imgsmall.png', 'Drug-resistant, treatment, TB, tuberculosis, Swaziland, southern Africa, blog, lessells', 'Drug-resistant tuberculosis in Swaziland: a concern for us all. Blog by Richard Lessells for SATuRN. In this blog he explains the new high-level drug resistance TB strains found in Swazi and southern Africa', NULL, NULL, NULL),
(2, NULL, '<p>A recently published report of tuberculosis strains resistant to all tested first- and second-line anti-TB drugs in Mumbai has garnered much attention in the media. What has actually been reported: Is this a new form of TB? What is the significance for global TB control?</p>', '<p><b>The report</b></p>\r<p>The <a href=\"#correspondence\"> correspondence in Clinical Infectious Diseases </a> describes four adults with M. tuberculosis isolates resistant to all tested first- and second-line drugs. All four patients had been previously treated with first-line drugs and for at least 12 months with one or more second-line agent. The timing of any specific diagnosis of MDR-TB or XDR-TB and the relation to the treatment provided in the four cases is not made clear. Drug susceptibility testing (DST) was performed for the following drugs: isoniazid, rifampicin, pyrazinamide, ethambutol, streptomycin, amikacin, kanamycin, capreomycin, moxifloxacin, ofloxacin, para-aminosalicylate (PAS), and ethionamide. Genotypic analysis (with the <a href=#assay\">Genotype MTBDRplus and MTBDRsl assays</a>) gave supportive evidence of mutations conferring resistance to rifampicin (rpoB), isoniazid (katG/inhA), fluoroquinolones (gyrA), and injectables (rrs). Interestingly, there is no mention of embB mutations (which can be detected by the MTBDRsl assay) for any of the four patients, although the assay is known to be less reliable in detecting ethambutol resistance.</p>\r<p></p>\r<p><b>Is this a novel finding?</b></p>\r<p>The simple answer is no. There have been previous reports of M. tuberculosis strains resistant to all tested first- and second-line drugs. Terms used previously include <b><i>\'extremely drug-resistant TB (XXDR-TB)\', \'super extensively drug-resistant TB\'</b></i>, and the term used in this report, <b><i>\'totally drug-resistant TB\'</b></i>. In 2007,<a href=\"#migli\"> Migliori <i>et al.</i> </a>reported XDR-TB cases from Italy with additional phenotypic  resistance to PAS and ethionamide, i.e. the same pattern as the isolates in the Mumbai report. In 2009 <a href=\"#vela\">Velayati <i>et al.</i></a> reported 15 patients with phenotypic resistance to all the tested first- and second-line agents (this included DST for cycloserine which was not performed for the Mumbai cases). Since the publication of this Indian report many TB physicians have argued that similar cases have been seen in their practice, usually in XDR-TB patients who fail treatment. It should be noted that the term <b><i>\'totally drug-resistant TB</b></i> has not been recognised by the WHO for reasons outlined here.</p>\r<p></p>\r<p><b>So why so much attention? </b>  </p>\r<p>The fact that this report originates from India is clearly important. India, with 1.5 million TB cases in 2009, accounts for about a quarter of all TB cases worldwide and is estimated to have a similar proportion of global MDR-TB cases. There is a huge gap between estimated MDR-TB cases and notified cases (only 2.3% of estimated cases were notified in 2009). There is a huge shortage in laboratory capacity for culture and drug resistance testing (one lab per 50 million population) so access to diagnosis and treatment of drug-resistant TB is extremely limited. Budgets for MDR-TB are inadequate and it is concerning to note that the Global Fund is the main source of funding for the MDR-TB budget. The latest <a href=\"#who\">WHO MDR/XDR-TB progress report </a>highlights significant expansion of laboratory capacity for diagnosis of drug-resistant TB (see p13 of report) yet it is clear that huge challenges exist in India. Seen in this context, it is not surprising that this report has been used to stress the dangers of inadequate attention to drug-resistant TB. </p>\r<p></p>\r<p><b>Who is to blame for these drug-resistant cases?</b></p>\r<p>The authors of the report point the finger of blame on private practitioners who provided treatment to the four cases. It would seem that private doctors are easy scapegoats but surely they are not the main source of the problem. The patients described in the report presumably sought care in the private sector because they had limited or no access to diagnosis or treatment in the public health system. There is a need for significant scale-up of diagnostic and treatment services for drug-resistant TB worldwide and simultaneous investment in research and development to generate better tools with which to manage the disease. </p>\r<p></p>\r<p><b>What is the relevance for global TB control?</b></p>\r<p>TB is a global disease and drug resistant strains emerge in all settings. XDR-TB has been reported from 69 countries and so the potential exists for the emergence of cases similar to those reported from India. Drug-resistant TB also spreads internationally, as highlighted recently in a <a href=\"#gram\">paper from our colleague Graham Cooke</a> at Imperial College, London. In this report, MDR-TB was diagnosed in London in a South African immigrant and both the patient and the isolate could be linked to the outbreak of drug-resistant TB centred on Tugela Ferry in KwaZulu-Natal, South Africa. This emphasises that drug-resistant TB must not be seen as a problem constrained to certain countries, but rather as a broader challenge for global health.  </p><br>\r<p><b>References and links</b></p>\r<p><a name=\"correspondence\"></a>Udwadia ZF et al. <a href=\"http://cid.oxfordjournals.org/content/early/2011/11/24/cid.cir889.extract\">Totally drug-resistant tuberculosis in India. Clin Infect Dis 2011 Dec 21 [Epub ahead of print]</a></p>\n<p><a name=\"assays\"></a><a href=\"http://www.hain-lifescience.de/en/products/microbiology/mycobacteria/genotype-mtbdrplus.html\">Genotypic analysis with the Genotype MTBDRplus </a>and <a href=\"http://www.hain-lifescience.de/en/products/microbiology/mycobacteria/genotype-mtbdrsl.html\">MTBDRsl assays</a>.</p>\r<p><a name=\"migli\"></a><a href=\"http://dx.doi.org/10.3201/eid1305.070200\">Migliori et al. reported XDR-TB cases from Italy</a>.</p>\r<p><a name=\"vela\"></a><a href=\"http://chestjournal.chestpubs.org/content/136/2/420.full.pdf\">Velayati et al. reported XDR-TB cases from Iran </a>.</p>\r<p><a name=\"who\"></a><a href=\"http://www.who.int/tb/publications/2011/mdr_report_2011/en/\">The latest WHO MDR/XDR-TB progress report</a>.</p>\n<p><a name=\"gram\"></a><a href=\"http://wwwnc.cdc.gov/eid/article/17/11/11-0291_article.htm\">Cooke and colleagues. International Spread of MDR TB from Tugela Ferry, South Africa. EID, volume 17, number 11 (2011).</a></p><br>\r', 'Richard Lessells', 'blog2img.png', NULL, '\'Totally drug-resistant\' tuberculosis in India: should we be worried?\r', '2012-01-23', 'blog2imgsmall.png', 'Totally, drug-resistant, TB, tuberculosis,  India, SATuRN, XDR, TDR, worried\r', 'Totally drug-resistant tuberculosis in India: should we be worried? Blog from Richard Lessells for SATuRN. This blog talks about the new strains of TB drug resistance in India\r', NULL, NULL, NULL),
(4, NULL, '<p>SATuRN and the Africa Centre Bioinformatics Unit are involved in many community engagement activities.  Over the last years we have presented on eight occasions to the community around Africa Centre. The presentations are focused on the origin of HIV, the causes and consequences of drug resistance development and how to successfully manage HIV and TB treatment. </p>', '<p>For example, we presented three times to primary schools (children aged 6 to 10) in the Umkhanyakude district in 2010. This series of presentations used cartoons that portray HIV as a lion (Ibhubesi translation in Zulu), CD4 cells as soldiers (Amasosha, Zulu translation) and that show how ARVs make the soldiers stronger as they provide them with armour. The Head of external relations at Africa Centre, Mr. Mbongiseni W. Buthelezi, also attended this series of presentations. He was excited by the presentation and commented <b><i>\'Thank you so much for your superb presentation to a group of Somkhele Primary school learners. You really rose to the occasion given their level of cognitive development. I have no doubt that such a graphic presentation drove the message home. One could see the faces of the kids beaming with excitement!\'</b></i></p>\r\r<p>In 2010 and 2011, a second series of three presentations was delivered to the Africa Centre Community Advisory Board (CAB), which has 75 participants from the local community and traditional authority. In this series of presentations, a physician (Dr. Richard Lessells) and a researcher (<a href=\"peopleid=1\">Dr. Tulio de Oliveira</a>) explained the effect of detectable viral load on immune reconstitution and drug resistance development. The presentations were very well received and the head of the CAB asked for a full day (6 hours section) on the topic, which was very well attended by members of CAB and the community and generated great discussions. </p>\r\r<p>As part of an end of the year function to high achievers at Matric level in 2010, Dr. Tulio de Oliveira presented at Grantleigh High school, in Empangeni. The graphical presentation explained that HIV originated from primates in West and West Central Africa and then infected humans, similar to tuberculosis (TB) from Bovine in cows, or buffalo as experienced locally; dispelling the myth that HIV was unique. Janet McGrath, Head of Department of Sciences, said: <b><i>\'Grantleigh saw a need for their academically talented students to be exposed to a scientific and cultural enrichment programme in order to inspire them.\' Illuminating science to students is another demonstration of Africa Centre\'s commitment to HIV research and interaction with the local community whilst maintaining its professional status in population-, clinical- and social science studies\'.</b></i> <a href=\"news.php?id=8\"> This event was covered by the Zululand Observer newspaper</a>. </p>\r \r<p>Recently, in December 2011, the Africa Centre bioinformatics unit and SATuRN helped two social workers to fund and present a summer camp workshop to adolescents failing ARVs in the clinics served by Africa Centre. The camp was attended by 22 adolescents (12-17 years) and presented over 4 days and involved many activities and presentations. A new blog entitled <a href=\"http://www.bioafrica.net/blogs.php?id=6\">Social Worker perspective: Adolescents on Antiretroviral (ARV) therapy - a VideoBlog</a> has been published. </p>\r', 'Tulio de Oliveira', 'blog4img.png', NULL, 'Scientific Community Engagement Activities in rural KwaZulu-Natal, South Africa', '2012-01-22', 'blog4imgsmall.png', 'SATuRN, Africa Centre, Bioinformatics, community, engagement, activities, presentations, origin of HIV, causes, consequences, drug, resistance, HIV , TB, treatment', 'SATuRN and the Africa Centre Bioinformatics Unit are involved in many community engagement activities.  Over the last years we have presented on eight occasions to the community around Africa Centre. The presentations are focused on the origin of HIV, the causes and consequences of drug resistance development and how to successfully manage HIV and TB treatment', NULL, NULL, NULL),
(6, NULL, '<p><b><i>What factors contribute to young people / adolescents on Highly Active Anti-Retroviral Treatment (HAART) failing treatment?</b></i> Quite a number of factors really, such as, lack of knowledge about the advantages of taking treatment, or the lack of knowledge about the length of time one is required to be on treatment. In fact, there are a number of factors that come into play, most of which are psychological and socio-economical in nature. Perhaps one underlying factor that seems to surface out of all of this, and that perhaps goes hand in hand with the factors mentioned above, is the notion that, for an adolescent, living life with HIV is a very long and lonely life. Anti-retroviral therapy (ART) social workers from Africa Centre for Health and Population Studies work with adolescents as part of the Hlabisa HIV and Care Treatment Program. In the end of 2011 they have organized many activities, including a four day workshop during the school holidays. targeted at adolescents, aged 12+ on ART, most of whom were failing ART. The aim of the workshop was to provide sufficient information to enhance adherence and to provide a support system.</p>', '<p><b><i>\'More information was needed about HIV drug resistance, and to let the participants know that ART is a life-long commitment\'</b></i>, these words were expressed by Pretty Nkosi and Nokuthula Skhosana, the ART social workers from Africa Centre and the main organizers of the workshop. They continued to say; <b><i>\'...having a sort of group setting with group discussions by teenagers sharing and facing more or less similar challenges, gives them (adolescents) an assurance that they are not alone in their circumstance and that they have support\'</b></i>. The 4 day programme of the workshop was designed to cater to the audience through infotainment sessions.</p>\r<p>The sessions ranged from self-reflecting exercises, where teenagers were required to do introspective exercises by looking in the mirror and expressing their feelings through group discussions; to an informative but fun session about ARVs, amasotsha (CD4) and HIV drug resistance by Dr Tulio de Oliviera (Africa Centre/SATuRN). Also included in the programme was an HIV activist, who had lived with HIV for more than 10 years, telling his story about his life with HIV. This reaffirming story confirming the fact that HIV is not a death sentence anymore and that one can live a long and a healthy life.</p>\r<p>Returning to the first line of this article, the question still remains, <b><i>\'how do we keep patients from failing treatment?\'</b></i>; further more how do we keep adolescents from failing treatment as they are  treatment naive, impoverished, and in most cases depressed.  Sometimes the antidote is not always clinical. It became apparent from the programme that this knowledge dispensing exercise was not a mechanical exercise, where one gives and another receives; more can be learned from these children, who know first hand about their experiences. So creating an environment where one learns from them too would ultimately shape the direction of research and interventions. All of the above make the work of social workers at the ART programme relevant, informative, and very need necessary.</p>\r<p>Part of the social activities for adolescents organized by the social workers in this report was funded by their own personel funds. This is not the first time that they have contributed with their time and money to help the community that they work. In addition, donations from indivudals from the Africa Centre and neighbouring community, including Prof. John Imrie (Africa Centre), Dr. Astrid Treffry-Goatley (Africa Centre) and family. In addition, they want to thanks Dr. Kevi Naidu head of the ART program at the Africa Centre, who encourage this kind of activity.</p>\r<p>If you would like more information on the work and/or would like to contribute with finantial support to their social activities please contact Mrs. Pretty Nkosi and Mrs. Nokuthula Skhosana at Tel: +27 35 550 75 00, Fax: +27 35 550 76 65 and by email at: pnkosi@africacentre.ac.za and nskhosana@africacentre.ac.za </p>', 'Pretty Nkosi, Nokuthula Skhosana, Lungani Ndwandwe and Tulio de Oliveira', NULL, NULL, 'Social Worker perspective: Adolescents on Antiretroviral (ARV) therapy - a VideoBlog', '2012-02-10', 'imgsocial.png', 'social, worker, adolescent, antiretroviral, arv, adhrence, saturn, drug resistance, workshop, activity, rural, africa, south Africa', 'Social Worker perspective: Adolescents on Antiretroviral (ARV) therapy. A videoblog from the Southern African Treatment and Resistance Network (SATuRN) at bioafrica website.', 'U70kUepvWHA', NULL, NULL),
(8, NULL, '<p>\rSATuRN<br>\rWith her circles of concern<br>\rStands firm despite fires that burn<br>\rWhether you are home-schooled or college<br>\rLet us all recognize and pay homage<br>\rTo her rings of infinite knowledge</p>', '<p>\rI heard once through the muttering air<br>\rHow proximity bred calamity<br>\rIntimacy came with unwanted seeds<br>\rAs broken families lay scattered<br>\rBy a way of life shattered<br>\rI heard with dismay <br>\rHow the calamity <br>\rRavaged nations<br>\rStole precious futures <br>\rLeaving in its wake<br>\rThe stench of death in the air</p>\r<p>\rI heard how once<br>\rNot so long ago<br>\rBoardrooms<br>\rCriss-crossed the earth in jet-fumes<br>\rSearching for answers<br>\rIn intellectual rhetoric<br>\rConsequently<br>\rAbstraction bred distraction<br>\rWhile ground zero<br>\rThat imperfect dust-cloud of unsung heroes<br>\rFaded into the limits of our ignorance</p>\r<p>\rI heard through the magic of Kalahari sand-dunes<br>\rHow contradictions added flavor<br>\rTo local superstitions<br>\rConspiracy theory suspicions<br>\rMixing with frivolous and expensive mind games<br>\rPeople dying while we asked<br>\rThe questions with no meaning<br>\rAnd offered them solutions with no sustainability</p>\r<p>\rI don\'t dare go back there<br>\rPast lessons should have be learnt well<br>\rAnd who in his right mind would chose hell<br>\rOver a heaven of their own making</p>\r<p>\rI don\'t mean to scare you<br>\rAt least not intentionally<br>\rHowever,<br>\rI implore thee<br>\rKnow your enemy<br>\rHe walks contemptuously<br>\rWith no fear<br>\rOver-riding the protocols<br>\rContinuously learning how to resist everything thrown at him</p>\r<p>\rWe need the new tools to fight the new challenges<br>\rWe must adapt or die<br>\rThe gauntlet truth has never been more apparent<br>\rWe must change<br>\rAfter all<br>\rOur enemy changes shells every so often<br>\rMutates into a multiplicity of variants</p>\r<p>\rThat\'s why we are thankful to be here<br>\rFor this is SATuRN<br>\rThe ringed planet<br>\rEach ring playing its part to create a beautiful world<br>\rThis is SATuRN<br>\rWhere the centre must hold the greatest importance<br>\rSo that the circles of concern can accommodate its needs<br>\rSo I implore you<br>\rAs we sit here<br>\rDeliberate here<br>\rAnd learn here<br>\rLet us remember the people<br>\rThey lie in the centre and are the centre<br>\rThey are the ground zero survivors waiting to participate in their own survival<br>\rNeeding the tools to see what we see<br>\rSo that they,  not us, <br>\rCan take the appropriate actions</p>\r<p>\rAnd finally,<br>\rThis is SATuRN<br>\rWhose effects will reverberate across these savanna plains<br>\rTo manifest into a bright future we can all live with<br>\rThis is SATuRN <br>\rWhere we have come to strengthen our resistance<br>\rAgainst the growing threat of drug resistance<br>\rThis is SATuRN<br>\rWhere hope and great minds have gathered<br>\rTo strengthen and expand our circles of concern</p><br>\n\n<p><b><i>Joshua Machao 2011</b></i><br>\nPoet. Writer. Performer<br>\nExodus Live Poetry! Collective</p>\n \n<p>Copyright<br>\nThe above body of work remains the intellectual and creative property of the artist and should remain intact. No further transmission or use of the work, in any form, electronic or otherwise permitted without the express written consent of the artist. Contact Joshua Machao at jtmachao@gmail.com</p>\n\n<p><a href=\"http://www.bioafrica.net\">SATuRN</a> is grateful for this beautiful poem that was recited in the openning of our 6th annual workshop in Botswana</p>', 'Joshua Machao', 'Joshua-T-MACHAO.png', 3, 'Poetry: Toward A SATuRN Hope', '2012-03-14', 'Joshua-T-MACHAOsm.png', 'poetry, saturn, southern, african, treatment, resistance, network, art, poet, joshua, machao, botswana', 'Towards a SATuRN hope: A beautiful poetry by Joshua Machao for the openning of the 6th Southern African HIV and TB Drug Resistance and Treatment Management Workshop', NULL, NULL, NULL),
(9, NULL, '<p>The diagnosis of drug resistance in pulmonary TB generally relies on performing susceptibility tests either directly on sputum specimens or on the isolate grown in sputum culture. An interesting article in Clinical Infectious Diseases addresses the question of whether the susceptibility pattern in sputum tells the whole story. </p>', '<p><b><i>Figure 1 - </b></i>These diagrams represent populations of M. tuberculosis bacilli within a lung cavity (large circle). Drug-resistant bacilli are present; the predominant population being resistant to drugs A& B. Due to spontaneous mutations, there are bacilli present with additional resistance to drugs C & D. <p>They report a case series, from a referral centre in the Republic of Georgia, of 50 drug-resistant TB cases that had undergone surgical lung resection and had paired sputum and lung tissue specimens, specifically from a lung cavity. The patients had been treated for drug-resistant TB for an average of just over one year. The specimens were cultured using either solid (Lowenstein-Jensen medium) or liquid (MGIT 960) media. Drug susceptibility testing (DST) for first- and second-line drugs was performed using the concentration method. </p>\r<p>Eighteen patients (36%) had a positive culture with DST results from both the pre-operative sputum specimen and lung tissue. In seven of these cases DST revealed additional resistance in the lung tissue isolate compared to the isolate cultured from sputum. In four cases this included extra resistance to the fluoroquinolone (ofloxacin) and in three cases this included extra resistance to injectable agents (kanamycin or capreomycin). Overall in four cases the sputum isolate would have been classified as pre-XDR whereas the tissue isolate would have been classified as XDR-TB. </p>\r<p>How can we explain these findings? This study was unable to confirm that the strains in sputum and lung tissue were identical (no genetic analysis was performed) so it is possible that this represented mixed strains within the same patient. However, a previous similar study did demonstrate identical strains but with different susceptibility patterns in sputum and lung tissue.</p>\r<p>It is well known that the compartmentalisation of bacilli promotes the acquisition of drug resistance in M. tuberculosis as certain drugs are more active in different environments. The penetration of second-line drugs into lung tissue, particularly lung cavities, is poorly understood. It is possible that differential penetration of drugs into the lung cavities predisposes to the emergence of further drug resistance in those populations (see Figure). </p>\r<p>Does this have any relevance for the diagnosis and management of drug-resistant TB? It is clearly neither practical nor desirable to obtain lung tissue for culture for all drug-resistant TB patients! But we should remember that the susceptibility pattern in sputum may not be completely representative of all the bacillary populations present at the site of disease. This is an important consideration in patient failing to respond to MDR/XDR-TB treatment. Whether modification of the drug regimen or surgical removal of the lung cavity leads to better clinical outcomes in these cases is open to question.  </p>\n<br><img src=\"imagesBIO/imgBlog9B.png\">\r<p><b><i>Figure 2 - </b></i>The bottom diagram shows the situation under treatment with a combination of drugs (drugs C + D + E): drugs D & E cannot penetrate into the lung cavity whereas drug C can. There is therefore effectively monotherapy within the lung cavity with drug C and this drug pressure enables the selective growth of bacilli resistant to drugs A & B & C, which then becomes the dominant population.</p>\n\r<p><b><i>References</b></i></p>\r<p><a href=\"http://cid.oxfordjournals.org/content/54/6/e51.full\">Kempker RR, Rabin AS, Nikolaishvili K, et al. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis.</a> Clin Infect Dis 2012; 54: e51-54</p>\r<p><a href=\"http://iai.asm.org/content/71/12/7099.abstract\">Kaplan G, Post FA, Moreira AL, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity.</a> Infect Immun 2003; 71: 7099-7108</p>\r', 'Richard Lessells', 'imgBlog9A.png', NULL, 'Drug resistance in Mycobacterium tuberculosis: do sputum specimens tell us everything?', '2012-03-14', 'imgBlog9Asm.png', 'Drug, resistance, Mycobacterium, tuberculosis, mtb, tb, sputum, assay, test, information, MDR', 'Drug resistance in Mycobacterium tuberculosis: do sputum specimens tell us everything?', NULL, NULL, NULL),
(10, NULL, '<p>Bedaquiline (TMC-207), a diarylquinolone, is an anti-TB drug based on a novel mode of action (inhibition of ATP synthase). Initial results from a phase 2 randomised, double blind, placebo-controlled trial were reported in the New England Journal of Medicine in 2009. A new article published ahead of print in Antimicrobial Agents and Chemotherapy provides longer term follow-up data on efficacy and safety up to 104 weeks. </p>\r', '<p>This was a multicentre trial within South Africa, enrolling individuals with pulmonary MDR-TB, most of whom were HIV negative (87%). All were treated with an individualised background drug regimen consisting at least of kanamycin, ethionamide, ofloxacin (all except one patient), in combination with other selected second-line TB drugs. Patients were randomised to the inclusion of bedaquiline or placebo in the regimen, administered only for the first eight weeks of therapy. Participants then continued on the background regimen and were followed up for two years (104 weeks).</p>\r<p>In total 47 patients were included in the trial (23 treated with bedaquiline, 24 with placebo). Two patients with XDR-TB at baseline were excluded from the efficacy analysis as was one patient with negative pre-treatment culture. </p>\r<p>The key findings were:</p>\r<p><b> - Time to 50% sputum conversion was 78 days in the bedaquiline arm vs 129 days in the placebo arm</p>\r<p> - At 24 weeks, 81.0% in the bedaquiline arm had culture conversion vs 65.2% in the placebo arm</p>\r<p> - Treatment success at 104 weeks was not substantially different between the two groups (52.4% for bedaquiline vs 47.8% for placebo). The precise definition of this outcome is not stated in the paper but it is presumed to represent standard WHO definitions, i.e. cure or completion</b></p>\r<p>Rates of discontinuation in the study were very high, with 49% of all study subjects discontinuing, over half of those within the first 24 weeks. It should be noted that many of these were discontinuation from study follow-up rather than necessarily discontinuation of treatment and that many study subjects were culture negative at the time of discontinuation.</p>\r<p>There was evidence that the accumulation of additional drug resistance was more frequent in the placebo arm (6 patients developed additional resistance vs one subject in the bedaquiline arm). Of particular concern was the emergence of fluoroquinolone resistance in four patients in the placebo arm. </p>\r<p>In the safety analysis, there was excess nausea in the bedaquiline arm (26.1% vs nil) but no other significant difference between the two arms. This is of concern given that nausea is a symptom that might affect adherence to therapy, especially outside the trial setting with less rigorous monitoring and follow-up. Having said that it is surprising that no nausea was reported in the placebo arm given the drug regimens used in this group and the frequency of this symptom in routine practice. It will be important to assess the frequency, severity, and effect on adherence of nausea in the continuing trials of bedaquiline.</p>\r<p>The second stage of the phase 2 trial (an open label trial comparing 24 weeks of bedaquiline vs placebo in combination with a background regimen for MDR-TB patients) has now completed recruitment and the results are awaited with much interest. It is expected that regulatory approval will be sought on the basis of these results. Furthermore, a phase 3 trial is planned, evaluating the use of bedaquiline as part of a 9-month treatment regimen for MDR-TB. </p>\r<p></p>\r<p><b><i>References</b></i></p>\r<p>Diacon AH, Pym A, Grobusch M, et al. The diarylquinolone TBC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405</p>\r<p><a href=\"http://www.unboundmedicine.com/medline/ebm/record/22391540/full_citation/Randomized_pilot_trial_of_8_weeks_of_bedaquiline__TMC207__for_MDR_TB:_long_term_outcome_tolerability_and_effect_on_emergence_of_drug_resistance_\">Diacon AH, Donald PR, Pym A, et al. Randomised pilot trial of 8 weeks of bedaquiline (TMC207) for MDR-TB: long-term outcome, tolerability and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012 (published ahead of print)</a></p>\r<p><a href=\"http://clinicaltrials.gov/ct2/show/NCT00910871?term=tmc207&rank=3\">http://clinicaltrials.gov/ct2/show/NCT00910871?term=tmc207&rank=3</a></p>\r<p><a href=\"http://www.resisttb.org/uploads/TMC-207_Phase_III_MDR-TB_Trial_Oct_29_2011.pdf\">http://www.resisttb.org/uploads/TMC-207_Phase_III_MDR-TB_Trial_Oct_29_2011.pdf</a></p>', 'Richard Lessells', 'imgBlog10.png', NULL, 'More follow-up data on phase 2 trial of bedaquiline (TMC-207)', '2012-03-15', 'imgBlog10sm.png', 'follow-up, data, phase 2, trial, bedaquiline, TMC-207, blog, TB, anti-TB, drug, Dr. Richard Lessells', 'More follow-up data on phase 2 trial of bedaquiline (TMC-207) a blog by Dr. Richard Lessells', NULL, NULL, NULL);
INSERT INTO `b_blogs` (`id`, `email`, `summary`, `summary2`, `authors`, `photo2`, `bioafricaSATuRN`, `title`, `date`, `image`, `keywords`, `topdescription`, `video`, `pubid`, `imagefront`) VALUES
(11, NULL, '<p>Over the past two decades Africa has experienced a sharp increase in the mortality rate due to dreadful diseases that have plagued the continent, such as Hepatitis B, Tuberculosis (TB), HIV/Aids, and Malaria, to name a few, some curable and most of which un-curable. This spread of diseases is heavily felt in this third world continent (Africa) and unfortunately a continent where there are less and less solid structures in place to control the spread. South Africa is a prime example of how burdensome this increase has been. </p>', '<p>Adding fuel to the fire in South Africa is the lack of human resource in the Health care system, particularly doctors; with or without field experience. South Africa alone has a significant gap in ratio of doctors to patients of 77: 100 000. This lack of or in adequacy thereof is exacerbated in rural hospitals and rural clinics. <b><i>\'It is largely just that doctors prefer to work in more developed, urban settings than in the rural areas so it is difficult to retain medical doctors in the rural areas after their community service\'</b></i> commented Dr Richard Lessells, a Clinical Research fellow at the London School of Hygiene and Tropical Medicine who is based at the Africa Centre for Health and Population Studies, an infectious diseases specialist and one of the few doctors working in the treatment of TB/HIV at the Hlabisa sub-district in KwaZulu Natal; this sub district with a population size of 220 000 has a high burden of unemployment and a high prevalence of HIV and TB, and most recently noted a high level of prevalence in HIV drug resistance. He added on to say <b><i>\'Whilst there have been some initiatives and incentives to retain doctors in rural areas, this has not been enough and South Africa is still not training enough doctors to cope with the burden of disease in the country\'</b></i>.</p>\r<p>Fairly speaking, this shortage does not only apply to doctors, but also to all healthcare professionals in general (doctors, nurses, etc) <b><i>\'nurses are forced to take on expanded roles without receiving appropriate training or supervision, and patients often not get seen by a doctor in circumstances where that level of expertise is required\'</b></i>, says Dr. Lessells. The victim in this whole shortage scenario is not the patient, as one would feel but the whole health care system. The high burden also puts a strain on doctors who are present which can lead to burn out? thus perpetuating a vicious cycle where doctors do not want to stay and thus the shortage continues and puts strain on the next group of doctors. <b><i>\'This causes high attrition rates, the inability to attract and retain staff in the public sector, which results in chronic understaffing\'</b></i> added Dr. Cloete van Vuuren, a physician and an HIV specialist working at the University of the Free State. According to Dr. van Vuuren, the implication of this to the patient is long queues and waiting times. </p>\r<p>Most of the articles published concerning this topic have focused on exposing how little government is doing to limit the shortage of doctors, however this blog do not want to do this as we have experienced (in the past 13 years working in South Africa) that the government has been trying very hard and achieving very good results on the expantion of HIV and TB treatment. Although longitudinally these articles tackle important points that have to be looked in to, however they fail to look at current state of the country and what is or not possible during this HIV/TB national emergency. Looking at the threat of TB/HIV drug resistance, and with limited doctors with or without experience in infectious diseases, one approach would be to look at this in a South African context, if not Africa as a whole; at the moment the closest person to the patient in clinical care is a nurse, and in one way or the other a patient will meet or be in contact with in a nurse in any/every clinic visit. If there is not a good supply of doctors, then they will be no choice but to use nurses to treat complex illnesses, to have confidence in implementing this approach the focus should also be on equipping and capacitating nurses to handle complex clinical cases. <b><i>\'We need to limit unnecessary expenditure, create an environment where people feel valued (resources for junior staff to attend conferences and courses), senior support at all levels for junior doctors etc\'</b></i> (Dr Cloete van Vuuren).   </p>\r<p>Dr. Lessells added on to say <b><i>\'We need to rapidly capacitate the health system to be able to manage drug-resistant HIV and TB cases, as specialist physicians will not be accessible to all patients. This means educating doctors, nurses, and allied health workers in drug resistance and cascading that knowledge through the health system. It also means a key role for surveillance and research so that we develop evidence-based treatment policies and work out the best way to implement these in the real world\'</b></i>. </p>\r<p>In conclusion, it is easy to pin point loopholes in the system, and not provide substantial solutions or suggestions to fill in the loopholes. While the South African heath ministry continuously strive to find better treatment of quality for all to treat its patients, it can never overlook the fact that the health care system itself needs to be treated, so in essence treat the health care system in order to treat patients. Recently, Dr. Tulio de Oliveira has been participating in discussions with the government (e.g. HIV and TB Research Summit) and believes that the public health system is advancing and that we are likely to see much better results in the near future!</p>\r', 'Lungani Ndwandwe, Tulio de Oliveira', 'imgBlog11.png', NULL, 'Shortage of doctors in rural South Africa?', '2012-03-29', 'imgBlog11sm.png', 'Shortage, medical, physicians, rural, south africa, kwazulu-natal, Africa', 'Shortage of doctors in rural South Africa? This blog describes the lack of human resource in the Health care system, particularly doctors', NULL, NULL, NULL),
(12, NULL, '<p>Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. Africa Centre is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health. It is based in rural, northern KwaZulu-Natal where the HIV epidemic is one of the most severe in the world with nearly 1 in 2 adults aged 35-40 being infected. This project aims to foster community discussion about scientific research and to bring evidence based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts. It involves developing, distributing and evaluating 3 CDs over 2 years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action.</p>', '<p>Two of the three CDs are now complete, and are being distributed free-of charge to key stakeholders in the local community including taxi drivers, shebeen owners and hair salon operators. Taxis are the main mode of transport in the Africa Centre research area with almost two thirds of the population (an estimated 50 to 60 thousand people) using a taxi on a weekly basis. Each one has a CD player, although most operators only have a couple of CDs to play. Thus, the primary target audience in this initiative is the users of local mini-bus taxis. On the 13th of February 2011 the project launch was held at the Mtubatuba Taxi Association. The event was well-attended with close to 200 taxi drivers present. At the launch drivers received two CDs together with an HIV fact sheet, a \'Jiving with science\' T-shirt and a meal. Once Africa Centre has received feedback from the drivers on commuter responses to these first two CDs, a third disc will be designed and distributed.</p>\r<p>This is a really exciting project because we anticipate that these informative CDs will improve the public understanding of HIV transmission and prevention strategies. Furthermore, through this project Africa Centre has engaged new sectors in the community who are now actively participating in its research and effort to prevent HIV transmission.  These partnerships are essential to the success of the project. For example, without the engagement and active participation of the taxi drivers, and the local taxi associations, these CDs will not be heard by the public. This project has also allowed Africa Centre to engage partners in the music industry who, in line with social responsibility agendas, have waivered the production rights on selected popular music tracks. In exchange Africa Centre has provided them with an opportunity to advertise and have their music heard in this often-inaccessible rural setting.  This is the first time that such a partnership has been developed in this area and we will use this project to gain a more sophisticated understanding of whether and how science communication and the needs of industry can work alongside each other in this context.</p>\r<p>To date, the support received from the music industry has been great. For example, DJ Tira, who is the owner of the famous Afrotainment studios and is originally from Hlabisa, has taken a special interest in this project. DJ Tira has donated 6 Afrotainment songs and also plays the part of the main actor in the dialogue. <b><i>We would like to say a big \'thank you\' to DJ Tira for his generosity and support. Another important contributor is Malcom Nhleko of Maltre Productions, who kindly recorded the CD dialogue at his studio in Newlands West. Other partners in the music industry who have provided the project with songs include Sheer Sound, EMI, Gallo, Abafana Bokuthula and Debrah Gumede. Currently, we are compiling the music for the third CD and are looking for hip songs to include. So far, DJ Bongz of Sony music has offered us two songs. </b></i>Any interested artists and production companies are most welcome to participate.</p>\r<p>This blog was published at the Africa Centre website <a href=\"http://www.africacentre.ac.za/Default.aspx?tabid=476\">http://www.africacentre.ac.za/Default.aspx?tabid=476</a></p>', 'Astrid Treffry-Goatley', 'Jivingwithscience.gif', NULL, 'Jiving with Science - an effective way of engaging the public', '2011-06-12', 'Jivingwithsciencesm.gif', 'Jiving with Science, effective way, engaging, community, public, music, health promotion, rual, kwaZulu-Natal, South Africa', 'Jiving with Science - an effective way of engaging the public. A community engagement project funded by the Wellcome Trust in rural KwaZulu-Natal, South Africa', NULL, NULL, NULL),
(13, NULL, '<p>In preventing the spread of HIV, STIs and TB infections and to mitigate the impact of the dual HIV and TB epidemics in society, the Department of Health (DoH) has developed a National Strategic Plan (NSP) that will shape the department activities for the next 5 years [2012 -2016], with regards to the handling of these diseases. </p>\r', '<p>The strategic plan builds on the progressive achievements of the previous strategic plan, which among others has made provisions to provide ARVs to more than a million people infected with HIV, and has also set course for early ART initiation of patients with CD4+ count of 350. What highlights this plan among others is the fact that the DoH has adopted it as a plan of action that will treat the epidemics as a state of emergency; the plan includes putting measures in place for everyone to know their HIV status and also have everyone screened for TB.</p>\r<p>The integration of TB, HIV and STIs is also a very interesting point of the current NSP. This should bring health workers and health professionals to integrate TB and HIV diagnosis and treatment at primary health care. This will ultimately ensure that TB patients who are also infected with HIV are initiated early for ART despite their CD4 count. This will hopefully reduce the number of preventable deaths and will also help to fight the stigma associated with people living with HIV and TB.</p>\r<p>The DoH has invited, in April 2012, many of the top researchers and public health officials to a summit in Johannesburg in order to discuss research priorities for HIV & TB as part of the current NSP. This was a very interesting meeting which SATuRN was present at it. In this meeting, reseach priorities for the next five years were identified and ranked. HIV & TB drug resistance ranked high in the priority list. </p>\r<p>The DoH has called on all sectors of society, organisations and individuals to collaborate in the implementation of this strategic plan. SATuRN supports this initiative and is already in talks with the department to find better solutions to the growing threat of HIV drug resistance. One of the major objectives outlined by the NSP is sustaining the health and wellness of patients on ART. </p>\r<p>SATuRN strongly believes that HIV drug failure is an emergency which has dire consequences on the well being of the patients and also to the patients clinical management. HIV drug resistance may soon undermine the success of the scale-up of ARVs by the DoH, in that way SATuRN will continue making efforts to collaborate and work together with academic intitutions, funders and government in curbing this threat.</p>\r<p>The Department does not only set the agenda, but has adopted a bottom-up approach which opens new grounds for participation by communities and private organisations. This is the perfect moment/opportunity for the scientific community to merge its strengths with the economical, sociological, and behavioural communities in order to implement comprehensive interventions to minimize the burden of the HIV/AIDS and TB epidemics in South Africa.</p>\r', 'Lungani Ndwandwe, Tulio de Oliveira', 'imgBlog13.png', NULL, 'National Strategic Plan 2012-2016: Integrating research and all sectors of society to fight HIV, STIs and TB in South Africa', '2012-04-20', 'imgBlog13sm.png', 'National, Strategic, Plan, 2012-2016, Integrating, research, society, fight, HIV, TB, STIs, South Africa, NSP. DoH, department of health, tulio de oliveira', 'SATuRN views on the National Strategic Plan 2012-2016: Integrating of research and all sectors of society to fight HIV.', NULL, NULL, NULL),
(14, NULL, '<p>The demand for dug resistance testing in resource limited settings has been exponentially increasing with the increasing numbers of patients accessing antiretroviral therapy. This needs to be backed up by increasing the number of specialist scientist required for drug resistance surveillance and monitoring. In an effort to capacitated laboratories in from resource limited settings to perform high quality genotyping service for HIV-1 drug resistance, the Africa Centre for Integrated Laboratory training (ACiLT) hosted the 1st practical course on quality assurance of HIV-1 drug resistance interpretation in sequence editing and data management between the 7th and 11th of May 2012. </p>', '<p>The course was facilitated by a pair of experts from the CDC (Mr. Joshua DeVos and Dr. Yang Chunfu) with support from local experts at the NICD (Dr. Gillian Hunt). The countries represented amongst the participants included South Africa, Zimbabwe, Botswana, Uganda, Ghana and Jamaica. The five day workshop main focus was on HIV-1 drug resistance surveillance and started with a review of the WHO strategy for HIV DR surveillance in RLS, including the use of dried blood spot for sample collection. This was followed by a review of the currently available commercial HIV-1 drug resistance genotyping methods as well as in-house methods. </p>\n<p>After the 1st day of reviews, the rest of the course focused on the theoretical and practical bioinformatics component drug resistance testing using methods that use Sanger sequencing protocols. The theoretical components involved reviews of some of the major bioinformatics tools. The use ABI Sequence Scanner for sequence data quality determination was reviewed and participants also had some time to do their own analysis and interpretation of the quality reports generated. Once the data was deemed to be of appropriate quality ChromasPro (Technelysium Pvt Lyd), and Recall (University of British Columbia?s Centre for Excellence in HIV/AIDS Research) for sequence assembly and sequence editing.  The use of   ClustalX, BioEdit, Mega  and Geneious (Biomatters) for sequence manipulation, alignment and phylogenetics analysis to test for any possibility of contaminations was also discussed and participants also spent some considerable amount of time getting their hand dirty with some analysis. The course participants accessed the <a href=\"http://bioafrica.mrc.ac.za/hivdb/\">SATuRN mirror of the Stanford University HIVDB programme</a> and Calibrated Population Resistance (CPR) were used for drug resistance interpretation and analyses. The HIVAlg programme also accessed through the HIVDB website was also used to compare the interpretation of drug resistance by the three major HIVDR interpretation algorithms (REGA, ANRS and HIVDB).</p>\n<p>At the end of the workshop most of the participants had a better understating of the quality assurance and quality control systems that needed to be in place to ensure the provision of high quality genotyping services. Participants were also able to identify quality related problems at the different stages of the genotyping process.</p>\n<br>\n<p>Interested in training and capacity building? Please visit our annual SATuRN workshop webpage:</p>\n<p><a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\">7th South African HIV & TB Drug Resistance and Treatment Monitoring Workshop, Cape Town International Conference Centre, 28 to 29 November 2012, Cape Town, South Africa.</a></p>', 'Justen Manasa, Tulio de Oliveira', 'imgBlog14.gif', NULL, 'ACiLT Practical Course on Quality Assurance of HIV-1 Drug Resistance Interpretation in Sequence Editing and Data Management Process, 7-11 May 2012', '2012-06-01', 'imgBlog14sm.gif', 'Course. Quality, Assurance, HIV-1, Drug, Resistance, Interpretation, Sequence, Editing, Data, Management Process, May 2012', 'Practical Course on Quality Assurance of HIV-1 Drug Resistance Interpretation in Sequence Editing and Data Management Process, 7-11 May 2012, Johannesburg, South Africa', NULL, NULL, NULL),
(15, NULL, '<p>\'Zwelethu had posed a question to me, to which I suspected he was still trying to find the answer, himself. What is the one thing that we could photograph that represents health?\'</p>', '<p>We were driving down the dusty roads of rural Somkhele, just after taking pictures of a flamboyant tree and an enthusiastic sangoma (traditional healer) who had let us into her sacred, traditional, ancestral hut made of reed straw, which is reserved for the sick and those in need of answers and divine intervention. Zwelethu had posed a question to me; I suspected he was still trying to find the answer himself. <b><i>\'What is the one thing that we could photograph that represents health?\'</b></i> We played around with a few ideas, such as a jumping child, a clinic, a gym - we even mentioned a sports field.</p>\n\n<p>It was not until after I had exhausted all my ideas that I realized that there is more to a picture than a memory in time. With a picture, one can tell a story and stir emotions of love, joy, peace and happiness or inspire feelings of hate, sadness, bitterness and sorrow. I was born and grew up in this community that I now work for, but never before have I seen it as vividly as I have over the past two weeks. During this time, I have led the photographer Zwelethu Mthethwa in an extensive exploration of the region. He has taken photos of joy in poverty, life in sickness and hope in sorrow, and I have documented this journey with pen and camera. It has been an eye-opening experience and I have come to realise that in a community such as this one, the subject of health is a complex one. There is often a divide between Western and traditional medicine: two frequently conflicting views that share the same objective of health.</p>\n<p><img src=\"imagesBIO/blogASZwelethu2.jpg\"></p>\n<p>I have come to realize that in this rural community, the subject of health is complex. It is a multilayered issue that cannot be understood without a good knowledge of the cultural, economic, political and geographic context. Perhaps that is why we will need to explore this topic through a series of images captured in a book or in a photographic exhibition about the residency.</p>\n<p>Images: Zwelethu Mthethwa with the local sangoma (traditional healer), L T Mncwango</p>\n<p><a href=\"http://www.wellcomecollection.org/whats-on/art-in-global-health/zwelethu-mthethwa/first-impressions/capturing-health-in-one-photo.aspx\">Blog published at the Wellcome Trust Art in Global Health website under title: Capturing Health in one Photo: a personal reflection</a></p>', 'Lungani Ndwandwe and Astrid Treffry-Goatley', 'blogASZwelethu1.jpg', NULL, 'Capturing Health in one Photo: a personal reflection', '2012-08-14', 'blogASZwelethu1sm.png', 'Capturing, Health, one, Photo, personal, reflection, astrid treffry-goatley, Lungani Ndwandwe, bioafrica, art & science, wellcome trust, blog, africa centre, KZN, sangoma', 'We were driving down the dusty roads of rural Somkhele, just after taking pictures of a flamboyant tree and an enthusiastic sangoma (traditional healer) who had let us into her sacred, traditional, ancestral hut made of reed straw, which is reserved for the sick and those in need of answers and divine intervention. Zwelethu Mtwenthwa had posed a question to me; I suspected he was still trying to find the answer himself. Blog, africa centre, KwaZulu-Natal, South Africa', NULL, NULL, NULL),
(16, NULL, '<p>As a summary of my activities during the meeting, I was able to attend several interesting sessions regarding mother to child transmission, viral latency and of course the viral resistance and an excellent talk on HIV/TB co-infection.  Below are a few of the highlights of my experience at AIDS2012.</p>', '<p>In the first plenary of the meeting, Anthony Fauci announced that the scientific knowledge now exists for us to envisage an HIV-free generation for the first time in the 3 decades since HIV was first described.  Breakthroughs in the field have been incremental over the years and include knowledge of the pathogenic mechanisms of HIV, understanding the early events following infection particularly at the mucosal surfaces, understanding the replication cycle and targets for interventions during this cycle. A key factor is not that we do not have the knowledge but that we implement what we know appropriately.  This theme was reiterated throughout the meeting.  Given the global economic downturn, several key speakers pointed out the need for resource-poor countries to reduce their complete dependency on funders, seek alternative and innovative funding strategies and ensure the sustainability of existing and future treatment and management programs.</p>\n<p>Of interest to the social scientists at the centre would have been a talk by Phil Wilson, an HIV positive gay man who highlighted the worrying epidemic among Black women in the US where approximately 44% of their epidemic is concentrated in only 12 states with the highest rates in the DC area.  His talk proposed that in order to end the epidemic biomedical as well as behavioral interventions must be fully integrated.  I also met the co-founder of the LIVE Consortium a US group that targets high risk groups including college and high school students for their education and behavioral interventions particularly in the Black communities.  The knowledge of HIV he maintains is sorely lacking and there remains significant stigma attached to the disease which I found surprising considering the US\'s first world status and their interventions in other countries of the world.</p>\n<p>It was a great privilege to hear the dynamic and eloquent US Secretary of State Hillary Clinton speak.  Her announcement of additional funding for HIV/AIDS research and interventions was welcomed.  The message that a multi-factorial approach is essential to eradicate the epidemic appears to have reached the funders as the US now pledged funds to address VTC, TasP, voluntary male circumcision, pMTCT.</p>\n<p>Anthony Harries gave an account of HIV/TB co-infection in his plenary and highlighted implementation of integrated HIV/TB programs that include the Isoniazid preventative treatment (IPT) and the Test and Treat strategies to reduce the HIV/TB burden worldwide.  He emphasised that in high-burden countries such as ours, parallel ART and TB treatment programs are wholly inadequate to disease prevention or management.  Instead, an integrated program aligned to social, behavioural and educational strategies nested within strong management programs would certainly stem the growing HIV/TB co-infection epidemic. </p>\n<p>Overall, there was much excitement regarding the amended WHO pMTCT guidelines to include Option B+ but a few voices of reason cautioned that implementation without proper research and infrastructure in place is a recipe for disaster.  After listening to the various arguments for and against the large-scale roll-out of Option B+, I wonder if we should perhaps amend the last statement in our Breast Milk paper to suggest B+ only if it is supported by the appropriate infrastructure, management programme and community support.  I had the pleasure of chatting with Prof Jerry Coovadia regarding the current and revised WHO pMTCT guidelines.  He found it of great concern that the B+ strategy was proposed without an investigation of the short and long term outcomes in women initiated on ART according to the B+ criteria and was eager to pursue a study, with Africa Centre, on the impact of Option B+ on pMTCT success.</p>\n<p>My poster was also well received with several useful comments and suggestions on future work.  I think it may be of interest to expand the current study of post-natal transmitters to include a study of the viral evolution in peri-natal transmitters to determine whether the timing of the introduction into the breast compartment, among other factors, may account for the timing of transmission (peri, versus- post natal) to the infant.  Interestingly, one of the basic scientists to visit my poster was Dr S. Tugizov from UCSF who has a similar interest in MTCT but his focus is the gut mucosa. </p>\n<p>Also interesting was the new findings regarding HIV, aging and congenital disease.  Again, the Africa Centre was mentioned in this talk.  In a growing number of countries, HIV is being managed as a chronic illness with related chronic disorders such as heart disease, osteoporosis and neurological disorders.  Evidence of accelerated aging in HIV positive patients was also presented. </p>\n', 'Siva Danaviah', 'imgBlog16.jpg', NULL, 'AIDS XIX 2012 conference: impressions of a South African researcher', '2012-09-12', 'imgBlog16sm.jpg', 'AIDS, 2012, conference, blog, Siva Danaviah, perspective, south Africa, scientist, researcher, presenter, pmtct, drug resistance, HIV, TB\n', 'As a summary of my activities during the meeting, I was able to attend several interesting sessions regarding mother to child transmission, viral latency and of course the viral resistance and an excellent talk on HIV/TB co-infection.  Below are a few of the highlights of my experience at AIDS2012', NULL, NULL, NULL),
(17, NULL, '<p>We turned our lenses to focus on home-based health care givers in rural South Africa this month of July 2012. As part of the Art in Science project by the Wellcome Trust, we felt that in order to capture a comprehensive picture of health, home based care could not be ignored. </p>', '<p>This very important level of health care service is much similar to that of a hospital and other institutional health care settings; however it presents an opportunity for treatment of patients where human resource constraints and inadequate hospital/health facilities exist. Home-based health care working environment is less controllable or predictable, and in most cases less standardized. It again becomes more complicated in rural settings with poor communities. Even though home-based care givers often work under these unfavorable conditions, they have since strived and compassionately offered their services despite.</p>\n<p>Zwelethu Mthethwa, an artist in residence and photographer working with the Africa Centre and I were invited by two home-based care givers in order to see them in action and hopefully snap a few photographs. One thing that one readily picked up on the day of the visit, of which is one of the benefits of home-based care is that the sick are surrounded by people they love and are familiar with, which makes the level of care flexible and at times stretched.  Patients in this type of care are often very sick and in this rural setting suffer from financial constraints. In this visit we met a woman who had been bedbound for a year; she was paralyzed after a complicated child birth procedure. She cannot move or take care of herself and relies heavily on the assistance from caregivers and family members. Fortunately her now one year old baby boy survived the procedure. Her biggest worry is that she cannot hold, feed, and take care of her baby as his mother. As mentioned above financial constraints have impacted negatively on the situation; the patient has to regularly go to the clinic to take bloods and this often requires her to hire transport to get to the clinic. As there are limited resources at the local clinic, the clinic can offer ambulance transport only in life threatening emergencies. This is one of many examples home-based care givers find themselves in, and on a day to day basis they see 2 to 3 patients with similar cases. </p>\n<p>Zooming out and looking at a bigger picture of the entire health system in South Africa, particularly in rural communities a lot has been achieved by the National Department of Health (NDoH) in training and employing home-based care givers. The NDoH is looking into installing a primary health home-based outreach team of volunteers in rural communities. This team of volunteers who will be accompanied by a trained nurse will visit patient\'s homes and take bloods where necessary. This great initiative will see to it that patients who cannot get to the clinic because of reasons relating to the shortage of money and being bedbound receive good, supervised treatment from the comfort of their beds.</p>\n<p>We would like to thank Dr. Kevi Naidu and Sister Dana Chirwa from the Africa Centre\'s ART program for making provisions for the above mentioned patient to be seen by a nurse and also for making provisions for her to take bloods. At the time of writing this article, she was able to go to the Home Affairs department and apply for a disability grant.</p>\n', 'Lungani Ndwandwe, Tulio de Oliveira', 'imgBlog17.jpg', NULL, 'Zooming in on home-based health care givers in rural South Africa', '2012-09-13', 'imgBlog17sm.jpg', 'home-based, health care givers, rural, South Africa, Art in Science, wellcome trust, photo, Lungani,  Zwelethu Mthethwa, Africa centre ', 'We turned our lenses to focus on home-based health care givers in rural South Africa this month of July 2012. As part of the Art in Science project by the Wellcome Trust, we felt that in order to capture a comprehensive picture of health, home based care could not be ignored', NULL, NULL, NULL),
(18, NULL, '<p>Graduating from the University of Southampton, I completed my medical internship in the UK and spent a year practicing rural medicine in New Zealand, before joining the MSc program in tropical medicine and international health at the London School of Hygiene and Tropical Medicine. Following my interest in multi-drug resistant tuberculosis, I was put in touch with Dr Richard Lessells at the Africa Centre but on arriving in Mtubatuba, was instantly inspired by the SATuRN group\'s groundbreaking work on HIV drug resistance, prompting me to focus my MSc thesis on this area.</p>', '<p>My thesis focused on patients presenting with virological treatment failure to first line ART; an increasing problem seen in the shadow of the huge scale-up of treatment for HIV. I was interested to see an increasing minority of patients who were failing treatment but who did not harbor any drug resistance (the wild type group).</p>\n<p> Using the detailed information collected within the failure clinics, I investigated whether any particular factors were associated with this group of patients. Baseline CD4 count, being female, having poor adherence to the HIV programme and remaining on the baseline ART regimen were shown to be predictors of this wild type group. These predictors could be utilised by the local ART programme to identify patients who may benefit from targeted resistance testing to direct their subsequent treatment.</p>\r\r<p>Coming to the Africa Centre was a great experience. Nestled in the hills off the main highway, its structure and ideals stand out boldly but yet sit comfortably with its local environs. Dr Tulio de Oliveira and his team were fantastically helpful. Joining Dr Lessells in the clinic gave real context to the data being collected.</p>\n<p> As a \'junior scientist\', I lived with some of the other MSc/PhD students at the Ilala guesthouse, where I was inspired by the exciting work and experiences of my fellow students. When things were going badly, there was always a helping hand with the STATA programming! Outside of work, I was able to visit the Imfolozi/Hluhluwe and St Lucia national parks, where I was able to see a lion, a giraffe and a zebra crossing the road! I learnt the art of \'Braai\' and developed my cheerleading skills at a local rugby game!</p>\r\n<p><center><img src=\"imagesBIO/imgBlog18img2.jpg\"></center></p>\r<p>I have now returned to clinical training in emergency medicine but look forward to keeping in touch with the SATuRN group and hearing more about the fantastic work being produced. I would certainly recommend any budding clinical MSc/ PhD student with an interest in this area to get in touch. </p>\r\r<p>A final thanks to Dr Richard Lessells, Dr Tulio De Oliveira, and all the staff and researchers at the Africa Centre for Health & Population Studies.</p>\r', 'Dr. Baljinder Singh', 'imgBlog18.jpg', NULL, 'It\'s all about the process - A doctor and LSHTM MSc student experiences at Africa Centre/SATuRN', '2012-10-01', 'imgBlog18sm.jpg', 'LSHTM, london School of Hygiene and Tropiocal Medicine, MSC, project, drug resistance, HIV, Africa, Bal Singh, Tulio de Oliveira, Richard Lessells, SATuRN, treatment resistance network, wildtype, adherence, stata', 'It\'s all about the process - A doctor and London School of Hygiene and Tropical Medicine (LSHTM) MSc student experiences at Africa Centre and the Southern African Treatment Resistance Network (SATuRN)', NULL, NULL, NULL),
(19, NULL, '<p>This blog covers one of the recent activities by SATuRN in the month of November 2012. As a growing network, SATuRN\'s work and research is widely being recognized not only by governments but by also recognized and reputable institutions in the health and economics sector. In the month of November SATuRN was invited to be among the three of the top research organizations show casing KZN research on HIV and AIDS and organizations that have contributed remarkably to health research in the Southern African region.</p>', '<p>The Africa Centre for Health and Population studies\' resistance team attended this event and was representing SATuRN. The event was held at the famous KZNSA Gallery in Durban. This event was titled <b><i>Getting to Zero: New HIV infections, discrimination, and AIDS related Deaths</b></i>.  Among the invited organizations at the event were the Health Economics And HIV/AIDS Research Division (HEARD), CAPRISA, Africa Centre/SATuRN, and the University of KwaZulu Natal Press. </p>\n<p>Each organization showcased its latest research activity or their area of focus. To give a brief outline, CAPRISA showcased its CAP 004 tenofovir gel study which showed that microbicides could provide women with some protection from HIV infection. HEARD showed a documentary titled Manguzi: Raising children in Rural South Africa, the film provides a personal account of the challenges faced by care givers of children in HIV-endemic communities in South Africa. Africa Centre/SATuRN highlighted their DNA sequencing and art and science projects including the use of DNA to solve HIV transmission cases and to determine ARV resistance levels, the system was explained by Dr Katherine Stott, who said that this sophisticated system for analyzing DNA, was used for patient management at a primary rural health clinic.</p>\n<p>One of the strong positive messages from the event was to promote collaboration. It became apparent from most of the talks/points that were put forward that neither one person nor a single organization would have the required strength to fight the epidemic and that is why collaboration was a necessity. Adding to this Dr Katherine Stott from the Africa Centre said, <b><i>\'One of the strengths of SATuRN has been drawn from collaborating with other institutions and individuals, and that has lead to the remarkable research outputs produced over the years\'</b></i>.</p>\n<p>The essence of the event and the exhibitions was to showcase what different NGOs in health research are currently doing in the continuous effort of Getting to Zero, especially in this Southern African part of the continent where the HIV endemic is ripe. The event precedes world aids day and such an event also highlights that the fight against HIV is still raging on, and that hope still exists.</p>\n', 'Lungani Ndwandwe, Tulio de Oliveira', 'imgKZNSA.png', NULL, 'The Southern African Treatment Resistance Network (SATuRN) at the KZNSA Gallery', '2012-12-01', 'imgKZNSAsm.png', 'SATuRN, art, science, gallery, exhibition, AIDS day, 2012, DNA sequencing, NSA, Durban, KZNSA, national art gallery, south africa, treatment, HIV, resistance, SATuRN, art, science, gallery, exhibition, AIDS day, 2012, DNA sequencing, NSA, Durban, KZNSA, national art gallery, south africa, treatment, HIV, resistance, SATuRN, art, science, gallery, exhibition, AIDS day, 2012, DNA sequencing, NSA, Durban, KZNSA, national art gallery, south africa, treatment, HIV, resistance', 'This blog covers one of the recent activities by SATuRN in the month of November 2012. As a growing network, SATuRN?s work and research is widely being recognized not only by governments but by also recognized and reputable institutions in the health and economics sector. In the month of November SATuRN was invited to be among the three of the top research organizations show casing KZN research on HIV and AIDS and organizations that have contributed remarkably to health research in the Southern African region. ', NULL, NULL, NULL),
(20, NULL, '<p>This is a very sad blog, which cover the recent suicide of Aaron Swartz. Aaron was a very bright 24-year-old Internet freedom activist that has developed some of the most popular collaborative websites (i.e. RSS and REDDITT).  </p>', '<p>His developments had the intention of increasing collaboration of the scientific community in order to create open access knowledge. Unfortunately, he committed suicide on 11 of January of 2013. At the time of his death, Aron Swartz was facing hacking chargers due to downloading, with intent to distribute, academic manuscripts from a subscription fee archive from the Michigan Institute of Technology (MIT), where he studied. </p>\n<p>BioAfrica and SATuRN deeply condemn the court case and criminal charges against Mr. Aaron Swartz. Furthermore, BioAfrica and SATuRN support the production of public data and publication of open access manuscripts. In our case, open access and free knowledge can save lives in developing nations. </p>\n<p>In order to stand by Mr. Aaron Swartz cause, we have spent the last couple of days re-coding our web-publication section of the bioafrica.net website. This was done with the intent to increase the distribution of our manuscripts and public datasets. We are also producing PowerPoint slides presentations from all of our publications and linking all of the media coverage in order to better communicate with the scientific and non-scientific community.</p>\n<p>More than ever, we need to come together and implement the OPEN ACCESS initiative! Long live Aaron Swartz ideology and efforts! We will keep flying your flag and working for a world where knowledge is open!</p>\n<p>Our publication section contains more public data, open access manuscripts, news coverage and presentations! All open accessible at <a href=\"http://www.bioafrica.net/publications.php\">http://www.bioafrica.net/publications.php</a></p>', 'Tulio de Oliveira', 'imgBlog20.png', NULL, 'Internet Freedom Activist Commit Suicide due to Criminal Charges for Distributing Academic Publications. We Increase the Open Distribution of our Publications!', '2013-01-15', 'imgBlog20sm.png', 'SATuRN, bioafrica, open access, publications, Aaron Swartz, suicide, open movement, internet freedom, tulio de oliveira,SATuRN, bioafrica, open access, publications, Aaron Swartz, suicide, open movement, internet freedom, tulio de oliveira,SATuRN, bioafrica, open access, publications, Aaron Swartz, suicide, open movement, internet freedom, tulio de oliveira', 'Internet Freedom Activist Commit Suicide due to Criminal Charges for Distributing Academic Publications ? BioAfrica/SATuRN Increase the Distribution of Open Access Manuscripts and Public Datasets! This is a very sad blog, which cover the recent suicide of Aaron Swartz. Aaron was a very bright 24-year-old Internet freedom activist that has developed some of the most popular collaborative websites (i.e. RSS and REDDITT)', NULL, NULL, NULL),
(21, NULL, '<p>A phase IIb trial using the MVA85A vaccine as a boost to BCG vaccination demonstrates acceptable safety but fails to show any protective effect against TB infection or disease in HIV-uninfected children </p>', '<p>There have been mixed responses to the results of a TB vaccine trial recently published in The Lancet. Understandably there was disappointment that the vaccine strategy explored in the trial failed to show any protective effect. However, there was also optimism not only about the lessons that could be learnt from the trial results but also around the fact that a large-scale vaccine trial had been conducted effectively in South Africa, at the epicentre of the global TB epidemic. </p>\n<p>The need for a new TB vaccine in high-burden settings is obvious and has been re-emphasised by this trial, demonstrating a substantial force of infection where one in eight of the young children in the study was infected with TB over the two years of follow-up. The vaccine under investigation in this trial was the MVA85A vaccine, which incorporates a highly attenuated strain of Vaccinia virus expressing the M. tuberculosis antigen 85A. Phase I studies had demonstrated that the vaccine induced high levels of antigen-specific IFN-gamma-secreting T cells in adults and infants. </p>\n<p>This phase IIb trial recruited healthy HIV-uninfected infants (4-6 months old) previously vaccinated with BCG and without evidence of TB infection (QuantiFERON-TB Gold In-Tube negative) from a rural community in the Western Cape. A total of 2797 infants were randomised to receive either the MVA85A vaccine or placebo and were then followed up for an average of two years. In terms of safety, there were no serious adverse events that were considered vaccine-related but local adverse events at the injection site were reported for almost all vaccine recipients (although there is quite limited information about these in the paper). It was demonstrated that vaccine induced an antigen-specific CD4+ T-lymphocyte response but this was less marked than that reported for adults. </p>\n<p>Using TB disease as an endpoint in vaccine studies is complicated by the difficulties faced in accurately diagnosing active TB disease in young children (perhaps highlighted by the fact that 13% of the children across both arms were placed on treatment for active TB disease during the course of the study). The researchers here used carefully-constructed definitions for TB disease as the primary efficacy endpoint. During follow-up, 32/1399 (2.3%) in the vaccine group and 39/1395 (2.8%) in the placebo group developed TB disease, providing no evidence of a difference between vaccine and placebo. The secondary efficacy outcome of TB infection (based on QuantiFERON-TB Gold In-Tube conversion) was reached in 178/1399 (12.7%) of vaccine recipients and 171/1395 (12.3%) in the placebo group, providing no evidence of protection from TB infection. </p>\n<p>There is discussion, both in the article itself and in the accompanying editorial, about why the vaccine may not have shown any protective efficacy. There is likely to be much additional work with the data and the samples collected for this study to give further insight into the lack of efficacy and to inform future studies. The vaccine has shown immunogenicity in HIV-infected adults and the efficacy for the prevention of TB disease is currently being investigated in another phase II trial with HIV-infected adults in South Africa and Senegal. Only time will tell whether or not these studies take us closer to the holy grail of a more effective TB vaccine.</p>\n<p></p>\n<p></p>\n<p><b><i>Sources</b></i></p>\n<p>Results of a TB vaccine trial - <a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60177-4/abstract\">Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H and the MVA85A 020 Trial Study Team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013 Feb 4 </a></p>\n<p>Editorial - <a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)60137-3/fulltext\">Dye C, Fine PEM. A major event for new tuberculosis vaccines. Lancet 2013 Feb 4 </a></p>\n<p>Immunogenicity paper - <a href=\"http://ajrccm.atsjournals.org/content/185/7/769\">Scriba TJ, Tameris M, Smit E, van der Merwe L, Hughes EJ, Kadira B, et al. A phase IIa trial of the new TB Vaccine, MVA85A, in HIV and/or M. tuberculosis infected adults. Am J Respir Crit Care Med 2012; 185: 769-778 </a></p>\n<p>Phase II trial information - <a href=\"http://www.clinicaltrials.gov/ct2/show/NCT01151189?term=MVA85A&rank=2\">ClinicalTrials.gov. Protective efficacy against tuberculosis (TB) disease, safety, and immunogenicity of MVA85A/AERAS-485 in HIV-infected adults. NCT01151189 </a></p>', 'Richard Lessells', 'imgBlog21.png', NULL, 'The search for a new TB vaccine - a step forward or backward?', '2013-02-21', 'imgBlog21sm.png', 'vaccine, TB, lancet, MVA85A, boost, BCG, vaccination, fails, protective, TB infection, disease, HIV-uninfected, children, vaccine, TB, lancet, MVA85A, boost, BCG, vaccination, fails, protective, TB infection, disease, HIV-uninfected, children, vaccine, TB, lancet, MVA85A, boost, BCG, vaccination, fails, protective, TB infection, disease, HIV-uninfected, children  ', 'A phase IIb trial using the MVA85A vaccine as a boost to BCG vaccination demonstrates acceptable safety but fails to show any protective effect against TB infection or disease in HIV-uninfected children ', NULL, NULL, NULL);
INSERT INTO `b_blogs` (`id`, `email`, `summary`, `summary2`, `authors`, `photo2`, `bioafricaSATuRN`, `title`, `date`, `image`, `keywords`, `topdescription`, `video`, `pubid`, `imagefront`) VALUES
(22, NULL, '<p>Researchers find evidence that virtually untreatable strains of tuberculosis have become established and are circulating in the Eastern Cape Province of South Africa. This may also help to explain the poor outcomes of XDR-TB treatment; highlighted in a separate report from KwaZulu-Natal where only one in five adult cases had a successful treatment outcome.</p>\n', '<p>When reports of <b><i>\'totally drug-resistant\'</b></i> tuberculosis from India hit the news about a year ago (<a href=\"http://www.bioafrica.net/blogs.php?id=2\">see blog</a>), there was acknowledgement that similarly-resistant Mycobacterium tuberculosis strains had probably become established elsewhere. This was particularly so in South Africa, where efforts to control multidrug-resistant TB (MDR) and extensively drug-resistant TB (XDR-TB) have been characterised by poor treatment outcomes. Now researchers from Stellenbosch University have used molecular techniques to provide strong evidence not only that such strains can been detected in the Eastern Cape Province but also that transmission of these strains has been occurring.</p>\n<p>The study by Marisa Klopper and colleagues, published in Emerging Infectious Diseases, reports analysis of 651 M. tuberculosis strains isolated from sputum cultures between July 2008 and July 2009 at the main provincial TB laboratory. Of the 342 strains that were resistant to rifampicin and isoniazid (MDR-TB) on routine testing, molecular analysis showed that 60% had pre-XDR-TB or XDR-TB (i.e. mutations conferring resistance to either or both a second-line injectable and fluoroquinolone). Increasing drug resistance was associated with one particular genotype of M. tuberculosis (atypical Beijing strain). Moreover, molecular analysis showed that the pre-XDR-TB and XDR-TB isolates were genetically very closely related, providing reasonable evidence that there had been transmission of these resistant strains (and that they had not all emerged independently in people exposed to second-line drugs). It was noteworthy that these strains were found in several districts within the province, rather than being clustered in one geographic area. The study was purely a laboratory-based study and there was no linkage to individual clinical information which to some extent limits interpretation of the data.</p>\n<p>Of the 103 atypical Beijing XDR-TB strains, the vast majority (95%) had evidence on genotypic testing of resistance to all the drugs tested: isoniazid (katG and inhA gene), rifampicin (rpoB), ethambutol (embB), pyrazinamide (pncA), streptomycin (rrs500), amikacin (rrs1400), kanamycin (rrs1400), capreomycin (rrs1400), ethionamide (inhA) and ofloxacin (gyrA). It should be noted, however, that there was poor correlation between the presence of genetic mutations and phenotypic drug susceptibility for ethambutol, ethionamide and capreomycin. Only a sub-sample was tested for susceptibility to p-aminosalicylic acid (PAS) using phenotypic methods and, of those, 20% were defined as resistant. No genotypic or phenotypic test was performed for cycloserine/terizidone. </p>\n<p>In a separate study from KwaZulu-Natal, also published in Emerging Infectious Diseases, Max O\'Donnell and colleagues present outcomes for 114 adults treated for XDR-TB at the provincial drug-resistant TB referral hospital in KwaZulu-Natal. All cases started treatment between December 2006 and October 2007 and outcomes were ascertained from routine hospital records. Most were treated with a standardised regimen consisting of capreomycin, pyrazinamide, PAS, ethionamide, ethambutol and cycloserine or terizidone. There was no laboratory data regarding drug susceptibility over and above the routine diagnostic tests used to identify the XDR-TB. Only around one in five cases (22%) had a successful outcome (cure or completion) - 42% died, 17% defaulted and 19% failed treatment. Of the 42 cases with culture conversion during treatment, one in six showed culture reversion, suggesting the emergence of additional resistance during treatment. </p>\n<p>The data provided in these two papers highlight the challenges faced in the response to drug-resistant TB in South Africa. Improved diagnostic and therapeutic strategies are urgently needed to address this problem. There is now a substantial body of evidence demonstrating poor outcomes with standardised drug regimens for MDR- and XDR-TB. The development of molecular tests that can detect the genetic mutations associated with resistance to second-line drugs offers the opportunity for more rapid detection of specific resistance patterns and might allow individually tailored regimens, but whether or not this leads to better outcomes need to be explored in rigorous studies. Collection and curation of genetic data might allow identification of individual marker mutations that are associated with particular patterns of drug resistance - this was seen with the Eastern Cape isolates (and previous research by the same group) where the presence of mutations in the inhA promoter region was associated with pre-XDR- and XDR-TB. Even with advances in diagnostics, however, there is a pressing need for new anti-TB drugs and regimens to offer a realistic hope of improved outcomes. Whilst there are new drugs undergoing clinical trials, the global TB community is pushing for accelerated evaluation and approval. These results from South Africa show us exactly why people cannot wait. </p>\n<p></p>\n<p><b><i>Sources</b></i></p>\n<p><a href=\"http://wwwnc.cdc.gov/eid/article/19/3/12-0246_article.htm\">Klopper M, Warren RM, Hayes C, van Pittius CG, Streicher EM, Muller B, Sirgel FA, Chabula-Nxiweni M, Hoosain E, Coetzee G, van Helden PD, Victor TC, Trollip AP. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis 2013 Mar </a>  </p>\n<p><a href=\"http://wwwnc.cdc.gov/eid/article/19/3/12-0998_article.htm\">O\'Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis 2013 Mar </a></p>', 'Richard Lessells', 'imgBlog22.png', NULL, 'Extensively drug-resistant tuberculosis in South Africa: are we now dealing with untreatable strains?', '2013-02-22', 'imgBlog22sm.png', 'xdr, tb, south africa, untreatable, lessells, blog, bioafria, extensive, drug, resistance, tuberculosis, xdr, tb, south africa, untreatable, lessells, blog, bioafria, extensive, drug, resistance, tuberculosis, xdr, tb, south africa, untreatable, lessells, blog, bioafria, extensive, drug, resistance, tuberculosis', 'Bioafrica blog - Researchers find evidence that virtually untreatable strains of tuberculosis have become established and are circulating in the Eastern Cape Province of South Africa. This may also help to explain the poor outcomes of XDR-TB treatment; highlighted in a separate report from KwaZulu-Natal where only one in five adult cases had a successful treatment outcome.', NULL, NULL, NULL),
(23, NULL, '<p>The SATuRN team had a once in a life time opportunity to sit on the chair of African Dreams and send their messages about their hope and dreams for a better future for Africa. This remarkable chair that goes around the world and that is truly a work of art, with special craftsmanship, contributed by more than 150 crafters.</p>', '<p><i>From Left: standing: Lungani Ndwandwe, Justen Manasa, Tulio de Oliveira, seating: Xolile Kineri and Zakhona Gumede. Photography by Astrid Treffry-Goatley.</i></p><p>One cannot help but sense an overwhelming feeling of positive energy and an inspiration feeling as one encounters this chair with its history and the stories/messages it bears with it.  The chair itself has won numerous awards for its creative and artistic design and has been coined as one of the most beautiful objects in South Africa. Again notable names have sat on the chair such as, Former Arch Bishop Desmond Tutu, singer and song writer Johnny Clegg, American civil rights activist Rev Jesse Jackson, to name just a few, making it one of the most famous chair if not inspiring chair in the world. Perhaps what makes this chair priceless is the history of how it came about and the people who contributed to the idea of making the chair. </p>\n<p>The chair of African Dreams was made by the Woza Moya Community Centre, a community Centre treating and caring for people living with HIV and AIDS. The idea for the chair came about after a body mapping workshop exercise where most of the patients and crafters showed a common trend in outline of their sad life stories <b><i>\'it was as if everyone in the group had stopped dreaming\'</b></i> says Thomson, the crafters co-coordinator. From this they decided to create something that would make people dream again and to encourage powerful and positive thoughts about their future, the future of the country and the African continent. </p>\n<p>The opportunity to sit on the chair couldn\'t have come at a better time, as SATuRN launched its HIV and TB Drug Resistance and Clinical Management Case Book, an open source book aimed at managing HIV and TB resistance cases and at building capacity to health workers working in health facilities managing patients on ART and TB therapy. This book comes at a perfect time, as there has been a significant response from the National Department of Health to the sounding call from research institutions and research networks such as SATuRN to the looming threat of HIV drug resistance. </p>\n<p>This significant SATuRN milestone resonates with it a sense of hope; hope that the worst can still be avoided. As Thomson says <b><i>\'the chair connects people to HIV in a non-threatening way\'</b></i>; this gave the SATuRN team a chance to sit on this magnificent chair, reflect and voice their messages of hope for Africa and what they would like to contribute towards the progress of the continent through their work with SATuRN.</p>\n<p>You can watch these short videos and follow us on our <a href=\"http://www.youtube.com/user/bioafricaSATURN\">new BioAfrica/SATuRN YouTube Channel here: (http://www.youtube.com/user/bioafricaSATURN)</a>.</p>', 'Lungani Ndwandwe, Justen Manasa, Xolile Kineri, Zakhona Gumede, Astrid Treffry-Goatley, Eduan Wilkinson, Tulio de Oliveira', 'imgBlog23.png', NULL, 'SATuRN on the Chair of African Dreams', '2013-04-06', 'imgBlog23sm.png', 'african, dream, chair, chair of Africa Dreams, SATuRN, HIV, TB, drug resistance, Lungani, de Oliveira, Tulio, blog, bioafrica, youtube, video, hope, african, dream, chair, chair of Africa Dreams, SATuRN, HIV, TB, drug resistance, Lungani, de Oliveira, Tulio, blog, bioafrica, youtube, video,african, dream, chair, chair of Africa Dreams, SATuRN, HIV, TB, drug resistance, Lungani, de Oliveira, Tulio, blog, bioafrica, youtube, video, hope', 'The SATuRN team had a once in a life time opportunity to sit on the chair of African Dreams and send their messages about their hope and dreams for a better future for Africa. This significant SATuRN milestone resonates with it a sense of hope; hope that widespread HIV and TB drug resistance can still be avoided.', NULL, NULL, NULL),
(24, NULL, '<p>A recent late breaker at CROI 2013 by D Persaud and colleagues documented a case where early ART may have prevented the establishment of a latent reservoir in an HIV-infected child and achieved a functional cure. A functional cure is different from a complete cure in that while the virus is not eliminated, it is kept under control in the absence of therapy and does not impact on patient well-being.</p>', '<p>In this case, the mother was diagnosed with HIV in labour. At the time, her viral load was very low (2423 copies/ml) and CD4 count was high (644 cells/ml), suggesting a low viral inoculum to the baby. The child was initiated on an AZT/3TC/NVP (NVP at full dose, without the 2 week \'lead-in\') regimen on second day of life following 2 separate positive HIV DNA and RNA tests (VL 19,812copies/ml). Three additional viral loads at day 7, 12 and 20 were positive. LPV/r was substituted for NVP from day 7 until discontinuation of therapy by the caregiver at 18 months. When the infant returned to care 8 months later, the HIV RNA was undetectable and remained so (<20 copies/ml) on 16 different measurements between 1 - 26 months despite discontinuation of treatment, and CD4% levels remained normal throughout. Using standard clinical assays, plasma viral load, PBMC DNA, and HIV-specific antibodies remained undetected following return to care. Using ultrasensitive methods, a single copy of HIV RNA was detected in plasma and 37 copies HIV DNA/million peripheral blood mononuclear cells (PBMC) were detected at age 24 months. At age 26 months HIV DNA was detected at 4 copies/million PBMC but with no 2-LTR circles. Follow-up of the child will continue to see if virus is once again detected in the child\'s blood. </p>\n<p>Similar reports of functional cures have been reported following cessation of therapy in adults identified shortly after infection. Whilst these cases provide exciting insights into mechanisms of viral control, they remain isolated incidents and should not be regarded as the norm. At this stage, early initiation of ART should not be a reason to discontinue ART without expert consultation and outside of a structured trial. It is essential that pregnant women receive appropriate ART for pMTCT.</p>\n<p>Further investigations and studies are critical to establish if aggressive and early treatment with ART may hold the key to functional cure (Saez-Cirion et al, PLoS Pathog 9(3): e1003211) and whether this can be translated into a treatment strategy. The case of the Mississippi baby, however, makes a compelling case for undertaking a diagnostic PCR in babies on day one of life or as soon as possible where pMTCT has been sub-optimal or non-existent, as in utero transmission (which is linked to rapid disease progression and death in young infants) is possible (Lillian et al, J Clin Microbiol 2012; 50: 2373-7). Here, early ART may be crucial.</p>\n<p><b>Further information:</b><p>\n<p>Later Breaker at CROI 2013 by D Persaud: <a href=\"http://www.retroconference.org/2013b/Abstracts/47897.htm\">http://www.retroconference.org/2013b/Abstracts/47897.htm</a></p>\n<p>Further reading: <a href=\"http://www.iavireport.org/Pages/default.aspx\">http://www.iavireport.org/Pages/default.aspx</a></p>\n<p>Similar reports in adults: <a href=\"http://www.nhs.uk/news/2013/03March/Pages/Early-treatment-may-hold-key-to-HIV-functional-cure.aspx\">http://www.nhs.uk/news/2013/03March/Pages/Early-treatment-may-hold-key-to-HIV-functional-cure.aspx</a></p>\n<p><b>Authors:</b> Dr Gillian Hunt and Dr Nono Mkhize, Centre for HIV and STI, NICD and Prof Mark Cotton, Department of Paediatrics and Child Health, Stellenbosch University.</p>', 'Gillian Hunt, Nono Mkhize, Mark Cotton', 'imgBlog24.png', NULL, 'The Mississippi baby? questions on a \'functional\' cure', '2013-04-10', 'imgBlog24sm.png', 'baby, functional, cure, gillian hunt, mark coton, ARVs, viral load, hiv, CROI, 2013, baby, functional, cure, gillian hunt, mark coton, ARVs, viral load, hiv, CROI, 2013, baby, functional, cure, gillian hunt, mark coton, ARVs, viral load, hiv, CROI, 2013, baby, functional, cure, gillian hunt, mark coton, ARVs, viral load, hiv, CROI, 2013', 'A recent late breaker at CROI 2013 by D Persaud and colleagues documented a case where early ART may have prevented the establishment of a latent reservoir in an HIV-infected child and achieved a functional cure. A functional cure is different from a complete cure in that while the virus is not eliminated, it is kept under control in the absence of therapy and does not impact on patient well-being.', NULL, NULL, NULL),
(25, NULL, '<p>This weekend when I was surfing the web I found a very interesting website called <b><i> Pirate Science</b></i>, which focus on summarizing  openly accessible evolutionary publications. I found it blogs, reviews and summaries very well written and would like to help to advertise it.</p>', '<p><i><center>Example of some of their summaries.</center></i></p>\n<p>This website is produced by four researchers at the Evolutionary Dynamics of Infectious Disease group at the Max Planck Institute. Their manifesto starts with a quote that says:</p><br>\n<p><b><i>\'That ideas should spread freely from one to another over the globe, for the moral and mutual instruction of man, and improvement of his condition, ... like the air ... incapable of confinement or exclusive appropriation\'.</b></i> - - Thomas Jefferson</p>\n<br>\n<p>The website objective is to make <b><i>\'open science\'</b></i> with the provision of free sharing of knowledge and ideas. The website focuses on open access publications and open source software applications. </p>\n\n<p>I was also very happy to ready that they reviewed a recent publication that I have collaborated with Prof. Olivier Gascuel group in Montpellier. This is an <a href=\"publications.php?pubid=63\">openly accessible publication in <i>Bioinformatics</i> that provides an open access web-interface for the analysis of large phylogenies.</a></p>\n\n<p>To end this blog, I would like quote their manifesto again. </p>\n<br>\n<p><b><i>\'Pirate science shares the adventure, the contextual ideas which surround and support the research ideas we develop, the change points as our intuition widens, alternative pathways considered, and the roadblocks encountered\'.</b></i></p>\n<br>\n<p>Long live Pirate Science! Long live open access!</p>\n\n<p>Pirate Science is accessible at: <a href=\"http://www.scipirate.com/\">http://www.scipirate.com/</a></p>', 'Tulio de Oliveira', 'piratescience.png', NULL, 'Pirate Science - an interesting website on open-access phylogenetic publications', '2013-04-28', 'imgnews72.png', NULL, NULL, NULL, NULL, NULL),
(26, NULL, '<p>This blog aims to highlight the achieved scientific excellence of HIV researchers in South Africa and to congratulate Prof. Salim Abdool Karim for his new appointment as head of the expert panel of UNAIDS. </p>\n\n<p>South African HIV scientists are among some of the most prolific researchers in the world. For example, researchers in South Africa were among the ones to prove that antiretroviral therapy can prevent infection. The first piece of evidence was in the ground breaking HTPN052 trial that showed a decrease of 96% of infection in negative partners if the positive one received treatment (ref. 1). Recently, Africa Centre\'s researchers have shown a decrease in 40% of incidence at population level with the increased coverage of Antiretroviral (ART) (ref. 2). In addition, in 2010, Science listed the results from CAPRISA Tenofovir gel as one of the 10 most important scientific discoveries of the year (ref 3). On the basic science, recent results from Prof. Lynn Morris\'s group have identified very potent antibodies that may guide new vacinnes (ref 4). The list goes on and on and it would be easy to list another ten manuscripts in the top scientific journals on the recent advances of HIV research in South Africa.</p>', '<p>The scientific excellence of South African researchers was acknowledged with the appointment of Professor Salim Abdool Karim, Director of CAPRISA at the University of KwaZulu-Natal and President of the South African Medical Research Council, as Chair of the newly established Joint United Nations Programme on HIV/AIDS (UNAIDS) Scientific Expert Panel and as Scientific Advisor to the Executive Director of UNAIDS.  The announcement was made by Executive Director of UNAIDS, Michel Sidibe, on 3 June 2013 during his opening address at a UNAIDS Scientific Symposium held at CAPRISA in Durban.</p>\n\n<p>The Scientific Expert Panel will advise UNAIDS on major new scientific discoveries, as well as gaps and strategic needs in AIDS research and on how UNAIDS can adjust its policies to address these needs and shape the AIDS response.  In addition, the panel will provide strategic advice on the relevance of new research and findings and how they can be rapidly implemented to best effect to prevent new HIV infections and improve the lives of people living with HIV.</p>\n<p>As part of its mandate, CAPRISA will convene international scientific consultations on behalf of UNAIDS and its Scientific Expert Panel, the first of which was recently held in Durban, South Africa and focused on the scientific advances and the implications for public health programmes in Africa.</p>\n<p></p>\n<p><b><i>\'To reach the end of the AIDS epidemic, we need to continue to embrace science and innovation and I am delighted that Professor Abdool Karim has agreed to take on the leadership of our new UNAIDS scientific panel,\'</b></i> said Mr Sidibe.</p>\n<p></p>\n<p>It is well recognized in the world that local high-level research can be quickly translated policies of national interest. In addition, local representation on the Scientific Expert Panel will allow the translation of scientific evidence to enhance the South Africa\'s response to the HIV epidemic. We, at SATuRN, want to applaud the major scientific and policy advances that South Africa has made in the past few years. Long live South Africa scientific excellence! </p>\n<p></p>\n<p><b><i>References:</b></i></p>\n<p>1 - Cohen MS, Chen YQ, McCauley M, et al. (August 2011). \"Prevention of HIV-1 infection with early antiretroviral therapy\". N. Engl. J. Med. 365 (6): 493-505 (2011).</p>\n<p></p>\n<p>2 - Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell M-L. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science; 339:966-71 (2013).</p>\n<p></p>\n<p>3 - Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, on behalf of the CAPRISA 004 Trial Group. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 329: 1168-1174 (2010)</p>\n<p></p>\n<p>4 - Moore PL, Gray ES, Wibmer CK, Bhiman JN, Nonyane M, Sheward DJ, Hermanus T, Bajimaya S, Tumba NL, Abrahams MR, Lambson BE, Ranchobe N, Ping L, Ngandu N, Abdool Karim Q, Abdool Karim SS, Swanstrom RI, Seaman MS, Williamson C, Morris L. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med. 2012 Nov;18(11):1688-92. doi: 10.1038/nm.2985. </p>', 'Tulio de Oliveira', 'imgBlog26Big.png', NULL, 'South African scientific excellence:  South African AIDS scientist to lead UNAIDS Expert Panel', '2013-07-01', 'imgBlog26.png', NULL, NULL, NULL, NULL, NULL),
(27, NULL, '<p>Current guidelines for the management of virological failure recommend excluding drug interactions and inter-current infections, intensifying adherence support and switching to second-line ART if a patient remains viraemic. The aim being to ensure that non-adherent patients receive appropriate adherence support and those with resistance switch regimens. </p>', '<p><i>Figure 2: First-line antiretroviral therapy drug concentrations in stored plasma samples taken prior to switching to second-line antiretroviral therapy</i></p><p>This study highlights that ongoing non-adherence remains a major contributor to first-line virological failure when switching regimens with 55% of patients in this study having sub-therapeutic first-line drug concentrations pre-switch. Perhaps unsurprisingly, these patients were less likely to achieve viral suppression once switched to second-line ART.  Furthermore, resistance to NRTIs did not increase risk of first-line failure.  In fact, overall patients with resistance did better, perhaps because it reflected a higher degree of adherence.  These findings suggest that efforts to intensify adherence support when switching regimens are often unsuccessful and lead to sub-optimal second-line outcomes. </p>\n<p>Sub-therapeutic drug concentrations also influenced the patterns of resistance mutations observed at switch; NRTI mutations were detected in 97% of patients on \'therapeutic\' first-line ART, compared to 31% on a \'sub-therapeutic\' regimen. In particular 47% versus 18% had >1 TAM detected and 26% versus 13% NRTI cross-resistance mutations. </p>\n<p>The findings from this study indicate that it is unresolved non-adherence at time of switch, not NRTI resistance, which drives early second-line failure.  These findings underline the need to develop simple point-of-care tools for reliably identifying patients in whom non-adherence continues to contribute to viraemia, including options such as simple bio-assays for therapeutic drug levels or other robust measures of adherence.  Drug resistance assays at the time of first-line failure appear to be mostly useful to assess adherence, but not for guiding ART management.  </p>\n<p><b><i>Open Access publication: </b></i></p><p><a href=\"http://jid.oxfordjournals.org/content/early/2013/08/13/infdis.jit411.full.pdf\">Johnston V, Cohen K, Wiesner L, Morris L, Ledwaba J, Fielding KL, Charalambous S, Churchyard G, Phillips A, Grant AD. Viral suppression following switch to second-line antiretroviral therapy: associations with NRTI resistance and sub-therapeutic drug concentrations prior to switch. J Infect Dis. 2013 Aug 13. [Epub ahead of print]</a>\n', 'Christopher Hoffmann', 'imgBlog27Big.png', 3, 'Unresolved non-adherence drives early 2nd line  ART failure', '2013-08-23', 'imgnews24.png', 'Unresolved, non-adherence, 2nd line, antiretroviral, failure, blog, chris hoffman, paper, lymnn Morris, SATuRN, drug concentration, adherence, south africa, Unresolved, non-adherence, 2nd line, antiretroviral, failure, blog, chris hoffman, paper, lymnn Morris, SATuRN, drug concentration, adherence, south africa, Unresolved, non-adherence, 2nd line, antiretroviral, failure, blog, chris hoffman, paper, lymnn Morris, SATuRN, drug concentration, adherence, south africa, Unresolved, non-adherence, 2nd line, antiretroviral, failure, blog, chris hoffman, paper, lymnn Morris, SATuRN, drug concentration, adherence, south africa', 'Current guidelines for the management of virological failure recommend excluding drug interactions and inter-current infections, intensifying adherence support and switching to second-line ART if a patient remains viraemic. The aim being to ensure that non-adherent patients receive appropriate adherence support and those with resistance switch regimens. ', NULL, NULL, NULL),
(28, NULL, '<p>Over the past few years SATuRN has collated approximately 7000 HIV drug resistance genotypes linked to clinical information and treatment in the Southern African region. </p>\n', '<p>SATuRN has developed a cross-national public health and virological research collaboration to implement innovative means of shared data collection, management, analysis, monitoring, and evaluating outcomes in response to ART in resource limited settings. This successful data collection and pro-patient output technique has been exacerbated by the fact that SATuRN hosts the two best HIV drug resistance database the Stanford and Rega HIV drug resistance database.</p>\n<p>The datasets grow everyday with more data added into the database. The database pertains longitudinal datasets consisting of pediatrics and adults cohorts of patients who are failing their ART treatment. The database has grown to be a rich database with interesting/significant variables in mapping the prevalence by demography, social context, and clinical information, to name just a few. With this data and clinical cases SATuRN has been able to train more than 2000 clinicians and nurses involved in treating patients failing ART. This data has come useful to researchers as many publications are arisen from this rich-dataset. </p>\n<p>Hacking back to the subject of this article, HIV drug resistance is a complex subject; with complexities that are better understood now rather than later. This of course begs for the data to be continuously cleaned and kept relevant. The SATuRN database is continuously curated. The Africa Centre, as a prime example, rigorously compares the information collected by its clinicians dealing with the patient with the central information stored at Hlabisa Hospital laboratory?s database called ARTemis, comparing and adding new Viral Loads, CD4 and treatment history in order to keep the data accurate and clean. </p>\n<p>Mistakes and errors can be fortunately also be picked up by the Africa Centre data curation staff, e.g. error on treatment regimen, viral measuraments, abnormal mutations inconsistent with the patient?s treatment. After this process the specialist physician who suggests/recommends treatment will oversee if the given information makes at a clinical level. Each result goes through 3 data curation points before it eventually comes back to the primary clinician managing the patient. The information in the Rega database is checked and updated every month to track the progress of patients who have received a genotype test.</p>\n<p>The question is; what should motivate one to keep quality/curated data? Or really what is the point of writing this article? The only answer must be this, what is collected is NOT just numbers, or \'just data for analysis\'; numbers equates to people, people who are failing treatment, individuals with families and loved ones. This is the back bone of the research and the fuelling factor in the immediate plans to have our drug resistance research outputs influence policy.</p>\n<p><b><i>Detailed information: </b></i><a href=\"http://www.bioafrica.net/saturn/index.php\">SATuRN website at bioafrica.net/saturn/</a></p>', 'Lungani Ndwandwe, Tulio de Oliveira', 'imgBlog28Big.png', NULL, 'Data Curation and its tenets', '2013-08-15', 'imgBlog28.png', 'data curation, hiv, drug resistance, saturn, africa, Lungani, Tulio de Oliveira, blog, bioafrica, southern african treatment resistance network,data curation, hiv, drug resistance, saturn, africa, Lungani, Tulio de Oliveira, blog, bioafrica, southern african treatment resistance network,data curation, hiv, drug resistance, saturn, africa, Lungani, Tulio de Oliveira, blog, bioafrica, southern african treatment resistance network,data curation, hiv, drug resistance, saturn, africa, Lungani, Tulio de Oliveira, blog, bioafrica, southern african treatment resistance network,data curation, hiv, drug resistance, saturn, africa, Lungani, Tulio de Oliveira, blog, bioafrica, southern african treatment resistance network,', 'Over the past few years SATuRN has collated approximately 7000 HIV drug resistance genotypes linked to clinical information and treatment in the Southern African region', NULL, NULL, NULL),
(29, NULL, '<p>Twenty-four percent, is the figure that I cannot stop thinking about when we land on Durban International Airport, South Africa. One out of four people living here in the province of KwaZulu-Natal is HIV-infected - a number that goes as high as 48% infection for the women living in the area. The impact of these figures becomes real when I immediately bump into a container providing free condoms at the airports restroom. This place is serious.</p>', '<p>We watch the houses scattered through the lush and hilly landscape as we drive to the Africa Center for Health and Population Studies in Mtubatuba. With the PharmAccess Studies to Evaluate Resistance (PASER) scientific team we are here to visit our colleagues of the Southern African Treatment Resistance Network (SATuRN). Both of us are working in the field of HIV drug resistance in sub-Saharan Africa where PASER is monitoring HIV drug resistance from the start of antiretroviral treatment, and SATuRN is monitoring resistance from the moment of treatment failure. This meeting enables us to share information on expertise, experience, existing resources and capacities, to explore a joint research agenda.</p>\n<p>SATuRN director Prof Tulio de Oliveira welcomes us at the Africa Centre and introduces us to its extensive demographic HIV surveillance including resistance testing. Prof Tobias Rinke de Wit explains the context of the PASER observational cohort studies and the PASER scientific output is further explained by Dr Raph Hamers for the adult studies and Dr Kim Sigaloff for the paediatric studies. Dr Pascale Ondoa explains the development and validation of affordable resistance testing within the PASER network. </p>\n<p>We learn from SATuRN\'s wide expertise in clinical and laboratory science and bioinformatics. Eduan Wilkinson takes us back in time with his phylogenetic research on the history and evolution of HIV-1 subtype C in Cape Town and in southern Africa. Thereafter Justen Manasa presents his genotyping results on acquired and transmitted HIV drug resistance, and shows us his novel approach to an open source protocol: a video detailing the methods of genotypic testing using an affordable in-house assay. The implications of resistance for clinical care become real when Dr Gert van Zyl from Stellenbosch University Cape Town explains the increase of resistance he found in South African adults and children receiving standardized first- and second-line regimens. </p>\n<p>Pascal Brandt who works for the nonprofit organization Jembi Health Systems in Cape Town, explains the ins-and-outs of database development for resistance data. SATuRN is using RegaDB, a free and open source system to store and analyze clinical and resistance data while supporting both clinicians and researchers in their work. As we wish to join forces for collaborative research, we explore the possibilities of the coordination of existing datasets.</p>\n<p>Furthermore, we make the first steps on a new joint research proposal, focusing the accessibility and marketing of low-cost resistance testing in HIV treatment programs. After spending 2,5 days together, we are all very enthusiastic about our collaboration and we found it hard to leave. Fortunately, we will see each other again for the joint workshop on HIV-TB resistance and treatment monitoring in November this year, in Bloemfontein!</p>\n<p><b><i>by By Sonia Boender, PhD student for PASER</b></i><p>\r\n<b><i>Links:</b></i></p>\n<p>Watch brief interviews on this meeting</p>\n<p><a href=\"http://www.youtube.com/watch?v=QprscXTr14A\">http://www.youtube.com/watch?v=QprscXTr14A</a></p>\n<p>SATuRN-PASER collaborative meeting in Bloemfontein (20-22 November 2013)</p>\n<p><a href=\"http://bioafrica.net/workshops/8thsaturnPaserresitanceworkshop.html\">http://bioafrica.net/workshops/8thsaturnPaserresitanceworkshop.html</a></p>\n<p><a href=\"http://bioafrica.net/workshops/8thSouthAfricaHIVDrugResistance.pdf\">http://bioafrica.net/workshops/8thSouthAfricaHIVDrugResistance.pdf</a></p>\n<p>SATuRN</p>\n<p><a href=\"http://bioafrica.net/saturn/\">http://bioafrica.net/saturn/</a></p>\n<p>Africa Center for Health and Population Studies</p>\n<p><a href=\"http://www.africacentre.ac.za/\">http://www.africacentre.ac.za/</a></p>\n<p>Jembi Health Systems </p>\n<p><a href=\"http://www.jembi.org/\">http://www.jembi.org/</a></p>\n', 'Sonia Boender', 'imgblog29.png', NULL, 'VideoBlog: SATuRN-PASER Scientific Meeting on HIV Drug Resistance in Africa', '2013-09-20', 'imgblog29sm.png', 'SATURN, PASER, scientific meeting, collaboration, video, videoblog, Sonia Boender, PhD, student, Amsterdam, Africa Centre, Mtubatuba, KZN, South Africa, drug resistance, HIV, SATURN, PASER, scientific meeting, collaboration, video, videoblog, Sonia Boender, PhD, student, Amsterdam, Africa Centre, Mtubatuba, KZN, South Africa, drug resistance, HIV, SATURN, PASER, scientific meeting, collaboration, video, videoblog, Sonia Boender, PhD, student, Amsterdam, Africa Centre, Mtubatuba, KZN, South Africa, drug resistance, HIV, SATURN, PASER, scientific meeting, collaboration, video, videoblog, Sonia Boender, PhD, student, Amsterdam, Africa Centre, Mtubatuba, KZN, South Africa, drug resistance, HIV', 'SATURN and PASER scientific meeting funded by the European Comission at the Africa Centre for Health and Population Studies 2013. Sonia Boender Blog on the event.', 'QprscXTr14A', NULL, NULL),
(30, NULL, '<p>A team of authors have described a method for multiplex allele-specific assay (MAS) for HIV-1 drug resistance mutations. This assay allows for the detection of PI mutations at 5 loci, NRTI mutations at 8 loci and NNRTI mutations at 7 loci associated with resistance to Anti-retroviral drugs used in resource limited settings. Five of the mutation loci had 2 mutations targeted, therefore 2 primers specific to those mutant alleles were designed. The assay included 20 wild-type alleles and 25 mutant alleles, to give a total of 45 primers for the assay. </p>\n', '<p>The primer design was based on HIV-1 Subtype C, but modifications for non-C subtypes are currently being investigated. This new method has significant implications in the Southern African context since it allows for the simultaneous detection of several resistance mutations for HIV-1 subtype C, which is predominant in this region. MAS assay can potentially reduce the costs associated with other resistance testing methods like population sequencing since equipment for suspension array technology is cheaper. Detection of mutations using MAS assay can be accomplished in a shorter time, making this method more time-efficient. </p>\n<p>The simultaneous detection of several resistance mutations within the protease and reverse transcriptase genes with MAS assay has an advantage over current allele-specific PCR methods, in which assays are tailored to single mutation sites. MAS assay allows for the addition or removal of primers for particular known mutation sites when they need to be included or excluded in the assay. When compared to population-based sequencing which detects virus mutations in abundance of 20%, this assay can detect low-frequency mutations with a sensitivity of up to 1.6% for some mutations. The results of low-frequency mutations detected by MAS in plasma samples were confirmed by 454 sequencing. </p>\n<p>This assay presents a methodology that is quick and easy to interpret. Therefore, it can be used in resource limited settings for surveillance and monitoring of transmitted or acquired HIV-1 drug resistance in countries where subtype C virus predominates. Mutations like K103N/R, Y181C and M184V are commonly described in South Africa for subtype C viruses, therefore this assay may prove to be useful for surveillance of these and other mutations. However, this assay cannot be used to detect new drug resistance mutations (unknown mutations) and may not be suitable for clinical diagnostics in patient management.</p>\n<p></p>\n<p><b><i>Blog by: Anna Salimo</b></i>, Medical Scientist, Centre for HIV and STIs, National Institute of Communicable Diseases, Johannesburg, South Africa.</p><br>\n<p><b><i>Manuscript title:</b></i> Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 Subtype C using a multiplex allele-specific (MAS) assay.</p>\n<p><b><i>Authors:</b></i> Zhang G, Cai F, Zhou Z, DeVos J, Wagar N, Diallo K, Zulu I, Wadonda-Kabondo N, Stringer JSA, Weidle PJ, Ndongmo CB, Sikazwe I, Sarr A, Kagoli M, Nkengasong J, Gao F and Yang Chunfu.</p>\n<p><b><i>Journal:</b></i> Journal of Clin Micro 28 August 2013, published online ahead of print.</p>\n<p><b><i>Link:</b></i><a href=\"http://jcm.asm.org/content/early/2013/08/23/JCM.01669-13.abstract\">http://jcm.asm.org/content/early/2013/08/23/JCM.01669-13.abstract</a></p>', 'Anna Salimo', 'imgBlog30Big.png', NULL, 'Simultaneous detection of major HIV-1 drug resistance mutations using a multiplex allele-specific assay', '2013-09-25', 'imgBlog30.png', 'Anna, Salimo, HIV, MAS, allele specific, PCR, subtype C, blog, NICD, South Africa, drug resistance, mutations, Anna, Salimo, HIV, MAS, allele specific, PCR, subtype C, blog, NICD, South Africa, drug resistance, mutations,Anna, Salimo, HIV, MAS, allele specific, PCR, subtype C, blog, NICD, South Africa, drug resistance, mutations,Anna, Salimo, HIV, MAS, allele specific, PCR, subtype C, blog, NICD, South Africa, drug resistance, mutations', 'A team of authors have described a method for multiplex allele-specific assay (MAS) for HIV-1 drug resistance mutations. This assay allows for the detection of PI mutations at 5 loci, NRTI mutations at 8 loci and NNRTI mutations at 7 loci associated with resistance to Anti-retroviral drugs used in resource limited settings. Five of the mutation loci had 2 mutations targeted, therefore 2 primers specific to those mutant alleles were designed', NULL, NULL, NULL),
(31, NULL, '<p>Protease inhibitors are highly potent drugs which have been widely used as part of highly active antiretroviral therapy. They are recognized for their high antiviral activity which results from the steep dose-response curves. Resistance to protease inhibitors occurs through mutations in the protease gene; however, many patients who fail protease inhibitor-based therapy do so without mutations in protease. This raises the question: do other parts of the HIV-1 genome contain mutations which confer resistance to protease inhibitors in patients failing therapy?</p>', '<p><i>Figure 1. Contribution of the inhibitory effect of protease inhibitors on each step of the viral life cycle.</i></p><p>To understand the molecular mechanisms responsible for the high antiviral activity of protease inhibitors, a group of researchers from John\'s Hopkins University experimentally tested each relevant step of the life cycle and measured the dose-response curves of three protease inhibitors (atazanavir, darunavir and lopinavir). Here they found that protease inhibitors do not affect the process of budding, but they do inhibit entry, reverse transcription and post-reverse transcription steps. Inhibition at the entry step was the most prominent thereby demonstrating the importance of entry inhibition in the overall effect of protease inhibitors. The researchers then cloned full-length envelope genes from patients who failed protease inhibitor-based therapy with no resistance associated mutations in protease. Pseudoviruses generated using these envelope genes cloned into a wild type backbone showed significant protease inhibitor resistance. </p>\n<p>In summary, by experimentally testing each relevant step of the viral life cycle, this study provided a mechanistic explanation for the exceptional efficacy of protease inhibitors. It also identified the envelope gene as a possible site of protease inhibitor resistance which suggests an additional mechanism for protease inhibitor failure. Commercially available phenotypic assays do not detect the change in inhibition of entry because it uses pseudoviruses with MLV-E instead of HIV-1 envelope. Currently, patient-specific changes in the envelope gene are not considered in standard genotypic or phenotypic resistance assays. </p>\n<p><b><i>Blog by Jennifer Giandhari</b></i>, PhD student, HIV Virology, Centre for HIV and STIs, National Institute of Communicable Diseases, Johannesburg, South Africa.</p> \n<p><b><i>Manuscript title:</b></i> Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance</p>\n<p><b><i>Authors:</b></i> S. Alireza Rabi, Gregory M. Laird, Christine M. Durand, Sarah Laskey, Liang Shan, Justin R. Bailey, Stanley Chioma, Richard D. Moore, and Robert F. Siliciano</p>\n<p><b><i>Journal:</b></i> J Clin Invest. 2013;123(9):3848-3860. doi:10.1172/JCI67399</p>\n<p><b><i>Link:</b></i> <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/23979165\">http://www.ncbi.nlm.nih.gov/pubmed/23979165</a></p>', 'Jennifer Giandhari', 'imgBlog31Big.png', NULL, 'Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance', '2013-10-10', 'imgBlog31.png', 'Jennifer, Multi-step, inhibition, HIV-1, protease, inhibitor, pharmacodynamics, resistance, Giandhari, SATuRN, southern African Treatment Resistance Network, NICD, Lynn Morris, Blog, Jennifer Giandhari, Jennifer, Multi-step, inhibition, HIV-1, protease, inhibitor, pharmacodynamics, resistance, Giandhari, SATuRN, southern African Treatment Resistance Network, NICD, Lynn Morris, Blog, Jennifer Giandhari, Jennifer, Multi-step, inhibition, HIV-1, protease, inhibitor, pharmacodynamics, resistance, Giandhari, SATuRN, southern African Treatment Resistance Network, NICD, Lynn Morris, Blog, Jennifer Giandhari, Jennifer, Multi-step, inhibition, HIV-1, protease, inhibitor, pharmacodynamics, resistance, Giandhari, SATuRN, southern African Treatment Resistance Network, NICD, Lynn Morris, Blog, Jennifer Giandhari, Jennifer, Multi-step, inhibition, HIV-1, protease, inhibitor, pharmacodynamics, resistance, Giandhari, SATuRN, southern African Treatment Resistance Network, NICD, Lynn Morris, Blog, Jennifer Giandhari', 'Protease inhibitors are highly potent drugs which have been widely used as part of highly active antiretroviral therapy. They are recognized for their high antiviral activity which results from the steep dose-response curves.', NULL, NULL, NULL);
INSERT INTO `b_blogs` (`id`, `email`, `summary`, `summary2`, `authors`, `photo2`, `bioafricaSATuRN`, `title`, `date`, `image`, `keywords`, `topdescription`, `video`, `pubid`, `imagefront`) VALUES
(32, NULL, '<p>Yesterday I presented an AIDSReviews paper on HIV Drug Resistance in Africa (<a href=\"http://bioafrica.net/publications.php?pubid=94\">Lessells, Avalos & de Oliveira, 2013</a>) at the Africa Centre Scientific Seminar (3pm to 4pm South Africa time) in Mtubatuba, South Africa. </p>\n<p>For the sake of interaction with the greater community, we decided to circulate the paper on twitter and ask for questions. We asked for Internet users to identify their questions with the HashTag: #HIVDRAfrica. We had received and answered many interesting questions. We had fun answering the questions and interacting with our audience!</p>\n<p>We whould like to thank our twitter participants! @jienchi, @frickjifang, @tomayates, @AvaAvalos, @DeenanDpillay & @rjlessells </p>', '<p>Q1:</p>\n<p>Jienchi Dorward @jienchi Jan 15 - @drug_resistance #HIVDRAfrica Patients switched TDF/3TC/EFV to TDF despite high VL: which regimen 1. while sorting adherence 2. 2nd line</p>\n<br>\n<p>SATuRN @drug_resistance - @jienchi continue while sorting adherence then switch to AZT/3TC/LPVr  but good example of where resistance testing useful</p>\n<br>\n<p>SATuRN @drug_resistance - @jienchi patient risk of having lost TDF through K65R so AZT may be safer option. Depends how long failing each regimen really.</p>\n<br>\n<p>Q2:</p>\n<p>Jienchi Dorward @jienchi - @drug_resistance Any data on how long it takes to get K65R if failing on TDF</p>\n<br>\n<p>SATuRN @drug_resistance - @jienchi it\'s a difficult one but sadly common as we know. See case 4 in the book http://www.bioafrica.net/cases.phpid=4 </p>\n<br>\n<p>Q3:</p>\n<p>frickjifang @frickjifang - #HIVDRAfrica possible to switch single drug in 2nd line ARVs regimens provided undetectable viral load and no mutation to the new drug</p>\n<br>\n<p>Ava Avalos @AvaAvalos  - @frickjifang Yes it fine to switch a single drug if the VL is undetectable. </p>\n<br>\n<p>frickjifang @frickjifang  - @AvaAvalos Thank you for ur answer!</p>\n<br>\n<br>\n<p>Q4:</p>\n<p>Tom Yates @tomayates - #HIVDRAfrica @drug_resistance is there any reason POC resistance testing can\'t be developed using XPERT platform Is anyone looking at this</p>\n<br>\n<p>SATuRN @drug_resistance - @tomayates Yes i think cepheid and partners have been working on that while developing xpert viral load assay - don\'t know details though</p>\n<br>\n<p>Q5:</p>\n<p>Tom Yates @tomayates Jan 15 - #HIVDRAfrica @drug_resistance is it possible to do viral loads on dried blood spots</p>\n<br>\n<p>Ava Avalos @AvaAvalos - @tomayates @drug_resistance Yes, we do dbs for children in Botswana regularly.</p>\n<br>\n<p>Q6:</p>\n<p>Tom Yates @tomayates Jan 15 -  #HIVDRAfrica @drug_resistance Should we put something inert and v slowly metabolised in ARVs to allow us to assay adherence Silly thought</p>\n<br>\n<p>SATuRN @drug_resistance - @tomayates Not silly. Spent some time thinking about this couple of yrs back. People already on case - will send link later.</p>\n<br>\n<p>SATuRN @drug_resistance - @tomayates problem though is regulatory as it would then be new drug/formulation</p>\n<br>\n<p>Q7:</p>\n<p>Tom Yates @tomayates Jan 15 - #HIVDRAfrica @drug_resistance is there any reason ARVs can\'t be given using an implanon type device, as we do with hormonal contraception</p>\n<br>\n<p>SATuRN @drug_resistance -  @tomayates no reason - there is development of long-acting depot ARVs but none made it to market yet</p>\n<br>\n<p> Tom Yates @tomayates - @drug_resistance I\'d be more worried about that. If there are side effects, harder to remove depot than an implant.</p>\n<br>\n<p>Deenan Pillay @DeenanDpillay -  @tomayates @drug_resistance of interest to at least one company I know</p>\n<br>\n<br>\n<p>Q8:</p>\n<p>Deenan Pillay @DeenanDpillay 15 Jan -  @drug_resistance isn\'t evidence needed for clinical utility of testing</p>\n<br>\n<p>SATuRN @drug_resistance - @DeenanDpillay yes absolutely - how do you think we should gather the evidence We need to define the research questions</p>\n<br>\n<p>Q9: </p>\n<p>Jienchi Dorward @jienchi 15 Jan - @drug_resistance #HIVDRAfrica Kids<35kg failing d4T/3TC/EFV. No Paeds TDF. SADoH say AZT/ABC/LPVr. Why no 3TC WHO say ABC/3TC/LPVr. Advice</p>\n<br>\n<p>SATuRN @drug_resistance - @jienchi Stick with SA guidelines but we need more evidence to inform treatment strategies for kids.</p>\n<br>\n<p>General comments:</p>\n<p>Jienchi Dorward @jienchi Jan 15 - @drug_resistance #HIVDRAfrica That\'s it for now. Wish could be there! And that could do one of your Phds!! :)</p>\n<p>Tom Yates @tomayates Jan 15 - HIVDRAfrica @drug_resistance that was fun, thanks! </p>\n<p>frickjifang @frickjifang  - @AvaAvalos Thank you for ur answer!</p>', 'Tulio de Oliveira', 'twitterBig.png', NULL, 'Wellcome Trust Africa Centre Seminar & Twitter Q&A on HIV drug resistance in Africa, 15-Jan-2014', '2014-01-16', 'ImgBlog32.png', NULL, NULL, NULL, 94, NULL),
(33, NULL, '<p>Rising levels of drug-resistant HIV as a result of the rapid scale-up of antiretroviral treatment programmes in sub-Saharan Africa are a potential threat to the control of the HIV epidemic. To discuss potential responses to this concern, the Amsterdam Institute for Global Health and Development (AIGHD) and the Pan-African Studies to Evaluate Resistance (PASER) network convened a closed policy meeting in Lusaka, Zambia on 6 May 2014. </p>\n<p>The Policy Meeting\'s main objective was to bring together national policy makers, health professionals, public health experts, and medical researchers. Cross-discipline interactions created the opportunity for enhanced information exchange and mutual learning about the specific policy challenges posed by emerging HIV drug resistance in the southern African region. Among the 31 participants were representatives of Ministries of Health (South Africa, Swaziland, Zambia and Zimbabwe), the World Health Organization (WHO), communities living with HIV in Zambia, and the Embassy of the Kingdom of the Netherlands. They were joined by the laboratory experts, clinicians, researchers, and the coordinator of the Southern African Development Community regional HIV/AIDS Programme.</p>', '<p>Two panel discussions, moderated by Dr. Moses Kamya (Professor of Medicine, Makerere University, Uganda) and Dr. Catherine Hankins (Deputy Director Science, Amsterdam Institute for Global Health and Development), saw lively exchanges. Countries reported good progress in the development of strategic national plans for preventing HIV drug resistance prevention within their national HIV programs. These will contribute to enhancing awareness of HIV drug resistance and early detection, while informing the deployment of preventive measures. </p>\n<p>Although Zimbabwe, Zambia, and South Africa have conducted surveys on acquired and transmitted HIV drug resistance recently, these have not yet been repeated and time trends are lacking. Such surveys provide information that is critical to maintaining effective antiretroviral drug regimens and can be pivotal in influencing policy. For instance, Zimbabwe\'s paediatric HIV drug resistance survey found high levels of resistance associated with non-nucleoside reverse transcriptase inhibitors (NNRTI), leading to a change in the treatment guidelines. Protease inhibitor-based antiretroviral therapy is recommended for treatment initiation before the age of 3 yrs.  WHO-recommended Early Warning Indicators (EWIs) for HIV drug resistance are routinely collected in many sites across Zambia and Zimbabwe, where drug stockouts remain a major challenge. EWIs include a timely feedback mechanism to individual sites so that action can be taken locally on programmatic deficiencies. </p>\n<p>WHO has launched updated guidelines on HIV drug resistance prevention that include an important shift in assessment strategies from a sentinel approach to nationally representative surveys. Country representatives at the policy meeting viewed this new approach as not only feasible but also likely to generate more useful information at national level. </p>\n<p>South Africa is implementing, in collaboration with SATuRN, a central HIV drug resistance database to curate, store and summarize data, including a dashboard to present data on drug resistance mutation patterns by region. Initially, the focus will be on the public sector, with the intention to expand to include private sector data. It is the first country in the region to implement routine viral genotyping for patients who experience therapy failure on their second-line regimen. A central panel of 4 expert clinicians assesses all cases being considered for third-line therapy. Educational efforts are needed to address an important knowledge gap among clinicians concerning when to request HIV drug resistance testing, how to interpret the results, and how to best use 2nd and 3rd line regimens. Current WHO guidelines make no explicit recommendation about the use of viral genotyping to guide antiretroviral drug switching for people who are failing second-line therapy. Discussions on this topic and the issue of optimized use of the dual nucleoside backbone are needed to inform changes in the WHO guidelines.</p>\n<p>To date, few laboratories in the region have been accredited by WHO to perform HIV drug resistance testing. Some are moving forward to develop more affordable diagnostic technologies, such as those on dried blood spots. The KEMRI-CDC laboratory in Kisumu is the first to have developed their in-house resistance test into a lab kit that can be purchased commercially. Zambia will begin HIV drug resistance testing at its University Teaching Hospital and Centre for Infectious Disease Research Zambia in the coming months. Zimbabwe and Swaziland do not have in-country laboratory capacity for HIV drug resistance genotyping, but they can make arrangements with existing reference laboratories in the region. </p>\n<p>Enhanced interaction between policy, science, and clinical practice is crucial, but creating fertile conditions for it appears challenging. Funding agencies can play a role by advocating for reciprocal interactions through diplomatic channels and can stimulate researchers to conduct effective knowledge translation by disseminating their results and the implications of their findings for public health and policy. </p>\n<p>As the community representative of the National Treatment Preparedness Coalition and TALC, Zambia highlighted, there is a lot of confusion, misunderstanding, and superstition about \'acquired\' and \'transmitted\' resistance among the general public and a very real need for investment in educating the general public about HIV drug resistance. Enhanced and concerted advocacy efforts, such as those successfully conducted to bring about price reductions for antiretroviral drugs, could bring down the price of diagnostics. However, as a South African clinician stated, the costs of viral load testing are still high and the benefits are not massive; priority should still be given to expanding access to HIV treatment and enhancing support for adherence.</p>\n<p></p>\n<p>PASER is sponsored by the Embassy of the Kingdom of the Netherlands through the regional HIV/AIDS programme for Southern Africa.</p>\n<p>The meeting coincided with the 8th International Workshop on HIV Treatment, Pathogenesis, and Prevention Research in Resource-poor Settings (INTEREST). Programme and presentations may be found at: http://www.infectiousdiseasesonline.com/event/workshop/8th-interest-2/.</p>', 'Jose IJedema, Sonia Boender & Tobias Rinke de Wit on behalf of PASER', 'pasermeeting.png', NULL, 'Report on Policy Meeting on HIV Drug Resistance, 6 May 2014, Lusaka, Zambia', '2014-07-05', 'road1.jpg', 'policy, meeting,  HIV, AIDS,  Drug Resistance, Africa, PASER, WHO, May 2014, Intercontinental Hotel, Lusaka, Zambia, ministry of health, south africa, SATuRN, policy, meeting,  HIV, AIDS,  Drug Resistance, Africa, PASER, WHO, May 2014, Intercontinental Hotel, Lusaka, Zambia, ministry of health, south africa, SATuRN, policy, meeting,  HIV, AIDS,  Drug Resistance, Africa, PASER, WHO, May 2014, Intercontinental Hotel, Lusaka, Zambia, ministry of health, south africa, SATuRN, policy, meeting,  HIV, AIDS,  Drug Resistance, Africa, PASER, WHO, May 2014, Intercontinental Hotel, Lusaka, Zambia, ministry of health, south africa, SATuRN, policy, meeting,  HIV, AIDS,  Drug Resistance, Africa, PASER, WHO, May 2014, Intercontinental Hotel, Lusaka, Zambia, ministry of health, south africa, SATuRN', 'Policy Meeting on HIV Drug Resistance, Tuesday 6 May 2014, Intercontinental Hotel, Lusaka, Zambia.To discuss potential responses to this concern, the Amsterdam Institute for Global Health and Development (AIGHD) and the Pan-African Studies to Evaluate Resistance (PASER) network convened a closed policy meeting in Lusaka, Zambia on 6 May 2014', NULL, NULL, NULL),
(34, NULL, '<p>In a recent publication, the replication fidelity of HIV-1 reverse transcriptase (RT) was investigated under physiological conditions. It is well known that HIV-1 RT is error prone. This, in combination with the high replication rate of the virus, result in the frequent generation of mutant virions of which many are resistant to drugs used in antiretroviral treatment.</p><p> The low fidelity of HIV-1 RT is not unique to HIV-1 since RT enzymes from other organisms share this characteristic (e.g., Alfalfa mosaic virus and Murine Leukemia Virus RTs). However, in vitro research into HIV-1 RT enzymology has given the impression that this enzyme has a particularly low fidelity.</p><p> In a new publication by Achuthan and colleagues, the authors indicate that the low fidelity of HIV-1 RT is on par with that of most other RT enzymes, under physiological conditions. The amount of dNTP and free Mg2+ can both impact on the fidelity of the enzyme. In assays optimized for HIV-1 RT enzymatic activity, Mg2+ concentrations are usually well above physiologically levels (e.g. in lymphocytes). The authors show that low free Mg2+ levels lead to an increase in HIV RT fidelity, with an error frequency that is ~10 times lower.Therefore, although HIV-1 RT has a low fidelity it is essential that in vitro experiments, particularly those concerned with fidelity, are carried out at free Mg2+ concentrations that resemble those in the cellular environment.</p>', '<p><i>Figure 1: PCR-based lacZ_ complementation system used to determine the fidelity of HIV RT. (A) An overview of the procedure used to assess polymerase fidelity. RNAs are indicated by broken lines and DNAs by solid lines. Primers have arrowheads at the 3= end. The _760-nucleotide template RNA used as the initial template for HIV RT RNA-directed DNA synthesis is shown at the top with the 3= and 5= ends indicated. The positions of PvuII and EcoRI restriction sites are indicated for reference to the vector. The filled box at the bottom of is the 115-base region of the lacZ_ gene that was scored in the assay. (B) Plasmid pBSM13PvuII1146 is shown. Relevant sites on the plasmid are indicated; numbering is based on that for the parent plasmid (pBSM13_ [Stratagene]). (C) The nucleotide and amino acid sequences for the 115-base region of the lacZ_ gene that was scored in the assay are shown. Both strands of the DNA plasmid are shown since HIV RT synthesis was performed in both directions (see panel A). </i></p>\n<p></p>\n<p><b><i>Publication:</b></i></p>\n<p><a href=\"http://jvi.asm.org/content/88/15/8514.full\">Human Immunodeficiency Virus Reverse Transcriptase Displays DramaticallyHigher Fidelity under Physiological Magnesium Conditions In Vitro</p>\n<p>Vasudevan Achuthan, Brian J. Keith, Bernard A. Connolly, and Jeffrey J.DeStefano</p>\n<p>J. Virol. August 2014 88:8514-8527; published ahead of print 21 May 2014,</p>\n<p>doi:10.1128/JVI.00752-14</p></p>', 'Adriaan E. Basson', 'blogAdrian.png', NULL, 'The fidelity of HIV-1 RT is not as bad as we thought', '2014-07-24', 'blogAdriansm.png', 'Blog, fidelity, HIV-1, HIV, reverse transcriptase, RT, not as bad, thought, Dr. Adriaan E. Basson,  publication, the replication fidelity, error prone, Blog, fidelity, HIV-1, HIV, reverse transcriptase, RT, not as bad, thought, Dr. Adriaan E. Basson,  publication, the replication fidelity, error prone, Blog, fidelity, HIV-1, HIV, reverse transcriptase, RT, not as bad, thought, Dr. Adriaan E. Basson,  publication, the replication fidelity, error prone, Blog, fidelity, HIV-1, HIV, reverse transcriptase, RT, not as bad, thought, Dr. Adriaan E. Basson,  publication, the replication fidelity, error prone, Blog, fidelity, HIV-1, HIV, reverse transcriptase, RT, not as bad, thought, Dr. Adriaan E. Basson,  publication, the replication fidelity, error prone', 'Blog, In a recent publication, the replication fidelity of HIV-1 reverse transcriptase (RT) was investigated under physiological conditions. It is well known that HIV-1 RT is error prone. This, in combination with the high replication rate of the virus, result in the frequent generation of mutant virions of which many are resistant to drugs used in antiretroviral treatment. This low fidelity of HIV-1 RT is not unique to HIV-1 since RT enzymes from other organisms share this characteristic (e.g., AMV and MuLV RTs)', NULL, NULL, NULL),
(35, NULL, '<p>The current South African guidelines for HIV-1 infected paediatric patients recommend the use of Abacavir (ABC) and Lamivudine (3TC) in the 1st-line regimen and Didanosine (ddI) and Zidovudine (AZT) in the 2nd-line regimen following virological failure.  This study aimed to assess the levels of cross-resistance to ddI following ABC and Stavudine (d4T)-containing 1st-line regimen in children.</p>\n', '<p><i>Figure 1. Prevalence of resistance to Nucleoside/tide Reverse Transcriptase Inhibitors. \nPrevalence of susceptible (S, solid bars), intermediate (I, striped bars) or high-level resistance (R, dotted bars) to nucleoside reverse transcriptase inhibitors (NRTIs) after exposure to an ABC containing regimen (n = 81, white) or d4T containing regimen (n = 273, grey). The numbers represent percentages. Abbreviations: ABC: abacavir, TDF: tenofovir, ddI: didanosine, d4T: stavudine, 3TC: lamivudine, FTC: emtricitabine, AZT: zidovudine.</i></p>\n<p>A group of researchers from the University of Witwaterstrand analysed a retrospective dataset from HIV-1 infected children failing either ABC (n= 81) or d4T (n= 273). It was shown that children who were administered ABC had high levels of resistance (n=50, 61.7%) while more children remained susceptible to d4T, irrespective of the exposure to ABC (n=63, 77.8%) or d4T (n=204, 75.5%), as illustrated on the figure below. In addition, a large number of children remained susceptible to AZT after receiving ABC (n=72, 88.9%) and d4T (n=217, 79.5%).  The ABC group showed high levels of cross resistance to ddI (n=49, 60.5%) compared to d4T (n=25, 9.2%), and the cross-resistance to ddI was attributed to mutation L74V/I (n=44). K65R mutation was more apparent in patients failing ABC (n=10, 12.3%) versus d4T (n=5, 1.8%). Of 108 PI-experienced children, 52 (47.7%) showed no resistance to PIs. A significant number of children (n=265) received NNRTI (EFV or NVP) and K103N (n=152, 57.4%) was the most common mutation in this drug class.</p>\n<p>This study had a significant impact on the change of ddI to AZT in the 2nd-line following ABC or d4T treatment. Going forward, this study proves that it is necessary to take into consideration the effects of mutations on new antiretroviral drugs especially in paediatric patients who have very limited treatment options. This will help to increase effectiveness and improve longevity of their regimens.</p>\n<p><b><i>Publication:</b></i></p>\n<p><a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016228/\">High-Level Cross-Resistance to Didanosine Observed in South African Children Failing an Abacavir- or Stavudine-Based 1st-Line Regimen. Kim Steegen, Leon Levin, Irene Ketseoglou, Michelle Bronze, Maria A.Papathanasopoulos, Sergio Carmona, Wendy Stevens. PLoS ONE 9(5): e97067. doi:10.1371/journal.pone.0097067</a></p>', 'Jennifer Giandhari and Joanna Ledwaba', 'imgblog35.png', NULL, 'High-Level Cross-Resistance to ddI Observed in South African Children Failing an ABC- or d4T-Based 1st-Line Regimen', '2014-07-25', 'imgblog35sm.png', 'blog, High-Level, Cross-Resistance, didanosive, ddI, South African, Children, Failing, ABC, abacavir, d4T, stavudine, 1st line, ARV, regimen, antiretroviral, therapy, NICD, Wits, Wendy Stevens, Jennifer Giandhari, Joanna Ledwaba,blog, High-Level, Cross-Resistance, didanosive, ddI, South African, Children, Failing, ABC, abacavir, d4T, stavudine, 1st line, ARV, regimen, antiretroviral, therapy, NICD, Wits, Wendy Stevens, Jennifer Giandhari, Joanna Ledwaba,blog, High-Level, Cross-Resistance, didanosive, ddI, South African, Children, Failing, ABC, abacavir, d4T, stavudine, 1st line, ARV, regimen, antiretroviral, therapy, NICD, Wits, Wendy Stevens, Jennifer Giandhari, Joanna Ledwaba', 'This is a blog that summarize a South African study showing a significant impact on the change of ddI to AZT in the 2nd-line following ABC or d4T treatment. Going forward, this study proves that it is necessary to take into consideration the effects of mutations on new antiretroviral drugs especially in paediatric patients who have very limited treatment options. This will help to increase effectiveness and improve longevity of their regimens.', NULL, NULL, NULL),
(36, NULL, '<p>With malaria causing around one million fatalities per year among African children, it is impotant to understand how the disease can be influenced by the environment, anti-malarial drugs and human genetics. However, the full impact of human genetics on resistance to the disease remains largely unexplored. Professor Andreas Ziegler from the University of Lubeck, Germany, who is taking a 6-month sabbatical at UKZN, presented a lecture at UKZN\'s Westville Campus on his recent publication at Nature that has identified two novel resistance loci at Human Genome that protects for severe Malaria in Africa.</p>', '<p><center><i>Figure 1. Prof. Ziegler (Middle back) and attendants at the seminar.</i></center></p>\n<p>Ziegler started his lecture explaining that researchers cannot study a virus in a location where the conditions are not suitable for the parasite to thrive, which is why many researchers of Malaria study the virus in Africa, East Asia and South America. In a recent study conducted in Kumasi, Ghana, Prof. Ziegler and collaborators had examined 2,662 malaria cases and 2,200 controls in order to detect if there is genetic differences that predispose to the disease, the researchers conducted a genome-wide association study (GWAS). GWAS was successful to identify genetic differences in many areas, such as cardiology, gastroenterology or oncology, however, in malaria and other infectious diseases, these studies have been only partly successful.</p>\n<p>Ziegler explained that malaria genetics are quite complicated due to the 3 components: the human being, the environment and the parasite. <b><i>\'In research, we try to see what genes make a human susceptible to malaria. When it comes to malaria and drug resistance in parasites, it is important to question if there is anything in the malaria parasite or human genes that can make it resistant to malaria treatment.\'</b></i></p>\n<p><b><i>\'Malaria infection depends on the age of the patient and their location of the disease, geographically. There are high exposition levels for those of younger age. Gender wise, girls who work in households and have to fetch water have a different exposure to infectious diseases than boys. While age plays a role, there are big variability\'s. We took careful control to make sure that the cases and controls matched in ethnicity, age and gender in order to determine if there are any patterns in the contraction of the disease.\'</b></i></p>\n\n<p>Through the use of GWAS approach his research group helped to unravel relevant genetic variants that protect against malaria. Ziegler and his colleagues identified two previously unknown loci which was associated with severe falciparum malaria in patients and controls from Ghana, West Africa. <b><i>\'One of the loci was identified on chromosome 1q32 within the ATP2B4 gene, which encodes the main calcium pump of erythrocytes. The second was indicated by an intergenic single nucleotide polymorphism on chromosome 16q22.2, possibly linked to a neighbouring gene encoding the tight-junction protein MARVELD3. The findings underline the potential of the GWAS approach to provide candidates for the development of control measures against infectious diseases in humans.\'</b></i></p>\n<br>\n\n<p><b>Publication details:</b></p><p><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22895189\">Timmann C, Thye T, Vens M, Evans J, May J, Ehmen C, Sievertsen J, Muntau B, Ruge G, Loag W, Ansong D, Antwi S, Asafo-Adjei E, Nguah SB, Kwakye KO, Akoto AO, Sylverken J, Brendel M, Schuldt K, Loley C, Franke A, Meyer CG, Agbenyega T, Ziegler A, Horstmann RD 2012. Genome-wide association study indicates two novel resistance loci for severe malaria. Nature 489:443-6. doi: 10.1038/nature11334.</a></p>\n\n<p>Professor Andreas Ziegler is Head of the Institute of Medical Biometry and Statistics at Lubeck University, Germany. He is currently a visiting Professor of Biostatistics on sabbatical  based in the School of Mathematics, Statistics and Computer Science, Pietermaritzburg Campus.</p>\n\n<p>The lecture was arranged in association with The Wellcome Trust Africa Centre Genomics Programme, UKZN MRC Flagship project & UKZN\'s School of Mathematics, Statistics and Computer Science as part of a monthly seminar series to present multidisciplinary and high-impact research in Africa. More info on the seminar series, please visit <a href=\"http://www.bioafrica.net/seminars.php\">http://www.bioafrica.net/seminars.php</a></p>\n', 'Zakia Jeewa and Tulio de Oliveira', 'imgblog37.png', NULL, 'Genetic study indicates two novel resistance loci for severe malaria in Africa', '2014-08-01', 'imgblog37sm.png', NULL, NULL, NULL, NULL, NULL),
(37, NULL, '<p>I have been working at the Swiss Institute of Bioinformatics (SIB) in Geneva for just over a week now and what an amazing place to be!  Geneva is a great city with old and magnificent buildings and the public transport is like no other.  I must admit, seeing buses powered by electrical cables was quite a first-world moment for me! And the mountains are beautiful; people are right when they say that every moment in Geneva is a picture perfect moment.</p>', '<p>Walking into the Swiss Institute of Bioinformatics (SIB) on my first day was a daunting experience and I would be lying if I said I was not nervous!  But it turns out I had no reason to be.  Everyone was very friendly and accommodating and welcomed me with open arms. </p>\n<p></p>\n<p>I started a MSc as part of the SSAJRP and NRF program under the supervision of Prof. Tulio de Oliveira and Prof. Paula Sommer. This involve a collaboration with SIB in Geneva. The group I am working at SIB focus their efforts on building a comprehensive database that annotates all known information pertaining to viruses.  This group has set up a website, ViralZone, which offers readers insight into the workings of different viruses and species, including their life cycle, host-virus interactions and viral proteins.  </p>\n<p></p>\n<p>Beautiful and scientifically accurate diagrams are also made by this group to help readers not only understand the information given, but visualize these interactions.  The ViralZone group is made up of Philippe Le Mercier, Patrick Masson and Chantal Hulo- and myself for two months!  They have graciously included me in their tight-knit group and have taught me so much- and it has only been a week!</p>\n<p></p>\n<p>What we as a group will be focusing on is building a bioinformatics resource that annotates the HIV life cycle.   This work will be split into roughly three parts; annotating the virus life cycle and its associated viral proteins, annotating known host-virus interactions and illustrating their role in the HIV life cycle, and describing where and how different antiretroviral drugs work to inhibit the HIV life cycle.  Patrick and myself will be focusing on curating and annotating the host-HIV interactions and together, as a group, we will be building this comprehensive HIV resource.</p>\n<p></p>\n<p>The first week has flown by, I have been taught and learnt so much- not just about HIV but also about other viruses and scientific research.   Philippe, Patrick and Chantal have helped me so much and my only hope is that I can help them in return with building this necessary HIV resource.  </p>\n<p></p>\n<p>I may have only been here one week but I already know I will be very sad to leave Geneva and SIB.  The work experience has been fantastic and I am so grateful to have this opportunity to learn and cement ties between Africa Centre and SIB.  This has been a once in a lifetime experience!</p>', 'Megan Druce', 'imgblogGeneva.png', NULL, 'First impressions of a South African student working in Geneva as part of Swiss South Africa Joint Research Programme (SSAJRP)', '2014-10-07', 'imgblogGenevasm.png', 'blog, swiss, bioinformatics, program, south africa, SIB, Africa Centre, UKZN, NRF, student, Geneva, switzerland, blog, megan, druce, Tulio, de Oliveira, blog, swiss, bioinformatics, program, south africa, SIB, Africa Centre, UKZN, NRF, student, Geneva, switzerland, blog, megan, druce, Tulio, de Oliveira, blog, swiss, bioinformatics, program, south africa, SIB, Africa Centre, UKZN, NRF, student, Geneva, switzerland, blog, megan, druce, Tulio, de Oliveira, blog, swiss, bioinformatics, program, south africa, SIB, Africa Centre, UKZN, NRF, student, Geneva, switzerland, blog, megan, druce, Tulio, de Oliveira, blog, swiss, bioinformatics, program, south africa, SIB, Africa Centre, UKZN, NRF, student, Geneva, switzerland, blog, megan, druce, Tulio, de Oliveira, blog, swiss, bioinformatics, program, south africa, SIB, Africa Centre, UKZN, NRF, student, Geneva, switzerland, blog, megan, druce, Tulio, de Oliveira', 'Megan Druce started a MSc as part of the SSAJRP and NRF program under the supervision of Prof. Tulio de Oliveira and Prof. Paula Sommer. This involve a collaboration with SIB in Geneva. The group she is  working with focus their efforts on building a comprehensive database that annotates all known information pertaining to viruses.  This group has set up a website, ViralZone, which offers readers insight into the workings of different viruses and species, including their life cycle, host-virus interactions and viral proteins. ', NULL, NULL, NULL),
(38, NULL, '<p>This year  ICOHRTA\'s workshop brought together local and international experts in HIV, TB and Malaria research as well as molecular diagnostics. The aim of the workshop was to update the participants on the current trends in the application of molecular diagnostic tools in the diagnosis and monitoring of HIV/ AIDS and its co-morbidities in resource limited settings.</p>', '<p>Some of the institutions represented in the faculty included Stanford University, BRTI, SATuRN, African Institute of Biomedical Science and Technology (AiBST), National Microbiology Reference Laboratory (NMRL), University of Zimbabwe, Africa University, National AIDS and TB Unit, CDC Zimbabwe, Lancet South Africa, Cepheid South Africa and Africa Centre for Health and Population Studies/SATuRN. Twenty participants from various public and private academic institutions, diagnostic companies from Zimbabwe and Zambia. They were drawn from various disciplines including Clinical Medicine, Biomedical Science, and Public Health. </p>\n<p></p>\n<p>The first day of the workshop mostly updated the participants about the HIV/AIDS epidemic with reviews of the epidemics in Africa and the US as well as clinical care and antiretroviral therapy in Zimbabwe. Dr. De La Cruz from Stanford University also introduced the participants to more participatory aspects of the workshop that involved journal club presentations. Everyday of the workshop the participants reviewed and presented papers that highlighted some of the most important aspects of molecular diagnostics, from technologies to applications. </p>\n<p></p>\n<p>Day two started with a glimpse into the development pipeline of the molecular diagnostic company Cepheid highlighting among other future products, the GenXpert based point of care viral load test. As the day progressed, the focus shifted to issues related to pediatric treatment and prevention of mother to child transmission (PMTCT). These included discussions on pediatric AIDS and drug resistance, progress made in the decentralization DBS testing for early infant diagnosis in Zimbabwe, the treatment programmes for children at the two largest central hospitals in Zimbabwe, barriers to provider-initiated testing and counseling for children, surveillance of pediatric drug resistance and point of care monitoring.</p>\n<p></p>\n<p>Day three was dedicated to advances in the diagnosis and drug resistance for TB, Malaria and cryptococcal meningitis. The talks included general overviews of the TB and Malaria epidemics in Zimbabwe, updates on various public health programmes to control the epidemics as well as new diagnostics for malaria as well updates on TB drug susceptibility testing. </p>', 'Justen Manasa', 'imgblog38.png', NULL, 'HIV, TB and Malaria Molecular Diagnostics Workshop, Harare, Zimbabwe 2014', '2014-10-06', 'imgblog38sm.png', 'molecular, workshop, ICOHRTA, Zimbabwe, Stanford, SATuRN, HIV, TB, Malaria, Drug resistance, 2014, training, capacity building, justen manasa, southern african treatment resistance network, Harare, Africa Centre, UKZN, molecular, workshop, ICOHRTA, Zimbabwe, Stanford, SATuRN, HIV, TB, Malaria, Drug resistance, 2014, training, capacity building, justen manasa, southern african treatment resistance network, Harare, Africa Centre, UKZN, molecular, workshop, ICOHRTA, Zimbabwe, Stanford, SATuRN, HIV, TB, Malaria, Drug resistance, 2014, training, capacity building, justen manasa, southern african treatment resistance network, Harare, Africa Centre, UKZN, molecular, workshop, ICOHRTA, Zimbabwe, Stanford, SATuRN, HIV, TB, Malaria, Drug resistance, 2014, training, capacity building, justen manasa, southern african treatment resistance network, Harare, Africa Centre, UKZN, molecular, workshop, ICOHRTA, Zimbabwe, Stanford, SATuRN, HIV, TB, Malaria, Drug resistance, 2014, training, capacity building, justen manasa, southern african treatment resistance network, Harare, Africa Centre, UKZN', 'This year  ICOHRTA\'s workshop brought together local and international experts in HIV, TB and Malaria research as well as molecular diagnostics. The aim of the workshop was to update the participants on the current trends in the application of molecular diagnostic tools in the diagnosis and monitoring of HIV/ AIDS and its co-morbidities in resource limited settings.', NULL, NULL, NULL),
(39, NULL, '<p>Over the past 5 years, there has been a revolution in higher education with the arrival of Massive Open Online Courses (MOOCs). These freely accessible courses represent a new generation of online education, provided by some of the top-ranked universities in the world and geared toward huge numbers of students.</p>', '<p> In the words of the Stanford-academic-turned-MOOC-founder Andrew Ng, the demand for such high-quality online educational platforms is <b><i>\'growing faster than Facebook\'</b></i>, and with his own site, Cousera, boasting over 9 million members from 190 countries, he may well be right. </p>\n<p>As a UK student of biochemistry and genetics transitioning without formal university education into the world of public health in South Africa, I have found MOOCs to be an incredible resource. I have learnt the basics of epidemiology from academics at UNC Chapel Hill and PennState, and large-scale biostatistics, bioinformatics and programming from world-leaders at Johns Hopkins. These courses, combined with more traditional books and journals, gave me a solid knowledge base which allowed me to streamline my learning when I got to engage face-to-face with my mentors.</p>\n<p>More recently, and of particular relevance to SATuRN, after being awarded a fellowship to work with Professor Tulio de Oliveira on understanding the transmission of HIV infection to adolescent girls in rural South Africa using phylogenetic approaches at the Wellcome Trust Africa Centre of Health and Population Studies, I have taken a fantastic course in computational molecular evolution run by the Technical University of Denmark. Spanning from introductory lectures on evolutionary theory to more advanced modules on Bayesian inferences of phylogeny, the course has really helped me to conceptually understand what is going on \'behind the scenes\' in the CPU when phylogenetic models are running.  </p>\n<p>Most MOOCs are very flexible and so you can engage with them as much or as little as you like. For some modules where I feel comfortable with the subject, I tend to just watch a few lectures. For others where the material is less familiar (as well as science I also enjoy some of the courses on philosophy and history), or if I need to acquire a certificate for completion, I try to complete all lectures, quizzes and assignments. </p>\n<p>The great advantage of these courses is that you can get top-quality education anywhere in the world with an internet connection. Together with TedTalks, and the rest of educational \'digital tsunami\', they represent a fantastic capacity-building resource, particularly in developing countries where traditional educational methods may be harder to access at high-quality. I am therefore very pleased to recommend them as a tool for bioinformatics education to the SATuRN partners. </p>\n<p><b><i>Rachael Dellar</b></i>, Research Fellow at Africa Centre for Health and Population Studies</p>\n<p></p>\n<p><b><i>Links:</b></i></p>\n<p><a href=\"https://www.coursera.org/\">Cousera</a></p>\n<p><a href=\"https://www.coursera.org/unc\">UNC Chapel Hill Cousera</a></p>\n<p><a href=\"https://www.coursera.org/psu\">Penn State Cousera</a></p>\n<p><a href=\"https://www.coursera.org/jhu\">Johns Hopkins Cousera</a></p>\n<p><a href=\"https://www.coursera.org/course/molevol\">Computational molecular evolution run by the Technical University of Denmark</a></p>\n<p><a href=\"http://www.ted.com/\">TedTalks </a></p>', 'Rachael Dellar', 'imgblog39.png	', NULL, 'Massive Open Online Courses: Huge potential for bioinformatics education', '2014-10-13', 'imgblog39sm.png', 'blog, online, bioinformatics, course, phylogeny, africa, education, Coursera, Rachael Dellar, Africa Centre, Youtube videos, cpacity building, stanford, bayesian, genomics, blog, online, bioinformatics, course, phylogeny, africa, education, Coursera, Rachael Dellar, Africa Centre, Youtube videos, cpacity building, stanford, bayesian, genomics, blog, online, bioinformatics, course, phylogeny, africa, education, Coursera, Rachael Dellar, Africa Centre, Youtube videos, cpacity building, stanford, bayesian, genomics, blog, online, bioinformatics, course, phylogeny, africa, education, Coursera, Rachael Dellar, Africa Centre, Youtube videos, cpacity building, stanford, bayesian, genomics, blog, online, bioinformatics, course, phylogeny, africa, education, Coursera, Rachael Dellar, Africa Centre, Youtube videos, cpacity building, stanford, bayesian, genomics, Durban, South Africa, Durban, South Africa', 'Over the past 5 years, there has been a revolution in higher education with the arrival of Massive Open Online Courses (MOOCs). These freely accessible courses represent a new generation of online education, provided by some of the top-ranked universities in the world and geared toward huge numbers of students. In the words of the Stanford-academic-turned-MOOC-founder Andrew Ng, the demand for such high-quality online educational platforms is ?growing faster than Facebook?, and with his own site, Cousera, boasting over 9 million members from 190 countries, he may well be right.', NULL, NULL, NULL),
(40, NULL, '<p>In a gripping, informative seminar, Dr van Zyl took the audience on a journey through a Tale of 4 Cities (Berlin, Mississipi, Cape Town, Pittsburg) in outlining researcher\'s strive towards a cure for HIV.  </p>', '<p>He began the journey in Berlin with the Berlin-patient who was apparently cured following a bone marrow transplant from an individual with the CCR5 Delta 32 mutation that appears to confer protection against HIV infection.  This patient\'s incredible recovery was hailed internationally but replicating this outcome on a larger scale is impractical given the unique nature of this patient\'s concomitant condition (leukemia) and the prohibitive cost of his treatment. Scepticism abounded among researchers but the hope of a cure based on the Delta 32 mutation persisted.  Several years of follow-up indicated that this patient remained suppressed showing no sign of viral rebound.</p>\n<p></p>\n<p>His next stop was Mississippi, USA and the infant who was initiated on treatment within days of birth in 2010, tested negative and remained suppressed for 27 months, a record in terms of period an individual has remained suppressed without antiretroviral treatment.  Again, hope was rekindled and thoughts of an AIDS free generation sprouted.  Eliminating HIV in the young ensures that mother-to-child transmission of HIV will no longer be a concern, that infants born infected with the disease no longer had to be exposed to life-long antiretroviral drugs and the associated toxicities and that we, the research community, were that much closer to eliminating this scourge to human health.  Alas, it was not to be for on the next leg of this journey, Melbourne, Australia and the International AIDS conference July 2014.  The conference followed on the heels of the staggering announcement that the Mississippi baby was found to have detectable viral load and was, in fact, not cured but had rebounded.  While extremely disappointing, this child represented the hope that a cure is not inconceivable and a wealth of lessons learnt that would certainly inform future research in the field.  </p>\n<p></p>\n<p>Finally, Dr van Zyl stopped off in his hometown of Cape Town and outlined his own research where he undertook highly sensitive qPCR assays to detect HIV RNA and DNA at single copy levels.  This work was conducted in Pittsburgh, USA and was supported by a Fogarty Award that Dr van Zyl received.  His preliminary findings revealed distinct viral kinetics in infants infected in-utero or during labour, diagnosed early (within 2 months of birth) and initiated immediately on ART.  One of the primary challenges he outlined in cure research is accurately detecting low-level viremia.  Current viral detection and quantification methods are not sensitive and reliable enough to detect virus at single-copy levels, they require specialised techniques or large volumes of blood making them challenging and prohibitive on a larger scale. As in the past with the Berlin patient and the Mississippi baby, declaring a patient \'cured\' may be premature without the ability to access latently infected cells that may be sequestered within remote or impenetrable anatomical sites.  The same is true for antiretroviral treatment that may not permeate to every anatomical and cellular site of HIV infection.</p>\n<p></p>\n<p>While Dr van Zyl highlighted these challenges inherent to research towards a cure for HIV he was hopeful that such a panacea would be forthcoming. All is not bleak, he emphasised but we do have a ways to go before we can declare that we do indeed have a cure for HIV.  </p>\n<p></p>\n<p>As part of the Africa Centre MRC Flagship seminar series held monthly in the KRITH Building, NRMSM, UKZN, Dr Gert van Zyl presented a talk titled <b><i>\'Antiretroviral therapy initiated before 2-months-of-age reduces transcriptionally active HIV-1 DNA persistence\'</b></i> on the 19th September 2014.  </p>\n<p></p>\n<p>Gert van Zyl (MBChB, FCPath(SA) Virology, PhD) is a South African trained medical doctor, who specialized in Virological Pathology. He is working for the South African National Health Laboratory Service at Tygerberg Academic Hospital, Cape Town, and is affiliated with Stellenbosch University, Division Medical Virology, where his roles include a diagnostic consultation service, laboratory quality assurance, research, undergraduate teaching and postgraduate supervision. His research interest lies in failure monitoring, antiretroviral resistance testing, factors associated with antiretroviral failure and resistance in adults and children from resource limited settings.  Recently he has become involved in the study of HIV-1 persistence in children on long-term antiretroviral therapy collaborating with Prof Mark Cotton, Stellenbosch University,  Dr John Mellors, University of Pittsburgh and Dr Mary Kearney, National Cancer Institute, USA.  </p>\n<p><b> <a href=\"seminars.php\">The Wellcome Trust Africa Centre Genomics Programme and the UKZN MRC Flagship Project present a monthly seminar<b> at the Nelson R Mandela School of Medicine, please visit our seminar webpage to see our current programme</a>.</p>', 'Siva Danaviah', 'imgblog40.png', NULL, 'Tale of 4 Cities in outlining researcher\'s strive towards a cure for HIV', '2014-10-14', 'imgblog40sm.png', 'tale, cure, HIV, seminar, gert Van Zyl, Durban, MRC seminar, Flagship, Stellenbosch, ARV, children, Siva, Danaviah, tale, cure, HIV, seminar, gert Van Zyl, Durban, MRC seminar, Flagship, Stellenbosch, ARV, children, Siva, Danaviah, tale, cure, HIV, seminar, gert Van Zyl, Durban, MRC seminar, Flagship, Stellenbosch, ARV, children, Siva, Danaviah, tale, cure, HIV, seminar, gert Van Zyl, Durban, MRC seminar, Flagship, Stellenbosch, ARV, children, Siva, Danaviah, tale, cure, HIV, seminar, gert Van Zyl, Durban, MRC seminar, Flagship, Stellenbosch, ARV, children, Siva, Danaviah, tale, cure, HIV, seminar, gert Van Zyl, Durban, MRC seminar, Flagship, Stellenbosch, ARV, children, Siva, Danaviah, ', 'In a gripping, informative seminar, Dr van Zyl took the audience on a journey through a Tale of 4 Cities (Berlin, Mississipi, Cape Town, Pittsburg) in outlining researcher?s strive towards a cure for HIV.', NULL, NULL, NULL),
(41, NULL, '<p>On the 16th of February 2015, three Masters students from Africa Centre were sent to the University of Western Cape (UWC), Cape Town, to partake in the Bioinformatics Support Platform Introduction to Bioinformatics Course 2015.  Sthembiso Msweli, Zandile Sibisi and Megan Druce are second year Masters students of Africa Centre (UKZN), who fall under the MRC Flagship Project.  Each student is involved in different projects, although each is related to HIV.  </p>\n', '<p>The Bioinformatics course ran from the 16th of February until the 2nd of April 2015 and was orchestrated by the South African National Bioinformatics Institute (SANBI).  During this time we were exposed to various Bioinformatics tools and techniques.  These included Python and BioPython programming, database construction using SQL and SQLite, Phylogenetic analysis, gene annotation, Next-Generation Sequencing analysis using tools like Galaxy and EMBOSS, and Biostatistics using RStudio.  Although limited to a time-constraint of seven weeks, this course was well planned and we were able to grasp the basic principles of each technique taught.  Throughout the course period we received training in Python programming, as well as navigating the terminal in a Linux-based environment.  Although seven weeks is not long enough to become an expert in any one of these techniques, we feel we came away with a much stronger Bioinformatics background and are confident enough to carry out simple computational biology tasks.  </p>\n\n<p>Overall, we were impressed with the course and SANBI.  SANBI is one of the few core Bioinformatics research institutes in South Africa and definitely one of the best.  They offer numerous Bioinformatics courses and studentships and are proficient in cutting-edge Bioinformatics techniques.  They are well versed in what is new in the Bioinformatics world and offer unique services to research institutes in South Africa and around the world.  </p>\n\n<p>It was an honor and great experience to be chosen to participate in this course.  We thoroughly enjoyed our time in Cape Town and interacting with other students involved in Bioinformatics-related fields.  A special thanks to Peter van Heusden for coordinating the course and for being an approachable and interesting lecturer.  We would also like to thank our supervisor, Prof. Tulio de Oliveira, for sending us on this course and encouraging our growth as scientists.  We hope to do Africa Centre proud by using our newly acquired skills in the future!</p>\n', 'Megan Druce, Zandile  Sibisi & Sthembiso Msweli', 'BSPSANBI2015.jpg', NULL, 'Experience of 3 UKZN/Africa Centre students at the 7-week national bioinformatics workshop 2015', '2015-04-23', 'BSPSANBI2015sm.jpg', NULL, NULL, NULL, NULL, NULL);
INSERT INTO `b_blogs` (`id`, `email`, `summary`, `summary2`, `authors`, `photo2`, `bioafricaSATuRN`, `title`, `date`, `image`, `keywords`, `topdescription`, `video`, `pubid`, `imagefront`) VALUES
(42, NULL, '<p>During my undergraduate and BSc Honours, I studied Genetics and developed an interest in human diseases, particularly their genetic basis.  This led me to applying and subsequently becoming part of the MRC Flagship Program at Africa Centre. Within this program, I began my Masters in Human Genetics under the supervision of Prof. Tulio de Oliveira (Africa Centre) and Dr. Paula Sommer (UKZN).  I worked on a collaborative project with the Swiss Institute of Bioinformatics (SIB) to develop two HIV bioinformatics resources; one housed in ViralZone (HIV virus) and one within BioAfrica (HIV-1 proteome).  During this time I had the opportunity to work in Switzerland at SIB with the Swiss-Prot ViralZone group to begin the development of the ViralZone HIV Resource.  In South Africa, I focused on upgrading the BioAfrica HIV-1 Proteome Resource with current data and additional information</p>', '<p>Both of these resources are very popular and were presented in two international conferences.  The ViralZone HIV Resource has been presented at the 12th Basel Computational Biology Conference (Basel, Switzerland) and the Biocuration 2016 conference (Geneva, Switzerland).  The BioAfrica HIV-1 Proteome Resource was presented by myself at the 6th ACM Conference on Bioinformatics, Computational Biology and Health Informatics (Atlanta, Georgia) and published in the BCB15 Proceedings.  Furthermore, a manuscript describing the upgrade to the <a href=\"http://bioafrica.net/publications.php?pubid=124\">BioAfrica resource was accepted for publication by the DATABASE (Oxford) journal</a>.</p>\n\n<p>In addition to carrying out Masters-related work, I took part in several courses including a Wellcome Trust and Sanger Institute course titled ?Advanced Course on Genomic Epidemiology in Africa?, a South African National Bioinformatics Institute (SANBI) course titled ?Bioinformatics Support Platform Introduction to Bioinformatics Course? and a K-RITH, Harvard and Ragon Institute funded course titled ?Intermediate Biostatistics Course?, among others.  Both of my supervisors supported my attendance to these courses and, when necessary, Africa Centre provided additional funding.</p>  \n\n<p>I have since completed my<i> <b> Masters degree, graduating with Cum Laude</b></i>, and have been accepted into the international PhD program at the German Cancer Research Institute (DKFZ).  I will begin my PhD at DKFZ in July under the supervision of Dr. Michael Milsom from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) and Prof. Dr. Benedikt Brors from the Applied Bioinformatics group at DKFZ.  My PhD will involve the analysis of the hematopoietic stem cell ageing process and its involvement in leukemogenesis. </p> \n\n<p><i>\'I am very thankful to my supervisors and everyone at Africa Centre, UKZN and SIB who have guided and supported me during my Masters career.  I am especially thankful for the wonderful opportunities I was given and the freedom to seek additional training.  This has helped shape me into a better scientist and helped me gain a position at one of the worlds most prestigious cancer research institutes.\'</i></p>\n<br><p><b><i>More Information:</b></i></p>\n<p> - Publication: <a href=\"http://bioafrica.net/publications.php?pubid=124\">Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource</a></p>\n<p> - Web resource:  <a href=\"http://www.bioafrica.net/proteomics/HIVproteome.html\">The BioAfrica HIV proteome resource.</a></p>\n<p> - Blogs:  <a href=\"http://www.bioafrica.net/blogs.php?id=41\">Experience of 3 UKZN/Africa Centre students at the 7-week national bioinformatics workshop 2015</a></p>\n<p> - News:  <a href=\"http://www.bioafrica.net/news.php?id=151\">First two South African MSc students graduate from the MRC Flagship Program: Inspiring blogs about their experiences and achievements.</a></p>\n\n\n', 'Megan Druce', 'imgblogGeneva.png', NULL, 'Megan Druce: from Cum Laude MSc to a Scholarship for a PhD in Germany...', '2016-04-18', 'imgblogGenevasm.png', 'Megan Druce, Swiss Institute of bioinformatics, MRC Flagship, MSC, masters, cum laude, Phd, fellowship, doctoral fellowship, Germany, South African, achievement, bioinformatics, proteome, Geneva, 2016, student, KRISP, Megan Druce, Swiss Institute of bioinformatics, MRC Flagship, MSC, masters, cum laude, Phd, fellowship, doctoral fellowship, Germany, South African, achievement, bioinformatics, proteome, Geneva, 2016, student, KRISP, Megan Druce, Swiss Institute of bioinformatics, MRC Flagship, MSC, masters, cum laude, Phd, fellowship, doctoral fellowship, Germany, South African, achievement, bioinformatics, proteome, Geneva, 2016, student, KRISP, Megan Druce, Swiss Institute of bioinformatics, MRC Flagship, MSC, masters, cum laude, Phd, fellowship, doctoral fellowship, Germany, South African, achievement, bioinformatics, proteome, Geneva, 2016, student, KRISP, Megan Druce, Swiss Institute of bioinformatics, MRC Flagship, MSC, masters, cum laude, Phd, fellowship, doctoral fellowship, Germany, South African, achievement, bioinformatics, proteome, Geneva, 2016, student, KRISP', 'KRISP Alumi Megan Druce have since completed her Masters degree, graduating with Cum Laude, and have been accepted into the international PhD program at the German Cancer Research Institute (DKFZ).  I will begin my PhD at DKFZ in July under the supervision of Dr. Michael Milsom from the Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) and Prof. Dr. Benedikt Brors from the Applied Bioinformatics group at DKFZ.  My PhD will involve the analysis of the hematopoietic stem cell ageing process and its involvement in leukemogenesis. ', NULL, NULL, 'imgblogGeneva2.png'),
(43, NULL, '<p>After working at Hlabisa Laboratory for 9 years as a Lab Technologist in 2014 I received a Masters scholarship from MRC Flagship to do MSc at UKZN. The scholarship provided tuition fees, monthly stipend as well as a very nice Mac book computer. My MSc project was based on the use of Next Generation Sequencing (Miseq) for HIV-1, determining drug resistance mutations from patients failing ART in Hlabisa district. The environment was very conducive and we had a very good team leading the laboratory work. </p>', '<p>During my two years at Genomic Centre at UKZN, weekly to monthly I have been able to interact with international Scientists when they come to do weekly seminar talks. The Centre also had several Post Docs [Alain, Anne, Eduan, Justen and Siva (senior scientist)] who were always willing to provide Mentorship and Coaching at all times to us. This made me realized that to be a good scientist I have to continuously learn and adapt to the latest trends. And it also provided different culture to the one I was used to. I was able align my research questions. </p>\n\n<p>In 2015, I did Biostatistics Reasoning Course with UKZN for two weeks; this course was so helpful on how to conduct my data analysis.  Furthermore, my supervisor (Prof. Tulio) sent us to University of Western Cape (SANBI) to do intense Bioinformatics Course. This for me came at a right time because my project needed some of bioinformatics? tools. We learned the use of Phylogenetics, Python programming, Statistics, SQL, System Biology and etc. We had opportunities to travel to any conferences be national or international for presentation.</p> \n\n<p><i>\'After the completion of my MSc I went back to the NHLS laboratory where I am currently working as laboratory manager at Bethesda. My future goals include going back to the university to do PhD in Virology, and continue to improve my bioinformatics skills.\'</i></p>     \n\n<br><p><b><i>More Information:</b></i></p>\n<p> - Blogs:  <a href=\"http://www.bioafrica.net/blogs.php?id=41\">Experience of 3 UKZN/Africa Centre students at the 7-week national bioinformatics workshop 2015</a></p>\n<p> - News:  <a href=\"http://www.bioafrica.net/news.php?id=151\">First two South African MSc students graduate from the MRC Flagship Program: Inspiring blogs about their experiences and achievements.</a></p>\n\n\n', 'Sthembiso Msweli', 'imgblog43.png	', NULL, 'Sthembiso Msweli: from Hlabisa to MSc and Further Promoted to Laboratory Manager...', '2016-04-17', 'imgblog43sm.png', NULL, NULL, NULL, NULL, NULL),
(44, NULL, '<p>Our little group, Veron Ramsuran, Ben Chimukangara and myself left the shores of South Africa to travel to Switzerland, the land of the Alps and chocolate on the 9th June. We ended up staying in a beautiful place called Lavaux, near Lausanne. Who would have thought Switzerland would have a place full of vineyards, along the giant Lake Geneva, which is listed as a UNESCO heritage site? The Lavaux vineyard area is unique with the narrow streets, tiny villages and many traditional family wine-making businesses along the way. It seemed almost surreal that we would be treated to the absolute splendour and peace of Lake Geneva, where all types of boats and watercraft were seen on the lake, as the Swiss take to the water for their exercise and enjoyment for the day. </p>', '<p>We spent the weekend experiencing the joy of public transport, jumping on and off trains, as well as missing a few of the trains coming through the small stations. In fact, the three of us got to know the train stations very well. We managed to make our way to Geneva where we did a lot of walking around, taking selfies and sightseeing within this amazing city. We found ourselves in a tiny Swiss shop full of chocolates and all sorts of goodies and purchased a few things for our families back home. </p>\n<p>Monday came around soon enough and all three of us, now armed with the knowledge of how the trains worked, managed to miss the first train that we needed, in order to get to the University of Lausanne, it might have had something to do with Ben not being a morning person. Luckily for us, our meeting with Ioannis Xenarios; the Director of Vital-IT and Swiss Institute of Bioinformatics (SIB), was about mid-morning so we jumped on the second train within the hour. We arrived on the doorstep of the Lausanne University and were introduced to Vital-IT\'s heads of department and settled into receiving a presentation from them about the structure of their scientific business. </p>\n<p>They have eight senior scientists who lead research and collaborative development projects at Vital-IT and their skills are inter-complementary with many domains of ability that involve computational sciences, algorithm development and data analysis. Vital-IT facilitates the provision of technical and scientific support, working with scientists and on research projects at the Schools of Higher Education. Vital-IT also coordinates the use of information technology and bioinformatics resources in life sciences. In particular, it supports research through integration with the genomics, proteomics and imaging core facilities in south-west Switzerland and by taking part in several SystemsX.ch and international projects. </p>\n<p>Their presentation was structured on the history of their business and how they built the business over the years using their knowledge, expertise and plenty of support from various sectors. Their key success point was to ensure the stability of harnessing all areas of expertise to utilise. They put their success down to harnessing all areas of expertise within their business as well as receiving funding from different sectors instead of relying on funding from a sole supplier. This point was very informative as it highlighted the need of working as a team in order to become successful. What their presentation emphasised was for KRISP to utilise the insight and ability from a successful group such as Vital-IT in order to become a successful model incorporating bioinformatics within the centre.</p>\n<p>It was our turn to present to their group. The presentation helped the Vital- IT team visualise our structure of KRISP and where we were with the setting up of KRISP. It also identified our weak areas within KRISP, which led to a fruitful discussion and some helpful suggestions so that the various heads could suggest solutions and options for us to discuss and ascertain if we could use those ideas. <b><i>\'One of the suggestions was to attract the right expertise to KRISP, expertise within our various fields in order to ensure we cover all services to provide the correct service to collaborators and third parties. Another useful suggestion was to ensure that we start with charging for omics data and bioinformatics analysis from the beginning as this is a costly exercise. They suggest that we should not starting by giving everything for free, as later on when you want to start charging for a service your clients and collaborators are going to want that service for free and it will be difficult, if not impossible, to have funding to retain top scientists.</b></i></p>\n<p><center><img src=\"imagesBIO/imgblog44b.png\"></a></center> </p>\n<p>On Wednesday, we packed up and left Lavaux at 3:30 am in the morning so that we could make the first flight out to Sweden and hopefully not miss any of the other flights along the way. After spending the day, running around the three different airports with our heavy luggage and not missing a single flight, we arrived in Sweden, the land of Abba and Swedish meatballs. It was our first experience of using the bus transport route only to miss our stop and end up a few kilometers down the road. Needless to say, we had to drag our heavy luggage around the town of Stockholm trying to figure out where our hotel was. </p>\n<p><center><img src=\"imagesBIO/imgblog44c.png\"></a></center> </p>\n\n<p>We were exhausted. Along the way, we bumped into a Swede who quite happily showed us the way to our hotel. En route, whilst we were chatting to him, we happened to meet Elina Staaf, the project coordinator from SciLife laboratory, who very kindly took us through to the hotel to check in. We then went for dinner to a restaurant down the road from the hotel without the luggage thank goodness!. We had a wonderful time chatting with her and finding out what the next few days were going to hold for us. We learnt that we were going to be introduced to all the heads of department at SciLife Laboratory, which is a national centre for molecular biosciences and focuses on health and environmental research. </p>\n<p>SciLife Lab is a national resource formed on a collaboration between four universities: Karolinska Institute, KTH Royal Institute of Technology, Stockholm University and Uppsala University. SciLife Laboratory combines both frontline technical expertise with advanced knowledge of translational medicine and molecular biosciences. This enables researchers from all over Sweden, to have access to the technology and the expertise at SciLife Laboratory with subsidised costs, whilst the users from commercial companies pay the full costs of the performed analysis. SciLife Lab\'s aim is to build a strong research community through education and collaborative exchange. </p>\n<p>We arrived at SciLife Laboratory and were privileged to experience the beautiful architecture and surroundings that host this prestigious Institute. Our days involved several presentations and group meetings where many heads of departments met with us, allowed us to questioned them and proposed different strategies and solutions for developing KRISP into a successful molecular biosciences platform using their knowledge and experience they had gained over the years to prevent mistakes and streamline KRISP\'s growth. <b><i>\'One of the suggestions was that we work together with collaborators to design the projects and to write grants applications as this will ensure that appropriate data is produced and funding is available for advanced analysis\'</b></i>. </p><p>We met some amazing scientific collaborators and hope to work with them in the future and bring some of their expertise to KRISP through future scientific projects and research.  We eventually made our way to the airport on the Friday afternoon, nearly missing our flight and started our long trek back home, we were filled with excitement and optimism for building up the future of KRISP.  </p>\n\n\n', 'Nicolette Crozier, Benjamin Chimukangara, Veron Ramsuran', 'imgblog44.png', NULL, 'Meeting of the Swiss, Swedes and South Africans minds', '2017-07-25', 'imgblog44sm.png', 'VitalIT, Swiss Institute of bioinformatics, SIB, SciLifeLab,Geneva, Lausanne, ioannis Xenarios, bioinformatics, blog, travel, computational biology, KRISP, team, Nicolette Crozier, Veron. Ben, trains, genomics, business plan, 2017, Sweede, Swiss, South Africa, minds, VitalIT, Swiss Institute of bioinformatics, SIB, SciLifeLab,Geneva, Lausanne, ioannis Xenarios, bioinformatics, blog, travel, computational biology, KRISP, team, Nicolette Crozier, Veron. Ben, trains, genomics, business plan, 2017, Sweede, Swiss, South Africa, minds, VitalIT, Swiss Institute of bioinformatics, SIB, SciLifeLab,Geneva, Lausanne, ioannis Xenarios, bioinformatics, blog, travel, computational biology, KRISP, team, Nicolette Crozier, Veron. Ben, trains, genomics, business plan, 2017, Sweede, Swiss, South Africa, minds, VitalIT, Swiss Institute of bioinformatics, SIB, SciLifeLab,Geneva, Lausanne, ioannis Xenarios, bioinformatics, blog, travel, computational biology, KRISP, team, Nicolette Crozier, Veron. Ben, trains, genomics, business plan, 2017, Sweede, Swiss, South Africa, minds', 'KRISP Blogs on travel to visit SciLifeLab in Sweeden and Bital-IT in Switzerland. KRISP met some amazing scientific collaborators in Sweeden and Switzerland and hope to work with them in the future and bring some of their expertise to KRISP through future scientific projects and research.  2017', NULL, NULL, 'imgblog44sm2.png'),
(45, NULL, '<p>I was doing an all-night shift in the hospital where I\'m working this year when I received an e-mail offering a 1,000 USD Travel Fellowship to attend a conference in Eastern Europe. But in order to receive the grant I had to register for the conference (and pay the not insignificant fees) by 9am the next day. Classic 419 scam, right?</p>', '<p>Fortunately, it wasn\'t, and today I find myself in Prague, Czech Republic, buzzing after three days at the world\'s premier bioinformatics and computational biology meeting: the annual meeting of the International Society for Computational Biology, the 25th Intelligent Systems in Molecular Biology Conference.</p>\n<p>I am an MSc candidate at KRISP, but this year I\'ve been a bit out of the scientific loop while completing my clinical community service at a small rural hospital in northern KwaZulu-Natal. In this small seven month small break, it feels like the ground has already shifted significantly. I am amazed at the work being done in the fields of personalised medicine, human-microbiome interactions and human data science. At times it felt a bit like I was an extra in a science fiction movie. I want to share a few highlights.</p>\n<br><p><b>1. Open Humans</b></p>\n<p>Madeleine Ball is the founder of the Open Humans Foundation, a not-for-profit organisation that seeks to give full control of personal genomic and health data to the individual from whom the data is collected. Currently this sort of data stays with the researchers who keep it safely locked away, inaccessible to the individuals or any scientist who may want to reuse the data. </p>\n<p>As could be predicted, the idea of sharing personally identifying data inspired some unease in the audience. Genetic discrimination. Uncovering the existence of a previously unknown relative. In discussing the various ethical, legal and social implications of personal data sharing, one delegate made an interesting point:</p>\n<p><b><i>\'A few decades ago a new technology was developed that could store personally identifying information such as disease risk profile, ethnicity or hidden parentage and there were similar concerns as those we\'re describing. But today just about everyone has a camera on their phone and shares photographs freely!\'</b></i></p>\n<br><p><b>2. Open Access Publishing</b></p>\n<p>The existing commercial scientific publishing model is as follows.</p>\n<p>- Public pays Scientist to do science.</p>\n<p>- Scientist does science.  </p>\n<p>- Scientist gives science to commercial Publisher, who does not pay Scientist, but takes over full copyright of science. Scientist may no longer share or use any of this work without Publisher\'s permission.</p>\n<p>- Reviewer, another scientist, reviews science but does not get paid for this service. </p>\n<p>- Science is published.</b></p>\n<p>- Public pays Publisher to access Science.</p>\n<p><b>See the problem?</b> The public pays twice. For a more comprehensive argument as to why scientific publishing needs an overhaul, see this piece in the Guardian.</p>\n<p>I had the pleasure of chatting to some of the Public Library of Science (PLoS) people at the conference. PLoS is a not-for-profit Open Access publisher, with a different funding model, allowing the public to pay for the science to be published and for the work to then be accessible to anyone with an internet connection. Commercial or Open Access, it is the same scientists do the same work, which is reviewed by the same peers, according to the same standards of scientific rigour. </p>\n<br><p><b>3. Open Data</b></p>\n<p>Fiona Nielsen started out as a frustrated PhD student, severely constrained by the inaccessibility of human genomic data, and has since transformed into an inspiring entrepreneur championing open data in human genomics. She was so determined that she established both a charity and a company in pursuit of the cause. She speaks about the FAIR principles of Open Data:</p>\n<p>1. Findable</p>\n<p>2. Accessible</p>\n<p>3. Interoperable</p>\n<p>4. Reusable</p>\n<p>Everyone loves a good acronym! She gave a keynote address at the Student Council Symposium and I want to be like her when I grow up. </p>\n<p>Here at KRISP we\'re developing a viral metagenomic pipeline, and access to suitable data for benchmarking remains a nightmare. I just hope that her company Repositive expands its services to include metagenomic data ASAP. </p>\n<br><p><b>4. Personalised medicine</b></p>\n<p>Christoph Bock delivered a keynote address entitled \'Bioinformatics for Personalized Medicine: Looking Beyond the Genome\' where he discussed how the complex function of our bodies requires trillions of individual cells to integrate, interact, and strike the right balance between stability and plasticity. This requires both the basic blueprint of all available possibilities as encoded in our genome, and other layers of regulation that switch on or turn off specific genes under appropriate circumstances. The latter is commonly referred to as the epigenome. With the use of CRISPR-cas9 technology we have the capacity to alter these epigenomic instructions, and thus influence the activity of our own genes. It is really quite fantastical. The best part? My colleague at KRISP, <a href=\"http://www.krisp.org.za/people.php?surname=Ramsuran\">Veron Ramsuran</a>, works precisely in this field. Maybe I didn\'t have to go all the way to Prague after all...</p>\n<p>I came back energised by all of the scientific ideas that we can implement in KRISP when I return, after only five more months of \'saving lives\'.</p>\n<br><p><i><b><a href=\"http://www.krisp.org.za/people.php?surname=Moosa\">Yumna Moosa</a> is an amateur mathematician who studied medicine by mistake, inspired by a naive desire to \'help people\'</b>. After completing her medical internship she came to her senses and registered for an MSc in Virology and Bioinformatics at KRISP, and is working to develop software for virome analysis. She is interested in human-microbiome interactions, and the way that these complex microbiological networks influence health and disease. This is partly because she has New Age tendencies and likes to believe that <b>\'We are all One\'</b>. She is currently completing her community service at Bethesda Hospital in rural KwaZulu Natal.</p>', 'Yumna Moosa', 'imgblogYumnaMoosa.jpg', NULL, ' Bioinformaticians are pioneering the future of science', '2017-07-28', 'imgblogYumnaMoosasm.jpg', NULL, NULL, NULL, NULL, 'imgblogYumnaMoosasm2.jpg');

-- --------------------------------------------------------

--
-- Table structure for table `b_casebook`
--

CREATE TABLE `b_casebook` (
  `id` int(11) UNSIGNED NOT NULL,
  `title` text NOT NULL,
  `link` tinytext
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_casebook`
--

INSERT INTO `b_casebook` (`id`, `title`, `link`) VALUES
(1, 'Title Page', 'http://www.bioafrica.net/manuscripts/HIVTB_book_title.pdf'),
(2, 'Foreword', 'http://www.bioafrica.net/manuscripts/HIVTB_book_foreword.pdf'),
(3, 'Acknowledgements', 'http://www.bioafrica.net/manuscripts/HIVTB_book_acknowledgements.pdf'),
(5, 'Chapter 1: HIV drug resistance introduction', 'http://www.bioafrica.net/manuscripts/HIVTB_book_chapter1_HIVresistance.pdf'),
(6, 'Chapter 2: TB drug resistance introduction', 'http://www.bioafrica.net/manuscripts/HIVTB_book_chapter2_TBresistance.pdf'),
(7, 'Chapter 3: South African guidelines and introduction to clinical cases', 'http://www.bioafrica.net/manuscripts/HIVTB_book_chapter3_SAguidelines.pdf'),
(8, 'Chapter 4: HIV drug resistance clinical cases (online version)', 'http://www.bioafrica.net/cases.php?org=1'),
(9, 'Chapter 5: TB drug resistance clinical cases (online version)', 'http://www.bioafrica.net/cases.php?org=2'),
(10, 'Abbreviations', 'http://www.bioafrica.net/manuscripts/HIVTB_book_abbreviations.pdf'),
(11, 'Glossary', 'http://www.bioafrica.net/manuscripts/HIVTB_book_glossary.pdf'),
(4, 'Preface', 'http://www.bioafrica.net/manuscripts/HIVTB_book_preface.pdf'),
(12, 'Download complete book in PDF (4Mb)', 'http://www.bioafrica.net/manuscripts/HIVTBDrugResistanceCaseBookSmallPDF.pdf'),
(13, 'Google Books version of HIV & TB Drug Resistance & Clinical Management Case Book', 'http://books.google.co.za/books?id=3oZtK85KfeIC&printsec=frontcover#v=onepage&q&f=false');

-- --------------------------------------------------------

--
-- Table structure for table `b_cases`
--

CREATE TABLE `b_cases` (
  `id` int(11) NOT NULL,
  `description1` longtext,
  `imagechart1` tinytext,
  `imageHIVDR1` tinytext,
  `GSSscore1` longtext,
  `interpretation2` longtext,
  `recommendation2` longtext,
  `authors` longtext,
  `questions2` longtext,
  `answers3` longtext,
  `keylearn3` longtext,
  `title1` longtext,
  `interpretation1` longtext,
  `org` char(5) DEFAULT NULL,
  `caseid` int(11) DEFAULT NULL,
  `keywords` longtext,
  `topdescription` longtext,
  `date` date DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_cases`
--

INSERT INTO `b_cases` (`id`, `description1`, `imagechart1`, `imageHIVDR1`, `GSSscore1`, `interpretation2`, `recommendation2`, `authors`, `questions2`, `answers3`, `keylearn3`, `title1`, `interpretation1`, `org`, `caseid`, `keywords`, `topdescription`, `date`) VALUES
(1, 'This 38 year old female patient initiated d4T/3TC/EFV in March 2008. Her baseline CD4 cell count was 108 cells/ul and WHO clinical stage 3. She had a past history of pulmonary TB in 2004. She has been documented to have good adherence, although it was noted that her treatment supporter was her 10-year old daughter.\r\n\r\n<p>She had a suboptimal initial virological response to ART (VL 1300 copies/ml at six months ) but then exhibited virological suppression at 12 months.  Subsequently she had three VL > 5000 copies/ml and a progressive decline in CD4 cell count, despite step-up adherence counselling. Genotypic resistance testing is performed.\r\n</p>\0', 'ca1chart.png', 'ca1HIVDR.png', 'Resistance Mutations: nil<br>\r<br>\rCurrent regimen GSS:  d4T + 3TC + EFV (GSS score: 3.0 = 1.0/1.0/1.0)<br>\r<br>\rStandard 2nd line regimen GSS:  TDF + 3TC + LPV/r  (GSS score: 3.0 = 1.0/1.0/1.0)<br>', '<b>Resistance genotype: </b>No HIV-1 drug resistance mutations where detected from this patient. Her HIV population is still predominantly wild-type.<br>\r', 'It seems as if this patient is not currently taking any ART and thus had no obvious mutations detected at this time. It is important to remember that she might well be harboring some mutations below the 20% limit of detection and that these might become relevant once she has restarted her ART.<br>\r<br>\r<b>Treatment recommendation:</b><br>\r It is recommend that she continues/re-starts her original ART, which was d4T, 3TC and EFV - and that the VL is monitored again in 4 to 6 months. If the VL becomes and remains undetectable for at least 6 months, the d4T can be switched to TDF. If the VL does not reach the lower than detectable target by 6 months, resistance testing should be repeated. <br>\r<br>\r<b>Adherence:</b><br>\rIntensive adherence support is needed and the use of alternative remedies and social deterrents to adherence should be thoroughly explored. This patient might benefit from an adult treatment supporter. <br>\r<br>\r<b>General comments:</b><br>\rThis patient has an increased risk of immune reconstitution inflammatory syndrome (IRIS) due to her low CD4 and high VL. She should be carefully followed up in the next 6 months.\0', 'Theresa Rossouw, Richard Lessells & Tulio de Oliveira', '<b>1. Why can we not be sure there are no resistance mutations?</b><br>\r<br>\r<b>2. Would it not be better to put her on tenofovir (TDF) now so as to avoid potential toxicities associated with d4T?</b><br>\r\0', 'I. Standard genotypic resistance tests can only detect a resistance mutation if more than 20% of the viral population has developed this mutation. In the absence of drug pressure e.g. if a patient is not taking any ART at the moment, wild type virus will overtake the mutant viral strain since it is generally more fit. The mutant strain will then become a minority strain and will represent less than 20% of the total viral population in the plasma and will hence not be detected by genotypic testing. Once the patient has been taking ART for a few (approximately 6) weeks again, drug pressure will cause the mutant strain to emerge since wild type virus will be suppressed to minority levels.   <br><br>\rII.  Even though there are no resistance mutations detected at this time, we now know that the patient might still be harbouring some mutations. The most common mutations would be M184V giving resistance to 3TC -  and any of the NNRTI mutations, such as K103N. If TDF is added to the new regimen in the place of d4T, there is thus a chance that the patient might effectively be on TDF monotherapy. We have learned that TDF has a very low genetic barrier to resistance, especially in subtype C. Resistance will then develop rapidly and by the time that the clinician realises that the patient is failing therapy, she might have developed complete resistance to tenofovir, thereby compromising future treatment options.<br><br>', 'I. Genotypic resistance testing cannot detect minority resistance viral species (<20% of the viral population)<br><br>\rII. A genotypic result reporting no resistance does not necessarily mean that the patient has not yet developed resistance mutations<br><br>\rIII. Genotypic resistance tests are better at determining which drugs will not work than determining which drugs will work<br><br>\rIV. A patient failing ART with no resistance mutations should be restarted on the same regimen. The viral load should be repeated after a minimum of six weeks when treatment response and the presence of resistance can be determined', 'Adult female with virological failure on first line d4T/3TC/EFV ', '<p><b>Clinical chart: </b></p>This patient last three viral loads have been above 5000 copies/ml despite being on therapy. Her CD4 count initially went up when she started her medication only to start a downward trend that went below the baseline count. The high viral load and CD4 trend are suggestive of possible non-adherence to the current drugs she is on.<br>', '1', 1, 'first, line, antiretroviral, ARV,  d4T, 3TC, EFV, pulmonary, TB, Genotypic, resistance, testing, no resistance, wild type', 'Adult patient on first line antiretroviral therapy consistin g of  d4T, 3TC, EFV. Patient had  pulmonary TB. Genotypic resistance testing show no resistance or wild type', '2012-01-20'),
(2, 'This 41 year old female patient initiated d4T/3TC/EFV in February 2008. Her baseline CD4 cell count was 14 cells/ul, WHO clinical stage 3 and weight 94.3kg. She was on TB treatment (Rifafour) at the time of ART initiation, having started two weeks previously (for smear negative pulmonary TB); she completed TB treatment in August 2008.<br>\r<br>\rShe had an excellent initial virological and immunological response to ART. In April 2009 she was seen with a history of drop attacks. The medical officer was concerned that these might be related to EFV and switched this to NVP. <br>\r<br>\rShe now reports that she continued NVP 200mg once daily for 3-4 months until she was informed that this was incorrect and then she increased dose to 200mg bd.<br>\r<br>\r\0', 'ca2chart.png', 'ca2HIVDR.png', '<br>\rResistance Mutations: M184V + K103N + V108I<br>\r<br>\rCurrent regimen GSS:  d4T + 3TC + NVP(GSS score: 1.0 = 1.0/0/0)<br>\r<br>\rStandard 2nd line regimen GSS:  TDF + 3TC + LPV/r  (GSS score: 2.0 = 1.0/0/1.0)<br>', '<b>Resistance genotype:</b><br>\rThis individual has resistance to three of the four ARVs that she has been exposed to and two of the three she is currently on. She has high-level resistance to NVP and EFV due to the NNRTI mutations K103N and V108I. She also has high level resistance to 3TC due to the NRTI mutation M184V. She has no TAMs and no mutations associated with tenofovir (TDF).<br>', '<b>Treatment recommendation:</b><br>\rIn the absence of major NRTI and NtRTI mutations, this patient should do well on a standard second line regimen consisting of TDF, 3TC and LPV/r. She can also use a regimen of AZT, 3TC and LPV/r but since her body mass index (BMI) is more than 27, increasing her risk of hyperlactataemia, TDF will be the preferred option.<br>\r<br>\r<b>Adherence:</b><br>\rThorough adherence counseling is indicated and the patient should be followed closely for the next 6 months to evaluate virological suppression\0', 'Theresa Rossouw, Richard Lessells & Tulio de Oliveira', '<b>What dose of NVP should she have been started on when switching from EFV?<br><br>\rWhy is it recommended to continue 3TC when the resistance test shows high-level resistance?<br></b>\r\0', 'I. Once a patient has been on medication like EFV that induces the hepatic cytochrome P450 system, for longer than 2 weeks, there is no need for a lead-in dose of NVP. This patient should therefore have started on a full dose of NVP i.e. 200mg b.d.<br>\r<br>\rII. Continuing 3TC will maintain drug pressure that ensures the persistence of the M184V mutation. This mutation is known to reduce viral fitness, delay the development of TAMs, increase susceptibility to AZT and decrease the IC50 of TDF. There is also considerable evidence that 3TC continues to contribute to the effectiveness of ART even after the development of the M184V mutation.<br>', 'I. When switching from EFV to NVP, there is no need for the lead-in dose of NVP, dose should be 200mg b.d.<br>\r\0<br>\rFurther reading<br></b>\r<p><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15090815\">Winston A, Pozniak A, Smith N et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals AIDS 2004, 18: 572-574</a></p>\r<p><a href=\"http://www.expert-reviews.com/doi/abs/10.1586/14787210.2.1.147\">Wainberg M. The impact of the M184V mutation on drug resistance and viral fitness. Expert Rev Anti-infect Ther 2004, 2(1):147-151</a></p>\r', 'Adult female patient with virological failure on first line therapy after substitution of EFV to NVP', '<p><b>Clinical chart:</b></p>\rThe patient first two viral loads show a very good response to ART. Her last three consecutive viral load were above 1000 copies/ml indicating treatment failure. She has had a remarkable improvement in CD4 count during her first two years on ART. However her last CD4 count is suggestive of immunological failure.', '1', 2, 'Adult, patient, virological, failure, drug, resistance, clinical, case, HIV, first line, antiretroviral, ARV,  therapy, substitution, efavirez, EFV, nevirapine, NVP', 'Adult patient with drug resistance on first line therapy substitution of EFV to NVP', '2012-01-20'),
(3, 'This 39 year old female patient was diagnosed with HIV infection during pregnancy in 2007 and received sdNVP at the time of delivery. She had a CD4 cell count <200cells/ul in January 2008 but did not start antiretroviral therapy. She initiated TDF/3TC/EFV in September 2010. \n<p>Adherence to clinic visits has been good according to her file: she attended on time for each clinic visit. She knows the names and dosages of her antiretrovirals. She has disclosed her HIV status and ART use to family members. Counselling has not revealed any specific barriers to adherence. </p>\r<br>\rFurther history reveals a diagnosis of epilepsy (for which she has been taking phenobarbitol 30mg nocte for 20 years) and asthma (for which she receives budesonide and salbutamol inhalers).<br>', 'ca3chart.png', 'ca3HIVDR.png', NULL, '\0<b>Resistance genotype:</b> It seems as if she has been failing for a short time and has thus accumulated only NNRTI resistance and the M184V mutation without any other NRTI mutations. AZT and TDF are therefore still viable options.<br>\r', '<b>Treatment recommendation:</b> Since the virus is still susceptible to TDF, the patient should do well on a standard second line consisting of TDF/3TC/LPV/r. However, given the high VL, an alternative regimen consisting of AZT/3TC/LPV/r would be more sensible in light of its higher barrier to adherence, provided the patient has a Hb>10 g/dl and does not have a high risk for metabolic complications.<br>\r<br>\r<b>Adherence:</b> Intensive adherence support is needed and the use of alternative remedies and social deterrents to adherence should be thoroughly explored.<br>\r<br>\r<b>General comments:</b> This patient has a high risk of IRIS in light of her high VL. She should be closely monitored for the development of IRIS during the first 6 months of treatment. If started on TDF, her renal function should be monitored before initiation and again at three months. If the patient has a high risk of renal disease, pre-existing renal compromise (especially HT and DM patients) or is taking any nephrotoxic drugs such as NSAIDs, ACE-inhibitor, streptomycin, monitoring can be done more frequently.<br>\r', 'Richard Lessells, Theresa Rossouw & Tulio de Oliveira', 'I. Give two reasons why this patient might have had developed antiretroviral resistance?<br><br>\rII. Would you make any other changes to her medication?<br>\r\0', 'I. There are two plausible reasons why resistance may have developed so rapidly:<br>\r<br>\rIa. Single dose nevirapine for prevention of mother-to-child transmission (PMTCT) is known to give rise to NNRTI-resistance mutations. Resistant strains can be archived during untreated HIV infection and, when ART is subsequently commenced, these drug-resistant strains are rapidly selected. The response to NNRTI-based ART has been shown to be inferior amongst women exposed to sdNVP. <br><br>\rIb. Phenobarbitone can interact with efavirenz through the cytochrome P450 system. This could potentially lead to reduced serum efavirenz levels thus compromising viral suppression. Many of the older anticonvulsants (phenobarbitone, phenytoin, and carbamazepine) have potential interactions with the NNRTIs and should ideally not be used in patients receiving ART.<br>\r<br>\rII. The phenobarbitone should be replaced by an alternative anticonvulsant, for example sodium valproate. Other newer anticonvulsants (lamotrigine, gabapentin, leviteracetam) also have less potential for interaction and can be used if available. Care should be taken to avoid adverse consequences of barbiturate withdrawal.<br>\r\0', '<p>Key learning points</p>\rI. Single dose NVP for PMTCT can give rise to resistance mutations which can persist for years and which can compromise future antiretroviral therapy<br>\r<br>\rII. Individuals requiring concurrent antiretroviral therapy and anticonvulsants should be prescribed sodium valproate or one of the newer anticonvulsants. Phenobarbitone, phenytoin and carbamazepine should be avoided due to the potential for drug interactions.   \0<br></b>\r<br>\r<p><b>Further reading</b></p>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/15942889\">Johnson JA, Li JF, Morris L et al. (2005). Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192: 16-23</a><br>\r<br>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20942666\">Lockman S, Hughes MD, McIntyre J (2010). Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 363: 1499-1509</a><br>\r<br>\r<a href=\"http://www.cmej.org.za/index.php/cmej/article/view/489\">Kredo T, Maartens G (2006). Therapeutic challenges: interactions between anticonvulsants and antiretrovirals. Continuing Medical Education 24: 528-530</a><br>\r\0', 'Adult female patient on treatment for epilepsy with virological failure on TDF/3TC/EFV; previous single dose NVP for PMTCT', '<p><b>Clinical chart:</b></p> The patient had suboptimal viral suppression at six months after ART initiation and has remained viraemic at 12 months. There was some immunological response with increase of CD4+ cell count from 96cells/ul at baseline to 171cells/ul at six months.<br>\r', '1', 3, 'Adult, female, patient, treatment , epilepsy , virological failure , TDF/3TC/EFV, previous, single dose, NVP , PMTCT, clinical, case, hiv, drug resistance', 'Adult female patient on treatment for epilepsy with HIV drug resistance virological failure on TDF/3TC/EFV, previous single dose NVP for PMTCT', '2012-01-20'),
(4, 'This 52 year old female patient was diagnosed with HIV infection in May 2007. At that time her CD4 cell count was 401cells/ul. After one year her CD4 cell count had dropped to 162cells/ul and she was initiated on d4T/3TC/EFV.<br>\r<br>\rIn April 2011 she was seen by the medical officer with symptoms consistent with symptomatic hyperlactataemia. The regimen was switched to TDF/3TC/EFV. <br>\r<br>\rOn review now she reports financial insecurity to the extent that she has struggled to attend clinic for adherence sessions. She had been referred to the home-based care team but stated that they were not useful because they did not give her any pills.<br>\r', 'ca4chart.png', 'ca4HIVDR.png', NULL, '\0<b>Resistance genotype:</b><br>\rThe patient has resistance to all of the four ARVs that she has been exposed to. The NNRTI mutations K103N, V106M, E138A and M230L confer high-level resistance to efavirenz (EFV) and nevirapine (NVP). She further has intermediate resistance to lamivudine (3TC) and tenofovir (TDF) as well as as low level resistance to stavudine (d4T) secondary to the NRTI/NtRTI mutations K65R and L74V. <br>\r\0', 'The treatment switch from d4T to TDF was made approximately 1 year after the VL was almost suppressed for the first time after 1.5 years on treatment. In light of the previous elevated VLs, the clinician should have a high index of treatment failure in this patient.\n<p> It should be noted that a single drug substitution should never be made when there are concerns about treatment failure, as resistance might develop very quickly if the VL is not suppressed at the time. Unfortunately, this patient did develop the K65R mutation and she can therefore not use TDF again. Before TDF is however discontinued, she should be tested for hepatitis B. If she tests positive, she should continue on TDF and will then be on a 4-drug regimen. In light of the hyperlactataemia, d4T and ddI are not acceptable options. </p>\r<p><b>Treatment recommendation:</b></p>\rThe only viable options for this patient is to use either AZT or ABC together with 3TC and LPV/r. AZT is in line with the South African national guidelines, AZT/3TC/LPV/r would have an acceptable GSS of 2.5 and is therefore the preferred treatment option. If the patient has active hepatitis B infection, she should continue with TDF and thus be on a four-drug regimen consisting of AZT, TDF, 3TC and LPV/r.</p>\r<p><b>Adherence:</b></p>\rIntensified adherence counseling is needed and all attempts should be made to address barriers to adherence that might have contributed to first-line failure.<br><br>\r<b>General comments:</b><br> This patient has a high risk of IRIS in light of her very low CD4 and high VL. She should be closely monitored for the development of IRIS during the first 6 months of treatment. Her Hb and neutrophil count should be monitored monthly for 3 months and then on a 6-monthly basis.\0', 'Theresa Rossouw, Richard Lessells & Tulio de Oliveira', 'I. Was it appropriate to switch d4T to TDF at the time of symptomatic hyperlactataemia? <br>What could have been done differently?<br>\r<br>\rII. After three months of her new ART regimen her Hb has dropped from 11.7g/dL to 5.6g/dL. What will you do now?<br>\r\0', 'I. No. It is always best to confirm that the VL is suppressed before a single drug substitution is made. If this is not possible i.e. ART needs to be stopped immediately as in cases of lactic acidosis, then the best strategy is to stop all the drugs but cover the tail of EFV with LPV/r for 2 weeks.<br>\r<br>\rII. This anaemia is almost certainly caused by AZT. Since the Hb is less than 6, AZT should be stopped and replaced with the only alternative, namely ABC. Remember to first do the VL to ensure that it is suppressed before a treatment switch is made!<br>\r', 'I. Always ensure that the VL is suppressed before a single drug substitution is made<br>\r<br>\rII. Never stop TDF without knowing the patient Hepatitis B status <br>\r<br>\rIII. Remember to monitor the Hb and neutrophil count in patients receiving AZT<br>\r\0', 'Adult female patient with virological and immunological failure after treatment interruption for symptomatic hyperlactataemia\r\n\0', '<p><b>Clinical chart:</b></p>\rThe patient viral load never fully suppressed to less than 25 RNA copies/ml in more than three years of ART. Her CD4 count also never responded to ART. It continued on a downward trend even after ART initiation. <br>', '1', 4, 'clinical, case, hiv, drug resistance, adult, patient , virological , immunological, failure, after, treatment, interruption , symptomatic, hyperlactataemia, antiretroviral\r\n\0', 'Adult female patient with HIV virological and immunological failure after antiretoroviral treatment interruption for symptomatic hyperlactataemia\r\n\0', '2012-01-20'),
(5, 'This 17 year old female initiated d4T/3TC/EFV in January 2008 (at the age of 14). She had a past history of pulmonary TB in 2003 for which she had completed six months of anti-TB therapy.  Her baseline CD4 cell count was 77cells/ul, WHO clinical stage 4. At initiation she had severe wasting, with baseline weight 23.4kg (weight-for-age below  5th centile). <br>\r<br>\rOn review it was discovered that her HIV status had not been properly disclosed to her by her family until 2010. She still had a relatively poor understanding of HIV and of antiretroviral therapy, although she knew the names and doses of her medication.<br>\r\0', 'ca5chart.png', 'ca5HIVDR.png', NULL, '<b>Resistance genotype:</b><br>\rThis individual has resistance to all three of the ARVs that she is currently receiving. She has high-level resistance to efavirenz (EFV), lamivudine (3TC) and stavudine. Her HIV population has multiple NNRTI-resistance mutations (K103N, V106M, F227L and M230L). She has the characteristic NRTI mutation, namely M184V, in addition to three TAMs (M41L, L210W and T215Y). The above TAM combination results in intermediate resistance to tenofovir (TDF).<br>\r', '<b>Treatment recommendation:</b><br>\rThis patient has been failing for a very long time and has unfortunately developed a complex resistance pattern. Her chance of suppressing on a standard regimen 2 may be limited, especially in light of her high VL. It is almost impossible to treat this patient without a new class of antiretroviral drug, like an integrase inhibitor. She already has significant resistance to etravirine, so this new class of NNRTI would not be an option. <br>\r<br>\rThe best combination seems to be an integrase inhibitor (raltegravir), CCR5 blocker (maraviroc) and LPV/r. Raltegravir is unfortunately not yet available in the public sector. Maraviroc can only be used if the patient has a R5 tropic virus, but the tropism test is expensive and neither the test nor the medication is available in the public sector. \n<p>Given these limitations, one probably has to settle for a suboptimal regimen and the most reasonable suggestion seems to be a combination of TDF and 3TC with a double-boosted PI. Even though this combination is controversial, it is widely used in the rest of Africa, apparently with some success. A possibility would be a combination of LPV/r with either saquinavir or atazanavir, whichever the pharmacy can make available.</p>\n<p> There is emerging data about the safety and tolerability of combining LPV/r and ATV. The drug interactions between TDF and ATV seem not to be clinically significant and should not deter one from using such a combination, provided the ATV is boosted with ritonavir. Once the VL is suppressed the second PI can be stopped. </p>\r<br>\r<b>Adherence:</b><br>\rIt is vital that issues of adherence are thoroughly explored and addressed before any treatment changes are made. If there are ongoing adherence problems, a holding strategy of 3TC monotherapy can be considered until such time as this has been sorted out. <br>\r', 'Theresa Rossouw, Richard Lessells & Tulio de Oliveira', 'I. \0Why has she developed so many resistance mutations?<br>\r<br>\rII. Is there any evidence that adolescents have poorer outcomes on antiretroviral therapy than older adults?<br>\r<br>\rIII. What interventions would you put in place for this patient before switching her antiretroviral therapy?<br>\r', 'I. This patient has been left on a failing regimen for a very long time, most probably in the presence of sub-optimal adherence. This allowed the virus to replicate in the presence of drug, thus facilitating the development of multiple mutations.<br>\r<br>\rII. Yes. Adolescents are well known to be a challenging group of patients to treat and poorer treatment outcomes have been described.<br>\r<br>\rIII. Intensive adherence support by a counsellor and possibly an adolescent support group, education about HIV, allocation of a treatment supporter, close monitoring and follow-up, exclude alcohol and substance use.<br>\r', 'I. There is increasing evidence from Southern Africa that outcomes for adolescents on antiretroviral therapy are poorer than for older adults. Additional interventions may be required for this group.<br>\r\0<br>\r<p>Further reading</p></b>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19282780\">Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009; 51:</b> 65-71</a><br>\r\0', 'Adolescent initiated on first line therapy of d4T/3TC/EFV with virological and immunological failure', '<b>Clinical chart:</b><br>\rThe first year on ART was good with decent viral suppression and Immunological recovery. However after that her viral load went on an upward trend and her CD4 started going down a year later. The accumulation of multiple mutations, including multiple TAMS is suggestive of long term treatment failure.<br>\r', '1', 5, 'clinical, case, hiv, drug resistance, Adolescent, initiated , first line, ARVs , therapy , d4T/3TC/EFV , virological , immunological, failure', 'Adolescent initiated on first line ARVs therapy of d4T/3TC/EFV with virological and immunological failure', '2012-01-20'),
(6, 'This was a 40-year old male patient who was brought to the clinic by Correctional Services at the end of 2005. He denied the prior use of ART. He had a CD4 count of 103 cells/ul that rapidly dropped to 64 cells/ul at the time of initiation, and a baseline VL of 390,000 copies/ml. \n<p>He was clinically well and was initiated on the routine treatment of that time, namely d4T, 3TC, EFV. EFV was switched to NVP due to neuropsychiatric side effects within 3 months and d4T was switched to AZT four months later because of the development of peripheral neuropathy.</p> \n<p>He was changed to regimen 2 approximately 1 year later. He frequently complained of painful feet and requested letters to the prison authorities to allow him to wear different shoes. The patient had ongoing adherence problems. He was incarcerated throughout and unfortunately passed away in October 2010. </p><br>\r', 'ca6chart.png', 'ca6HIVDR.png', NULL, '<b>Resistance genotype:</b> <br>\rThe genotype was performed approximately six months after treatment was changed to second-line. The VL was 210,000 copies/ml at the time. The patient has a most unusual resistance pattern with only NNRTI (one mutation) and PI resistance (1 minor and 2 major mutations). There is no evidence of any NRTI resistance.  <br>\r', '<b>Treatment recommendation:</b><br>\rAt the time of the treatment switch, tenofovir was not yet available in the public sector. There was also no access to new classes of drugs or new generation PIs, such as Darunavir. If I could treat him today, I would recommend a combination of TDF, 3TC and boosted Darunavir. Given the limitations of the time, however, this patient was treated with a triple NRTI combination (AZT, ddI, ABC) and LPV/r. Given the previous history of peripheral neuropathy and ongoing painful feet, it might have been better to drop ddI and rather give AZT and ABC or AZT, ABC and 3TC, in combination with LPV/r.<br>\r<br>\r<b>Adherence:</b><br>\rThis patient had ongoing adherence problems that were never resolved. Some of the non-adherence could have been driven by the toxicity of the medication.<br>\r', 'Theresa Rossouw, Richard Lessells & Tulio de Oliveira', 'I. Why did the patient VL increase after initiation of treatment?<br>\r<br>\rII. How might one explain the absence of NRTI mutations in this patient?<br>\r<br>\rIII. How many PI mutations are needed for complete resistance to LPV/r?<br>\r<br>', 'I. \0The patient most probably stopped his ART soon after initiation when he developed side effects on EFV. He might have reported this to the clinic doctor, but it was not recorded in the file and probably not addressed satisfactorily until three months later, when the EFV was changed to NVP.<br>\r<br>\rII. It is rather difficult to explain how this patient could have PI mutations in the absence of any NRTI mutations. It is possible that the patient was not taking any of the NRTIs since he associated them with his painful feet. He would then be on PI monotherapy and we know that this sets the stage for the development of PI mutations. He did however accumulate the PI mutations very rapidly. It might therefore also be possible that the patient had previous PI exposure that he did not declare, and when he restarted the PI, the archived mutations re-appeared.<br>\r<br>\rIII. As a rule, a patient needs to accumulate 7 or 8 mutations for complete resistance to LPV/r. PI experienced patients need 6 or more mutations. Certain mutations, such as I47A and V32I, are however associated with high-level resistance.<br>\r<br>', 'I. Always listen to your patient complaints of medication side effects and address these appropriately.<br>\r<br>\rII.  There is no point in switching to a second line regimen when adherence issues, causing first-line failure, have not been addressed. <br>\r<br>\rIII. More drugs are not necessarily better, even if the GSS is improved. A balance should be struck between the best possible virological suppression and treatment toxicity.<br></b>\r\0<br>\r<p><b>Further reading</p></b>\r<a href=\"http://hivdb.stanford.edu/pages/pdf/primaryPI.pdf\">Kantor R, Fessel WJ, Zolopa AR et al. Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy. Antimicrobial agents and chemotherapy, 2002;46(4):1086-1092.</a><br><br>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16308226\">Kristiansen TB, Pedersen AG, Eugen-Olsen I et al. Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression. Scandinavian Journal of Infectious Diseases, 2005; 37:</b> 890-901 </a><br>\r', 'Adult male patient with adverse effects and multiple ARV treatment switches. No virological response to LPV/r based second line therapy', '<p><b>Clinical chart</b></p>\rThis patient never suppressed his VL. In fact, after initiation, his VL actually increased to nearly double the pre-treatment value. Even though the VL did decrease after that, it never reached undetectable levels.\r<p>The patient CD4 count initially increased on ART but then dropped below pre-treatment values. It never went over 200 cells/ul. His last CD4 count was 6 cells/ul.</p><br>', '1', 6, 'clinical, case, hiv, drug resistance, Adult , male,  patient , adverse, effects , multiple, ARV, treatment, switches, No virological response, lopinavir, ritonavir,  LPV/r,  second line, therapy', 'Adult male patient with adverse effects and multiple ARV treatment switches. No virological response to LPV/r based second line therapy', '2012-01-20'),
(7, 'This is a 14 year old female patient. She started on ART in the middle of 2010. She admits poor adherence since the start of treatment with many missed doses. Her mother passed away and she is now being looked after by her aunt. <p>The aunt assumed that the child was taking her medicine, but the child says she was not. The d4T was replaced with ABC due to metabolic side effects on d4T after approximately 6 months on treatment.</p><br>\r', 'ca7chart.png', 'ca7HIVDR.png', NULL, '<b>Resistance genotype:</b><br>\rThe mutations present in the viral population of this patient include M184V, which confers high-level resistance to 3TC as well as potential low-level resistance to abacavir. Additionally, the NNRTI mutations, K103S and V106M, confer high-level resistance on EFV and NVP.<br>\r', '<p>Teenagers can be difficult to manage. This patient has obvious adherence problems and does not have an active caregiver. Since she has been taking her medication intermittently, it is possible that she might have some TAMS that are currently below the level of detection. Since this is probably our last chance to treat her effectively, all effort should be made to ensure adherence before a treatment switch is made.</p>\n<p>There is no point in trying a new regimen until the adherence and support issues have been sorted out. While these are being addressed, it is an option to put the child on 3TC monotherapy (300mg daily). The CD4 can be repeated after 3 months and 3-6 monthly thereafter. There is no point in doing serial VLs. When the patient CD4 drops below 250 cells/ul, it is imperative to start a new regimen.</p>\r<p>Once the patient is ready to re-start ART, there are two available options. She can either take AZT, ddI, LPV/r, but she could potentially also take the more tolerable combination of TDF, 3TC and Aluvia. She is old enough to tolerate TDF, although she will need monitoring of her bone mineral density (if feasible), electrolytes and renal function. </p><br>\r', 'Theresa Rossouw, Richard Lessells & Tulio de Oliveira', 'I.What GSS is needed for virological suppression?<br>\r<br>\rII. Is there any evidence for a 3TC holding strategy when serious adherence issues are identified?<br>\r', 'I. Clinical trials have shown that patients on regimens with a GSS = 3 have a significantly higher chance of achieving an undetectable VL.<br>\r<br>\rII. There is some evidence for this strategy and it is sometimes advised when there are major adherence issues or when waiting for access to new treatment options, especially in children. One randomized study demonstrated that in patients harboring a 3TC-resistant virus, 3TC monotherapy may lead to a better immunological and clinical outcome than complete therapy interruption. This strategy should however never be undertaken in any patient who ever had a low CD4 and this strategy can only be utilized while the CD4 count remains above at least 250 cells/ul.<br>\r', 'I. Adolescents can be a difficult group to manage<br>\rII. A short-term strategy of 3TC monotherapy could be considered when there are  ongoing adherence problems that could compromise the next regimen.<br></b>\r\0<br>\r<p><b>Further reading</b></p>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19551816\">Castor D, Vlahov D, Hoover DR et al. The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. J Med Virol. 2009 Aug;81(8):1323-35</a>.\r<p><a href=\"http://www.sajhivmed.org.za/index.php/sajhivmed/article/view/593\">Levin LJ. Changing antiretroviral therapy in children. Southern African Journal of HIV Medicine, Dec 2009:</b>85-90.</a></p>\r<p><a href=\"http://www.medscape.com/viewarticle/531695\">Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus:</b> a randomized pilot study (E-184V study). AIDS 2006, 20:</b> 795-803.</p></a><br>\r', 'Adolescent case with  adherence and toxicity problems\0 ', '<p><b>\0Clinical chart:</b></p>\nThis patient\'s CD4 count dropped and remained below 400 cells/ul.  The viral load fluctuated but followed an increasing trend. Despite a drop from approximately 10 000 copies/ml in the last quarter of 2010, the viral load was approximately 5000 copies/ml in July 2011.<br>\r\r', '1', 7, 'clinical, case, hiv, drug resistance, Adolescent,  case , ARV , adherence , toxicity , problems\0 ', 'Adolescent case with ARV adherence and toxicity problems\0 ', '2012-01-24'),
(8, 'This 33 year old male patient initiated d4T/3TC/EFV in March 2008 with baseline CD4+ cell count 34 cells/ul and clinical stage 3 (pulmonary TB). He admits to having had adherence problems early on due to concerns about taking TB therapy at the same time as ART he was poorly informed about the need for combined TB treatment and ART. He reports that, as a result, he did not take ART reliably until July 2009.  His results show that, despite some immunological recovery, he has persistent high-level viraemia.  <br>\r<p>Adherence to clinic visits is now excellent and adherence to ART is assessed as very good using the tools in the South African national ART guidelines (>95%).  He is now well informed and self-motivated  without any obvious barriers to adherence. In terms of adverse drug effects, he has  only evidence of mild lipodystrophy (not noticed by patient himself).</p<<br>\r', 'ca8chart.png', 'ca8HIVDR.png', NULL, '<b>Resistance genotype:</b> This individual has developed M184V and K65R but also the Q151M complex (consisting of Q151M mutation with V75I, F77L, F116Y) which together will confer high-level resistance to all NRTI/NtRTIs. In addition the common NNRTI mutation K103N mutation is present accompanied by P225H, which increases EFV resistance.<br>\r', '<b>Treatment recommendation:</b> This is a very difficult case. Since the patient has high-level resistance to the entire NRTI class, options for second-line therapy are really limited. A standard second-line regimen would effectively be lopinavir/ritonavir monotherapy, which might have some efficacy but is unlikely to lead to durable virological suppression. Ideally one would like to construct a new regimen consisting of lopinavir/ritonavir and lamivudine combined with two novel agents raltegravir and etravirine (GSS 2.5). If neither raltegravir or etravirine are available, another option would be a double boosted protease inhibitor regimen, e.g. lopinavir/ritonavir + atazanavir, although the long-term efficacy of such regimens is also doubtful. <br>\r<br>\r<b>Adherence:</b> Intensive adherence support is needed regardless of the regimen selected. It is important that the patient and his treatment supporter are both educated and informed fully about the new regimen and the importance of adherence. <br>\r<br>\r<b>General comments:</b> It is important to screen comprehensively for TB disease, given the persistent low CD4+ cell count and past history of TB. TB therapy might impact on the dose of second-line ART (certainly the dose of lopinavir/ritonavir and possibly also raltegravir).<br>\r', 'Richard Lessells, Theresa Rossouw & Tulio de Oliveira', 'I. \0What is the Q151M complex and how does it develop?<br>\r<br>\rII. Is there any evidence for the effectiveness of LPV/r monotherapy in second-line therapy in resource-limited settings?<br>\r', 'I. \0The Q151M mutation is selected by NRTI therapy and, on its own, confers intermediate resistance to ZDV, d4T ddI and ABC. When Q151M is accompanied by mutations at codon 75,77 and 116 (Q151M complex) then this complex confers high-level resistance to these NRTIs plus intermediate resistance to 3TC and TDF. Selection of the Q151M complex seems to be related to the duration of NRTI treatment and so far the reported prevalence in patients failing first-line ART in Southern Africa is low. It is noteworthy, however, that one cross-sectional study of patients failing first-line ART in Malawi, where routine virological monitoring is not performed, reported an extremely high prevalence of Q151M complex (19.1%).<br>\r<br>\rII. There is some <a href=\"#preliminary\">preliminary data </a>that LPV/r monotherapy leads to potent virological suppression in the short term. Longer term data is awaited from<a href=\"http://www.clinicaltrials.gov/ct2/show/study/NCT00357552\"> this study </a> and from <a href=\"http://www.clinicaltrials.gov/ct2/show/NCT00988039\">Randomized Control Trials</a>. LPV/r monotherapy currently seems best suited in patients where simplification of regimen is required after virological suppression had already been achieved.<br>\r\0', 'I. The Q151M complex is uncommon but it confers high-level resistance to almost all NRTIs. When present with the K65R and M184V mutations, there will be high-level resistance to the entire NRTI class.<br></b>\r\0<br>\r<p><b>Further reading:</p><br>\r<a href=\"http://www.jstor.org/pss/4462803\">Zaccarelli M, Perno CF, Forbici F et al. Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy. Clin Infect Dis 2004; 38:</b> 433-437</a><br><br>\r<a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2896488/\">Hosseinipour MC, van Oosterhout JJG, Weigel R et al. The public health approach to identify antiretroviral therapy failure:</b> high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:</b> 1127-1134</a><br><br>\r<a name=\"preliminary \"></a><a href=\"http://www.medscape.com/viewarticle/531695\">Bartlett J, Aga E, Ribaudo H et al. A pilot study of LPV/r monotherapy following virologic failure of fisrt-line NNRTI-containing regimens in resource-limited settings: the week-24 primary analysis of ACTG 5230. 18th Conference on Retroviruses and Opportunistic Infections, Boston, 2011 [abstract 583] http://www.retroconference.org/2011/Abstracts/42469.htm </a><br>\r\0', 'Adult patient initiated on first line d4T/3TC/EFV with low CD4+ cell count (34 cells/ul) and concurrent TB treatment', '<p><b>Clinical chart:</b></p> The patient has never had a viral load <1000 copies/ml and indeed the viral load has steadily increased since July 2009 despite supposed good adherence to ART.<br>\r', '1', 8, 'clinical, case, hiv, drug resistance, Adult, patient, initiated , first line , ARVs , d4T ,3TC, EFV,  low CD4\n, cell count, concurrent, TB, treatment, subtype C, south Africa, public program', 'Adult patient initiated on first line ARVs of d4T/3TC/EFV with low CD4+ cell count - 34 cells/ul - and concurrent TB treatment', '2012-01-25'),
(9, 'This 29 year old patient transferred into the programme from another public sector programme in the province. She had initiated TDF/3TC/NVP in November 2010 with a baseline CD4+ cell count of 2 cells/ul. <p>The transfer letter states that after 6-month of ART, her CD4+ cell count was 23 cells/ul and viral load 240,508 copies/ml.  </p>\r<p>CD4+ cell count and viral load were repeated on transfer (12 months on ART) and show persistent high-level viraemia and CD4+ cell count <50 cells/ul.</p>\r<p>Initial questioning does not reveal any adherence problems. However, in-depth counselling reveals deep psychological issues around the death of her grandmother the same year. She is now living with her mother who is also on ART and is documented to have excellent adherence and VL <40 copies/ml. </p>\r<p>She reports no previous use of ART or PMTCT before November 2010. She reports that, although her partner HIV status is not known to her, she is aware that the partner has concurrent sexual partners, and knows at least one of them to be taking ART. </p><br>', 'ca9chart.png', 'ca9HIVDR.png', NULL, '<b>Resistance genotype:</b> Dual class resistance has seemingly developed within one year of therapy which is of major concern. The M184I mutation confers high-level resistance to 3TC and FTC. K65R confers intermediate resistance to TDF, ABC, ddI, 3TC and FTC. Y181C confers high-level  resistance to NVP and EFV.  The rapid emergence of mutations and lack of any virological response to ART does raise the possibility of primary drug resistance in this case.<br>\r', '<b>Treatment recommendation:</b> The viral populations remain fully susceptible to AZT . Indeed both the K65R and Y181C mutations cause AZT hypersusceptibility. So a standard second-line regimen of AZT, 3TC and LPV/r would be appropriate in this case.<br>\r<br>\r<b>Adherence:</b> It is essential that the psychological issues that have been identified  are comprehensively addressed. This might include referral to a clinical psychologist or consideration of pharmacological therapy. It is important to ensure that the patient now also enrolls the full support of her mother, especially given the documented good adherence of the mother.<br>\r<br>\r<b>General comments:</b> A full drug history should be taken to ensure no potential drug-drug interactions with her second-line regimen. She needs to be screened for TB disease and for sexually transmitted infections. It is important to ensure that she is currently taking cotrimoxazole therapy. Counselling about condom use is particularly important given the knowledge of the partner concurrent sexual partners.<br>\r', 'Richard Lessells, Theresa Rossouw & Tulio de Oliveira', 'I. We are much more used to seeing the M18V mutation ? <br> What is the significance of the M184I mutation seen in this case?<br>\r<br>\rII. How do certain mutations cause hypersusceptibility to certain antiretroviral drugs, e.g. K65R and AZT?<br>\r\0', 'I. M184I arises as a result of a G to A substitution at position 184 (ATG, methionine to ATA, isoleucine). M184V in contrast arises as a result of an A to G substitution (ATG, methionine to GTG, valine). M184I mutants are generally observed earlier during therapy than M184V as RT is more prone to G to A substitutions. M184I confers high-level resistance to 3TC and FTC but also significantly reduces the replication rate of the virus. In the presence of continued drug pressure, the frequency of M184V mutants increases, as the M184V mutants have a fitness advantage over M184I mutants. <br>\r<br>\rII.K65R confers hypersusceptibility to AZT by partially preventing the excision of incorporated AZT. This leads to increased stability of AZT as a chain terminator. The mechanism by which the K65R mutation counteracts TAM-mediated NRTI excision seems to be that the K65R mutation constrains the mobility of the RT fingers loop domain, explaining the decreased incorporation and decreased excision of NRTIs observed for K65R. The clinical impact of this hypersusceptibility is not entirely clear. <br>\r', 'I. Initiation of ART in the presence of primary drug resistance may lead to further rapid accumulation of antiretroviral resistance. The possibility of primary drug resistance should be considered in patients who exhibit poor early virological response to ART. Lack of response should not always be assumed to be due to suboptimal adherence<br>\r<br>\rII. The M184I mutation appears earlier in therapy than the M184V mutation but also confers high-level resistance to 3TC and FTC\0<br></b>\r<br>\r<p><b>Further reading</b><br>\r<p><a href=\"http://www.nejm.org/doi/full/10.1056/NEJMoa013552\">Little SJ, Holte S, Routy JP et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347: 385-394</a></p>\r<p><a href=\"http://jvi.asm.org/content/74/14/6262.abstract\">Frost SDW, Nijhuis M, Schuurman R et al. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J Virol 2000, 74: 6262-6268</a></p>\r<p><a href=\" A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R\">White KL, Margot NA, Ly JK et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005, 19: 1751-1760</a></p>\r<p> a href=\"http://www.ncbi.nlm.nih.gov/pubmed/16640096\">White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006, 11: 155-163.</a></p><br>\r\0', 'Adult patient initiated on TDF/3TC/NVP with a low baseline CD4+ cell count, patient transferred from another programme in South Africa', '<p><b>Clinical chart:</b></p> This patient has had no virological or immunological response to ART. This would  normally suggest substantial problems with adherence to ART. Other possibilities to think about would be malabsorption, incorrect drug dosage or major drug-drug interaction. It is also important to consider the possibility of pre-existing antiretroviral resistance, either from previous PMTCT or from acquisition of resistant virus. <br>\r', '1', 9, 'clinical, case, hiv, drug resistance, Adult, patient, initiated , TDF, tenofovir, 3TC, NVP , baseline, low CD4, transfered', 'Adult patient initiated on ARVs TDF/3TC/NVP with a baseline CD4+ cell count of 2, patient transfered ', '2012-01-26');
INSERT INTO `b_cases` (`id`, `description1`, `imagechart1`, `imageHIVDR1`, `GSSscore1`, `interpretation2`, `recommendation2`, `authors`, `questions2`, `answers3`, `keylearn3`, `title1`, `interpretation1`, `org`, `caseid`, `keywords`, `topdescription`, `date`) VALUES
(104, 'A 34 year old male patient is referred due to failure of TB treatment. He had been treated for smear-positive pulmonary TB with regimen 1. AFB smears had remained positive at 2 months so the intensive phase  (HRZE) had been extended an extra month. AFB smears were then negative at 3 months and standard continuation phase (HR) was given for four months.  AFB smears were positive (+++)  at the end of treatment so the outcome was recorded as treatment failure and he was referred to the medical officer for further management.<br>\r<br>\rHe reported another previous episode of smear positive pulmonary TB four years previously for which he had completed six months of therapy (there was no documentation about whether or not he had been cured). He was HIV-infected and had been on ART for four years. His current regimen was TDF/3TC/EFV, his latest viral load <40 copies/ml and latest CD4+ cell count 371 cells/ul. <br>\r<br>\rOn review of his TB case file, a result was found of culture/DST taken prior to treatment for this latest TB episode.  The culture was positive for M. tuberculosis and phenotypic DST was reported as resistant to isoniazid and streptomycin but susceptible to rifampicin, kanamycin and ofloxacin.<br>\r<br>\rHe remains symptomatic with cough, night sweats, chest pain, and weight loss. Sputum is obtained for Xpert MTB/RIF testing and culture/DST. <br>', 'ca104chart.png', 'cawhite.png', NULL, '<p>However, although the Xpert MTB/RIF assay has detected the presence of M. tuberculosis, it has not detected any mutations associated with rifampicin resistance. This would suggest that MDR-TB is not present, although it cannot exclude the continued presence of INH mono-resistance</p>', '<p><b>Treatment recommendation</b></p>\r<p>It is important to ensure that a specimen is sent for culture/DST given the clinical history. In the meantime, a standard regimen of HRZE should be commenced and continued until further results from the culture/DST are available. Streptomycin should not be included in the regimen as the previous isolate had demonstrated resistance to streptomycin and so the patient would be exposed to potential toxicity with very low likelihood of effectiveness.</p>\r<p><b>Case resolution</b></p>\r<p>The patient was commenced on HRZE. Culture was positive for M. tuberculosis and the Genotype MTBDRplus assay was reported as showing resistance to rifampicin and isoniazid. He was referred to the specialist MDR-TB referral centre and was commenced on a standardised MDR-TB regimen consisting of kanamycin, ofloxacin, ethionamide, terizidone, and pyrazinamide. Phenotypic DST \0subsequently confirmed resistance to rifampicin and isoniazid but susceptibility to kanamycin and ofloxacin\0.</p>', 'Richard Lessells', 'I. How should his initial episode of INH mono-resistant TB have been managed?<br>\r<br>\rII. Why did the Xpert MTB/RIF assay not detect resistance to rifampicin?<br>\r\0<br>', '<p>I. This case illustrates some of the deficiencies of existing diagnostics for TB. The DST result was received once the patient was well established on treatment and it was not brought to the attention of a doctor. The diagnostic test therefore did not lead to a beneficial outcome for the patient as the result was not appropriately acted upon. If the result was received at around two months, when the smears had not converted, then suspicion of further drug resistance should have prompted a repeat specimen for culture/DST. </p>\r<p>Having said all that, national and international guidelines do not give clear guidance on management of INH mono-resistant TB and are informed by poor quality evidence. Historically it was thought that standardised regimens were appropriate for INH mono-resistant disease but there is now increasing evidence that outcomes with standardised regimens are often poor.</p>\r<p>One option in this case would have been to continue rifampicin, ethambutol and pyrazinamide for a total duration of 6 months (this is recommended in US guidelines). This is, however, also not based on high quality evidence and there is an urgent need for better quality evidence to inform treatment strategies. </p>\r<P>II. Further interrogation of the output from the Xpert MTB/RIF assay helps us to understand why it was reported as showing no rifampicin resistance in this case.</p>\n<img src=\"imagesBIO/ca104extraanswer.png\">\r\n\0<p>Analysis of the primary curves here and the assay result in section 2 show that one probe (probe E) has a delayed cycle threshold (Ct) and significantly lower endpoint (EndPt).</p>\n<p>The definition of resistance is based on the difference between highest and lowest Ct. Under the original algorithm rifampicin resistance was defined with a difference between highest and lowest Ct >3.5. The algorithm was changed (to improve specificity of the assay) such that resistance is now defined with a difference between highest and lowest Ct >5. In this case the test would have been defined as resistant under the original algorithm (Difference between highest and lowest Ct = 3.6 [24.9-21.3])\0</p>\n<p>The reason that there is some signal from this probe rather than complete probe drop-out (contrast with the results shown for case 1) may be due to mixed populations of RIF-resistant and RIF-sensitive strains, which would make sense given what we know about the evolution of resistance in this case. The initial analytical studies on the Xpert MTB/RIF assay showed that the ability to detect mutant DNA within mixed populations was dependent on the specific mutation, e.g. the L533P mutation could only be detected if 100% of the DNA was mutant.</p><br>\r\n\0\r', '<p>Isoniazid mono-resistant disease should not be treated with normal TB regimens. Ideally patients should be referred to a specialist physician. A regimen consisting of 6HZE can be used but the patient should be monitored closely for the emergence of MDR-TB.</p>\r<p>The Xpert MTB/RIF assay may not detect rifampicin resistance if there are mixed populations of RIF-resistant and RIF-sensitive strains.</p></b>\r\r<p><b>Further reading</b></p>\r<p><a href=\"http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1000150\">Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009, 6: e1000150</a></p>\n<p><a href=\"http://cid.oxfordjournals.org/content/53/4/369.abstract\">Jacobson KR, Theron D, Victor TC, et al. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011, 53: 369-372</a></p>\r<p><a href=\"http://jcm.asm.org/content/48/7/2495.short\">Blakemore R, Story E, Helb D, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J Clin Microbiol 2010, 48: 2495-2501</a></p>\r\0', 'HIV-infected TB case with treatment failure on regimen 1 and previous unrecognised isoniazid mono-resistance', '<p><b>Interpretation:</b></p>\r<p>The clinical history gives a high degree of suspicion for MDR-TB. The result showing INH mono-resistance seemingly had gone unnoticed at the time and the patient had received standard regimen 1, albeit with an extra month of HRZE as intensive phase. The reversion of AFB smears to positive on HR continuation phase would be consistent with the emergence of MDR-TB.</p>\r', '2', 4, 'clinical, case, tb, mtb, xdr, drug resistance, HIV-infected, TB, case , treatment, failure , regimen 1 , previous, unrecognised , isoniazid, mono-resistance, Xpert, GeneXpert, point of care', 'HIV-infected TB case with treatment failure on regimen 1 and previous unrecognised isoniazid mono-resistance', '2012-01-27'),
(103, '<p>A result is received  from the laboratory on a 38 year old male patient. It is the results of phenotypic drug susceptibility testing (DST) on a cultured M. tuberculosis isolate from a lymph node aspirate taken ten months previously. This reports XDR-TB (resistance to rifampicin, isoniazid, ofloxacin, and kanamycin).  The patient is contacted and brought for review. He reports previous TB history as shown below:</p>\n<img src=\"imagesBIO/ca103chart.png\"><br>\n<p>On review he is asymptomatic with no evidence of lymph node disease. He reports that the lymph node swelling was in his neck in 2010 and TB treatment was started on clinical grounds, treatment was then stopped some time later (exact timing not clear) because it was not working. </p>\r<p>He is HIV-infected and has been on ART for three years. His current regimen is TDF/3TC/EFV, the latest viral load is <40 copies/ml and CD4+ cell count 197 cells/ul. </p>\r<p>Chest X-ray is performed which shows  left lower zone and right lateral pleural opacification, consistent with previous TB disease. Sputum culture is sent and a decision is made to monitor his clinical condition.</p>\r<p>Two months later he returns complaining of swelling of the right hand. On examination he has soft tissue swelling of the dorsal aspect of the first web space.  Pus is aspirated and sent for TB culture & DST.  The sputum culture sent previously has been reported as negative.</p>\r', 'cawhite.png', 'ca103HIVDR.png', NULL, '', '<p><b>Treatment recommendation</b></p>\r<p>The patient has active extrapulmonary TB disease, which seems on the current evidence to be confined to soft tissue disease. This certainly warrants antituberculous chemotherapy. </p>\r<p>One option would be to wait for full phenotypic DST results on the current isolate to inform selection of an individualised drug regimen. However, that risks progression of soft tissue TB disease and possible dissemination to other sites. </p>\r<p>The second option would to treat as rifampicin monoresistance, with a standardised regimen consisting of isoniazid, kanamycin, moxifloxacin, pyrazinamide, ethionamide, and terizidone. However, that risks suboptimal therapy and amplification of drug resistance if the isolate is confirmed as XDR-TB.</p>\r<p>The third option is to take into account the previous growth of XDR-TB and to institute an XDR regimen such as capreomycin, moxifloxacin, ethionamide, terizidone, PAS, and clofazimine. </p>\r<p>Evidence to inform which of these strategies is best is extremely limited. There is also limited information regarding penetration of second-line anti-TB drugs into different tissues, so the efficacy of selected drugs in different forms of extrapulmonary TB is relatively poorly understood.</p>\r<p><b>Case resolution</b></p>\r<p>The patient was commenced on a standardised regimen consisting of isoniazid, kanamycin, ofloxacin, pyrazinamide, ethionamide, and terizidone. Sputum cultures were negative. Phenotypic DST on the isolated cultured from the aspirate revealed\0 monoresistance to rifampicin, with phenotypic susceptibility to isoniazid, ofloxacin, and kanamycin. The soft tissue swelling reduced significantly in the first month of treatment and his drug regimen including isoniazid was continued.</p>\r', 'Richard Lessells', '<p>I. How common is drug-resistant TB in extrapulmonary TB disease?</p>\n<p>II. Should this patient have been treated for XDR-TB when the initial laboratory result was received?\r\n\0</p>\r', '<p>I. The burden of drug resistance in extrapulmonary TB has not been well characterised. Case series from uMzinyathi district in KwaZulu-Natal have suggested relatively high prevalence of XDR-TB from pleural and lymph node aspirates (7/21 or 33.3% of culture-positive isolates were XDR) and also from blood cultures (20/41 or 48.8% of culture-positive isolates were XDR). However, these series had inherent bias as aspirates were more likely to be performed when there was pre-existing concern about drug resistance. In addition this sub-district continues to have different epidemiology of drug resistance than elsewhere so the results may not be representative. There is some preliminary evidence that the Xpert MTB/RIF assay can be performed with extrapulmonary specimens and it is hoped this may bring some new understanding to the epidemiology of drug resistance in EPTB.</p>\r\n\0\r<p>II. It is important to remember always to treat the patient and not the laboratory result. In this case, at the time the initial laboratory result (showing XDR-TB) was received, there was no strong evidence of active TB disease. Instituting treatment with the inherent risks of toxicity would not have been in the best interests of the patient. Full reassessment of the patient for active disease and then close follow-up and monitoring of symptoms and signs is appropriate. Ultimately the strain isolated from the soft tissue disease had a different susceptibility pattern and an appropriate treatment regimen has been instituted. </p>\r', '<p><b>Drug-resistant extrapulmonary TB should generally be treated with the same regimens and for the same duration as for pulmonary disease</p>\r\n<p>Always remember to treat the patient and not the laboratory result. Diagnostic test results should always be considered in conjunction with the clinical features before a management decision is made</p>\r\n\0</b></b>\r<p><b>Further Reading</b>\0</p>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20202446\">Heysell SK, Moll AP, Gandhi NR, et al. Extensively drug-resistant Mycobacterium tuberculosis from aspirates, rural South Africa. Emerg Infect Dis 2010; 16: 557-560</a><br><br>\r<a href=\"http://www.biomedcentral.com/1471-2334/10/344\">Heysell SK, Thomas TA, Gandhi NR, et al. Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study. BMC Infect Dis 2010; 10: 344</a><br><br>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21593262\">Vadwai V, Boehme C, Nabeta P, et al. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol 2011; 49: 2540-2545</a><br><br>\r\r\0', 'HIV-infected adult male with a laboratory report showing extensively drug-resistant TB (XDR-TB)', '<p>The culture from the aspirate is positive for M. tuberculosis. The Genotype MTBDRplus assay is performed on the culture isolate and is reported as resistant to rifampicin but sensitive to isoniazid.</p>\r\0<p><b>Interpretation</b></p>\r<p>The Genotype MTBDRplus assay is an example of a line probe assay (LPA). This allows the simultaneous detection of M. tuberculosis complex and the most common mutations in the rpoB, katG and inhA genes.  Line probe technology involves DNA extraction, DNA amplification by polymerase chain reaction (PCR) and hybridization of PCR products with oligonucleotide probes embedded in a strip. Subsequent colorimetric change as a result of hybridization allows discrimination between  wild-type and mutant strains. Mutations are identified by lack of binding to wild-type probes combined with binding to a specific mutation probe (Figure 1). </p>\0\r<p>In this case rifampicin monoresistance has been identified with the LPA. However, there is also the previous growth of XDR-TB from a lymph node aspirate to consider. It remains possible that the current isolate could be XDR-TB (or MDR-TB). The Genotype MTBDRplus assay has suboptimal sensitivity for INH resistance as not all mutations associated with INH resistance are incorporated in the assay.</p>', '2', 3, 'clinical, case, tb, mtb, xdr, drug resistance, HIV-infected, adult , male , extensively, drug-resistant TB , XDR-TB', 'HIV-infected adult male with extensively drug-resistant TB (XDR-TB)', '2012-01-20'),
(105, 'A 35 year old male patient is referred to clinic because of smear non-conversion on TB regimen 1 (HRZE). He was started on treatment for smear positive pulmonary TB two months previously. His baseline smears were +++/++ and his smears at two months were +++/+++.  No specimen was sent for culture/DST at baseline. He remains symptomatic with cough, night sweats, chest pain, and has not gained weight on treatment. <br><br>\rHe reports good adherence to TB treatment with no significant side-effects.  He had one previous episode of smear positive TB ten years ago, for which he received six months of treatment and was cured. He reports that his brother who works as a miner in Johannesburg  had TB the previous year but apparently had improved with standard TB treatment. <br><br>\rHe is HIV-infected with recent CD4+ cell count of 187 cells/ul but has not yet started ART.  He plans to start ART in the private sector through his medical aid scheme. <br>\r<br>\rSputum is obtained and tested with the Xpert MTB/RIF assay<br>\r\r', 'ca105chart.png', 'cawhite.png', NULL, '', '<p><b>Treatment recommendation</b></p>\r<p>It is important to ensure that a specimen is sent for culture/DST to confirm the drug resistance and to obtain the full susceptibility profile. </p>\r<br>\r<p>The patient should be commenced on a standardised MDR-TB regimen consisting of and injectable agent (kanamycin or amikacin), a fluoroquinolone (ideally moxifloxacin), ethionamide, terizidone and pyrazinamide and should continue isoniazid. This regimen should be re-evaluated in 2-3 months based on the DST results and the initial response to treatment.</p>\r<p><b>Case resolution</b></p>\r<p>The patient was commenced on isoniazid, kanamycin, ofloxacin, ethionamide, terizidone and pyrazinamide. Culture was positive for M. tuberculosis and the Genotype MTBDRplus assay was reported as showing resistance to both rifampicin and isoniazid. Isoniazid was discontinued and the standard MDR-TB regimen was continued. He commenced ART through the private sector as planned.\r\n\0</p>\r', 'Richard Lessells', 'I. What are the potential reasons for sputum smear non-conversion?<br>\r<br>\rII. What is meant by the term amplification of drug resistance?<br>\r', '<p>I. \0Drug resistance is only one cause of sputum smear non-conversion. Most patients under normal circumstances (in the absence of drug resistance) should have negative smears at two months. Table 1 illustrates other potential causes to be considered in any case where the sputum smears have not converted. It should be noted that HIV infection per se is not a reason for non-conversion. </p>\r<p><center> <img src=\"imagesBIO/ca105extraanswer.png\"></center></p>\r<p>II.Amplification of drug resistance means the development of further drug resistance whilst receiving anti-TB treatment. In this case, for example, if MDR-TB was present prior to treatment initiation, then effectively whilst on HRZE the patient was receiving dual therapy (ZE). </p>\n<p>This increases the likelihood of the development of mutations conferring ethambutol and pyrazinamide resistance. In addition further RIF or INH drug-resistance mutations may develop, which might have consequences in terms of cross-resistance, e.g. inhA mutations and resistance to ethionamide. This underscores the importance of moving to a system whereby rapid drug susceptibility testing is available for all TB cases.</p>\r', '<p>Smear non-conversion should prompt full re-assessment of the patient to explore potential causes</p>\r\n<p>Treatment of undiagnosed drug-resistant tuberculosis with standardised first-line drug regimens could lead to the amplification of drug resistance, which in turn compromises future treatment options</p></b>\r\n\r<p><b>Further reading</b></p>\n<p><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/8762846\">Rieder HL. Sputum smear conversion during directly observed treatment for tuberculosis. Tuberc Lung Dis 1996; 77: 124-129</a></p>\r\n<p><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/18808360\">Temple B, Ayakaka I, Ogwang S, et al. Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis 2008; 47(9): 1126-1134</a></p>\r\n<p><a href=\"http://www.ncbi.nlm.nih.gov/pubmed/20113557\">Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16: 264-271</a></p>', 'HIV-infected TB case with smear non-conversion on regimen 1 despite good adherence', '<center><img src=\"imagesBIO/ca105extraHIVDB.png\"></center>\n<p><b>Interpretation</b></p>\r<p>The clinical history alone gives a high degree of suspicion for MDR-TB. His sputum smears show no response to standard TB treatment in the face of apparently good adherence. He has reported risk factors for MDR-TB both in terms of his previous TB episode (albeit ten years ago) and the contact with his brother who reportedly developed TB disease whilst working as a miner (drug-resistant TB is highly prevalent in the mines around Johannesburg)\0</p>\r', '2', 5, 'clinical, case, tb, mtb, xdr, drug resistance, HIV-infected , TB, case , smear, non-conversion , regimen 1, despite, good adherence', 'HIV-infected TB case with smear non-conversion on regimen 1 despite good adherence', '2012-01-28'),
(101, 'A 32 year old HIV-infected female presents with three weeks of cough, night sweats, chest pain, and dyspnoea. Her past medical history includes one previous episode of smear positive pulmonary TB in 2001, for which she took six months of therapy and was cured. <p>She had been diagnosed with HIV infection in 2008 and had been attending the primary health care clinic for regular CD4 monitoring but had not started antiretroviral therapy. Her most recent CD4 cell count five months before presentation was 350 cells/ul. </p>\r<br>\rShe reports that her sister, with whom she lived, had died whilst taking TB treatment 11 months prior to presentation. It was the first TB episode for her sister and she had been receiving regimen 1 (HRZE). <br>\r<br>\rA sputum specimen is obtained and tested with the Xpert MTB/RIF system<br>\r', 'ca101chart.png', 'ca101HIVDR.png', NULL, NULL, '<p><b>Treatment recommendation</b></p>\r<p>She could be treated with a standard MDR-TB regimen. However, given the issue with false positives highlighted above this would risk treatment with suboptimal potency in the event of drug-sensitive TB. In actual fact, she was treated with a hybrid regimen pending confirmation of MDR-TB through culture & phenotypic drug susceptibility testing. </p>\n<p>The regimen consisted of eight TB drugs: rifampicin (R), isoniazid (H), ethambutol (E), pyrazinamide (Z), kanamycin (Km), ofloxacin (Ofx), ethionamide (Eto), and terizidone (Trd). The rifampicin and isoniazid were subsequently discontinued when MDR-TB was confirmed with phenotypic DST.</p><br>\r', 'Richard Lessells', '\0I. By what mechanisms might this individual have developed drug-resistant TB disease?<br>\r<br>\rII. Should she be commenced on antiretroviral therapy (ART)?  If so, when should this be done and which regimen should be used?<br>\r', '<p>I. There are three aspects of this case that might be of particular relevance in terms of the drug resistance:</p>\r<p>Ia. It is plausible that she harboured drug-resistant strains from her first TB episode, despite the fact that this was 10 years prior to this episode and that she was documented to have been cured</p>\r<p>Ib. The death h of the sister on TB treatment might be of relevance. The death of any household contact whilst on TB treatment in this setting should raise suspicion of possible drug-resistant TB</p>\r<p>Ic. She has been attending her primary health care clinic regularly for HIV care and CD4 monitoring. The potential for health-care associated acquisition of drug-resistant TB therefore should be considered</p>\r<p>II. Yes she should be commenced on ART. In South Africa patients with MDR-TB and XDR-TB are eligible for ART regardless of CD4 cell count. The use of ART will be a major factor in determining her outcome from MDR-TB. There is no evidence to inform the timing of ART specifically in drug-resistant TB but most practitioners would recommend initiation of ART within 4-8 weeks of the start of TB treatment, as long as the TB treatment is being tolerated. There is also no evidence on the optimal ART regimen. There are no known interactions between second-line TB drugs and NRTIs or NNRTIs so a standard first-line regimen can be used. The potential for overlapping toxicities (see table below) should be understood and patients should be monitored closely.</p>\n<center> <img src=\"imagesBIO/ca101extraanswer.png\"></center>\r', 'The positive predictive value of the Xpert MTB/RIF system for detection of drug resistance will depend on the prevalence of rifampicin resistance in the population being tested<br>\r<br>\rAll HIV-infected individuals with MDR-TB or XDR-TB should be commenced on antiretroviral therapy<br>\r</b>\r<p><b>Further reading</b></p>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21507477\">Boehme CC, Nicol MP, Nabeta P, et al (2011). Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet; 377: 1495-1505</a><br>\r<br>\r<a href=\"http://whqlibdoc.who.int/publications/2011/9789241501569_eng.pdf\">World Health Organization (2011). Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operationalHow-to; practical considerations.</a>  <br>\r<br>\r<a href=\"http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf\">World Health Organization (2011). Guidelines for the programmatic management of drug-resistant tuberculosis -2011 update. </a> <br>\r\0', 'HIV-infected TB suspect with previous history of TB treatment: Xpert MTB/RIF test', '<center><img src=\"imagesBIO/ca101extraHIVDB.png\"></center>\n<p><b>Interpretation</b></p>\r<p>The result is MTB DETECTED LOW; Rif Resistance DETECTED. This molecular test has detected M. tuberculosis and at least one of the mutations in the rpoB gene which confer resistance to rifampicin. Rifampicin resistance is considered a reliable proxy for multidrug resistance (MDR) as rifampicin mono-resistance is relatively rare (>98% of rifampicin-resistant strains in the Xpert MTB/RIF demonstration study were MDR on conventional DST). </p>\r<p>Given the relatively high pre-test probability of TB in this case from the clinical features, the detection of M. tuberculosis in sputum is very likely to indicate active TB disease. </p>\r<p>The detection of rifampicin resistance is more complicated. In the large demonstration study for Xpert MTB/RIF, the sensitivity and specificity for detection of rifampicin resistance were 94.4% and 98.3% respectively (compared to the reference standard of phenotypic DST). To understand the significance of a positive result for rifampicin resistance, it is necessary to consider predictive values. Predictive values depend on the underlying prevalence of the condition in question. </p>\n <p>The table below shows how the positive predictive value (PPV) varies according to the prevalence of rifampicin resistance (i.e. the proportion of TB isolates that are rifampicin resistant) and illustrates how this would translate to true positive and false positive resistance results in a hypothetical population of 1000 TB cases. In South Africa, approximately 5% of all TB cases are rifampicin resistant so the PPV for rifampicin resistance if used in unselected TB cases would be approximately 74%. </p>\r<p>Certain groups have a much higher prevalence of rifampicin resistance, e.g. re-treatment cases and contacts of drug-resistant cases. Use in these selected groups will significantly reduce the occurrence of false positive rifampicin results. </p> <br>\r', '2', 1, 'clinical, case, tb, mtb, xdr, drug resistance, TB suspect , history , TB treatment, Xpert , MTB/RIF, test, GeneXpert', 'HIV-infected TB suspect with previous history of TB treatment: Xpert MTB/RIF test', '2012-01-20'),
(102, 'A 61 year old HIV-infected female on antiretroviral therapy presents with three weeks of cough, night sweats and chest pain. She has been taking TDF/3TC/LPVr (her first ART regimen commenced in the private sector) for almost two years. Her latest results are CD4 470 cells/ul and viral load <40 copies/ml. She reports a previous episode of smear negative pulmonary TB in 2009 for which she completed six months of treatment.\r<p>A sputum specimen is obtained and tested with the Xpert MTB/RIF system.  In addition a chest  X-ray is performed. Routine bloods include creatinine 92 micromol/L (calculated creatinine clearance 58ml/min).</p>\r<p>Further history reveals that her co-resident 27 year old son commenced treatment for MDR-TB four months prior to her presentation. In addition her two year old grandson (who was also living with them) had recently been admitted to hospital in Durban for pneumonia. </p><br>\r', 'ca102chart.png', 'ca102HIVDR.png', NULL, '<b>Interpretation</b><br><br>\rThe chest X-ray demonstrates bilateral apical fibrosis and left lower lobe consolidation with early cavity formation. This is consistent with active TB disease.<br>', '<b>Treatment recommendation</b><br>\rThis lady has specific risk factors for MDR-TB: the history of TB treatment two years prior to this presentation and the household contact with diagnosed MDR-TB. In this context the Xpert MTB/RIF suggests a very high likelihood of MDR-TB.<br>\r<br>\rShe should be commenced on a standard MDR-TB regimen with at least four drugs which are expected to be active. A recommended regimen would be: kanamycin (Km), ofloxacin (Ofx), ethionamide (Eto), terizidone (Trd) and pyrazinamide (Z).  If not done already, a further sputum specimen should be sent for culture and phenotypic DST.<br>\r', 'Richard Lessells', 'I. Why has this individual developed TB disease whilst on suppressive antiretroviral therapy?<br>\r<br>\rII. What further information regarding the son might be useful in managing the patient?<br>\r<br>\rIII. Is there any information given that would make you alter the dosage of any TB drugs?<br>\r<br>\rIV. Should the current ART regimen be continued or changed?<br>\r<br>\rV. What advice would you give regarding the grandson?<br>\r', 'I. Unfortunately TB disease can still develop in HIV-infected individuals on suppressive ART. Indeed studies show that the incidence of TB disease on ART remains significantly higher than the background population rate (Brinkhof 2007).<br>\r<br>\rII. Information should be sought regarding the susceptibility profile of the son TB isolates and his response to MDR-TB treatment. In this case it was determined that the son at baseline had pre-XDR-TB (resistance to kanamycin but not ofloxacin) and had remained smear and culture positive in the first six months of treatment. This might increase the likelihood that our patient has additional resistance and might also have an unfavourable response to standard MDR-TB treatment.  This makes it critical that full phenotypic DST is performed.<br>\r<br>\rIII. She has chronic kidney disease stage 3 (creatinine clearance 58ml/min). The dosing frequency of the injectable agent should be reduced from five days per week to three days per week. The creatinine should be monitored at least monthly whilst on kanamycin.<br>\r<br>\rIV. There is no evidence with which to guide antiretroviral regimen choice in patients on second-line TB drugs. It should be noted that ritonavir may interact with second-line TB drugs through inhibition of the cytochrome P450 (CYP450) system. Of the common second-line TB drugs, ethionamide is known to be metabolized through this CYP450 system so there is the potential for increased drug levels (no specific studies have been performed). Given the current virological suppression, it would be sensible to continue her current ART regimen but she should be monitored very closely for toxicity.<br>\r<br>\rV. The report of the grandson being admitted with pneumonia should be of concern. The child needs to be assessed for active TB disease with Mantoux test, chest X-ray, gastric washings, and HIV test. <br>\r', 'I. In MDR-TB cases with a household contact also on MDR-TB treatment, information should be sought about the drug susceptibility profile and response to treatment of the contact, this might help to tailor the regimen pending full DST results<br>\r<br>\rII. Child contacts of MDR-TB cases should all be referred for assessment. Symptomatic contacts should undergo investigation with Mantoux test, chest X-ray, gastric aspirates, and HIV testing<br></b><br>\r<p>\r<b>\0Further reading</b></p>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/17990236\">Brinkof MW, Egger M, Boulle A (2007). Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007; 45: 1518-1521</a><br>\r<br>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/19256042\">Coyne KM, Pozniak AL, Lamorde M, Boffito M (2009). Pharmacology of second-line antituberculosis drugs and potential for interactions with antiretroviral agents. AIDS 23: 437-446</a><br>\r<br>\r<a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21943839\">Grandjean L, Crossa A, Gilman RH et al (2011). Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 15: 1164-1169</a><br>\r\0', 'HIV-infected TB suspect with household MDR-TB contact: Xpert MTB/RIF test', '<p>The Xpert MTB/RIF result is MTB DETECTED MEDIUM. Rif Resistance DETECTED. This molecular test has detected M. tuberculosis and at least one of the mutations in the rpoB gene which confer resistance to rifampicin, which can be considered a reliable proxy for MDR-TB.</p>\r', '2', 2, 'clinical, case, tb, mtb, xdr, drug resistance, HIV-infected, TB suspect , household , MDR-TB,  contact , Xpert, MTB/RIF, test, assay, GeneXpert', 'HIV-infected TB suspect with household MDR-TB contact Xpert MTB/RIF test', '2012-01-20');

-- --------------------------------------------------------

--
-- Table structure for table `b_cmds`
--

CREATE TABLE `b_cmds` (
  `cmd_id` int(4) NOT NULL,
  `cmd_name` varchar(25) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_cmds`
--

INSERT INTO `b_cmds` (`cmd_id`, `cmd_name`) VALUES
(1, 'bl2seq'),
(2, 'blastall'),
(3, 'blastclust'),
(4, 'blastpgp'),
(5, 'blat'),
(6, 'faToNib'),
(7, 'alc'),
(8, 'determine-phred'),
(9, 'guidance.pl'),
(10, 'bam2hints'),
(11, 'espoca'),
(12, 'etraining');

-- --------------------------------------------------------

--
-- Table structure for table `b_databases`
--

CREATE TABLE `b_databases` (
  `id` int(11) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `b_expertises`
--

CREATE TABLE `b_expertises` (
  `id` int(11) UNSIGNED NOT NULL,
  `topics_1` int(11) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- --------------------------------------------------------

--
-- Table structure for table `b_grants`
--

CREATE TABLE `b_grants` (
  `id` int(11) UNSIGNED NOT NULL,
  `short_title` varchar(100) DEFAULT NULL,
  `title` varchar(300) DEFAULT NULL,
  `PIs` char(200) DEFAULT NULL,
  `result` enum('idea','to be submitted','scored','awarded','rejected','not submitted') DEFAULT NULL,
  `award_letter` varchar(200) DEFAULT NULL,
  `contract` varchar(200) DEFAULT NULL,
  `scientifc_proposal` varchar(200) DEFAULT NULL,
  `proposal_type` enum('doc','pdf') DEFAULT NULL,
  `budget` varchar(200) DEFAULT NULL,
  `budget_justification` varchar(200) DEFAULT NULL,
  `abstract` longtext,
  `keywords` longtext,
  `collaborators` longtext,
  `topic_primary` enum('bioinformatics','phylogenetics','drug resistance','human genetics','epidemiology','social sciences/ethics','operational science','core','capacity building') DEFAULT NULL,
  `topic_secondary` enum('bioinformatics','phylogenetics','drug resistance','human genetics','epidemiology','social sciences/ethics','operational science','core','capacity building') DEFAULT NULL,
  `costcentre` char(10) DEFAULT NULL,
  `organism` enum('HIV','HCV','Arbovirus','all virus','STIs','human') DEFAULT NULL,
  `funder` varchar(200) DEFAULT '',
  `call_doc` varchar(200) DEFAULT NULL,
  `call_website` varchar(200) DEFAULT NULL,
  `start_date` date DEFAULT NULL,
  `end_date` date DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_grants`
--

INSERT INTO `b_grants` (`id`, `short_title`, `title`, `PIs`, `result`, `award_letter`, `contract`, `scientifc_proposal`, `proposal_type`, `budget`, `budget_justification`, `abstract`, `keywords`, `collaborators`, `topic_primary`, `topic_secondary`, `costcentre`, `organism`, `funder`, `call_doc`, `call_website`, `start_date`, `end_date`) VALUES
(1, 'MRC Flagship', 'A multi-disciplinary approach to understand the causes and consequences of HIV\rtransmission and drug resistance in a hyper-epidemic setting in rural South Africa', 'Tulio de Oliveira and Frank Tanser', 'awarded', 'deOliveiraTanser_MRCFlagship_letter.pdf', NULL, 'deOliveiraTanser_MRCFlag_proposal.doc', 'doc', 'AfricaCentreMRCBudgetExtension.xlsx', NULL, '<p>Background - Three decades after the first reported cases of AIDS, for the first time there is scientific consensus that the tools now exist to control and reverse the HIV epidemic. Central to this optimism is the recent empirical evidence from the Africa Centre published in the journal Science 2013 that convincingly showed at a population level that risk of acquiring HIV significantly declines with increasing coverage of ART. Indeed mathematical models suggest that the epidemic could halted by 2050 if high-levels of ART coverage are achieved (in combination with other effective interventions such as medical male circumcision). Key to devising the most efficient and cost-effective combination of interventions will be a clear understanding of patterns of HIV transmission in a typical rural African hyper-endemic setting. Recent methodological innovations in viral gene sequencing technology combined with a reduction in cost provide an unparalleled opportunity to understand patterns of HIV transmission and drug resistance and to establish the the most effective HIV prevention and treatment approaches in a typical rural sub-Saharan South African setting. </p>\n<p>Aims - The overall aim of the research is to quantify HIV transmission and drug resistance patterns and to identify the most effective combination of HIV prevention and treatment approaches in a hyperendemic rural South African setting. Our specific objectives are to: </p>\n<p>1. Use molecular epidemiological approaches to develop a clear understanding of HIV transmission dynamics in a typical rural African population and to characterize the individuals and sub-populations responsible for a disproportionately large number of transmission events. </p>\n<p>2. Identify clinical, demographic, genetic and social factors associated with failure of antiretroviral treatment and development of drug resistance in a rural primary health care-based public HIV treatment and care programme. </p>\n<p>3. Optimise scientific collaboration between phylogeneticists, geneticists, geographers, public health professionals, health economists, computer scientists, social scientists, modelers and epidemiologists from the Africa Centre, UKZN and external organizations to develop new approaches to address the overarching aim and objectives 1 and 2. </p>\n<p>4. To rapidly translate scientific findings into policy by ensuring close collaboration with the National Department of Health and international health policies agencies </p>\n<p>Methods - The proposal brings together a diverse set of experts to identify the most effective combination of HIV prevention interventions through a thorough exploration of the social, epidemiological and molecular characteristics of HIV transmission networks and the quantification of emergence of drug resistance. Furthermore, as a matter of urgency given decreasing support for global HIV programmes, we will combine these results with cost data to directly inform the most cost-effective combination of interventions (measured in terms of cost per HIV infection averted). </p>\n<p>We will genetically sequence existing blood samples from 4,000 HIV positive individuals identified through the Africa Centres annual population-based HIV surveillance (2004-2012) and from 600 HIV individuals failing ART resident in the Africa Centres surveillance area, for whom socio-demographic and clinical data are available since 2000. This dataset will be added to ?1,500 genotypes already produced at Africa Centre. We will then apply molecular epidemiological techniques to describe the characteristics of HIV transmission networks and statistical techniques to identify factors associated to the development of drug resistance in the study population. Additional data mining and machine learning techniques may also be applied to these problems. These results will be combined with detailed demographic information to identify key characteristics of transmitters. This data will further be combined with approximately 10,000 HIV sequences from other settings in South Africa, generated by the SATuRN consortium, to determine the impact of imported strains on the local transmission dynamics. The SATuRN data and the data from patients failing ART in the Africa Centre DSS will be used to identify factors determining failure and drug resistance development in order to devise strategies to decrease to prevent a drug resistant epidemic. </p>\n<p>Anticipated outcomes - Identification of the most effective HIV prevention and treatment approaches based on clear understanding of the patterns and determinants of HIV transmission and drug resistance acquisition in a typical rural sub-Saharan South African setting.</p>', 'UKZNHIVEPI, SAMRC, epidemiology, phylogenetics, HIV, geographic information system, drug resistance', NULL, 'phylogenetics', 'epidemiology', '99AW', 'HIV', 'SAMRC', NULL, NULL, '2014-04-01', '2019-03-31'),
(2, 'PANGEA', 'Phylogenetics Networks to Adress Transmission of HIV', 'Deenan Pillay', 'awarded', NULL, NULL, 'PANGEA_Submitted_Full_Proposal.doc', 'doc', 'Appendix_b_budget_spreadsheet_Africa Centre_REVISED v2.xlsm', 'App_C_Budget_Narrative_WTSI_REVISED v2.doc', NULL, 'BMGF, PANGEA, HIV, phylogenetics, networks, whole genome sequencing, transmission, PANGEA_HIV', 'Paul Kellam, Christophe Fraser, Andrew Leigh-Brown, Tulio de Oliveira', 'phylogenetics', 'epidemiology', '99BJ', 'HIV', 'BMGF', NULL, NULL, '2013-08-01', '0000-00-00'),
(3, 'CAPRISA ACC', 'CAPRISA Advanced Clinical Care', 'Kogie Naidoo', 'awarded', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '', NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `b_grants_results`
--

CREATE TABLE `b_grants_results` (
  `id` int(11) UNSIGNED NOT NULL,
  `result` varchar(100) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_grants_results`
--

INSERT INTO `b_grants_results` (`id`, `result`) VALUES
(1, 'idea'),
(2, 'preparing submission'),
(3, 'in review'),
(4, 'scored'),
(5, 'awarded'),
(6, 'rejected'),
(7, 'not submitted');

-- --------------------------------------------------------

--
-- Table structure for table `b_installed_sw`
--

CREATE TABLE `b_installed_sw` (
  `sw_id` int(3) NOT NULL,
  `sw_name` varchar(50) NOT NULL,
  `sw_url` varchar(200) NOT NULL,
  `sw_desc` varchar(200) NOT NULL,
  `cat_id` int(2) NOT NULL,
  `subcat_id` int(3) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_installed_sw`
--

INSERT INTO `b_installed_sw` (`sw_id`, `sw_name`, `sw_url`, `sw_desc`, `cat_id`, `subcat_id`) VALUES
(1, 'blast-2.2.26', 'ftp://ftp.ncbi.nih.gov/blast/', 'Legacy NCBI BLAST', 1, 1),
(2, 'clustalw', 'http://www.ebi.ac.uk/clustalw/', 'ClustalW 2', 3, 3),
(3, 'ncbi-blast-2.2.26+', 'http://www.ncbi.nlm.nih.gov/BLAST/', 'NCBI BLAST finds regions of similarity between biological sequences', 1, 1),
(4, 'ncbi-blast-2.2.28+', 'http://www.ncbi.nlm.nih.gov/BLAST/', 'NCBI BLAST finds regions of similarity between biological sequences', 1, 1),
(5, 'paup2', 'http://paup.csit.fsu.edu/\n', 'PAUP* is a computational phylogenetics program for inferring evolutionary trees', 2, 1),
(6, 'paup4a146_centos64', 'http://paup.csit.fsu.edu/', 'PAUP* is a computational phylogenetics program for inferring evolutionary trees', 2, 1),
(7, 'paup4a147_centos64', 'http://paup.csit.fsu.edu/', 'PAUP* is a computational phylogenetics program for inferring evolutionary trees', 2, 1),
(8, 'paup4a158_centos64', 'http://paup.csit.fsu.edu/', 'PAUP* is a computational phylogenetics program for inferring evolutionary trees', 2, 1),
(9, 'paup4a-linux', 'http://paup.csit.fsu.edu/', 'PAUP* is a computational phylogenetics program for inferring evolutionary trees', 2, 1),
(10, 'puzzle', 'http://www.tree-puzzle.de/', 'TREE-PUZZLE: Maximum likelihood analysis for nucleotide, amino acid, and two-state data ', 2, 1),
(11, 'tgf10rc4', 'http://treegraph.bioinfweb.info/Help/wiki/TGF', 'TreeGraph: automated drawing of complex tree figures using an extensible tree description format', 2, 1),
(12, 'tree-puzzle-5.3.rc16-linux', 'http://www.tree-puzzle.de/', 'TREE-PUZZLE: Maximum likelihood analysis for nucleotide, amino acid, and two-state data ', 2, 1),
(13, 'bcftools-1.1', 'https://samtools.github.io/bcftools/bcftools.html', 'Tools (written using htslib) for manipulating next-generation sequencing data', 6, 6),
(14, 'beagle-lib', 'https://github.com/beagle-dev/beagle-lib', 'Library for evaluating the likelihood of sequence evolution on trees', 6, 6),
(15, 'BEASTv2.1.2', 'https://github.com/beast-dev/beast-mcmc', 'Bayesian Evolutionary Analysis Sampling Trees', 2, 1),
(16, 'BEASTv1.8.2', 'https://github.com/beast-dev/beast-mcmc', 'Bayesian Evolutionary Analysis Sampling Trees', 2, 1),
(17, 'BEASTv1.8.4', 'https://github.com/beast-dev/beast-mcmc', 'Bayesian Evolutionary Analysis Sampling Trees', 2, 1),
(18, 'BEASTv2.0.2', 'https://github.com/beast-dev/beast-mcmc', 'Bayesian Evolutionary Analysis Sampling Trees', 2, 1),
(19, 'bedGraphToBigWig', 'http://hgdownload.cse.ucsc.edu/admin/', 'Convert bedGraph to bigWig file', 7, 1),
(20, 'bedtools2', 'https://github.com/arq5x/bedtools2', 'A powerful toolset for genome arithmetic', 6, 6),
(21, 'BioPerl-1.6.1', 'http://search.cpan.org/dist/BioPerl/', 'Perl Modules for Biology', 4, 2),
(22, 'bowtie2-2.2.4', 'https://github.com/BenLangmead/bowtie', 'An ultrafast, memory-efficient short read aligner', 6, 5),
(23, 'bwa', 'http://bio-bwa.sourceforge.net/', 'Burrows-Wheeler Aligner (BWA)', 6, 5),
(24, 'clustal-omega-1.2.1', 'http://www.clustal.org/omega/', 'Clustal Omega', 3, 3),
(26, 'devtools-1.1.repo', 'https://cran.r-project.org/web/packages/devtools/index.html', 'devtools: Tools to Make Developing R Packages Easier', 4, 2),
(27, 'FastME_2.07', 'https://gite.lirmm.fr/atgc/FastME/', 'Comprehensive, accurate and fast distance-based phylogeny inference program', 2, 1),
(28, 'fastme-2.08', 'https://gite.lirmm.fr/atgc/FastME/', 'Comprehensive, accurate and fast distance-based phylogeny inference program', 2, 1),
(29, 'FastQC', 'http://www.bioinformatics.babraham.ac.uk/projects/fastqc', 'A quality control tool for high throughput sequence data', 6, 7),
(30, 'gcta64', 'http://cnsgenomics.com/software/gcta/', 'A tool for Genome-wide Complex Trait Analysis', 3, 1),
(31, 'hyphy-2.2.4', 'https://veg.github.io/hyphy-site/', 'Hypothesis testing using phylogenies', 2, 1),
(32, 'iqtree', 'http://www.cibiv.at/software/iqtree', 'Efficient phylogenetic software by maximum likelihood', 2, 1),
(33, 'iva-0.11.4', 'http://sanger-pathogens.github.io/iva/', 'A de novo assembler designed to assemble virus genomes', 3, 1),
(34, 'iva-0.11.6', 'http://sanger-pathogens.github.io/iva/', 'A de novo assembler designed to assemble virus genomes', 3, 1),
(35, 'Jellyfish-1.5.5', 'https://github.com/gmarcais/Jellyfish', 'Fast, Parallel k-mer Counting for DNA', 6, 6),
(36, 'jellyfish-2.2.3', 'https://github.com/gmarcais/Jellyfish', 'Fast, Parallel k-mer Counting for DNA', 6, 6),
(37, 'khmer-master', 'https://github.com/dib-lab/khmer', 'k-mer counting, filtering, and graph traversal FTW!', 6, 6),
(38, 'kraken-0.10.5-beta', 'https://ccb.jhu.edu/software/kraken/', 'Taxonomic sequence classification system', 6, 6),
(39, 'mosaik', 'https://codeload.github.com/wanpinglee/MOSAIK/zip/master', 'Maps next generation sequencing (NGS) reads to a reference genome', 6, 5),
(40, 'mrbayes_3.2.2', 'http://mrbayes.sourceforge.net', 'Bayesian Inference of Phylogeny', 2, 1),
(41, 'MUMmer3.23', 'http://www.genome.umd.edu/masurca.html', 'Whole genome assembly software', 6, 8),
(42, 'muscle-3.8.3', 'http://www.drive5.com/muscle/', 'Multiple sequence alignment', 3, 3),
(44, 'PhyML-3.1', 'https://github.com/stephaneguindon/phyml', 'PhyML: Phylogenetic estimation using Maximum Likelihood', 2, 1),
(45, 'plink-1.07-x86_64', 'https://www.cog-genomics.org/plink3', 'Whole-genome association analysis toolset', 6, 6),
(46, 'plink1.90', 'https://www.cog-genomics.org/plink4', 'Whole-genome association analysis toolset', 6, 6),
(47, 'poretools', 'https://github.com/arq5x/poretools', 'Poretools: a toolkit for analyzing nanopore sequence data', 3, 1),
(48, 'Python-3.3.3', 'http://www.python.org/', 'An interpreted, interactive, object-oriented programming language', 4, 4),
(49, 'Python-3.7.0b1', 'http://www.python.org/', 'An interpreted, interactive, object-oriented programming language', 4, 4),
(50, 'QUASR_v6.08', 'https://bioconductor.org/packages/release/bioc/html/QuasR.html', 'Quantify and Annotate Short Reads in R', 3, 1),
(51, 'R-3.4', 'http://www.r-project.org', 'A language for data analysis and graphics', 8, 4),
(52, 'RAxML', 'http://sco.h-its.org/exelixis/web/software/raxml/index.html', 'Randomized Axelerated Maximum Likelihood', 2, 1),
(53, 'samtools-1.1', 'https://github.com/samtools', 'Tools (written using htslib) for manipulating next-generation sequencing data', 6, 6),
(54, 'sickle-master', 'https://github.com/najoshi/sickle', 'sickle - A windowed adaptive trimming tool for FASTQ files using quality', 6, 7),
(55, 'smalt-0.7.5', 'http://www.sanger.ac.uk/science/tools/smalt-0', 'Aligns DNA sequencing reads with a reference genome', 3, 1),
(56, 'SPAdes-3.10.1-Linux', 'http://cab.spbu.ru/software/spades/', 'St. Petersburg genome assembler', 6, 8),
(57, 'standard-RAxML-master', 'https://github.com/stamatak/standard-RAxML', 'Phylogenetic Analysis and Post-Analysis of Large Phylogenies', 2, 1),
(58, 'tn93', 'https://github.com/veg/tn93', 'Computes pairwise distances between aligned nucleotide sequences', 3, 1),
(59, 'Trimmomatic-0.33', 'http://www.usadellab.org/cms/?page=trimmomatic', 'Trimmomatic: A flexible read trimming tool for Illumina NGS data', 6, 6),
(60, 'vicuna', 'https://www.broadinstitute.org/viral-genomics/vicuna', 'A de novo assembly program targeting populations with high mutation rates', 6, 8),
(61, 'wise-2.4.1', 'http://www.mybiosoftware.com/wise-2-2-0-compare-protein-sequence-genomic-dna-sequence.html', 'Compare Protein Sequence to Genomic DNA Sequence', 3, 1),
(62, 'paup', 'http://paup.csit.fsu.edu/', 'PAUP is a computational phylogenetics program for inferring evolutionary trees', 2, 1),
(64, 'blast-2.5.0', 'ftp://ftp.ncbi.nih.gov/blast/', 'Legacy NCBI BLAST', 1, 1),
(65, 'treePuzzle', 'http://treegraph.bioinfweb.info/Help/wiki/TGF', 'TreeGraph: automated drawing of complex tree figures using an extensible tree description format', 2, 1),
(66, 'treeGraph', 'http://treegraph.bioinfweb.info/Help/wiki/TGF', 'TreeGraph: automated drawing of complex tree figures using an extensible tree description format', 2, 1),
(67, 'diamond', 'https://ab.inf.uni-tuebingen.de/software/diamond/', 'Aligning DNA reads or protein sequences against a protein reference database', 6, 5),
(69, 'SPAdes-3.10.1', 'http://cab.spbu.ru/software/spades/', 'St. Petersburg genome assembler', 6, 8),
(70, 'samtools', 'https://github.com/samtools', 'Tools (written using htslib) for manipulating next-generation sequencing data', 6, 6),
(72, 'vsearch', 'https://github.com/torognes/vsearch', 'Versatile open-source tool for metagenomics ', 6, 6);

-- --------------------------------------------------------

--
-- Table structure for table `b_links`
--

CREATE TABLE `b_links` (
  `id` int(11) UNSIGNED NOT NULL,
  `title` longtext,
  `webpage` longtext,
  `bioafricaSATuRN` int(11) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_links`
--

INSERT INTO `b_links` (`id`, `title`, `webpage`, `bioafricaSATuRN`) VALUES
(1, 'Wellcome Trust Collection  - Art of Global Health project ', 'www.wellcomecollection.org/global', 4),
(2, 'Pediatrician in Swaziland Blog and Website', 'pediatrician-in-swaziland.blogspot.com/', 4);

-- --------------------------------------------------------

--
-- Table structure for table `b_main_orgn_info`
--

CREATE TABLE `b_main_orgn_info` (
  `org_no` mediumint(5) NOT NULL DEFAULT '0',
  `reg_date` datetime NOT NULL DEFAULT '0000-00-00 00:00:00',
  `name` varchar(50) COLLATE latin1_general_ci NOT NULL DEFAULT '',
  `reg_status` text COLLATE latin1_general_ci NOT NULL,
  `org_type` set('PLC','NGO','CBO') COLLATE latin1_general_ci NOT NULL DEFAULT '',
  `reg_country` tinyint(3) NOT NULL DEFAULT '0',
  `phy_address` text COLLATE latin1_general_ci,
  `post_address` text COLLATE latin1_general_ci,
  `phone` varchar(30) COLLATE latin1_general_ci DEFAULT NULL,
  `fax` varchar(30) COLLATE latin1_general_ci DEFAULT NULL,
  `email` varchar(50) COLLATE latin1_general_ci DEFAULT NULL,
  `url` varchar(100) COLLATE latin1_general_ci DEFAULT NULL,
  `spoc` varchar(30) CHARACTER SET latin1 DEFAULT NULL,
  `logo` varchar(150) COLLATE latin1_general_ci DEFAULT NULL,
  `done_by` varchar(20) COLLATE latin1_general_ci NOT NULL DEFAULT '',
  `main_org` enum('Yes','No') COLLATE latin1_general_ci NOT NULL DEFAULT 'Yes'
) ENGINE=MyISAM DEFAULT CHARSET=latin1 COLLATE=latin1_general_ci;

--
-- Dumping data for table `b_main_orgn_info`
--

INSERT INTO `b_main_orgn_info` (`org_no`, `reg_date`, `name`, `reg_status`, `org_type`, `reg_country`, `phy_address`, `post_address`, `phone`, `fax`, `email`, `url`, `spoc`, `logo`, `done_by`, `main_org`) VALUES
(3, '2018-02-13 13:40:01', 'KRISP', 'SionaPros was registered as a Charity under NGO act, Charity No. S.5914/1857. It is also registered as a limited company, limited by guarantee.', 'NGO', 1, 'KIRTH Building, Umbilo Road', 'Private bag 7134', '0725290848', '', 'sanemmanueljames@gmail.com', 'http://krisp.ukzn.ac.za', 'sanem', './images//9ad21112b393f882206931bb08cc59d0.png', '', 'Yes');

-- --------------------------------------------------------

--
-- Table structure for table `b_media`
--

CREATE TABLE `b_media` (
  `id` int(11) DEFAULT NULL,
  `link` longtext,
  `file` longtext,
  `title` longtext,
  `authors` longtext,
  `description` longtext,
  `image` tinytext,
  `summary` longtext,
  `summary2` longtext,
  `keywords` longtext,
  `date` date DEFAULT NULL,
  `intro` longtext
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_media`
--

INSERT INTO `b_media` (`id`, `link`, `file`, `title`, `authors`, `description`, `image`, `summary`, `summary2`, `keywords`, `date`, `intro`) VALUES
(1, '<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=2\">Jiving with Science CD 2: Indaba kaTira</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=3\">Jiving with Science CD 3: Uhlelo lukaMroza</a></p>', NULL, 'Music: Jiving with Science CD 1: Indaba kaMamBiyela - Africa Centre research and HIV/AIDS', 'Astrid Treffry-Goatley, Mduduzi Mahlinza, John Imrie', 'BioAfrica Art & Science area feature Music: Jiving with Science CD 1: Indaba kaMamBiyela - Africa Centre research and HIV/AIDS', 'CD_1_FRONT_SMALL.jpg', '<br><b> Introduction:</b> CD 1, Indaba kaMamBiyela is targeted at adult listeners and features\na selection of jazz, gospel and maskanda songs. It follows local\nnotable MamBiyela in her quest to find out more about Africa Centre research and\nHIV/AIDS. Starting at her home, it takes the listener on a ride in a\ntaxi where she has a discussion with a nurse and then to a road show\nwhere she speaks to a counsellor about antiretrovirals (ARVs).&nbsp;\nThrough MamBiyela, we discover more about Africa Centre, HIV and TB testing, HIV\nstigma, breastfeeding, mother to child transmission and ARVs. <br>\n            <br>\n            <table class=\"main\">\n              <tbody>\n                <tr>\n                  <td>&nbsp;<br>\n                  <b>Scripts: </b> click to download a <a href=\"manuscripts/cd1_english_script.pdf\"><u>English</u></a> or <a href=\"manuscripts/cd1_zulu_script.pdff\"><u>Zulu</u></a> script used in the CD.\n                  <br>\n                  </span><br>\n                  </td>\n                </tr>\n              </tbody>\n            </table>\n  <b>Music:</b> click <a href=\"newmedia/CD1forweb.mp3\"><u>here</u></a> to download sample of the CD.<small> Please note that songs are restricted to 30 seconds clips for copyright reasons.</span></small><br><br>\n              <b>Music:</b> click below to stream a sample of the CD. <small> Please note that songs are restricted to 30 seconds clips for copyright reasons.</small><small> You will need QuickTime player.</small><br>\n            <embed src=\"newmedia/CD1forweb.mp3\" autostart=\"false\" loop=\"FALSE\" &gt;play=\"\" the=\"\" complete=\"\" cd=\"\" with=\"\" messages=\"\" height=\"40\" width=\"200\"><b><br>\n            </b></span>', '<p><b>Sponsors:</b> we would like to thank the following individuals and companies for their generous contribution to the creation of this CD: Wellcome Trust, EMI, Sheer Sound, Maltre Productions, Gallo Music Publishers, Mtubatuba Taxi Association, Abafana Bokuthula and Deborah Gumede</p>\n\n<p><b>Starring staff from Africa Centre\'s Community Engagement Office:</b> Mduduzi Mahlinza, Xolile Kineri, Ntombikayise Mnyango, Siboniso Buthelezi, Bongi Gumede, Ncengani Mthethwa and Busangani Ngwenya.</p>\r', 'BioAfrica, Art, Science, Music, Jiving with Science ,CD,  Indaba kaMamBiyela, Africa Centre, research, HIV, AIDS', '2012-03-29', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. Africa Centre is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health.</p>\n<p>This project involves developing, distributing and evaluating 4 CDs over 2 years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action. The aim is to foster community discussion about scientific research and to bring evidence based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.</p>'),
(5, NULL, NULL, 'Poetry: Toward A SATuRN Hope', 'Joshua Machao', 'Towards a SATuRN hope: A beautiful poetry by Joshua Machao for the openning of the 6th Southern African HIV and TB Drug Resistance and Treatment Management Workshop', 'Joshua-T-MACHAO.png', '', '<p>\rSATuRN<br>\rWith her circles of concern<br>\rStands firm despite fires that burn<br>\rWhether you are home-schooled or college<br>\rLet us all recognize and pay homage<br>\rTo her rings of infinite knowledge</p>\n<p>\rI heard once through the muttering air<br>\rHow proximity bred calamity<br>\rIntimacy came with unwanted seeds<br>\rAs broken families lay scattered<br>\rBy a way of life shattered<br>\rI heard with dismay <br>\rHow the calamity <br>\rRavaged nations<br>\rStole precious futures <br>\rLeaving in its wake<br>\rThe stench of death in the air</p>\r<p>\rI heard how once<br>\rNot so long ago<br>\rBoardrooms<br>\rCriss-crossed the earth in jet-fumes<br>\rSearching for answers<br>\rIn intellectual rhetoric<br>\rConsequently<br>\rAbstraction bred distraction<br>\rWhile ground zero<br>\rThat imperfect dust-cloud of unsung heroes<br>\rFaded into the limits of our ignorance</p>\r<p>\rI heard through the magic of Kalahari sand-dunes<br>\rHow contradictions added flavor<br>\rTo local superstitions<br>\rConspiracy theory suspicions<br>\rMixing with frivolous and expensive mind games<br>\rPeople dying while we asked<br>\rThe questions with no meaning<br>\rAnd offered them solutions with no sustainability</p>\r<p>\rI don\'t dare go back there<br>\rPast lessons should have be learnt well<br>\rAnd who in his right mind would chose hell<br>\rOver a heaven of their own making</p>\r<p>\rI don\'t mean to scare you<br>\rAt least not intentionally<br>\rHowever,<br>\rI implore thee<br>\rKnow your enemy<br>\rHe walks contemptuously<br>\rWith no fear<br>\rOver-riding the protocols<br>\rContinuously learning how to resist everything thrown at him</p>\r<p>\rWe need the new tools to fight the new challenges<br>\rWe must adapt or die<br>\rThe gauntlet truth has never been more apparent<br>\rWe must change<br>\rAfter all<br>\rOur enemy changes shells every so often<br>\rMutates into a multiplicity of variants</p>\r<p>\rThat\'s why we are thankful to be here<br>\rFor this is SATuRN<br>\rThe ringed planet<br>\rEach ring playing its part to create a beautiful world<br>\rThis is SATuRN<br>\rWhere the centre must hold the greatest importance<br>\rSo that the circles of concern can accommodate its needs<br>\rSo I implore you<br>\rAs we sit here<br>\rDeliberate here<br>\rAnd learn here<br>\rLet us remember the people<br>\rThey lie in the centre and are the centre<br>\rThey are the ground zero survivors waiting to participate in their own survival<br>\rNeeding the tools to see what we see<br>\rSo that they,  not us, <br>\rCan take the appropriate actions</p>\r<p>\rAnd finally,<br>\rThis is SATuRN<br>\rWhose effects will reverberate across these savanna plains<br>\rTo manifest into a bright future we can all live with<br>\rThis is SATuRN <br>\rWhere we have come to strengthen our resistance<br>\rAgainst the growing threat of drug resistance<br>\rThis is SATuRN<br>\rWhere hope and great minds have gathered<br>\rTo strengthen and expand our circles of concern</p><br>\n\n<p><b><i>Joshua Machao 2011</b></i><br>\nPoet. Writer. Performer<br>\nExodus Live Poetry! Collective</p>\n \n<p>Copyright<br>\nThe above body of work remains the intellectual and creative property of the artist and should remain intact. No further transmission or use of the work, in any form, electronic or otherwise permitted without the express written consent of the artist. Contact Joshua Machao at jtmachao@gmail.com</p>\n\n<p><a href=\"http://www.bioafrica.net\">SATuRN</a> is grateful for this beautiful poem that was recited in the openning of our 6th annual workshop in Botswana</p>', 'poetry, saturn, southern, african, treatment, resistance, network, art, poet, joshua, machao, botswana, art, science, section, bioafrica', '2012-04-14', 'In this exciting new section of bioafrica.net art we feature creative projects that celebrate, investigate and/or communicate biomedical science. Here, we share blogs, news articles, tweets, audio and audiovisual media to increase public awareness of innovative collaborations between art and science.'),
(2, '<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=1\">Jiving with Science CD 1: Indaba kaMamBiyela</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=3\">Jiving with Science CD 3: Uhlelo lukaMroza</a></p>', NULL, 'Music: Jiving with Science CD 2 - Indaba kaTira - HIV testing, ARVs, positive living and HIV prevention', 'Astrid Treffry-Goatley, Mduduzi Mahlinza, John Imrie', 'BioAfrica Art & science are feature Music: Jiving with Science CD 2 - Indaba kaTira - HIV testing, ARVs, positive living and HIV prevention', 'CD_2_FRONT_SMALL.jpg', '<b> Introduction:</b> CD 2 is targeted at the youth in the community and includes a selection of popular hip-hop, house and RnB tracks. It is endorsed by the local star DJ Tira and features his songs and voice as the main character in the story. The narrative follows Tira on a journey by taxi as he travels to meet different people and chats to them about Africa Centre research, HIV testing, ARVs, positive living and HIV prevention.            <br>\n             <br>\n     <table class=\"main\">\n              <tbody>\n                <tr>\n                  <td>&nbsp;<br>\n                  <b>Scripts: </b> click to download a <a href=\"manuscripts/cd2_english_script.pdf\"><u>English</u></a> or <a href=\"manuscripts/cd2_zulu_script.pdff\"><u>Zulu</u></a> script used in the CD.\n                  <br>\n                  </span><br>\n                  </td>\n                </tr>\n              </tbody>\n            </table>\n    <b>Music:</b> click <a href=\"newmedia/CD2forweb.mp3\"><u>here</u></a> to download sample of the CD.<small> Please note that songs are restricted to 30 seconds clips for copyright reasons.</span></small><br><br>\n              <b>Music:</b> click below to stream a sample of the CD. <small> Please note that songs are restricted to 30 seconds clips for copyright reasons.</small><small> You will need QuickTime player.</small><br>\n            <embed src=\"newmedia/CD2forweb.mp3\" autostart=\"false\" loop=\"FALSE\" &gt;play=\"\" the=\"\" complete=\"\" cd=\"\" with=\"\" messages=\"\" height=\"40\" width=\"200\"><b><br>\n            </b></span>', '<p><b>Sponsors:</b> we would like to thank the following individuals and companies for their generous contribution to the creation of this CD: Wellcome Trust, Sheer Sound, Maltre Productions and Afrotainment.</p>\n<p><b>Starring DJ Tira and staff from Africa Centre\'s Community Engagement Office:</b> Mduduzi Mahlinza, Xolile Kineri, Ntombikayise Mnyango, Siboniso Buthelezi, Bongi Gumede, Ncengani Mthethwa and Busangani Ngwenya.</p>', 'BioAfrica, Art,  science,  Music:, Jivin,  Science, CD 2, Indaba, kaTira, DJ Tira, HIV testing, ARVs, positive living, HIV prevention', '2012-03-29', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. Africa Centre is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health.</p>\n<p>This project involves developing, distributing and evaluating 4 CDs over 2 years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action. The aim is to foster community discussion about scientific research and to bring evidence based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.</p>'),
(3, '<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=1\">Jiving with Science CD 1: Indaba kaMamBiyela</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=2\">Jiving with Science CD 2: Indaba kaTira</a></p>', NULL, 'Music: Jiving with Science CD 3: Uhlelo lukaMroza - benefits of regular and repeated HIV testing, the management of HIV as a chronic disease', 'Astrid Treffry-Goatley, Mduduzi Mahlinza, John Imrie', 'BioAfrica Art & Science area features Music: Jiving with Science CD 3: Uhlelo lukaMroza - benefits of regular and repeated HIV testing, the management of HIV as a chronic disease', 'CD3_frontcover_final.jpg', '<br><b> Introduction:</b> CD 3, or <i>Uhlelo lukaMroza</i> (Mroza Show) focuses on regular and repeated HIV testing. Since this theme concerns a wide cross section of the population, the CD is targeted at more of a mixed audience. It features a selection of maskanda, kwaito and gospel songs and is endorsed by the Ukhozi FM radio DJ, Mroza Buthelezi. The narrative is framed within a radio talk show hosted by Mroza. A local nurse is a special guest on the show and answers questions about the benefits of regular and repeated HIV testing, the management of HIV as a chronic disease and the availability of HIV testing facilities and ART in the community. <br>\n\n     <table class=\"main\">\n              <tbody>\n                <tr>\n                  <td>&nbsp;<br>\n                  <b>Scripts: </b> click to download a <a href=\"manuscripts/cd3_english_script.pdf\"><u>English</u></a> or <a href=\"manuscripts/cd3_zulu_script.pdff\"><u>Zulu</u></a> script used in the CD.\n                  <br>\n                  </span><br>\n                  </td>\n                </tr>\n              </tbody>\n            </table>\n   <b>Music:</b> click <a href=\"newmedia/CD3forweb.mp3\"><u>here</u></a> to download sample of the CD.<small> Please note that songs are restricted to 30 seconds clips for copyright reasons.</span></small><br><br>\n              <b>Music:</b> click below to stream a sample of the CD. <small> Please note that songs are restricted to 30 seconds clips for copyright reasons.</small><small> You will need QuickTime player.</small><br>\n            <embed src=\"newmedia/CD3forweb.mp3\" autostart=\"false\" loop=\"FALSE\" &gt;play=\"\" the=\"\" complete=\"\" cd=\"\" with=\"\" messages=\"\" height=\"40\" width=\"200\"><b><br>\n            </b></span>', '<p><b>Sponsors:</b> we would like to thank the following individuals and companies for their generous contribution to the creation of this CD: The Wellcome Trust, Mtubatuba Taxi Association, EMI, Sony Music, Emabalabala Entertainment, Megastar Productions, Mroza Buthelezi, Afrotainment, Bula Music, Sande Entertainment, Sizwe Zako Productions, Na Swagga Formulated Music and Maltre Productions. </p>\n\n<p><b>Starring Mroza Buthelezi and staff from Africa Centre including:</b> Nelisiwe Mbatha, Lungani Masinga, Velaphi Gumede, Siboniso Buthelezi, Nomonde Mthiya and Bongiwe Njoko. </p>', 'BioAfrica, Art, Science, area, Music,  Jiving with Science, CD 3, Uhlelo lukaMroza, DJ Mroza, south africa, benefit,  regular, repeated, HIV testing, management of HIV,  chronic disease', '2012-03-29', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. Africa Centre is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health.</p>\n<p>This project involves developing, distributing and evaluating 4 CDs over 2 years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action. The aim is to foster community discussion about scientific research and to bring evidence based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.</p>'),
(4, '<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=1\">Jiving with Science CD 1: Indaba kaMamBiyela</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=2\">Jiving with Science CD 2: Indaba kaTira</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=3\">Jiving with Science CD 3: Uhlelo lukaMroza</a></p>', NULL, 'Music: Introduction: Jiving with Science', 'Astrid Treffry-Goatley, Mduduzi Mahlinza, John Imrie', 'BioAfrica Art & Science features Music: Introduction: Jiving with Science, a wellcome trust funded community engagement project', 'jivingwithsciencedancing.png', '<p>Jiving with Science is a public engagement initiative of the Africa Centre for Health and Population Studies, an international research facility based in a rural region of high HIV prevalence in KwaZulu-Natal, South Africa. The Wellcome Trust, through its International Public Engagement grant Scheme is the principal funder of Jiving with Science.</p> ', '<p>This project aims to foster community discussion about scientific research and to bring evidence-based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts. It involves developing, distributing and evaluating 4 CDs over two years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action. </p>\r<p>The primary target audience is the users of local mini-bus taxis. Taxis are the main mode of local transport with an estimated 50 to 60 000 people using a taxi on a weekly basis. 600 copies of each CD have been distributed free of charge to local taxi drivers, tavern owners and hair salon operators. Currently, Africa Centre Centre is compiling the fourth CD that will focus on the prevention of HIV transmission from mother to child. </p>\r<p>This project has facilitated the engagement of new sectors in the community who are now actively participating in its research and efforts to prevent HIV transmission.  Music industry partners have also supported the project by waiving production rights on selected popular music tracks to meet social responsibility agendas. In exchange, they have been given an opportunity to have their music heard in this often-inaccessible rural setting.</p>\r', 'BioAfrica, Art , Science, , Music, Introduction, Jiving with Science,  wellcome trust, funded, community, engagement, project, kwaZulu-Natal, South Africa', '2012-04-01', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. Africa Centre is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health.</p>\n<p>This project involves developing, distributing and evaluating 4 CDs over 2 years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action. The aim is to foster community discussion about scientific research and to bring evidence based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.</p>'),
(6, '<p><a href=\"http://www.bioafrica.net/blogs.php?id=6\">http://www.bioafrica.net/blogs.php?id=6</a></p>', NULL, 'Video: Social Worker perspective: Adolescents on Antiretroviral (ARV) therapy ', 'Pretty Nkosi, Nokuthula Skhosana, Lungani Ndwandwe and Tulio de Oliveira', 'BioAfrica Art & Science features Video: Social Worker perspective: Adolescents on Antiretroviral (ARV) therapy ', 'imgsocial.png', '<center><p><b><a href=\"http://www.bioafrica.net/blogs.php?id=6\">Click here to access the Video and blog on this art & science project</a></b></p></center>', '<p><b><i>\'More information was needed about HIV drug resistance, and to let the participants know that ART is a life-long commitment\'</b></i>, these words were expressed by Pretty Nkosi and Nokuthula Skhosana, the ART social workers from Africa Centre and the main organizers of the workshop. They continued to say; <b><i>\'...having a sort of group setting with group discussions by teenagers sharing and facing more or less similar challenges, gives them (adolescents) an assurance that they are not alone in their circumstance and that they have support\'</b></i>. The 4 day programme of the workshop was designed to cater to the audience through infotainment sessions.</p>\r<p>The sessions ranged from self-reflecting exercises, where teenagers were required to do introspective exercises by looking in the mirror and expressing their feelings through group discussions; to an informative but fun session about ARVs, amasotsha (CD4) and HIV drug resistance by Dr Tulio de Oliviera (Africa Centre/SATuRN). Also included in the programme was an HIV activist, who had lived with HIV for more than 10 years, telling his story about his life with HIV. This reaffirming story confirming the fact that HIV is not a death sentence anymore and that one can live a long and a healthy life.</p>', 'BioAfrica, Art, Science,Video, Social, Worker, perspective, Adolescents, Antiretroviral, ARV, therapy, south africa\n', '2012-01-14', '<p><b><i>What factors contribute to young people / adolescents on Highly Active Anti-Retroviral Treatment (HAART) failing treatment?</b></i> Quite a number of factors really, such as, lack of knowledge about the advantages of taking treatment, or the lack of knowledge about the length of time one is required to be on treatment</p>'),
(7, '<p><a href=\"http://www.bioafrica.net/blogs.php?id=4\">Scientific Community Engagement Activities in rural KwaZulu-Natal, South Africa</a></p>\n<p><a href=\"http://pediatrician-in-swaziland.blogspot.com/\">Pediatrician in Swaziland - A pediatrician named Ryan Phelps from Denison, TX tells tales about his work in Swaziland with the Baylor International Pediatric AIDS Initiative, among other things.</a></p>', NULL, 'Cartoon: HIV as a lion, CD4 as soldiers and ARVs make the soldiers stronger! (translated to Zulu)', 'Tulio de Oliveira', 'BioAfrica Art & Science features Cartoon: HIV as a lion, CD4 as soldiers and ARVs make the soldiers stronger! (translated to Zulu)', 'ARVsoldierLion.png', '<p>This series of presentations used cartoons that portray HIV as a lion (Ibhubesi translation in Zulu), CD4 cells as soldiers (Amasosha, Zulu translation) and that show how ARVs make the soldiers stronger as they provide them with armour. </p>\n\n<p>BioAfrica and SATuRN use art to present scientific facts. We are involved in many community engagement activities. Over the last years we have presented on eight occasions to the community around Africa Centre. The presentations are focused on the origin of HIV, the causes and consequences of drug resistance development and how to successfully manage HIV and TB treatment.</p>\n', '<p>The Head of external relations at Africa Centre, Mr. Mbongiseni W. Buthelezi, also attended this series of presentations. He was excited by the presentation and commented <b><i>\'Thank you so much for your superb presentation to a group of Somkhele Primary school learners. You really rose to the occasion given their level of cognitive development. I have no doubt that such a graphic presentation drove the message home. One could see the faces of the kids beaming with excitement!\'</b></i></p>\n<center><p><b><a href=\"manuscripts/ARVSoldierLionArtScience.pptx\">Click here to download the cartoons in powerpoint format</b></a></p></center>', 'BioAfrica, Art, Science, Cartoon, HIV, lion, CD4, soldiers, ARVs, zulu, ibhubesi, amasosha, africa, community, engagement', '2012-05-01', 'In this exciting new section of bioafrica.net art we feature creative projects that celebrate, investigate and/or communicate biomedical science. Here, we share blogs, news articles, tweets, audio and audiovisual media to increase public awareness of innovative collaborations between art and science.'),
(8, '<p><a href=\"http://www.bioafrica.net/blogs.php?id=4\">Scientific Community Engagement Activities in rural KwaZulu-Natal, South Africa</a></p>\n', NULL, 'Cartoon: ARVs stop the production of virus and restore the immune system', 'Tulio de Oliveira and Richard Lessells', 'BioAfrica Art & Science features Cartoon: ARVs stop the production of virus and restore the immune system', 'ARVHouseJar.png', '<p>This series of presentations used cartoons that portray antiretroviral (ARVs) as a jar that keep HIV from killing CD4 cells. The presentation shows that ARVs do not get rid of HIV from the body ? they stop the production of virus. If the HIV is not controlled then the virus will multiply and our immune system will get weaker. It shows that the body has an immune system that helps to prevent infection in the same way a house protects us from rain and cold and that people should not wait until they feel sick to get HIV testing & CD4 count. </p>', '<p>BioAfrica and SATuRN use art to present scientific facts. We are involved in many community engagement activities. Over the last years we have presented on eight occasions to the community around Africa Centre. The presentations are focused on the origin of HIV, the causes and consequences of drug resistance development and how to successfully manage HIV and TB treatment.</p>\r\r<center><p><b><a href=\"manuscripts/ARVHouseJar.pptx\">Click here to download the cartoons in powerpoint format</b></a></p></center>', 'BioAfrica, Art, Science,  Cartoon, ARVs, stop, production, virus, restore, immune system, presentation, community, engagement, south africa, kwaZulu-Natal', '2012-01-18', 'In this exciting new section of bioafrica.net art we feature creative projects that celebrate, investigate and/or communicate biomedical science. Here, we share blogs, news articles, tweets, audio and audiovisual media to increase public awareness of innovative collaborations between art and science.'),
(9, '<p><a href=\"http://www.wellcomecollection.org/global\">http://www.wellcomecollection.org/global</a> and <a href=\"http://http://www.bioafrica.net/artscience.php\">BioAfrica Art & Science</a></p>', NULL, 'Photo: Photographic Workshop with Zwelethu Mthethwa ', 'Astrid Treffry-Goatley', 'Photographic Workshop with Zwelethu Mthethwa at Umkhanyakude sub-district in KwaZulu-Natal.\r\n', 'PhotWorkshop.png', '<p>This photographic workshop will provide training in the use of digital photography in art and will consist of critiques focusing on composition, aesthetics and social political reading of an image. The visual topic is Good Health and it will be presented by one of South Africa\'s finest photographers, Zwelethu Mthethwa.</p>\r\n', '<center><p><b>Who can participate?</b></p>\n<p>The workshop is targeted at artistically-talented local youth from Umkhanyakude sub-district in KwaZulu-Natal.</p>\n<p><b>Deadline for application:</b> 15th June 2012</p>\n<p>(Applications forms available at Africa Centre reception)</p>\n<p><b>Venue:</b> Africa Centre, Somkhele</p>\n<p><b>Dates of the workshop:</b> 28 June & 29 June 2012</p>\n<p><b>Registration is free of charge</b></p>\n<p>The workshop is limited to 10 participants. </p>\n<p>Workshop includes lectures, lunch and coffee-break. </p>\n\n<p><b>For more information contact:</b> Dr. Astrid Treffry-Goatley</p>\n<p>email: atreffrygoatley@africacentre.ac.za </p>\n<p>Tel: 035  550 7626, Fax: 035 550 7565</p>\n<p><b><a href=\"manuscripts/Photography_Workshop.pdf\">Download poster of the workshop</a></b></p></center>', 'Photographic, Workshop, Zwelethu Mthethwa, good heatlh, africa centre, wellcome trust, art, science, bioafrica, Umkhanyakude, KwaZulu-Natal', '2012-06-02', 'In this exciting new section of bioafrica.net art we feature creative projects that celebrate, investigate and/or communicate biomedical science. Here, we share blogs, news articles, tweets, audio and audiovisual media to increase public awareness of innovative collaborations between art and science.');

-- --------------------------------------------------------

--
-- Table structure for table `b_news`
--

CREATE TABLE `b_news` (
  `id` int(11) NOT NULL,
  `image` char(50) DEFAULT NULL,
  `webpage` char(250) DEFAULT NULL,
  `title` char(150) DEFAULT NULL,
  `journal` char(100) DEFAULT NULL,
  `pubid` int(11) DEFAULT NULL,
  `date` date DEFAULT NULL,
  `summary` longtext,
  `file` char(50) DEFAULT NULL,
  `bioafricaSATuRN` int(11) DEFAULT NULL,
  `summary2` longtext,
  `keywords` longtext,
  `topdescription` longtext,
  `feature` char(1) DEFAULT ''
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_news`
--

INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(1, 'imgworkshop2011c.png', '', 'Meeting to Discuss the Growing Threat of HIV & TB Drug Resistance in South Africa and Botswana', 'CDC - South Africa', 0, '2011-11-04', 'JOHANNESBURG - A group of renowned HIV and TB scientists, public health officials and physicians will meet at the University of Botswana in Gaborone, this coming Monday and Tuesday (7th & 8th of November) to discuss the growing problem of HIV and TB drug resistance in southern Africa.', NULL, 3, '</p>\r<p>At this meeting new information will also be presented regarding HIV & TB drug resistance diagnostic tests which will soon become available for impoverished population in southern Africa.  The Workshop will host local HIV and TB physicians from across Botswana, South Africa and neighbouring countries, who will be trained on the optimum management of HIV and TB treatment failures, given the treatment resources available. Overall, 225 local and international participants are expected to attend.</p>\r<p>While resistance to antiretroviral (ARV) medication has not become a threat to regional treatment programmes yet, as sure a night follows day, the continued expansion of antiretroviral therapy will be followed by an increase in HIV antiretroviral drug resistance over time.  Nearly every major infectious disease has developed resistance to drugs commonly used for treatment.  Drug resistance in tuberculosis is a well-described and longstanding problem. With the recent increases in multiple TB drug resistance and the outbreak of extremely-drug resistant tuberculosis, clinicians and public health officials need to be on heightened alert for the possibility of drug resistance, seek training in the management of drug-resistant cases and increase efforts to monitor and control its transmission.</p>\r<p>At present, Botswana has placed 171,065 adults and children on ARVs, which accounts to nearly 10% of its population.  South Africa has now over 1.2 million patients on ARVs.  While much care, financial resources and great effort has been generated to ensure the expansion of these programmes, the same level of attention has not given to the management of patients failing ARV and TB treatment with resistance strains. One reason for this is that drug resistance testing is expensive, time consuming and dependent on high-level technology (such as genetics, biotechnology and bioinformatics). However, this situation is now changing.</p>\r<p>The good news is that recent advances in technologies and effective collaboration between the Botswana Ministry of Health and partnerships with South African academic organizations, government and biotechnology companies allow resistance genotype tests to be reduced in price from approximately ZAR 3,300 per test to less than ZAR 1,000 per test. However, even at the higher of these prices it is known resistance testing is cost-neutral to ARV programmes as its saves unnecessary switches to more complex and costly ARV treatment regimens by providing valuable information to the physician/nurse to better manage patients failing on ARVs. Discounted resistance test capacity will soon be available at national scale in Botswana and South Africa.  </p>\r<p>Experts from academia, industry and government institutions in the region have collaborated in the development of the discounted HIV resistance test under the leadership of SATuRN. <b><i>\'SATuRN is an exciting academic and government collaboration that provides access to resistance interpretation to clinicians at primary health care facilities and allows comprehensive surveillance of the levels of resistance in the region</b></i>\', said Dr. Tulio de Oliveira, one of the organizers of the meeting, who is from the Africa Centre for Health and Population Studies, University of KwaZulu-Natal (UKZN), a rural HIV & TB treatment and research centre in South Africa.</p>\r<p>Although drug resistance is a growing concern, effective partnerships between researchers, clinicians, and public health officials can ensure that resistance levels are accurately traced and managed. Dr. Tendani Gaolathe, speaking on behalf of the Botswana Ministry of Health explained, <b><i>\'Information and training on HIV and TB resistance is urgently needed to guide treatment options and to ensure that southern Africa\'s HIV & TB treatment programmes are highly effective and financially sustainable</b></i>\'.  Dr. Madisa Mine, director of the HIV Reference Laboratory, added, <b><i>\'Developing the capacity of laboratory scientists to meet the future challenges that long-term ARV use pose will go far to safe-guard the gains made in Botswana\'s fight against HIV and TB.</b></i>\' </p>\r<p>In addition, the workshop will also launch an open access book on HIV / TB drug resistance and clinical management that will be available free of charge. The 6th Southern Africa HIV/TB Drug Resistance and Treatment Monitoring Workshop is sponsored by the Botswana Ministry of Health in collaboration with the Africa Centre for Health and Population Studies, The South African Medical Research Council (MRC),The Southern African Treatment and Resistance Network (SATuRN) in collaboration with Life Technologies, the European Commission (EC), the Canadian International Development Agency (IDRC), the Wellcome Trust and the US PEPFAR/CDC. For more information, http://www.bioafrica.net/saturn/</p>\r<p></p>\r<br>\n<p>Interested in training and capacity building? Please visit our annual SATuRN workshop webpage:</p>\n<p><a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\"><b>7th South African HIV & TB Drug Resistance and Treatment Monitoring Workshop</b>, Cape Town International Conference Centre, 28 to 29 November 2012, Cape Town, <b>South Africa.</b></a></p>', 'Meeting, Growing, Threat,  HIV , TB, Drug, Resistance, South Africa, Botswana, SATuRN', 'Meeting to Discuss the Growing Threat of HIV & TB Drug Resistance in South Africa and Botswana', NULL),
(3, 'imgworkshop2011b.png', 'http://www.mmegi.bw/index.php?sid=1&aid=1312&dir=2011/November/Tuesday8', 'Botswana hosts Africa HIV/TB drug resistance workshop', 'Mmegionline', 0, '2011-11-04', 'GABARONE - For the first time, Botswana is hosting the Africa HIV/TB Drug Resistance and Clinical Management workshop. The two-day workshop started yesterday at the University of Botswana (UB). Scientists, public health officials and physicians from across the world are attending the event to discuss the growing problem of HIV and TB drug resistance in Southern Africa.', NULL, 3, '<p>The European Union, CDC, University of Columbia, Stanford, Harvard, Rio de Janeiro, the University College of London, the London School of Hygiene and Tropical Medicine, Nelson Mandela School of Medicine and Stellenbosh are some of the institutions that have sent representations to the workshop.</p>\r<p>When addressing delegates yesterday, director of the Department of HIV/AIDS Prevention and Care, Dr Refeletsoe Lobelonyane said that the workshop has come at a critical time, where ensuring the long term sustainability of Botswana\'s ARV treatment programmes is keeping the country awake as donor funds are drying up.</p>\r<p>\'<b><i>With almost 180,000 patients on ART in Botswana and an estimated 150,000 in need of treatment in the coming years, sustainability depends not only on the prevention of new HIV infections but also on the prevention of the development and transmission of HIV and TB drug resistant strains which is an inevitable consequence of ARV treatment. We do have a challenge here,\'</b></i> she noted.</p>\r<p>She said that to meet this challenge, scientists from around the world must collaborate to build the necessary capacity in every country to stay ahead of the growing threat of HIV and TB drug resistance. Lobelonyane said that the fact that Botswana has integrated HIV prevention and treatment into public health centres for over a decade, drug resistance has become a reality in Botswana. \'<b><i>So having managed patients with ARV for a decade now, ARV drug resistance is not another theory to us but a reality and we hope by the end of this workshop, participants would be better equipped to detect and manage (the problem),\'</b></i> she said.</p>\r<p>Meanwhile, spokesperson for the United States Embassy, Laona Segaetsho has said that while resistance to ARV medication has not become a threat to regional treatment programmes yet, the continued expansion of ARV therapy will be followed by an increase in ARV drug resistance over time. He said that nearly every major infectious disease has developed resistance to drugs commonly used for treatment. He added that drug resistance in TB is a well-known longstanding problem.</p>\r<p>\'<b><i>With the recent increases in multiple TB drug resistance and the outbreak of extremely-drug resistant tuberculosis, clinicians and public health officials need to be on heightened alert for the possibility of drug resistance, seek training in the management of drug-resistant cases and increase efforts to monitor and control its transmission,\'</b></i> he said.</p>\r<p>Segaetsho added that presently, Botswana has placed 171,065 adults and children on ARVs. This accounts for nearly 10 percent of the population. South Africa has now over 1.2 million patients on ARVs. Sagaetsho said that while much care, financial resources and great effort has been generated to ensure the expansion of the anti-HIV programmes, the same level of attention has not been given to the management of patients failing ARV and TB treatment with resistance strains. \'<b><i>One reason for this is that drug resistance testing is expensive, time consuming and dependent on high-level technology,\'</b></i> he said. He asserted that the situation is however, changing.</p>\r', 'Botswana, , Africa, HIV, TB, treatment, drug, resistance, workshop', 'Botswana hosts Africa HIV and TB drug resistance workshop', NULL),
(4, 'imgnews24.png', 'http://m.news24.com/citypress/SouthAfrica/News/Alarm-bells-on-HIV-drug-resistance-20111105', 'Alarm bells on HIV-drug resistance - Study raises fears as patients develop immunity to antiretroviral therapy', 'News24 City Press', 0, '2011-11-06', 'JOHANNESBURG - The prevalance of HIV-positive people who have developed a resistance to life-prolonging antiretroviral treatment (ART) is a cause for concern for South Africa, scientists warn.', NULL, 3, '\rWhile scientists have known about HIV-drug resistance since 2002, a new study raises fears that the new form of the virus could spread rapidly if not controlled.</p>\r<p>\rA study researching resistance to treatment and published in the latest Lancet Infectious Diseases Journal followed 2 590 participants in six African countries South Africa, Kenya, Uganda, Ghana, Zambia and Zimbabwe.</p>\r<p>\rFindings showed that of the 2 436 participants who remained part of the study until the end, 139 were resistant to antiretrovirals (ARVs) such as nevirapine, tenofovir, zidovudine, efavirenz and lamivudine.</p>\r<p>\rA total of 176 South Africans participated in the research, which showed that two of them had developed resistance to ART. Both had never taken \rARVs before.</p>\r<p>\rWhile drug resistance has been reported recently in people who had begun ART, the new study has sparked fears among scientists that the country could be heading for another severe drug-resistance outbreak similar to the one experienced in 2005.</p>\r<p>\rSix years ago, 52 people died within three weeks after KwaZulu-Natal was hit by an extensive drug-resistant tuberculosis (XDR-TB) outbreak. </p>\r<p>\rLike the HIV drug resistance currently detected, XDR-TB started with one case in 2001 and exploded in 2005, leaving more than 230 people dead a year later.</p>\r<p>\rDr Dave Spencer, head of the adult antiretroviral programme at the non-profit organisation Right to Care, admitted this week that if primary HIV drug resistance (resistance in people who have never used ARVs) was not controlled, it could become problematic.</p>\r<p>\r\'<b><i>The number of people with primary HIV drug resistance at our clinic at Helen Joseph Hospital is still relatively low, but we are concerned that the numbers will increase in time. Data from Gauteng suggests that the rate of primary resistance is around 5%,\'</b></i> he said. </p>\r<p>\rRight to Care provides clinical care and treatment to people living with HIV. It is estimated that 800 000 people between the ages of 15 and 49 are HIV positive in Gauteng. Of those, 40 000 are likely to have developed drug resistance.</p>\r<p>\rHealth Minister Aaron Motsoaledi said government had set up a surveillance centre to monitor HIV drug resistance.</p>\r<p>\r\'<b><i>We can\'t take our eyes off the ball because if we do, we may find ourselves in a similar situation as with the drug-resistant TB. We need to keep track of what is happening and ensure that people do not default on treatment,\'</b></i> he said.</p>\r<p>\rWhile there are no official statistics for the population of people infected with HIV in South Africa, experts believe that the resistance rate in people who have never used ARVs is very low.</p>\r<p>\rThe scientists\' estimations do not stray far from the findings of the study, which found that the overall prevalence of primary resistance in the participating countries was 5.6%. It also revealed that South Africa had the lowest resistance rate (at 1.1%), while Uganda had the highest (at 12.3%).</p>\r<p>\rResearchers attributed the high rate in the East African country to the fact that ART was started earlier there than in the other five countries.</p>\r<p>\rIt also highlighted that countries scaling up their ART programmes, like South Africa, were at a greater risk of increased resistance as more people defaulted on treatment, developed resistance and then transmitted HIV-drug resistance to their partners.</p>\r<p>\rDr Francesca Conradie from the Clinical HIV Research Unit at the University of Witwaters-rand and co-author of the study, said primary HIV-drug resistance was not at the stage where it could be considered an \'<b><i>emergency\'</b></i> in South Africa. However, she warned that the longer the ARV programme continued, the more drug resistance would develop.</p>\r<p>\r\'<b><i>What we should focus on right now is ensuring that resistance is kept to a minimum by encouraging all those on ARVs to take their medication regularly, continue using condoms and strengthening surveillance systems for detecting transmitted resistance,\'</b></i> she said.</p>\r<p>\rThe latest data on HIV-drug resistance are expected to be released on Tuesday when scientists and medical experts meet for the <a href=\"http://www.bioafriac.net/saturn\">sixth South African HIV and TB Drug Resistance and Treatment Monitoring Workshop </a> in Botswana.<br><br>', 'Alarm , HIV-drug resistance, study, fears , patients, develop, immunity, antiretroviral, therapy', 'Alarm bells on HIV-drug resistance - Study raises fears as patients develop immunity to antiretroviral therapy', NULL),
(5, 'imgoxfordblueprint.png', NULL, 'New scientific evidence in Libya HIV death penalty case', 'University of Oxford - BluePrint News', 22, '2006-12-07', 'OXFORD - New molecular evidence from Oxford Zoology Department casts significant doubt on charges against six medical workers who are facing execution in Libya.\rThe medical workers are charged with deliberately contaminating more than 400 children with HIV in 1998.However, new evidence published online in Nature from the Evolutionary Biology Group at Oxford, in collaboration with several European universities, shows that the subtype of HIV involved began infecting patients well before the medical workers arrived in Libya.<br>', 'BluePrintOxfordNewsletter.pdf', 1, '\r Researchers used the genetic sequences of HIV and Hepatitis C viruses that were isolated from the patients to reconstruct the transmission history of the strains involved and work out when the outbreaks began. By analysing mutations that accumulate over time, they were able to work out the timescale of the outbreaks and when they started. </p>\r<p> A body of scientific evidence already indicates that the outbreak was caused by poor hospital hygiene and not by deliberate transmission. These results provide the first direct molecular evidence. </p>\r<p> For ten years the Evolutionary Biology Group has been developing and honing state-of-the-art methods for reconstructing the epidemic and evolutionary history of viruses from genetic data, and has researched both HIV and the Hepatitis C Virus.Authors Dr Tulio de Oliveira, Dr Oliver Pybus and Dr Andrew Rambaut are world experts on this type of analysis. Together they worked around the clock to analyse the genomes of the viruses isolated from blood samples collected by a network of European clinical research centres that are involved in treating the infected children. </p>\r<p> Dr Pybus said: \'<b><i>We\'ve demonstrated that the HIV and Hepatitis C Virus strains involved in the Al Fateh Hospital outbreaks were present and being transmitted locally for some time before the arrival of the Bulgarian medical staff.\'</b></i> </p>\r<p> The trial of the six workers, which has been taking place in Tripoli, ended on 4 November and a verdict is expected on 19 December. They are charged with knowingly infecting more than 400 children with HIV at the Al-Fateh Hospital in Benghazi in 1998. Last month 114 Nobel Laureates wrote an open letter to Colonel Gaddafi urging the appropriate authorities to hear independent science-based evidence, and reaffirming the need for a fair trial. The new research represents a thorough and peer-reviewed scientific investigation of the new genetic and molecular data available from the outbreaks. </p>\r<p> Lead author Dr Tulio de Oliveira said: \'<b><i>All the lines of scientific evidence point in the same direction: towards a longstanding infection control problem at the hospital, dating back to the mid 1990s or earlier.\'</b></i></p>\r<p> ', 'scientific, evidence, Libya, HIV, death, penalty, case', 'New scientific evidence in Libya HIV death penalty case', NULL),
(6, 'capenews.png', 'http://www.google.com/url?sa=t&rct=j&q=world-class%20scientist%20due%20to%20join%20uwc%20team%20tack', 'World-class scientist due to join UWC team tackling HIV/Aids treatment in SA.', 'Cape Times', 0, '2007-01-14', 'CAPE TOWN - A world-class molecular biologist whose research on HIV and anti-retrovirals (ARVs) could dramatically improve the treatment of HIV/Aids in South Africa. Doctor Tulio de Oliveira, an expert in bioinformatics at Oxford University, will join the SA National Bioinformatics Institute at UWC.', NULL, 1, '\r<b><i>\"It makes a lot of sense to be where the epidemic is,\" he said.</b></i><br>\r<br>\rDe Oliveira recently made news as part of an international team of scientists that analysed samples of the HIV virus found in 400 Libyan children, allegedly infected by six medical workers.', 'World-class, scientist, tulio, de oliveira, bioinformatics, team, HIV, Aids, treatment, SA, south africa, africa', 'World-class scientis, Dr. Tulio de Oliveira to join bioinformatics team tackling HIV/Aids treatment in South Africa', NULL),
(7, 'imggettested.png', 'http://152.111.1.87/argief/berigte/dieburger/2008/09/10/TP/14/hbsaids.html', 'Believe in ART, get tested please', 'Die Burger', 0, '2008-09-10', 'CAPE TOWN - Believe that anti-retroviral treatment (ART) medication works and get yourself tested. People who are infected with the virus are able to live longer, healthier lives, provided they use their medication and seek treatment early enough. This was the key message Dr. Tulio de Oliveira, a bio-informatics researcher from SATuRN wanted to be convey to the general public.<br>\r', NULL, 3, 'Oliveira said patients have added 50 years to their lives by just following this advice.</p>\r<p>He spoke during a workshop on HIV drug resistance last Friday, attended by 130 clinicians from SA and as far afield as Zambia.</p>\r<p>Delegates included nurses, virologists, medical students and doctors who are currently involved with patients on ART medication.</p>\r<p>\'<b><i>A lot has happened with regard to the spread of HIV/Aids since it was first discovered at a blood bank in the mid-1980s in South Africa.</p>\r<p>\'Today, South Africa is the country with the largest HIV infection rate in the world.\'</b></i></p>\r<p>De Oliveira added that new reports have been released which confirm that 5-million South Africans are currently infected with the virus. The national prevalence is estimated at 28% in pregnant women.</p>\r<p>He said that HIV infection rates started reaching epidemic status in the beginning of the 1990s, when it passed the 20% infection rate.</p>\r<p>De Oliveira told TygerBurger that despite the country\'s shocking statistics, current drugs available decrease the circulation of the virus by 99% in an infected person.</p>\r<p>He said most patients responded extremely well to treatment.</p>\r<p>Compared to other examples abroad, a tendency for patients to become ART resistant has taken effect, but in SA, where the C-strain virus is prevalent, there is growing evidence that the C-strain virus responds rapidly to medication.</p>\r<p>He said that the conference was an important opportunity to get the medical profession together to maintain the status quo.</p>\r<p>\'<b><i>It is important for the medical profession to know exactly how to curb resistance, as it is not possible without proper medical treatment.\'</b></i></p>\r<p>About current challenges he said, \'<b><i>Definitely, the apartheid history of having limited infrastructure in poorer and specifically rural areas, where clinics and hospitals still haven\'t been built, played a role.\rThis leads to problems in expanding treatment to all areas.\rAlso, training medical personnel and the subsequent cost, coupled with many medical professionals leaving the country, are the main challenges we face.</b></i></p>\r<p>More good news is that government has started making ART medication more freely available in the private and public sector. This move makes it clear that there is a concerted effort to urgently react to the crisis.\'</p>\r<p>De Oliveira said it is also encouraging to know that 28 different types of drugs are available today. South Africans should draw their strength from the example of Brazil, which has the same level of economic development and who had the same levels of HIV/Aids in 1992. In 1992, free treatment was introduced, and the infection rate is now less than 1%.</p>\r', 'Believe, antiretroviral, hiv, treatment, ART, get, tested, africa, south africa', 'Believe in ART, get tested please', NULL),
(8, 'imghivorigin.png', 'http://www.africacentre.ac.za/Default.aspx?tabid=319', 'Stirring students with science', 'Zululand Observer', 0, '2010-06-18', 'RICHARDS BAY - A team from Africa Centre for Health and Population Studies explained the origins of Human Immunodeficiency Virus (HIV) for scholars of the Aiglon Society at Grantleigh College last Tuesday.\nThe challenge to incorporate high-level bioinformatics and molecular evolutionary analysis into a high-school format of genetic variation and HIV life cycle was facilitated by senior researcher, Dr Tulio de Oliveira.', NULL, NULL, 'In a graphic presentation, he said that HIV originated from primates in West and West Central Africa and then infected humans, similar to tuberculosis (TB) from Bovine in cows, or buffalo as experienced locally; dispelling the myth that HIV was unique.\n\n<p>He highlighted that \'primates have lived normally for over 200 000 years carrying the Simian Immunodeficiency Virus (SIV - a virus similar to HIV) whilst their immune systems have learnt to function independantly. </p>\n\n<p>It is only humans that HIV causes the immune system to break down.  HIV-1 and HIV-2 are two types of the virus that were transmitted from five different primate sources, namely three events from chimpanzees in HIV-1 and two from a species of monkey (Sooty mangabeys) with HIV-2.  The most probable cause of transmission is thought to be via butchered meat as monkey in West Africa is considered a delicacy.\'  Today, we face 30 million people with HIV, transferred from person to person.</p>\n\n<p>Janet McGrath, Head of Department fro Sciences, said: <i><b>\'Grantleigh saw a need for their academically talented students to be exposed to a scientific and cultural enrichment programme in order to inspire them.\'</i></b>  Illuminating science to students is another leaf in the cap from Africa Centre\'s commitment to HIV research and interaction with the local community whilst maintaining professional status in population-, clinical- and social science studies.</p>', 'Stirring, KwaZulu-Natal, high school, matric, students,  HIV, science', 'Stirring students with science in KwaZulu-Nral. HIV origins talk by Dr. Tulio de Oliveira', NULL),
(9, 'imgimpilo.png', 'http://www.cegaa.org/Issue02IMPILODIALOGUEStakeholderNewsletter25June2011.pdf', 'Public database for HIV drug resistance in southern Africa', 'Impilo Dialogues - DoH newsletter', 1, '2011-06-25', 'PRETORIA - We would like to draw attention to an HIV-1 drug resistance database, a scientific resource for regional and global HIV research that will enhance surveillance programmes in southern Africa.The database was established by investigators from the Southern African Treatment and Resistance Network (SATuRN), in collaboration with researchers from the United States & Europe. SAT- uRN will provide national de- partments of health with high quality, up-to-date information to guide delivery of antiretroviral ther- apy, helping to ensure the long -term success of antiretroviral treatment programmes.', NULL, 3, NULL, 'Public, database, HIV, treatment, drug, resistance, southern, Africa, south Africa, department of Health, Impilo', 'Public database for HIV drug resistance in southern Africa. Media coverage on the SATuRN databases by the department of health from South Africa.', NULL),
(10, 'imgbbcmedics.png', 'http://news.bbc.co.uk/2/hi/health/6213054.stm', 'Study backs Libya HIV case medics', 'BBC', 22, '2006-12-06', 'LONDON - Scientists have cast doubt on charges that five Bulgarian nurses and a Palestinian doctor deliberately infected Libyan children with HIV. The medics could face the death penalty if found guilty by a court in Tripoli later this month.', NULL, 1, 'An international team analysed samples taken from the infected patients.<br>\rWriting in Nature, they said their work showed the HIV subtype involved began infecting patients in Libya well before the medical workers arrived in 1998.<br><br>\r<b><i>\"All the lines of scientific evidence point in the same direction\"<br>\rDr Tulio de Oliveira, \rOxford University</i></b><br><br>\rAn initial trial condemned the medics to death in 2004, but the Libyan Supreme Court overturned the verdicts, and ordered a retrial.<br><br>\rThe defendants are accused of knowingly infecting more than 400 children with HIV in the eastern town of Benghazi.<br><br>\rThe medics say that they were tortured into giving false confessions.<br><br>\rThe first trial lasted almost six years, and the medics have been in jail since 1999.<br><br>\rThey say the children were infected through poor hygiene - and a body of scientific work supports their claims.<br><br>\r<p><b>History of outbreak</p></b>\rThe researchers worked on blood samples collected by a network of European clinical research centres that are involved in treating the infected children.<br><br>\rBy analysing mutations in the genetic material of the HIV virus found in the samples they were able to reconstruct the history of the outbreak.<br>\rIn a statment, researchers Dr Tulio de Oliveira and Dr Oliver Pybus, from Oxford University, said: <b><i>\"All the lines of scientific evidence point in the same direction, towards a long standing infection control problem at the hospital, dating back to the mid 1990s or earlier.\"</b></i><br><br>\rDr Thomas Leitner, of Los Alamos National Laboratory, has provided forensic evidence in many HIV cases.<br><br>\rWriting in Nature, he said the latest research was \"compelling evidence that the outbreak had started before the accused could have started it.\"<br>\rThere has been mounting international pressure on Libya to hear independent scientific evidence.<br><br>\rInternational experts say the scientific report used in the trial was nothing but \'conjecture\' and \'supposition\'.<br><br>\rLast month 114 Nobel Laureates wrote an open letter to Colonel Gaddafi urging the appropriate authorities to hear independent science-based evidence, and reaffirming the need for a fair trial.<br>\n<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>', 'Study, backs, Libya, HIV, case, medics, bbc, oxford, bulgaria.', 'Study backs Libya HIV case medics, BBC coverage on the paper by de Oliveira and colleagues in Nature', NULL),
(11, 'imgscience.png', 'http://evolve.zoo.ox.ac.uk/Evolve/15_mins_files/ScienceNOW6Dec06.pdf', 'Genetic Analysis Clears Accused\rMedics', 'Science', 22, '2006-12-20', '<p>A new molecular study provides the strongest scientific evidence yet that six foreign medics held in Libya are innocent of charges that they deliberately infected more than 400 children with HIV. Accumulated mutations in the virus genomes reveal that the outbreak began well before the medics arrived in the country. The Libyan supreme court is set to decide on 19 December whether to execute the medics. It is unclear whether the new study will influence its verdict. </p>', 'ScienceNOW6Dec06.pdf', NULL, '<p>International criticism of the Libyan government has intensified since October, when the country\'s supreme court refused to consider scientific evidence in the case against the medics (ScienceNOW, 24 October). Prosecutors charge that the medics--five Bulgarian nurses and one Palestinian doctor--infected 426 children at a hospital in Benghazi as an act of bioterrorism. But European scientists who gained access to the hospital\'s records in 2004 discovered that 32 of the infected children had been treated at the hospital before the accused medics had even arrived. Also, the diversity of viruses, which include several strains of hepatitis in addition to HIV, suggested a classic hospital outbreak due to poor hygiene practices rather than a deliberate inoculation from a single source. </p>\r<p></p>\r<p>The new genetic analysis of the viruses tells a similar story. <b><i>A team led by Tulio de Oliveira & Oliver Pybus, an evolutionary biologist at the University of Oxford, U.K., obtained blood samples from 66 of the Libyan children who had been sent to European hospitals for care.</b></i> They extracted and sequenced RNA from 41 strains of HIV as well as 61 strains of hepatitis C virus infecting the children. Because the viruses accumulate mutations as they reproduce and spread, differences between their genomic sequences can be used like a molecular clock to estimate how long ago they last shared a common ancestor. The more mutations that have accumulated in each strain, the longer back in time that the hospital outbreaks must have occurred. </p>\r<p></p>\r<p>The molecular evidence is solidly in favor of the medics\' innocence, Pybus and his coauthors conclude. All of the analyses performed put the date of the outbreak well before the medics\' arrival in Libya in March 1998, the team reports online today in Nature. For some strains of the hepatitis C virus, the most likely date of the original hospital infection was before 1995, indicating that poor hygiene practices--such as reuse of needles and improper sterilization techniques--have been causing accidental infections there for more than a decade.<b><i> \"I am persuaded,\" says Jeff Thorne, a molecular biologist at North Carolina State University in Raleigh who specializes in viral evolution. \"This study shows that the accused medical staff are innocent beyond a reasonable doubt.\"</b></i></p>\r<p></p>\r<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>', 'genetic, analysis, genomics, HIV, case, medics, science, oxford, bulgaria', 'Genetic Analysis Clears Accused Medics. Science coverage of the paper by de Oliveira and collegues in Nature that cleared the accused medics', NULL),
(12, 'imgNewScientist.jpg', 'http://evolve.zoo.ox.ac.uk/Evolve/15_mins_files/NewSci.pdf', 'New evidence in Libyan HIV trial', 'New Scientist', 22, '2006-12-20', '<p>New and compelling scientific evidence has emerged in support of five Bulgarian nurses and a Palestinian doctor accused of deliberately spreading HIV to 426 Libyan children in 1998.</p>\r', 'NewScie.pdf', NULL, '<p>The evidence redoubles the international pressure on Libyan president Colonel Muammar al- Gaddafi to ensure that the six are acquitted when the Libyan court issues its verdict on 19 December.</p>\r<p>By examining viral extracts from some of the children, Oliver Pybus of the University of Oxford and his colleagues were able to work backwards to establish that specific mutations in 40 per cent of the HIV cases evolved before the nurses arrived at the Al-Fateh Hospital in Benghazi in March 1998. Likewise, 70 per cent of the children with hepatitis C, which can also be spread through dirty needles, contracted it before the arrival of the nurses (<a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</a> - Nature, DOI: 10.1038/nature44836a). The analysis concludes that both viruses spread through poor hospital hygiene.</p>\r<p>The big question now is whether the court accepts the evidence even though the trial ended on 4 November.<b><i> \"We\'d like it to be heard or taken into account somehow,\" </b></i>  says Pybus.</p>\n<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>', 'New, scientist,  evidence, Libyan, HIV, trial', 'New evidence in Libyan HIV trial. New scientist coverage on de Oliveira and colleagues Nature paper', NULL),
(13, 'imgGuardian.jpg', 'http://evolve.zoo.ox.ac.uk/Evolve/15_mins_files/Guardian17Dec06.pdf', 'Medics face death while Libya uses HIV children as diplomatic pawns', 'The Guardian', 22, '2006-12-17', '<p>Alex Duval Smith The Observer, Sunday 17 December 2006 13.12 GMT - The death in Libya six weeks ago of nine-year-old Marwa Annouiji from Aids was much more than just another developing world statistic. In her short, life, dominated by illness, the frail child was a pawn in a high-level game of international relations. Marwa, from al-Bayda on the Mediterranean coast, was the 52nd Libyan child to die as a result, Libya claims, of a deliberate operation by foreign medical workers to pump HIV-infected blood into 426 girls and boys at the al-Fatah Hospital in Benghazi. </p>\r', 'Guardian17Dec06.pdf', NULL, '<p>On Tuesday, barring some extraordinary intervention, the six medics - a Palestinian doctor and five Bulgarian nurses who have been in prison in Libya for seven years - will have their sentence confirmed by a court in the capital, Tripoli: execution by firing squad. The case has sparked unprecedented mobilisation in support of the medics among international scientists who have found the Libyan evidence groundless. European governments and the United States stand accused of abandoning the medical workers for powerful strategic and economic reasons. </p>\r<p></p>\r<p>\'We are still hoping wisdom will prevail,\' said the head of the nurses\' defence team, French lawyer Emmanuel Altit. \'The court has not granted the defence its rights, the Libyan evidence in the case is discredited, and the medics\' confessions were extracted under mental, physical and sexual torture.\' </p>\r<p></p>\r<p>The six - Dr Ashraf al-Hajuj and nurses Kristiyana Vatcheva, Nasya Nenova, Valentina Siropulo, Valya Chervenyashka and Snezhana Dimitrova - took up government contracts at the hospital in Libya\'s second city in March 1998. The first cases of HIV infection were reported the same year. A World Health Organisation report found that the virus had probably been spread because of a lack of proper medical equipment. The six were imprisoned in March 1999. Libyan courts ordered reports from the world\'s top Aids scientists and epidemiologists, including Luc Montagnier, one of the discoverers of HIV. Montagnier found the high rate of hepatitis B and C at the hospital suggested that poor hygiene was to blame for the spread of HIV. But the prosecution ignored his report and ordered one from Libyan researchers in 2003. </p>\r<p></p>\r<p>On 6 May, 2004, the death sentences were pronounced. On Christmas Day last year the Libyan Supreme Court ordered a retrial, which led to a new call for the death sentence this August. A verdict is expected on Tuesday.</p>\r<p></p>\r<p>European doctors who, under a 2m (1.3m) EU initiative, have treated the children in Libya say most are now aged around 12. They suffer from tuberculosis and other Aids-related illnesses. </p>\r<p></p>\r<p>According to a French foreign ministry spokesman: <b><i> \'They cannot so much as go to the dentist in Benghazi because the Aids stigma is so powerful in Libya. It also appears that, because most of them are outpatients, their parents are not all administering their tablets correctly.\' </b></i>As a result of care problems in Libya, the 374 surviving children are now outpatients at hospitals in Italy and France. </p>\r<p></p>\r<p>Libyan President Muammar Gadaffi, who is reportedly terrified of dissent in the opposition hotbed of Benghazi, is paying millions of euros for their treatment at the Vatican\'s Bambino Gesu Hospital as well at French clinics in Lyon, Montpellier, Strasbourg and Toulouse. Experts on Libya say Gadaffi is using the children as a pawn.</p>\r<p></p>\r<p>Experts on Libya say Gadaffi is using the children as a pawn in his discussions with Western powers over burning issues including contracts for oil, arms and aircraft and diplomatic relations in the Middle East. Gadaffi also remains bitter about the pariah status he acquired after the 1988 Lockerbie bombing. Earlier this year Libya said Bulgaria should pay the families of the children $2.7bn (1.8bn) in compensation - which is exactly the sum paid by Libya for the 270 lives lost in the Pan Am 103 bombing. International scientists say the 2003 Libyan report was written by \'pseudo experts\' and has no value. Last week a paper in Nature magazine by a team led by Tulio de Oliveira and Oliver Pybus -  paper from <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</a> showed that the Benghazi strain of HIV was introduced at the hospital before the arrival of the medics. </p>\r<p></p>\r<p>Pybus & de Oliveira, of Oxford University, said: <b><i>\'By looking at the genome sequence of the virus found in children at Bambino Gesu hospital, we established that the estimated date of the most common recent ancestor for each cluster predated March 1998, sometimes by several years. The virus is of a kind found in West Africa, which makes sense as Libya has a large population of guest workers from there.\' </b></i></p>\r<p></p>\r<p>The medics\' lawyers hope that, even if the death sentences are confirmed on Tuesday, the case will return to the Supreme Court where a judicial council could throw it out for a second time. But Altit said diplomatic efforts to secure the medics\' release after more than seven years in jail had been disappointing. <b><i>\'Libya is coming out of the cold and there are many lucrative contracts in the works. If the sentences are confirmed it will be a disgrace for the European Union. If there is one thing Europe stands for, it is values, such as justice.\'</b></i> A Foreign Office spokesman would not comment on the accusation that European governments were sacrificing the medics in the name of trade relations. But he said:<b><i> \'The case is not over yet and we understand it will go to the Supreme Court. The EU has made significant efforts to help the families and upgrade facilities at the hospital. We hope these efforts show that everyone sympathises with the families.\'</b></i><br>\n<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>', 'guardian, HIV, Libya, medics, paper, nature, de oliveira, innocence', 'Medics face death while Libya uses HIV children as diplomatic pawns. Guardian coverage of the paper published in Nature by de Oliveira et al that prove the medics innocence', NULL),
(14, 'imgbbc2.png', 'http://evolve.zoo.ox.ac.uk/Evolve/15_mins_files/BBC%20NEWS%2019%20Dec%202006.pdf', 'Libya sentences medics to death', 'BBC', 22, '2006-12-19', '<p>A Libyan court has sentenced five Bulgarian nurses and a Palestinian doctor to death for knowingly infecting hundreds of Libyan children with HIV. </p>\r', NULL, NULL, '<p>The medics have been in detention since 1999, during which time 52 of the 426 infected children have died of Aids. </p>\r<p></p>\r<p>The nurses and doctor were sentenced to death in 2004, but the Supreme Court quashed the ruling after protests over the fairness of the trial.</p>\r<p></p>\r<p>The defendants say they are being made scapegoats for unhygienic hospitals. </p>\r<p></p>\r<p>Defence lawyers said the medics would appeal against the new verdict, expected to be the final appeal allowed under Libyan law.</p>\r<p></p>\r<p>The defence team told the court that the HIV virus was present in the hospital, in the town of Benghazi, before the nurses began working there in 1998.</p>\r<p></p>\r<p>Western nations had backed the medics\' case, calling for their release. </p>\r<p></p>\r<p>Bulgarian officials quickly condemned the verdicts. </p>\r<p></p>\r<p>Foreign Minister Ivailo Kalfin described the ruling a<b><i>s \"deeply disappointing\".</b></i> EU Justice Commissioner Franco Frattini expressed his shock at the verdict and urged the Libyan authorities to review the decision. </p>\r<p></p>\r<p>But the BBC\'s Rana Jawad in Tripoli, says it is highly unlikely that Libya\'s leadership will become involved in the case, at least in public. </p>\r<p></p>\r<p>Celebrations </p>\r<p></p>\r<p>Parents of the infected children said they were happy with the verdicts. </p>\r<p></p>\r<p>Some cried out in court as the verdicts were delivered, while others were gathered outside carrying banners. </p>\r<p></p>\r<p><b><i>\"For the second time, justice has spoken out with a ruling against those criminals and the punishment they deserve, because they violated their obligations and sold their consciences to the devil,\" </b></i>Abdullah Maghrebi, the father of one infected child, told the BBC. </p>\r<p></p>\r<p>Tsvetanka Siropoula, the sister-in-law of one of the convicted nurses, told the Reuters news agency that the sentence of death was to be expected. </p>\r\r<p><b><i>\"I am sure they will be released, but it will take time. It is so sad that so many years have passed and they are still in jail.\"</b></i> </p>\r<p></p>\r<p>Evidence contested </p>\r<p></p>\r<p>The medics protested their innocence throughout the case, retracting confessions that they said were obtained under torture. </p>\r<p></p>\r<p>Medical experts including the French co-discoverer of the HIV virus had testified on behalf of the medics. </p>\r<p></p>\r<p>And the World Medical Association and the International Council of Nurses said Tuesday\'s verdict ignored scientific evidence. </p>\r<p></p>\r<p>Oxford University in the UK said the verdict ran counter to findings by scientists from its Zoology Department. </p>\r<p></p>\r<p>A research team had concluded that <b><i>\"the subtype of HIV involved began infecting patients long before March 1998, the date the prosecution claims the crime began\" </b></i>paper from <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</a>, a statement from the university said. </p>\r<p></p>\r<p></p>\r<p>Libya has asked for 10m euros (6.7m) compensation to be paid to each of the families of victims, suggesting the medics\' death sentences could be commuted in return. </p>\r<p></p>\r<p>But Bulgaria has rejected the proposal, saying any payment would be seen as an admission of guilt.</p>\n\n<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>', 'Libya, sentences, medics, death, despite, new, scientific, evidence, innocence, bbc', 'Libya sentences medics to death. BBC coverage of the HIV case in Lybia', NULL),
(15, 'imgnature.png', 'http://evolve.zoo.ox.ac.uk/Evolve/15_mins_files/nated1.pdf', 'Molecular HIV evidence backs accused medics', 'Nature', 22, '2006-12-06', '<p>International experts in DNA forensics say that a paper published online by Nature this week provides a firm alibi for the six medical workers facing the death penalty in Libya. The workers have been charged with deliberately infecting more than 400 children with HIV in 1998. </p>\r', NULL, NULL, '<p>In the study, an international team led by researchers from Oxford and Rome used the genetic sequences of the viruses isolated from the patients to reconstruct the exact phylogeny, or  family tree, of the outbreak. Analysing the mutations that accumulated over time allowed the researchers to work out when different outbreaks occurred. They showed that the strain of HIV with which the children had been infected was already present and spreading locally in the mid-1990s, long before the medics arrived in Libya in 1998. </p>\r<p></p>\r<p>The trial of the six medical workers ended in Tripoli on 4 November, and a verdict is expected on 19 December. Despite mounting international pressure to free them, defence lawyers are pessimistic about the outcome, and Nature has fast-tracked publication to make this new evidence available before the verdict (see Nature 444, doi:10.1038/nature444836a; 2006). </p>\r<p></p>\r<p></p>\r<p>There was already a body of scientific evidence indicating that the outbreak was caused not by deliberate transmission, but by poor hygiene at the Al-Fateh hospital in Benghazi, where the outbreak took place (see Nature 443, 888, 889; 2006). Analysis of hospital records suggested that the outbreak began before the medics arrived. And almost half of the HIV-infected children were also infected with hepatitis B or C, pointing to poor hospital practices as the cause. </p>\r<p></p>\r<p></p>\r<p><b><i>\'The new results provide independent genetic confirmation of these findings. As well as showing that the outbreaks predated the medics arrival, the study suggests that the HIV strain is related most closely to strains from West Africa, suggesting a natural introduction, probably via the many migrant workers in Libya\'</b></i>, says co-author <b>Tulio de Oliveira</b> of the University of Oxford, UK.  </p>\r<p></p>\r<p>Other phylogenetic analyses of HIV have been used in court cases involving allegations of HIV infection. The first was in 1991, when a Florida dentist was shown to have contaminated his patients. The technique has since been accepted as evidence in dozens of cases involving rape, hospital infection transmissions and people with HIV knowingly exposing others in Sweden, France and elsewhere. </p>\r<p></p>\r<p>Thomas Leitner of Los Alamos National Laboratory in New Mexico has provided forensic HIV evidence in more than 30 such cases over the past 15 years. He describes <b><i>the de Oliveira paper as \"compelling evidence that the outbreak had started before the accused could have started it\', a view shared by every expert that Nature contacted (see Expert opinion\").</b></i> </p>\r<p></p>\r<p>Leitner points out that calculating evolutionary timescales is tricky, but that because HIV has such a fast mutation rate, even recent events can be pinpointed quite accurately. De Oliveira et al. have tested and evaluated the clock and its uncertainty using several methods, he says. <b><i>\"I find their analysis well done and timely, and hope it will affect the judgement in the Libyan court.\"</b></i>\n<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>\n', 'Molecular, HIV, evidence, backs, accused, HIV, libya, Nature, medics, de oliveira, expert, open review', 'Molecular HIV evidence backs accused medics. Nature coverage of the case and de Oliveira paper', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(16, 'imgnature2.png', 'http://evolve.zoo.ox.ac.uk/Evolve/15_mins_files/NatureJuly07.pdf', 'High noon in Libya', 'Nature', 22, '2007-07-19', '<p>This week sees yet another crisis point in the Libyan case of six foreign health professionals sentenced to death on charges of injecting hundreds of children with HIV. Declan Butler traces the efforts of scientists to help establish the truth. </p>', 'NatureJuly07', NULL, '<p>Rich Roberts did not realize what he was getting into last October, when he decided to mobilize his fellow Nobel laureates to draw attention to a death-penalty case in Libya. Six medical workers, five nurses from Bulgaria and a Palestinian doctor were charged with deliberately infecting more than 400 children with the virus that causes AIDS. Roberts, like many scientists, was shocked at how scientific evidence exonerating the medical workers had been ignored, and decided to do something about it. </p>\r<p></p>\r<p>For Roberts, a 1993 Nobel laureate in medicine or physiology, it was the start of a relentless commitment. Over the past nine months, he has had a string of meetings with top-level diplomats, and on 10 June he even flew to Libya for a late-night meeting at the Corinthian Hotel in Tripoli with Seif al-Islam Gaddafi, son of the Libyan leader Muammar al-Gaddafi, to try to help find a solution. </p>\r<p></p>\r<p>Roberts has also spent endless hours gathering an eventual 120 signatures from Nobel laureates, a record , for an open letter to Muammar al-Gaddafi. <b><i>\'A miscarriage of justice will take place without proper consideration of scientific evidence\'</b></i>, warned the letter (see Nature 444, 146; 2006). And it called on the appropriate authorities to take the necessary steps to permit such evidence to be used in this case. </p>\r<p></p>\r<p>On 31 October, just days before it was published, Roberts hand-delivered the letter to Libya ambassador to the United Nations, Attia Omar Mubarak. Their meeting in New York lasted an hour and a half. Mubarak was dismayed about the letter, arguing that the Islamic way was to try to negotiate a settlement between the accused and the injured. But, says Roberts, Mubarak did admit the possibility that the whole thing was an accident that had been seized on by prosecutors. As Nature went to press this week.</p>\r<p></p>\r<p>Meanwhile, a team of European experts in the molecular phylogenetics of viruses decided to apply their expertise to the HIV sequences of the infected children being treated in Europe. The initiative of the group, who until then knew little about the case apart from what they had read in the news, was to provide crucial new evidence. </p>\r<p></p>\r<p>The initial phylogenetic analyses of the sequences confirmed epidemiological evidence that the infection had started at the hospital before the medical workers had started working there. As the retrial drew to a close, the researchers worked night and day to finish their analyses, suspending all other uses of their 40-processor cluster supercomputer to dedicate it solely to analysis of the Libyan sequences. </p>\r<p></p>\r<p>Given the stakes, the team tested and retested their findings using multiple models. <b><i>\'We decided to throw the book at the data\'</b></i>, recalls Oliver Pybus, an evolutionary biologist at the University of Oxford, UK. The results of every model were concordant; the start of the outbreak predated the March 1998 arrival of the medical workers. The paper (-  paper from <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</a>) was published online in Nature on 6 December, just before the scheduled court verdict (see Nature 444, 836, 837; 2006).</p>\n\n<p>More information: Original paper: <a href=\"http://bioafrica.net/publications.php?pubid=22\">de Oliveira T et al. Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak</p></a>', 'High, noon, Libya, Nature, HIV, libya, de oliveira, tulio, innocence', 'High noon in Libya. Medics are free. Manuscript by de Oliveira and colleagues prove medics innocence in Nature.', NULL),
(18, 'imgaidsmap.png', 'http://www.aidsmap.com/Treatment-in-children-and-adolescents/page/1856371/#item1856383', 'Drug Resistance Increasing in Children', 'AIDSmap', 22, '2011-06-27', '<p>Indeed, drug resistance is emerging in children on ART in South Africa.</p>\r', NULL, NULL, '<p>One study described a large number of resistance mutations found in thirteen children at Kalafong Hospital in Pretoria, who were started on a protease inhibitor-based regimen when they were younger than 36 months of age (mean age 22.4 months), some of whom had already been switched to a second line NNRTI regimen. The mean duration of treatment at testing was 45.9 months. <b><i>\'All these children were deemed to be at high risk as they suffered co-morbid conditions and had documented poor adherence,\' </b></i>according to the posters authors. Three of the children had WHO Stage 3 disease, and ten had WHO stage 4 disease; while 62% of their caregivers reported poor adherence, and 54% had a history of missed clinic appointments. Only one had ever achieved an undetectable viral load.</p>\r<p></p>\r<p>Resistance testing found that all of these children had virus resistant to nucleoside analogues (the 3TC-related M184V mutation being the most common), five had major protease inhibitor resistance mutations, and nine had resistance to mutations to non-nucleoside analogue reverse transcriptase inhibitors (NNRTI, i.e. efavirenz or nevirapine)  only one of these had been exposed to nevirapine as PPTCT.</p>\r<p></p>\r<p>A second poster presentation found drug resistance was more common in paediatric than adult patients experiencing virological failure on their second line protease inhibitor-based regimen at Tshwane Academic Hospital (Pretoria).8 All patients had been started on d4T/3TC with either nevirapine or efavirenz, and they were all switched to either AZT/ddI/ or a variation (AZT/abacavir) with ritonavir-boosted lopinavir (Kaletra / Aluvia).</p>\r<p></p>\r<p>About half of the failing adult patients showed no evidence of resistance at all, suggesting that they simply were not taking their treatment, but the virus from 91% of the children (30 out of 33) of the paediatric patients failing treatment had resistance mutations. In these children, virus in seven out of 33 (21%) had major PI mutations, five had more than three PI mutations, and 27.3% still showed evidence of the K103 mutation conferring resistance to NNRTIs (note, the mutation would probably have been detected in more children if they were still taking nevirapine or efavirenz). Finally, 75.8% of the children had virus that was resistant to 3TC, and 18.2 % had multiple thymidine analogue mutations (TAMs) that significantly decrease the chances of responding to subsequent nucleoside analogues.</p>\r<p></p>\r<p>Notably, some of these children had only moderate levels of viral load which in the presence of less than universal resistance to the PIs,  suggested that they may have been taking their treatment, but that adherence was suboptimal.</p>\r<p></p>\r<p>Nevertheless, the authors concluded that children exhibited increased levels of resistance to all three drug classes, perhaps because of higher levels of viral replication that typically occur in children or perhaps because some of them had previous exposure to unboosted PI therapy (ritonavir monotherapy).</p>\r<p></p>\r<p><b><i>Dr Theresa Rossouw of the University of Pretoria, who was the lead author of the latter poster, also gave an oral presentation describing findings from the Southern African Treatment and Resistance Network (SATuRN)</b></i>, which is monitoring emerging patterns of drug resistance in the region.9 She described higher rates of resistance among 49 children in SATuRN (though it is not clear to what extent these patients overlap) with PI resistance being documented in almost one third of the patients and three or more PI resistance mutations in 20.4%. NNRTI Resistance was seen in 21/49 (42.86%). Resistance to the nucleoside analogues was detected in 41/49 (83.67%), with eleven out of 49 (22.45%) with TAMS, and eight out of 49 (16.28%) with three or more TAMs.  She noted several other South African cohorts have also documented high levels of resistance among children failing treatment.</p>\r<p></p>\r<p>Resistance, and limited treatment options will make it more difficult for these children to live with HIV into adolescence, when other challenges to treatment success seem to emerge.</p>', 'Drug, Resistance, Increasing, South, Africa, Children, media, coverage, Rossouw, SATuRN, pretoria', 'Drug Resistance Increasing in Children in South Africa, SAtuRN report shows.', NULL),
(21, 'imgUKZN.png', 'http://www.ukzn.ac.za/news.aspx?id=445', 'Highly Specialized Team to Tackle HIV Drug Resistance Problem in Southern Africa', 'UKZN', 1, '2012-02-22', '<p>DURBAN, SOUTH AFRICA, 24-26 FEB 2012 - A small, highly specialized multidisciplinary team of doctors and statisticians from South Africa, Botswana, the USA and the UK will meet in Durban this weekend with the express purpose of pooling their resources, knowledge and expertise in an attempt to improve understanding the problem of HIV drug resistance in southern Africa.  ', NULL, NULL, '<p>Resistance to HIV drug treatment threatens to undermine the success of South Africa\'s ARV (Antiretroviral) campaign and should thus be handled with the utmost urgency. To this end, collaboration is essential; this meeting is a response to this need. The meeting is coordinated by SATuRN (Southern African Treatment and Resistance Network), a non-profit network devoted to developing innovative means of collaborating and sharing data in response to anti- HIV and TB treatment in southern Africa.</p>\r\n<p>The following southern African institutions are represented in the meeting: KwaZulu-Natal Research Institute for TB and HIV (K-RITH at UKZN), Africa Centre for Health and Population Studies (UKZN), Computer Science Department at UKZN, University of Stellenbosch Medical School, University of the Free State Medical School, University of Pretoria School of Medicine, National Institute of Communicable Diseases (NICD), National Health Laboratory Services (NHLS), Jembi health Systems, Medical Research Council, Botswana Ministry of Health, Aurum Institute. International participants are from the following institutions: John Hopkins School of Medicine, London School of Hygiene and Tropical Medicine and Stanford University.</p>\n\r<p>In this first SATuRN Comprehensive Analysis Meeting, the focus will be on analyzing the vast amount of data that has recently become available from several independent surveys of drug resistance in the region. This group will use these data to learn more about the current situation and to suggest ways that treatment programmes could be improved. Their responsibility as scientists and doctors is to analyze and interpret this data rigorously and then share that information as widely as possible, most importantly with the policy makers at the Department of Health, so that the information can be used to improve care for people living with HIV in this region. Thus far, results from these independent surveys show both good and bad news for the region. The good news is that ARV treatment has expanded very fast and now includes over 1,3 million individuals, it has saved 1000s of lives and there is little evidence that transmission of drug resistant viruses from people on treatment to uninfected people is a problem (<5%). The bad news, however, is that a growing number of HIV infected individuals on treatment start to develop high-level resistance after only a few years on life-long ARV therapy. </p>\r\r<p>SATuRN\'s first Analysis Meeting comes after years of preparation and a sustained and collaborative effort to collate the largest drug resistance dataset ever produced in southern Africa. <b><i>\'The data contains over 7,000 genetic (i.e. DNA) codes of drug resistance viruses in the region, and detailed clinical, and in some cases social information, on the patients failing treatment\'</b></i> says Dr. Tulio de Oliveira, a bioinformatician from the Africa Centre for Health and Population Studies at UKZN and the co-director of SATuRN. He continues <b><i>\'The genetic code of the virus is used to estimate the presence of drug resistance and, if combined with other associated data, it can shed light on the reasons for the development of resistance, which, in many cases, may be social rather than clinical.\'</b></i> </p>\r\r<p><b><i>\'All patient information is anonymous and has been collected following stringent academic ethics reviews. It is made available on what are considered to be the two best drug resistance databases in the world.\'</b></i> says Dr. Cloete Van Vurren, a specialized HIV physician and researcher from the University of the Free State.  He continues <b><i>\'It is a great opportunity to work together with some of best scientists and professional statisticians in the region in order to properly analyze the data\'</b></i>. Two internationally renowned statisticians, Dr. Nuala McGrath (London School of Hygiene and Tropical Medicine, U.K. and the Africa Centre, UKZN) and Dr. George Melikian (Stanford University, U.S.) will be present at the meeting and will not only provide analytical support but also specialized training in data analysis, training which will continue after the meeting ends, so that the participants develop the necessary skills to independently, and as a multi-disciplinary team, survey resistance levels in the region. </p>\r\r', 'multidisciplinary team,  doctor, statisticians , South Africa, Botswana, the USA , UK, Durban, understanding , problem , HIV drug resistance , southern Africa, news, bioafrica, SATuRN', 'A small, highly specialized multidisciplinary team of doctors and statisticians from South Africa, Botswana, the USA and the UK will meet in Durban this weekend with the express purpose of pooling their resources, knowledge and expertise in an attempt to improve understanding the problem of HIV drug resistance in southern Africa.  ', NULL),
(19, 'imgNYtimes.jpg', 'http://www.nytimes.com/2006/12/07/world/africa/07libya.html', 'New Evidence Disputes Libya Case in H.I.V. Trial', 'NY Times', 22, '2006-12-07', '<p>LONDON, Dec. 6 (Reuters) - Scientists have produced new evidence that casts doubt on charges against five Bulgarian nurses and a Palestinian doctor accused by Libya of deliberately infecting 426 children with the virus that causes AIDS in 1998.</p>\r', NULL, NULL, '<p>A team of international scientists who reconstructed the history of the virus from samples from the Libyan children has shown that a subtype of H.I.V. began infecting patients at Al Fateh Children?s Hospital in Benghazi before the foreign medical team arrived.</p>\r<p><b><i>?The evidence shows the chain of infection started a few years before the arrival of the foreign staff accused of causing it deliberately,?</b></i> Dr. Tulio de Oliveira, a molecular virologist at Oxford University, said in an interview.</p>\r<p>A retrial of the six health workers ended in Tripoli last month. The prosecutor demanded the death penalty after five Libyan experts in H.I.V. and AIDS stood by their 61-page report, written in 2003, that found that the infections of the Libyan children had resulted from an intentional act.</p>\r<p>A Libyan court is expected to deliver a verdict on Dec. 19.</p>\r<p>The six medical workers, who have protested their innocence and said their confessions were made under torture, arrived in Libya in March 1998. They have been detained since 1999.</p>\r<p>The international team of scientists, whose findings were published online Wednesday by the journal Nature, analyzed the genetic code of H.I.V. and hepatitis C viruses from the children to determine when the outbreaks started. ?All of them give a date for the start of the epidemic around the mid-1990s,? Dr. de Oliveira said.</p>\r<p>He added that a team of 10 specialists from around the world who reviewed the research concluded that the results were ?extremely solid.?</p>\r<p>The medical workers were sentenced to death by firing squad after being convicted in a trial in 2004. The verdict was quashed last year by Libya?s Supreme Court, and the case was sent to a lower court.</p>\r<p>In an open letter to the Libyan leader, Col. Muammar el-Qaddafi, published last month in Nature, more than 100 Nobel laureates in the sciences called for a fair trial for the medical workers.</p>', 'New york times, de oliveira, tulio, Libya, HIV, HCV', 'New Evidence Disputes Libya?s Case in H.I.V. Trial. NY Times coverage on the manuscript by de Oliveira and colleagues, Nature.', NULL),
(20, 'imgnewbio.png', 'http://www.bioafrica.net', 'New and interactive section of BioAfrica and SATuRN website', 'BioAfrica', 0, '2012-01-14', '<p>One of our main aims for this development is for users and collaborators to become more involved in the website. It has added over 100 new webpages to bioafrica.net, including blogs, open access publications, media coverage, clinical cases tutorials and twitter. It has also increased the number of people collaborating in the development of our website! </p>\r', NULL, NULL, '<p>We would like to highlight some of the new sections and information that you can find here:</p>\r\r<p><a href=\"output.php\">SATuRN output: HIV & TB drug resistance reports, clinical cases & publications on bioinformatics in Africa and HIV and TB treatment resistance</a></p>\r\r<p><a href=\"15minutes.php\">15 minutes: BioAfrica and SATuRN work at a glance: News, tweets & blogs on bioinformatics in Africa, HIV and TB drug resistance</a></p>\r\r<p><a href=\"news.php\">News section: printed and online media coverage articles, blogs and tweets on the key aspects of our bioinformatics and drug resistance work</a></p>\r\r<p><a href=\"blogs.php\">Blogs section: Bogs and tweets about our work and other related topics of interest. For example, here you will find a number of blogs from Dr. Richard Lessells on TB drug resistance and Lungani Ndwandwe on social and political aspects of the HIV epidemic</a></p>\r\r<p><a href=\"report.php\">Reports section: Open access annual reports on HIV and TB drug resistance, which are directed at public health practitioners, policies makers, doctors, researchers and the general public</a></p>\r\r<p><a href=\"cases.php\">HIV and TB clinical cases: present cases published in the HIV/TB Drug Resistance & Clinical Management Case Book. These cases have been presented to over 1000 medical doctors in southern Africa at the annual SATuRN Drug Resistance Workshops</a></p>\r\r<p><a href=\"publications.php\">Publications section: We provide you with our peer-reviewed publications, number of citations and impact factor of each publications. All publications are open access and the PDF can be downloaded from our website</a></p>\r\r<p><a href=\"people.php\">People section: This section gives information on all members of bioafrica group. It also a one-stop place to get publications, blogs, cases, news and other information about each member of the group</a></p>\r\r<p>We would like you to help us to develop a truly collaborative site where information is accurate and up-to-date so our tools and databases become more useful for research and the implementation of prevention and treatment programmes affecting human health in Africa.</p>\r\r<p>We hope you enjoy our new website as much we did developing it!</p>', 'bioafrica, new, website, output, blogs, twiiter, cases, information, saturn, webpage', 'New and interactive section of BioAfrica and SATuRN website has been developed. One of our main aims for this development is for users and collaborators to become more involved in the website. This development has added over 100 new webpage to bioafrica.net., including: open access publications, clinical cases tutorial, reports, news coverage, blogs, twitter, etc', NULL),
(23, 'imgCGD.png', 'http://www.cgdev.org/content/publications/detail/1424207', 'The Race Against Drug Resistance', 'Center for Global Development', 0, '2010-06-14', '<p> by Rachel Nugent, Emma Back, and Alexandra Beith - In an increasingly interconnected world, drug resistance does not stop at a patient\'s bedside, it threatens global health. It has slowed gains against the fatal ravages of childhood dysentery and pneumonia, drastically increased the costs of fighting tuberculosis and malaria, and imperiled efforts to effectively treat people living with HIV/AIDS. Tens of millions of lives are at stake; quality of life for scores of millions more is under threat.</p>', NULL, NULL, '<p>The conclusions of the Center for Global Development\'s Drug Resistance Working Group make clear the need for urgent action to address this growing crisis. While there is no simple solution, there are achievable steps, as are described in this report, which the health community, governments, donors, and the pharmaceutical industry can and must take to slow the spread of drug resistance. Retaining the drugs we have now, developing new drugs and other technology, and ensuring these resources continue to save lives in future generations must become a priority for global and national health organizations, both public and private.</p>\n<p> The highly accomplished members of the working group have reviewed <a href=\"http://www.bioafrica.net/saturn/\">SATuRN HIV drug resistance databases</a> and have concluded that our databases are important resources to fight drug resistance in Africa.</p>\n<p>More detailed info on the <a href=\"http://127.0.0.1/bioafrica/report.php?id=10\">HIV drug resistance report section of the bioafrica.net website</a> and on the center for global development website, which is listed below.</p>', NULL, NULL, NULL),
(22, 'imgIAS.png', 'http://www.iasociety.org/Default.aspx?pageId=5&elementId=14379', 'Transmitted Drug Resistance Rate Remains Below 5% in South Africa', 'IAS', 41, '2012-03-05', '<p>by Mark Mascolini - Analysis of South Africans with newly diagnosed, untreated HIV infection indicates low levels of transmitted antiretroviral-resistant HIV across the country through 2010 and no evidence of transmitted drug-resistant HIV in rural KwaZulu Natal</p>', NULL, NULL, '<p>Monitoring regional levels of transmitted antiretroviral-resistant HIV is crucial to planning treatment strategies. In countries with high rates of transmitted resistant virus, authorities usually recommend routine genotyping of virus from people starting their first antiretroviral regimen to ensure that they take drugs to which their virus remains sensitive.</p>\r<p>This analysis of transmitted drug resistance rates in South Africa involved several methods: (1) a literature review, (2) analysis of 72 sequences from newly diagnosed people in rural KwaZulu Natal identified in the Africa Centre\'s 2010 HIV surveillance round, and (3) publicly available data on transmitted drug resistance from Genbank.</p>\r<p>Viral samples collected in 2010 from newly infected people in rural KwaZulu Natal yielded no evidence of transmitted drug resistance. KwaZulu Natal province has the highest HIV prevalence in South Africa, 22.3% among women and 11.5% among men.</p>\r<p>Among 1618 viral samples collected in 10 datasets from 2000 through 2010 across South Africa, the rate of transmitted drug resistance peaked at 6.67% (95% confidence interval 3.09% to 13.79%) in 2002. In subsequent years, the rate of transmitted drug resistance always lay below 5%, the World Health Organization cutoff for low-level transmitted resistance. After 2002, there was no statistically significant increase in transmitted drug resistance across South Africa.</p>\r<p>The most frequently identified resistance mutations were those associated with nonnucleoside reverse transcriptase inhibitors the K103N mutation, followed by Y181C and Y188C/L. Five viral sequences analyzed had multiple mutations associated with nonnucleoside resistance.</p>\r<p><b><i>\'In Southern Africa as antiretroviral therapy access and treatment programs grow,\'</b></i> the authors caution, <b><i>\'it is critical to maintain surveillance among recent seroconverters, treatment-naive and treated populations.\'</b></i></p>\r<p>They add that <b><i>\'programs, covering well-defined geographic areas and populations, minimize the biases inherent in transmitted drug resistance surveillance and provide guidance in implementing risk reduction and secondary prevention to maintain the effectiveness of first-line treatment.\'</b></i></p>\r<p>Source: <a href=\"http://www.bioafrica.net/publications.php?pubid=41\">Justen Manasa, David Katzenstein, Sharon Cassol, Marie-Louise Newell, Tulio de Oliveira. Primary drug resistance in South Africa: data from 10 years of surveys. AIDS Research and Human Retroviruses. Online ahead of print. doi:10.1089/AID.2011.0284</a>.</p>', 'Transmitted, Drug,hiv, antiretroviral, Resistance, Rate, Remains, Below, 5%, South Africa', 'Transmitted Drug Resistance Rate Remains Below 5% in South Africa, paper from Justen Manasa, de Oliveira and colleagues', NULL),
(24, 'imgnews24.gif', 'http://enewsletter.ukzn.ac.za/Story.aspx?id=231', 'JIVING WITH SCIENCE - Music CDs', 'UKZN', 0, '2011-03-04', '<p>Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. The Africa Centre, a joint project of the UKZN and the Medical Research Council of Southern Africa, is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health. It is based in rural, northern KwaZulu-Natal where the HIV epidemic is one of the most severe in the world with nearly one in two adults aged 35-40 being infected.</p>', NULL, NULL, '<p>Jiving with Science aims to foster community discussion about scientific research and to bring evidence-based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts. It involves developing, distributing and evaluating three CDs over two years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action.</p>\r<p>Two of the three CDs are now complete, and are being distributed free-of-charge to key stakeholders in the local community including taxi drivers, shebeen owners and hair salon operators. Taxis are the main mode of transport in the Africa Centre research area, with almost two-thirds of the population (an estimated 50 to 60 000) using a taxi on a weekly basis. Each has a CD player, although most operators only have a couple of CDs to play. Thus, the primary target audience in this initiative is the users of local mini-bus taxis. On February 13 the project was launched at the Mtubatuba Taxi Association. The event was well-attended with close to 200 taxi drivers present. At the launch drivers received two CDs together with an HIV fact sheet, a Jiving with Science t-shirt and a meal. Once the Africa Centre has received feedback from the drivers on commuter responses to these first two CDs, a third disc will be designed and distributed.</p>\r<p>The Africa Centre anticipates that these informative CDs will improve the public understanding of HIV transmission and prevention strategies. Furthermore, through this project the Centre has engaged new sectors in the community who are now actively participating in its research and efforts to prevent HIV transmission.  This project has also enabled the Africa Centre to engage partners in the music industry who, in line with social responsibility agendas, have waived the production rights on selected popular music tracks. In exchange the Centre has provided them with an opportunity to advertise and have their music heard in this often-inaccessible rural setting.</p>\r<p>DJ Tira, who is the owner of the famous Afrotainment studios and is originally from Hlabisa, has taken a special interest in this project. DJ Tira has donated six Afrotainment songs and also plays the part of the main actor in the dialogue. Another important contributor is Malcom Nhleko of Maltre Productions, who recorded the CD dialogue at his studio in Newlands West. Other partners in the music industry who have provided the project with songs include Sheer Sound, EMI, Gallo, Abafana Bokuthula and Debrah Gumede. Currently, the Centre is compiling the music for the third CD and is looking for hip songs to include.</p>\r<p>For more information, please contact <b><i>Dr. Astrid Treffry-Goatley </b></i>(email: atreffrygoatley@africacentre.ac.za)</p>\n\r\n<p><b>Jiving with science webpages</b></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=1\">Jiving with Science CD 1: Indaba kaMamBiyela</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=2\">Jiving with Science CD 2: Indaba kaTira</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=3\">Jiving with Science CD 3: Uhlelo lukaMroza</a></p>', 'jiving, with, science, music, cds, health, promotion, south africa, UKZN, africa Centre, afrotaiment, DJ tira', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies using music CDs to foster community discussion about scientific research and to bring evidence-based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.', NULL),
(25, 'imgnews25.gif', 'http://www.africacentre.ac.za/Default.aspx?tabid=456', 'Taxis on board - Spreading the word while jiving', 'Zululand Observer', 0, '2011-03-20', '<p>Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. Africa Centre is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KZN Department of Health.  The Mtubatuba-based centre is where the HIV epidemic is one of the most severe in the world, with nearly one in two adults aged 35-40 being infected. </p>\r', NULL, NULL, '<p>The project aims to foster community discussion about scientifc research and to bring evidence-based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.  It involves developing, distributing and avaluating three CDs over two years.  Each CD contains a raduio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action.</p>\r<p>The project launch was held at Mtubatuba Taxi Association in February.  The event was well-attended with close to 200 taxi drivers present.  At the launch drivers received two CDs together with an HIV fact sheet, a \'Jiving with Science\' T-shirt and a meal.</p>\r<p>This project has also allowed Africa Centre to engage partners in the music industry who, in line with social responsibility agendas, have waived the production rights on selected popular music tracks.  In exchange, Africa Centre has provided them with an opportunity to advertise and have their music heard in this often inaccessible rural setting.</p>\r<p>To date, the support received from the music industry has been great.  For example, DJ Tira, who is the owner of the famous Afrotainment studios and is originally from Hlabisa, has taken a special interest in this project.  DJ Tira has donated six Afrotainment songs and also plays the part of the main speaker in the dialogue.</p>\r<p>Contact Astrid Treffry-Goatley (atreffrygoatley@africacentre.ac.za) or Mduduzi Mahlinza at the Africa Centre Community Office (mmahlinza@africacentre.ac.za) for more information.</p>\r\r\n<p><b>Jiving with science webpages</b></p></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=1\">Jiving with Science CD 1: Indaba kaMamBiyela</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=2\">Jiving with Science CD 2: Indaba kaTira</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=3\">Jiving with Science CD 3: Uhlelo lukaMroza</a></p>', 'Taxis, public, transport, science, project, spreading, jiving with science, music, CD, health, promotion', 'Taxis on board - Spreading the word while jiving. Jiving with Science Music project funded by the Wellcome Trust as a community engagement project', NULL),
(26, 'imgnews26.gif', 'http://www.doh.gov.za/docs/newsletters/2011/research_brief141.pdf', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies', 'SA DoH research brief newsletter', 0, '2011-03-08', '<p>Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies. The Africa Centre, a joint project of the University of KwaZulu-Natal (UKZN) and the Medical Research Council of Southern Africa, is an international HIV research facility with a partnership HIV testing, treatment and care programme run jointly with the KwaZulu-Natal Department of Health.</p>', NULL, NULL, '<p> It is based in rural, northern KwaZulu-Natal where the HIV epidemic is one of the most severe in the world with nearly one in two adults aged 35- 40 being infected. Jiving with Science aims to foster community discussion about scientific research and to bring evidence-based HIV health promoting messages to everyday spaces such as public transportation, leisure spaces and shopping precincts.</p>\r<p>It involves developing, distributing and evaluating three CDs over two years. Each CD contains a radio-style information interview, interspersed with popular music, targeted HIV health promotion messages and calls to action. Two of the three CDs are now complete, and are being distributed free-of-charge to key stakeholders in the local community including taxi drivers, shebeen owners and hair salon operators. Taxis are the main mode of transport in the Africa Centre research area, with almost two-thirds of the population (an estimated 50 to 60 000) using a taxi on a weekly basis. Each has a CD player, although most operators only have a couple of CDs to play. Thus, the primary target audience in this initiative is the users of local mini-bus taxis. The Africa Centre anticipates that these informative CDs will improve the public understanding of HIV transmission and prevention strategies. Furthermore, through this project the Centre has engaged new sectors in the community who are now actively participating in its research and efforts to prevent HIV transmission. This project has also enabled the Africa Centre to engage partners in the music industry who, in line with social responsibility agendas, have waived the production rights on selected popular music tracks. In exchange the Centre has provided them with an opportunity to advertise and have their music heard in this often-inaccessible rural setting.</p>\r\n<p><b>Jiving with science webpages</b></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=4\">Introduction: Jiving with Science </a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=1\">Jiving with Science CD 1: Indaba kaMamBiyela</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=2\">Jiving with Science CD 2: Indaba kaTira</a></p>\n<p><a href=\"http://www.bioafrica.net/artscience.php?id=3\">Jiving with Science CD 3: Uhlelo lukaMroza</a></p>', 'Jiving with Science, new, public, engagement, initiative, Africa Centre for Health and Population Studies, department of health, research brief, newsletter', 'Jiving with Science is a new public engagement initiative of the Africa Centre for Health and Population Studies featured at the research brief of the Department of Health of South Africa.', NULL),
(28, 'imgBlog10sm.png', 'http://www.msf.org.za/publication/open-letter-medicines-control-council-south-africa', 'Open letter  on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa', 'MSF', 0, '2012-04-11', 'BioAfrica & SATuRN Supports this Open Letter!\r<p>Open letter to the Medicines Control Council and Ministry of Health on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDRTB in South Africa.</p>\r', NULL, NULL, '<p>Dear Professor Eagles, Ms. Hela and Honorable Dr. Motsoaledi,</p>\r\r<p>We urge you to take action to expedite compassionate use access for bedaquiline (TMC207) for persons with drug-resistant strains of tuberculosis in South Africa. Access to improved medicines to treat extensively drug resistant tuberculosis (XDR-TB) and pre-XDR-TB[1] is essential given the enormous public health threat that the drug-resistant TB epidemic exemplifies.</p>\r\r<p>As you know, drug-resistant TB is a serious problem in South Africa, and the few treatment options that exist are only efficacious for a few patients, have major toxicity issues and are often unavailable. Patients have died, and are dying, and will continue to die because current drugs are failing to cure XDR-TB save for in a select few patients. Bedaquiline is the first TB drug in a new class to have been developed in 60 years. We agree with experts from the medical field that bedaquiline should be provided to select patients, to whom it offers the opportunity to be cured when no other options exist.</p>\n<br><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2012.pdf\"><img src=\"imagesBIO/imgnews28openletter.png\" alt=\"Open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa\"></a>\n\r\r<p>Please <br><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2012.pdf\">\nclick link to read the Open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa.</a>', 'Open letter,  urgent, need, compassionate, use, bedaquiline, XDR-TB, pre-XDR-TB, tuberculosis, South Africa', 'MSF and researchers Open letter  on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa', NULL),
(27, 'imgnews27.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2012.pdf', 'SATuRN Newsletter Vol. 1 Number 1,  Jan-Mar 2012', 'BioAfrica', 0, '2012-04-15', 'The newsletter idea is that anyone with 15 minutes to spare can learn about our work and its application in everyday life.', NULL, NULL, '<p>The newsletter is presented in a PDF document, which is linked to complete articles at the bioafrica.net website. The newsletter is more useful if seen in the computer screen  than printed as web links give access to open access documents. In this first issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative\0</p>\r<br><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2012.pdf\"><img src=\"imagesBIO/imgnews27newsletter.png\" alt=\"saturn newsletter, southern african treatment resistance network newsletter information on hiv and tb drug resistance\"></a>\n\r\r<b><p>Highlights:</p>\r<p>News: <a href=\"news.php?id=22\">Transmitted Drug Resistance Rate Remains Below 5% in South Africa</a></p>\r<p>Blog: <a href=\"blogs.php?id=11 \">Shortage of doctors in rural South Africa?</p>\r<p><a href=\"bioinformaticsworkshop.html \">1st Nurses & Health Care Workers HIV & TB Drug Resistance Workshop, 22 May, Africa Centre, South Africa</a></p>\r<p><a href=\"publications.php?pubid=42\">Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact</a></p></b>\r<p>Produced by: Tulio de Oliveira, Richard Lessells, Lungani Ndwandwe, Justen Manasa, Cloete van Vuuren & Chris Seebregts</p>\r\n\n', 'saturn, newsletter, contains, news, blogs, reports, tweets, publication, training, Southern African, drug resistance, network, press material, media information, PDF', 'In this first issue of SATuRN\'s newsletter we have included interesting HIV & TB drug resistance news, blogs, reports, tweets, publications and training information produced by our network', NULL),
(29, 'jivingwithsciencedancing.png', 'http://www.bioafrica.net/artscience.php', 'BioAfrica Art & Science section is open!', 'BioAfrica', 0, '2012-05-10', '<p>In this exciting new section of bioafrica.net art we feature creative projects that celebrate, investigate and/or communicate biomedical science. Here, we share blogs, news articles, tweets, audio and audiovisual media to increase public awareness of innovative collaborations between art and science.</p>', NULL, NULL, '<p>\n<center><a href=\"artscience.php\"><img src=\"imagesBIO/jivingwithsciencedancing.png\"></a></center></p>\n<b><p>Highlights:</p>\r<p>Cartoon: <a href=\"artscience.php?id=7\">HIV as a lion, CD4 as soldiers and ARVs make the soldiers stronger! (translated to Zulu)</a></p>\r<p>Poetry:  <a href=\"artscience.php?id=5\">Toward A SATuRN Hope</p>\r<p>Music: <a href=\"artscience.php?id=4\">Music: Introduction: Jiving with Science</a></p>\r<p>Music: <a href=\"artscience.php?id=2\">Jiving with Science CD 2 - Indaba kaTira - DJ Tira - HIV testing, ARVs, positive living and HIV prevention</a></p></b><br>\r<p>Produced by: Tulio de Oliveira, Richard Lessells, Lungani Ndwandwe and Astrid Treffry-Goatley</p>', 'news, bioafrica, art, science, section, music, video, poetry, photography, health, community, engagement', 'News about the BioAfrica Art & Science section! Thi section present projects that celebrate, investigate and/or communicate biomedical science. Here, we share blogs, news articles, tweets, audio and audiovisual media to increase public awareness of innovative collaborations between art and science.', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(30, 'imgTBCconf.png', 'http://www.tbconference.co.za/', 'SATuRN\'s tweet coverage about drug resistance at the 3rd SA TB conference', 'SATuRN', 0, '2012-06-15', '<p>We participated, presented and tweeted about the 3rd South African TB conference, 12-15 June 2012, ICC, Durban. We had covered all the sessions that present TB drug resistance results. Please find below our tweets from our participation in our national TB conference. </a></p>', NULL, NULL, '<br>\n<p><center><b>SATuRN Tweets at the 3rd SA TB Conference:</center></b></p>\n<p><center><b>14 june 2012</b></center></p>\n<p>Dr Sheela Shenoi: survival from XDR-TB in Tugela Ferry remains poor. Urgent need for new drugs/regimens #SATB</p>\n<p>Lesibana Malinga: second-line drug resistance complex. MTBDRsl assay accuracy not very impressive, especially for injectables #SATB</p>\n<p>Anura David: MTBDRplus assay version 2 can detect ~160 bacilli per ml of sputum #SATB</p>\n<p>#SATB MARTI presentation: lots of potential! Blood based, potentially poct, better on sm- cases, active disease only, $5 per electrode #TB</p>\n<p>#SATB Dr S Charalambous: high rates of undiagnosed #TB in SA prisons but urine LAM v low sensitivity to detect</p>\n<p>#SATB Natalie Baylis: in Jo\'burg 1/5 rpoB mutants are Rif monorestistant, 1/5 #MDRTB may benefit from high dose INH</p>\n<p>#SATB Natalie Baylis: high levels of Strep and EBM resistance in Jo\'burg #MDRTB</p>\n<p>#SATB Andreas Diacon - \"we are very well prepared for the next mouse TB epidemic!\" #TB #tuberculosis</p>\n<p>HIV-TB-IRIS = TB recurrence and immune damage, can even develop TB-meningitis 2 weeks after ARVs initiation. Prof. Wilkinson #SATB</p>\n<p>The three keynotes presentations today were great! #drug development, immunology and diagnostic. All SA research! Follow #SATB</p>\n<p>Next up in plenary session is Prof Mark Nicol talking about TB diagnostics #SATB</p>\n<p>Next up is Rob Wilkinson with the difficult task of trying to explain TB immunology! #SATB</p>\n<p>Prof Diacon: we must develop regimens not single TB drugs! #SATB</p>\n<p>Ready for day 2 of #SATB. First up is Andreas Diacon talking about new TB drugs and regimens</p>\n<br>\n<p><center><b>13 June 2012</b></center></p>\n<p>We meet Prof. Paul Van Helden at #SATB He accepted to present SATuRN HIV/TB Drug Resistance workshop, CTICC, 28-29 Nov http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop</p>\n<p>Great news to coincide with #satb UNITAID APPROVES US$ 30 MILLION FOR ROLLOUT OF XPERT MTB/RIF AT REDUCED COST http://www.unitaid.eu/resources/news/releases/943-unitaid-approves-us-30-million-for-innovative-project-to-roll-out-ground-breaking-tuberculosis-test-at-reduced-cost</p>\n<p>Dr Helen Cox-treating MDR-TB with the existing drugs is extremely difficult. We desperately need new drugs and new regimens! #SATB</p>\n<p>South Africa: Deaf or Dead? Better Drugs Needed to Stop #Drug-Resistant #TB http://allafrica.com/stories/201206131046.html #SATB</p>\n<p>SATuRN very impressed that #drugresistance is one of the main topics at #SATB Many interesting talks starting with Prof. van Helden talk...</p>\n<p>Depression is a cause and consequence of failing #arvs and anti-TB medicine. How to deal with this? SATuRN @drug_resistance question #satb</p>\n<p>#MDR #TB treatment can generate psychosis in patients, interesting talk by Ms Ana Kelly at #SATB</p>\n<p>Stavudine still an option in HIV-infected patients with MDR-TB. Seems that peripheral neuropathy not a huge problem in the short-term #SATB</p>\n<p>Fantastic discussion on the operationalising of #Xpert MTB/RIF session at #SATB great to learn on real world implementation!</p>\n<p>Dr. Helen Cox - as more we use #Xpert more discrepancy #MDR results we will find, but the most we will learn... #SATB</p>\n<p></p>\n<p>Thanks @TAC for following us, we are very proud of your great work!</p>\n<p>Lots of interesting questions for Dr. Lessels on implementation of #xpert at rural setting #SATB</p>\n<p>Positioning at clinic #Xpert allows start of treatment quicker than if at lab. Good for patients but more staff need training #SATB</p>\n<p>Go Dr. Richard Lessells ! 2 talks in different sessions at the same time, run, run...</p>\n<p>Randomized trial #tb #Xpert rural #SouthAfrica - median CD4 of HIV individuals is 270. Good news Patients testing early! Dr. Lessells #SATB</p>\n<p>Preliminary results - clinical care is improved when #Xpert is used at rural KZN by Dr. Lessells from @LSHTM_TB</p>\n<p>Operational feasibility of #xpert MTB/Rif in rural primary health care clinic by @rjlessells from @LSHTM_TB at #SATB</p>\n<p>Limpopo and Mapumalanga show a high number of #Rif resistance TB strains, maybe a new #MDR outbreak? Mr Ramdin NLHS/NICD at #SATB</p>\n<p>NHLS data warehouse for #tb results very important resource for #MDR surveillance in #SouthAfrica. 120,000 drug resistance tests 2011 #SATB</p>\n<p>Feasibility and implementation session of #Xpert at #SATB is very interesting. Good to see the how it perform in rural settings.</p>\n<p></p>\n<p>Lots of presentation on GenXpert in the #SATB conference, however we still need good evaluation trials for #Rif resistance in #SouthAfrica</p>\n<p>Need continuous surveillance performance of #Xpert at population level to determine reasons for discrepancy results Dr. Lessels #SATB</p>\n<p>Mixed strains/heteroresistance #TB rif resistance are still difficult to detect specially in high #Tb incidence regions #SATB</p>\n<p>Eye opening case Dr. Lessells show that false negative #Xpert due to new interpretation rule act > 5. Physicians should read values! #SATB</p>\n<p>WHO recommendation to use #xpert on MDR suspects, #SouthAfrica went further and offer for all #tb suspects, Dr. Lessells at #SATB</p>\n<p>Very good #LSHTM @rjlessells presentation on #xpert from Hlabisa on discordant results at #SATB</p>\n<p>Dr. Aza presentation on the use of #xpert in Mozambique show that advanced AIDS patients that developed #tb have a high xpert result #SATB</p>\n<p>Rapid #tb diagnostics are revolutionizing #MDR identification and treatment in #SouthAfrica</p>\n<p>about to start the diagnostics and guidelines section, we are exciting to see our colleague @rjlessells presentation at #SATB</p>\n<p>South Africa 23% coverage of #GenXpert, more than 50% of tests in the world. Still room to improve, rapid testing is helping to fight #TB</p>\n<p></p>\n<p>Dr. David Mametja @satb2012 NSP short term plan is to decrease time to treatment to 2 days susceptible #TB and 5 days for #MDR</p>\n<p>Dr. David Mametja @satb2012 NSP plan is to increase short term (next 5 years) TB treatment success rates to 90%</p>\n<p>Dr. David Mametja @satb2012 TB cure rates have increased in SA now at 73% this is up from less than 50% a few years ago.</p>\n<p>Dr. David Mametja @satb2012 - South Africa is number 3 on TB cases but number 1 on burden of TB per population with 940/100,000 TB cases</p>\n<p>Paul Van Helden @satb2012 Molecular epidemiology results show that around 60 % of the MDR in South Africa is transmitted.</p>\n<p>KwaZulu-Natal responsible for about 30% of all TB cases nationally #SATB</p>\n<p>Next plenary is Dr David Mametja talking about the National Strategic Plan #SATB</p>\n<p>Excellent presentation by Prof van Helden - really challenging us to focus on transmission rather than latency #SATB</p>\n<p>In South Africa the TB epidemic is driven largely by transmission #SATB</p>\n<p>Much recurrent TB disease is reinfection rather than relapse #SATB</p>\n<p>Need for improved surveillance systems and research for TB and #drugresistance</p>\n<p>Dr Nazir Ismail - MDR-TB fairly stable according to NHLS data 2007-2011 #drugresistance</p>', 'tb, conference, south africa, saturn, tweeting, presenting, drug resistance, coverage, 2012, 3rd TB conference', 'SATuRN will be tweeting about drug resistance presentations at the 3rd TB conference', NULL),
(31, 'imgnews31.gif', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_2_2012A4.pdf', 'SATuRN Newsletter V.1 Num.2 (Apr-Jun 2012) - Featured partners, news, blogs, tweets & publications', 'SATuRN', 0, '2012-07-02', 'In this second issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.', NULL, NULL, '<p><a href=\"manuscripts/SATuRNnewsletter_2_2012A4.pdf\"><img src=\"imagesBIO/imgnews31newsletter.gif\" alt=\"f\"></a></p>\n<p>The concept behind this newsletter is that anyone with  15 minutes to spare can learn about the work of SATuRN. The newsletter is presented as a PDF document with links to complete articles at the bioafrica.net website. </p>\n\n<p>In this second issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.</p>\n\n<p><b>Highlights:</b></p>\n\n<p><a href=\"http://www.bioafrica.net/report.php?id=12\">Report: 1st Nurses & Health Care Workers Drug Resistance Workshop</a></p>\n\n<p><a href=\"http://www.bioafrica.net/news.php?id=30\">News: SATuRN at the 3rd SA TB conference</a></p>\n\n<p><a href=\"http://www.bioafrica.net/report.php?id=13\">SATuRN\'s Featured Partner: Division of Medical Virology, Stellenbosch University</a></p>\n\n<p><a href=\"http://www.bioafrica.net/report.php?id=15\">SATuRN\'s Featured Partner: New TB centre at the  London School of Hygiene and Tropical Medicine</a></p>\n\n<p><a href=\"http://www.bioafrica.net/artscience.php\">Art/Science: BioAfrica/SATuRN Art & Science section is launched</a></p>\n\n<p><a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\">Upcoming event: 7th Southern African HIV & TB Drug Resistance & Clinical Management Workshop, CTICC, 28-29 November 2012</a></p>\n\n<p><a href=\"http://www.sahivsoc2012.co.za/\">Upcoming event: SA HIV Clinicians Society Conference, CTICC, 25-28 November 2012</a></p>\n', 'saturn, newsletter, Southern African, drug resistance, network, press material, media information, TB conference, workshop, 2012, Division of Medical Virology, Stellenbosh University, TB centre at the London School of Hygiene and Tropical Medicine, partners', 'In this second issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. Report: 1st Nurses & Health Care Workers Drug Resistance Workshop. SATuRN at the 3rd SA TB conference. Featured Partner: Division of Medical Virology, Stellenbosh University.  New TB centre at the London School of Hygiene and Tropical Medicine', NULL),
(32, 'imgnews32.gif', 'http://www.ahp.org.za/news-detail/339/sahivsocs-first-conference', 'SAHIVSOC\'S First Conference, 25-28 November 2012, Cape Town ICC', 'Africa Health Placements', 0, '2012-07-02', '<p>The Southern African HIV Clinicians Society will be hosting its first Conference: Striving for Clinical Excellence, 25-28 November 2012 at the Cape Town ICC.</p>', NULL, NULL, '<p>The Conference boasts a stellar international faculty, renowned South and Southern African clinicians and researchers as local faculty, and a cutting-edge, practically-oriented programme of plenaries, panel discussions, debates, master-classes, meet the professor sessions, case studies and skills-building sessions. The tracks will focus on ARVs, HIV Complications, Women\'s Health, Child and Adolescent, Prevention, Operations Research and Laboratory Sciences. The Conference is fully CPD-accredited. Draft programme available on-line.</p>\n<p>The Southern African HIV Clinicians Society will also be releasing and workshopping several new sets of guidelines during the conference.</p>\n<p>Post our conference, there will be a series of Clinical-Lab Interface workshops, including <a href=\"http\"//www.biofrica.net/saturn/\">ARV Resistance Testing and Paediatric Resistance, together with partners SATuRN</a>, IeDEA, QCMD and ASLM. The ASLM conference then commences at the same venue the following week.</p>\n<p>Registrations are now open, and space is limited. Please go on-line at: <a href=\"www.sahivsoc2012.co.za\">www.sahivsoc2012.co.za</a> to register and to access more information. The call for abstracts is now open. Please note mentoring support is available for those who are able to beat the abstract deadline. Limited partial scholarships are also available for young scientists and clinicians.</p>', 'Southern African HIV Clinicians Society, first, 25-28 November, 2012, Cape Town ICC, SATuRN, partner, drug resistance, TB', 'The Southern African HIV Clinicians Society will be hosting its first Conference: Striving for Clinical Excellence, 25-28 November 2012 at the Cape Town ICC. SATuRN is one of the partners on the HIV & TB drug resistance program of the conference.', NULL),
(33, 'imgnews33.png', 'http://www.aids2012.org/', 'SATuRN meeting, presentations & tweet coverage at the XIX International AIDS 2012 Conference, Washington', 'SATuRN', NULL, '2012-07-14', '<p>WASHINGTON, 22-27 July 2012 - We are hosting a meeting, presenting many talks and posters and tweeting on the XIX International AIDS 2012 Conference.</p>\n', NULL, NULL, '<p>Together with Life Technologies, we will be hosting a meeting on 24 July 2012 on <b><i>the Uses of Next Generation Sequencing Technologies in HIV Patient Management.</b></i> Please contact us if you would like to be invited to this meeting.</p>\n<p>We will have a great number of SATuRN collaborators at this conference, some of our international collaborators presenting in the conference include Prof. David Katzenstein, Prof. Bob Shafer, Prof. Peter Godfrey-Faussett, Prof. Mark A. Wainberg, Prof. Amilcar Tanuri, Prof. Jeffrey Klausner and Prof. Anne-Mieke Vandamme. </p>\n<p>We also have a large delegation from southern Africa, including among others Prof. Wolfgang Preiser, Dr. Carole Wallis, Dr. Cloete van Vuuren, Prof. Susan Engelbrecht,  Dr. Ava Avalos, Dr. Tendani Gaolathe, Prof. Wendy Stevens, Prof. Maria Papathanasopoulos, Dr. Siva Danaviah and Dr (to be) Justen Manasa.</p>\n\n\n<br>\n<center><p><b>Sessions on HIV drug Resistance:</b></p> \n<br>\n\n\n<p><b>HIV Drug Resistance Surveillance and Control: A Global Concern</b><br>22.07.2012, 11:15 - 13:15 -Mini Room 8</p>\n\n<p><b>Treatment as Prevention: A Work in Progress</b><br> Monday, 23.07.2012, 13:00 - 14:00 - Mini Room 6</p>\n\n<p><b>Antiretroviral Resistance</b><br> Tuesday, 24.07.2012, 14:30 - 16:00 - Session Room 4</p></center>\n<br>\n\n<p>Please come to these sections to meet with SATuRN people! <b>Follow us our tweet coverage at @drug_resistance</b></p>', 'SATuRN, meeting, presentations, tweet coverage, tweeter, XIX International AIDS, 2012, Conference, Washington, USA, drug resistance, HIV', 'SATuRN meeting, presentations & tweet coverage on HIV Drug Resistance and Clinical Management at the XIX International AIDS 2012 Conference, Washington. ', NULL),
(34, 'imgnews24.png', 'http://www.bbc.co.uk/news/health-18924648', 'Drug-resistant HIV \'on increase\' in sub-Saharan Africa', 'BBC', 0, '2012-07-22', '<P>Drug-resistant HIV has been increasing in parts of sub-Saharan Africa over the last decade, according to experts writing in the Lancet</P>', NULL, NULL, '<p>Studies on 26,000 untreated HIV-positive people in developing countries were reviewed by the team.</p>\n\n<p>They said resistance could build up if people fail to stick to drug regimes, and because monitoring could be poor.</p>\n\n<p>A UK HIV organisation said resistance was a serious problem in Africa where alternative treatments were lacking.</p>\n\n<p>The researchers, from the World Health Organization (WHO) and University College London (UCL) found the most rapid increase in drug resistance occurred in East Africa, at 29% per year. In Southern Africa, it was 14% per year.</p>\n\n<p>There was no change in resistance over time in Latin America and in West and Central Africa.</p>\n\n<p><b>\'Early warning\'</b></p>\n\n<p>Writing in the Lancet, authors <b><i>Dr Silvia Bertagnolio from the WHO and Dr Ravindra Gupta at UCL</b></i> said: <b><i>\"Without continued and increased national and international efforts, rising HIV drug resistance could jeopardise a decade-long trend of decreasing HIV/Aids-related illness and death in low- and middle-income countries.\"</b></i></p>\n\n<p><b><i>\"We do expect to see drug resistance, and it\'s at around 10% in the UK and US. But here, we monitor people regularly and switch people to different drugs if they develop resistance.\"</b></i></p>\n\n<p>He said that quite basic measures could help people to better adhere to drug regimes in developing countries, such as access to food and clean water so they can take their drugs, and monitoring patients as effectively as possible.</p>\n\n<p>The researchers said no changes were needed to the drug regimes, but Dr Gupta said: <b><i>\"This work gives us an early-warning that things could get worse.\"</b></i></p>\n\n<p>Deborah Jack, chief executive of the UK\'s National Aids Trust (NAT), said: \"In the UK we are fortunate that drug resistance is not a serious problem, and if a person has drug resistance there are other combinations of anti-retroviral therapy that we can use to address this.</p>\n\n<p><b><i>\"Sadly in sub-Saharan Africa fewer treatment options are available. If drug resistance occurs there doesn\'t tend to be an alternative therapy.</b></i></p>\n\n<p><b><i>\"We need further research into the causes of this drug resistance in Africa, and urgent action to support people daily access to their medication.\"</b></i></p>\n<p>END OF NEWS</p>\n<p>SATuRN collaborates with the authors of the study and it is attending a meeting in at the WHO Geneva in October to discuss with the authors guidelines for HIV drug resistance.</p>', 'drug, resistance, HIV, on the rise, southern Africa, WHO, HIV, bbc, news, drug, resistance, HIV, on the rise, southern Africa, WHO, drug, resistance, HIV, on the rise, southern Africa, WHO, ', 'Drug-resistant HIV \'on increase\' in sub-Saharan Africa. WHO and UCL report on the Lancet, BBC news.', NULL),
(45, 'imgnews45.jpg', 'http://www.research-europe.com/magazine/HEALTHCARE2/EX2/index.html', 'Dissecting diagnostics - TB drug resistance in rural South Africa', 'International Innovation', 0, '2012-09-20', '<p>Researchers based in northern KwaZulu-Natal in rural South Africa are exploring the impact of novel molecular tuberculosis diagnostic system on clinical outcomes for patients with multidrug-resistance TB.</p>', NULL, NULL, '<p>Tuberculosis (TB) is an infectious disease caused by strains of mycobacteria, usually <i>Mycobacterium tuberculosis</i> (MTB). Typically, TB attacks the lungs and is spread through the air via droplets as a result of coughing and sneezing. Treatment requires the administration of antibiotics over a long period of time, although antibiotic resistance is a growing problem which has led to multidrug-resistance TB infections?</p>\n<p>In rural areas of developing countries, TB has been a major public health problem for decades and deficiencies in diagnostics have been critical, contributing to the failure of TB control. The dual burdens of TB and HIV also place enormous strain on already fragile health systems. One such region is the Hlabisa sub-district in northern KwaZulu-Natal in South Africa, where a research project is now underway aiming to explore whether positioning a TB diagnostic test at a peripheral level of the rural health system will lead to beneficial outcomes.</p>\n<p><img src=\"imagesBIO/imgnews45magazine.jpg\"></p>\n<p>Through collaboration with the Southern African Treatment and Resistance Network (SATURN), Lessells is also involved in education and training of physicians, nurses, pharmacists and other healthcare workers on issues of TB and HIV drug resistance in southern Africa, both through training workshops and through the provision of educational material. SATuRN uses a case-base learning approach: <b><i>\'Physicians and nurses in the area see a huge number of TB and HIV cases and we fund that, by using informative cases, they can very easily recognize the clinical scenarios and remember similar cases from their own experience\' </b></i>, Lessells reflects. <b><i> \'It also means that they are able to put what they have learnt into practice straight away.\' </b></i></p>\n\n<p>Full text of the three pages article (page 62 to 64) can be downloaded from the link below.</p>', 'international innovation, TB, saturn, diagnostic, drug resistance, SATuRN, KwaZulu-Natal, South Africa, Southern African Treatment Resistance Network, Richard Lessells', 'In rural areas of developing countries, TB has been a major public health problem for decades and deficiencies in diagnostics have been critical, contributing to the failure of TB control. The dual burdens of TB and HIV also place enormous strain on already fragile health systems. One such region is the Hlabisa sub-district in northern KwaZulu-Natal in South Africa, where a research project is now underway aiming to explore whether positioning a TB diagnostic test at a peripheral level of the rural health system will lead to beneficial outcomes', NULL),
(46, 'imgnews26.gif', 'http://www.doh.gov.za/docs/newsletters/2012/Newsletter_Research_Brief_173.pdf', 'Tainted Milk from Surrogate Feeder', 'SA DoH research brief', 58, '2012-08-25', '<p>A baby girl who contracted HIV after being breast-fed by a well-meaning aunt has become the first proven case in South Africa to have contracted HIV from a surrogate feeder or \'wet nurse\'. The case contained in new research highlights the importance of HIV testing of mothers and surrogate feeders at a time when the government is phasing out free infant formula in its clinics.</p>', NULL, NULL, '<p>The research study entitled <a href=\"http://www.bioafrica.net/publications.php?pubid=58\">\'The Tainted Milk of Human Kindness\'</a>, conducted by researchers from the University of the Free State, University of KwaZulu-Natal and the National Health Laboratory Services has been published in respected medical journal <b><i>\'The Lancet\' </b></i>, used the baby girl as a case study.</p>\n\r<p>Research findings shown that HIV-positive women can breast-feed, but their babies need to be given antiretroviral treatment and breast-feeding needs to be done exclusively for six months.</p>', 'south africa, national department of health, NDoH, DoH, research, brieft, hiv, surrogate, transmission, goverment, phasing out, free, infant formula, clinics', 'The case contained in new research highlights the importance of HIV testing of mothers and surrogate feeders at a time when the South African government is phasing out free infant formula in its clinics. ', NULL),
(47, 'imgTBcentre.jpg', 'http://tb.lshtm.ac.uk/events/tb-centre-annual-retreat', 'SATuRN activities at the London School of Hygiene and Tropical Medicine TB Centre', 'LSHTM tbcentre', 0, '2012-10-01', '<p>SATuRN activities were highlighted at the LSHTM TB Centre Annual Retreat, which was held in Downing College, Cambridge.</p>', NULL, NULL, '<p>The objectives of the inaugural annual retreat for TB Centre members were: </p>\n<p></p>\n<p>(a) to provide a space for meeting and interaction, and for sharing of scientific ideas and perspectives, with a view to exploring future collaboration opportunities, and </p>\n<p></p>\n<p>(b) to provide an opportunity for participants to contribute to shaping the long?term strategy of the TB centre, with a focus on working out what the TB Centre should be, should do and should look like going forward. </p>\n<p></p>\n<p>The retreat programme was developed during the preceding months with the help of an informal working group of Jackie Cliff, Alison Grant and Richard White. Presentation slides (PDF format):</p>\n<p><img src=\"imagesBIO/SATURNTBcentre.jpg\"></p>', 'London scool hygeane and tropical medicine, TB, centre, LSHTM, SATURN, drug resistance, africa, TB, HIV', '<p>Souhtern African Treatment Resistance Network (SATuRN) activities are highlighted at the London School of Hygiene and Tropical Medicine (LSHTM) TB Centre Annual Retreat was held in Downing College, Cambridge.</p>', NULL),
(36, 'imgnews36.png', 'http://www.latimes.com/health/boostershots/la-heb-hiv-drug-resistance-aids-meeting-20120725,0,6960407.story', 'HIV drug resistance is spreading in Africa, experts say', 'Los Angeles Times', 70, '2012-07-23', '<p>WASHINGTON (By Erin Loury, LA Times) - Scaling up the distribution of HIV medication over the last decade has vastly increased the number of people receiving treatment around the world.  An estimated 8 million infected people received the antiretroviral drugs in 2011, compared to just 400,000 in 2003.</p> \n', NULL, NULL, '<p>But with this massive roll-out comes an inevitable and potentially dangerous consequence: The AIDS virus can more easily develop resistance to these life-saving drugs.</p>\n<p></p>\n<p>The first study to assess the global trend in HIV drug resistance in low- and middle-income countries concluded that it has been rising in parts of sub-Saharan Africa since the antiretrovirals became widely available.</p>\n<p></p>\n<p>Researchers examined data from dozens of studies on HIV drug resistance that included more than 26,000 patients in 42 countries. They focused their attention on people with HIV who were older than 15 and had never received treatment. If these people already had some resistance to the drugs, it would be a sure sign that more dangerous versions of the virus were spreading from person to person.</p>\n<p></p>\n<p>The research team reported the highest increases in drug resistance in East Africa, where it has climbed 29% every year since widespread roll-out of medication. In southern Africa, drug resistance increased at an annual rate of 14%.</p>\n<p></p>\n<p>Among the the HIV-positive people surveyed, 7.4% in East Africa had drug resistance, as did 3% in southern Africa. The results were published Sunday by the medical journal Lancet.</p>\n<p></p>\n<p>A major problem was growing resistance to a class of drugs called non-nucleoside reverse transcriptase inhibitors, which are the most common first-line antiretroviral drugs used to treat HIV in Africa. This class of drugs is also used to prevent virus transmission from mother to child.</p>\n<p></p>\n<p>The researchers did not observe significant changes in drug resistance in Latin America or the Caribbean. In Asia, the results varied too greatly among countries to assess an overall trend for the region.</p>\n<p></p>\n<p>The study authors said the rates of increase were expected, but they warned that the situation requires careful monitoring to make sure the problem doesn\'t escalate.</p>\n<p></p>\n<p><b><i>\'The good news is that it\'s still modest, contained, and not alarming,\'</b></i> <b><i>said Dr. Silvia Bertagnolio of the World Health Organization</b></i>, who presented a related study this week at the International AIDS Conference in Washington. <b><i>\'But we have to be vigilant\'</b></i> to make sure the rates don\'t keep going up, she added.</p>\n<p></p>\n<p>HIV becomes drug-resistant through random mutations that occur when the virus copies its genetic material. Antiretroviral medications prevent HIV from replicating, but if a person doesn\'t take these pills daily, drug resistance can arise.</p>\n<p></p>\n<p>Taking pills every day for life is a challenging order, and many people may lapse without proper support or access to clinics. Patchy supplies of drugs in developing countries can also interrupt treatment. And the new push to start treatment earlier to help prevent the transmission of HIV increases the odds that someone will develop drug resistance over his or her lifetime.</p>\n<p></p>\n<p>HIV may develop resistance to one type of medication but not others. Catching resistance early and switching a patient\'s medication attacks HIV from a different angle. This type of surveillance is essential to keep drug resistance from running rampant, Bertagnolio said.</p>\n<p></p>\n<p>However, drug resistance monitoring is not available in many poorer parts of the word.  And once people develop resistance to the standard first-line drugs, they must switch to more potent second-line medications that are in short supply in many developing countries. Continued spread of drug resistance could jeopardize efforts to curtail the AIDS epidemic in the developing world.</p>\n<p></p>\n<p>Bertagnolio said the WHO report reveals that many clinics lose contact with up to one-third of the people who start antiretroviral treatment. Following up with all patients is a key to ensuring they take their medication without fail.</p>\n<p></p>\n<p>In light of these results, <b><i>\'the greatest challenge is to reduce the frequency of treatment failure and cases of drug resistance\', Dr. Douglas Richman, director of the Center for AIDS Research at UC San Diego</b></i>, wrote in a commentary also published in Lancet. <b><i>\'Weak drug supply chains and drug stock-outs jeopardize the treatment of even highly adherent patients.\'</b></i></p>\n<p></p>\n<p>Richman pointed out that health officials in the United States in Europe also faced the risk of increasing HIV drug resistance as treatment became more widespread, but doctors and patients have filled in the gaps to keep resistance from rising.</p>\n<p></p>\n<p>In a related study presented at the AIDS conference, researchers from South Africa found that about 20% of patients treated in 17 rural clinics there were failing their first-line drug treatment. Members of the team analyzed samples of HIV collected from 240 of the patients and found that 87% had some kind of mutation for drug resistance.</p>\n<p></p>\n<p>At least 1.8 million people in South Africa currently receive treatment, <b><i>said Justen Manasa, a doctoral student in virology at the University of KwaZulu-Natal</b></i> who presented the study results on Tuesday. <b><i>\'The rapid scale-up of antiretroviral therapy in South Africa has put enormous strain on health systems,\'</b></i> he said.</p>\n<p></p>\n<p>Manasa said these rates of drug resistance are not unique to South Africa - Botswana and Zimbabwe show similar trends.</p>', 'hiv, drug, resistance, increase, africa, hlabisa, rural, south africa, justen manasa, la times, news', 'HIV drug resistance is spreading in Africa, experts say. by By Erin Loury, Washington during the AIDS 2012 international conference.', NULL),
(37, 'imgGenomeWeb.jpg', 'http://www.genomeweb.com/mdx/life-tech-saturn-collaborate-dx-antiretroviral-resistance-hiv-africa', 'Life Tech, SATuRN Collaborate on Dx for Antiretroviral Resistance in HIV in Africa', 'GenomeWeb', 0, '2012-07-26', '<p>NEW YORK (GenomeWeb News) - Life Technologies today announced a collaboration with the Southern African Treatment and Resistance Network (SATuRN) covering sequencing-based diagnostics for HIV patients in Africa.</p>', NULL, NULL, '<p>The partners have developed a sample-to-answer solution for antiretroviral (ARV) drug resistance to HIV therapies based on Life Tech\'s Applied Biosystems\' line of Sanger sequencers, which are broadly installed in African hospitals and HIV testing centers. The tests developed by Life Tech and SATuRN are being made available to African partners at <b><i>\"a highly economic cost per test.\" </b></i></p>\n<p></p>\n<p>While ARV drugs are increasingly available in the developing world, resistance to these therapies develops in many HIV-infected individuals. By sequencing two viral genes, resistance can be monitored, but the cost of the technology makes routine use prohibitive in most parts of Africa, Life Tech said.</p>\n<p></p>\n<p>The methods developed by Life Tech and SATuRN <b><i>\"have the potential to become the most accurate and cost-effective method\"</b></i> for diagnosing resistance pathogens in Africa as the price of DNA/RNA genotyping continues to fall. Also, software applications to be used and which will be further developed are open source and available in Africa.</p>\n<p></p>\n<p><b><i>\"We have trained 1,315 physicians and medical personnel on the interpretation of HIV drug resistance in southern Africa,\" Tulio de Oliveira, director of SATuRN and senior researcher at Wellcome Trust-Africa Centre</b></i>, said in a statement. <b><i>\"The region has more than 2 million patients on ARV treatment, and we believe that now is the time for the use of genotyping technology to fight the battle against drug resistance\"</b></i>.</p>\n<p></p>\n<p><b><i>\"This partnership with Life will allow more laboratories to use genotyping techniques and large surveys on drug resistance to be produced to inform national department of health and policy makers in the region\"</b></i>, he said.</p>\n<p></p>', 'Life Technologies, Life, SATuRN, collaborate, increase, acces, HIV, drug, resistance, genotype, genomeweb, Africa, south africa, southern african treatment resistance network', 'Life Technologies today announced a collaboration with the Southern African Treatment and Resistance Network (SATuRN) covering sequencing-based diagnostics for HIV patients in Africa', NULL),
(38, 'sabcnews.png', 'http://www.sabc.co.za/news/a/e8d75a004c5f2c20b951bde0eede81ca/Breastfeeding-in-the-spotlight-20121608', 'Breastfeeding in the spotlight', 'SABC', 58, '2012-08-16', '<p>A  case where an aunt infected her niece with HIV through breastfeeding has drawn attention to feeding practices in South Africa. The case was published in the medical journal Lancet and highlighted the risk of HIV transmission from a surrogate carer, the Africa Centre for Health and Population Studies said today.</p>', NULL, NULL, '<p>A mother in Bloemfontein presented to the hospital a 74-day-old infant infected with HIV, while she had a negative status. It was initially suspected to be a hospital transmission.</p>\n\n<p>However, when social workers intervened, the mother confirmed that her sister had breastfed the baby intermittently from six weeks of age. Doctors and social workers found that the aunt and her five-month-old child were HIV-positive. </p>\n\n<p>The case supported the scenario of surrogate transmission between the aunt and her niece, the organisation said. \"This case highlights the need for safe and appropriate infant feeding practices in Africa, including HIV testing of all breastfeeding surrogates and mothers,\" it said.</p>\n\n<p>The organisation said transmission of the HIV virus to infants was important in South Africa because of government\'s decision to halt the provision of formula feeds at public health facilities.  It said the policy was backed by the expanded use of antiretroviral (ARV) drugs and a recent decrease of mother-to-child  HIV transmission in the country.</p>\n\n\n<p>\"In that case, we used similar DNA analysis techniques to support the scenario of nosocomial (hospital-acquired) based HIV transmission.\"</p>\nSouth Africa had one of the highest rates of HIV/Aids infection and one of the lowest exclusive breastfeeding rates in the word, where fewer than 10% of infants were exclusively breastfeed. \"The aunt breastfed the infant out of great kindness so the mother could go back to work. However, this ended up as a tragedy,\"  said Tulio de Oliveira, a senior researcher at the centre. </p>\n\n<p>De Oliveira said he got involved because his previous work on the DNA analysis of HIV in a hospital infection case in Libya. In the Libyan case, 418 infants were infected in Al-Fateh hospital, he said.</p>\n\n<p> \"In that case, we used similar DNA analysis techniques to support the scenario of nosocomial (hospital-acquired) based HIV transmission.\"</p>\n   \n<p>He said the case had also been used to prove the innocence of medical personnel, who were accused of deliberately infecting children with HIV. \"In the current case... we could clearly show that the virus infecting the aunt, cousin and infant was linked.</p>\n\n <p>\"This and other evidence ruled out the nosocomial transmission scenario,\" said De Oliveira. He said the South African case highlighted the potential role of  surrogate breastfeeding in the transmission of HIV.</p>\n \n <p>\"South Africa will have to work hard to ensure that public health  facilities can identify the HIV status of all mothers and surrogate  feeders, and make sure that the HIV-exposed infant starts ARVs as soon as possible,\" he said.</p>\n   \n<p>The Africa Centre for Health and Population Studies is based at the University of KwaZulu-Natal. </p>', 'breastfeed, breastfeeding, surrogate, hiv transmission, sabc, south africa, feeding practices, Africa Centre for Health and Population Studies, de oliveira, lancet', 'A  case where an aunt infected her niece with HIV through breastfeeding has drawn attention to feeding practices in South Africa. The case was published in the medical journal Lancet and highlighted the risk of HIV transmission from a surrogate carer, the Africa Centre for Health and Population Studies said today.', NULL),
(39, 'wellcomeNews.png', 'http://www.wellcome.ac.uk/News/2012/News/WTVM056159.htm', 'DNA sequencing confirms HIV transmission through surrogate breastfeeding', 'Wellcome Trust', 58, '2012-08-23', '<p>DNA sequencing has provided evidence of HIV-1 transmission from an infected woman breastfeeding her niece in South Africa, drawing attention to infant feeding practices and the need for HIV testing of all breastfeeding surrogates as well as mothers. </p>', NULL, NULL, '<p>The case, published in the <b><i>\'Lancet\'</b></i>, describes a ten-week-old girl who was taken to hospital by her HIV-negative mother. Once the daughter was diagnosed, HIV transmission was initially thought to have taken place in hospital; however, the mother confirmed that her sister had been breastfeeding the baby intermittently over the past four weeks. The sister and her own five-month-old child were subsequently found to be HIV positive.</p>\n\n<p>DNA sequencing of virus samples from the girl, the aunt and the cousin confirmed that the girl had indeed been infected through the surrogate breastfeeding of her aunt.</p>\n\n<p>Dr Tulio de Oliveira from the Africa Centre for Health and Population Studies in South Africa, senior author of the case study, said: <b><i>\'This was a devastating case for a family in South Africa. The aunt breastfed the infant out of great kindness so the mother could go back to work. However, this ended up as a tragedy. \'</b></i></p>\n\n<p>The World Health Organization supports six months of exclusive breastfeeding for all infants, including HIV-exposed infants, who should receive antiretroviral therapy to prevent mother-to-child transmission.</p>\n\n<p>The study highlights the need to identify the HIV status of surrogate breastfeeders as well as mothers, in order to ensure that HIV-exposed infants have access to antiretroviral therapy as early as possible to minimise the risk of transmission. </p>\n\n<p><b><i>Reference</b></i></p>\n<p><a href=\"http://www.bioafrica.net/publications.php?pubid=58\">Goedhals D, Rossouw I, Hallbauer U, Mamabolo M, de Oliveira T. <b>The tainted milk of human kindness Lancet,380:702 (2012).</b></a></p>', 'DNA sequencing, DNA analysis, evidence, HIV-1, transmission, breastfeeding, niece, South Africa, surrogate, wellcome trust, lancet, tulio de oliveira, the tainted milk of human kindness, phylogeny', 'DNA sequencing has provided evidence of HIV-1 transmission from an infected woman breastfeeding her niece in South Africa, paper published in the Lancet 2012, by Dominique Goedhals, Tulio de Oliveira, news at the wellcome trust', NULL),
(40, 'capenews.png', 'http://www.iol.co.za/news/south-africa/western-cape/tainted-milk-from-wet-nurse-hiv-risk-1.1369793', '\'Tainted milk\' from wet nurse HIV risk', 'Cape Argus', 58, '2012-08-26', '<p>By BIANCA CAPAZORIO - A BABY girl who contracted HIV after being breast-fed by a well-meaning aunt has become the first proven case in SA to have contracted HIV from a surrogate feeder or <b><i>\'wet nurse\'</b></i>.</p>', NULL, NULL, '<p>MAKING CHOICES: A woman involved in a KZN study by the Africa Centre for Health and Population Studies into infant feeding choices breast-feeds her baby. A new study released by the centre has discovered the country\'s first proven case of HIV transmission through a surrogate feeder in Bloemfontein.</p>\n<p>The case, contained in new research released last week, highlights the importance of HIV testing of mothers and surrogate feeders at a time when the government is phasing out free infant formula in its clinics.</p>\n<p>The Bloemfontein baby, born to an HIV-negative mother, was admitted to hospital with pneumonia in 2009. Research entitled <a href=\"http://www.bioafrica.net/publications.php?pubid=58\">\'The Tainted Milk of Human Kindness\'</a>, conducted by researchers from the University of the Free State, University of KwaZulu-Natal and the National Health Laboratory Services, published in respected medical journal The Lancet last week, uses the baby girl as a case study. It casts light on the issue of wet nursing in HIV transmission, which has received little attention in SA.</p>\n<p>Senior researcher Dr Tulio de Oliveira of the Africa Centre for Health and Population Studies at UKZN said the findings were important because the government was halting the provision of free formula in its clinics.</p>\n<p>Research has shown that HIV-positive women can breast-feed, but their babies need to be given antiretroviral treatment, and breast-feeding needs to be done exclusively for six months.</p>\n<p>In April 2009, the 10-weekold baby was admitted to the paediatric intensive care unit of a Bloemfontein hospital.</p>\n<p>She was weak, lethargic, coughing and breathing at a rate of 75 breaths aminute.</p>\n<p>Her mother was HIV-tested during pregnancy, and another test confirmed her negative status.</p>\n<p>At first, in-hospital infection was suspected, but it later emerged that the baby?s aunt had been breast-feeding her intermittently after the mother returned to work. DNA sequencing supported this scenario. The baby also had a high CD4 count which indicated a recent infection.</p>\n<p>De Oliveira said lab records indicated the aunt had tested positive for HIV in 2008. Her baby was also HIV positive. <b><i>\'It cannot be confirmed whether the aunt was counselled regarding this result, but she claimed that she was not aware of her HIV status,\'</b></i> he said. <b><i>\'This was a devastating case for a family in South Africa. I cannot imagine the pain suffered by them. The aunt breast-fed the baby out of great kindness so the mother could go back to work.\'</b></i></p>\n<p>The researchers say that information on the practice of breast-feeding by a surrogate in SA is <b><i>\'scarce\'</b></i>. A small study conducted in the Free State by the Human Sciences Research Council found that 1.7 percent of children surveyed had been breast-fed by a woman other than their mother. HIV-positive babies were 17 times more likely to have been breast-fed by someone not their mother than HIV-negative ones. The HSRC study states that in instances where the mother is HIV negative, with an infected baby, breast-feeding by a nonbiological caregiver was the <b><i>\'single most important risk factor\'</b></i>.</p>\n<p>In a UKZN study, focus groups were asked to discuss the acceptability of donated breast milk. Participants said wet nursing was no longer practised or no longer <b><i>\'right\'</b></i> because of associated risks.</p>\n<p>A study into infant feeding in Nigeria found that it was rarely practised, but when it was, it was done by relatives, neighbours or <b><i>\'co-wives\'</b></i> in polygamous relationships.</p>\n<p>The health department discourages wet nursing. Where used, the woman must agree to an HIV test before commencing, and another after six to eight weeks.</p>\n<p>Capazorio is a 2012 International Women\'s Media Foundation HIV/Aids Investigative Journalism Fellow.</p>\n<p>Open access manuscript: <a href=\"http://www.bioafrica.net/publications.php?pubid=58\">Goedhals D, Rossouw I, Hallbauer U, Mamabolo M, de Oliveira T. <b>The tainted milk of human kindness Lancet,380:702 (2012).</b></a></p>', 'HIV, breast-fed, aunt, first proven, case, south africa, contracted, HIV, surrogate, feeder, wet nurse', 'By BIANCA CAPAZORIO - A BABY girl who contracted HIV after being breast-fed by a well-meaning aunt has become the first proven case in SA to have contracted HIV from a surrogate feeder or wet nurse.', NULL),
(41, 'imgnews41.jpg', 'http://www.zululandobserver.co.za/Pages/f34story8.html', 'Local centre proves \'surrogate\' HIV infection', 'Zululand Observer', 58, '2012-08-24', '<p>The Africa Centre for Health and Population Studies, Zululand\'s HIV-AIDS research hub based near Mtubatuba, has revealed the first proven HIV surrogate transmission case in South Africa.</p> ', NULL, NULL, '<p>This breakthrough research using DNA sequencing was published in respected UK medical journal The Lancet last week. In November 2009 a woman brought her 74 day-old infant to a Bloemfontein hospital and discovered the child was infected with HIV, in spite of her own negative status. According to the report it was initially suspected that the transmission was nosocomial, meaning that it had occurred in hospital.</p>\n\n<p>However, when social workers interviewed the mother they discovered that the mother?s sister had breastfed the baby intermittently from six weeks of age. The sister and her five month-old child were subsequently found to be HIV positive. DNA sequencing confirmed the sister had unknowingly infected her sister?s child. <b><i>\' This was a devastating case for a family in South Africa,\'</b></i> said senior researcher Tulio de Oliveira, <b><i>\' The aunt breastfed the infant out of great kindness so the mother could go back to work. <b><i>\' However, this ended up in tragedy,\'</b></i> he said.</p>\n<p>De Oliveira explained that the use of DNA analysis enabled Africa Centre to prove the virus infecting the aunt, cousin and infant were linked and simultaneously prove the innocence of medical personnel who had cared for the baby when it was born. Formula removal concerns <b><i>\' This case highlights the need for safe and appropriate infant feeding practices in Africa, including HIV testing of all breastfeeding surrogates and mothers. South Africa has one of the highest HIV/AIDS epidemics and one of the lowest exclusive breastfeeding rates in the world, where fewer than 10% of infants are exclusively breastfeed. However, even in the light of the AIDS epidemic, evidence has shown that mixed breast and formula feeding and exclusive formula feeding has a higher impact on infant?s mortality and morbidity\'</b></i>.</p>\n<p>\'</b></i> Research at Africa Centre has shown that the mixing of breast and formula feeding of infants by HIV-positive mothers has been shown to increase a baby\'s risk of contracting HIV from breast milk as artificial formulas strip the child?s intestines of natural defences to subsequent infection. Formula feeding also potentially exposes infants to contaminated water used to mix the formula, resulting in diarrhea and other conditions. Health authorities are now encouraging exclusive breastfeeding, even for children of HIV-positive mothers, for up to six months. <b><i>\' However, HIV-exposed infants must receive antiretrovirals to prevent mother-tochild transmission,\'</b></i> said De Oliveira.  In order to increase the rate of exclusive breastfeeding, the Health Ministry of SA recently announced that formula feeding should be removed from all public health facilities in the country.</p>\n<p><b><i>\'This policy is backed by the expanded use of antiretroviral drugs and a recent decrease of mother to child HIV transmission in the country.  However, South Africa will have to work hard to ensure that public health facilities can identify the HIV status of all mothers and surrogate feeders and make sure that the HIV-exposed infant starts ARVs as soon as possible, as otherwise this new decision and policy could backfire\'</b></i></p>\n<p>Open access manuscript: <a href=\"http://www.bioafrica.net/publications.php?pubid=58\">Goedhals D, Rossouw I, Hallbauer U, Mamabolo M, de Oliveira T. <b>The tainted milk of human kindness Lancet,380:702 (2012).</b></a></p>', 'The Africa Centre for Health and Population Studies, Zululand, HIV-AIDS, research, hub, Mtubatuba, first, proven, HIV, surrogate, transmission, case, South Africa.', 'The Africa Centre for Health and Population Studies, Zululand\'s HIV-AIDS research hub based near Mtubatuba, has revealed the first proven HIV surrogate transmission case in South Africa.', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(42, 'imgreuters.jpg', 'http://www.google.com/url?sa=t&rct=j&q=reuters%20life%20technologies%20corporation%20and%20southern%20african%20treatment%20and%20resistance%20network', 'Life Technologies Corporation And Southern African Treatment and Resistance Network Collaborate To Increase Access To HIV Testing In Africa', 'Reuters', 0, '2012-07-24', '<p>Life Technologies Corporation announced a collaboration with the Southern African Treatment and Resistance Network (SATuRN) on sequencing-based diagnostics for HIV-infected individuals in Africa.  </p>\n', NULL, NULL, '<p>Antiretroviral (ARV) drugs are becoming increasingly available in the developing world, due to facilitation by both governmental and non-governmental organizations, as well as reductions in price and international trade restrictions by pharmaceutical companies. </p>\n\n<p>Resistance to these drugs develops in many HIV-infected individuals, however, and resistance is therefore coming to the forefront of the global health agenda. Resistance can be monitored by genetic sequencing of two viral genes, but current costs have made routine use prohibitive in most African countries. </p>\n\n<p>Life Technologies has developed together with SATuRN a simple-to-answer solution for ARV resistance testing, which is being made available to African partners at an economic cost per test. The test can be run on Life\'s Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers. Additional collaborators on the test development include the Stanford HIV Drug Resistance Database.</p>\n\n<p>Life Technologies has developed together with SATuRN a simple-to-answer solution for ARV resistance testing, which is being made available to African partners at an economic cost per test. The test can be run on Life\'s Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers. Additional collaborators on the test development include the Stanford HIV Drug Resistance Database.</p>\n', 'Life Technologies, Corporation, announced, collaboration, Southern African Treatment and Resistance Network, SATuRN,  DNA,  sequencing-based, diagnostics. HIV-infected. individuals. Africa', 'Life Technologies Corporation announced a collaboration with the Southern African Treatment and Resistance Network (SATuRN) on sequencing-based diagnostics for HIV-infected individuals in Africa.', NULL),
(44, 'imgnews44.jpg', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_3_2012A4.pdf', 'SATuRN Newsletter, Sept 2012, News, blogs, conferences, publications on HIV/TB drug resistance and phylogenetics', 'SATuRN', 0, '2012-09-14', 'In this third issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.', NULL, NULL, '<p><a href=\"manuscripts/SATuRNnewsletter_3_2012A4.pdf\"><img src=\"imagesBIO/imgnews43newsletter.gif\"></a></p>\n<p>The concept behind this newsletter is that anyone with  15 minutes to spare can learn about the work of SATuRN. The newsletter is presented as a PDF document with links to complete articles at the bioafrica.net website. </p>\n\n<p>In this second issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.</p>\n\n<p><b>Highlights:</b></p>\n\n<p><a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\">Upcoming event: 7th Southern African HIV & TB Drug Resistance & Clinical Management Workshop, CTICC, 28-29 November 2012</a></p>\n\n<p><a href=\"http://www.bioafrica.net/blogs.php?id=15\">Blog: Capturing Health in one Photo: a personal reflection</a></p>\n\n<p><a href=\"http://www.bioafrica.net/blogs.php?id=17\">Blog: Zooming in on home-based health care givers in rural South Africa</a></p>\n\n<p><a href=\"http://www.bioafrica.net/publications.php?pubid=57\">Report: SATuRN features on the WHO HIV drug resistance report 2012</a></p>\n\n<p><a href=\"http://www.bioafrica.net/publications.php?pubid=58\">Publication: The tainted milk of human kindness, Lancet, 2012</a></p>\n\n<p><a href=\"http://www.sahivsoc2012.co.za/\">Upcoming event: SA HIV Clinicians Society Conference, CTICC, 25-28 November 2012</a></p>', 'saturn, newsletter, 3, conference, blogs, tweets, de oliveira T, southern African treatment resistance network, home-base, health care, work, HIV, TB conference', 'The concept behind this newsletter is that anyone with  15 minutes to spare can learn about the work of SATuRN. Upcoming event: 7th Southern African HIV & TB Drug Resistance & Clinical Management Workshop, CTICC, 28-29 November 2012. Blog: Capturing Health in one Photo: a personal reflection. Blog: Zooming in on home-based health care givers in rural South Africa.', NULL),
(43, 'imgWSJ.jpg', 'http://www.marketwatch.com/story/life-technologies-and-saturn-collaborate-to-increase-access-to-hiv-testing-in-africa-2012-07-24', 'Life Technologies and SATuRN Collaborate to Increase Access to HIV Testing in Africa', 'The Wall Street Journal', 0, '2012-07-24', '<p>Life and Southern African Treatment and Resistance Network (SATuRN) Partner in Sequencing-Based Surveillance of Drug Resistance</p>', NULL, 1, '<p>CARLSBAD, Calif., July 24, 2012 /PRNewswire via COMTEX/ -- Life Technologies Corporation LIFE -1.24% today announced a collaboration with the Southern African Treatment and Resistance Network (SATuRN - http://www.bioafrica.net/saturn ) on sequencing-based diagnostics for HIV-infected individuals in Africa.</p>\n\n<p>Antiretroviral (ARV) drugs are becoming increasingly available in the developing world, due to facilitation by both governmental and non-governmental organizations, as well as reductions in price and international trade restrictions by pharmaceutical companies. Resistance to these drugs develops in many HIV-infected individuals, however, and resistance is therefore coming to the forefront of the global health agenda. Resistance can be monitored by genetic sequencing of two viral genes, but current costs have made routine use prohibitive in most African countries.</p>\n\n<p>Life Technologies has developed together with SATuRN a simple-to-answer solution for ARV resistance testing, which is being made available to African partners at a highly economic cost per test. The test can be run on Life\'s Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers.</p>\n\n<p>The methods developed as part of this collaboration have the potential to become the most accurate and cost-effective method for the diagnosis of resistance pathogens in Africa and the referral of patients for appropriate care. The reasons for this are that the price of DNA/RNA genotyping is rapidly decreasing as technology is evolving at great speed, and the software applications to be used and further developed are all open source and available in Africa (Dr. Tulio de Oliveira on behalf of SATuRN - Public HIV Drug Resistances Databases in Africa, published in the journal NATURE 2010).</p>\n\n<p><b><i>\'Drug resistance testing is an essential cornerstone of clinical practice in the developed world,</b></i>\' said Ronnie Andrews, president of medical sciences at Life Technologies. <b><i>\'We are proud to partner with SATuRN to make resistance testing possible for a broad base of HIV-infected patients in Africa.</b></i>\'</p>\n\n<p><b><i>\'We have trained 1,315 physicians and medical personnel on the interpretation of HIV drug resistance in southern Africa. The region has more than 2 million patients on ARV treatment, and we believe that now is the time for the use genotyping technology to fight the battle against drug resistance,</b></i>\' said Dr. Tulio de Oliveira, director of SATuRN and senior researcher at Wellcome Trust-Africa Centre. <b><i>\'This partnership with LIFE will allow more laboratories to use genotyping techniques, and large surveys on drug resistance to be produced to inform national department of health and policy makers in the region.</b></i>\'</p>\n\n<p>Additional collaborators on the test development include the Stanford HIV Drug Resistance Database.</p>\n', 'Life, Southern African Treatment and Resistance Network, SATuRN, Partner, Sequencing-Based, Surveillance, Drug, Resistance, the wall street journal, WST', 'Life and Southern African Treatment and Resistance Network (SATuRN) Partner in Sequencing-Based Surveillance of Drug Resistance, the Wall street journal market watch', NULL),
(48, 'imgnews31.gif', 'http://www.k-rith.org/official-opening/', 'HIV and TB bioinformatics presentation and tweet coverage at K-RITH opening, 9-11 October 2012', 'SATuRN', NULL, '2012-10-04', 'SATuRN is presenting a talk at the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH) opening. This symposium has a fantastic scientific program, with some of the leading researchers and funders in the world! Please follow our tweeter coverage!</p>', NULL, NULL, '<p><center><img src=\"imagesBIO/krithopenning.jpg\"></center></p>\n<p>K-RITH will celebrate its official Opening Ceremony on Tuesday October 9, 2012. The ceremony will take place in the new K-RITH Building on the site of the Nelson R. Mandela School of Medicine in Durban, South Africa.</p>\n<p>Malegapuru William Makgoba, MBCHB DPhil, Vice Chancellor of the University of KwaZulu-Natal and Robert Tjian, PhD, President of the Howard Hughes Medical Institute, will both be present to inaugurate the new building.</p>\n<p></p>\n<p>Scientific Symposium</p>\n<p>Following the Opening Ceremony, there will be a Scientific Symposium with the theme \"The Intersection of Technology and Global Health.\" The 2-day symposium will be held from October 10-11, 2012 at the Hilton Hotel, Walnut Road, Durban, and will feature distinguished scientists from South Africa and the United States. </p>\n<p></p>\n<p>Confirmed symposium speakers include:</p>\n<p>Dr. Robert Tjian, President, Howard Hughes Medical Institute, USA</p>\n<p>Dr. Anthony Fauci, Director, National Institutes of Allergy and Infectious Diseases, USA</p>\n<p>Dr. David Baltimore, Robert Andrews Millikan Professor of Biology, California Institute of Technology, USA</p>\n<p>Ronald J. Daniels, President, Johns Hopkins University, USA</p>\n<p>Dr. Peter Agre, Director, Johns Hopkins Malaria Institute, USA</p>\n<p>Dr. Sean Brady, HHMI Early Career Scientist, The Rockefeller University, USA</p>\n<p>Mark Dean, Chief Technology Officer, IBM Middle East and Africa</p>\n<p>Gary Cohen, Chair, IBM Africa</p>\n<p>Prof. Salim Abdool Karim, Director, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa</p>\n<p>Prof. Bongani M. Mayosi, Head of Department of Medicine, University of Cape Town, South Africa</p>\n<p>Dr. Thomas Kodadek, Professor of Chemistry and Cancer Biology, The Scripps Research Institute, USA</p>\n<p>Prof. Thumbi Ndung\'u, HHMI International Early Career Scientist and Director, HIV Pathogenesis Programme, South Africa</p>\n<p>Dr. Tulio de Oliveira, senior researcher and bioinformatics leader at the Wellcome Trust-Africa Centre for Health and Population Studies, South Africa</p>\n<p></p>\n<p>Please follow our tweeter coverage of this great event! The Hash tag for the opening is: <b>#krithopening</b></p>', 'K-RITH, opening, SATuRN, bioinformatics, symposium, hiv, tb, kwaZulu-Natal, Howard Hughes, institute, Wellcome Trust, Tulio de Oliveira', 'Southern African Treatment Resistance Network (SATuRN) presentation on HIV/TB bioinformatics & Tweet coverage of the KwaZulu-Natal Research Institute for Tuberculosis and HIV opening scientific symposium (K-RITH) opening, 9-11 October 2012', NULL),
(49, 'imgUnion.png', 'https://twitter.com/drug_resistance', 'SATuRN at the 43rd Union World Conference on Lung Health', 'TB Union', 0, '2012-11-20', '<p>KUALA LUMPUR, MALAYSIA, 14-17 Nov 2012, SATuRN researchers Dr. Richard Lessells and Dr. Tulio de Oliveira had a very successful TB conference. In this post we cover their presentations, workshops participation and tweeter coverage.\r', NULL, NULL, '<p> Dr. Lessells delivered two oral posters presentation, which covered the Wellcome Trust trail of GenExpert in rural KwaZulu-Natal. In addition, they both attended a very interesting pre conference post-graduate workshop on diagnostics implementation, an official work dinner with the TB centre from the London School of Hygiene and Tropical Medicine and a couple of invited discussion meetings with the TB alliance and TB-KNVC. </p>\r<p><center><b>Tweeter coverage - used the official conference tag #Kuala2012</b></center></p>\n<p><center><b><i>17 November 2012</b></i></center></p>\n<p>Very interesting presentations on the usage of GIS to map drug resistance and laboratory quality in Uganda! #kuala2012</p>\n<p>South Africa on target to reach 2.5m on #HIV treatment by 2014 http://bit.ly/UtKPc9 </p>\n<p>Fear of high pill burden for HIV & TB dual treatment is one of the main reasons for not starting dual therapy in Mozambique. #Kuala2012</p>\n<p>Jurgens Peters: policies on integrated HIV-TB services in pregnancy are not implemented properly in Northern Cape #SA #kuala2012</p>\n<p>Sheila Tlou: a well-trained and motivated workforce is critical to addressing the HIV and TB epidemics #kuala2012</p>\n<p>Sheila Tlou: community support keeps people on antiretroviral therapy #kuala2012 #adherence</p>\n<p>UN Political declaration 2011 - Halve #TB deaths among amount people living with HIV. SATuRN say halve drug resistance! #Kuala2012</p>\n<p>Prof. S Tlou, Botswana, show compiling evidence that ARVs decrease by five-fold #TB incidence on HIV+ patients. #kuala2012</p>\n<p>Very good to see molecular diagnostics to be used for #TB treatment management! Many interesting new platforms arising #Kuala2012</p>\n<p>\"Every day I cry for an hour; injections leave me unable to walk\" - MDR TB patient on treatment in India, quoted by MSF #kuala2012 #tbposse</p>\n<p>Great presentation by Wendy Stevens on the scalability of #TB GeneXpert in South Africa, the top country on use of GeneXpert #kuala2012</p>\n<p>Nice to see photo of Eduan and Kat from Africa Centre in @HEARD_UKZN photos http://fb.me/2xfg4ITkd </p>\n<p>Great photos! RT @HEARD_UKZN: I posted 17 photos on Facebook in the album \"Showcasing KZN Research on HIV and AIDS\" http://fb.me/2xfg4ITkd </p>\n<p>MSF Uganda: yield of microscopy & culture similar from string test compared to induced sputum in patients unable to expectorate #kuala2012</p>\n\n<p><center><b><i>16 November 2012</b></i></center></p>\n<p>Rein Houben @LSHTM_TB: surprisingly little genetic variation between linked cases but uncertainty over time since transmission complicates</p>\n<p>Rein Houben of @LSHTM_TB: lots still to learn about how whole genome sequencing can help us understand TB transmission #kuala2012</p>\n<p>Rein Houben of @LSHTM_TB presenting on using whole genome sequencing to understand transmission in Malawi #kuala2012</p>\n<p>Guy Marks: need relevant skills and tools to diagnose and manage lung diseases at primary health care clinics #pointofcare #kuala2012</p>\n<p>Guy Marks: addressing social determinants is critical for reducing global burden of lung diseases #kuala2012 #globalburdendisease</p>\n<p>Excellent RESIST-TB annual preliminary results meeting tomorrow they will present their published results! Exciting developments #Kuala2012</p>\n<p>Guy Marks: Disability Adjusted Life Years (DALYs) should be used as a common currency when comparing difference disease burdens #Kuala2012</p>\n<p>@iambaikong Add to this: less than 3-10% people with #MDRTB get access to services,90-97% receive NO care #lungweek #tuberculosis #kuala2012</p>\n<p>\'Cure rate for MDRTB using the current drugs is only 50%. The other half dies\' - Dr. Balasegaram #Kuala2012 #Lungweek #TB</p>\n<p>Christian Lienhardt - New TB drugs on the horizon ? 4 repurposed drugs, 6 new drugs and 3 new classes ? http://www.newtbdrugs.org  #Kuala2012</p>\n<p>Q3: Is possible to use TB individualized drug resistance treatment without drug resistance testing??? #Kuala2012</p>\n<p><center><b><i>15 November 2012</b></i></center></p>\n<p>TBAlliance proposes new \'rescue\' study in XDR-/TDR-TB to learn new regimens, interesting new trials - http://www.tballiance.org/  #Kuala2012</p>\n<p>TB alliance Trial Signals Major Milestone in Hunt for New TB Drug Resistance Drugs - Lancet paper - http://www.tballiance.org/newscenter/view-brief.php?id=1046 ? #kuala2012</p>\n<p>Nice quote from AD. Harris \'what\'s written doesn\'t disappear...\' > talking bout why the emphasis on papers. #Kuala2012 #Lungweek #TB</p>\n<p>Bob Horsburgh RESIST-TB : Top 10 questions to turn the tide on MDR-TB\" - http://www.resisttb.org/  #Kuala2012</p>\n<p>#TB: Old drugs, new purpose: Retooling Existing drugs for Optimized Treatment of Resistance TB - open access http://www.resisttb.org/  #Kuala2012</p>\n<p>SATuRN is attending the annual RESIST-TB meeting #Kuala2012, interesting DR-TB trials results for new #TB MDR effective regimens</p>\n<p>Results of Global Burden of Disease study to be released 12/14 at @RoyalSociety in London http://www.healthmetricsandevaluation.org/news-events/event/rapid-health-transitions-findings-and-implications-global-burden-disease-2010-stud ? #globalhealth #research</p>\n<p>Amir Khan: TB Reach project in Karachi and Dhaka - about 20% GXP positivity and 7% RIF resistance overall #kuala2012</p>\n<p>Harry Hausler in KZN GXP and decentralised MDR-TB management means more than 50% start MDR treatment within 5 days. Great stuff! #kuala2012</p>\n<p>Harry Hausler: implementing Genexpert in rural KwaZulu-Natal. Low yield especially from mobile HCT sites and household screening #kuala2012</p>\n<p>Training and laboratory capacity building in Rwanda to face HIV TB drug resistance, a success history by Dr. Nyaruhirira. #Kuala2012</p>\n<p>Jane Carter: TB Reach project in Kenya - Xpert and culture can add to case finding but also need to improve systems/processes #kuala2012</p>\n<p>Good morning. Today we will be covering #TB diagnostics, molecular epidemiology, drug resistance & lab science. Please follow... #Kuala2012</p>\n<p><center><b><i>14 November 2012</b></i></center></p>\n<p>Finally congratulations to Dr Karen Weyer - winner of the Karel Styblo Public Health prize #kuala2012 #southafrica</p>\n<p>Congratulations to Dick Menzies - winner of the Union Scientific Prize #kuala2012</p>\n<p>Congratulations to David Dowdy - winner of the Union Young Investigator Prize #kuala2012</p>\n<p>Congratulations to Dr Marcos Espinal - winner of the Princess Chichibu global TB memorial award #kuala2012</p>\n<p>Time has finally run out ? #TB cases increasingly resistant to all drugs, study warns http://www.guardian.co.uk/world/2012/aug/30/tb-cases-increasingly-resistant-drugs ? #Kuala2012</p>\n<p>Global increase of drug resistance #TB is a time bomb getting ready to explode. Prof. Lee B. Reichman, #Kuala2012 #LungWeek</p>\n<p>@SpeakTB Two researchers from Southern African Treatment Resistance Network (SATuRN) are tweeting at @unionconference, please follow us!</p>\n<p>Question 2: Which is worse: TB under-treatment or TB over-treatment? Send your answer #kuala2012</p>\n<p>Question 1: Treat more vs. treat better? Will widespread TB treatment increase TB drug resistance in resource limited settings? #kuala2012</p>\n<p>@tomayates Thanks for sending a response to our questions. Social factors & safe environment play a role on treatment success #kuala2012</p>\n<p>2 new drugs to treat #TB are expected to come to market in 2013 & both active against #DRTB http://ow.ly/fgY3R  #Kuala2012 #Lungweek</p>\n<p>David Dowdy - More active #TB more transmission! We need to identify and decrease active TB in order to decrease transmission #kuala2012</p>\n<p>#TB drug resistance increases substantially the cost of treatment programs! It can cost half of a whole national budget! #kuala2012</p>\n<p>Great practical session with David Dowdy demystifying cost-effectiveness analysis for diagnostics #kuala2012</p>\n<p>@bobbyramakant Dear CNS, just posted the questions again, please help to us to get those discussed by the community. Thanks @drug_resistance</p>\n<p>Q2: Which is worse: #TB under-treatment or #TB over-treatment? How much worse? Send your answer #kuala2012</p>\n<p>Q1: Treat more vs treat better? Will widespread TB treatment increase TB-MRD in resource limiting settings? Send your answer #kuala2012</p>\n<p>For those of you who havnt seen it yet. Check out a preview of \'They Go to Die\' @TheyGoToDieFilm http://youtu.be/-A-chpwhVmU  via @youtube</p>\n<p>Answer 2 from diagnostic workshop: TB Under-treatment is worse (36/40), 10x worse. However depends on many factors? Do you agree?#kuala2012</p>\n<p>Which is worse: #TB under-treatment or over-treatment? How much worse? Send your answer #kuala2012 #LungWeek</p>\n<p>Treat more vs treat better? Will more widespread TB treatment spread TB-MRD in resource limiting settings? Send your answer #kuala2012</p>\n<p>GenXpert research map site http://xrmt.treattb.org  26 research projects listed, please register your #TBMDR diagnostic project! #kuala2012</p>\n<p>Academia & governments need to work together in a quick manner so patients can advance from new TB molecular diagnostics #kuala2012</p>\n<p>Diagnostic workshop - Clear algorithms for dealing with #TBMDR suspects are not there, in spite of national surveillance systems #kuala2012</p>\n<p>Patient #TB LPA question? What is our advantage? How much will cost me? #kuala2012</p>\n<p>Policy makers #TB LPA question? What is the cost effectiveness of scaling up LPA testing as compared to other technologies? #kuala2012</p>\n<p>Clinician #TB LPA question? Does it reduce the time to appropriate TB-MDR treatment? #kuala2012 #LungWeek</p>\n<p>Laboratory #TB LPA question? What is the infrastructure available for drug resistance testing? will be sustainable for scale-up? #kuala2012</p>\n<p>\"Bertie\" Squire diagnostic workshop - main questions from the patient, clinician, laboratory and policy makers follow #kuala2012 #LungWeek</p>\n<p>Bertie Squire, #LSTM presenting an interactive workshop on assessing new #TB diagnostics, thinking out of the box! #kuala2012 #LungWeek</p>\n<p>Proper evaluation of #TB diagnostics assays are needed but treatment is what make the difference! A. Ramsay, WHO, #kuala2012 #LungWeek</p>\n<p>Andy Ramsay WHO, GenXpert discounts do not apply to Indian\'s private labs that detect 60% of infections, serology is still used #kuala2012</p>\n<p>Andy Ramsay, WHO, great presentation on #TB diagnostics in India and the world. Serology vs molecular in the field #kuala2012 #LungWeek</p>\n<p>We started our tweeter coverage of the 43 Union Conference #kuala2012 #lungweek please follow us and retweet our coverage!</p>\n', 'Kuala Lumpur, 2012, TB conference, SATURN, LSHTM, de Oliveira, Lessells, SATuRN, TB drug resistance, Tweeter coverage, twitter, Kuala Lumpur, 2012, TB conference, SATURN, LSHTM, de Oliveira, Lessells, SATuRN, TB drug resistance, Tweeter coverage, twitter, Kuala Lumpur, 2012, TB conference, SATURN, LSHTM, de Oliveira, Lessells, SATuRN, TB drug resistance, Tweeter coverage, twitter', 'KUALA LUMPUR, MALAYSIA, 14-17 Nov 2012, SATuRN researchers Dr. Richard Lessells and Dr. Tulio de Oliveira had a very successful TB conference. In this post we cover their presentations, workshops participation and tweeter coverage.', NULL),
(50, 'imgheard.png', 'http://www.heard.org.za/downloads/heard-event-2012.pdf', 'SATuRN/Africa Centre, CAPRISA and HEARD/UKZN: An event showcasing KZN research on HIV and AIDS', 'HEARD', 0, '2012-11-14', '<p>DURBAN, SOUTH AFRICA, 14 Nov 2012.  We have organized and presented an event at the KZN National Art Gallery that portrait our DNA sequencing and Art & Science work.</p>', NULL, NULL, NULL, NULL, 'During July 2012, the acclaimed researcher, Dr Tulio de Oliveira from the Southern African Treatment Research Network (SATuRN), was invited to CAPRISA to visit CAPRISA\'s eThekwini Clinical Research Site. He also presented latest developments on affordable HIV and TB drug resistance testing and open access, public, drug resistance databases to CAPRISA\'s management team, followed by discussions on possible opportunities for collaboration.', NULL),
(51, 'imgheard2.png', 'http://www.ukzn.ac.za/news/2012/11/29/ukzn-research-centres-collaborate-to-celebrate-world-aids-day', 'UKZN Research Centres Collaborate to Celebrate World AIDS Day', 'UKZN', 62, '2012-11-29', '<p>The Health Economics and HIV and AIDS Research Division (HEARD) in collaboration with CAPRISA, SATuRN/Africa Centre and the University of KwaZulu-Natal Press hosted Getting to Zero: Showcasing KZN Research on HIV and AIDS on 14 November at the KZNSA Gallery.</p>', NULL, NULL, '<p>The event brought together over 150 people from research, educational and government institutions working in the field of HIV and AIDS to discuss latest research developments and scientific trends in prevention and treatment ahead of World AIDS Day.</p>\n<p>The event was spearheaded by HEARD which invited partners in the field, the Centre for the AIDS Programme of Research in SA (CAPRISA), the Africa Centre/SATuRN and UKZN Press to participate in showcasing latest HIV related research and materials.</p>\n<p>The theme for the event was: Getting to Zero: Zero New Infections, Discrimination and AIDS-related Deaths, and one of the highlights was the screening of HEARD\'s  documentary titled: Manguzi: Raising Children in Rural South Africa, which had its premier recently at the International AIDS Conference in Washington DC.</p>\n<p>The documentary provided the audience with a personal account of the challenges faced by caregivers of children in HIV- endemic communities in South Africa. The documentary follows the world\'s first large-scale quantitative study of the impacts of familial HIV and AIDS on children. The life expectancy for the Manguzi area is 43 years.</p>\n<p>According to the documentary, 5,6 million people in South Africa live with HIV which is the largest number in the world; 1,9 million South African children have lost one or both parents to AIDS, and 74% of households care for orphaned children.</p>\n<p>The documentary also showcased the challenges infected people face in being accepted in the community.</p>\n<p>Representatives from CAPRISA, HEARD and the Africa Centre presented work of the organisations and their current research findings.</p>\n<p>CAPRISA\'s Head of Community Programme, <b><i>Ms Janet Frohlich, told the audience about their microbicide research, including the vaginal microbicide study undertaken in 2010 - the CAPRISA 004 Tenofovir Gel Trial</b></i>.</p>\n<p>The study showed that microbicides could provide women with some protection from HIV infection. CAPRISA continues to undertake research for a safe and effective microbicide that could have a profound impact on the dynamics of HIV transmission.</p>\n<p><b><i>Dr Katharine Stott</b></i>, HIV Programme Physician at the SATuRN/Africa Centre, <b><i>said there was a provable reduction in infections but there was still a problem with HIV and TB drug resistance</b></i>.</p>\n<p>UKZN Press\'s <b><i>Ms Debra Prim spoke about the publisher\'s range of books on HIV/AIDS. The books were showcased and on sale at the event</b></i>,</p>\n<p>HEARD\'s Research Director, <b><i>Dr Kay Govender, highlighted HEARD\'s core research areas the Division was involved in. He told the audience about the Young Carers Project - a multi-agency collaboration between HEARD, the Universities of Cape Town and Witwatersrand, the University of Oxford and the South African government</b></i>. The project aims to inform policy and programming in order to improve the health and wellbeing of children and their families in South Africa.</p>\n<p>Executive Director of HEARD, Professor Alan Whiteside, thanked the audience, the HEARD team and the participating organisations for making the project happen and for its success.</p>\n', 'africa centre, SATuRN, DNA, analysis, sequencing, HIV, art & science, Katharine Stott, Physician, art gallery, exhibition, Durban 2012, UKZN, HEARD, CAPRISA,africa centre, SATuRN, DNA, analysis, sequencing, HIV, art & science, Katharine Stott, Physician, art gallery, exhibition, Durban 2012, UKZN, HEARD, CAPRISA,africa centre, SATuRN, DNA, analysis, sequencing, HIV, art & science, Katharine Stott, Physician, art gallery, exhibition, Durban 2012, UKZN, HEARD, CAPRISA', 'The Health Economics and HIV and AIDS Research Division (HEARD) in collaboration with CAPRISA, Africa Centre and the University of KwaZulu-Natal Press hosted Getting to Zero: Showcasing KZN Research on HIV and AIDS on 14 November at the KZNSA Gallery.', NULL),
(52, 'imgMIT.png', 'http://www.technologyreview.com/featuredstory/508576/the-machine-that-will-help-end-tb/', 'The Machine That Will Help End TB', 'MIT Technology review', 0, '2012-12-11', '<p>By Jon Cohen on December 11, 2012 - Nearly 1.5 million people die from tuberculosis every year, even though most cases can be cured with routine antibiotic treatments. One country\'s fight to get the ancient scourge under control has an unlikely hero: a simple diagnostic test.</p>', NULL, NULL, '<p><img src=\"imagesBIO/feature.tbx588.jpg\"><b><i>Figure 1 - TB bacteria in a GeneXpert cartridge (blue, foreground) can be detected in under two hours. Sputum samples (purple and green caps) take weeks to culture.</b></i></p>\n<p>KwaMsane Township sits amid rolling hills in South Africa\'s KwaZulu-Natal Province. Drive 30 minutes to the west and elephants, giraffes, zebras, and rhinos often stroll by the side of a highway that cuts through a game park. A few kilometers to the east lie sprawling sugarcane fields, which shimmer in the subtropical sun and appear to spill into the Indian Ocean. KwaMsane is beautiful, but it has one of the world\'s highest rates of multidrug-resistant (MDR) tuberculosis, an often fatal form of the disease.</p>\n<p>In November 2011, Jabu Ngcobo, 25, felt a pain in her side and went to the KwaMsane clinic, which resembles a trailer park. The clinic\'s trailers \'called parkhomes here\' surround a small covered courtyard that serves as a waiting room, with patients sitting in plastic chairs. \'I was all along thinking I had MDR TB because my two brothers and my sister had it,\' says Ngcobo.</p>\n<p>Her siblings learned they had the dangerous form of the disease only after giving sputum samples, which had to be transported to a laboratory in Durban, 275 kilometers to the south. The lab then had to nurture cultures of Mycobacterium tuberculosis until the colonies were large enough to be subjected to drug susceptibility tests. At best, the process takes six weeks; in reality, given the need to transport the samples, the likelihood of lab backlogs, and delays in reporting the results, three months often pass before patients in rural towns like KwaMsane learn whether they will benefit from a relatively simple, six-month course of antibiotics or instead need an 18-month barrage of heavy-duty drugs. The delay can mean the difference between permanent lung damage, or even death, and recovering with no long-term consequences.</p>\n<p>Ngcobo indeed had the drug-resistant form of TB ?and she began treatment the next day. Richard Lessells, a Scottish physician who treated her and her family members at KwaMsane clinic, notes that for Ngcobo\'s siblings, the months that passed without proper treatment came at a steep cost: one of her brothers suffered lung damage that will never heal. Jabu, in contrast, had no detectable levels of the bacteria a month after diagnosis, because she immediately started taking 22 pills a day as well as injections of anti-TB drugs.</p>\n<p>Ngcobo\'s speedy diagnosis and recovery were made possible by a machine called a GeneXpert, which sits atop a counter inside one of the trailers and resembles a high-end espresso maker. Although the advanced molecular tricks it uses to identify the DNA of M. tuberculosis would have been unimaginable outside a state-of-the-art biology lab a few years ago, the device is simple to use. A technician squirts a sputum sample from a patient into what looks like a printer cartridge and then clicks that into the machine, which performs a reaction that amplifies specific bits of M. tuberculosis DNA if they are present. Fluorescent molecules light up when they come in contact with the targeted DNA, and the machine detects the fluorescence, sending the information to a computer. The entire process takes a mere two hours. Not only can GeneXpert detect the presence of the TB-causing bacteria, but it can accurately determine whether the bacterial DNA has the mutations known to make the disease resistant to the most commonly used drug.</p>\n<p>Tuberculosis, which routinely spreads through the air, infects one-third of the human population. For almost all of those people it\'s harmless, and most don\'t even know they have been infected. And for much of the world, it is a disease mainly of historical significance. But in many poor countries, particularly in much of central and southern Africa, it remains at epidemic proportions. In 2011, an estimated 8.7 million people became sick from M. tuberculosis. Roughly 1.4 million people die of TB each year; HIV is the only infectious agent that kills more.</p>\n<p><img src=\"imagesBIO/feature.tb3_.jpg\"></p><p><b><i>Figure 2 - Durban TB doctor Iqbal Master welcomes the GeneXpert but says it creates many challenges.</b></i></p>\n<p>One critical reason this epidemic continues is that there\'s no effective and affordable way to tell who is infected. TB goes undiagnosed in some three million people each year. Some simply are never tested. Others, because of antiquated diagnostic technologies, are wrongly given a clean bill of health. Traditional diagnosis for TB relies on staining a sputum sample with dyes and then examining a slide under a microscope to look for the bacteria. This \'smear\' test, developed 125 years ago, detects fewer than 60 percent of all cases and doesn\'t identify drug resistant strains. The more precise culture test to determine sensitivity to certain drugs takes longer, costs more, and needs to be done in a well-equipped lab so it is used sparingly. That means roughly 80 percent of the drug-resistant cases in the world go undetected, according to the World Health Organization. Together, these undiagnosed individuals represent a vast reservoir for the bacteria, including drug-resistant strains. Infection flourishes and leapfrogs through communities, devastating the most vulnerable people, such as those already weakened by HIV.</p>\n<p>A practical, quick, and powerful diagnostic tool could change that deadly dynamic. Brought to market by a public-private partnership between the University of Medicine and Dentistry of New Jersey, the Foundation for Innovative New Diagnostics in Geneva, Switzerland, and Cepheid, a manufacturer based in Sunnyvale, California, the GeneXpert TB detection machine gained approval from the WHO in December 2010. A few months later, South Africa\'s health minister, Aaron Motsoaledi, compared the machines to \'bazookas\' in the war against TB and pledged to place them in each of the country\'s 52 districts.</p>\n<p>The GeneXpert machine alone will not be enough to break the back of the massive TB problem in South Africa or anywhere else. That would probably take a powerful vaccine combined with much more potent drugs than now exist. But meanwhile, for countries walloped by TB, including increasing numbers of cases resistant to increasing numbers of drugs, such a diagnostic tool is a crucial and necessary first step. Deploying it widely throughout a country like South Africa, where much of the population lacks access to advanced medical care, will be a logistical and financial challenge. But failing to do so could be deadly. To understand the stakes, it is worth considering the outbreak a few years ago of a nightmare TB strain just a few hundred kilometers from KwaMsane Township.</p>\n<p><big><b>Dreams</b></big></p>\n<p>One of the most frightening aspects of TB is that humans have treated it with such indifference. All too often, patients start treatment, soon feel better, and then stop taking their pills or take them only sporadically. This creates a perfect opportunity for resistance to develop, because the bacteria with mutations that make them least susceptible to the drug will be likely to survive the incomplete treatment. Then there is the scariest scenario of all: inappropriately diagnosed or incompletely treated MDR TB can foster \'extensively\' drug-resistant (XDR) mutants that dodge two of the main classes of TB drugs. An outbreak of just such a strain was reported for the first time in 2006. And it took place in KwaZulu-Natal.</p>\n<p>Tugela Ferry, about a four-hour drive from KwaMsane Township, is a small town in the central part of the province. In August 2006, headlines around the world described the startling news that 52 of 53 TB patients who had checked into the Church of Scotland Hospital there had died on average, within 16 days of admission. Tests later revealed that they had XDR strains. The outbreak forced South Africa to look long and hard at the public-health failures that had allowed these dangerous strains to evolve and spread. Front and center was the lack of appropriate diagnostic tools. Given that even under ideal circumstances it would take more than a month to diagnose drug-resistant TB, the patients had no chance: all died before they ever learned they had a deadly form of the disease.</p>\n<p><img src=\"imagesBIO/feature.tb5_.jpg\"></p><p><b><i>Figure 3 - Technician Gregory Mkhize shows off the largest GeneXpert machine in Africa, at Prince Mshiyeni Memorial Hospital. It can process 48 samples at once.</b></i></p>\n<p>In the wake of Tugela Ferry, the government designated wards at King George V Hospital, a 75-year-old TB facility in Durban, solely for drug-resistant cases. The goal was both to improve treatment outcomes and to slow the spread of the disease. The hospital has seven wards with 32 beds each, including one devoted exclusively to children. There\'s a waiting list to get in, although Iqbal Master, the doctor who manages the program, is proud that all sick patients, and those with XDR TB, are now admitted within a few weeks of being referred; in January 2007, delays ran to four months. \'We had patients dying while on a waiting list,\' he says.</p>\n<p>Patients like Nomthandzau Elizabeth Mjwara, a 48-year-old woman who has HIV and MDR TB, are grateful to secure one of the 224 beds. \'It\'s like I\'m staying at my home,\' says Mjwara, who has lived in the hospital since April. After she fell seriously ill, four months passed before she sought care, gave a sputum sample, received her TB diagnosis, and was admitted to King George V to begin treatment. Many HIV-infected patients arrive at the hospital at such an advanced stage of AIDS that even the proper TB treatment is too little, too late. Fortunately, despite the diagnostic delays, Mjwara still had enough of an immune system left to respond to the drugs.</p>\n<p>Despite the upbeat attitude of patients like Mjwara and the first-rate care they receive, many at King George V suffer from advanced cases of TB, and many leave in coffins. The ones who survive, like Mjwara, have to endure several months of painful daily injections that can cause hearing loss and psychosis. Coughs punctuate the wards day and night, and to discourage airborne infection, windows stay open even when the temperature drops.</p>\n<p><big><b><i>Almost everything positive that\'s said about tuberculosis is followed by a \'but.\'</b></big></i></p>\n<p>Most of the doctors and nurses who work the ward wear face masks. Master pointedly does not, in part because the patients with hearing loss rely heavily on reading lips. He has a sympathetic and wistful smile, accented by a wise man\'s bushy salt-and-pepper beard. \'The beard protects me from TB,\' Master jokes.</p>\n<p>If GeneXpert is used effectively in South Africa, it will ultimately ease pressures on hospitals like King George V, slowing the spread of resistant cases by speeding their detection and starting people on the proper treatment earlier. However, almost everything positive that\'s said about TB is followed by a \'but,\' and Master is quick to stress the limitations of the technology. One is technical. Culture tests remain more accurate than GeneXpert. What\'s more, testing of cultures remains the only way to accurately diagnose XDR TB. Finally, the aggressive drive to start using GeneXpert countrywide is taxing the health-care system. While identifying those with the active disease will provide a long-term public-health benefit, it will increase the immediate number of patients seeking medical care. Master cites studies suggesting that GeneXpert will increase the patient load by up to 500 percent in the short term. \'They haven\'t sorted out the logistics of what\'s the ideal way to roll out GeneXpert,\' he says. \'It\'s going to take time.\'</p>\n<p>On a brisk September morning, Master stops by Mjwara\'s bed and admires one of her many craft projects, a desktop pencil holder she fashioned from empty toilet paper rolls and tongue depressors. \'So that\'s where my tongue depressors went!\' he teases. Her sweatshirt has a word stitched across it: \'Dreams.\'</p>\n<p><big><b>Waiting for a Vaccine</big></b></p>\n<p>Although many parts of South Africa are wealthy, Durban\'s Prince Mshiyeni Memorial Hospital is a reminder that much of the country is still extremely poor and lacks modern medical facilities. The 1,200-bed hospital has guards at its entrance, narrow halls filled with sickly patients, and crowds of people constantly moving down the corridors. Durban doctors who do not work there often roll their eyes at the mention of its name, and recent news stories recount problems with a shortage of staff, long lines at the dispensary, security lapses (including a missing dead body), and an outbreak of bacterial infection that killed five babies. But on the grounds of this sprawling hospital is the largest GeneXpert machine in Africa. Unveiled by Health Minister Motsoaledi on World TB Day in March 2011, the mammoth machine is two meters tall and 2.5 meters long. It can process 48 cartridges at a time; they move through the contraption by means of conveyor belts and a robotic arm.</p>\n<p>A few years ago Motsoaledi helped lead a successful countrywide campaign to test 15 million people for HIV and administer retroviral drugs to everyone with a severely damaged immune system. Now he\'s optimistic that GeneXpert, which he vowed would be in every public facility in South Africa that needed one by the end of 2012, will \'revolutionize\' the control of tuberculosis. \'When we launched the campaign [to test for HIV] in 2010, there was no GeneXpert, so the TB screening was done with five questions,\' Motsoaledi says. \'Just asking five questions and deciding on the basis of your answers?\' he asks incredulously. \'Now in most of the testing stations we make sure that GeneXpert is there.\'</p>\n<p><big><b><i>The costs of the diagnostic machines are dwarfed by the expense of providing months of hospital care for TB patients.</big></b></i></p>\n<p>But merely having the machines isn\'t enough. On one weekday in September, the 48-cartridge machine at Prince Mshiyeni Memorial Hospital was running only one sample. That\'s because the rapid scale-up of advanced TB testing has stressed the system to the buckling point. Only one supplier provides cartridges, and there already have been shortages, leading to a \'huge backlog of unprocessed specimens,\' says Stephen Carpenter, clinical manager of the Don McKenzie Hospital in Botha Hills, outside Durban. GeneXpert had yet to reach his own hospital. \'We were promised that it would be rolled out all over the province and the district, but there have been all sorts of financial and logistical delays,\' he says.</p>\n<p><img src=\"imagesBIO/feature.tb6_.jpg\"></p><p><b><i>Figure 4 - Because GeneXpert doesn\'t require culturing TB, it reduces risks to lab workers.</b></i></p>\n<p>Indeed, deploying GeneXpert requires a significant investment by South Africa\'s government. A four cartridge machine with a desktop computer sells for $17,000, and cartridges go for $9.98. Analyses show that a GeneXpert test in South Africa, including staff time and machine maintenance, costs roughly $25 per sample, versus $3 for a sputum smear and $12 to $16 for a culture. The increased cost is offset to a degree by the fact that GeneXpert incorporates resistance testing traditional drug sensitivity testing for first-line treatments costs $72 per test but all told, a paper published by PLOS ONE found, South Africa will have to spend 55 percent more per suspected TB case if it fully scales up the use of the technology as planned.</p>\n<p>The flip side is that the country will receive serious bang for its rand, because the costs of the machine are dwarfed by the expense of providing months of hospital care for TB patients. \'The diagnosis costs are a very, very small fraction of the total TB control program, and there\'s substantial benefit,\' says Mark Nicol, a clinical microbiologist who has a joint appointment at the University of Cape Town and the government\'s National Health Laboratory Service. Nicol notes that poorer countries with high TB burdens will need outside help. \'But it\'s a price that South Africa certainly can afford,\' he says.</p>\n<p>He is not alone in considering the test worthwhile. \'GeneXpert has transformed the way we diagnose TB,\' says Nesri Padayatchi, who previously managed the TB wards at King George V and now works across town on TB and HIV at the Centre for the AIDS Programme of Research in South Africa. But here comes the inevitable \'but\': \'You can identify all these patients, but it\'s not addressing the central problem.\' TB clinicians like Padayatchi have long dreamed of better medicines to both prevent and treat the disease. A TB vaccine was actually introduced nearly a century ago and is widely used. But so much controversy surrounds its efficacy that the United States, for one, does not generally recommend it. \'It\'s a wonder vaccine you wonder whether it works,\' jokes Padayatchi. Eleven TB vaccines are currently in clinical trials, a reflection of the intense efforts over the past decade to rejuvenate the field, but none has yet warranted a full-scale efficacy study. The World Health Organization estimates that the earliest a vaccine could be licensed is 2020.</p>\n<p><img src=\"imagesBIO/feature.tb7_.jpg\"></p><p><b><i>Figure 5 - Jabu Ngcobo developed drug-resistant TB but was quickly diagnosed with GeneXpert and recovered fully.</b></i></p>\n<p>As for treatments, no new class of TB drugs has come to market in 40 years, though two are expected to finish human testing this year; each appears to work against resistant strains. Nine other compounds are at various stages of human studies. Still, the future of these drugs remains uncertain.</p>\n<p>International health agencies have agreed on a plan to reduce TB to less than one case per million people by 2050. That would be a drop from 8.7 million cases globally today to roughly 7,000. The partnership specifies that the key to success is an effective vaccine combined with treatments capable of defeating drug-susceptible M. tuberculosis within two months. There is no guarantee, of course, that either of those will be developed by 2050. But GeneXpert can at least move the world closer to the goal of nearly eliminating this disease.</p>\n', 'MIT, technology, review, richard Lessells, KwaMsane, KwaZulu-Natal, TB, drug resistance, resistant, MDR, XDR, pre-XDR, GeneXpert, Jabu Ngcobo, John Cohen, south africa, RIF, MIT, technology, review, richard Lessells, KwaMsane, KwaZulu-Natal, TB, drug resistance, resistant, MDR, XDR, pre-XDR, GeneXpert, Jabu Ngcobo, John Cohen, south africa, RIF, SATuRN, news, MIT, technology, review, richard Lessells, KwaMsane, KwaZulu-Natal, TB, drug resistance, resistant, MDR, XDR, pre-XDR, GeneXpert, Jabu Ngcobo, John Cohen, south africa, RIF', 'By Jon Cohen on December 11, 2012 - Nearly 1.5 million people die from tuberculosis every year, even though most cases can be cured with routine antibiotic treatments. One country\'s fight to get the ancient scourge under control has an unlikely hero: a simple diagnostic test. Interview with Dr. Richard Lessells from the Africa Centre and Wellcome Trust Fellow on his GeneXpert trial in KwaMsane, KZN, South Africa.', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(53, 'imgshare.png', 'http://www.hivsharespace.net/node/2672', 'The 2012 Southern African ARV drug resistance testing guidelines', 'Share', 61, '2013-01-13', '<p>Antiretroviral therapy (ART) has converted HIV infection from an almost universally fatal illness to a chronic manageable disease. Adherence to therapy is essential for full viral suppression and optimal immune reconstitution.</p>', NULL, NULL, '<p>If antiretroviral (ARV) drug levels are suboptimal, the risk of developing ARV drug resistance is high due to the high rate of HIV replication and the lack of proofreading capacity in the viral reverse transcriptase enzyme. Continuation of a failing ART regimen can affect both the treated individual and the community, as resistant viral strains can be transmitted to other persons.</p>\n<p>Resistance can be minimised by uninterrupted supply of medication, scientifically sound prescribing practices, long-term adherence support, viral load (VL) monitoring, and rapid responses to demonstrated virological failure with timeous changes of therapy. The Southern African HIV Clinicians Society developed consensus guidelines for HIV resistance testing that consider international best practice and the financial constraints encountered in southern Africa.</p> \n<p>The guidelines, presented here, are based on the levels of resistance in the community as reported in the 2012 World Health Organization (WHO) HIV drug resistance report. The North American and British resistance testing guidelines, although ideal, are not affordable nor applicable in most southern African situations. These guidelines are aimed at southern African clinicians who manage individuals with HIV infection in both the private and public sectors in our region.</p>\n', 'Antiretroviral, therapy, ART, HIV, infection,chronic,  manageable, disease, Adherence, therapy, viral, suppression, immune, reconstitution', 'Antiretroviral therapy (ART) has converted HIV infection from an almost universally fatal illness to a chronic manageable disease. Adherence to therapy is essential for full viral suppression and optimal immune reconstitution.', NULL),
(54, 'imgLabMed.png', 'http://www.labmedica.com/microbiology/articles/294741961/collaboration_to_undertake_hiv_resistance_testing_in_africa.html', 'Collaboration to Undertake HIV Resistance Testing in Africa', 'LabMedica', 1, '2012-08-06', '<p>Sequencing-based diagnostics for human immunodeficiency virus (HIV)-infected individuals will be carried out in Africa in order to determine resistance to antiretroviral drugs.</p>', NULL, NULL, '<p>Life Technologies Corp. (Carlsbad, CA, USA) is collaborating with the Southern African Treatment and Resistance Network (SATuRN) to develop a simple-to-answer solution for antiretroviral (ARV) drug resistance testing, which is being made available to African partners at a reasonable cost per test. The test can be run on Life\'s Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers.</p>\n\n<p>Antiretroviral (ARV) drugs for HIV treatment are becoming increasingly available in the developing world but resistance to these drugs develops in many HIV-infected individuals. Resistance can be monitored by genetic sequencing of two viral genes, but current costs have made routine use prohibitive in most African countries.</p>\n\n<p>The methods developed as part of this collaboration have the potential to become the most accurate and cost-effective methods for the diagnosis of resistance pathogens in Africa and the referral of patients for appropriate care. The price of DNA/RNA genotyping is rapidly decreasing as technology evolves rapidly, and the software applications to be used and further developed are all open source and available in Africa.</p>\n\n<p>Additional collaborators on the test development include the Stanford HIV Drug Resistance Database). </p>\n\n<p><b><i>\'We have trained 1,315 physicians and medical personnel on the interpretation of HIV drug resistance in southern Africa. The region has more than 2 million patients on ARV treatment, and we believe that now is the time for the use of genotyping technology to fight the battle against drug resistance,\'</b></i> said Dr. Tulio de Oliveira, director of SATuRN and senior researcher at Wellcome Trust-Africa Centre. <b><i>\'This partnership with LIFE will allow more laboratories to use genotyping techniques, and large surveys on drug resistance to be produced to inform national department of health and policy makers in the region.\'</b></i> </p>\n\n<p>SATuRN is a consortium of virologists, clinicians, epidemiologists, bioinformaticians, policy makers, public health specialists, and social scientists working on HIV treatment and care in southern Africa. SATuRN has developed an approach to virological failure clinical management that ensures the delivery of drug resistance genotyping and clinical management to remote clinics without them needing elaborate computer systems or infectious disease specialists on site. </p>\n\n<p>By applying telemedicine and off site laboratories, specialists and physicians from medical centers across the world can review cases, including clinical and resistance data, and give feedback and advice to the clinician managing the patient at the primary clinic. </p>\n\n<p>Life Technologies Corp. is a global biotechnology company. It has more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety, and animal health. </p>', 'labmedica, collaboration, hiv resistance, testing, Africa, SATuRN, Stanford, Life Technologies', 'Sequencing-based diagnostics for human immunodeficiency virus (HIV)-infected individuals will be carried out in Africa in order to determine resistance to antiretroviral drugs', NULL),
(55, 'imgACILT.png', 'http://www.cdc.gov/globalaids/resources/laboratory/lab-course-calendar.html', 'Practical Course on Quality Assurance of HIV-1 Drug Resistance Interpretation in Sequence Editing and Data Management Processes', 'ACILT', 0, '2013-01-16', '<p>The African Centre for Integrated Laboratory Training (ACILT) present the HIV-1 drug resistance practical course, 22-26 April, Johannesburg, South Africa. </p>', NULL, NULL, '<p><b><i>Learn how to:</b></i> </p>\n<p>- Determine the quality of sequencing data and understand the potential causes for poor data quality </p>\n<p>- Understand the importance of sequencing and editing quality in the interpretation of HIV drug resistance mutations </p>\n<p>-  Properly use software for drug resistance analysis </p>\n<p>-  Maintain continuous data quality through proper training and following SOPs </p>\n<p>-  Obtain quality assured HIV drug resistance data </p>\n<p>-  Implement quality control measures to ensure quality sequencing data  </p>\n\n<br><p><b><i>For more information:</b></i></p>\n<p><a href=\"workshops/HIVDRApplicationForm2013.pdf\">Download application form</a> and the <a href=\"workshops/HIVDRFlyer2013.pdf\">flyer of HIV Drug Resistance the workshop</a>. </p>\n<br>\n<p>Background information: The African Centre for Integrated Laboratory Training (ACILT) was established in 2008 on the Johannesburg campus of the South African National Institute for Communicable Diseases (NICD) and the National Health Laboratory Service (NHLS). The aim of this new centre is to build a new generation of laboratory experts, particularly in the fields of HIV, TB and malaria throughout Africa. </p>', 'acilt,  African Centre for Integrated Laboratory Training, HIV, drug resistance, training, johannesburg, CDC, PEPFAR< NICD, NHLS, sequencing, acilt,  African Centre for Integrated Laboratory Training, HIV, drug resistance, training, johannesburg, CDC, PEPFAR< NICD, NHLS, sequencing, acilt,  African Centre for Integrated Laboratory Training, HIV, drug resistance, training, johannesburg, CDC, PEPFAR< NICD, NHLS, sequencing', 'Practical Course on Quality Assurance of HIV-1 Drug Resistance Interpretation in Sequence Editing and Data Management Processes. The African Centre for Integrated Laboratory Training (ACILT) present the HIV-1 drug resistance practical course, 22-26 April, Johannesburg, South Africa. ', NULL),
(56, 'imgcomminit.png', 'http://www.comminit.com/content/scientific-community-engagement-activities-rural-kwazulu-natal-south-africa', 'Comminit News: Scientific Community Engagement Activities in Rural KwaZulu-Natal, South Africa', 'The Communication Initiative Network', 0, '2012-11-30', '<p>BioAfrica, Southern African Treatment and Resistance Network (SATuRN), and the Africa Centre Bioinformatics Unit use art to present scientific facts in Rural KwaZulu-Natal, South Africa. They are involved in many community engagement activities, presenting to African communities about the origin of HIV, the causes and consequences of drug resistance development, and how to successfully manage HIV and tuberculosis (TB) treatment.</p>', NULL, NULL, '<p>Communication Strategies: </p>\n<p>One focus of this initiative is on reaching out to children and youth with scientific information in a medium that will hopefully resonate. Their graphic presentation on antiretrovirals (ARVs) (see the presentation below) features cartoons that portray HIV as a lion (Ibhubesi, Zulu translation) and CD4 cells as soldiers (Amasosha, Zulu translation). Designed to educate children, the cartoons show how ARVs make the soldiers stronger as they provide them with armour. In 2010, organisers used this presentation 3 times in primary schools (children aged 6 to 10) in the Umkhanyakude district. In 2010 and 2011, a second series of 3 presentations was delivered to the Africa Centre Community Advisory Board (CAB), which has 75 participants from the local community and traditional authority. In this series of presentations, a physician (Dr. Richard Lessells) and a researcher (Dr. Tulio de Oliveira) explained the effect of detectable viral load on immune reconstitution and drug resistance development. <b><i>\'The presentations were very well received and the head of the CAB asked for a full day (6 hours section) on the topic, which was very well attended by members of CAB and the community and generated great discussions.\'</b></i></p>\n\n<p>At the end of 2010, Dr. Tulio de Oliveira presented at Grantleigh High school, in Empangeni. The idea was that academically talented students could be exposed to a scientific and cultural enrichment programme in order to inspire them as part of Africa Centre\'s goal of illuminating science to students. The graphical presentation explained that HIV originated from primates in West and West Central Africa and then infected humans, similar to TB from bovine in cows or buffalo, as experienced locally, in an attempt to dispel the myth that HIV was unique. This event was covered by the Zululand Observer newspaper.</p>\n<p>In December 2011, the Africa Centre bioinformatics unit and SATuRN helped 2 social workers fund and present a summer camp workshop to adolescents failing ARVs in the clinics served by Africa Centre. The camp was attended by 22 adolescents (12-17 years) and presented over 4 days and involved many activities and presentations. The sessions included, for example, self-reflecting exercises (where teenagers were required to do introspective exercises by looking in the mirror and expressing their feelings through group discussions) and an information session about ARVs, CD4, and HIV drug resistance presented in an approachable and fun style. Also included in the programme was an HIV activist, who had lived with HIV for more than 10 years, telling his story about his life with HIV. <a href=\"http://www.bioafrica.net/blogs.php?id=6\">A blog - Social Worker perspective: Adolescents on Antiretroviral (ARV) therapy - a VideoBlog</a> - has been published that details this experience.</p>', 'comminit, community, engagement, network, SATuRN, bioafrica, HIV, TB, rural, South Africa, news, science,Southern African Treatment Resistance Network, comminit, community, engagement, network, SATuRN, bioafrica, HIV, TB, rural, South Africa, news, science,comminit, community, engagement, network, SATuRN, bioafrica, HIV, TB, rural, South Africa, news, science', 'BioAfrica, Southern African Treatment and Resistance Network (SATuRN), and the Africa Centre Bioinformatics Unit use art to present scientific facts in Rural KwaZulu-Natal, South Africa. They are involved in many community engagement activities, presenting to African communities about the origin of HIV, the causes and consequences of drug resistance development, and how to successfully manage HIV and tuberculosis (TB) treatment', NULL),
(57, 'imgdocguide.png', 'http://www.pslgroup.com/dg/2645ba.htm', 'Drug Resistance After Failure of First-Line ART Increasing in Rural South Africa: Presented at AIDS 2012', 'Doctor\'s Guide Global Edition', 0, '2012-07-27', '<p>By Nancy A. Melville - WASHINGTON, DC - July 27, 2012 - As antiretroviral therapy (ART) for HIV becomes widely accessible in Southern Africa, the risk for drug resistances is on the rise, and as many as 1 in 6 adults show acquired drug resistance to standard second-line drug regimens, researchers said here on July 24 at the 19th International AIDS Conference.</p>', NULL, NULL, '<p>Justen Manasa, PhD, University of KwaZulu-Natal, Africa Centre for Health and Population Studies, Somkhele, South Africa, and colleagues evaluated data from the 17 clinics in the Hlabisa HIV Treatment and Care Programme.</p>\n<p>The data included clinical records as well as drug resistance genotyping performed using the in-house SATuRN/Life Technologies system. Sequences were analysed and genotypic susceptibility scores (GSS) were calculated using RegaDB and Stanford HIVDB 6.0.5 algorithms.</p>\n<p>Using the criteria of HIV-infected patients aged older than 16 years with virological failure (2 x viral load >1,000 copies/mL) on first-line non-nucleoside reverse transcriptase inhibitors (NNRTI)-based ART, the researchers identified 240 genotyped patients for analysis.</p>\n<p>Their median time on ART was 42 months, and the median time on a failing regimen was 27 months.</p>\n<p>The genotyping showed that as many as 208 of the 240 (87%) had at least 1 drug resistance mutation. Of the patients showing resistance, 199 (83%) had NNRTI resistance and 195 (81%) had NRTI resistance.</p>\n<p>Thymidine analogue mutations (TAMs) were detected in 88 (36.1%) patients, and 39 (16.3%) patients had > 3 TAMs. The K65R and Q151M mutations were found in 5% and 2% of patients, respectively.</p>\n<p>In total, 40 individuals (70%) had a significantly compromised standardised second-line regimen, defined as GSS scores of <2, according to the authors.</p>\n<p>A univariate analysis showed a history of NRTI substitution to be significantly associated with a GSS score <2 (odds ratio, 4.39; P <.001).</p>\n<p>Other factors, including time on a failing regimen, gender, the regimen at initiation or the time of genotyping, and baseline viral load, were not significantly associated with a GSS of <2.</p>\n<p>Limitations of the study include that only patients that started stavudine and zidovudine-based regimens were evaluated, while tenofovir is now the standard first-line regimen, however subtype C seems to develop resistance very fast, the authors noted.</p>\n<p>Our results suggest a role for genotypic resistance testing in routine care and highlights the need for increased attention to quality of care and to virological monitoring guidelines.</p>\n<p>[Presentation title: High Levels of Drug Resistance After Failure of First-Line Antiretroviral Therapy in Rural South Africa: Impact on Standardised Second-Line Regimens. Abstract TUAB0304]</p>', 'doctors, guide, hiv, drug resistance, washington, justen manasa, rural, south africa, AIDS 2012, conference, high-level, TAMS, doctors, guide, hiv, drug resistance, washington, justen manasa, rural, south africa, AIDS 2012, conference, high-level, TAMS, doctors, guide, hiv, drug resistance, washington, justen manasa, rural, south africa, AIDS 2012, conference, high-level, TAMS', 'By Nancy A. Melville - WASHINGTON, DC - July 27, 2012 - As antiretroviral therapy (ART) for HIV becomes widely accessible in Southern Africa, the risk for drug resistances is on the rise, and as many as 1 in 6 adults show acquired drug resistance to standard second-line drug regimens, researchers said here on July 24 at the 19th International AIDS Conference.', NULL),
(58, 'imgcaprisa.png', 'www.caprisa.org/Lists/Newsletters/Attachments/24/August%202012%20Newsletter.pdf', 'Creating access to HIV/TB drug resistance testing', 'CAPRISA', 1, '2012-08-01', '<p>During July, the acclaimed researcher, Dr Tulio de Oliveira from the Southern African Treatment Research Network (SATuRN), was invited to CAPRISA to visit CAPRISA\'s eThekwini Clinical Research Site. He also presented latest developments on affordable HIV and TB drug resistance testing and open access, public, drug resistance databases to CAPRISA\'s management team, followed by discussions on possible opportunities for collaboration.</p>', NULL, NULL, '<p>Together with its 24 research partners, SATuRN has collated over 7000 resistance genotypes linked to treatment and clinical information in Southern Africa. Its research and development strategy has drastically reduced the cost of drug resistance genotyping and, as part of its capacity building efforts, the network has delivered training in drug resistance testing and management to 1346 physicians and nurses in southern Africa. Later this year it will hold its 7th annual workshop at the Cape Town International Convention Centre. </p>\n<p></p>\n<p>Dr de Oliveira is a senior researcher at the Wellcome Trust-Africa Centre for Health and Population Studies in Mtubatuba, KwaZulu Natal. He is also a director of the (SATuRN) in KwaZulu Natal, which has developed the advanced diagnostic technologies. Using genotyping analysis, SATuRN aims to create cost effective HIV and TB resistance testing, which Dr Oliveira would like to see being widely implemented to patients and providers. </p>\n<p>For more information, visit: <a href=\"http://www.bioafrica.net/saturn/\">www.bioafrica.net/saturn</a></p>', 'CAPRISA, Slim Karim, Tulio de Oliveira, Africa Centre, SATuRN, drug resistance, database, affordable, genotyping, HIV, TB,CAPRISA, Slim Karim, Tulio de Oliveira, Africa Centre, SATuRN, drug resistance, database, affordable, genotyping, HIV, TB,CAPRISA, Slim Karim, Tulio de Oliveira, Africa Centre, SATuRN, drug resistance, database, affordable, genotyping, HIV, TB,CAPRISA, Slim Karim, Tulio de Oliveira, Africa Centre, SATuRN, drug resistance, database, affordable, genotyping, HIV, TB', 'During July 2012, the acclaimed researcher, Dr Tulio de Oliveira from the Southern African Treatment Research Network (SATuRN), was invited to CAPRISA to visit CAPRISA\'s eThekwini Clinical Research Site. He also presented latest developments on affordable HIV and TB drug resistance testing and open access, public, drug resistance databases to CAPRISA\'s management team, followed by discussions on possible opportunities for collaboration.', NULL),
(59, 'imgnews59.png', 'http://www.bioafrica.net/cases.php', 'HIV/TB Drug Resistance and Clinical Management Workshop & Book Launch, Ghost Mountain Inn, Mkuze, South Africa, 7-8 Mar 2013', 'SATuRN', 64, '2013-02-18', '<p>Organised by the Africa Centre for Health and Population Studies and Southern African Treatment and Resistance Network (SATuRN) in collaboration with the uMkhanyakude District Health Office. This workshop is aimed at developing knowledge and skills around the prevention and management of drug resistance and treatment failure in both HIV and TB.</p>', NULL, NULL, '<p><img src=\"imagesBIO/imgHIVTBDrugResistanceBook.png\" ></p>\n<p> Participants will develop understanding of HIV and TB drug resistance and will learn how to apply that knowledge to the management of individual patients and to the prevention and management of drug resistance at programmatic level.</p>\n<p>The workshop will combine theoretical and case-based learning. It is aimed at doctors, nurses and pharmacists, particularly those taking a key role in the delivery of HIV and TB treatment and care in their sub-district. </p>\n<p></p>\n<p>The event will also be accompanied by the launch of a new book <b><i>HIV&TB Drug Resistance and Clinical Management Case Book</b></i>.</p>\n<p>The workshop will start at 9am,Thursday 7 March and end at 4pm, Friday 8 March</p>\n<p><b><i><center>Workshop attendees will be eligible for 12 CPD points</center></b></i> </p>\n<p>Lunch & tea/coffee will be provided each day. Accommodation can be provided if required.</p>\n<p></p>\n<p>Contact: <a href=\"people.php?peopleid=13\">Richard Lessells</a> or <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a></p>\n<p><center><img src=\"imagesBIO/imgHIVTBDrugResistanceBookSponsors.png\"></center></p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></p></a></center><br>\n', 'book, launch, mkuze, hiv, TB, drug resistance, clinical management, casebook, case, book, de Oliveira, Rossouw, Lessells, book, launch, mkuze, hiv, TB, drug resistance, clinical management, casebook, case, book, de Oliveira, Rossouw, Lessells,book, launch, mkuze, hiv, TB, drug resistance, clinical management, casebook, case, book, de Oliveira, Rossouw, Lessells', 'This workshop is aimed at developing knowledge and skills around the prevention and management of drug resistance and treatment failure in both HIV and TB.  Participants will develop understanding of HIV and TB drug resistance and will learn how to apply that knowledge to the management of individual patients and to the prevention and management of drug resistance at programmatic level', NULL),
(60, 'imgnews60.png', 'http://www.sciencemag.org/content/339/6122.cover-expansion', 'Africa Centre major scientific achievements! Two Science papers showing that antiretroviral therapy increases life expectance and reduces transmission', 'Science', 0, '2013-02-22', '<p>Africa Centre, South Africa, 22 February 2013 - Today, colleagues from the Wellcome Trust Africa Centre for Health and Population Studies have published two breakthrough scientific manuscripts at Science. </p>', NULL, NULL, '<p>The first paper by Prof. Frank Tanser is entitled: <b><i>\'High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa\'</b></i>, and the other paper by Prof. Till Barnighausen entitled: <b><i>\'Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment\'</b></i>.</p>\n<p>Both papers focus on the impact of ART on our population; the first one shows for the first time in real-life that when 30% or so of all HIV infected adults in a community are on HIV treatment the incidence in that community substantially and significantly decreases. The second paper summarises the impact of ART on mortality in terms of the considerable increase in life expectancy. </p>\n<p>The director of the Africa Centre - Prof Marie-Louise Newell - praised the KwaZulu-Natal Department of Health and the National Department of Health (NDoH) for their continued effort in getting large numbers of patients onto ART, at all primary health care clinics in the area. <b><i>\'The Africa Centre is pleased and honoured to have been able to support the Department of Health in this remarkable effort\'</b></i>, she said.</p>\n<p>These papers paint a very successful history of the expansion of antiretroviral therapy (ART) in South Africa. Both papers contain good news and are a credit to the SA DOH in their effort and commitment to roll-out ART to many infected people.</p>\n<p>The Southern African Treatment Resistance Network (SATuRN) congratulates our colleagues and friends at the Africa Centre for these great achievements and success histories. SATuRN, more than ever, is committed to work with the Africa Centre and NDoH to increase drug resistance testing in South Africa. Clinical management of patients with drug resistance failing ART means that quality of life is extended together with longevity. It also means that virus can be suppressed, contributing to reducing HIV transmission.</p>\n\n<p><b><i>For more information, please access the press releases:</b></i></p>\n<p>Press release I: <a href=\"\">High Coverage of ART associated with decline in risk of HIV acquisition in rural</a></p>\n<p>Press release II: <a href=\"\">Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment</a></p>\n\n<p><b><i>Manuscripts</b></i></p>\n<p><a href=\"http://www.sciencemag.org/content/339/6122/966.abstract\">\'High Coverage of ART Associated with Decline in Risk of HIV Acquisition in Rural KwaZulu-Natal, South Africa\'</a>\n<p><a href=\"http://www.sciencemag.org/content/339/6122/961.abstract\">\'Increases in Adult Life Expectancy in Rural South Africa: Valuing the Scale-Up of HIV Treatment\'</a></p>', 'science, africa centre. antiretroviral treatment, arv, art, incidence, life expectancy, science, africa centre. antiretroviral treatment, arv, art, incidence, life expectancy, science, africa centre. antiretroviral treatment, arv, art, incidence, life expectancy', 'Africa Centre achieve major scientific success! Two Science papers showing that antiretroviral therapy increases life expectance and reduces transmission at a population level', NULL),
(61, 'imgnews61.png', 'http://regaweb.med.kuleuven.be/veme-workshop/2013/index.php', '18th International Bioinformatics Workshop on Virus Evolution & Molecular Epidemiology, USA, 25-30 Aug 2013', 'Leuven & Univ. Florida', NULL, '2013-02-27', '<p>We are announcing the organization of the international workshop on Virus Evolution and Molecular Epidemiology (VEME) in 2013, hosted by the Emerging Pathogens Institute in the warm city of Gainsville and sponsored by several local partners.</p>', NULL, NULL, '<p>We plan to organize a <b><i>\'Phylogenetic Inference\'</b></i> module, which is coordinated by <b><i>Dr. Tulio de Oliveira, Wellcome Trust Africa Centre/UKZN</b></i>, that offers the theoretical background and hands-on experience in phylogenetic analysis for those who have little or no prior expertise in sequence analysis.</p>\n<p>An <b><i>\'Evolutionary Hypothesis Testing\'</b></i>, coordinated by <b><i>Dr. Philippe Lemey, Leuven Catholic University</b></i>, is targeted to participants who are well familiar with alignments and phylogenetic trees, and would like to extend their expertise to likelihood and Bayesian inference in phylogenetics, coalescent and phylogeographic analyses (\'phylodynamics\') and molecular adaptation.</p>\n<p> A <b><i>\'Large Dataset Analysis\'</b></i> module will cover the more complex analysis of full genomes, huge datasets of pathogens including Next Generation Sequencing data, and combined analyses of pathogen and host.</p>\n<p>Practical sessions in these modules will involve software like, PHYLIP, PAUP*, PHYML, MEGA, PAML or HYPHY, TREE-PUZZLE, SplitsTree, BEAST, MrBayes Simplot and RDP3.</p>\n<p>We recommend participants to buy The Phylogenetic Handbook as a guide during the workshop, and to bring their own data set.</p>\n<p>For further information and applications we refer to a dedicated website that will be announced here soon. <b><i>Abstract and application  deadline is April 14th.</b></i></p>\n<p>Selections will be made by end of May 2013.</p>\n<p>The registration fee of 1000 USD covers attendance, lunches and coffee breaks.</p>\n<p>Participation is limited to 25 scientists in each module and is dependent on a selection procedure based on the submitted abstract and statement of motivation. </p><p>A limited number of grants are available for scientists who experience difficulties to attend because of financial reasons.</p>\n<p><b><i>Organizers of the workshop are: Prof. Marco Salemi and Prof. Anne-Mieke Vandamme</b></i></p>', 'international, bioinformatics, workshop, virus evolution, molecular epidemiology, phylogenetic inference, Tulio de Oliveira, Marco Salemi, Anne-Mieke Vandamme, VEME, 2013, University of Florida, Gainsville,international, bioinformatics, workshop, virus evolution, molecular epidemiology, phylogenetic inference, Tulio de Oliveira, Marco Salemi, Anne-Mieke Vandamme, VEME, 2013, University of Florida, Gainsville,international, bioinformatics, workshop, virus evolution, molecular epidemiology, phylogenetic inference, Tulio de Oliveira, Marco Salemi, Anne-Mieke Vandamme, VEME, 2013, University of Florida, Gainsville', 'We are announcing the organization of the international workshop on Virus Evolution and Molecular Epidemiology (VEME) in 2013, hosted by the Emerging Pathogens Institute in the warm city of Gainsville and sponsored by several local partners.', NULL),
(62, 'imgnews62.png', 'http://www.bioafrica.net/cases.php', 'PRESS RELEASE: Book Launch: HIV and TB Drug Resistance & Clinical Management Case Book', 'Africa Centre', 64, '2013-03-06', '<p>Prof Eric Buch, Dean of the Faculty of Health Sciences at the University of Pretoria, in partnership with European Delegation to South Africa, MRC Inflammation and Immunity Unit and the Africa Centre for Health and Population Studies, UKZN, invite members of the media to attend the launch of the \'HIV and TB Resistance & Clinical Management Case Book\' that is authored by Dr Theresa Rossouw of UP and Drs Richard Lessells and Tulio de Oliveira of the Africa Centre for Health and Population Studies. The details are as follows:</p>\n', NULL, NULL, '<p><b><i>Date: Friday, 15 March 2013</p>\n<p>Time: 10h00 - 13h00</p>\n<p>Venue: Faculty of Health Sciences, School of Dentistry, Room 1-20</b></i> </p>\n<p></p>\n<p>Drug resistance is one of the main challenges confronting HIV and TB programmes in Africa. Facing these challenges requires understanding how drug resistance develops as well as up-to-date knowledge of how to diagnose and manage drug-resistant HIV and TB disease.</p>\n<p></p>\n<p>This book uses a case-based learning approach to present to health care workers the most important information needed to offer their patients the best possible care; and to improve their programmes to prevent the emergence and spread of drug resistance. The focus is on the interpretation of diagnostic tests related to drug resistance.</p>\n<p></p>\n<p>This book will help health care workers to:</p>\n<p>- Learn how drug resistance develops in HIV and Mycobacterium tuberculosis </p>\n<p>- Understand when to suspect drug resistance and which diagnostic tests can be used to diagnose resistance </p>\n<p>- Get up-to-date knowledge on how to interpret genotypic resistance tests for HIV and new diagnostic tests for TB, including Xpert MTB/RIF </p>\n<p>- Acquire information on how to select second-line regimens for HIV and TB and how to offer comprehensive care for patients with drug-resistant HIV and TB </p>\n<p></p>\n<p>The book is published by the MRC and was funded by the MRC with grants from the European Delegation to South Africa, the US CDC/PEPFAR & the Wellcome Trust. It is published under an open access license. Approximately 2,000 copies of the book will be sent to health facilities and medical personnel in South Africa. </p>\n<p>This book is part of the long-standing capacity building program of the Southern African Treatment Resistance Network (SATuRN), which has trained 1,650 clinicians, nurses and pharmacists in Southern Africa via free capacity building workshops. The book launch is preceded by a workshop to 50 ?front-line? clinicians and nurses in uMkhanyakude district, which is one of the most deprived districts in South Africa and at the epicentre of the HIV and TB syndemic, with particularly high levels of drug-resistant TB.</p>\n<p><b><i>\'This book is published at a very important time as the National Department of Health has expanded TB drug resistance testing to most of the facilities in South Africa and is planning to do the same for HIV drug resistance testing.\'</b></i> Says <b><i>Dr. Tulio de Oliveira</b></i>, director of SATuRN and senior researcher at the Africa Centre. </p>\n<p><b><i>\'The cases presented in the book were produced from years of experience in treating patients with drug-resistant infections and from training of junior clinicians. The cases should cover many of important aspects of managing patients failing ARVs and anti-TB medication\'</b></i> complements Dr. Theresa Rossouw, HIV clinician and researcher at the Department of Immunology, University of Pretoria.</p>\n<p>Some comments from reviewers of the Case Book:</p>\n<p><b><i>\'This book is an excellent practical compendium of knowledge in the field of HIV and TB drug resistance that will be of immense use to clinicians, nurses, and other caregivers. It provides expert guidance as to what to do in difficult clinical situations and what steps should be taken to prevent the emergence and transmission of drug resistance.\'</b></i></p>\n<p>Professor Mark A. Wainberg, McGill University, Canada, former president of the International AIDS Society (IAS)</p>\n<p></p>\n<p><b><i>\'This is indeed a wonderful book that will be very handy for clinicians, virologists and bacteriologists. It presents a simple but expert introduction to the field of HIV & TB drug resistance, including a brief review of technical details that are needed to understand the cases. The cases are presented in a very structured way, and I specifically like the key learning points. I have no doubt that this will be a book on everybody\'s desk, either in the office or in the clinic\'</b></i></p>\n<p> Professor Anne-Mieke Vandamme, Rega Institute, AIDS Reference Laboratory, Belgium</p>\n<p></p>\n<p>For more information on the book or would like to conduct an interview, please do not hesitate to contact:</p>\n<p></p>\n<p><b><i>Mrs Jane Moshoeshoe</b></i><br>\nHOD Marketing & Communication<br>\nFaculty of Health Sciences<br>\nTel: 012 354 1669, Cell: 081 247 533<br>\nE-mail: jane.moshoeshoe@up.ac.za <br>\n\n<p><b><i>Dr. Theresa Rossouw</b></i> <br>\nCell: 082 894 2224<br>\nE-mail: theresa.rossouw@up.ac.za<br>\n<p>For more media information about the University of Pretoria, please contact:</p>\n\n<p><b><i>Sanku Tsunke</b></i><br>\nMedia Liaison Officer<br>\nDepartment of University Relations<br>\nUniversity of Pretoria<br>\nTel: 012 420 2276, Fax: 012 420 4269, Cell: 071 008 0187<br>\nE-mail: sanku.tsunke@up.ac.za</p>\n<p><b><i>Download press release: </b></i><a href=\"http://www.bioafrica.net/manuscripts/Book_Launch_press_release_UP.pdf\">PDF (High-resolution)</a>, <a href=\"http://www.bioafrica.net/manuscripts/Book_Launch_press_release_UPsmall.pdf\">PDF (Low-resolution)</a></p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p><br>\n', 'PRESS, RELEASE, press release, Book, Launch, HIV, TB, MDR, open access, Drug, Resistance, Clinical, Management, Case, Book, Prof Eric Burch, University of Pretoria, UKZN, Africa Centre, Wellcome Trust, European Comission, PRESS, RELEASE, press release, Book, Launch, HIV, TB, MDR, open access, Drug, Resistance, Clinical, Management, Case, Book, Prof Eric Burch, University of Pretoria, UKZN, Africa Centre, Wellcome Trust, European Comission, PRESS, RELEASE, press release, Book, Launch, HIV, TB, MDR, open access, Drug, Resistance, Clinical, Management, Case, Book, Prof Eric Burch, University of Pretoria, UKZN, Africa Centre, Wellcome Trust, European Comission', 'Prof Eric Buch, Dean of the Faculty of Health Sciences at the University of Pretoria, in partnership with European Delegation to South Africa, MRC Inflammation and Immunity Unit and the Africa Centre for Health and Population Studies, UKZN, invite members of the media to attend the launch of the \'HIV and TB Resistance & Clinical Management Case Book\' that is authored by Dr Theresa Rossouw of UP and Drs Richard Lessells and Tulio de Oliveira of the Africa Centre for Health and Population Studies.', NULL),
(63, 'imgnews63.png', 'http://www.bioafrica.net/manuscripts/InviteUPBookLaunchHIVTB.pdf', 'Invitation to the launch of the HIV and TB drug resistance & clinical management case book', 'University of Pretoria', 64, '2013-03-05', '<p>University of Pretoria invites you to attend the launch of the publication HIV and TB resistance & clinical management case book. The invitation is writen in three official South African languages: Afrikaans, English and Sepedi. </p>\n', NULL, NULL, '<p>Prof Eric Buch, Dean of the Faculty of Health Sciences at the University of Pretoria, in partnership with the Delegation of the European Union to the Republic of South Africa, the South African Medical Research Council Inflammation and Immunity Unit, the Africa Centre for Health and Population Studies and the University of Kwazulu-Natal, invites you to attend the launch of the publication HIV and TB resistance & clinical management case book, written by Dr Theresa Rossouw of the University of Pretoria and Drs Richard Lessells and Tulio de Oliveira of the Africa Centre for Health and Population Studies.</p>\n<p><b><i>Date: Friday 15 March 2013</b></i></p>\n<p><b><i>Time: 10:00-13:00</b></i></p>\n<p><b><i>Venue: Room 1-20, School of Dentistry, Faculty of Health Sciences, Prinshof Campus</b></i></p>\n<p><b><i>RSVP: Jane Moshoeshoe, jane.moshoeshoe@up.ac.za, 012 354 1669 by 11 March</b></i></p>\n<p>Drug resistance is one of the main challenges confronting HIV and TB programmes in Africa. Facing these challenges requires an understanding of how drug resistance develops, as well as up-to-date knowledge of how to diagnose and manage drug-resistant HIV and TB diseases. This book uses a case-based learning approach to present healthcare workers with the most important information needed to enable them to offer their patients the best possible care, and to improve their programmes and prevent the emergence and spread of drug resistance.</p>\n<br><hr>\n<p><b>Uitnodiging na die bekendstelling van \'n gevalleboek oor weerstand teen middele vir die behandeling van MIV en TB en kliniese bestuur</b></p>\n<p>Prof Erich Buch, Dekaan van die Fakulteit Gesondheidswetenskappe aan die Universiteit van Pretoria, in samewerking met die Afvaardiging van die Europese Unie na die Republiek van Suid-Afrika, die Suid-Afrikaanse Mediese Navorsingsraad se Inflammasie- en Immuniteitseenheid, die Afrika-sentrum vir Gesondheid- en Bevolkingstudies en die Universiteit van KwaZulu-Natal, nooi verteenwoordigers hiermee uit na die bekendstelling van die publikasie HIV and TB resistance & clinical management case book, geskryf deur dr Theresa Rossouw van die Universiteit van Pretoria en drs Richard Lessells en Tulio de Oliveira van die Afrika-sentrum vir Gesondheid- en Bevolkingstudies.</p>\n<p><b><i>Datum: Vrydag 15 Maart 2013</b></i></p>\n<p><b><i>Tyd: 10:00-13:00</b></i></p>\n<p><b><i>Plek: Kamer 1-20, Skool vir Tandheelkunde, Fakulteit Gesondheidswetenskappe, Prinshofkampus</b></i></p>\n<p><b><i>RSVP: Jane Moshoeshoe, jane.moshoeshoe@up.ac.za, 012 354 1669 teen 11 Maart</b></i></p>\n<p>Middelweerstand is een van die hoofuitdagings vir MIV- en TB-programme in Afrika. Om hierdie uitdagings die hoof te bied, verg begrip van hoe middelweerstand ontwikkel, asook die jongste kennis oor die diagnose en bestuur van middelweerstandige MIV- en TB-siektes. Die boek het \'n leerbenadering wat op werklike gevalle gebaseer is ten einde aan gesondheidswerkers die belangrikste inligting te gee wat hulle benodig om aan hul pasiente die beste moontlik sorg te bied, asook om hul programme te verbeter en die ontstaan en verspreiding van weerstand teen middele te voorkom.</p>\n<br><hr>\n<p><b>Taletso go tsebiso ya puku ya direkote tsa HIV le TB tsa go retelela dihlare le taolo ya kalafo</b></p>\n<p>Prof Eric Buch, Hlogo ya Lefapha la Thutamahlale a Maphelo la Yunibesithi ya Pretoria, ka tshomisano le Kemedi ya Dinagakopano tsa Yuropa go Repabliki ya Afrika-Borwa, Lekala la Tshonto le Keko ya Lekgotla la Dinyakisiso tsa Kalafo la Afrika-Borwa, Senthara ya Afrika ya Dithuto tsa Maphelo le Batho, le University of Kwazulu-Natal, di laletsa maloko a bobegaditaba go tsenela thakgolo ya phatlalatso ya HIV and TB resistance & clinical management case book , ya go ngwalwa ke Dr Theresa Rossouw wa Yunibesithi ya Pretoria, le Dr Richard Lessells le Dr Tulio de Oliveira ba Senthara ya Afrika ya Dithuto tsa Maphelo le Batho.</p>\n<p><b><i>Tsatsikgwedi: Labohlano 15 Hlakola 2013</b></i></p>\n<p><b><i>Nako: 10:00-13:00</b></i></p>\n<p><b><i>Lefelo: Phaposi 1-20, Sekolo sa Thutameno, Lefapha la Thutamahlale a Maphelo, Khamphase ya Prinshof</b></i></p>\n<p><b><i>Phetolo: Jane Moshoeshoe, jane.moshoeshoe@up.ac.za, 012 354 1669 pele ga la 11 Hlakola</b></i></p>\n<p>Go retelela dihlare ke yengwe ya ditlhohlo tse di kgolo ya go lebana le mananeo a HIV le TB mo Afrika. Go lwantsha ditlhohlo tse go nyaka kwesiso ya gore go retelela dihlare go thoma bjang, le yona tsebo ye e feletsego ya bjale ya gore malwetsi a HIV le TB a go retelela dihlare a lemogwa le go laolwa bjang. Puku ye e somisa mokgwa wa go ithuta wa go thewa godimo ga dinyakisiso go fa bahlankedi ba tsa maphelo tshedimoso ya bohlokwahlokwa yeo e nyakegago gore ba kgone go fa balwetsi ba bona tlhokomelo ya kalafo ye kaone ka mo go kgonegago, le go kaonafatsa mananeo a bona le go thibela go thoma le go phatlalala ga go retelela dihlare.</p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p>\n', 'Invitation, launch, HIV, TB, drug, resistance, clinical, management, case, book, university of Pretoria, saturn, 2013, MRC, EC, de Oliveira, Lessells, Rossouw,Invitation, launch, HIV, TB, drug, resistance, clinical, management, case, book, university of Pretoria, saturn, 2013, MRC, EC, de Oliveira, Lessells, Rossouw,Invitation, launch, HIV, TB, drug, resistance, clinical, management, case, book, university of Pretoria, saturn, 2013, MRC, EC, de Oliveira, Lessells, Rossouw', 'Prof Eric Buch, Dean Health Sciences, University of Pretoria invites you to attend the launch of the publication HIV and TB resistance & clinical management case book. 15 March 2013. The invitation is writen in three official South African languages: Afrikaans, English and Sepedi. ', NULL),
(64, 'imgnews64.png', 'http://www.ukzn.ac.za/news//2013/03/15/transferring-critical-knowledge-and-skills-to-frontline-medical-personnel-fighting-the-hiv-tb-epidemics-in-rural-south-africa', 'Transferring Critical Knowledge and Skills to Frontline Medical Personnel Fighting the HIV & TB epidemics in rural South Africa', 'UKZN', 64, '2013-03-15', '<p>UKZN\'s Africa Centre for Health and Population Studies, based in the College of health Sciences, has once again made huge strides in HIV management. Recently, the Centre\'s, Dr Richard Lessells and Dr Tulio de Oliveira together with the University of Pretoria\'s, Dr. Theresa Rossouw; launched a book entitled, <b><i>\'HIV and TB: Drug Resistance and Clinical Management Case Book\'</b></i>.</p>\n', NULL, NULL, '<p>According to de Oliveira, the aim of the book was to create awareness and understanding of the issues related to the management of HIV and TB drug resistance. <b><i>\'We felt this is important given the increasingly complex case mix facing frontline health care workers in South Africa with the rapid scale-up of antiretroviral therapy and the ongoing epidemic of drug-resistant TB\'</b></i>.</p>\n<p></p>\n<p>\'<b><i>Among the top challenges of the HIV & TB epidemics are issues related to patient adherence to their antiretroviral and anti-TB drug regimens and the absence of reliable tools to measure adherence\'</b></i>, remarked de Oliveira.</p>\n<p></p>\n<p>A workshop was also held in order to introduce the book to frontline workers based in five hospitals of the uMkhanyakude District of northern KwaZulu-Natal. In total, 52 clinicians, senior nurses and pharmacists attended from the hospitals. Also present were HIV and TB specialists from The Africa Centre, Centre for the AIDS Programme of Research in South Africa (CAPRISA), King Edward VIII hospital, and Botswana.</p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p>\n', 'skills, frontline, medical, personel, fighting, HIV, TB, epidemics, rural, south africa, CAPRISA, Africa Centre, workshop, book, launch, drug resistance, MDR, HIVDR, UKZN, skills, frontline, medical, personel, fighting, HIV, TB, epidemics, rural, south africa, CAPRISA, Africa Centre, workshop, book, launch, drug resistance, MDR, HIVDR, UKZN,skills, frontline, medical, personel, fighting, HIV, TB, epidemics, rural, south africa, CAPRISA, Africa Centre, workshop, book, launch, drug resistance, MDR, HIVDR, UKZN,skills, frontline, medical, personel, fighting, HIV, TB, epidemics, rural, south africa, CAPRISA, Africa Centre, workshop, book, launch, drug resistance, MDR, HIVDR, UKZN', 'Transferring Critical Knowledge and Skills to Frontline Medical Personnel Fighting the HIV & TB epidemics in rural South Africa. UKZN Africa Centre for Health and Population Studies, based in the College of health Sciences, has once again made huge strides in HIV management. Recently, the Centre?s, Dr Richard Lessells and Dr Tulio de Oliveira together with the University of Pretoria?s, Dr. Theresa Rossouw; launched a book entitled, \'HIV and TB: Drug Resistance and Clinical Management Case Book\n', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(65, 'imgnews65.png', 'http://enewsletter.ukzn.ac.za/Story.aspx?id=128&storyid=1687', 'BOOK ON MANAGEMENT OF HIV AND TB DRUG RESISTANCE LAUNCHED', 'UKZNonline', 64, '2013-03-16', '<p>HIV and TB: Drug Resistance and Clinical Management Case Book - a book co-authored by two academics from the Africa Centre for Health and Population Studies - has been presented to frontline health workers at a workshop in northern KwaZulu-Natal.</p>', NULL, NULL, '<p>The Centre\'s Dr Richard Lessells and Dr Tulio de Oliveira wrote the book with the University of Pretoria\'s Dr Theresa Rossouw.</p>\n<p>According to de Oliveira, the aim of the book was to create awareness and understanding of the issues related to the management of HIV and TB drug resistance. <b><i>\'We felt this is important given the increasingly complex case mix facing frontline health care workers in South Africa with the rapid scale-up of antiretroviral therapy and the ongoing epidemic of drug-resistant TB.\'</b></i></p>\n<p><b><i>\'Among the top challenges of the HIV and TB epidemics are issues related to patient adherence to their antiretroviral and anti-TB drug regimens and the absence of reliable tools to measure adherence,\'</b></i> said de Oliveira.</p>\n<p>The workshop was attended by 52 clinicians, senior nurses and pharmacists based in five hospitals in the uMkhanyakude District. Also present were HIV and TB specialists from the Africa Centre, the Centre for the AIDS Programme of Research in South Africa (CAPRISA), King Edward VIII Hospital in Durban, and representatives from Botswana.</p>\n<p>The event facilitated a discussion of common clinical management challenges related to the management of HIV and TB drug resistance and treatment failure within a rural district with a huge dual burden of HIV and TB. The factors that contribute to suboptimal adherence were explored in group discussion sessions and the importance of thinking beyond patient factors and thinking more broadly about health system factors and community factors were emphasised.</p>\n<p>The complexities of the management of co-infections, especially involving multidrug-resistant and extensively drug-resistant TB (pulmonary and extra-pulmonary) and HIV with high-level resistance to the standard first-line regimens, were also discussed. All these challenges were explored in the context of primary health care clinics and district hospitals where there are still critical shortages of human resources and limited access to advanced diagnostic and monitoring facilities.</p>\n<p>Dr Hervey Vaughan-Williams, District Family Physician at the uMkhanyakude Health District Office, said: <b><i>\'I think it was a great success on a number of levels, not least the number of District staff attracted to attend. Gatherings such as these are valuable both for District staff education and bonding between institutions, which is invaluable in times of stress or crisis, as well as enriching the working environment.\'</b></i></p>\n<p>A total of 250 copies of the book, published by the Medical Research Council (MRC), were given free-of-charge to the five hospitals to be distributed to clinicians; nurses and pharmacists involved in managing HIV and TB cases at the hospitals and primary health care clinics.</p>\n<p><b><i>\'The book is a compilation of informative clinical cases from South Africa that together highlight some of the major challenges that clinicians face in the management of HIV and TB drug resistance and that also illustrate some of the important lessons to be learnt in trying to limit the spread of drug resistance in our programmes and communities,\'</b></i> said de Oliveira.</p>\n<p>The book was published under an open source licence and is thus freely available in print and also in electronic form at the Southern African Treatment Resistance Network (SATuRN) website (<a href=\"www.bioafrica.net/saturn\">www.bioafrica.net/saturn</a>) The free distribution of the book was made possible through the generous support of the European Commission, CDC and the Wellcome Trust.</p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p>\n', 'UKZN, online, HIV & TB, book launch, africa centre, KwaZulu-Natal, workshop, academics, health workers, drug resistance, clinical management, MDR-TB, HIVDR,UKZN, online, HIV & TB, book launch, africa centre, KwaZulu-Natal, workshop, academics, health workers, drug resistance, clinical management, MDR-TB, HIVDR,UKZN, online, HIV & TB, book launch, africa centre, KwaZulu-Natal, workshop, academics, health workers, drug resistance, clinical management, MDR-TB, HIVDR', 'HIV and TB: Drug Resistance and Clinical Management Case Book - a book co-authored by two academics from the Africa Centre for Health and Population Studies - has been presented to frontline health workers at a workshop in northern KwaZulu-Natal.The Centre\'s Dr Richard Lessells and Dr Tulio de Oliveira wrote the book with the University of Pretoria?s Dr Theresa Rossouw. According to de Oliveira, the aim of the book was to create awareness and understanding of the issues related to the management of HIV and TB drug resistance. ?We felt this is important given the increasingly complex case mix facing frontline health care workers in South Africa with the rapid scale-up of antiretroviral therapy and the ongoing epidemic of drug-resistant TB.', NULL),
(66, 'imgnews66.png', 'http://web.up.ac.za/default.asp?ipkCategoryID=8641&articleID=15854', 'University of Pretoria and partners launch a book', 'University of Pretoria', 64, '2013-03-19', '<p>By Sanku Tsunke, Pretoria, 19 March 2013. Drug resistance is one of the main challenges confronting HIV and TB programmes in Africa. Facing these challenges requires an understanding of how drug resistance develops, as well as up-to-date knowledge of how to diagnose and manage drug resistance in HIV and TB patients. </p>', NULL, NULL, '<p>It is against this background that the University of Pretoria, in collaboration with the University of KwaZulu-Natal, the Medical Research Council (MRC), the Delegation of the European Union to the Republic of South Africa, and the Africa Centre for Health and Population Studies have launched HIV and TB drug resistance and clinical management case book.</p>\n<p></p>\n<p>This book uses a case-based learning approach to present healthcare workers with the most important information needed to offer their patients the best possible care and to improve their programmes to prevent the emergence and spread of drug resistance. The focus is on the interpretation of diagnostic tests related to drug resistance.</p>\n<p></p>\n<p>The book will help healthcare workers to:</p>\n<p></p>\n<p>- Learn how drug resistance develops in HIV and Mycobacterium tuberculosis;</p>\n<p>- Understand when to suspect drug resistance and which diagnostic tests can be used to diagnose resistance;</p>\n<p>- Obtain up-to-date knowledge on how to interpret genotypic resistance tests for HIV and new diagnostic tests for TB, including Xpert MTB/RIF; and</p>\n<p>- Acquire information about how to select second-line regimens for HIV and TB and how to offer comprehensive care to patients with drug-resistant HIV and TB.</p>\n<p>Published by the MRC, the book is also funded by the Council, together with grants from the Delegation of the European Union to the Republic of South Africa, Centers for Disease Control and Prevention (CDC)/the United States President\'s Emergency Plan for Aids Relief (PEPFAR) and the Wellcome Trust. It is published under an open-access licence. Approximately 2 000 copies of the book will be sent to health facilities and medical personnel in South Africa.</p>\n<p></p>\n<p>The book forms part of the long-standing capacity-building programme of the Southern African Treatment and Resistance Network (SATuRN) which has trained 1 650 clinicians, nurses and pharmacists in Southern Africa via free capacity-building workshops. Preceding the launch is a workshop for 50 \'front-line\' clinicians and nurses in the uMkhanyakude district, one of the most deprived districts in South Africa and at the epicentre of the HIV and TB syndemic, with particularly high levels of drug-resistant TB.</p>\n<p></p>\n<p>Dr Theresa Rossouw, HIV Clinician and Researcher at the Department of Immunology at the University of Pretoria and also the author of the book, says that the cases presented in the book were produced from years of experience in treating patients with drug-resistant infections and from training junior clinicians. She goes on to say that the cases should cover many important aspects of managing patients not responding to ARVs and anti-TB medication. <b><i>\'The purpose of the book is to raise awareness among the health workers to the possibilities of drug awareness development, explaining how this resistance develops and how it can be prevented; and also how the consequences of this resistance can be limited so that it does not get worse in cases of patients who have already developed resistance,\'</b></i> she emphasises.</p>\n<p></p>\n<p>Dr Tulio de Oliveira, co-author of the book and a Director of SATuRN and Senior Researcher at the Africa Centre for Health and Population Studies, says that the book is published at a very important time as the National Department of Health has expanded TB drug-resistance testing to most of the facilities in South Africa and is planning to do the same for HIV drug-resistance testing. Another co-author, Dr Richard Lessells, also a Researcher at the Africa Centre for Health and Population Studies, explains that this book will give healthcare workers an understanding of why HIV patients on ARVs fail, especially with regards to problems of adherence to medication. He goes on to say that it would also help healthcare workers who see many patients. Sometimes such healthcare workers are deprived of an opportunity to further their knowledge, but the book will help them to learn from some of the cases which may be unfamiliar to them.</p>\n<p></p>\n<p>The Vice-Chancellor and Principal at the University of Pretoria, Prof Cheryl de la Rey, appreciates and acknowledges not only the authors and the work, but also the partnership with the University of KwaZulu-Natal. She is a strong advocate of partnerships between South African universities which she says <b><i>\'enhance the contribution of the academic proposition to our country and to the continent\'</b></i>.</p>\n<p></p>\n<p>Prof Eric Buch, Dean of the Faculty of Health Sciences at the University of Pretoria, also reiterates the same sentiment and says that the collaboration of the two institutions fills a void in dealing with the HIV/Aids and TB epidemics. <b><i>\'The challenge of the next decade is going to be drug resistance, and if we don\'t get that right, we are going to face resurgence of HIV/Aids and tuberculosis that is going to overturn all the public health gains that we have achieved\'</b></i>, he explains.</p>\n<p></p>\n<p>Prof Buch concludes by stating that the book is a pioneer that sets a path in going forward towards good quality care for patients with drug resistance in HIV and TB, and it would help ensure that patients get the correct treatment. A resulting reduced number of infections would not only benefit the patients, but society as a whole.</p>\n<p> </p>\n<p></p>\n<p><center><img src=\"imagesBIO/imgbooklaunch1.jpg\"></center></p>\n<p><i>From left to right is Dr Richard J Lessels (Africa Centre for Health and Population Studies, University of KwaZulu-Natal\'s Department of Clinical Research)(Senior Researcher at the Africa Centre for Health and Population Studies, also from the University of KwaZulu-Natal\'s Department of Research and Infection, and also Director of the Southern African Treatment Resistance Network (SATuRN), Prof Ronnie Anderson (Director of Medical Research Council - Inflammation and Immunity Unit - at UP)Dr Theresa Rossouw (HIV Clinician in the Tshwane Metsweding District, and also from the Department of Immunology at the University of Pretoria), and Roland van de Geer (The European Union Ambassador to South Africa)</i></p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p>', 'University of Pretoria, UP, European commission, launch book, Erich Burch, HIV, TB, pretoria, March, ambassador, drug resistance, de oliveira, Lessells, Rossouw, clinical management, University of Pretoria, UP, European commission, launch book, Erich Burch, HIV, TB, pretoria, March, ambassador, drug resistance, de oliveira, Lessells, Rossouw, clinical management, University of Pretoria, UP, European commission, launch book, Erich Burch, HIV, TB, pretoria, March, ambassador, drug resistance, de oliveira, Lessells, Rossouw, clinical management', 'By Sanku Tsunke, Pretoria, 19 March 2013. Drug resistance is one of the main challenges confronting HIV and TB programmes in Africa. Facing these challenges requires an understanding of how drug resistance develops, as well as up-to-date knowledge of how to diagnose and manage drug resistance in HIV and TB patients.', NULL),
(67, 'imgnews67.png', 'http://web.up.ac.za/download.asp?ipkMediaReleaseID=556&file=2', 'Universiteit van Pretoria en vennote stel boek vry oor weerstand teen\nmiddels wat gebruik word om MIV en tuberkulose te bekamp', 'Universiteit van Pretoria', 64, '2013-03-15', '<p>Weerstand teen medikasie is een van die belangrikste struikelblokke wat programme om MIV en tuberkulose in Afrika te bestry te bowe moet kom. Om hierdie uitdagings die hoof te bied, word \'n begrip vereis van hoe weerstand teen die middels tot stand kom, sowel as vertroudheid met die jongste metodes om weerstand teen die medikasie in MIV- en tuberkulosepasiente te diagnoseer en bestuur.</p>', NULL, NULL, '<p> Dit is teen die agtergrond dat die Universiteit van Pretoria, in samewerking met die Universiteit van KwaZulu-Natal, die Mediese Navorsingsraad (MNR), die Afvaardiging van die Europese Unie aan die Republiek van Suid-Afrika en die Afrika-sentrum vir Gesondheid- en Bevolkingstudies, HIV and TB drug resistance and clinical management case book vrygestel het.</p>\n<p>Die boek gebruik onderrigbenadering wat berus op die aanwending van gevallestudies ten einde gesondheidswerkers van die belangrikste inligting te voorsien wat hulle nodig het om die beste pasientesorg te verseker en om hul programme te verbeter ten einde die voorkoms en verspreiding te voorkom van weerstand teen middels wat gebruik word om MIV en tuberkulose te bekamp. Die klem in die boek is op die vertolking van diagnostiese toetse vir weerstand teen medikasie. </p>\n<p>Die boek help gesondheidwerkers om:</p>\n<p>te leer hoe weerstand teen middels in die MIV-virus en Mycobacterium tuberculosis ontwikkel; </p>\n<p>te begryp wanneer om te vermoed dat weerstand teen middels voorgekom het, en watter diagnostiese toetse aangewend kan word om die vermoede te bevestig;</p>\n<p>die jongste inligting te bekom oor hoe om toetse vir genotipeweerstand vir MIV en nuwe diagnostiese toetse vir tuberkulose, met inbegrip van Xpert Mtuberkulose/RIF, te vertolk; en </p>\n<p>kennis te verkry oor hoe om die gepaste tweede-linie behandelingsprotokolle vir MIV en tuberkulose te kies en hoe om omvattende sorg te bied aan pasiente wat ly aan MIV en tuberkulose en wat weerstand teen middels ontwikkel het. </p>\n<p>Die boek word deur die MNR uitgegee en ook gedeeltelik befonds. Dit word ook befonds deur bewilligings van die Afvaardiging van die Europese Unie aan die Republiek van Suid-Afrika, die Centers for Disease Control and Prevention (CDC)/United States President\'s Emergency Plan for Aids Relief (PEPFAR) en die Wellcome-stigting. Dit word uitgegee onderhewig aan outeursreglisensie wat ope toegang verleen. Ongeveer 2 000 eksemplare van die boek word aan gesondheidsinrigtings en personeel in Suid-Afrika gestuur.</p>\n<p>Die boek maak deel uit van die gevestigde kapasiteitsbouprogram van die Southern African Treatment and Resistance Network (SATuRN), wat reeds 1 650 klinici, verpleers en apteekkundiges in Suider-Afrika opgelei het deur die aanbieding van werksessies vir kapasiteitbou. Voor die vrystelling van die boek is werksessie vir 50 klinici en verpleers aangebied, wat in die voorste linie in die distrik uMkhanyakude werk  een van die mees agtergeblewe distrikte in Suid-Afrika wat gelee is op middelpunt van die MIV- en tuberkulosesindemie in Suid-Afrika en waar besonder hoe vlakke van weerstand teen tuberkulosemiddels voorkom.</p>\n<p></p>\n<p>Dr Theresa Rossouw, mede-outeur van die boek en MIV-klinikus en Navorser in die Departement Immunologie aan die Universiteit van Pretoria, se dat die gevalle wat in die boek behandel word, die vrug is van jare lange ondervinding met die behandeling van pasiente met infeksies wat bestandheid teen die middels wat gebruik word ontwikkel het, en die opleiding van junior klinici. Sy se voorts dat die gevalle wat aangebied word, aandag skenk aan talle belangrike aspekte van die bestuur van pasiente wat nie op behandeling met ARV\'s en tuberkulosemedikasie reageer nie, en sy verduidelik dat die doel van die boek is om gesondheidswerkers bewus te maak van die moontlikhede wat gebied word deur die ontwikkeling van groter bewustheid van medikasieweerstand en deur te verduidelik hoe die weerstand ontstaan en hoe dit voorkom kan word en hoe die gevolge van medikasie-weerstand beperk kan word sodat dit nie erger word by pasiente wat dit reeds opgedoen het nie. </p>\n<p>Dr Tulio de Oliveira, mede-outeur van die boek en Direkteur van SATuRN en Senior Navorser verbonde aan die Afrika-sentrum vir Gesondheid- en Bevolkingstudies, se dat die boek se verskyning plaasvind in baie belangrike tyd, aangesien die Nasionale Departement van Gesondheid die toetsing vir tuberkuloseweerstand teen middels uitgebrei het na die meeste van die tuberkulosefasiliteite in Suid-Afrika en beplan om dieselfde te doen vir die toetsing vir MIV-weerstand. Nog mede-outeur, dr Richard Lessells, ook Navorser verbonde aan die Afrika-sentrum vir Gesondheid- en Bevolkingstudies, het verduidelik dat die boek gesondheidswerkers sal help om te begryp waarom die gebruik van ARV-middels om MIV-pasiente te behandel soms misluk veral as gevolg van probleme om te volhard met die korrekte gebruik van die middels. Hy voeg by dat die boek ook gesondheidswerkers sal help wat aan baie pasiente moet aandag skenk en wat dikwels nie die geleentheid het om hul kennis verder uit te brei nie. Die boeke sal laasgenoemde help om kers op te steek by gevalle waarmee hulle dalk nie voorheen bekend was nie.</p>\n<p>Die Visekanselier en Rektor van die Universiteit van Pretoria, prof Cheryl de la Rey, het haar waardering uitgespreek nie alleen teenoor die outeurs van die boek nie, maar ook ten opsigte van die beginsel van vennootskap met die Universiteit van KwaZulu-Natal. Sy is sterk voorstander van vennootskappe tussen Suid-Afrikaanse universiteite wat, soos sy dit stel, die bydrae van die akademiese waardeproposisie aan die land en vasteland sal versterk.</p>\n<p>Prof Eric Buch, Dekaan van die Fakulteit Gesondheidswetenskappe aan die Universiteit van Pretoria, het die Rektor se siening beaam en bygevoeg dat die samewerking tussen die twee universiteite leemte vul in die bekamping van die MIV/Vigs- en tuberkulose-epidemies. Die volgende dekade gaan, aldus hom, dekade van weerstand teen beskikbare medikasie wees en, tensy die uitdaging daarvan effektief die hoof gebied word, sal daar hernude opwelling van die MIV/Vigs- en tuberkulose-epidemies wees wat al die vordering wat daar op die gebied van openbare gesondheid gemaak is met die bekamping daarvan, sal negeer. </p>\n<p>Prof Buch het ten slotte opgemerk dat die boek baanbrekerswerk doen en die weg vorentoe aandui vir gesondheidsorg van gehalte vir pasiente wat weerstand ontwikkel het teen MIV- en tuberkulosemiddels en sal help om te verseker dat pasiente die regte behandeling ontvang. Verlaging van die infeksievlakke sal nie alleen tot voordeel van pasiente wees nie, maar ook van die samelewing as geheel.</p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p>', 'medikasie, belangrikste, struikelblokke, MIV, tuberkulose, Afrika, Universiteit van Pretoria, Universiteit van KwaZulu-Natal, Mediese Navorsingsraad (MNR), Afvaardiging van die Europese Unie, Afrika-sentrum vir Gesondheid- en Bevolkingstudies, HIV and TB drug resistance and clinical management case book,medikasie, belangrikste, struikelblokke, MIV, tuberkulose, Afrika, Universiteit van Pretoria, Universiteit van KwaZulu-Natal, Mediese Navorsingsraad (MNR), Afvaardiging van die Europese Unie, Afrika-sentrum vir Gesondheid- en Bevolkingstudies, HIV and TB drug resistance and clinical management case book,medikasie, belangrikste, struikelblokke, MIV, tuberkulose, Afrika, Universiteit van Pretoria, Universiteit van KwaZulu-Natal, Mediese Navorsingsraad (MNR), Afvaardiging van die Europese Unie, Afrika-sentrum vir Gesondheid- en Bevolkingstudies, HIV and TB drug resistance and clinical management case book\n\n', 'Weerstand teen medikasie is een van die belangrikste struikelblokke wat programme om MIV en tuberkulose in Afrika te bestry te bowe moet kom. Om hierdie uitdagings die hoof te bied, word \'n begrip vereis van hoe weerstand teen die middels tot stand kom, sowel as vertroudheid met die jongste metodes om weerstand teen die medikasie in MIV- en tuberkulosepasinte te diagnoseer en bestuur. Dit is teen di agtergrond dat die Universiteit van Pretoria, in samewerking met die Universiteit van KwaZulu-Natal, die Mediese Navorsingsraad (MNR), die Afvaardiging van die Europese Unie aan die Republiek van Suid-Afrika en die Afrika-sentrum vir Gesondheid- en Bevolkingstudies, HIV and TB drug resistance and clinical management case book vrygestel het', NULL),
(68, 'imgnews68.png', 'http://www.bioafrica.net/manuscripts/PretoriaNewsBook2013.pdf', 'Casebook aims to curb drug resistance', 'PretoriaNews', 64, '2013-03-19', '<p>Pretoria News - 19 March 2013, DOCTORS from the University of Pretoria (UP) and University of KwaZulu-Natal (UKZN) have stepped up to the challenge of providing a clinical management casebook for health care workers treating patients with HIV and TB drug resistance.</p>', NULL, NULL, '<p>Drug resistance is one of the main challenges facing HIV and TB programmes in Africa.</p>\n<p></p>\n<p>Dealing with these challenges requires an understanding of how drug resistance develops as well as up-to-date knowledge about diagnosing and managing patients.</p>\n<p></p>\n<p>It is against this background that UP, in collaboration with the UKZN, Medical Research Council (MRC), the European Delegation and the Africa Centre for Health and Population Studies launched the HIV and TB Drug Resistance and Clinical Management Case Book.</p>\n<p></p>\n<p>This book uses a case-based approach to present health care workers with the most important information needed to offer their patients the best possible care and improve their programmes to prevent the emergence and spread of drug resistance.</p>\n<p></p>\n<p>It will help health care workers learn how drug resistance develops and which diagnostic tests can be used.</p>\n<p></p>\n<p>The book is being published and funded by the MRC with grants from the European Delegation to South Africa, the US CDC/President\'s Emergency Plan For Aids Relief and the Wellcome Trust. Nearly 2 000 copies of the book are to be sent to health facilities.</p>\n<p></p>\n<p>This book is part of the capacitybuilding programme of the Southern African Treatment Resistance Network (SATuRN), which has trained 1 650 clinicians, nurses and pharmacists in southern Africa at free workshops.</p>\n<p></p>\n<p>Dr Theresa Rossouw, an HIV clinician and researcher in the Department of Immunology at UP and author of the book, said the cases presented were taken from years of experience in treating patients with drug-resistant infections and from the training of junior clinicians.<b><i>\'The purpose of the book is to raise awareness among health workers of the possibilities of drug awareness development, explaining how it develops and how it can be prevented.(It also explains) how the consequences of resistance can be limited so it does not get worse in patients who have developed it.\' </b></i></p>\n<p></p>\n<p>Dr Tulio de Oliveira, a co-author of the book, director of SATuRN and senior researcher at the Africa Centre for Health and Population Studies, said the book was being published at an important time as the National Department of Health had expanded TB drug resistance testing to most of the facilities and planning to do the same for HIV drug resistance testing.</p>\n<p></p>\n<p>Another co-author, Dr Richard Lessells, a researcher at the Africa Centre for Health and Population Studies, said the book would give health care workers an understanding of why HIV patients on ARVs failed to adhere to the medication.</p>\n<p></p>\n<p>The vice-chancellor and principal of UP, Professor Cheryl de la Rey, acknowledged not only the authors and the work at Friday\'s launch, but also the partnership with the UKZN. She is an advocate of partnerships between universities which she said <b><i>\'It will enhance the contribution of the academic proposition to our country and to the continent\'.</b></i></p>\n<p></p>\n<p>Professor Eric Buch, the dean of the Faculty of Health Sciences at UP, said the collaboration of the two institutions filled a void in dealing with the HIV and Aids and TB epidemics<b><i> \'The challenge of the next decade is going to be drug resistance, and if we don\'t get that right, we are going to face a resurgence of HIV/Aids and tuberculosis that is going to overturn all the public health gains that we have achieved\'</b></i>, he said.</p>\n<p></p>\n<p>The book would ensure that patients received correct treatment, benefiting society as a whole due to a reduced number of infections, he said.</p>\n<p><center><img src=\"imagesBIO/imgbooklaunch2.jpg\"></center></p>\n<p><i>Authors of HIV and TB Drug Resistance and Clinical Management Case Book, from left, Dr Richard Lessells, Dr Theresa Rossouw and Dr Tulio de Oliveira.</i></p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></a></center></p>', 'pretorianews, newspaper, news, pretoria, book, launch, curb, resistance, hiv, tb, MDR, de oliveira, lessells, rossouw, clinical management, pretorianews, newspaper, news, pretoria, book, launch, curb, resistance, hiv, tb, MDR, de oliveira, lessells, rossouw, clinical management, pretorianews, newspaper, news, pretoria, book, launch, curb, resistance, hiv, tb, MDR, de oliveira, lessells, rossouw, clinical management', 'Pretoria News - 19 March 2013, DOCTORS from the University of Pretoria (UP) and University of KwaZulu-Natal (UKZN) have stepped up to the challenge of providing a clinical management casebook for health care workers treating patients with HIV and TB drug resistance.', NULL),
(69, 'imgnews69.png', 'http://www.rudasa.org.za', 'SATuRN will have a session at the 17th Rural Health Conference', 'RUDASA', 64, '2013-03-31', '<p>The 17th Annual Rural Health Conference will be held in St. Lucia, KwaZulu-Natal, South Africa, from 8 to 10 August 2013. SATuRN will have a session (approximately 2-3 hours) in the conference and will distribute the HIV & TB Drug Resistance and Clinical Management Case Book.</p>', NULL, NULL, '<p><b><i>CALL FOR ABSTRACTS:</b></i> We invite the submission of Abstracts for oral papers, poster presentation and workshops for the conference.</p>\n<p><b><i>ABSTRACT SUBMISSION DEADLINE:</b></i> 30 April 2013</p>\n<p>Abstracts submitted should not exceed 300 words in Word format, in either Time New Roman or Arial font size 12.</p>\n<p>Abstracts should be submitted to: abstracts@rudasa.org.za</p>\n<p><img src=\"imagesBIO/imgnews69big.png\"></p>\n<p><b><i>DOWNLOAD:</b></i> Poster of the <a href=\"manuscripts/17ruralhealthposter.pdf\">17th Rural Health Conference</a></p>\n<p> SATuRN will have a session (approximately 2-3 hours) in the conference, which we will present HIV & TB drug resistance clinical cases and distribute the <a href=\"http://www.bioafrica.net/cases.php\">HIV & TB Drug Resistance and Clinical Management Case Book</a>.</p>', '17th rural, health, conference, saint lucia, saturn, book, session, abstract, KwaZulu-natal, RuReSa, Rural doctors, RudaSA, associations, south africa, saturn, hiv tb, drug resistance, cases, book,17th rural, health, conference, saint lucia, saturn, book, session, abstract, KwaZulu-natal, RuReSa, Rural doctors, RudaSA, associations, south africa, saturn, hiv tb, drug resistance, cases, book,17th rural, health, conference, saint lucia, saturn, book, session, abstract, KwaZulu-natal, RuReSa, Rural doctors, RudaSA, associations, south africa, saturn, hiv tb, drug resistance, cases, book', 'SATuRN will have a session at the 17th Rural Health Conference. The 17th Annual Rural Health Conference will be held in St. Lucia, KwaZulu-Natal from 8 ? 10 August 2013. The conference is organized by Rudasa, Rural Doctors Association of Southern Africa.', NULL),
(70, 'imgnews70.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2013A4.pdf', 'SATuRN Newsletter, Mar 2013: News, blogs, events, publications and a case book on HIV/TB drug resistance', 'SATuRN', 0, '2013-04-01', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN. The newsletter is presented as a PDF document with links to complete articles at the bioafrica.net website.</p>', NULL, NULL, '<p>In this first issue of 2013 (V.2 N.1) we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.</p>\n<p><a href=\"manuscripts/SATuRNnewsletter_1_2013A4.pdf\"><img src=\"imagesBIO/imgnews70big.png\"></a></p>\n<p><b><i>Highlights:</b></i></p>\n\n<p><a href=\"http://www.bioafrica.net/news.php?id=69\">17th Rural Health Conference, Saint Lucia, 8-10 August 2013</a></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=55\">Practical Course on Quality Assurance of HIV-1 Drug Resistance Interpretation in Sequence Editing and Data Management Processes, Johannesburg, 22- 26 April 2013 </a></p>\n<p><a href=\"http://www.bioafrica.net/blogs.php?id=24\">The Mississippi baby ? questions on a ?functional? cure </a></p>\n<p><a href=\"http://www.bioafrica.net/blogs.php?id=22\">Extensively drug-resistant tuberculosis in South Africa: are we now dealing with untreatable strains? </a></p>\n<p><a href=\"http://www.bioafrica.net/report.php?id=19\">Transferring knowledge and skills to frontline medical personnel fighting the HIV & TB epidemics in rural South Africa </a></p>\n<p><a href=\"http://www.bioafrica.net/cases.php\">HIV & TB Drug Resistance & Clinical Management Case Book</a>', 'saturn, newsletter, 2013, book, hiv tb, practical course, hiv sequencing editing, 17 rural health conference, baby cured, TB XDR, south africa, treatment resistance network, news, saturn, newsletter, 2013, book, hiv tb, practical course, hiv sequencing editing, 17 rural health conference, baby cured, TB XDR, south africa, treatment resistance network, news, saturn, newsletter, 2013, book, hiv tb, practical course, hiv sequencing editing, 17 rural health conference, baby cured, TB XDR, south africa, treatment resistance network, news', 'SATuRN Newsletter, Mar 2013: News, blogs, events, publications and a case book on HIV/TB drug resistance. The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN. The newsletter is presented as a PDF document with links to complete articles at the bioafrica.net website', NULL),
(71, 'imgnews41.jpg', 'http://www.zululandobserver.co.za/Pages/m16hum3.html', 'Case book tackles HIV and TB drug resistance', 'Zululand Observer', 64, '2013-04-15', '<p>By Jonathan Davis, 15 April 2013 - Researchers from the Africa Centre for Health and Population Research near Mtubatuba have published a important book to help rural doctors, nurses and pharmacists working on the frontline of the country\'s interlinked HIV and tuberculosis (TB) pandemics manage increasing levels of resistance to the drugs needed to fight the diseases.</p>', NULL, NULL, '<p>While the broad provision of antiretroviral (ARV) drugs to HIV sufferers has been shown to not only reduce mortality from the disease but also inhibit its spread, where patients fail to take their medication properly, drug-resistant strains of the virus take root. With millions of South Africans now expected to take complex ARV regimes for the rest of their lives, the threat of resistance is huge.</p>\n\n<p>This is especially true for rural patients, where difficulties in reaching hospitals and clinics or even simply a lack of food make taking the drugs, which have unpleasant side effects, a challenge. Similarly, TB, which takes advantage of the weakened immune system of many HIV sufferers, can be treated but only through months of faithful adherance to treatment.</p>\n\n<p>Rural health systems are already struggling to manage multiple-drug resistant (MDR) and extreme drug resistance (XRD) forms of the disease. The HIV & TB Drug Resistance & Clinical Management Case Book, edited by Africa Centre HIV and TB specialist Dr Richard Lessels and virologist and bioinformatician Tulio de Oliveira, together with University of Pretoria HIV expert Dr Theresa Roussouw, was published by the Medical Research Council last month.</p>\n\n<p>The book is a compilation of informative clinic cases from across South Africa that illustrate the challenges health workers face in managing increasingly complex forms of resistance. The book was launched last month at a two-day workshop at the Ghost Mountain Inn near Mkhuze, attended by doctors and senior nursing and pharmacy staff from the five district hospitals in the uMkhanyakude District.</p>\n\n<p>The meeting, sponsored by Africa Centre and the uMkhanyakude Health District, was also attended by HIV and TB specialists from the University of KZN, Durban\'s King Edward Hospital and from as far away as Botswana. <b><i>Dr Hervey Vaughan-Williams</b></i>, District Family Physician at the uMkhanyakude Health District Office said he was pleased with the number of district staff who attended the workshop.</p>\n\n<p><b><i>\'Gatherings such as these are valuable both for District staff education and bonding between institutions, which is invaluable in times of stress or crisis, as well as enriching the working environment,\'</b></i> he said. Two hundred and fifty copies of the book were donated by Africa Centre to staff of the five hospitals in the district.</p>\n\n<p>However, in order to allow dissemination of the information, Dr Lessels said the book had been published under an <b><i>\'open source\'</b></i> licence that allows it to be freely shared both in print copies and electronically. Publication was supported by the European Commission\'s Centre for Disease Control and UK charity Wellcome Trust. A similar launch event was also held in Pretoria to promote the case book among HIV and TB specialists there. </p>', 'Mtubatuba, africa centre, book, hiv, tb, drug resistance, zululand, observer, ARV, lessells, de oliveira, Hervey Vaughan-Williams, uMkhanyakude, Health District, Mkuze, case book, doctors, Mtubatuba, africa centre, book, hiv, tb, drug resistance, zululand, observer, ARV, lessells, de oliveira, Hervey Vaughan-Williams, uMkhanyakude, Health District, Mkuze, case book, doctors, Mtubatuba, africa centre, book, hiv, tb, drug resistance, zululand, observer, ARV, lessells, de oliveira, Hervey Vaughan-Williams, uMkhanyakude, Health District, Mkuze, case book, doctors', 'Researchers from the Africa Centre for Health and Population Research near Mtubatuba have published a important book to help rural doctors, nurses and pharmacists working on the frontline of the country?s interlinked HIV and tuberculosis (TB) pandemics manage increasing levels of resistance to the drugs needed to fight the diseases.', NULL),
(73, 'imgnews71sm.png', 'http://www.bioafrica.net/manuscripts/SATuRNnetworkMaker2013.pdf', 'The Network Marker', 'International Innovation', 1, '2013-04-22', '<p>Drug resistance poses significant potential problems in the fight against HIV and TB, but little is known about how best to tackle it. Dr Tulio de Oliveira heads a network that aims to fill this knowledge gap.</p>', NULL, NULL, '<p>Widely deployed, antiretroviral and anti-tuberculosis therapies are saving lives in southern Africa, but at the price of increasing drug resistance. An initiative by researchers at the Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal in South Africa is showing success in bucking this trend.</p>\n<p><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnetworkMaker2013.pdf\"><img src=\"imagesBIO/imgnews71.png\"></a></p>\n<p>Southern Africa represents one of the world\'s hotspots in the fight against HIV and tuberculosis (TB). With statistics indicating some of the highest percentages of prevalence on the planet, any impact made on the diseases\' infection rate could produce a lasting legacy, improving the life expectancies of a large swathe of the population.</p>\n<p></p>\n<p>Recent efforts by the medical community have resulted in a wider distribution of HIV/AIDS antiretroviral (ART) and anti-TB therapy in an attempt to reduce the chances of further infection among the adult population and the transmission of the disease to newborn babies. In South Africa - one of the countries hardest hit by HIV and TB, with the highest patient burden in the world ? the rapid expansion of the HIV and TB treatment programme has brought positive results. However, at the same time it has created a new set of problems researchers have to grapple with. </p>\n<p></p>\n<p><b><i>Risk of drug resistance </b></i></p>\n<p></p>\n<p>The massive scaling up of ART and anti-TB therapy has led to an increased risk of individuals developing drug resistance, a grave threat to the sustained achievements of this strategy. Drug resistance limits the impact of proven treatments, eventually reducing their effectiveness and slowing down containment of an infection. This situation is made worse by the lack of laboratory resources and trained personnel to set up a working drug resistance monitoring programme and assist patients who develop resistance. </p>\n<p></p>\n<p>Under the directorship of Dr Tulio de Oliveira from the Africa Centre for Health and Population Studies of the University of KwaZulu-Natal and Professor Christopher Seebregts from the South African Medical Research Council, the Southern African Treatment Resistance Network (SATuRN) aims to build capacity to support an effective response to the HIV epidemic over the long term, developing collaborations between active researchers, clinicians and policy makers, and focusing on the monitoring, evaluation and delivery of ART in Africa. </p>\n<p></p>\n<p>At the same time, SATuRN is centred on collecting, analysing and distributing data on drug resistance, having established two of the most detailed databases in the world on this crucial subject - the Stanford HIV Drug Resistance Database and the RegaDB Clinical Management and Drug resistance Database - in South Africa and Botswana...</p>\n', 'international, innovation, southern african treatment resistance network, SATuRN, tulio de Oliveira, HIV, TB, drug resistance, south africa, databases, stanford, regaDB, wellcome trust, africa centre for health and population studies, international, innovation, southern african treatment resistance network, SATuRN, tulio de Oliveira, HIV, TB, drug resistance, south africa, databases, stanford, regaDB, wellcome trust, africa centre for health and population studies, chris, Seegrebts, international, innovation, southern african treatment resistance network, SATuRN, tulio de Oliveira, HIV, TB, drug resistance, south africa, databases, stanford, regaDB, wellcome trust, africa centre for health and population studies', 'Drug resistance poses significant potential problems in the fight against HIV and TB, but little is known about how best to tackle it. Dr Tulio de Oliveira heads a network that aims to fill this knowledge gap. Widely deployed, antiretroviral and anti-tuberculosis therapies are saving lives in southern Africa, but at the price of increasing drug resistance. An initiative by researchers at the Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal in South Africa is showing success in bucking this trend', NULL),
(74, 'imgnews72.png', 'http://www.scipirate.com/2013/01/searching-for-virus-phylotypes/', 'Searching for Virus Phylotypes', 'Pirate Science', 63, '2013-01-22', '<p>Viral phylogenies have wide use: studying evolution, tracing the origin of epidemics, establishing dominant mode of transmission, identifying the apparition of drug resistance, even tracking individual body compartments.</p>', NULL, NULL, '<p>Many tools infer ancestral state, few interpret it. Hence the need for a fast, easy to use exploratory tool, PhyloType. Given a phylogeny, it allows inference of ancestral traits, along with hypothesis testing, with a speed which makes it applicable for exploratory analysis and/or datasets with thousands of samples.</p>\n\n<p>Define: Viral Phylotype. a subset of studied taxa that share a common history. \"History\" has a twofold definition. First, based on the phylogeny: a phylotype must be part of a clade, and the root of the clade must be the MRCA of the members of the phylotype. Second, common traits or annotations: if the phylotype root has a unique annotation A (which is conserved), then all members of the phylotype also have annotation A.</p>\n\n<p>The term phylotype is common in microbiology, and refers to a (taxon-neutral) classification based on phylogenetic relationship to other organisms.</p>\n\n<p>Method: Infer ancestral annotations using maximum parsimony. Use this annotation to induce a set of phylotypes, defined by MRCA and path-conservation. Apply combinatorial, numerical, and statistical criteria to select relevant phylotypes.</p>\n\n<p>One example is the study of the origin of the <a href=\"ppublications.php?pubid=15\">Albanian HIV epidemic</a>.', 'pirate, science, pirate science, phylotypes, searching for phylotypes, interface, between, science, society, open access, pirate, science, pirate science, phylotypes, searching for phylotypes, interface, between, science, society, open access, pirate, science, pirate science, phylotypes, searching for phylotypes, interface, between, science, society, open access', 'Pirate Science recreates the interface between science and society by reviewing and publishing online comments about important and open access publications. They review the manuscript entitled Searching for Cirus Phylotypes. Viral phylogenies have wide use: studying evolution, tracing the origin of epidemics, establishing dominant mode of transmission, identifying the apparition of drug resistance, even tracking individual body compartments.', NULL),
(75, 'imgnews75.png', 'http://advanced-courses-wellcome.msgfocus.com/q/1MvUkyPtJQwMVh/wv', 'Infectious Disease Genomics and Global Health Wellcome Trust Conference', 'Wellcome Trust', 0, '2013-05-24', '<p>We are pleased to announce that we are presenting at the Sixth Infectious Disease Genomics and Global Health conference, Cambridge, U.K, 16-18 October 2013. The focus of this meeting is the application of genomic technologies to the problems of infectious disease in a global health context.</p>', NULL, NULL, '<p><b><i>Topics will include:</b></i><br>- Epidemiology and public health\n<br>- Genomics of viral diseases\n<br>- Genomics of bacterial diseases\n<br>- Population genomics\n<br>- Parasites and vectors\n<br>- Neglected tropical diseases</p>\n<p><b><i>Abstract and Bursary deadline</b></i>: 4 September  </p>\n<p><b><i>Registration deadline:</b></i> 25 September</p>\n\n\n<p>Infectious disease is a major burden on healthcare throughout the world, particularly in developing countries. Disease agents do not respect borders; therefore, an integrated global approach is necessary to understand transmission and evolution of infectious disease agents. Recent advances in genomic technologies are delivering new approaches to these problems, and these will be the major focus of the meeting. These technologies promote cross-fertilisation amongst previously disparate fields, and we therefore welcome abstracts covering any area in this field. Please note that several oral presentations will be chosen from the abstracts submitted. Full details are available on the <a href=\"http://advanced-courses-wellcome.msgfocus.com/q/1MvUkyPtJQwMVh/wv\"> conference website.</a></p>\n<p></p>\n<p><b><i>Scientific organising committee</b></i></p>\n<p>Matt Berriman (Wellcome Trust Sanger Institute, UK)</p>\n<p>Jane Carlton (New York University, USA)</p>\n<p>Nicky Mulder (University of Cape Town, South Africa)</p>\n<p>Julian Parkhill (Wellcome Trust Sanger Institute, UK)</p>\n<p>George Weinstock (Washington University School of Medicine, USA)</p>\n<p><b><i>Confirmed speakers</b></i></p>\n<p>Frank Aarestrup (DTU, Denmark)</p>\n<p>Swaine Chen (National University of Singapore and Genome Institute of Singapore)</p>\n<p><a href=\"people.php?peopleid=1\">Tulio de Oliveira</a> (Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa)</p>\n<p>Maria Gloria Dominguez-Bello (New York University School of Medicine, USA)</p>\n<p>Jennifer Gardy, British Columbia Centre for Disease Control, Canada</p>\n<p>Dag Harmsen (University Munster, Germany)</p>\n<p>Duccio Medini (Novartis Vaccines & Diagnostics, Italy)</p>\n<p>Bill Petri (University of Virginia, USA)</p>\n<p>Gerd Pluschke (Swiss Tropical and Public Health Institute, Switzerland)</p>\n<p>Joana Silva (University of Maryland School of Medicine, USA)</p>\n<p>Phil Tarr (Washington University School of Medicine, USA) </p>\n<p>Joanne P. Webster (Imperial College, London, UK)</p>', 'wellcome trust, global health, genomics, conference, cambridge, 2013, tulio de oliveira, sanger, infectious diseases, wellcome trust, global health, genomics, conference, cambridge, 2013, tulio de oliveira, sanger, infectious diseases, wellcome trust, global health, genomics, conference, cambridge, 2013, tulio de oliveira, sanger, infectious diseases, wellcome trust, global health, genomics, conference, cambridge, 2013, tulio de oliveira, sanger, infectious diseases', 'We are pleased to announce that we are presenting at the Sixth Infectious Disease Genomics and Global Health conference, Cambridge, U.K, 16-18 October 2013. The focus of this meeting is the application of genomic technologies to the problems of infectious disease in a global health context.', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(76, 'imgnews76.png', 'http://www.bioafrica.net/news.php?id=78', 'Bioinformatics in the tropics I: 1st International Bioinformatics & Molecular Viral Evolution Workshop, Salvador, Bahia, Brazil, 22-26 July 2013', 'FioCruz', 0, '2013-06-01', '<p>This is the first workshop of the bioinformatics in the tropics series, which will be presented at the Oswaldo Moniz Research Center (CPqGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Bahia, Brazil, 22 to 26 July 2013. </p>', NULL, NULL, '<p><b><i>Workshop topics and who should apply</b></i></p>\n<p>The workshop involves theoretical lectures and practical sessions on the usage and interpretation of bioinformatics applications for the study of viruses drug resistance, molecular epidemiology and immunology.  This workshop is targeted at scientists and post-graduate students working in research projects in Africa and Latin America.</p>\n<p>The bioinformatics in the tropics series is part of a south to south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America. </p>\n<p><b>To apply, please visit the <a href=\"http://www.bahia.fiocruz.br/workshopbio\">FioCruz workshop website</a></b>.</p>\n<p><b><i>Organizing Institutions:</b></i></p>\n<p>Oswaldo Cruz Foundation (FIOCRUZ), in Salvador-Bahia, Brazil, with the National Council for Scientific and Technological Development (CNPQ) and the The Wellcome Trust Africa Centre for Health and Population Studies</p>\n<p><b><i>Workshop Organizers:</b></i></p>\n<p>Luiz Carlos Alcantara, Paula Ristow, Anne-Mieke Vandamme and  Tulio de Oliveira</p>\n<p></p>\n<p><b><i>Dates:</b></i> 22 to 26 of July, Oswaldo Moniz Research Center (CPqGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Bahia, Brazil. (Deadline for application: 15 June)</p>\n<p></p>\n<p><b><i>Presenters:</b></i></p>\n<p>Aline Cristina Mota Miranda, Ph.D. UFBA/Bahia</p>\n<p>Anne-Mieke Vandamme, Ph.D. Catholic University of Leuven/Rega Institute for Medical Research, Leuven, Belgica</p>\n<p>Artur Trancoso Lopo de Queiroz, Ph.D. CPqGM/FIOCRUZ, Salvador, Bahia</p>\n<p>Bernardo Galvao-Castro, Ph.D. CPqGM/FIOCRUZ, Salvador-Ba</p>\n<p>Brian Foley Ph.D. Los Alamos National Laboratory, New Mexico, EUA</p>\n<p>Charbel Nino El-Hani, Ph.D. Instituto de Biologia/UFBA</p>\n<p>Eduardo Paulino Castam, Ph.D. Universidade Estadual Paulista, Botucatu, Sao Paulo</p>\n<p>Filipe Ferreira de Almeida Rego, CPqGM/FIOCRUZ, Salvador, Bahia</p>\n<p>Fernanda Khouri, LHGB/CPqGM/FIOCRUZ, Salvador, Bahia.</p>\n<p>Genoveffa Franchini. Ph.D. National Cancer Institute/National Institutes of Health, Bethesda-MD, EUA</p>\n<p>Gonzalo Bello, Ph.D. IOC/FIOCRUZ-Rio de Janeiro, Brasil</p>\n<p>Hugo Naya, Ph.D, Instituto Pasteur, Montevideo, Uruguai</p>\n<p>Joana Paixao Monteiro, Ph.D. UFBA/Bahia</p>\n<p>Katherine Stott, Ph.D. University of Cambridge, Cambridge, Inglaterra.</p>\n<p>Luciane dos Santos Amorim, Yale University, New Haven EUA</p>\n<p>Lucia Spangenberg, Ph.D, Instituto Pasteur, Montevideo, Uruguai</p>\n<p>Luiz Carlos Junior Alcantara. Ph.D. CPqGM/FIOCRUZ, Salvador-Ba</p>\n<p>Manoel Barral Netto, Ph.D. Diretor de Cooperacao Institucional do Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)</p>\n<p>Joao Lidio Vianez, Ph.D. Centro de Inovacoes Tecnologicas e Nucleo de Bioinformatica do Instituto Evandro Chagas, Para, Brasil</p>\n<p>Luciano Kalabric, Ph.D. Centro de Pesquisas Goncalo Moniz / FIOCRUZ</p>\n<p>Marcio Oliveira Silva, LHGB/CPqGM/FIOCRUZ, Salvador, Bahia</p>\n<p>Marco Salemi Ph.D. Department of Pathology, Immunology and Laboratory Medicine, College of Medicine & Emerging Pathogens Institute, University of Florida Gainesville, Florida, EUA</p>\n<p>Marilda de Souza Goncalves, Ph.D. LHGB/CPqGM/FIOCRUZ e UFBA</p>\n<p>Mitermayer Galvao dos Reis, Ph.D. Centro de Pesquisas Goncalo Moniz/FIOCRUZ; Pesquisador Chefe do LPBM/CPqGM/FIOCRUZ</p>\n<p>Mohamed Cherif Rahimy, Ph.D. Faculty of Health Sciences Cotonou, Rep of Benin</p>\n<p>Nuno Faria, Ph.D. Catholic University of Leuven/Rega Institute for Medical Research, Leuven, Belgica</p>\n<p>Paula Carvalhal Lage von Buettner Ristow, Ph.D. Instituto de Biologia, UFBA, Bahia, Brasil</p>\n<p>Renata Guerra de Sa, Ph.D. Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais.</p>\n<p>Ricardo Camacho, Ph.D. Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal</p>\n<p>Ricardo Khouri, Ph.D. Catholic University of Leuven/Rega Institute for Medical Research, Leuven, Belgica</p>\n<p>Robert Gifford, Ph.D. Aaron Diamond AIDS Research Center, Nova York, EUA</p>\n<p>Roberto Paulo Machado Lopes, Ph.D. Diretor Geral da Fundacao de Amparo a Pesquisa do Estado da Bahia (FAPESB)</p>\n<p>Simone Kashima, Ph.D. Fundacao Hemocentro de Ribeirao Preto, USP</p>\n<p>Sueli Almuna Holmer Silva, Ph.D. Diretora do Instituto de Biologia da UFBA</p>\n<p>Suetoslav Nanev Slavov, Ph.D. Fundacao Hemocentro de Ribeirao Preto, USP</p>\n<p>Thessika Hialla Almeida Araujo, LHGB/CPqGM/FIOCRUZ</p>\n<p>Tulio de Oliveira, Ph.D., Africa Centre for Health and Population Studies, Nelson R Mandela School of Medicine Oliveira. Ph.D. Africa, University of KwaZulu-Natal, Durban, Africa do Sul.\n<p><b><i>Registration for workshops in 2013 is free of charge:</b></i> Workshop includes lectures, lunch and coffee-break. However, applicants need to fund their travel and accommodation costs.</p>\n<p><center><a href=\"workshops/BioinformaticsTropicsA3final.pdf\"><img src=\"imagesBIO/imageBioTropics.png\"></a></center></p>\n\n<p>', 'brazil, bioinformatics, tropics, fiocruz, africa centre, south africa, tulio de oliveira, molecular evolution, salvador, bahia, CNPQ, workshop, 2013, brazil, bioinformatics, tropics, fiocruz, africa centre, south africa, tulio de oliveira, molecular evolution, salvador, bahia, CNPQ, workshop, 2013, brazil, bioinformatics, tropics, fiocruz, africa centre, south africa, tulio de oliveira, molecular evolution, salvador, bahia, CNPQ, workshop, 2013, brazil, bioinformatics, tropics, fiocruz, africa centre, south africa, tulio de oliveira, molecular evolution, salvador, bahia, CNPQ, workshop, 2013, brazil, bioinformatics, tropics, fiocruz, africa centre, south africa, tulio de oliveira, molecular evolution, salvador, bahia, CNPQ, workshop, 2013', 'The workshop 22 to 26 of July, Oswaldo Moniz Research Center (CPqGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Bahia, Brazil involves theoretical lectures and practical sessions on the usage and interpretation of bioinformatics applications for the study of viruses drug resistance, molecular epidemiology and immunology. This workshop is targeted at scientists and post-graduate students working in research projects in Africa and Latin America.', NULL),
(77, 'imgnews77.png', 'http://www.bioafrica.net/news.php?id=78', 'Bioinformatics in the tropics II: Large data sets analysis workshop: HIV phylogenetics and drug resistance, Durban, South Africa, 23-26 Sept 2013', 'Africa Centre/SATuRN', 0, '2013-06-02', '<p>This is the second workshop of the bioinformatics in the tropics series, which will be presented by the Wellcome Trust Africa Centre for Health and Population Studies at K-RITH at the University of KwaZulu-Natal, Durban, South Africa, 23 to 27 September 2013. The bioinformatics in the tropics series is part of a south to south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America. </p>', NULL, NULL, '<center><p><b><i>Workshop topics?</center></b></i></p>\n<p>The workshop involves theoretical lectures and practical sessions on the usage and interpretation of bioinformatics applications for the study of large data sets of HIV genomic data. This workshop will be focused on the statistical analysis of HIV drug resistance and phylogenetic inference and interpretation of large trees. \n<p><center><b>Who should apply?</center></b></i></p>\nThis workshop is targeted at scientists and post-graduate students working in drug resistance and molecular epidemiology research projects in Africa.</p>\n<p><center><b><i>Application forms:</b></i></p>\n<b>Please download the <a href=\"workshops/bioinformaticstropicsSouthAfrica.doc\">application form here!!!</b></a>.</p><p><b>(Deadline for application: 20 August 2013)</b></p></center><br>\n<p><center><b><i>Contact information:</b></i></center></p>\n<p>For more information please contact:<br>Dr. Eduan Wilkinson (ewilkinson - at - africacentre.ac.za), <br>Dr. Justen Manasa (jmanasa - at - africacentre.ac.za), <br>Dr.  Deo Ssemwanga (Deogratius.Ssemwanga - at - mrcuganda.org) or <br>Dr. Jonathan Kayondo (jkayondo - at - uvri.go.ug)</p>\n<p><center><b><i>Presenters:</center></b></i></p>\n<p>Luiz Carlos Alcantara, Francois Chevenet, Stephen Cose, Tulio de Oliveira,  Siva Danaviah, Michelle Gordon, Josh Herbeck, Olivier Gascuel, Jonathan Kayondo, Justen Manasa, Chris Parry,  Deo Ssemwanga, Marco Salemi, Eduan Wilkinson and Anne-Mieke Vandamme.</p>\n<p></p>\n<p><center><b><i>Organizing Institutions:</center></b></i></p>\n<p>- The Wellcome Trust Africa Centre for Health and Population Studies, South Africa,</p> \n<p>- The Wellcome Trust MUII program at the Makerere University & Ugandan Virus Research Institute (UVRI), </p> \n<p>- The Medical Research Council (MRC)/UVRI Uganda Research Unit on AIDS, and </p> \n<p>- The Oswaldo Cruz Foundation (FIOCRUZ), in Salvador-Bahia, Brazil, with the National Council for Scientific and Technological Development (CNPQ).</p>\n<p><center><b><i>Workshop Series Organizers:</center></b></i></p>\n<p>Tulio de Oliveira, Alison Elliott, Pontiano Kaleebu and Luiz Carlos Alcantara. </p>\n<p></p>\n<p><b><i>Registration for two workshops in 2013 is free of charge:</b></i> Workshop includes lectures, lunch and coffee-break. However, applicants need to fund their travel and accommodation costs.</p>\n<p><center><a href=\"workshops/BioinformaticsTropicsA3final.pdf\"><img src=\"imagesBIO/imageBioTropics.png\"></a></center></p>\n', 'bioinformatics, tropics, workshop, large dataset, analysis, phylogeny, drug resistance, africa centre, wellcome trust, south africa, bioinformatics, tropics, workshop, large dataset, analysis, phylogeny, drug resistance, africa centre, wellcome trust, south africa, bioinformatics, tropics, workshop, large dataset, analysis, phylogeny, drug resistance, africa centre, wellcome trust, south africa, bioinformatics, tropics, workshop, large dataset, analysis, phylogeny, drug resistance, africa centre, wellcome trust, south africa', 'This is the second workshop of the bioinformatics in the tropics series, which will be presented by the Wellcome Trust Africa Centre for Health and Population Studies in Mkuze, South Africa, 23 to 27 September 2013. The bioinformatics in the tropics series is part of a south to south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America.', NULL),
(78, 'imgnews78.png', 'http://www.bioafrica.net/news.php?id=78', 'Bioinformatics in the tropics workshop series 2013-2014', 'Bioinformatics in the Tropics', 0, '2013-05-30', '<p>This is a series of four workshops, which will be presented in Brazil (2013 & 2014), South Africa (2013) and Uganda (2014) as part of a south to south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America. </p>', NULL, 4, '<p><center><a href=\"workshops/BioinformaticsTropicsA3final.pdf\"><img src=\"imagesBIO/imageBioTropics.png\"></a></center></p>\n<br>\n<p><center><b><i>Workshops 2013:</b></i></center></p>\n\n<a href=\"news.php?id=76\"><b>1st International Bioinformatics & Molecular Viral Evolution Workshop, 22 to 26 of July 2013 </b>, Oswaldo Moniz Research Center (CPqGM), Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Bahia, Brazil. (Deadline for application: 15 June)</a></p>\n<p></p>\n<p><a href=\"news.php?id=77\"><b>Large HIV data sets analysis workshop: phylogenetics, molecular epidemiology and drug resistance,  23 to 27 September 2013</b> Africa Centre for Health and Population Studies, Mtubatuba, KwaZulu-Natal, South Africa. (Deadline for application: 20 August)</a></p>\n\n<p><center><b><i>Workshop topics and who should apply?</center></b></i></p>\n<p>The workshop involves theoretical lectures and practical sessions on the usage and interpretation of bioinformatics applications for the study of viruses and TB drug resistance, molecular epidemiology and immunology.</p>\n<p>This workshop is targeted at scientists and post-graduate students working in research projects in Africa and Latin America.</p>\n<p>The objective is to train post-doctoral researchers to become trainers and post-graduate students to use bioinformatics and phylogenetic software applications needed for their research.</p>\n<p></p>\n<p><center><b><i>Organizing Institutions:</center></b></i></p>\n<p>- The Wellcome Trust Africa Centre for Health and Population Studies, South Africa,</p> \n<p>- The Wellcome Trust MUII program at the Makerere University & Ugandan Virus Research Institute (UVRI), </p> \n<p>- The Medical Research Council (MRC)/UVRI Uganda Research Unit on AIDS, and </p> \n<p>- The Oswaldo Cruz Foundation (FIOCRUZ), in Salvador-Bahia, Brazil, with the National Council for Scientific and Technological Development (CNPQ).</p>\n<p><center><b><i>Workshop Series Organizers:</center></b></i></p>\n<p>Tulio de Oliveira, Alison Elliott, Pontiano Kaleebu and Luiz Carlos Alcantara. </p>\n<p>*Please note that each workshop will have its organizing committee.</p>\n<p></p>\n<p><center><b><i>Funders:</b></i></center></p>\n<p>European Union, CDC/PEPFAR, Wellcome Trust, National Council for Scientific and Technological Development (CNPQ).</p>\n', 'bioinformatics, tropics, workshop, series, Uganda, Brazil, South africa, genomics, wellcome trust, MRC,bioinformatics, tropics, workshop, series, Uganda, Brazil, South africa, genomics, wellcome trust, MRC, bioinformatics, tropics, workshop, series, Uganda, Brazil, South africa, genomics, wellcome trust, MRC, bioinformatics, tropics, workshop, series, Uganda, Brazil, South africa, genomics, wellcome trust, MRC', NULL, 'N'),
(79, 'imgnews79.png', 'http://www.sajhivmed.org.za/index.php/sajhivmed/article/view/931', 'BOOK REVIEW - HIV & TB Drug Resistance & Clinical Management Case Book', 'Southern African Journal of HIV Medicine', 64, '2013-06-20', '<p>by Sigaloff & Hamers, The Southern African Journal of HIV Medicine, Book Review on the HIV  & TB Drug Resistance & Clinical Management Case Book by Rossouw, Lessells and de Oliveira</p>', NULL, NULL, '<p>South Africa (SA) is home to the highest number of HIVinfected people in any country, and has the largest HIV treatment program worldwide, with 2 million patients currently receiving combination antiretroviral therapy (ART). The country also has a massive tuberculosis (TB) epidemic, and TB/HIV co-infection is a common challenge for clinicians. The increasing number of patients who are infected with drug-resistant strains of TB and/ or HIV in Southern Africa poses a mounting threat to successful treatment. Drug-resistance testing for patients failing therapy is available at reference laboratories, which contrasts the situation in many countries in sub-Saharan Africa. This provides an important tool to protect the sustained effectiveness of available TB and HIV therapies; however, interpretation of drug resistance reports is complex and expert guidance to clinicians may be required for optimal clinical management. </p>\n<p>In this context, the recently published HIV & TB Drug Resistance & Clinical Management Case Book by Rossouw, Lessells and de Oliveira, is an important aid to clinicians in SA and beyond, who are managing complex cases of patients with HIV and TB drug resistance. It provides a comprehensive background to the development of drug resistance as well as up-to-date clinical knowledge on how to diagnose and manage drug-resistant infections. The book uses an instructive casebased learning approach, with 14 HIV and 6 TB cases. After a brief review of technical details, each clinical case is presented in a structured manner. The description of the case is followed by the clinical chart and drug-resistance results. The drugresistance report is translated into a clear and evidence-based recommendation for clinical management. Lessons from each case are excellently summarised in <b><i>\'key learning points\'</b></i>. The cases cover diverse and illustrative examples of adult and paediatric patients with therapy failure, thus addressing actual problems that clinicians will deal with in daily practice. </p>\n<p><b><i>Many of the cases in the book highlight errors in management that contributed to the emergence of drug resistance. These \'preventable\' cases of drug resistance provide important lessons; avoiding these mistakes will advance clinical practice and benefit patients. Preventing acquired drug resistance in patients receiving treatment will also have major public health consequences, as these cases are the source of onward transmission of drug resistance to newly infected individuals.</b></i> </p>\n<p>A common feature of the HIV cases is that they used the SATuRN RegaDB drug resistance database to construct a complete clinical chart and resistance report for each patient. This database conveniently summarises all clinical and laboratory information into a clinical chart including treatment history, CD4 counts and viral load results. It also interprets the drug-resistance genotype using the Stanford HIVDB algorithm. The SATuRN information management system provides an excellent example of how bioinformatics tools can be utilised to the benefit of the physician and patient. </p>\n<p>In conclusion, this book is an excellent practical compendium of knowledge in the field of HIV and TB drug resistance, set in the highly relevant context of Southern Africa where drugresistant strains of HIV and TB are increasingly reported. It provides expert guidance in difficult clinical situations and explains the steps to be taken to prevent the emergence and transmission of drug resistance. This book highlights the fact that education and training are fundamental steps in the implementation of technologies such as viral-load and drugresistance testing, so that they can be used to full advantage. </p>\n<p></p>\n<p><b><i>Authors:</b></i></p>\n<p>K C E Sigaloff, MD, PhD </p>\n<p>R L Hamers, MD, PhD </p>\n<p>Department of Global Health, Academic Medical Center of the University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</p>\n<p><b><i>Download:</b></i><a href=\"manuscripts/Sigaloff_Hamers_BookReview2013.pdf\"> full-text book review article</a>.</p>\n', 'book, review, hiv, tb, drug resistance, clinical management, southern African journal of HIV medicine, sigaloff, hamers, de oliveira, Lessells, Rossouw,book, review, hiv, tb, drug resistance, clinical management, southern African journal of HIV medicine, sigaloff, hamers, de oliveira, Lessells, Rossouw,book, review, hiv, tb, drug resistance, clinical management, southern African journal of HIV medicine, sigaloff, hamers, de oliveira, Lessells, Rossouw,book, review, hiv, tb, drug resistance, clinical management, southern African journal of HIV medicine, sigaloff, hamers, de oliveira, Lessells, Rossouw', 'BOOK REVIEW - ?HIV & TB Drug Resistance & Clinical Management Case Book? by Sigaloff & Hamers, The Southern African Journal of HIV Medicine Book Review on the HIV & TB Drug Resistance & Clinical Management Case Book by Rossouw, Lessells and de Oliveira\n', NULL),
(80, 'imgnews80.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_2_2013A4.pdf', 'SATuRN Newsletter, Aug 2013: Special Edition - Training and Capacity Building', 'SATuRN', 0, '2013-08-06', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN. The newsletter is presented as a PDF document with links to complete articles at the bioafrica.net website.</p>	', NULL, NULL, '<p>In this second issue of 2013 our newsletter we focus on training and capacity building.</p>\n<p>We want to let you know that we have finalized the organization of our annual meeting (<a href=\"http://bioafrica.net/workshops/8thsaturnPaserresitanceworkshop.html\"><b>8th Southern Africa HIV &TB Drug resistance Workshop, 20-22 Nov 2013, Bloemfontein, South Africa</b></a>) and remind you that the deadline for applications is on <b><i>10 September 2013</b></i>. Please do not forget to apply!</p>\n<p>We have also included interesting news, blogs, reports, tweets and publications produced by our network. </p>\n<p>We hope you enjoy it and find it informative. We welcome any feedback about content or format.</p>\n<p><a href=\"manuscripts/SATuRNnewsletter_2_2013A4.pdf\"><img src=\"imagesBIO/imgnews80big.png\"></a></p>\n<p><b><i>Highlights:</b></i></p>\n<p><a href=\"http://bioafrica.net/blogs.php?id=26\">South African AIDS scientist to lead UNAIDS Expert Panel</a></p>\n\n<p><a href=\"http://bioafrica.net/report.php?id=20\">Major data analysis determines the trends of HIV-1 drug resistance mutations in South Africa</a></p>\n\n<p><a href=\"http://www.bioafrica.net/manuscripts/bioafricaKRITHTBbioinformaticscourse.pdf\">Comparative Genomics of M. tuberculosis Workshop, K-RITH, Durban, South Africa, 16 to 20 Sept 2013</a></p>\n\n<p><a href=\"http://www.bioafrica.net/news.php?id=77\">Large data sets analysis workshop: HIV phylogenetics and drug resistance, Durban, South Africa, 23-27 Sept 2013</a></p>\n\n<p><a href=\"http://awacc.org/\">Annual Workshop on Advanced Clinical Care - AIDS (AWACC). Durban, South Africa, 26 to 27 September 2013</a></p>\n\n<p><a href=\"http://www.bioafrica.net/news.php?id=75\">Infectious Disease Genomics and Global Health Wellcome Trust Conference, Cambridge, U.K., 16-18 Oct 2013</a></p>\n\n<p><a href=\"http://bioafrica.net/workshops/8thsaturnPaserresitanceworkshop.html\">8th Southern African HIV & TB Drug Resistance and Treatment Monitoring Workshop, University of the Free State, Bloemfontein, South Africa, 20-22 Nov 2013</a></p>\n\n', 'saturn, newsletter, 2013, hiv tb, practical course, training, capacity building, caprisa, bioinformatics, 8th southern african, treatment, resistance, workshop, awacc, saturn, newsletter, 2013, hiv tb, practical course, training, capacity building, caprisa, bioinformatics, 8th southern african, treatment, resistance, workshop, awacc, saturn, newsletter, 2013, hiv tb, practical course, training, capacity building, caprisa, bioinformatics, 8th southern african, treatment, resistance, workshop, awacc, saturn, newsletter, 2013, hiv tb, practical course, training, capacity building, caprisa, bioinformatics, 8th southern african, treatment, resistance, workshop, awacc', 'In this second issue of 2013 our newsletter we focus on training and capacity building.We want to let you know that we have finalized the organization of our annual meeting (8th Southern Africa HIV &TB Drug resistance Workshop, 20-22 Nov 2013, Bloemfontein, South Africa. We have also included interesting news, blogs, reports, tweets and publications produced by Southern African Treatment Resistance Network (SATuRN)', NULL),
(81, 'imgnews81.png', 'http://www.wellcome.ac.uk/News/Media-office/Press-releases/2013/WTP053805.htm', 'New Director named for leading HIV research centre in South Africa', 'Wellcome Trust', NULL, '2013-09-02', '<p>Deenan Pillay, Professor of Virology at UCL (University College London), is today named as the new Director of the Africa Centre for Health and Population Studies, one of the Wellcome Trust\'s major overseas programmes.</p>\n<p></p>\n', NULL, NULL, '<p>The Africa Centre is part of the University of KwaZulu-Natal (UKZN) and is based within a rural population with one of the highest burdens of HIV in the world. There, it carries out research into the impact of the virus on the local community and, in partnership with the local Department of Health, runs one of the region\'s largest rural, primary-care-level antiretroviral therapy programmes. It also has a strong capacity-building programme, providing opportunities for staff to study towards university degrees, including Master\'s degrees and doctorates, and for community members to gain other skills-based training.</p>\n<p></p>\n<p>Deenan Pillay is Professor of Virology, and Co-Director of the Division of Infection and Immunity, at University College London. He is a clinical virologist, having trained in London, Newcastle and San Diego, and has a long standing research and clinical interest in HIV virology, particularly related to the study of global HIV drug resistance andtransmission. He helped establish the Bloomsbury Research Institute, a partnership betweeninfectious disease research groups from UCL and the London School of Hygiene and Tropical Medicine.</p>\n<p></p>\n<p><b><i>Dr Ted Bianco</b></i>, Acting Director of the Wellcome Trust, says: <b><i>\'We are delighted that Deenan Pillay has agreed to take up the role of Director of the Africa Centre. Deenan is a highly respected clinical investigator in the research and public health communities.He has shown great leadership in creating partnerships amongst researchers and institutions, as illustrated by the Bloomsbury Research Institute.Such experience will prove extremely valuable in building the collaborative relationships that will maximise the value of the Africa Centre.\' </b></i></p>\n<p></p>\n<p><b><i>Professor Pillay</b></i> says: <b><i>\'This is a very exciting new challenge. The potential to answer some of the key remaining questions relating to spread of infections such as HIV and TB is immense. To do so in the dynamic setting of South Africa, with its rapidly emerging biomedical research strength, is a tremendous privilege.\' </b></i></p>\n<p></p>\n<p><b><i>Professor Nelson Ijumba</b></i>, UKZN\'s Deputy Vice-Chancellor: Research, says: <b><i>\'UKZN would like to congratulate Professor Pillay on his appointment and hope that, through his leadership, the Africa Centre will continue to be at the forefront of knowledge production and community empowerment in HIV/AIDS.\' </b></i></p>\n<p></p>\n<p>The Africa Centre was established by the Wellcome Trust in partnership with the South African Medical Research Council in 1998 and employs around 350 people, including around 25 scientists. The cornerstone of its research programme is a biannual household demographic survey that since 2000, has collected data on births, deaths, marriage and migration events, as well as household economics. The survey covers a population of around 90,000 people in 11,000 households.</p>\n<p></p>\n<p>An additional annual HIV surveillance study, established in 2003, covers adults 15 years and older, collecting data on HIV status, sexual behaviour and relationships, and other health issues. The Centre also has a virology laboratory at the Medical School in Durban, with research relating to the dynamics of HIV in breast milk and population viral phylogenetics.</p>\n<p></p>\n<p>The Centre has been behind several high profile research papers recently, including two papers in the journal Science this year demonstrating for the first time the positive impact of antiretroviral therapy on the rate of new HIV infections in a community setting (1) and that such therapies are a highly cost-effective investment for the people of South Africa (2).</p>\n<p></p>\n<p>Professor Pillay will take up his post at the Africa Centre on a secondment from UCL on 1 November 2013. His appointment follows the decision by Professor Marie-Louise Newell to return to the UK to take up a position at the University of Southampton. Professor Newell has been Director of the Africa Centre since 2005.</p>', 'Deenan Pillay, wellcome trust, director, Africa Centre, Africa Centre for Health and Population Studies, South Africa, Mtubatuba, UKZN, University of KwaZulu-Natal, Africa, Deenan Pillay, wellcome trust, director, Africa Centre, Africa Centre for Health and Population Studies, South Africa, Mtubatuba, UKZN, University of KwaZulu-Natal, Africa, Deenan Pillay, wellcome trust, director, Africa Centre, Africa Centre for Health and Population Studies, South Africa, Mtubatuba, UKZN, University of KwaZulu-Natal, Africa, Deenan Pillay, wellcome trust, director, Africa Centre, Africa Centre for Health and Population Studies, South Africa, Mtubatuba, UKZN, University of KwaZulu-Natal, Africa', 'Deenan Pillay, Professor of Virology at UCL (University College London), is today named as the new Director of the Africa Centre for Health and Population Studies, one of the Wellcome Trust?s major overseas programmes.The Africa Centre is part of the University of KwaZulu-Natal (UKZN) and is based within a rural population with one of the highest burdens of HIV in the world. There, it carries out research into the impact of the virus on the local community and, in partnership with the local Department of Health, runs one of the region\'s largest rural, primary-care-level antiretroviral therapy programmes.', NULL),
(82, 'imgnews82.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_3_2013A4.pdf', 'Newsletter, Oct 2013: News, blogs, manuscripts & Youtube videos!', 'SATuRN', 70, '2013-10-01', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN. In this third issue of 2013 our newsletter we focus on our digital videos activities. We have also included interesting news, blogs, reports, tweets, publications and training information produced by our network.</p>', NULL, NULL, '<p><a href=\"manuscripts/SATuRNnewsletter_23_2013A4.pdf\"><img src=\"imagesBIO/imgnews82big.png\"></a></p>\n<br><p><b><i>This issue\'s highlights are:</b></i></p>\n<br><p><a href=\"http://bioafrica.net/blogs.php?id=27\">Blog & Publication: Unresolved non-adherence drives early 2nd line ART failure</a></p>\n<p><a href=\"http://bioafrica.net/blogs.php?id=30\">Blog: Simultaneous detection of major HIV-1 drug resistance mutations using a multiplex allele-specific assay</a></p>\n<p><a href=\"http://bioafrica.net/blogs.php?id=31\"> Blog: Multi-step inhibition explains HIV-1 Protease inhibitor pharmacodynamics and resistance</a></p>\n<p><a href=\"http://bioafrica.net/videos.php?id=1\">Video: HIV & TB drug resistance and clinical management casebook</a></p>\n<p><a href=\"http://bioafrica.net/publications.php?pubid=70\">Video & Publication: High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa.</a></p>\n<p><a href=\"http://bioafrica.net/blogs.php?id=29\">VideoBlog: SATuRN and PASER Scientific Meeting</a></p>\n<p><a href=\"http://www.uwc.ac.za/Faculties/CHS/soph/Announcements/Pages/Call-for-Emerging-Voices-of-Global-Health-(EV4GH)-AIDS-in-Africa,-ICASA-2013.aspx\"> Workshop: Emerging Voices for Global Health (EV4GH), School of Public Health (SoPH), University of the Western Cape, Cape Town, South Africa, 25 November till 13 December 2013</a>\n<br><p><b><i>Produced by:</b></i> Tulio de Oliveira, Tobias Rinke de Wit, Justen Manasa, Lungani Ndwandwe, Sonia Boender, Christopher Hoffmann, Raph Hamers, Lynn Morris, Anna Salimo, Jennifer Giandhari & Chris Seebregts</a>', 'SATuRN, newsletter, 2013, october, youtube, videos, publications, drug resistance, hiv, de oliveira, SATuRN, newsletter, 2013, october, youtube, videos, publications, drug resistance, hiv, de oliveira, SATuRN, newsletter, 2013, october, youtube, videos, publications, drug resistance, hiv, de oliveira, SATuRN, newsletter, 2013, october, youtube, videos, publications, drug resistance, hiv, de oliveira', 'In this third SATuRN newsletter issue of 2013  we focus on our digital videos activities. We have also included interesting news, blogs, reports, tweets, publications and training information produced by our southern African Treatement Resistance Network.', NULL),
(83, 'imgnews83.png', 'http://www.ukzn.ac.za/news//2013/10/31/multi-million-rand-award-to-ukzn-scientists-for-cutting-edge-hiv-research', 'Multi-million rand award to UKZN scientists for Cutting-Edge HIV Research', 'UKZN', 0, '2013-10-30', '<p>Professor Frank Tanser and Professor Tulio de Oliveira from UKZN\'s Africa Centre for health and Population studies were recently awarded a large grant to fight HIV drug resistance and transmission in rural KwaZulu-Natal. The grant, funded by the Medical Research Council (MRC) Flagship Projects is part of the MRC\'s strategy to sustain vibrant medical research in South Africa.</p>', NULL, NULL, '<p>With the expansion of HIV/TB treatment in South Africa and over 1.8 million patients on antiretrovirals (ARVs), drug resistance is fast becoming a growing concern. Despite significantly rolling out ARVs country-wide, attention to the management of individual patients with resistance strains has been neglected. Drug resistance testing is considered expensive, time consuming and dependent on high-level technology (such as genetics, biotechnology and bioinformatics). However, the focus is likely to change now.</p>\n\n<p>This award will allow de Oliveira, a bioinformatician, and Tanser, an epidemiologist specializing in GIS, to work together to produce a unique framework to understand HIV-1 transmission and resistance. In addition, the award will allow them to collaborate closely with six other leading research groups based at UKZN (HEARD, K-RITH, HIV Pathogenesis Programme, Computer Science, Genetics and Infectious Diseases) to develop a framework to prevent HIV transmission and resistance.</p>', 'UKZN, news, website, multi-million award, MRC, flagship, Africa Centre, UKZN, HIV, transmission, drug resistance,UKZN, news, website, multi-million award, MRC, flagship, Africa Centre, UKZN, HIV, transmission, drug resistance,UKZN, news, website, multi-million award, MRC, flagship, Africa Centre, UKZN, HIV, transmission, drug resistance,UKZN, news, website, multi-million award, MRC, flagship, Africa Centre, UKZN, HIV, transmission, drug resistance', 'Professor Frank Tanser and Professor Tulio de Oliveira from UKZN?s Africa Centre for health and Population studies were recently awarded a R16.5 million grant to fight HIV drug resistance and transmission in rural KwaZulu-Natal. The grant, funded by the Medical Research Council (MRC) Flagship Projects is part of the MRC?s strategy to sustain vibrant medical research in South Africa.', NULL),
(84, 'imgnews84.png', 'http://www.bioafrica.net/manuscripts/DVC_COMM_MRC_GRANT.pdf', '16.5 million rand to convert cutting-edge HIV research in rural South Africa into national policy', 'Africa Centre & UKZN DVC', 1, '2013-10-31', '<p>Professor Salim Abdool Karim and Health Minister, Dr Aaron Motsoaledi, awarded a R16.5 million grant to fight HIV drug resistance and transmission in rural KwaZulu-Natal.</p>\n', NULL, NULL, '<p>This grant was awarded to support the work of two scientists at the Wellcome Trust\'s Africa Centre for Health and Population Studies, a rural HIV & TB research centre in Hlabisa, South Africa, which is based in the University of KwaZulu-Natal. Professor Tulio de Oliveira and Professor Frank Tanser recently showed that antiretroviral treatment can decrease HIV-1 transmission; however the success of the national treatment programme is threatened by rapid drug resistance. </p>\n<p><img src=\"imagesBIO/imgnews84big.png\"></p>\n<p><i>Prof. Tulio de Oliveira receives the award from the Department of Science and Technology (DST) Deputy Minister,  advocate Michael Masutha.</b></i></p>\n<p>With the expansion of HIV/TB treatment in South Africa and over 1.8 million patients on antiretrovirals (ARVs), drug resistance is fast becoming a growing problem. Hence, despite significantly rolling out ARVs country-wide, not a lot of attention was given to the individual management of patients with resistance strains. Drug resistance testing was considered to be expensive, time consuming and dependent on high-level technology (such as genetics, biotechnology and bioinformatics). However, the focus is likely to change now.</p>\n<p></p>\n<p>The two ground-breaking studies by Tanser and de Oliveira were published in the leading scientific journal, Science and Nature respectively. Tanser\'s study found that widespread antiretroviral therapy curbed the rate of new HIV infections in Africa. de Oliveira\'s study indicated that genomic data which can be used for the clinical management of patients with resistance strains and to understand patterns of HIV transmission, can now be produced cost effectively- locally. </p>\n<p></p>\n<p>This award will allow de Oliveira, a bioinformatician, and Tanser, an epidemiologist specializing in GIS, to work together to produce a unique framework to understand HIV-1 transmission and resistance. In addition, the award will allow them to collaborate closely with six other leading research groups based at UKZN (HEARD, K-RITH, HIV Pathogenesis Programme, Computer Science, Genetics and Infectious Diseases) to develop a framework to prevent HIV transmission and resistance.</p>\n<p></p>\n<p><b><i>\'HIV drug resistance is a very serious problem in South Africa, and the recent advances in resistance testing technology and in understanding patterns of transmission will allow us not only to extend the life of patients failing treatment but also to produce policies of national interest that save hundreds of millions of rand in government programs in the next few years\'</b></i>, according to de Oliveira.</p>\n<p>Tanser added, <b><i>\'We are delighted to have received this award. It provides us with an unparalleled opportunity to understand patterns of HIV transmission and drug resistance in hyper-endemic southern African populations. The results will contribute directly to establishing the most effective treatment and prevention strategies in such settings.\'</b></i></p>\n<p></p>\n<p>Professor Moses Chimbari, Dean of Research at the College of Health Sciences at UKZN argues <b><i>\'a multi-disciplinary approach is needed to understand these complex problems in order to translate research results into policies of national interest and to ensure that southern Africa\'s HIV treatment programs are highly effective. In this regard we welcome this award and expect it to contribute substantial scientific insights into ways of halting and reversing the HIV epidemic\'</b></i>. </p>\n<p></p>\n<p>###</p>\n<p>The Flagship Project grants are the largest medical research grants from the MRC. </p>', 'President, Medical Research Council, MRC, Professor Salim Abdool Karim, Health Minister, Dr Aaron Motsoaledi, award,  R16.5 million, grant, fight, HIV, drug resistance, transmission, rural, KwaZulu-Natal, Prof. Tulio de Oliveira, Department of Science and Technology, DST, Deputy Minister, advocate Michael Masutha, President, Medical Research Council, MRC, Professor Salim Abdool Karim, Health Minister, Dr Aaron Motsoaledi, award,  R16.5 million, grant, fight, HIV, drug resistance, transmission, rural, KwaZulu-Natal, Prof. Tulio de Oliveira, Department of Science and Technology, DST, Deputy Minister, advocate Michael Masutha, President, Medical Research Council, MRC, Professor Salim Abdool Karim, Health Minister, Dr Aaron Motsoaledi, award,  R16.5 million, grant, fight, HIV, drug resistance, transmission, rural, KwaZulu-Natal, Prof. Tulio de Oliveira, Department of Science and Technology, DST, Deputy Minister, advocate Michael Masutha', 'Cape Town, 31 October 2013. Yesterday, President of the Medical Research Council (MRC), Professor Salim Abdool Karim and Health Minister, Dr Aaron Motsoaledi, awarded a R16.5 million grant to fight HIV drug resistance and transmission in rural KwaZulu-Natal.Prof. Tulio de Oliveira receives the award from the Department of Science and Technology (DST) Deputy Minister, advocate Michael Masutha.', NULL),
(85, 'imgnews85.png', 'http://www.mrc.ac.za/pressreleases/2013/6press2013.htm', 'The SA Medical Research Council announces funding of R190 million for high impact research projects', 'MRC', NULL, '2013-11-01', '<p>The MRC has established a new high-profile R190 million funding opportunity for Medical Schools and Universities to undertake <b>\'Flagship Projects\'</b> aimed at addressing South Africa\'s key health problems.  The winning projects, led by some of South Africa\'s most accomplished scientists, were announced at a media briefing at the MRC in Cape Town on Wednesday evening.</p>', NULL, NULL, '<p><a href=\"manuscripts/MRCFlagshipAwardsGuide.pdf\"><img src=\"imagesBIO/imgnews85big.png\"></p>\n<p><i>MRC Awards information guide 2013 (pdf format, 2275 kb) contains information on all of the projects awarded</i></p></a>\n<p>The introduction of these high impact flagship projects to undertake large scale projects comes after National Treasury provided funding to the MRC under its Economic Competitiveness and Support Package to support the rejuvenation of medical research in South Africa.</p>\n<p></p>\n<p>A total of R150 million, over three years, has been granted to twelve projects at Universities across the country whilst five MRC intramural projects have been granted R40 million over the same period. All seventeen of these projects address the health priorities of the nation and aim to place South African medical research and innovation at the highest platform globally. </p>\n<p></p>\n<p><b><i>\'University professors were complaining that they couldn\'t do the research they needed to do,\' </b></i>said MRC President Professor Salim Abdool Karim at the media briefing attended by dignitaries and world renowned scientists. <b><i>\'And so this money is for the revitalisation of medical research in South Africa. We want our universities to be the best in the world.\'</b></i></p>\n<p></p>\n<p>The MRC received 29 applications for Flagship projects from 18 Universities. The applications were then subjected to rigorous international peer-review, which led to 12 of the Universities (66%) being successful. About two out of every five applications (about 40%) were successful, indicating just how competitive it is to get one of these grants. The grants provide about R16million for a large project and R8million for a moderately large research project.  </p>\n<p></p>\n<p>The research programme areas of these flagship projects cover a wide number of disease areas including HIV, Tuberculosis, Malaria, Burden of Disease, Cardiovascular and Metabolic Disease, Alcohol and Drug Abuse and Women\'s Health; areas of health that present a major challenge in South Africa.</p>\n<p></p>\n<p><br><b><i>\'There is a need for research to be conducted locally,\'</b></i> said Minister of Health, Dr Aaron Motsoaledi, <b><i>\'and these flagship projects will address this urgent need and show the world that we can also produce world-class scientists.\'</b></i></p>\n<p><b>News coverage on the MRC Flagship Project awarded to Prof. Tulio de Oliveira & Frank Tanser:</b></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=84\">16.5 million rand to convert cutting-edge HIV research in rural South Africa into national policy</a></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=83\">Multi-million rand award to UKZN scientists for Cutting-Edge HIV Research</a>', 'MRC, award, Cape Town, Medical Research council, 2013, tulio de oliveira, Salim Karim, MRC, award, Cape Town, Medical Research council, 2013, tulio de oliveira, Salim Karim, MRC, award, Cape Town, Medical Research council, 2013, tulio de oliveira, Salim Karim, MRC, award, Cape Town, Medical Research council, 2013, tulio de oliveira, Salim Karim', 'The MRC has established a new high-profile R190 million funding opportunity for Medical Schools and Universities to undertake Flagship Projects aimed at addressing South Africa key health problems.  The winning projects, led by some of South Africa most accomplished scientists, were announced at a media briefing at the MRC in Cape Town on Wednesday evening.', NULL),
(86, 'imgnews86.png', 'http://www.bioafrica.net/workshops/WAD_UKZN_HIV_PANEL_DISCUSSION_INVITE_2013_A3.pdf', 'A UKZN panel discussion: Bringing the \'I\' into HIV - New approaches in developing person-centred interventions to fight the HIV epidemic', 'UKZN, CAPRISA & HEARD', 0, '2013-11-08', '<p>A UKZN panel discussion on 26 November 2013: \'Bringing the \'I\' into HIV - New approaches in developing person-centred interventions to fight the HIV epidemic\' as part of World AIDS Day 2013 activities.</p>', NULL, NULL, '<p>The event will take place on Tuesday 26 November 2013 from 12h00-14h00 in the new lecture theatre L7, 3rd floor, Nelson R Mandela School of Medicine, Umbilo Road.</p>\n<p></p>\n<p>Professor Rob Slotow, Deputy Vice-Chancellor and Head of the College of Health Sciences at UKZN, will be the programme director, and our confirmed panelists include:</p>\n<br>\n<p><b>Professor Alan Whiteside, Executive Director of HEARD</b></p>\n<p> - Prevention is key to stop AIDS: We can\'t treat our way out of the epidemic</p>\n<p><b>Professor Thumbi N\'dungu, K-RITH Investigato</b>r</p>\n<p> - An HIV-1 vaccine is possible</p>\n<p><b>Professor Salim S Abdool Karim, Director of CAPRISA</b></p>\n<p>- Promising HIV/AIDS research and implications for health policy and guidelines</p>\n<p><b>Dr Themba Moeti, CEO of Health Systems Trust</b></p>\n<p>- Reflections on patient and community perspectives of translating research innovations into policy and practice</p>\n<p><b>Professor Tulio de Oliveira, Research Professor: College of Health Sciences</b></p>\n<p>- DNA sequencing and bioinformatics for the study of the explosive HIV epidemic in Southern Africa</p>\n<br>\n<p>At the end of the debate, the panellists will be invited to light a candle and pose for a photograph.</p>\n<p></p>\n<p>An information desk will be set up outside the venue where each organisation will display promotional material.</p>\n<p></p>\n<p>We are all looking forward to an exciting, informative and energetic debate.</p>\n<p></p>\n<p>Warm regards</p>\n<p></p>\n<p><b>The Organising Committee:</b></p>\n<p></p>\n<p>MaryAnn Francis, UKZN; Judith Annakie-Eriksen, CAPRISA; Shela McCullough, HEARD; Linda Mtambo, HEARD; Judith King, Health Systems Trust; Wendy Jasson da Costa, Health Systems Trust; Emma Mackie, K-RITH; Notokozo Majozi, National Health Laboratory Service', 'panel, Alan Witheside, Salim Karim, tulio de oliveira, Thumbi ndungu, UKZN, 2013, aids, hiv, discussion, Nelson R Mandela School of Medicine, south africa, panel, Alan Witheside, Salim Karim, tulio de oliveira, Thumbi ndungu, UKZN, 2013, aids, hiv, discussion, Nelson R Mandela School of Medicine, south africa, panel, Alan Witheside, Salim Karim, tulio de oliveira, Thumbi ndungu, UKZN, 2013, aids, hiv, discussion, Nelson R Mandela School of Medicine, south africa', 'A UKZN panel discussion on 26 November 2013: \'Bringing the \'I\' into HIV - New approaches in developing person-centred interventions to fight the HIV epidemic\' as part of World AIDS Day 2013 activities. This panel include some of the high-caliber researchers at UKZN, including Prof Tulio de Oliveira, Prof Slim Karim, Prof, Thumbi Ndungu, Prof Alan Whiteside ', NULL),
(87, 'sabcnews.png', 'http://www.bioafrica.net/newmedia/TuliodeOliveiraSAFM.mp3', 'SAFM Radio Interview with Prof. Tulio de Oliveira on their HIV Drug Resistance and Transmission Research and Award', 'SAFM', NULL, '2013-11-03', '<p>Radio interview by Sisanda Jonas at SAfm weekend pmlive show 3 Nov 2013</p>', NULL, NULL, '<p><b><i>Interview Questions:</b></i></p>\n<p>** Briefly explain the work you do at the UKZN\'s Africa Centre for Health and Population Studies</p>\n<p> </p>\n<p>** Recently you and Professor Frank Tanser  showed that antiretroviral treatment can decrease HIV-1 transmission; however the success of the national treatment programme is threatened by rapid drug resistance....  and you have also highlighted that the attention of the management of individual patients with resistance strains has been neglected.... elaborate on this and how serious is the problem of HIV drug resistance in South Africa?</p>\n<p> </p>\n<p>** Your ground-breaking study published in the leading scientific journals, Science and Nature  indicated that genomic data, which can be used for the clinical management of patients with resistance strains and to understand patterns of HIV transmission, can now be produced cost effectively, locally...briefly take us through your findings?</p>\n<p> </p>\n<p>** In light of this what is the significance of this funding , how will it help your work, what will it allow you to do?</p>\n<p> </p>\n<p>** What is the long term goal of your work and what is the importance of understanding these complex problems and the benefit for Southern Africa?</p>\n<p><b>Listen to the 5 minutes interview by Prof. Tulio de Oliveira:</b></p>\n<p> <embed src=\"newmedia/TuliodeOliveiraSAFM.mp3\" autostart=\"false\" loop=\"FALSE\" &gt;play=\"\" the=\"\" complete=\"\" cd=\"\" with=\"\" messages=\"\" height=\"40\" width=\"200\"><b></p>\n', 'MRC, award, tulio de oliveira, radio interview, 2013, SABC, live, HIV treatment, drug resistance, award, grant, medical research council, MRC, award, tulio de oliveira, radio interview, 2013, SABC, live, HIV treatment, drug resistance, award, grant, medical research council, MRC, award, tulio de oliveira, radio interview, 2013, SABC, live, HIV treatment, drug resistance, award, grant, medical research council', 'Radio interview on Sunday pmlive show of SABC/SAfm radio. In this interview Sisanda Jonas interview Prof. Tulio de Oliveira, Africa Centre UKZN on their research and grant awarded on HIV drug resistance and transmission 2013.', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(88, 'imgnews88.png', 'http://www.bioafrica.net/manuscripts/PressReleaseUFSworkshop2013.pdf', 'International Workshop in Bloemfontein to Translate Research and Clinical Knowledge into Clinical Practice to Fight HIV & TB Drug Resistance in Africa', 'UFS Press Release', 0, '2013-11-19', '<p>BLOEMFONTEIN, 21 November 2013. Today, a large intentional workshop on HIV & TB drug resistance starts, which will bring some of the top international researchers, clinicians and policy makers to the University of the Free State in order to discuss strategies to manage and prevent drug resistance in Africa. </p>', NULL, NULL, '<p>Furthermore, during this event a new DNA sequencer will be launched at University of the Free State that will allow the Free State province to produce viral and bacterial genetic data to fight the local development of drug resistance.</p>\n\n<p>The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world with over 2 million patients on treatment. However, these successful treatment programs are now being threatened by the appearance of drug resistance. The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2,000 medical officers in the treatment of drug resistance strains. </p>\n\n<p>The Department of Medical Microbiology and Virology at the Medical School at UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV & TB drug resistance results. This new machine will allow enable cutting-edge research to take place with the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques.</p>\n\n<p><b><i>\'HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients failing treatment appropriately and use the results to cost effectively extend and improve patients lives\'</b></i>, says Dr. Cloete Van Vuuren, an Infectious Diseases Specialist at the Medical School, University of the Free State. Dr. Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at UFS adds: <b><i>\'We have been looking forward to expanding our work with the clinicians and researchers to use DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province\'</b></i>.  </p>\n\n<p><b><i>\'This workshop is a very important event, as nearly 200 South African medical officers will be trained to manage patients with resistance strains\'</b></i> argues Prof. Tulio de Oliveira, a geneticist from the Wellcome Trust Africa Centre for Health and Population Studies at the University of KwaZulu-Natal and the director of the Southern African Treatment Resistance Network (SATuRN). He continues, <b><i>\'It is the third time that this workshop has been hosted in Bloemfontein. Our decision to host the workshop here is due to the commitment and expertise of local researchers and clinicians. This year, we have managed to bring some of the top researchers and clinicians from the USA, Canada, the U.K., Brazil, the Netherlands and Switzerland to teach at the workshop\'</b></i>.</p>\n\n<p>This workshop is considered to be one of the best clinical training programs on HIV drug resistance in Africa. Lectures and organizers of the workshop have published a clinical HIV & TB casebook, which has now reached <b><i>\'best-seller\'</b></i> status, following the printing and distribution of more than 10,000 copies of the book in Southern Africa. The workshop includes 38 presenters, many of whom have been working with the National Department of Health (NDoH) in South Africa and other African countries to translate the results of their research and clinical knowledge into national policy and clinical guidelines.</p>\n\n<p>###</p>\n<p>The 8th Southern African HIV & TB Drug Resistance and Treatment Monitoring workshop is taking place at the University of the Free State Medical School from the 21 to 22 November 2013. Approximately 200 participants from 24 countries will participate in the workshop. </p>\n<p>### END</p>\n\n<p>For more information please contact:</p>\n\n<p>University of the Free State Public Relations Manager</p>\n<p>University of the Free State</p>\n<p>Bloemfontein, South Africa</p>', 'Bloemfontein, SATuRN. workshop, DNA sequencing, 2013, Tulio de Oliveira, Cloete Van Vuuren, University of the Free State, UFS, drug resistance, hiv, tb, workshop, international, policy, Bloemfontein, SATuRN. workshop, DNA sequencing, 2013, Tulio de Oliveira, Cloete Van Vuuren, University of the Free State, UFS, drug resistance, hiv, tb, workshop, international, policy, Bloemfontein, SATuRN. workshop, DNA sequencing, 2013, Tulio de Oliveira, Cloete Van Vuuren, University of the Free State, UFS, drug resistance, hiv, tb, workshop, international, policy', 'BLOEMFONTEIN, 21 November 2013. Today, a large intentional workshop on HIV & TB drug resistance starts, which will bring some of the top international researchers, clinicians and policy makers to the University of the Free State in order to discuss strategies to manage and prevent drug resistance in Africa.', NULL),
(89, 'imgnews89.png', 'http://www.ufs.ac.za/templates/archive.aspx?news=3865', 'DNA sequencer launched at the University of Free State', 'UFS news', NULL, '2013-11-25', '<p>The University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus. </p>', NULL, NULL, '<p>The DNA sequencer will allow the Free State province to produce viral and bacterial genetic data to fight the local development of HIV/ Aids and TB drug resistance. </p>\n\n<p>The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world, with over 2 million patients on treatment. However, these successful treatment programmes are now being threatened by the appearance of drug resistance. </p>\n\n<p>The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2 000 medical officers in the treatment of drug resistance strains. </p>\n\n<p>The Department of Medical Microbiology and Virology in the Medical School at the UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV and TB drug-resistance results. This new machine will enable cutting-edge research to take place, using the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques. </p>\n\n<p><b><i>\'HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients appropriately who fail treatment, and use the results to cost-effectively extend and improve patients\' lives\'</b></i> says Dr Cloete van Vuuren, Specialist in Infectious Diseases at the UFS\'s Faculty of Health. </p>\n\n<p>Dr Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at the UFS, adds: <b><i>\'We have been looking forward to expanding our work with the clinicians and researchers, using DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province.\'</b></i></p>', 'new, DNA, sequencer, University of the Free State, Saturn, drug resistance, hiv, launche, medical school, bloemfontein, HIV, TB, genomics, genotypes, ABI3500,new, DNA, sequencer, University of the Free State, Saturn, drug resistance, hiv, launche, medical school, bloemfontein, HIV, TB, genomics, genotypes, ABI3500,new, DNA, sequencer, University of the Free State, Saturn, drug resistance, hiv, launche, medical school, bloemfontein, HIV, TB, genomics, genotypes, ABI3500,new, DNA, sequencer, University of the Free State, Saturn, drug resistance, hiv, launche, medical school, bloemfontein, HIV, TB, genomics, genotypes, ABI3500', 'he University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus.', NULL),
(90, 'imgnews90.png', 'http://chs.ukzn.ac.za/News/13-11-29/Putting_the_i_into_HIV', 'Putting the I into HIV - World Aids Day UKZN', 'UKZN', 0, '2013-11-30', '<p>Leading scientists in HIV/AIDS research discussed the diversity of the HIV epidemic, new scientific  evidence and the promising interventions on the  horizon to tackle it.</p>', NULL, NULL, '<p><img src=\"imagesBIO/imgnews90Big.png\"></p>\n<p><i>Prof. Rob Slotow, Prof. Salim Abdool Karim, Prof. Alan Whiteside, Prof. Thumbi Ndung\'u, Prof. Tulio de Oliveira and Dr. Themba Moeti at the event at the Nelson R Mandela School of Medicine, 26 Nov 2013.</i></p><br>\n<p>UKZN\'s College of Health Sciences, Caprisa, K-RITH, Heard, Health Systems Trust and the National Health Laboratory Services commemorated World Aids Day with a panel discussion featuring prominent researchers in the field. Each of these stakeholders have made significant contributions to addressing the worldwide challenges of the epidemic through research that has guided international health policies, the hosting of the National Aids Conference, the improvement of health systems in the country and through building capacity.</p>\n\n<p>The panel discussion, with the theme  \'Bringing the \'I\' into HIV\' focussed on new approaches in developing person-centred interventions to fight the HIV epidemic.</p>\n<p><b>Professor Rob Slotow, Deputy Vice-Chancellor and Head of the College of Health Sciences at UKZN,</b></p>\n<p> - Introduction to UKZN\'s AIDS research</p>\n<p><b>Professor Alan Whiteside, Executive Director of HEARD</b></p>\n<p> - Prevention is key to stop AIDS: We can\'t treat our way out of the epidemic</p>\n<p><b>Professor Thumbi N\'dungu, K-RITH Investigato</b>r</p>\n<p> - An HIV-1 vaccine is possible</p>\n<p><b>Professor Salim S Abdool Karim, Director of CAPRISA</b></p>\n<p>- Promising HIV/AIDS research and implications for health policy and guidelines</p>\n<p><b>Dr Themba Moeti, CEO of Health Systems Trust</b></p>\n<p>- Reflections on patient and community perspectives of translating research innovations into policy and practice</p>\n<p><b>Professor Tulio de Oliveira, Research Professor: College of Health Sciences</b></p>\n<p>- DNA sequencing and bioinformatics for the study of the explosive HIV epidemic in Southern Africa</p>\n<br>\n<p><b>Complete report of the event, please visit <a href=\"http://chs.ukzn.ac.za/News/13-11-29/Putting_the_i_into_HIV\">Putting the I into HIV report at the College of Health Sciences at UKZN</a></b></p>\n', 'panel discussion, AIDS day, 2013, UKZN, Prof Salim Abdool Karim, Alan Whiteside, Thumbi Ndungu, Tulio de Oliveira, Nelson R Mandela School of Medicine, panel discussion, AIDS day, 2013, UKZN, Prof Salim Abdool Karim, Alan Whiteside, Thumbi Ndungu, Tulio de Oliveira, Nelson R Mandela School of Medicine, panel discussion, AIDS day, 2013, UKZN, Prof Salim Abdool Karim, Alan Whiteside, Thumbi Ndungu, Tulio de Oliveira, Nelson R Mandela School of Medicine, panel discussion, AIDS day, 2013, UKZN, Prof Salim Abdool Karim, Alan Whiteside, Thumbi Ndungu, Tulio de Oliveira, Nelson R Mandela School of Medicine', 'Leading scientists in HIV/AIDS research discussed the diversity of the HIV epidemic, new scientific  evidence and the promising interventions on the  horizon to tackle it. The panel discussion was presented in light of AIDS day 2013 at the Nelson R Mandela School of Medicine, UKZN, South Africa, participants included Profs Salim Karim, Alan Whiteside, Tulio de Oliveira and Thumbi Ndungu', NULL),
(91, 'imgnews91.png', 'http://www.k-rith.org/news-updates/2013/hiv-1-vaccine-is-possible-says-prof-thumbi-ndungu', '\'An HIV-1 vaccine is possible\' says Prof Thumbi Ndung\'u at UKZN AIDS Day 2013', 'K-RITH', NULL, '2013-11-29', '<p>Ahead of World AIDS Day 2013, leading HIV/AIDS researchers in Durban have urged society to focus on insights, innovation and integrity in the journey into an HIV-free future and to put people at the centre of health services.</p>', NULL, NULL, '<p>Senior biomedical and development scientists dialogued with a seminar audience on evidence of the latest promising interventions to deal with the diverse dimensions of HIV and AIDS.  The discussion was hosted by the University of KwaZulu-Natal\'s College of Health Sciences on the theme \'Putting the \'I\' back into HIV\' new approaches in developing person-centred interventions to fight the epidemic\'.</p>\n\n<p>UKZN Deputy Vice-Chancellor and College head Professor Rob Slotow introduced the panel of speakers as individuals who had led significant contributions to HIV science which have been translated into national and international health policy.  This new knowledge had enabled health leadership, particularly in KwaZulu-Natal, to mobilise the roll-back of HIV.</p>\n\n<p>Speaking on the prospects of a viable HIV vaccine, Professor Thumbi Ndung\'u of the KwaZulu-Natal Research Institute for TB and HIV (K-RITH) said that although research had not yet yielded a vaccine solution eligible for licencing, there was evidence that a vaccine is possible. Animal studies were working on vectors that can produce immune system responses with 50% protection rates; antibodies from HIV-positive patients were being tested to block the virus in uninfected subjects; computational biologists were creating sequence diversity to corner off the virus and its pathways, providing no escape from the body\'s immune response. </p>\n\n<p><b><i>\'An HIV vaccine is an enormous challenge,\'</b></i> he explained, <b><i>\'because the virus is a formidable enemy: even in one infected person, it swarms around the body, replicating in the key structures of the immune system, and there is no known natural cure.\'</b></i> Asked whether it was feasible to pursue an HIV vaccine in the context of funding shortages, Ndung\'u argued that we must invest in deeper understanding of the human immune system. <b><i>\'In 1935, no-one believed that a polio vaccine would work, but scientists persisted and eventually triumphed.  We are doomed as a society if we don\'t keep trying to know more.\'</b></i></p>\n\n<p>Focusing on sexual transmission of HIV as the key driver of infection, Professor Salim Abdool Karim, head of CAPRISA and President of the Medical Research Council of SA, said that over the last three years, there had been an explosion of research evidence compiled on HIV prevention using antiretroviral drugs as prophylaxis more than had been available during the first 30 years of the epidemic.  This evidence has changed the global approach to HIV prevention methods, and offered real hope for reducing levels of incidence.</p>\n\n<p>Professor Alan Whiteside of HEARD (Health Economics and AIDS Research Division) emphasised the financial burden of not curbing new HIV infections. <b><i>\'Along with the tragic spread of illness and loss, the financial challenge of treating the 12,3% of South Africa\'s population who are HIV-positive is considerable,\'</b></i> he said.</p>\n\n<p><b><i>\'The cost of drug supplies and staff will compromise the health budget in some other area. ARVs have preventative effects, but we cannot treat our way out of AIDS.  On our current health funding, we can\'t afford to follow the established guidelines for treatment. Overseas donor aid is diminishing; we can\'t increase our domestic resources, so we must spend them more efficiently.\'</b></i></p>\n\n<p>Responding to these points, audience members called for the establishment of a local drug industry that could produce medicines for a broad range of infectious and non-communicable illnesses, questioned the standards of primary health care service delivery, and raised the issue of more radical programmes for behaviour change prevention messaging.</p>\n\n<p>Abdool Karim confirmed that much can be reduced and saved through cost-effective models of care that should not compromise clinical outcomes.  <b><i>\'Right now, we are not managing our resources well and corruption eats into our supply chains,\'</b></i> he said.  <b><i>\'South Africa should be making our own ARV active ingredients this would be a rate-limiting element in the cost of drug manufacturing and supply, cut out the importation costs in foreign exchange, and create local jobs.  Necessity drives innovation, and because of the sheer need to address HIV-related problems, we\'re now doing things differently for a number of diseases such as TB, asthma, hypertension and diabetes, we have home-based and point-of-care testing, as well as task-shifting to optimise our health worker capacity.\'</b></i></p>\n\n<p>On behaviour change, Abdool Karim noted that smoking has been successfully addressed by structural driver adjustments such as raising the cost of cigarettes and prohibiting smoking in public areas, along with public education on the dangers of smoking. More studies are needed on behaviour change solutions for HIV prevention that focus on structural drivers one example being a cash incentive for staying HIV-negative.</p>\n\n<p>The panelists and audience agreed that gender violence and discrimination, particularly in relation to the vulnerability of young women to HIV infection, had to be confronted in concrete ways.</p>\n\n<p>Whiteside argued that HIV has become over-medicalised: <b><i>\'We shouldn\'t need all these drugs, because people shouldn\'t be getting infected,\'</b></i> he said. \'We need a social compact, so that people\'s right to treatment, care and support is balanced by their responsibility to respect each other, practise safe sex and adhere to treatment regimes.\'</b></i></p>\n\n<p>HIV genetic analysis and molecular evolution was presented by Professor Tulio de Oliveira, a researcher in genomics at the Wellcome Trust\'s Africa Centre for Health and Population Studies.  Using HIV genetic data and bioinformatics to examine the epidemiological patterns of HIV transmission, more can be understood about the direction of infection, which helps to guide treatment interventions. </p>\n\n<p><b><i>\'We can also study drug resistance more closely with these techniques and characterise how the disease is spreading,\'</b></i> he said. <b><i>\'This work will be of significant benefit for South Africa\'s generalised epidemic, and where rural communities are highly vulnerable.  Rather than drive more stigma into the disease by terrifying people with harsh prevention messages, we should find out more about the linkages between and characteristics of transmission agents and targets.  For instance, who is infecting young women?\'</b></i></p>\n<p>Dr Themba Moeti, CEO of Health Systems Trust, reminded the gathering that the real benefits of new discoveries accrue to patients and communities at the end of a long process of translating the findings into policy and practice. <b><i>\'Access to the interventions and services is only possible and impactful once they are taken to scale,\'</b></i>he said. <b><i>\'so, beyond the essential biomedical tools and political will needed to advance this, we need the commitment and involvement of citizens themselves.\'</b></i></p>\n\n<p><b><i>\'While the choices made by leadership have changed the path of the epidemic, people must be placed at the centre of change,\'</b></i> he said. <b><i>\'Human behaviour will determine long-term prevention and the eventual elimination of HIV as a major public health challenge.  There are many forms and aspects of the epidemic across the different types of individuals who are part of it, so social and behavioural research is crucial now.\'</b></i></p>\n\n<p>Moeti added that with the co-epidemic of HIV and TB still ranking as the highest cause of death, we must prioritise massive investment in health systems strengthening.  <b><i>\'People are living longer with HIV and will succumb to non-communicable illnesses, and we have to ensure that all these diseases can be managed efficiently.?\'</b></i> </p>\n\n<p>An audience member was concerned that despite the advances made in different scientific fields, implementation of basic prevention on the ground is still not as easy as one would suppose, citing a church-owned clinic in Lesotho that would not provide patients with male condoms.  Moeti replied that any organisation having agency to serve their constituencies pragmatically and with compassion would be morally wrong to deprive people of simple protection from disease, and that we cannot stop educating and encouraging society to practise rights-based responses for health.</p>\n\n<p>Closing the seminar, Professor Slotow noted that there had been clear recognition of the role of young, emerging researchers leading innovative responses to HIV and AIDS.  He said that the discussion had compellingly drawn the roles of science and society together:  <b><i>\'It is people with our insights, activism, behaviour and responses that will take all the science forward to create an AIDS-free future.\'</b></i>', NULL, NULL, NULL),
(92, 'imgnews92.png', 'http://www.k-rith.org/news-updates/2013/biomedical-research-is-undergoing-revolution', 'BioMedical research is undergoing a revolution', 'K-RITH', 0, '2013-10-25', '<P>\'Intensive\', \'Comprehensive\', \'Fulfilling\' and \'Exciting\' were just some of the words used by students to describe the first Bioinformatics course hosted by the KwaZulu-Natal Research Institute for TB and HIV (K-RITH) in partnership with the US-based Broad Institute and the NIH recently.</p>', NULL, NULL, '<p><img src=\"imagesBIO/imgnews92Big.png\"></p>\n<p><i>Faculty of the TB Genomics & Bioinformatics workshop included Prof. Bruce Birren and his team from Broad/MIT institute and Prof. Tulio de Oliveira and Dr. Eduan Wilkinson from Wellcome Trust Africa Centre for Health and Population Studies, UKZN.</i></p><br>\n<p>The course brought together 45 outstanding research students from across Africa to spend a rigorous week advancing their ability to analyse biological data.</p>\n\n<p><b><i>\'BioMedical research is undergoing a revolution\'</b></i> says course instructor Bruce Birren, who is Director of the Genomic Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. <b><i>\'As much as anything, it is becoming an information science, where it is now possible to produce and access huge amounts of genomic data.  Powerful analytical tools are being developed to help mine these data to reveal the biological and clinical significance of genome information.\'</b></i></p>\n\n<p>Bioinformatics uses computational science, mathematics, engineering and statistics to provide these tools.  When combined with functional information from biological studies, its interdisciplinary approach has the potential to have a major impact on how we study diseases such as TB and HIV.</p>\n\n<p><b><i>\'TB is a problem that is too big to be solved by a single discipline,\'</b></i> says Birren, <b><i>\'and thus it is crucial that we actively recruit researchers across discipline boundaries.  The Broad has a history of sharing tools, promoting collaboration and working together.\'</b></i></p>\n\n<p><b><i>\'K-RITH has had the pleasure of collaborating with the Broad Institute over the past few years,\'</b></i> says K-RITH Education and Training Director, Dr. Victoria Kasprowicz.  <b><i>\'Our joint partnership on the delivery of this bioinformatics course is just another example of how international collaboration and an inter-disciplinary approach can help to build capacity amongst scientists in Africa.\'</b></i></p>\n\n<p>Course participant Imane Allali who came all the way from Morocco to attend the course said that she found the course interesting and hands-on and the speakers and teaching assistants attentive and helpful.  Currently in the second year of her PhD in bioinformatics, Imane who won the UNESCO-L\'Oreal fellowship for the best female PhD student in Morocco in December 2012, was particularly impressed by the practical afternoon sessions.  <b><i>\'The techniques we have learnt apply directly to my research and it is helpful to apply what we have learnt in the morning to more practical examples in the afternoon,\'</b></i> she said.  <b><i>\'I specifically benefitted from learning more about Linux and the commands that it uses.\'</b></i></p>\n\n<p><b><i>\'It has been a privilege to have the chance to interact with students this smart and open to new methods,\'</b></i> says Birren.  <b><i>\'Our participants are young, fearless, and phenomenal. They really are the cream of the crop and our Instructors had to up the ante to keep up.\'</b></i></p>\n\n<p><b><i>\'K-RITH is very gratified by the positive reception this course has had,\'</b></i> says Interim Director Dr. Dennis McKearin.  <b><i>\'We hope to be able to host more courses like this one over the coming months and year.\'</b></i>', NULL, NULL, NULL),
(93, 'imgnews93.png', 'http://aighd.org/news/2013/11/26/potential-resistance-free-hiv-drug/', 'SATURN-PASER unites international minds & reveals potential resistance free HIV drug', 'AIGHD', NULL, '2013-11-26', '<p>By Inez Rossouw, 26 Nov 2013, Bloemfontein - Dolutegravir, a drug aimed against the human immunodeficiency virus (HIV), might not elicit any resistance to it.  This was revealed at the Southern African HIV/TB drug resistance and monitoring workshop hosted by the Southern African Treatment and Resistance Network (SATuRN) at the Medical School of the University of the Free State. </p>', NULL, NULL, '<p>Prof Mark Wainberg from the McGill University AIDS Centre in Montreal, Canada, unravelled data gained from three studies (called SPRING, SINGLE and FLAMINGO) indicating that no mutations developed against dolutegravir over a period of 2 years of treatment.  Furthermore, the virus did not develop resistance against any other drugs used in combination with dolutegravir to make up the highly active trio needed to effectively treat HIV infection.  This was only seen in patients started on dolutegravir as part of first line treatment and not when used as second or third line treatment as mutations already induced by other drugs negated this effect.  A success rate of 88 to 90 % in suppressing viral replication when dolutegravir was used as first line therapy was diminished to about 63% when it was introduced after the failure of other drugs.  </p>\n<p>Prof Tulio de Oliviera from the Africa Centre for Health and Population Studies, University of KwaZulu-Natal and director of SATuRN responded: <b><i>\'It is very exciting that a drug of this potential is currently being investigated, but similar expectations were held for another group of HIV drugs, the protease inhibitors.  Not all of those were met.  We should be cautious and await more evidence.\'</b></i></p>\n<p>For two days the hallways of the medical school sizzled with heated discussions in foreign languages.  Delegates from around the globe were attracted to the 8th workshop of this kind.  HIV resistance cases, new treatment regimens, approaches to the problem of non-adherence among patients, were passionately debated and thought through.  A new feature of this workshop was its association with the largest African network on HIV drug resistance monitoring: PASER (Pan-African Studies to Evaluate Resistance), led by Prof Tobias Rinke de Wit from the Amsterdam Institute for Global Health and Development at the Academic Medical Center, University of Amsterdam. Highly esteemed academics like Prof Mark Wainberg, Prof David Katzenstein from Stanford University in the USA, Prof Deenan Pillay from the University College London and the new head of the Africa Centre, Dr Catherine Orrell from the Desmond Tutu HIV Foundation in Cape Town, Dr Ava Avalos from Botswana, Prof Sulaiman Akanmu from Nigeria and Prof John Frater from the Oxford University in England were among the delegates and speakers.  Uganda, Kenya, Belgium, Brazil, the Netherlands, Switzerland, Zambia, Lesotho, Swaziland and Zimbabwe added further colour to the kaleidoscope of participating countries.  Thorough discussion of patient cases from these regions allowed the more than 200 delegates to learn from one another\'s experiences, translating HIV resistance testing outcomes into better clinical care for current and future patients. </p>\n<p>The lead representative from the World Health Organisation in the area of HIV drug resistance, Dr Silvia Bertagnolio, gave an overview of the WHO strategies in this area.  South Africa has recently adopted even more ambitious guidelines in this respect, with routine drug resistance testing for all South Africans who fail 2nd line treatment.</p>\n<p>Resistance testing is an essential tool in the management of some HIV patients, but it is recognised that its added value rests upon the so called \'viral load tests\'.  These tests, already widely used in Southern Africa, give essential information regarding the ability of the drugs to prevent the virus from replicating.  Low viral load means few viruses detected in the blood stream.  This implies the drugs are working and the virus is not resistant to them (yet).  Of the utmost importance is that a high viral load must be recognised as a possible emergency.  The action required upon this high viral load is an intensive effort of several months to motivate the patient to take the HIV drugs each and every day.  A subsequent follow up viral load is then done and if still high it means the drugs have stopped working; the virus might be resistant and replicating freely.  A decision must then be taken to either change the patient to a new regimen or send the patient for a drug resistant test to help decide which regimen to prescribe next.</p>\n<p>The workshop was preceded by a joint meeting of the PASER and SATURN networks, which are working towards increased collaboration.  New projects and progress reports on existing ones were scrutinized and technical information related to HIV drug resistance testing was shared.  The clinical implications of laboratory work were teased from the data and applied to resistance programs in the Southern African region.</p>\n<p>Sponsors invested in this excellent workshop which will positively impact on the clinical ability and knowledge of all participants and ultimately on the care of HIV patients.  The sponsors include the CDC (Centers for Diseases Control and Prevention, USA), the Embassy of the Kingdom of the Netherlands in Pretoria, the Wellcome Trust, the European Union, PASER, the Africa Centre and the University of the Free State.</p>\n<p> </p>\n<p>###</p>\n<p> </p>\n<p>About SATURN</p>\n<p>SATuRN includes 24 research partners in southern Africa.  They have collated more than 7000 resistance genotypes linked to treatment and clinical information and host two of the best HIV drug resistance databases in the world.  They have been working with a network of academic laboratories to develop and implement a cheaper resistance genotype test.  They have also delivered training in drug resistance testing and management to over 2500 physicians and nurses in southern Africa and recently published a case book, which has already achieved best-seller status with approximately 10 000 copies printed and distributed.</p>\n<p>Website: <a href=\"http://www.bioafrica.net/saturn\">www.bioafrica.net/saturn</a></p>\n<p> </p>\n<p>About PASER</p>\n<p>PASER is a project supported by the Amsterdam Institute for Global Health and Development, which aims to provide sustainable solutions to major health problems across the planet, by forging synergies between disciplines, health care delivery, research and education.</p>\n<p>PASER has as objective to monitor and survey HIV drug resistance in adults and children in sub-Saharan Africa, build capacity, expand access to affordable diagnostics, put HIV drug resistance on the international agenda and inform African policy makers to make best-possible decisions with respect to national HIV treatment programs.</p>\n<p>Website: <a href=\"http://wwwaighd.org/projects/paser\">http://wwwaighd.org/projects/paser</a></p>\n', NULL, NULL, NULL),
(94, 'imgnews94.png', 'http://www.bioafrica.net/manuscripts/WorldAids_Day2013_SundayTimes.pdf', 'Heroes in the battle for health', 'Sunday Times', 0, '2013-12-01', '<p>There have been major successes in the fight agains the disease since it was first identified in 1983. Bianca Capazorio speaks to some young South Africans at the forefront of work in the field.</p>', NULL, NULL, '<p><a href=\"manuscripts/WorldAids_Day2013_SundayTimes.pdf \"><img src=\"imagesBIO/SundayTimes2013.png\"></a></p>\n<p>This is a Sunday times world AIDS Day report that highlight successful work done by researchers in South Africa. This includes Vivek Naranbhai, Landon Myer, Thumbi Ndung\'u, Ntlotleng Mabena, Sindisiwe van Zyl, <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a> and Zenda Woodman</p>\n\n', 'sunday times, AIDS day, south africa, 2013, heroes, battle, heatlh, HIV, AIDS, Tulio de Oliveira, Landon Myer, Vivek Naranbhai, sunday times, AIDS day, south africa, 2013, heroes, battle, heatlh, HIV, AIDS, Tulio de Oliveira, Landon Myer, Vivek Naranbhai, sunday times, AIDS day, south africa, 2013, heroes, battle, heatlh, HIV, AIDS, Tulio de Oliveira, Landon Myer, Vivek Naranbhai, sunday times, AIDS day, south africa, 2013, heroes, battle, heatlh, HIV, AIDS, Tulio de Oliveira, Landon Myer, Vivek Naranbhai, sunday times, AIDS day, south africa, 2013, heroes, battle, heatlh, HIV, AIDS, Tulio de Oliveira, Landon Myer, Vivek Naranbhai', 'This is a Sunday times world AIDS Day report that highlight successful work done by researchers in South Africa. This includes Vivek Naranbhai, Landon Myer, Thumbi Ndung\'u, Ntlotleng Mabena, Sindisiwe van Zyl, Tulio de Oliveira and Zenda Woodman. There have been major successes in the fight agains the disease since it was first identified in 1983. Bianca Capazorio speaks to some young South Africans at the forefront of work in the field', NULL),
(95, 'imgnews95.png', 'http://www.bioafrica.net/manuscripts/MRC_Supplement_2013.pdf', 'SA Medical Research Council Scientific Awards', 'Mail & Guardian', NULL, '2013-12-08', '<p>In his address to MRC award and grant winners at a prestigious ceremony in Cape Town, outgoing MRC Chairperson Professor Lizo Mazwai described the South African Medical Research Council (MRC) as \'richer, more focused, more efficient and better placed to deliver a healthy nation through research.\'</p>', NULL, NULL, '<p><a href=\"manuscripts/MRC_Supplement_2013.pdf\"><img src=\"imagesBIO/MRC_Supplement_2013.png\"></a></p>\n<p>This is a three-pages MRC supplement that was published in the Mail & Guardian, The Star, Cape Argus and Mercury. The insert highlights the MRC?s achievement - to which <a href=\"people.php?peopleid=1\">Prof. Tulio de Oliveira</a> research has contributed.</p>  ', 'mail & guardian, MRC, supplement, flagship, december 2013, south african, medical, research concil, tulio de oliveira, hiv transmission, mrc medals, Salim Karim, mail & guardian, MRC, supplement, flagship, december 2013, south african, medical, research concil, tulio de oliveira, hiv transmission, mrc medals, Salim Karim, mail & guardian, MRC, supplement, flagship, december 2013, south african, medical, research concil, tulio de oliveira, hiv transmission, mrc medals, Salim Karim, mail & guardian, MRC, supplement, flagship, december 2013, south african, medical, research concil, tulio de oliveira, hiv transmission, mrc medals, Salim Karim', 'This is a three-pages MRC supplement that was published in the Mail & Guardian, The Star, Cape Argus and Mercury. The insert highlights the MRC\'s achievement - to which Prof. Tulio de Oliveira research has contributed.', NULL),
(96, 'imgnews96.png', 'http://www.bioafrica.net/manuscripts/PosterUKZNMolEpi2.pdf', 'PhD Scholarship available - Genomics, Bioinformatics & Epidemiology II - HIV dynamics', 'UKZN & Africa Centre', 0, '2013-12-13', '<p>The causes and consequences of HIV transmission and drug resistance - PhD studentship available for Genomics, Epidemiology and Bioinformatics at UKZN for the MRC Flagship research project. Supervisors: Prof. Tulio de Oliveira & Prof. Frank Tanser, Africa Centre, UKZN</p>\n\r\n', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/PosterUKZNMolEpi2.pdf\"><img src=\"imagesBIO/PosterUKZNMolEpi2.png\"></a></center></p>\n<p>PhD and MSc fellows will be awarded a scholarship that will cover their tuition costs in addition to a competitive stipend salary. Interested students should send an application, which should contain a CV and a motivation letter (max. 500 words) by 30 January 2014 to Mrs. Xolile Kineri @ email: xkineri@africacentre.ac.za, Tel: 035 550 7500, Fax: 035 550 7565. </p>\r\n<p>In total, we are advertising 7 PhDs and up to 4 MScs fellowships that can be taken in different departments at UKZN. This includes the following disciplines Clinical Infectious Diseases, Computer Science, Epidemiology, HIV Pathogenesis, Human Genetics, Genomics & Bioinformatics and Social & Economical Sciences.  More info: <a href=\"http://www.bioafrica.net\">www.bioafrica.net</a></p>\r\n\n', 'PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship, medical research council, PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship, medical research council, PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship, medical research council, PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship, medical research council', 'The causes and consequences of HIV transmission and drug resistance -  PhD and MSc studentships available at UKZN for the MRC Flagship research project. Genomics, Bioinformatics & Epidemiology II - Prof. Tulio de Oliveira & Prof. Frank Tanser at Africa Centre, University of KwaZulu-Natal 2014\r\n', NULL),
(97, 'imgnews96.png', 'http://www.bioafrica.net/manuscripts/PosterUKZNMolEpi1.pdf', 'PhD Scholarship available - Genomics, Bioinformatics & Epidemiology I - HIV Drug Resistance', 'UKZN & Africa Centre', NULL, '2013-12-13', '<p>The causes and consequences of HIV transmission and drug resistance - HIV Drug resistance PhD studentship at Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal (UKZN). Funded by a MRC Flagship research project. Supervisors: Prof. Tulio de Oliveira & Prof. Frank Tanser, Africa Centre, UKZN </p>\n\r\n', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/PosterUKZNMolEpi1.pdf\"><img src=\"imagesBIO/PosterUKZNMolEpi1.png\"></a></center></p>\n<p>PhD and MSc fellows will be awarded a scholarship that will cover their tuition costs in addition to a competitive stipend salary. Interested students should send an application, which should contain a CV and a motivation letter (max. 500 words) by 30 January 2014 to Mrs. Xolile Kineri @ email: xkineri@africacentre.ac.za, Tel: 035 550 7500, Fax: 035 550 7565. </p>\r\n<p>In total, we are advertising 7 PhDs and up to 4 MScs fellowships that can be taken in different departments at UKZN. This includes the following disciplines Clinical Infectious Diseases, Computer Science, Epidemiology, HIV Pathogenesis, Human Genetics, Genomics & Bioinformatics and Social & Economical Sciences.  More info: <a href=\"http://www.bioafrica.net\">www.bioafrica.net</a></p>\r\n\n', 'hiv drug resistance, PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship, HIV, drug, resistance, PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship, PhD, position, 2014, south africa, durban, UKZN, genomics, bioinformatics, epidemiology, doctoral, fellowship, scholarship, Tulio de Oliveira, Wellcome Trust, Africa Centre for Health and Population Studies, MRC flagship', 'The causes and consequences of HIV transmission and drug resistance - HIV Drug Resistance PhD and MSc studentships available at UKZN for the MRC Flagship research project. Genomics, Bioinformatics & Epidemiology II - Prof. Tulio de Oliveira & Prof. Frank Tanser at Africa Centre, University of KwaZulu-Natal 2014\r\n', NULL),
(98, 'imgnews96.png', 'http://www.bioafrica.net/manuscripts/PosterUKZNGenetics.pdf', 'PhD and/or MSc Scholarship available - Human Genetics', 'UKZN Genetics & Africa Centre', 0, '2013-12-13', 'The causes and consequences of HIV transmission and drug resistance -  Human Genetics PhD and/or MSc studentships available at UKZN Genetics department in collaboration with Wellcome Trust Africa Centre for Health and Population Studies. Funded by a MRC Flagship research project. Supervisors: Dr. Paula Sommer, Genetics Department, UKZN & Prof. Tulio de Oliveira, Africa Centre, UKZN\r\n\r\n', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/PosterUKZNGenetics.pdf\"><img src=\"imagesBIO/PosterUKZNGenetics.png\"></a></center></p>\n<p>PhD and MSc fellows will be awarded a scholarship that will cover their tuition costs in addition to a competitive stipend salary. Interested students should send an application, which should contain a CV and a motivation letter (max. 500 words) by 30 January 2014 to Mrs. Xolile Kineri @ email: xkineri@africacentre.ac.za, Tel: 035 550 7500, Fax: 035 550 7565. </p>\r\n<p>In total, we are advertising 7 PhDs and up to 4 MScs fellowships that can be taken in different departments at UKZN. This includes the following disciplines Clinical Infectious Diseases, Computer Science, Epidemiology, HIV Pathogenesis, Human Genetics, Genomics & Bioinformatics and Social & Economical Sciences.  More info: <a href=\"http://www.bioafrica.net\">www.bioafrica.net</a></p>\r\n\n', 'Human, genetics, PhD, fellowship, University of KwaZulu-Natal, MRC flagship, tulio de oliveira, paula sommer, HIV, transmission, drug resistance, scholarship, UKZN, south africa, Durban, Human, genetics, PhD, fellowship, University of KwaZulu-Natal, MRC flagship, tulio de oliveira, paula sommer, HIV, transmission, drug resistance, scholarship, UKZN, south africa, Durban, Human, genetics, PhD, fellowship, University of KwaZulu-Natal, MRC flagship, tulio de oliveira, paula sommer, HIV, transmission, drug resistance, scholarship, UKZN, south africa, Durban, Human, genetics, PhD, fellowship, University of KwaZulu-Natal, MRC flagship, tulio de oliveira, paula sommer, HIV, transmission, drug resistance, scholarship, UKZN, south africa, Durban', 'The causes and consequences of HIV transmission and drug resistance - Human Genetics PhD and MSc studentships available at Genetics department at UKZN for the MRC Flagship research project. Start date 2014. Supervisor: Dr. Paula Sommer, Genetics Department, UKZN & Prof. Tulio de Oliveira, Africa Centre, UKZN\r\n', NULL),
(99, 'imgnews96.png', 'http://www.bioafrica.net/manuscripts/PosterUKZNHEARD.pdf', 'PhD and/or MSc Scholarship available - Social Sciences', 'HEARD & Africa Centre', NULL, '2013-12-13', 'The causes and consequences of HIV transmission and drug resistance -  Social Sciences PhD and/or MSc studentships available at HEARD/UKZN Genetics department in collaboration with Wellcome Trust Africa Centre for Health and Population Studies. Funded by a MRC Flagship research project. Potenital Supervisors: Dr Kaymarlin Govender, Ms Samantha Willan & Mr. Andrew Gibbs, HEARD, UKZN.\r\n\r\n', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/PosterUKZNHEARD.pdf\"><img src=\"imagesBIO/PosterUKZNHEARD.png\"></a></center></p>\n<p>PhD and MSc fellows will be awarded a scholarship that will cover their tuition costs in addition to a competitive stipend salary. Interested students should send an application, which should contain a CV and a motivation letter (max. 500 words) by 30 January 2014 to Mrs. Xolile Kineri @ email: xkineri@africacentre.ac.za, Tel: 035 550 7500, Fax: 035 550 7565. </p>\r\n<p>In total, we are advertising 7 PhDs and up to 4 MScs fellowships that can be taken in different departments at UKZN. This includes the following disciplines Clinical Infectious Diseases, Computer Science, Epidemiology, HIV Pathogenesis, Human Genetics, Genomics & Bioinformatics and Social & Economical Sciences.  More info: <a href=\"http://www.bioafrica.net\">www.bioafrica.net</a></p>\r\n\n', 'social, sciences, HIV, HEARD, transmission, drug resistance, africa centre, MRC, flagship, PhD, scholarships, studenships, social, sciences, HIV, HEARD, transmission, drug resistance, africa centre, MRC, flagship, PhD, scholarships, studenships, social, sciences, HIV, HEARD, transmission, drug resistance, africa centre, MRC, flagship, PhD, scholarships, studenships, social, sciences, HIV, HEARD, transmission, drug resistance, africa centre, MRC, flagship, PhD, scholarships, studenships, UKZN, 2014, 2014, Wellcome Trust, ', 'The causes and consequences of HIV transmission and drug resistance - Social Science PhD and MSc studentships available at HEARD/UKZN for the MRC Flagship research project. Start date 2014. Supervisors: Dr Kaymarlin Govender, Ms Samantha Willan & Mr. Andrew Gibbs, HEARD, UKZN.\r\n', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(100, 'imgnews100.png', NULL, 'Bioinformatics in the Tropics Uganda 2014, UVRI, Entebbe, Uganda, 7th to 10th April 2014', 'UVRI', 0, '2014-01-06', '<p>This is a series of four workshops, which will be presented in Brazil (2013 & 2014), South Africa (2013) and Uganda (2014) as part of a south to south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America. The objective is to train post-doctoral researchers to become trainers and post-graduate students to use bioinformatics and phylogenetic software applications needed for their research.</p>', NULL, NULL, '<p><center><a href=\"workshops/BioinformaticsTropicsUganda2014A4.pdf\"><img src=\"imagesBIO/PosterBITUganda2014.png\"></a></center></p>\n\n<p><b><i>Workshop topics and who should apply?</b></i></p>\n<p>The workshop involves theoretical lectures and practical sessions on the usage and interpretation of bioinformatics applications for the study of viruses and TB drug resistance, molecular epidemiology and immunology. This workshop is targeted at scientists and post- graduate students working in research projects in Africa and Latin America.</p>\n\n<p><b><i>Invited Presenters:</b></i></p>\n<p>Luiz Carlos Alcantara, Alison Elliott, Pontiano Kaleebu, Justen Manasa, Eduan Wilkinson, Siva Danaviah, Deo Ssemwanga, Jonathan Kayondo , Olivier Gascuel, Francois Chevenet, Tulio de Oliveira, Marco Salemi, Josh Herbeck, Manon Ragonnet and Andrew J. Leigh Brown</p>\n\n<p><b><i>Workshop Series Organizers:</b></i></p>\n<p>Tulio de Oliveira, Alison Elliott, Pontiano Kaleebu and Luiz Carlos Alcantara.</p>\n\n<p><b><i>Dates:</b></i></p>\n<p>7th to 10th April 2014, Uganda Virus Research Institute, Entebbe, Uganda.\n(Deadline for application: 31st January 2014) </p>\n<p><b><i>Application form:</b></i></p>\n<p><a href=\"workshops/Bioinformatics_Application1_Uganda_2014.doc\">Application form can be obtained at here</a> and at <a href=\"http://www.muii.org.ug/\">http://www.muii.org.ug/</a></p>\n\n<p><b><i>Registration for the workshop is free of charge.</b></i> However, applicants need to fund their travel and accommodation costs.</p>', 'Bioinformatics, tropics, workshop, uganda, 2014, welcome trust, UVRI, Africa Centre, Tulio de Oliveira, Pontiano Kallebu, Andrew Leigh Brown, Marco Salemi, CNPQ, Brazil, FioCruz, Africa, Bioinformatics, tropics, workshop, uganda, 2014, welcome trust, UVRI, Africa Centre, Tulio de Oliveira, Pontiano Kallebu, Andrew Leigh Brown, Marco Salemi, CNPQ, Brazil, FioCruz, Africa, Bioinformatics, tropics, workshop, uganda, 2014, welcome trust, UVRI, Africa Centre, Tulio de Oliveira, Pontiano Kallebu, Andrew Leigh Brown, Marco Salemi, CNPQ, Brazil, FioCruz, Africa, Bioinformatics, tropics, workshop, uganda, 2014, welcome trust, UVRI, Africa Centre, Tulio de Oliveira, Pontiano Kallebu, Andrew Leigh Brown, Marco Salemi, CNPQ, Brazil, FioCruz, Africa, Bioinformatics, tropics, workshop, uganda, 2014, welcome trust, UVRI, Africa Centre, Tulio de Oliveira, Pontiano Kallebu, Andrew Leigh Brown, Marco Salemi, CNPQ, Brazil, FioCruz, Africa', 'This is a series of four workshops, which will be presented in Brazil (2013 & 2014), South Africa (2013) and Uganda (2014) as part of a south to south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America. The objective is to train post-doctoral researchers to become trainers and post-graduate students to use bioinformatics and phylogenetic software applications needed for their research.', NULL),
(101, 'imgnews101.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_4_2013A4.pdf', 'SATuRN Newsletter, Dec 2013: News, workshops, manuscripts & PhD/MSC positions available!\n', 'SATuRN', NULL, '2014-01-06', '<p>The newsletter idea is that anyone with 15 minutes to spare can learn about our work and its application in everyday life. In our last issue of 2013 our newsletter we focus on our capacity building programme. We also advertise 7 PhDs and 4 MScs positions in this issue!</p>\n', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_4_2013A4.pdf\"><img src=\"imagesBIO/imgnews101Big.png\"></a></center> </p>\n\n<p><b><i>In this issue our highlights are:</b></i></p>\n \n<p><a href=\"http://www.bioafrica.net/news.php?id=94\">News: Heroes in the battle for health, Sunday Times</a></p>\n \n<p><a href=\"http://www.bioafrica.net/publications.php?pubid=94\">Publication: Implementing HIV-1 Genotypic Resistance Testing in Antiretroviral Therapy Programs in Africa: Needs, Opportunities, and Challenges</a></p>\n \n<p><a href=\"http://www.bioafrica.net/news.php?id=93\">News: SATURN-PASER unites international minds & reveals potential resistance free HIV drug</a></p>\n \n<p><a href=\"http://www.bioafrica.net/publications.php?pubid=93\">Publication: An Investigation of Classification Algorithms for Predicting HIV Drug Resistance without Genotype Resistance Testing</a></p>\n \n<p><a href=\"http://www.youtube.com/bioafricaSATURN\">Videos: SATuRN Data Curation & Affordable SATuRN/Life Technologies Genotyping Assay</a></p>\n \n<p><a href=\"http://www.bioafrica.net/news.php?id=100\">Workshop: Bioinformatics in the Tropics - Uganda 2014. Uganda Virus Research Institute, Entebbe, Uganda, 7th to 10th April 2014</a></p>\n \n \n<p>The newsletter is open accessible at:</p>\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_4_2013A4.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_4_2013A4.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>', 'newsletter, saturn, southern african treatment resistance network, 2013, december, publications, news, blogs, tulio de oliveira, paser, workshops, Deenan Pillay, africa centre, videos, newsletter, saturn, southern african treatment resistance network, 2013, december, publications, news, blogs, tulio de oliveira, paser, workshops, Deenan Pillay, africa centre, videos, newsletter, saturn, southern african treatment resistance network, 2013, december, publications, news, blogs, tulio de oliveira, paser, workshops, Deenan Pillay, africa centre, videos, newsletter, saturn, southern african treatment resistance network, 2013, december, publications, news, blogs, tulio de oliveira, paser, workshops, Deenan Pillay, africa centre, videos', 'The newsletter idea is that anyone with 15 minutes to spare can learn about our work and its application in everyday life. In our last issue of 2013 our newsletter we focus on our capacity building programme. We also advertise 7 PhDs and 4 MScs positions in this issue!', NULL),
(102, 'imgnews96.png', 'http://www.bioafrica.net/manuscripts/PosterUKZNComputerScience.pdf', 'PhD and/or MSc Scholarship available - Computer Science', 'CAIR/UKZN & Africa Centre', 0, '2014-01-16', 'The causes and consequences of HIV transmission and drug resistance -   Computer Science  PhD and/or MSc studentships available at UKZN/CSIR Meraka Centre for Artificial Intelligence Research (CAIR) in collaboration with Wellcome Trust Africa Centre for Health and Population Studies. Funded by a MRC Flagship research project. Potential  Supervisors: Dr. Deshen Moodley & Prof. Hugh Murrell, CAIR, UKZN', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/PosterUKZNComputerScience.pdf\"><img src=\"imagesBIO/PosterUKZNComputerScience.png\"></a></center></p>\n<p>PhD and MSc fellows will be awarded a scholarship that will cover their tuition costs in addition to a competitive stipend salary. Interested students should send an application, which should contain a CV and a motivation letter (max. 500 words) by 30 January 2014 to Mrs. Xolile Kineri @ email: xkineri@africacentre.ac.za, Tel: 035 550 7500, Fax: 035 550 7565. </p>\r\n<p>In total, we are advertising 7 PhDs and up to 4 MScs fellowships that can be taken in different departments at UKZN. This includes the following disciplines Clinical Infectious Diseases, Computer Science, Epidemiology, HIV Pathogenesis, Human Genetics, Genomics & Bioinformatics and Social & Economical Sciences.  More info: <a href=\"http://www.bioafrica.net\">www.bioafrica.net</a></p>', 'computer, science, bioinformatics, artificial, inteligence, PhD, MSC, scholarship, funding, Univestity of KwaZulu-Natal, UKZN, Wellcome Trust, Africa Centre, MRC, flagship, computer, science, bioinformatics, artificial, inteligence, PhD, MSC, scholarship, funding, Univestity of KwaZulu-Natal, UKZN, Wellcome Trust, Africa Centre, MRC, flagship, computer, science, bioinformatics, artificial, inteligence, PhD, MSC, scholarship, funding, Univestity of KwaZulu-Natal, UKZN, Wellcome Trust, Africa Centre, MRC, flagship, computer, science, bioinformatics, artificial, inteligence, PhD, MSC, scholarship, funding, Univestity of KwaZulu-Natal, UKZN, Wellcome Trust, Africa Centre, MRC, flagship, computer, science, bioinformatics, artificial, inteligence, PhD, MSC, scholarship, funding, Univestity of KwaZulu-Natal, UKZN, Wellcome Trust, Africa Centre, MRC, flagship', 'The causes and consequences of HIV transmission and drug resistance - Computer Science PhD and MSc studentships available at UKZN/CSIR Meraka Centre for Artificial Intelligence Research (CAIR) for the MRC Flagship research project. Start date 2014. Supervisors: Dr. Deshen Moodley & Prof. Hugh Murrell, CAIR, UKZN', NULL),
(103, 'imgnews103.png', 'http://www.bioafrica.net/manuscripts/Comercial_Seminar_MRCFlagship_March2014.pdf', 'From sample to sequencing: an introduction to Longhorn\'s primesuite of technologies', 'WTAC Genomics Programme', NULL, '2014-03-28', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a presentation, 28 March 2014, Durban</p>\n\n', NULL, 4, '<p><center><img src=\"imagesBIO/Seminar_MRCFlagship_March2014Commercial.png\"></center></p>\n<p><b>by Dr Luke Daum & Chris Helm</b>, (University of Texas / LongHorn Vaccines & Diagnostics)</p>\n<p>Date: 28 March 2014</p>\n<p>Time: 12:00-13:00 (Lunch will be served)</p>\n<p>Venue: K1 Auditorium, K-RITH Tower Builidng, Nelson R Mandela School of Medicine, Durban, South Africa</p>', 'commercial, presentation, TB, MRC seminar, UKZN, Genomics Programme, Africa Centre, Wellcome Trust, Durban, K-RITH, Luke Daum, primestore, mycobacterium, tuberculosis, commercial, presentation, TB, MRC seminar, UKZN, Genomics Programme, Africa Centre, Wellcome Trust, Durban, K-RITH, Luke Daum, primestore, mycobacterium, tuberculosis, commercial, presentation, TB, MRC seminar, UKZN, Genomics Programme, Africa Centre, Wellcome Trust, Durban, K-RITH, Luke Daum, primestore, mycobacterium, tuberculosis, March 2014,March 2014,March 2014,March 2014', NULL, NULL),
(104, 'imgnews104.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_March2014.pdf', 'Seminar: Next-generation sequencing for identifying drug resistance in Mycobacterium Tuberculosis', 'KRISP Talks', NULL, '2014-03-28', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar, 28 March 2014, Durban</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_March2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_March2014.png\"></a></center></p>\n<p><b>by Dr Luke Daum</b>, (University of Texas / LongHorn Vaccines & Diagnostics)</p>\n<p>Date: 28 March 2014</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser-Stein Auditorium, K-RITH Tower Builidng, Nelson R Mandela School of Medicine, Durban, South Africa</p>', 'seminar, mach 2014, Africa Centre, Wellcome Trust, Durban, TB, pncA, gene, MTB, sputum, specimens, Next-Generation Sequencing, mycobacterium, tuberculosis, genomics, Wellcome Trust, lecture, public, Nelson R Mandela School of Medicine, seminar, mach 2014, Africa Centre, Wellcome Trust, Durban, TB, pncA, gene, MTB, sputum, specimens, Next-Generation Sequencing, mycobacterium, tuberculosis, genomics, Wellcome Trust, lecture, public, Nelson R Mandela School of Medicine, seminar, mach 2014, Africa Centre, Wellcome Trust, Durban, TB, pncA, gene, MTB, sputum, specimens, Next-Generation Sequencing, mycobacterium, tuberculosis, genomics, Wellcome Trust, lecture, public, Nelson R Mandela School of Medicine, seminar, mach 2014, Africa Centre, Wellcome Trust, Durban, TB, pncA, gene, MTB, sputum, specimens, Next-Generation Sequencing, mycobacterium, tuberculosis, genomics, Wellcome Trust, lecture, public, Nelson R Mandela School of Medicine', NULL, NULL),
(108, 'imgnews69.png', 'http://www.bioafrica.net/blogs.php?id=32', 'Seminar: Implementing HIV-1 Genotypic Resistance Testing in Antiretroviral Therapy Programs in Africa: Needs, Opportunities, and Challenges.', 'KRISP Talks', NULL, '2014-01-15', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Tulio de Oliveira, 15 January 2014, Africa Centre headquarters, Mtubatuba</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Jan2014A.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Jan2014A.png\"></a></center></p>\n<p><b>by Prof. Tulio de Oliveira</b>, (Africa Centre, UKZN / University College of London)</p>\n<p>Date: 15 January 2014</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: Stein-Susser Auditorium, Africa Centre for Health and Population Studies, Somkhele, Mtubatuba, South Africa</p>\n<p>This presentation also included a live <b><a href=\"http://www.bioafrica.net/blogs.php?id=32\">Twitter Question and Answers section, see responses to answers in our blog</b></a>.<br>\n<p>We also provide open access to the paper <b><a href=\"http://www.bioafrica.net/publications.php?pubid=94\">Implementing HIV-1 Genotypic Resistance Testing in Antiretroviral Therapy Programs in Africa: Needs, Opportunities, and Challenges. </b></a>, which was presented in this seminar.\n', 'seminar, wellcome trust, january, 2014, tulio de oliveira, twitter, africa centre, MRC flagship, UKZN, South Africa, HIV treatment, drug resistance, clinical management, saturn model, AIDS reviews, seminar, wellcome trust, january, 2014, tulio de oliveira, twitter, africa centre, MRC flagship, UKZN, South Africa, HIV treatment, drug resistance, clinical management, saturn model, AIDS reviews, seminar, wellcome trust, january, 2014, tulio de oliveira, twitter, africa centre, MRC flagship, UKZN, South Africa, HIV treatment, drug resistance, clinical management, saturn model, AIDS reviews', 'Wellcome Trust Africa Centre Genomics Programme Seminar in Durban, 15 January 2014. Implementing HIV-1 Genotypic Resistance Testing in Antiretroviral Therapy Programs in Africa: Needs, Opportunities, and Challenges by Prof. Tulio de Oliveira, Africa Centre, UKZN & UCL. ', NULL),
(105, 'imgnews105.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Jan2014.pdf', 'Seminar: 30 years of HIV diversity research: a personal perspective', 'KRISP Talks', NULL, '2014-01-31', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Susan Engelbrecht, 31 January 2014, Durban</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Jan2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Jan2014.png\"></a></center></p>\n<p><b>by Professor Susan Engelbrecht</b>, (Stellenbosch University / Tygerberg NHLS)</p>\n<p>Date: 31 January 2014</p>\n<p>Time: 11:30-12:30</p>\n<p>Venue: K2 seminar room, K-RITH Tower Builidng, Nelson R Mandela School of Medicine, Durban, South Africa</p>', 'seminar, susan, engelbrecht, Stellenbosch University, Tygerberg NHLS, Durban, January, 2014, presentation, public, genomics programme, wellcome trust Africa Centre, South Africa, K-RITH, Nelson R Mandela School of Medicine, UKZN, 30 years, HIV diversity research, personal perspective, seminar, susan, engelbrecht, Stellenbosch University, Tygerberg NHLS, Durban, January, 2014, presentation, public, genomics programme, wellcome trust Africa Centre, South Africa, K-RITH, Nelson R Mandela School of Medicine, UKZN, 30 years, HIV diversity research, personal perspective, seminar, susan, engelbrecht, Stellenbosch University, Tygerberg NHLS, Durban, January, 2014, presentation, public, genomics programme, wellcome trust Africa Centre, South Africa, K-RITH, Nelson R Mandela School of Medicine, UKZN, 30 years, HIV diversity research, personal perspective', 'Wellcome Trust Africa Centre Genomics Programme Seminar in Durban, January 2014. 30 years of HIV diversity research: a personal perspective by Prof. Susan Engelbrecht, Stellenbosch University.', NULL),
(106, 'imgnews41.jpg', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Feb2014.pdf', 'Seminar: HIV-1 Transmission during Early Infection in Men Who Have Sex with Men: A Phylodynamic Analysis', 'KRISP Talks', NULL, '2014-02-19', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr. Eduan Wilkinson, 19 February 2014, Africa Centre headquarters, Mtubatuba</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Feb2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Feb2014.png\"></a></center></p>\n<p><b>by Dr Eduan Wilkinson</b>, (Africa Centre, UKZN)</p>\n<p>Date: 19 February 2014</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: Stein-Susser auditorium, Africa Centre for Health and Population Studies, Shomkele, Mtubatuba, South Africa</p>', 'seminar, phylodynamics, february, 2014, eduan, wilkinson, mtubatuba, wellcome trust, africa centre, UKZN, genomics programme, bioafrica,seminar, phylodynamics, february, 2014, eduan, wilkinson, mtubatuba, wellcome trust, africa centre, UKZN, genomics programme, bioafrica,seminar, phylodynamics, february, 2014, eduan, wilkinson, mtubatuba, wellcome trust, africa centre, UKZN, genomics programme, bioafrica,seminar, phylodynamics, february, 2014, eduan, wilkinson, mtubatuba, wellcome trust, africa centre, UKZN, genomics programme, bioafrica, HIV, phylogeny', 'Wellcome Trust Africa Centre Genomics Programme Seminar in Mtubatuba, February 2014.HIV-1 TRANSMISSION DURING EARLY INFECTION IN MEN WHO HAVE SEX WITH MEN: A PHYLODYNAMIC ANALYSIS by Dr. Eduan Wilinson, Africa Centre, UKZN.', NULL),
(107, 'imgnews77.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Mar2014B.pdf', 'Seminar: Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance', 'KRISP Talks', NULL, '2014-03-12', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr. Justen Manasa, 12 March 2014, Africa Centre headquarters, Mtubatuba</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Mar2014B.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Mar2014B.png\"></a></center></p>\n<p><b>by Dr Justen Manasa</b>, (Africa Centre, UKZN)</p>\n<p>Date: 12 March 2014</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: Stein-Susser auditorium, Africa Centre for Health and Population Studies, Shomkele, Mtubatuba, South Africa</p>', 'seminar, HIV, drug resistance, wellcome trust, africa centre, protease, genome, HIV-1, justen manasa, UKZN, March 2014, seminar, HIV, drug resistance, wellcome trust, africa centre, protease, genome, HIV-1, justen manasa, UKZN, March 2014, seminar, HIV, drug resistance, wellcome trust, africa centre, protease, genome, HIV-1, justen manasa, UKZN, March 2014, seminar, HIV, drug resistance, wellcome trust, africa centre, protease, genome, HIV-1, justen manasa, UKZN, March 2014, seminar, HIV, drug resistance, wellcome trust, africa centre, protease, genome, HIV-1, justen manasa, UKZN, March 2014, ', NULL, NULL),
(109, 'imgnews108.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Mar2014C.pdf', 'Seminar: Trends and causes of hospitalisation in adults receiving ART', 'KRISP Talks', NULL, '2014-03-19', '<p>The Wellcome Trust Africa Centre Population Epidemiology Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr. Portia Mutevedzi, 19 March 2014, Africa Centre headquarters, Mtubatuba</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Mar2014C.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Mar2014C.png\"></a></center></p>\n<p><b>by Dr Portia Mutevedzi</b>, (Africa Centre, UKZN)</p>\n<p>Date: 19 March 2014</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: Stein-Susser auditorium, Africa Centre for Health and Population Studies, Shomkele, Mtubatuba, South Africa</p>\n', 'seminar, africa centre, population, epidemiology, programme, portia, Trends, causes, hospitalisation, adults, receiving, ART, rural, South Africa, Mtubatuba, Portia Mutevedzi, Frank Tanser, March, 2014, seminar, africa centre, population, epidemiology, programme, portia, Trends, causes, hospitalisation, adults, receiving, ART, rural, South Africa, Mtubatuba, Portia Mutevedzi, Frank Tanser, March, 2014, seminar, africa centre, population, epidemiology, programme, portia, Trends, causes, hospitalisation, adults, receiving, ART, rural, South Africa, Mtubatuba, Portia Mutevedzi, Frank Tanser, March, 2014', 'Wellcome Trust Africa Centre Genomics Programme Seminar in Mtubatuba, March 2014. Trends and causes of hospitalisation in adults receiving ART by Dr. Portia Mutevedzi, Africa Centre, UKZN.', NULL),
(110, 'imgnews92.png', 'http://www.bioafrica.net/manuscripts/biostatisticsKRITH2014.pdf', 'Interactive Biostatistics Course, Durban, 26-30 may 2014', 'K-RITH', NULL, '2014-03-13', '<p>K-RITH is offering an innovative course in the biostatistical methods used in medical research. This hands-on course is taught by Harvard biostatistician, Dr. Lori Chibnik.</p>', NULL, NULL, '<p><center><a href=\"manuscripts/biostatisticsKRITH2014.pdf\"><img src=\"imagesBIO/biostatisticsKRITH2014.png\"></a></center></p>\n<p>Participants will apply these techniques to their own research. Better understand results presented in medical literature.</p>\n\n<p><b>Travel scholarships are available.</b></p>\n<p>To apply please visit: <b><a href=\"http://www.k-rith.org\">www.k-rith.org</a></p>\n<p><b>Deadline:</b> 31 march 2014.</p>\n', 'k-rith, biostatistics course, durban, May 2014, harvard, medical research, UKZN, Nelson R Mandela School of Medicine, k-rith, biostatistics course, durban, May 2014, harvard, medical research, UKZN, Nelson R Mandela School of Medicine, k-rith, biostatistics course, durban, May 2014, harvard, medical research, UKZN, Nelson R Mandela School of Medicine, ', 'K-RITH is offering an innovative course in the biostatistical methods used in medical research. This hands-on course is taught by Harvard biostatistician, Dr. Lori Chibnik. Interactive Biostatistics Course, Durban, 26-30 may 2014', NULL),
(111, 'imgnews69.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Mar2014D.pdf', 'Seminar: Unlocking the potential of TB genomics', 'KRISP Talks', NULL, '2014-03-27', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr. Siva Danaviah, 26 March 2014, Africa Centre headquarters, Mtubatuba</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Mar2014D.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Mar2014D.png\"></a></center></p>\n<p><b>by Dr Siva Danaviah</b>, (Africa Centre, UKZN)</p>\n<p>Date: 26 March 2014</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: Stein-Susser auditorium, Africa Centre for Health and Population Studies, Shomkele, Mtubatuba, South Africa</p>\n', 'seminar, TB genomics, Africa Centre, siva danaviah, MTB, tuberculosis, genome, next generation data, South Africa, Mtubatuba, UKZN, MRC Flagship, seminar, TB genomics, Africa Centre, siva danaviah, MTB, tuberculosis, genome, next generation data, South Africa, Mtubatuba, UKZN, MRC Flagship, seminar, TB genomics, Africa Centre, siva danaviah, MTB, tuberculosis, genome, next generation data, South Africa, Mtubatuba, UKZN, MRC Flagship', 'Wellcome Trust Africa Centre Genomics Programme Seminar in Mtubatuba, March 2014. Unlocking the potential of TB genomics by Dr. Siva Danaviah, Africa Centre, UKZN.', NULL),
(112, 'imgnews112.png', 'http://www.bioafrica.net/manuscripts/Seminar_PeterPiot_AfricaCentre_Apr2014.pdf', 'Seminar: Old and new challenges for HIV control', 'KRISP Talks', NULL, '2014-04-01', '<p>The Wellcome Trust Africa Centre for Health and Population Studies and the University of KwaZulu-Natal (UKZN) cordially invites you to a seminar presented by Prof. Peter Piot, 1 April 2014, Africa Centre headquarters, Mtubatuba</p>\n', NULL, 5, '<br><p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_PeterPiot_AfricaCentre_Apr2014.pdf\"><img src=\"imagesBIO/Seminar_PeterPiot_AfricaCentre_Apr2014.png\"></a></center></p>\n<p><b>by Prof. Peter Piot</b><br>Director - London School of Hygiene and Tropical Medicine, U.K.</p>\n<p>Date: 1 April 2014</p>\n<p>Time: 11:30-12:30</p>\n<p>Venue: Stein-Susser auditorium, Africa Centre for Health and Population Studies, Shomkele, Mtubatuba, South Africa</p>\n', 'Peter Piot, UNAIDS, London School of Hygiene and Tropical Medicine, U.K., Old and new challenges for HIV control, Africa Centre, Seminar, April 2014, South Africa, Mtubatuba, Deenan Pillay, wellcome Trust, Peter Piot, UNAIDS, London School of Hygiene and Tropical Medicine, U.K., Old and new challenges for HIV control, Africa Centre, Seminar, April 2014, South Africa, Mtubatuba, Deenan Pillay, wellcome Trust, Peter Piot, UNAIDS, London School of Hygiene and Tropical Medicine, U.K., Old and new challenges for HIV control, Africa Centre, Seminar, April 2014, South Africa, Mtubatuba, Deenan Pillay, wellcome Trust, Peter Piot, UNAIDS, London School of Hygiene and Tropical Medicine, U.K., Old and new challenges for HIV control, Africa Centre, Seminar, April 2014, South Africa, Mtubatuba, Deenan Pillay, wellcome Trust', 'The Wellcome Trust Africa Centre for Health and Population Studies and the University of KwaZulu-Natal (UKZN) cordially invites you to a seminar presented by Prof. Peter Piot, 1 April 2014, Africa Centre headquarters, Mtubatuba', NULL),
(113, 'imgnews113.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2014A4.pdf', 'SATuRN Newsletter, Mar 2014: News, publications, videos & new seminar series!', 'SATuRN', NULL, '2014-04-02', '<p>The newsletter idea is that anyone with 15 minutes to spare can learn about our work and its application in everyday life. In our first issue of 2014 (Vol. 3 Num. 1) our newsletter we focus on our new seminar series and publications and results from SATuRN partners. We also included interesting news, blogs, reports, tweets and training information produced by our network.</p>', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2014A4.pdf\"><img src=\"imagesBIO/imgnews113Big.png\"></a></center> </p>\n\n<p><b><i>In this issue our highlights are:</b></i></p>\n \n<p><a href=\"http://www.bioafrica.net/news.php?id=112\">Seminar: Prof. Peter Piot (LSHTM) - Old and new challenges for HIV control </a></p>\n\n<p><a href=\"http://www.bioafrica.net/news.php?id=104\">Seminar: Dr. Like Daum (Texas) - Next-generation sequencing for identifying drug resistance in Mycobacterium Tuberculosis</a></p>\n\n<p><a href=http://jid.oxfordjournals.org/content/early/2014/01/16/infdis.jiu026\">Publication: Sensitive TDF Resistance Screening of HIV-1 From the Genital and Blood Compartments of Women With Breakthrough Infections in the CAPRISA 004 TDF Gel Trial</a></p>\n\n<p><a href=\"http://www.bioafrica.net/publications.php?pubid=97\">Publication: Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.</a></p>\n\n<p><a href=\"http://aighd.org/projects/paser/\">CROI: Favorable Long-term Outcomes of 2nd-line ART Despite Drug-Resistant HIV-1 in Sub- Saharan Africa: PASER-M cohort</a></p>\n\n<p><a href=\"http://www.bioafrica.net/videos.php?id=20\">Video: HIV-1 Drug Resistance in Children in rural South Africa</a></p>\n\n<p><a href=\"http://www.bioafrica.net/bioinformaticsworkshop.html\">Workshop: Bioinformatics in the Tropics IV, 29 May to 1 June 2014, Fiocruz, Salvador, Brazil</a></p> \n \n<p>The newsletter is open accessible at:</p>\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2014A4.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2014A4.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>', 'newsletter, saturn, 2014, vol 3, number 1, seminars, peter piot, hiv, tb, drug resistance, southern african treatment resistance network, Bioinformatics in the tropics, TDF drug resistance, CAPRISA 004, PASER, clinical outcome, second line, ARVs, ART, antiretroviral, MDR, XDR, newsletter, saturn, 2014, vol 3, number 1, seminars, peter piot, hiv, tb, drug resistance, southern african treatment resistance network, Bioinformatics in the tropics, TDF drug resistance, CAPRISA 004, PASER, clinical outcome, second line, ARVs, ART, antiretroviral, MDR, XDR, newsletter, saturn, 2014, vol 3, number 1, seminars, peter piot, hiv, tb, drug resistance, southern african treatment resistance network, Bioinformatics in the tropics, TDF drug resistance, CAPRISA 004, PASER, clinical outcome, second line, ARVs, ART, antiretroviral, MDR, XDR', 'The SATuRN newsletter idea is that anyone with 15 minutes to spare can learn about our work and its application in everyday life. In our first issue of 2014 our newsletter we focus on our seminars, manuscripts on HIV and TB drug resistance, youtube videos and oterh activities of the Southern African Treatment Resistance Network', NULL),
(114, 'imgnews41.jpg', 'http://www.bioafrica.net/manuscripts/Seminar_AfricaCentre_Apr2014B.pdf', 'Seminar: Cause-specific mortality: Standardised measurements and comparisons', 'KRISP Talks', NULL, '2014-04-09', '<p>The Wellcome Trust Africa Centre Deputy Director iShare Programme cordially invites you to a seminar presented by Prof. Peter Byass, 09 April 2014, Africa Centre headquarters, Mtubatuba</p>', NULL, 5, '<br><p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_AfricaCentre_Apr2014B.pdf\"><img src=\"imagesBIO/Seminar_AfricaCentre_Apr2014B.png\"></a></center></p>\n<p><b>by Prof. Peter Byass</b><br>Professor of Global Health at the University of Umea,Sweden & Director of the Umea Centre for Global Health Research\n</p>\n<p>Date: 9 April 2014</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: Stein-Susser auditorium, Africa Centre for Health and Population Studies, Shomkele, Mtubatuba, South Africa</p>\n', 'Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014, Peter, Byass, seminar, south africa, africa centre, ishare, april, 2014', 'The Wellcome Trust Africa Centre Deputy Director iShare Programme cordially invites you to a seminar presented by Prof. Peter Byass, 09 April 2014, Africa Centre headquarters, Mtubatuba', NULL),
(115, 'imgnews104.png', 'http://www.bioafrica.net/manuscripts/PostdoctoralResearchFellowsHIV_AfricaCentre.pdf', 'Postdoctoral Research Fellows in HIV', 'WT Africa Centre, UCL & LSHTM', NULL, '2014-07-17', '<p>We invite applications from ambitious clinical or non-clinical postdoctoral scientists, to undertake research in a Flagship programme of the Wellcome Trust & MRC in South Africa</p>', NULL, NULL, '<p>We wish to attract high quality postdoctoral scientists to undertake HIV research at the Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa (http://www.africacentre.ac.za & http://www.bioafrica.net).</p> \n<p>The Centre is funded by the Wellcome Trust and is developing close academic links with University College London and London School of Hygiene and Tropical Medicine.</p> \n\n<p>Up to five Postdoctoral Fellowships are available.  Potential areas of study include population and biological aspects of HIV in the context of the South African epidemic although other areas of investigation will be considered. We particularly invite applications related to:</p>  \n<p> - HIV transmission dynamics</p> \n<p> - Biostatistical approaches to epidemic causality</p> \n<p> - Causal impact evaluation of HIV interventions</p> \n<p> - Emergence of HIV drug resistance</p> \n<p> - Molecular epidemiology  host-pathogen interaction</p> \n<p> - Geospatial approaches to the design of targeted HIV prevention strategies</p> \n<br><p><b><i>The Genomics Programme provides example of three post-docs fellowships topics:</b></i></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=125\">HIV Genomics & Bioinformatics I - This Fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of complete HIV-1 genomes.</a></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=124\">HIV Genomics & Phylogenetics II - This Fellowship aims to develop and/or apply phylogenetic software applications to create a framework to identify epidemiologically important HIV strains.</a></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=123\">HIV & HTLV Bioinformatics & Phylogenetics III - This fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of HIV-1 and HTLV-1 complete genomes.</a></p><br>\n<p>Applicants will have demonstrated their potential to become successful scientists through high quality publications and an innovative research plan. The successful candidates will be supported to apply for externally funded personal fellowships, which should be based at UCL or LSHTM in the UK. In such cases, we will supplement the Fellowship award with further research funding. The positions are based at the Africa Centre, which has a surveillance base near Mtubatuba (2 hours north of Durban) and superb laboratory facilities in Durban, although flexibility exists for time in South Africa and the UK</p> \n \n<p>Candidates will therefore be required to consider mentors at the Africa Centre as well as UCL/LSHTM. Please see:</p>  \n<p>https://www.ucl.ac.uk/infection-immunity/research</p> \n<p>http://www.ucl.ac.uk/iph/research</p> \n<p>https://www.lshtm.ac.uk/</p> \n<p>http://www.bioafrica.net</p> \n\n<p>Interested candidates holding a PhD, and with clear evidence of internationally competitive research (through high quality publications), are invited to send their CV?s and discuss their interest informally with one or more the following Africa Centre staff in the first instance, prior to formal application:</p> \n\n<p><b><i>Professor Deenan Pillay</b></i>, Director of the Africa Centre. HIV drug resistance and pathogenesis (dpillay@africacentre.ac.za)</p> \n<p><b><i>Professor Tulio de Oliveira</b></i>, Director of the Genomics Programme at Africa Centre. Molecular Epidemiology, Bioinformatics & Host/Pathogen Genomics (tdeoliveira@africacentre.ac.za)</p> \n<p><b><i>Professor Frank Tanser</b></i>. Epidemiology (ftanser@africacentre.ac.za)</p> \n<p><b><i>Professor Till Barnighausen</b></i>, Biostatistics, Health Economics (tbarnighausen@africacentre.ac.za)</p> ', 'Postdoctoral, PosDoc, hiv, research, bioinformatics, molecular epidemiology, host, pathogen, genomics, tulio de oliveira, south africa, UKZN, Africa Centre, LSHTM, UCL, fellowships, positions,Postdoctoral, PosDoc, hiv, research, bioinformatics, molecular epidemiology, host, pathogen, genomics, tulio de oliveira, south africa, UKZN, Africa Centre, LSHTM, UCL, fellowships, positions,Postdoctoral, PosDoc, hiv, research, bioinformatics, molecular epidemiology, host, pathogen, genomics, tulio de oliveira, south africa, UKZN, Africa Centre, LSHTM, UCL, fellowships, positions,Postdoctoral, PosDoc, hiv, research, bioinformatics, molecular epidemiology, host, pathogen, genomics, tulio de oliveira, south africa, UKZN, Africa Centre, LSHTM, UCL, fellowships, positions,Postdoctoral, PosDoc, hiv, research, bioinformatics, molecular epidemiology, host, pathogen, genomics, tulio de oliveira, south africa, UKZN, Africa Centre, LSHTM, UCL, fellowships, positions', 'We wish to attract high quality postdoctoral scientists to undertake HIV research at the Africa Centre for Health and Population Studies, University of KwaZulu Natal, South Africa (http://www.africacentre.ac.za & http://www.bioafrica.net). The Centre is funded by the Wellcome Trust and is developing close academic links with University College London and London School of Hygiene and Tropical Medicine.', NULL),
(125, 'imgpostdoc.png', 'http://www.bioafrica.net/manuscripts/BioinformaticsPostDocs1A4.pdf', 'Postdoc Fellowship available - HIV Genomics & Bioinformatics I', 'WTAC, UCL, LSHTM & UKZN', NULL, '2014-07-26', '<p>We invite applications from ambitious post doctoral scientists, to undertake research in a Flagship programme of the Wellcome Trust & MRC in South Africa.This Fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of complete HIV-1 genomes. </p>', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/BioinformaticsPostDocs1A4.pdf\"><img src=\"imagesBIO/BioinformaticsPostDocPoster1A4.png\"></a></center></p>\n<p>This Fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of complete HIV-1 genomes. The research aims to investigate the use of next generation genomic data and  phylogenetic and bioinformatics techniques in order to characterize HIV-1 transmission and drug resistance in a well defined population phenotype. The candidate\'s expertise should include computer programming in Java, C++, PERL, Python or other computer languages.</p><p> The successful applicant  will have access to some of the best genomic HIV-1 complete genome datasets produced in the world using next generation sequencing techniques and will have access to world class genomics and bioinformatics facilities.  The applicant should either have a computer science degree or be a biologist able to write computer software applications. Previous experience  of phylogenetics will be an advantage. Successful applicants will have to demonstrate their potential to become successful scientists, through high quality publications and the production of innovative bioinformatics software applications</p>\n<p></p>\n<p>Fellowship promoters will be appointed at the Wellcome Trust Africa Centre/UKZN in South Africa and at University College of London (UCL) or London School of Hygiene and Tropical Medicine (LSHTM) in the U.K. Postdoctoral Fellows will be awarded a well paid tax-free fellowship in South African currency for up to 3 years. Once appointed, the successful candidates will be expected to apply for externally funded personal fellowships to be hosted by UCL or LSHTM. The positions are based at superb facilities in Durban, although flexibility exists for time in South Africa and abroad.</p>\n<p></p>\n<p>Interested candidates holding a PhD, and with clear evidence of internationally competitive research are invited to send their CV\'s and discuss their interest (which is not restricted to the above mentioned fellowship topic) informally with Prof. Tulio de Oliveira in the first instance, prior to formal application. Please email Mrs Xolile Kineri (Prof. de Oliveira\'s administrator)  at email: xkineri@africacentre.ac.za for further information, Tel: 035 550 7500, Fax: 035 550 7565. </p>\n<p></p>\n<p>In total, we are advertising up to five Post-Doctoral Fellowships. Potential areas of study include population and biological aspects of HIV in the context of the South African epidemic. </p>', 'postdoc, fellowship, scholarship, bioinformatics, genomics, phylogenetics, africa centre, wellcome trust, programming, JAVA, HIV, research, Tulio de Oliveira, postdoc, fellowship, scholarship, bioinformatics, genomics, phylogenetics, africa centre, wellcome trust, programming, JAVA, HIV, research, Tulio de Oliveira, postdoc, fellowship, scholarship, bioinformatics, genomics, phylogenetics, africa centre, wellcome trust, programming, JAVA, HIV, research, Tulio de Oliveira, postdoc, fellowship, scholarship, bioinformatics, genomics, phylogenetics, africa centre, wellcome trust, programming, JAVA, HIV, research, Tulio de Oliveira	', 'We invite applications from ambitious post doctoral scientists, to undertake research in a Flagship programme of the Wellcome Trust & MRC in South Africa.This Fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of complete HIV-1 genomes', NULL),
(124, 'imgpostdoc.png', 'http://www.bioafrica.net/manuscripts/BioinformaticsPostDocs2A4.pdf', 'Postdoc Fellowship available - HIV Bioinformatics & Phylogenetics II', 'WTAC, UCL, LSHTM & UKZN', NULL, '2014-07-26', '<p>We invite applications from ambitious post doctoral scientists, to undertake research in a Flagship programme of the Wellcome Trust & MRC in South Africa.This Fellowship aims to develop and/or apply phylogenetic software applications to create a framework to identify epidemiologically important HIV strains.</p>', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/BioinformaticsPostDocs2A4.pdf\"><img src=\"imagesBIO/BioinformaticsPostDocPoster2A4.png\"></a></center></p>\n<p>The fellow will develop and apply molecular epidemiology and phylogeography techniques to describe the epidemiologically important HIV strains in Africa. These results will be combined with geographic information software in order to produce an online software application to characterize the African and worldwide HIV diversity. The Fellow will have access to some of the best genomic and spatial datasets produced in the world using next generation sequencing techniques and will also have access to a world class genomics and bioinformatics facility.</p><p>The candidate\'s expertise should include advanced of phylogenetics analysis and/or computer programming in Java, C++, PERL, Python or other computer languages. Successful applicants will have to demonstrate their potential to become successful scientists, through high quality publications and the production of innovative bioinformatics software application</p>\n<p></p>\n<p>Fellowship promoters will be appointed at the Wellcome Trust Africa Centre/UKZN in South Africa and at University College of London (UCL) or London School of Hygiene and Tropical Medicine (LSHTM) in the U.K. Postdoctoral Fellows will be awarded a well paid tax-free fellowship in South African currency for up to 3 years. Once appointed, the successful candidates will be expected to apply for externally funded personal fellowships to be hosted by UCL or LSHTM. The positions are based at superb facilities in Durban, although flexibility exists for time in South Africa and abroad.</p>\n<p></p>\n<p>Interested candidates holding a PhD, and with clear evidence of internationally competitive research are invited to send their CV\'s and discuss their interest (which is not restricted to the above mentioned fellowship topic) informally with Prof. Tulio de Oliveira in the first instance, prior to formal application. Please email Mrs Xolile Kineri (Prof. de Oliveira\'s administrator)  at email: xkineri@africacentre.ac.za for further information, Tel: 035 550 7500, Fax: 035 550 7565. </p>\n<p></p>\n<p>In total, we are advertising up to five Post-Doctoral Fellowships. Potential areas of study include population and biological aspects of HIV in the context of the South African epidemic. </p>', 'postdoctoral, south african, UCL, London School of Hygeane and tropical medicine, durban, bioinformatics, phylogenetics, tulio de oliveira, HIV, applications, phylogeography, UKZN, wellcome trust, 3 years, 2014, postdoctoral, south african, UCL, London School of Hygeane and tropical medicine, durban, bioinformatics, phylogenetics, tulio de oliveira, HIV, applications, phylogeography, UKZN, wellcome trust, 3 years, 2014, postdoctoral, south african, UCL, London School of Hygeane and tropical medicine, durban, bioinformatics, phylogenetics, tulio de oliveira, HIV, applications, phylogeography, UKZN, wellcome trust, 3 years, 2014, postdoctoral, south african, UCL, London School of Hygeane and tropical medicine, durban, bioinformatics, phylogenetics, tulio de oliveira, HIV, applications, phylogeography, UKZN, wellcome trust, 3 years, 2014', 'This Fellowship aims to develop and/or apply phylogenetic software applications to create a framework to identify epidemiologically important HIV strains.', NULL),
(123, 'imgpostdoc.png', 'http://www.bioafrica.net/manuscripts/BioinformaticsPostDocs3A4.pdf', 'Postdoc Fellowship available - HIV & HTLV Bioinformatics & Phylogenetics III', 'WTAC, UKZN, FioCruz, CNPQ', NULL, '2014-07-26', 'We invite applications from ambitious post doctoral scientists, to undertake research in a collaborative programme of the the Wellcome Trust Africa Centre and the FioCruz Foundation in South Africa and Brazil.This fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of HIV-1 and HTLV-1 complete genomes', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/BioinformaticsPostDocs3A4.pdf\"><img src=\"imagesBIO/BioinformaticsPostDocPoster3A4.png\"></a></center></p>\n<p>Promoters: Prof. Dr. Luiz Carlos Alcantara & Prof. Dr. Tulio de Oliveira\n</p>\n<p>The research aims to investigate the use of next generation genomic data,  phylogenetics and bioinformatics techniques in order to characterize HIV-1 & HTLV-1 origin in Africa and South America as well the effect of co-infection on viruses evolution. The candidate expertise should include computer programming in Java, C++, PERL, Python or other computer language. The successful applicant  will have access to some of the best genomic HIV-1 and HTLV-1 datasets produced in the world using next generation sequencing techniques and access to world class genomics and bioinformatics facility.</p><p>Successful applicants should either have a computer science degree or be a biologist able to write computer software applications. Previous experience on phylogenetics is an advantage. The successful candidate will be supported to become a successful scientist and to develop open source bioinformatics software applications</p>\n<p>Fellow will be appointed at FioCruz in Salvador, Brazil and spend half of the time at Wellcome Trust Africa Centre for Health and Population Studies in Durban, South Africa. \n</p>\n<p>Post-Doc fellows will be awarded a post-doctoral fellowship (PDJ  from CNPQ), which includes a salary, travel and research allowance. The fellowship is awarded for 1 year, which can be extended for another year based on successful review. Interested fellow should send an application, which should contain a CV and a motivation letter (max 500 words) by 1 August 2014 to email: bioinformatica@bahia.fiocruz.br and xkineri@africacentre.ac.za, Tel: +55 71 3176 2255 (Brazil) and Tel: +27 35 550 7500 (South Africa).</p>\n<p></p>\n<p></p>\n<p>In total, we are advertising up to five Post-Doctoral Fellowships. Potential areas of study include population and biological aspects of HIV in the context of the South African epidemic. </p>', 'postdoc, sciencia sem fronteiras, brasil, africa do sul, durban, fiocruz, UKZN, wellcome trust, bioinformatics, phylogeny, tulio de oliveira, luiz carlos alcantara, hiv, html, molecular evolution, software application, fellowship, postdoc, sciencia sem fronteiras, brasil, africa do sul, durban, fiocruz, UKZN, wellcome trust, bioinformatics, phylogeny, tulio de oliveira, luiz carlos alcantara, hiv, html, molecular evolution, software application, fellowship, postdoc, sciencia sem fronteiras, brasil, africa do sul, durban, fiocruz, UKZN, wellcome trust, bioinformatics, phylogeny, tulio de oliveira, luiz carlos alcantara, hiv, html, molecular evolution, software application, fellowship, postdoc, sciencia sem fronteiras, brasil, africa do sul, durban, fiocruz, UKZN, wellcome trust, bioinformatics, phylogeny, tulio de oliveira, luiz carlos alcantara, hiv, html, molecular evolution, software application, fellowship', 'We invite applications from ambitious post doctoral scientists, to undertake research in a collaborative programme of the the Wellcome Trust Africa Centre and the FioCruz Foundation in South Africa and Brazil.This fellowship aims to apply and develop bioinformatics software applications to analyze large datasets of HIV-1 and HTLV-1 complete genomes', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(116, 'imgnews116.png', 'http://www.bioafrica.net/news.php?id=78', 'Bioinformatics in the Tropics blog: Molecular Evolution & Phylogenetics Workshop Entebbe Uganda 7th-10th April 2014', 'WTAC & UVRI', NULL, '2014-06-25', '<p>By: Deogratius Ssemwanga, Jonathan Kayondo, Siva Danaviah and Jaffer Zaidi. The bioinformatics in the tropics series is part of a south-to-south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America.</p>', NULL, NULL, '<p><center><img src=\"imagesBIO/BioinformaticsTropicsUganda2014B.png\"></a></center></p>\n<p>The workshop was jointly funded and organized by the Makerere University/Uganda Virus Research Institute Infection and Immunity (MUII) Training Programme, Wellcome Trust, the MRC/UVRI Uganda Research Unit on AIDS, the Africa Centre for Health and Population Studies and the University of Kwazulu-Natal, South Africa.</p>\n\n<p>The workshop was designed for scientists, graduate students, postdoctoral research fellows, and exceptional undergraduates interested in becoming familiar with tools for phylogenetic and genomic analyses. The course attracted over 35 applicants but due to space limitations, 25 participants from several African countries including Uganda, Kenya, Zimbabwe, Malawi and Sudan were invited to attend. Eight (8) course teachers from Uganda, South Africa, the United States of America and the United Kingdom facilitated at the course.</p>\n<p>The four-day workshop involved theoretical lectures and practical sessions on the usage and interpretation of bioinformatics applications for the study of small and large data sets of HIV and other genomic data. Softwares used in the practical sessions include PHYLIP, PAUP*, PHYML, MEGA, TREE-PUZZLE, BEAST, Simplot, MrBayes, RegaDB and other software. This workshop also included statistical analysis of HIV drug resistance and phylogenetic inference and interpretation of phylogenetic trees.</p>\n\n<p>The first day of the workshop had a lecture on the general introduction to phylogenetics and its biological applications, which set the ground for the course. The course took the students through the various sequencing technologies, denovo sequence assembly and quality control. The students were taken through the theory and practical sessions on sequence alignments.</p>\n\n<p>On the second day, more practical sessions on multiple sequence alignments were held. This was followed by lectures and practical sessions on the easy maths of trees, the basic principles of building and interpreting trees. A keynote presentation open to the UVRI community on the Molecular Epidemiology of HIV-1 in concentrated Epidemics was done. Students were later through a practical session on phylogenetic graphics using the Cluster Picker software.</p>\n\n<p>The third day involved lectures on the various substitution models, JModel test and a practical on Maximum Likelihood using PhyML. A second keynote lecture open to the UVRI community on exploring epidemic structure in HIV and influenza using phylodynamics was made. This was followed by a practical session on Bayesian inference using the BEAST software.</p>\n\n<p>The fourth and final day had a theory and practical session on detecting recombination using the various available free online and commercial softwares. Students were later taken through the processes of generating and analyzing HIV drug resistance data. The various drug resistance databases were also explored during this session. Students at the workshop were also encouraged to utilize their own sequence data with the help of the teachers. The course was concluded with a certificate award to the students and a workshop barbeque. </p>\n\n<p>The course feedback was very encouraging with useful suggestions on how best to improve future courses. The south-to-south series have been a success and we are looking forward to continue this model of collaboration possibly even in other areas.</p', 'bioinformatics, tropics, Uganda, report, 2014, workshop, Deogratius Ssemwanga, Jonathan Kayondo, Siva Danaviah, Jaffer Zaidi, next, generation, bioinformaticians, Africa, Latin America,south-to-south, capacity building, programme, Africa Centre, UKZN, UVRI, MRC, Wellcome trust, bioinformatics, tropics, Uganda, report, 2014, workshop, Deogratius Ssemwanga, Jonathan Kayondo, Siva Danaviah, Jaffer Zaidi, next, generation, bioinformaticians, Africa, Latin America,south-to-south, capacity building, programme, Africa Centre, UKZN, UVRI, MRC, Wellcome trust, bioinformatics, tropics, Uganda, report, 2014, workshop, Deogratius Ssemwanga, Jonathan Kayondo, Siva Danaviah, Jaffer Zaidi, next, generation, bioinformaticians, Africa, Latin America,south-to-south, capacity building, programme, Africa Centre, UKZN, UVRI, MRC, Wellcome trust', 'Report on Bioinformatics in the tropics: Molecular Evolution and Phylogenetics Workshop Entebbe Uganda 7th ? 10th April 2014. By: Deogratius Ssemwanga, Jonathan Kayondo, Siva Danaviah and Jaffer Zaidi. The bioinformatics in the tropics series is part of a south-to-south capacity building programme to develop the next generation of bioinformaticians in Africa and Latin America.', 'Y'),
(117, 'imgnews105.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Jul2014.pdf', 'Seminar: Genomics & Bioinformatics: The need to engage biologists, mathematicians & computer scientists.', 'KRISP Talks', NULL, '2014-06-25', '<p>The Wellcome Trust Africa Centre Genomics Programme, the UKZN MRC Flagship project and School of Mathematics, Statistics and Computer Science, UKZN, cordially invites you to a seminar presented by Prof. Tulio de Oliveira, 7 July 2014, UKZN, Pietermaritzburg, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Jul2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Jul2014.png\"></a></center></p>\n<p><b>by Prof. Tulio de Oliveira</b>, (Africa Centre, UKZN)</p>\n<p>Date: 7 July 2014</p>\n<p>Time: 14:10-15:00</p>\n<p>Venue: Room F47 Science Building, School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg</p>', 'bioinformatics, seminar, genomics, computer science, statistics, tulio de oliveira,  School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg presentation, Wellcome trust, MRC Flagship, \r\nbioinformatics, seminar, genomics, computer science, statistics, tulio de oliveira,  School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg presentation, Wellcome trust, MRC Flagship, \r\nbioinformatics, seminar, genomics, computer science, statistics, tulio de oliveira,  School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg presentation, Wellcome trust, MRC Flagship, \r\nbioinformatics, seminar, genomics, computer science, statistics, tulio de oliveira,  School of Mathematics, Statistics and Computer Science, University of KwaZulu-Natal, Pietermaritzburg presentation, Wellcome trust, MRC Flagship', 'The Wellcome Trust Africa Centre Genomics Programme, the UKZN MRC Flagship project and School of Mathematics, Statistics and Computer Science, UKZN, cordially invites you to a seminar presented by Prof. Tulio de Oliveira, 7 July 2014, UKZN, Pietermaritzburg, South Africa\n', NULL),
(118, 'imgnews118.png', 'http://www.bioafrica.net/manuscripts/deOliveiraposter.pdf', 'Inaugural Lecture: Bioinformatics, Genomics and HIV Research in Africa: A Brief Personal History', 'UKZN', NULL, '2014-07-14', 'The Vice-Chancellor and Principal Professor Malegapuru Makgoba cordially invites you and your spouse/partner to attend an inaugural lecture presented by Professor Tulio de Oliveira, 30 July 2014, K-RITH, Durban', NULL, 4, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/deOliveiraposter.pdf\"><img src=\"imagesBIO/deOliveiraposter.png\"></a></center></p>\n<p><b>by Prof. Tulio de Oliveira</b>, (BSc(UFRGS), BSc Hons, PhD (UKZN))</p>\n<p>Date: 30 July 2014</p>\n<p>Time: 17:30</p>\n<p>Venue: K1 and K2 Seminar Rooms, K-RITH Tower Building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n<p><b><i>RSVP:</b></i> (Acceptances only): Sandhia Ramsuroop</p>\n<p>Tel: 031 260 7069 | E-mail: graduations@ukzn.ac.za or complete electronic reply card by clicking on\n <a href=\"http://www.ukzn.ac.za/inauglecreply\">http://www.ukzn.ac.za/inauglecreply</a></p>\n<p>All Welcome, Guests to be seated by 17h15</p>\n<p>Refreshments will be served after the lecture</p>\n', 'inaugural, lecture, professor, tulio de oliveira, Durban, south Africa, bioinformatics, genomics, HIV, Africa, University of KwaZulu-Natal, Nelson Mandela School of Medicine, College of Health Sciences, inaugural, lecture, professor, tulio de oliveira, Durban, south Africa, bioinformatics, genomics, HIV, Africa, University of KwaZulu-Natal, Nelson Mandela School of Medicine, College of Health Sciences, inaugural, lecture, professor, tulio de oliveira, Durban, south Africa, bioinformatics, genomics, HIV, Africa, University of KwaZulu-Natal, Nelson Mandela School of Medicine, College of Health Sciences, inaugural, lecture, professor, tulio de oliveira, Durban, south Africa, bioinformatics, genomics, HIV, Africa, University of KwaZulu-Natal, Nelson Mandela School of Medicine, College of Health Sciences', 'The Vice-Chancellor and Principal Professor Malegapuru Makgoba cordially invites you and your spouse/partner to attend AN INAUGURAL LECTURE PRESENTED BY Professor Tulio de Oliveira, entitled: Bioinformatics, Genomics and HIV Research in Africa: A Brief Personal History, 30 July 2014, Durban, South Africa', NULL),
(119, 'imgnews119.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Aug2014.pdf', 'Seminar: Genome-wide association study indicates two novel resistance loci for severe malaria', 'KRISP Talks', NULL, '2014-07-15', '<p>KRISP Talks by <b>Prof. Andreas Ziegler</b>, 1 August 2014, Council Chambers, Westville Campus, UKZN, Durban.</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Aug2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Aug2014.png\"></a></center></p>\n<p><b>by Prof. Andreas Ziegler</b>, (Head of the Institute of Medical Biometry and Statistics at the Luebeck University, Germany)</p>\n<p>Date: 1 August 2014</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Council Chambers, Westville Campus, UKZN, Durban, University of KwaZulu-Natal, Westville, South Africa</p>', 'seminar, malaria, statistics, genomics, wide, association, MRC flagship, Andreas Ziegler, South Africa, seminar, UKZN, Africa Centre, August 2014, Durban, seminar, malaria, statistics, genomics, wide, association, MRC flagship, Andreas Ziegler, South Africa, seminar, UKZN, Africa Centre, August 2014, Durban, seminar, malaria, statistics, genomics, wide, association, MRC flagship, Andreas Ziegler, South Africa, seminar, UKZN, Africa Centre, August 2014, Durban, seminar, malaria, statistics, genomics, wide, association, MRC flagship, Andreas Ziegler, South Africa, seminar, UKZN, Africa Centre, August 2014, Durban', 'The Wellcome Trust Africa Centre Genomics & Pop. Epidemiology Programme, the UKZN MRC Flagship project and School of Mathematics, Statistics and Computer Science, UKZN, cordially invites you to a seminar presented by Prof. Andreas Ziegler, 1 August 2014, UKZN, Westville, South Africa', NULL),
(120, 'imgnews120sm.png', 'http://www.nicd.ac.za', 'NICD accredited by WHO for HIVDR testing using DBS specimens', 'NICD', NULL, '2014-07-20', '<p>By Anna Salimo, South Africa, 20 July 2014. The NICD laboratory in Johannesburg has been performing HIV-1 drug resistance (HIVDR) testing for surveillance purposes using plasma or serum specimens. The World Health Organization (WHO) have adjusted their requirements for accreditation to include HIVDR testing on dried blood spots (DBS) due to their ease of collection, handling, transportation and storage.</p>\n', NULL, 3, '<p><center><img src=\"imagesBIO/imgnews120.png\"></center></p>\n<p><i>Figure: An example of a DBS specimen (prepared on whatman 903 paper) used in HIVDR testing.</i></p>\n<p>To achieve this, validation of the in-house genotyping assay on DBS specimens using <a href=\"http://www.who.int/hiv/pub/drugresistance/HIVDR_Mod_7_Assay_Validation.ppt\"> WHO guidelines</a> was performed, wherein parameters tested included sensitivity, accuracy, precision and reproducibility. The laboratory has also successfully participated in external quality assessments (EQA) programs.</p>\n<p> Based on the successful validation of in-house assay on DBS specimens and EQA completion, the NICD laboratory was deemed competent and awarded accreditation by the WHO to perform HIVDR testing on DBS for HIVDR Surveys. The laboratory is the second to achieve such accreditation in South Africa. NICD will offer support and assistance on HIVDR testing on DBS for the Sub-Saharan/SADC region.</p>\n ', 'NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, dry blood spots, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, dry blood spots, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, dry blood spots, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, NICD, SATuRN, DBS, WHO, drug resistance, testing, genotyping, HIV, ARVs, dry blood spots	', 'The NICD laboratory in Johannesburg has been performing HIV-1 drug resistance (HIVDR) testing for surveillance purposes using plasma or serum specimens. The World Health Organization (WHO) have adjusted their requirements for accreditation to include HIVDR testing on dried blood spots (DBS) due to their ease of collection, handling, transportation and storage.', NULL),
(121, 'imgnews121sm.png', 'http://www.bioafrica.net/manuscripts/SATuRNnewsletter_2_2014A4.pdf', 'SATuRN Newsletter, Jul 2014: Annual HIVDR Workshop, News, Publications & Blogs', 'SATuRN', NULL, '2014-07-24', '<p>The newsletter idea is that anyone with 15 minutes to spare can learn about our work and its application in everyday life. In our second issue of 2014 (Vol. 3 Num. 2), we advertise our annual workshop, which will be presented as part of the Annual Workshop on Advanced Clinical Care - AIDS (AWACC), Durban, 8-9 Oct 2014. We also included interesting news, blogs and publications produced by our network and partners.</p>', NULL, NULL, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_2_2014A4.pdf\"><img src=\"imagesBIO/imgnews121.png\"></a></center> </p>\n\n<p><b><i>In this issue our highlights are:</b></i></p>\n \n<p><a href=\"http://www.bioafrica.net/news.php\">Positions available! 6 Post-Doc fellowships in HIV research at Wellcome Trust Africa Centre.</a></p>\n\n<p><a href=\"http://www.awacc.org\">Workshop: Annual Workshop on Advanced Clinical Care (AWACC), Durban, 9-10 October 2014.</a></p> \r\r<p><a href=\"http://www.bioafrica.net/blogs.php?id=33\">Meeting: Policy Meeting on HIV drug resistance, Lusaka, Zambia, 6 May 2014.</a></p>\r\r<p><a href=\"http://www.bioafrica.net/news.php?id=118\">Inaugural lecture: Prof. Tulio de Oliveira, Nelson Mandela School of Medicine, UKZN, Durban, 30 Jul 2014.</a></p>\r\r<p><a href=\"http://www.bioafrica.net/publications.php?pubid=102\">Publication: Circulating Biomarkers of Immune Activation Distinguish Viral Suppression from Nonsuppression in HAART-Treated Patients with Advanced HIV-1 Subtype C Infection. </a></p>\r\r<p><a href=\"http://journals.lww.com/aidsonline/pages/articleviewer.aspx?year=2014&issue=07170&article=00014&type=abstract\"Publication: Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.</a></p>\r\r<p><a href=\"http://www.bioafrica.net/blogs.php?id=35\">Blog & Publication: High-Level Cross-Resistance to Didanosine in Children Failing 1st-Line Regimen in South Africa.</a></p>\r\n\n<p><a href=\"http://www.bioafrica.net/seminars.php\">Our active and well attended seminar series!</a></p>\n<p>The newsletter is open accessible at:</p>\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_2_2014A4.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_2_2014A4.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>', 'SATuRN, newsletter, post-doc positions, annual workshop, AWACC, seminars, inaugural lecture, hiv, drug resistance, malaria, TB, southern African treatment resistance network, SATuRN, newsletter, post-doc positions, annual workshop, AWACC, seminars, inaugural lecture, hiv, drug resistance, malaria, TB, southern African treatment resistance network, SATuRN, newsletter, post-doc positions, annual workshop, AWACC, seminars, inaugural lecture, hiv, drug resistance, malaria, TB, southern African treatment resistance network, SATuRN, newsletter, post-doc positions, annual workshop, AWACC, seminars, inaugural lecture, hiv, drug resistance, malaria, TB, southern African treatment resistance network, SATuRN, newsletter, post-doc positions, annual workshop, AWACC, seminars, inaugural lecture, hiv, drug resistance, malaria, TB, southern African treatment resistance network', 'Newsletter of the Southern African Treatment and Resistance Network (SATuRN).  In our second issue of 2014, we would like to bring to your attention our annual workshop, which will be presented as part of the 2014 Annual Workshop on Advanced Clinical Care - AIDS (AWACC), Durban, 8-9 Oct 2014.', NULL),
(122, 'imgnews63.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Aug2014B.pdf', 'Seminar: Nanotechnology and the Treatment of HIV Infection', 'KRISP Talks', NULL, '2014-08-22', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr. Louis Chonco Jimenez, 22 August 2014, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Aug2014B.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Aug2014B.png\"></a></center></p>\n<p><b>by Dr . Louis Chonco Jimenez </b>, (Antiviral Research Group, Department of Virology at \r\nUKZN/NHLS, Inkosi Albert Luthuli Central Hospital, South Africa)</p>\n<p>Date: 22 August 2014</p>\n<p>Time: 11:00am-12:00pm</p>\n<p>Venue: K2 room, K-RITH, University of KwaZulu-Natal, Durban, South Africa</p>\n', 'seminar, nanotechnology, mrc flagship, hiv, treatment, infection, Genomics, Durban, K-RITH, Africa Centre, AIDS, seminar, nanotechnology, mrc flagship, hiv, treatment, infection, Genomics, Durban, K-RITH, Africa Centre, AIDS, seminar, nanotechnology, mrc flagship, hiv, treatment, infection, Genomics, Durban, K-RITH, Africa Centre, AIDS, seminar, nanotechnology, mrc flagship, hiv, treatment, infection, Genomics, Durban, K-RITH, Africa Centre, AIDS, seminar, nanotechnology, mrc flagship, hiv, treatment, infection, Genomics, Durban, K-RITH, Africa Centre, AIDS', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr. Louis Chonco Jimenez, 22 August 2014, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n\n', NULL),
(126, 'imgnews71sm.png', NULL, 'Doris Duke Annual Seminar for Medical Students from Harvard and UKZN', 'SATuRN & Harvard', 0, '2014-10-09', '<p>Each year during AWAAC, the Doris Duke International Research Fellowship at Harvard Medical School sponsors a special seminar for medical students who will be attending the conference. During the seminar, invited faculty members discuss journals article that they select with a group of medical students from the US who are engaging in research in sub-Saharan Africa and a group of South African medical students from UKZN. This year 20-25 students will attend the seminar.</p>\n<p></p>\n', NULL, 3, '<p>The purpose of the session is to give the students an opportunity to interact with senior researchers and academic leaders in HIV. Therefore, the session is intended to be interactive and informal. Faculty members select one article that the students should review in advance of the session. </p>\n<p></p>\n<p>The faculty this year are: </p>\n<p>- <b><i>Prof. Francois Venter</b></i>, Wits & Southern African Clinicians Society</p>\n<p>- <b><i>Prof. Tulio de Oliveira</b></i>, Africa Centre for Health and Population Studies, UNZK; University College London & SATuRN director</p>\n<p>- <b><i>Prof. Deenan Pillay</b></i>, Africa Centre for Health and Population Studies, UNZK; University College London (UCL) </p>\n<p>- <b><i>Dr. Brian Zanoni</b></i>, Infectious Disease Division at Massachusetts General will moderate the session</p>\n<p></p>\n<p>The faculty have selected three articles this year. These are:</p>\n<p></p>\n<p>1) <a href=\"manuscripts/Harling2014.pdf\">Do Age-Disparate Relationships Drive HIV Incidence in Young Women?Evidence from a Population Cohort in Rural KwaZulu-Natal, South Africa. Guy Harling et al. JAIDS 2014</a></p>\n<p></p>\n<p>2) <a href=\"manuscripts/Paton2014.pdf\">Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa. Paton et al. NEJM 2013</a></p>\n<p></p>\n<p>3) <a href=\"manuscripts/Barnighausen2014.pdf\">HIV Treatment-as-Prevention Research at a Crossroads. Barnighausen et al. PLoS Med 2014</a></p>\n<p></p>\n<p></p>\n<p></p>\n<p></p>\n<p></p>\n<p>Discussion in the workshop will include:</p>\n<p>- What are the implications of the findings of this article on future research? </p>\n<p>What are the policy reprecussions? </p>\n<p></p>\n<p>The medical students from the Harvard, US are senior students (between 3rd and 4th year) who are conducting research in a wide variety of areas - HIV, TB, surgical outcomes, diarrheal disease etc. Some are working in labs; others are conducting more clinically oriented research. They are working in RSA, Uganda, Kenya, Malawi etc. </p>\n<p></p>\n<p>The session will be held on Thursday as part of AWACC workshop, Oct 9th at 11:00-13:00.</p>', 'harvard, saturn, medical students, doris duke, seminar, durban, 2014, awacc, francois venter, tulio de oliveira, treatment as prevention, UKZN, Africa Centre, harvard, saturn, medical students, doris duke, seminar, durban, 2014, awacc, francois venter, tulio de oliveira, treatment as prevention, UKZN, Africa Centre, harvard, saturn, medical students, doris duke, seminar, durban, 2014, awacc, francois venter, tulio de oliveira, treatment as prevention, UKZN, Africa Centre, harvard, saturn, medical students, doris duke, seminar, durban, 2014, awacc, francois venter, tulio de oliveira, treatment as prevention, UKZN, Africa Centre, harvard, saturn, medical students, doris duke, seminar, durban, 2014, awacc, francois venter, tulio de oliveira, treatment as prevention, UKZN, Africa Centre	', 'Each year during AWAAC, the Doris Duke International Research Fellowship at Harvard Medical School sponsors a special seminar for medical students who will be attending the conference. During the seminar, invited faculty members discuss journals article that they select with a group of medical students from the US who are engaging in research in sub-Saharan Africa and a group of South African medical students from UKZN. This year 20-25 students will attend the seminar', NULL),
(127, 'imgnews104.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Oct2014.pdf', 'Seminar: Transcriptional profiling in human tuberculosis', 'KRISP Talks', 0, '2014-10-10', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Robert J Wilkinson, 10 October 2014, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Oct2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Oct2014.png\"></a></center></p>\n<p><b>by Prof. Robert J Wilkinson\r\n</b>, (Wellcome Trust Senior Fellow and Professor in Infectious Diseases, Imperial College London and University of Cape Town)</p>\n<p>Date: 10 October 2014</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K2, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>', 'seminar, TB, rob wilkinson, MRC flagship, UKZN, KRITH, UCT, Senior fellow, wellcome trust, South Africa, Transcriptional, profiling, human, tuberculosis, seminar, TB, rob wilkinson, MRC flagship, UKZN, KRITH, UCT, Senior fellow, wellcome trust, South Africa, Transcriptional, profiling, human, tuberculosis, seminar, TB, rob wilkinson, MRC flagship, UKZN, KRITH, UCT, Senior fellow, wellcome trust, South Africa, Transcriptional, profiling, human, tuberculosis, seminar, TB, rob wilkinson, MRC flagship, UKZN, KRITH, UCT, Senior fellow, wellcome trust, South Africa, Transcriptional, profiling, human, tuberculosis', 'The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Robert J Wilkinson, 10 October 2014, K-RITH building, Nelson R Mandela School of Medicine, Durban', NULL),
(128, 'ImgBlog32.png', 'http://www.awacc.org', 'AWACC & SATuRN conference a success! Please see twitter summary', 'SATuRN & AWACC', NULL, '2014-10-13', '<p>SATuRN annual workshop run in partnership with AWACC (UKZN, NDoH & Harvard). In total 346 participants attended the two days workshop. The workshop discussions were also very good. Here, we summarize the Tweeter coverage of the event, which contains information on the topics discussed and questions raised.</p>', NULL, 3, '<p><center><img src=\"imagesBIO/imgAwacc1.png\"></center></p>\n<p><i><b>The workshop was presented at Elangeni Hotel, Durban, 9-10 Oct 2014.</b></i></p>\n<br>\n<p>Please follow <a href=\"http://www.twitter.com/drug_resistance\">SATuRN & Bioafrica Twitter</a> to recieve the tweets in real time!</p>\n<br>\n<p><b>Tweets covering the event:</b></p>\n<br> <p> SATuRN @drug_resistance Oct 10</p>\n<p>Ethical values are higher than legal rules in HIV. How do we deal with this dilemma? #AWACC_AIDS @AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 10</p>\n<p>Second ethical principe - Beneficence - refers to balance the benefits of HIV treatment agains the risks and costs. #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 10</p>\n<p>The four ethical principles for HIV - Autonomy - making sure that patients are well informed #AWACC_AIDS #SATURN</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 10</p>\n<p>Wonderful to be part of the AWACC_AIDS SATuRN @drug_resistance is very proud to be involved in this great workshop! #AWACC_AIDS</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 10</p>\n<p>#AWACC_AIDS , doctors should prescribe drugs and advocate for the patients to have the drugs available.</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 10</p>\n<p>#AWACC_AIDS AWACC_AIDS get the impression you are not receiving my tweets today</p>\n<p></p>\n<br> <p> Siraaj Adams @SiraajAdams Oct 10</p>\n<p>#AWACC_AIDS Excellent clinical HIV conference. Well done to Henry Sunpath and organising team </p>\n<p></p>\n<br> <p> Siraaj Adams @SiraajAdams Oct 10</p>\n<p>#AWACC_AIDS 2.5million on ARV,majority on TDF,according to NHLS 72 %VL suppression,is the risk high 4 undiagnosed TDF induced renal failure</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 10</p>\n<p>#AWACC_AIDS unable to tweet you today</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 10</p>\n<p>#AWACC_AIDS , more than 8 weeks to access MDR TB Rx. Any concern?</p>\n<p></p>\n<br> <p> Siraaj Adams @SiraajAdams Oct 10</p>\n<p>#AWACC_AIDS will starting ARV at a CD4 of 500 , will it not encourage early HIV testing and increase average baseline CD4?</p>\n<p></p>\n<br> <p> ordoli dabibi @ordoli Oct 10</p>\n<p>#awacc_aids what will be the recommended dosing schedule for PrePEP</p>\n<p></p>\n<br> <p> ordoli dabibi @ordoli Oct 10</p>\n<p>#awacc_aids what is the risk of HIV transmission in oral sex to the male partner</p>\n<p></p>\n<br> <p> Siraaj Adams @AdamsSiraaj Oct 10</p>\n<p>#AWACC_AIDS will starting ARV at CD4 500 , not benefit SA by encouraging early testing and increase the average baseline CD4</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 10</p>\n<p>#AWACC_AIDS, do medical schemes cover Ral as PEP?</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 10</p>\n<p>#AWACC_AIDS, PEP should be 3 drugs, HAART. My opinion</p>\n<p></p>\n<br> <p> Hervey Williams @herveyvw Oct 10</p>\n<p>#AWACC_AIDS What dose of iron do you recommend for iron deficiency anaemia?</p>\n<p></p>\n<br> <p> Nkosinathi Sithole @spuku_snr Oct 10</p>\n<p>@AWACC_AIDS What\'s the relationship between metformin, diabetes, tenofovir, and renal impairment?</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Do you think that ERNEST will change guidelines in resistance test in 1st world? Or only in Africa? @AWACC_AIDS #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Do you think that ERNEST trial provided evidence that resistance to first line ia not important? Q to Deenan @AWACC_AIDS #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Deenan Pillay from @wellcometrust Africa Centre present on new evidence that drug resistance test may not be need for 1st line! @AWACC_AIDS</p>\n<p></p>\n<br> <p> Shafrudeen Amod @Shafrudeen Oct 9</p>\n<p>@AWACC_AIDS </p>\n<p>Do you think that increased doses of rifampicin(900mg to 1350mg) for eg TB meningitis will have pharmacological implications</p>\n<p></p>\n<br> <p> kirsty mcharry @kirstymcharry Oct 9</p>\n<p>@AWACC_AIDS what is LAM?</p>\n<p>Is it available?</p>\n<p></p>\n<br> <p> kirsty mcharry @kirstymcharry Oct 9</p>\n<p>@AWACC_AIDS Has 3 monthly refills helped or hindered?</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Vincent Marconi @HARVARDAIDS gave an excellent presentation on social & economic causes of virological failure @AWACC_AIDS #SATURN workshop</p>\n<p></p>\n<br> <p> mzimela bongani @mngunibw_20855 Oct 9</p>\n<p>@AWACC_AIDS does having the elite controllers mean we have done away with hiv carriers</p>\n<p>View conversation</p>\n<p></p>\n<br> <p> DOMINIQUE KABENGELE @DKABENGELE Oct 9</p>\n<p>@AWACC_AIDS DVT, HIV & Warfarin: Ideally frequent monitoring than in HIV negative & warfarin dosing calculator (app) help prevent Yo-Yo INR!</p>\n<p></p>\n<p>Durban</p>\n<br> <p> philani mnguni @philani_mnguni Oct 9</p>\n<p>@AWACC_AIDS why the combination of NNRTIs and NRTIs only as the first line regimen instead of NNRTIs, NRTIs and PIs?</p>\n<p></p>\n<p>Durban</p>\n<br> <p> Ntokozo Mzimela @Ntokzie Oct 9</p>\n<p>@AWACC_AIDS , Prof Dungu: Doesn\'t treatment interruption increase the risk of resistance?</p>\n<p></p>\n<br> <p> Vusi @vusimabena95 Oct 9</p>\n<p>@AWACC_AIDS is there a blood type which is </p>\n<p>View conversation</p>\n<p></p>\n<br> <p> Olufunso @fonzy67 Oct 9</p>\n<p>@AWACC_AIDS can these elite controllers be the future source of HIV vaccine development?</p>\n<p></p>\n<br> <p> DOMINIQUE KABENGELE @DKABENGELE Oct 9</p>\n<p>@AWACC_AIDS with no baseline VL at testing and no pre-Rx VL monitoring and new eligibility, it will be difficult to detect elite controllers</p>\n<p></p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Do you think that ERNEST will change guidelines in resistance test in 1st world? Or only in Africa? @AWACC_AIDS #AWACC_AIDS</p>\n<p></p>\n<br> <p> Siraaj Adams @SiraajAdams Oct 9</p>\n<p>#AWACC_AIDS Ernest study suggests no need for first line arv failure genotype test. Will clinicians society amend guide lines?</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Do you think that ERNEST trial provided evidence that resistance to first line ia not important? Q to Deenan @AWACC_AIDS #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Dr. Marconi, \"virological failure is an emergence, with or without drug resistance testing\" #AWACC_AIDS</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 9</p>\n<p>#AWACC_AIDS, Prof Moosa please be flexible on Raltegravir : scenario of renal failure!</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 9</p>\n<p>#AWACC_AIDS, 2nd of T/3tc/Aluvia, what if renal impairment not resolved?</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Great discussions with @HarvardAIDS and @UKZN medical students #AWACC_AIDS http://bioafrica.net/news.php?id=126 </p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Lovely to see Cloete usage of ERNEST trial results for clinical management. #AWACC_AIDS #SATURN </p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Understanding the mechanisms behind elite controllers critical for the elimination of HIV #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Great presentation by Prof Ndungu and Dr. Ndlovu on HIV controllers and other key populations for novel interventions #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>We just reviewed the ERNEST trial, which show at at level of 1st line therapy the 2nd </p>\n<p>Line work! Cloete any comment? #AWACC_AIDS #SATURN</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Great presentation by Cloete Van Vurren of clinical case at #AWACC_AIDS #SATURN </p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 9</p>\n<p>#AWACC_AIDS, would you support the practice of obtaining a VL with naive HAART pts with high CD4?</p>\n<p></p>\n<br> <p> Yunus Moosa @UnnieMoo Oct 9</p>\n<p>#AWACC_AIDS how do you assess the viral reservoir in patients</p>\n<p></p>\n<br> <p> Yunus Moosa @UnnieMoo Oct 9</p>\n<p>#AWACC_AIDS why do elite controllers drop CD4 count.</p>\n<p></p>\n<br> <p> Yunus Moosa @UnnieMoo Oct 9</p>\n<p>#AWACC_AIDS when does the virus appear in the blood after stopping ART in someone fully suppressed</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 9</p>\n<p>#AWACC_AIDS, would you initiate TDF on a patient with a resolved AKI, normal Cr Cl but slightly elevated creatinine ~ 109 mmol/ l ?</p>\n<p></p>\n<br> <p> Bijoux Mimpongo @bijouknysna Oct 9</p>\n<p>@AWACC_AIDS #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>We started with 3 clinical presentations on HIV. Interesting to see how medicine is not an exact science, but an art ;-) #AWACC_AIDS #SATURN</p>\n<p></p>\n<br> <p> AWACC @AWACC_AIDS Oct 9</p>\n<p>Dr N Madala- HIV and renal failure In An Environment With Restricted Renal Replacement #AWACC_AIDS </p>\n<p></p>\n<br> <p> AWACC @AWACC_AIDS Oct 9</p>\n<p>Dr AB Maharaj- Management of HIV associated Arthropathy #AWACC_AIDS </p>\n<p></p>\n<br> <p> bioafrica.net @bioafrica Oct 9</p>\n<p>We are really enjoying #AWACC_AIDS #SATURN in Durban, Great first presentation on surgery and HIV and the second started really funny ;-)</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Interesting question! How to avoid clinicians to refuse operation in low CD4+ patients? #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>First question, which Greek God has his liver torn by an eagle????? Where will Prof. Cacala take us? #AWACC_AIDS, tweet your answers!</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>1st presentation focus on surgery in HIV patients by Prof. Cacala @UKZN shows that in general surgery do not impact HIV disease #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Also great that twitter is being used for questions! Please send your question to #AWACC_AIDS & #SATURN on HIV and TB clinical care</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Really cool idea of the electronic voting system! 80% medical doctors in public sector! Great to see the translational power of #AWACC_AIDS</p>\n<p></p>\n<br> <p> SATuRN @drug_resistance Oct 9</p>\n<p>Thanks #AWACC_AIDS for inviting #SATURN to co-share the conference! We are very excited to be here via @drug_resistance</p>\n<p></p>\n<br> <p> AWACC @AWACC_AIDS Oct 9</p>\n<p>AWACC Conference finally here, please make sure to follow us on twitter on #AWACC_AIDS, post your questions as they come to mind.', 'twetter coverage, AWACC, saturn, hiv clinical management, hiv drug resistance, workshop, 2014, Durban, Harvard, UKZN, Africa Centre, southern African treatment resistance network, twetter coverage, AWACC, saturn, hiv clinical management, hiv drug resistance, workshop, 2014, Durban, Harvard, UKZN, Africa Centre, southern African treatment resistance network, twetter coverage, AWACC, saturn, hiv clinical management, hiv drug resistance, workshop, 2014, Durban, Harvard, UKZN, Africa Centre, southern African treatment resistance network, twetter coverage, AWACC, saturn, hiv clinical management, hiv drug resistance, workshop, 2014, Durban, Harvard, UKZN, Africa Centre, southern African treatment resistance network', 'AWACC workshop on aids clinical care and SATuRN annual workshop in 2014 was a successful event that attracted 346 pariticipants. During the two days workshop we saw lots of presentations from CAPRISA, Harvard, Africa Centre, UCL and other top research organizations. The workshop also use social media technology like Twitter. Here we summarize the tweets of the event.', NULL),
(130, 'imgnews130.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Nov2014.pdf', 'Seminar: Whole genome sequence interrogation of drug resistant Mycobacterium tuberculosis', 'KRISP Talks', NULL, '2014-11-21', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Samantha Sampson, 21 November 2014, Susser & Stein Seminar Room, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Nov2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Nov2014.png\"></a></center></p>\n<p><b>by Prof. Samantha Sampson\r\n</b>, (Dept of Biomedical Sciences, Stellenbosch University)</p>\n<p>Date: 21 November 2014</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser & Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>', 'MTB, Micobacterium, tuberculosis, complete genome, seminar, MRC Flagship, Durban. K-RITH, Prof Samantha Sampson, Stellenbosch, South Africa, Durban, talk, presentation, drug resistant, MDR, XDR, Mycobacterium tuberculosis, TB, MTB, Micobacterium, tuberculosis, complete genome, seminar, MRC Flagship, Durban. K-RITH, Prof Samantha Sampson, Stellenbosch, South Africa, Durban, talk, presentation, drug resistant, MDR, XDR, Mycobacterium tuberculosis, TB, MTB, Micobacterium, tuberculosis, complete genome, seminar, MRC Flagship, Durban. K-RITH, Prof Samantha Sampson, Stellenbosch, South Africa, Durban, talk, presentation, drug resistant, MDR, XDR, Mycobacterium tuberculosis, TB, MTB, Micobacterium, tuberculosis, complete genome, seminar, MRC Flagship, Durban. K-RITH, Prof Samantha Sampson, Stellenbosch, South Africa, Durban, talk, presentation, drug resistant, MDR, XDR, Mycobacterium tuberculosis, TB, UKZN, UKZN, UKZN', 'The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar entiled Whole genome sequence interrogation of drug resistant Mycobacterium tuberculosis, presented by Samantha Sampson, 21 November 2014, Susser & Stein Seminar Room, K-RITH building, Nelson R Mandela School of Medicine, Durban', NULL),
(129, 'imgnews103.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Sep2014.pdf', 'Seminar: ARV Therapy Initiated Before 2-Months-of-Age Reduces Transcriptionally Active HIV-1 DNA Persistence', 'KRISP Talks', NULL, '2014-09-19', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Gert Van Zyl, 19 September 2014, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_Sep2014.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_Sep2014.png\"></a></center></p>\n<p><b>by Dr. Gert Van Zyl\r\n</b>, (University of Stellenbosch)</p>\n<p>Date: 19 September 2014</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K2, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>', 'ARV, University, Stellenbosch, seminar, durban, 2014, Gert Van Zyl, ARV, Therapy, Initiated, Before 2-Months-of-Age, Reduces, Transcriptionally, Active, HIV-1, DNA, Persistence, MRC, Flagship, Seminar, UKZN,   ARV, University, Stellenbosch, seminar, durban, 2014, Gert Van Zyl, ARV, Therapy, Initiated, Before 2-Months-of-Age, Reduces, Transcriptionally, Active, HIV-1, DNA, Persistence, MRC, Flagship, Seminar, UKZN,   ARV, University, Stellenbosch, seminar, durban, 2014, Gert Van Zyl, ARV, Therapy, Initiated, Before 2-Months-of-Age, Reduces, Transcriptionally, Active, HIV-1, DNA, Persistence, MRC, Flagship, Seminar, UKZN,   Africa Centre, Durban', 'The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Gert Van Zyl, 19 September 2014, K-RITH building, Nelson R Mandela School of Medicine, Durban', NULL),
(131, 'imgnews105.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_January2015.pdf', 'Seminar: An Unexpected Influence of Genome Secondary Structure on Recombination in HIV', 'KRISP Talks', NULL, '2015-01-09', '<p>The Wellcome Trust Africa Centre Genomics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Darren Martin, 9 January 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_January2015.pdf\"><img src=\"imagesBIO/Seminar_MRCFlagship_January2015.png\"></a></center></p>\n<p><b>by Prof. Darren Martin\r\n</b>, (University of Cape Town, Wellcome Trust Fellow)</p>\n<p>Date: 9 January 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K1 Auditorium K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>', NULL, NULL, NULL),
(132, 'imgnews75.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipFeb2015KRITH.pdf', 'Seminar: Virus and host genetics: where and how to look in big data for associations with infectious disease', 'KRISP Talks', NULL, '2015-02-13', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Paul Kellam, 13 February 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipFeb2015KRITH.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipFeb2015KRITH.png\"></a></center></p>\n<p><b>by Prof. Paul Kellam\n\n</b>, (Viral Genomics Group Leader, Wellcome Trust Sanger Institute & University College London, UCL)</p>\n<p>Date: 13 February 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K2 Seminar room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'Wellcome trust, Sanger, institute, Africa Centre, Paul Kellam, bioinformatics, South Africa, Seminar, MRC Flagship, Virus, host, genetics, big data, infectious, diseases, february, 2015, Durban, KRITH, Wellcome trust, Sanger, institute, Africa Centre, Paul Kellam, bioinformatics, South Africa, Seminar, MRC Flagship, Virus, host, genetics, big data, infectious, diseases, february, 2015, Wellcome trust, Sanger, institute, Africa Centre, Paul Kellam, bioinformatics, South Africa, Seminar, MRC Flagship, Virus, host, genetics, big data, infectious, diseases, february, 2015, Wellcome trust, Sanger, institute, Africa Centre, Paul Kellam, bioinformatics, South Africa, Seminar, MRC Flagship, Virus, host, genetics, big data, infectious, diseases, february, 2015', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Paul Kellam, 13 February 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>\n', NULL),
(133, 'imgnews133.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipMarch2015.pdf', 'Seminar: Whole genome sequence interrogation of drug resistant Mycobacterium tuberculosis', 'KRISP Talks', NULL, '2015-03-20', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Samantha Sampson, 20 February 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipMarch2015.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipMarch2015.png\"></a></center></p>\n<p><b>by Prof. Samantha Sampson\n</b>, (Dept of Biomedical Sciences, Stellenbosch University, South Africa)</p>\n<p>Date: 20 February 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser & Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'Seminar, TB drug resistance, whole genome, Stellenbosch University, Nelson R Mandela School of Medicine, drug resistant, wellcome trust, Durban, Sotuh Africa, UKZN, Seminar, TB drug resistance, whole genome, Stellenbosch University, Nelson R Mandela School of Medicine, drug resistant, wellcome trust, Durban, Sotuh Africa, UKZN, Seminar, TB drug resistance, whole genome, Stellenbosch University, Nelson R Mandela School of Medicine, drug resistant, wellcome trust, Durban, Sotuh Africa, UKZN, Seminar, TB drug resistance, whole genome, Stellenbosch University, Nelson R Mandela School of Medicine, drug resistant, wellcome trust, Durban, Sotuh Africa, UKZN, Seminar, TB drug resistance, whole genome, Stellenbosch University, Nelson R Mandela School of Medicine, drug resistant, wellcome trust, Durban, Sotuh Africa, UKZN', 'Whole genome sequence interrogation of drug resistant Mycobacterium tuberculosis seminar presented by Prof. Samantha Sampson, 20 March 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', NULL);
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(134, 'imgnews134.png', 'http://www.bioafrica.net/manuscripts/IlluminaUserConferenceSouthAfrica2015.pdf', 'Our genomics and bioinformatics research program was selected as a keynote presentation in the 1st South African Illumina User Group Meeting, 2015', 'Illumina User Meeting', NULL, '2015-03-31', '<p>By: <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>, Franschoek, South Africa, 31 March 2015 - Continuing advances in next generation genomic analysis are rapidly changing the way we approach our research. The setup of our high-throughput genomics facility at the Nelson R Mandela School of Medicine, in collaboration with Africa Centre and Health and Population Studies allowed our research group to produce HIV-1 complete genomes at an unprecedented scale. </p>', NULL, 3, '<p><center><img src=\"imagesBIO/IlluminaFranshoeck.png\"></center></p>\n<p>We had been invited by Illumina to showcase our new genomics facility and our scientific results. I had the great privilege to present in 45 minutes the process of setting up our genomics and bioinformatics facility at Nelson R Mandela School of Medicine. I also showed how we had produced 500 HIV-1 whole genomes in the first 6 months of this facility.  The presentation also highlighted some of our recent results, which shows that hot spots of HIV transmission and increase of drug resistance in rural South Africa.</p>\n<p>The user meeting was attended by approximate 100 delegates, including a number of senior researchers and professors from South Africa. In addition, 7 staff from Illumina came to South Africa for this meeting. I had found very useful as a forum to discuss cutting edge genomics and bioinformatics applications with specialists.</p>\n<p><b><i>For more information, please see:</b></i></p>\r<p>-	<a href =\"http://www.bioafrica.net/manuscripts/IlluminaUserConferenceSouthAfrica2015.pdf\">Abstract from the 1st South African Illumina User Group Meeting, 9-10 March 2015, Franschoek, South Africa.</a>\r<p>-	<a href =\"videos.php\"> Videos that highlight the construction of our genomics facility.</a>\r<p>-	<a href =\"genomicsUKZN.php\">Webpage of our genomics facility at Nelson R Mandela School of Medicine, UKZN in collaboration with Africa Centre.</a>\n<p>- <a href =\"people.php?peopleid=1\">Tulio de Oliveira webpage at bioafrica.net.</a>\r\n', 'Illumina, genomics, facility, UKZN, Durban, South Africa, Tulio de Oliveira, 1st user meeting, Franschoek, March 2015, Nelson R Mandela School of Medicine,Africa Centre, bioinformatics, HIV, complete genomes, Next generation sequencing, miseq, Illumina, genomics, facility, UKZN, Durban, South Africa, Tulio de Oliveira, 1st user meeting, Franschoek, March 2015, Nelson R Mandela School of Medicine,Africa Centre, bioinformatics, HIV, complete genomes, Next generation sequencing, miseq, Illumina, genomics, facility, UKZN, Durban, South Africa, Tulio de Oliveira, 1st user meeting, Franschoek, March 2015, Nelson R Mandela School of Medicine,Africa Centre, bioinformatics, HIV, complete genomes, Next generation sequencing, miseq, Illumina, genomics, facility, UKZN, Durban, South Africa, Tulio de Oliveira, 1st user meeting, Franschoek, March 2015, Nelson R Mandela School of Medicine,Africa Centre, bioinformatics, HIV, complete genomes, Next generation sequencing, miseq, Illumina, genomics, facility, UKZN, Durban, South Africa, Tulio de Oliveira, 1st user meeting, Franschoek, March 2015, Nelson R Mandela School of Medicine,Africa Centre, bioinformatics, HIV, complete genomes, Next generation sequencing, miseq', 'Continuing advances in next generation genomic analysis are rapidly changing the way we approach our research. The setup of our high-throughput genomics facility at the Nelson R Mandela School of Medicine, in collaboration with Africa Centre and Health and Population Studies allowed our research group to produce HIV-1 complete genomes at an unprecedented scale. ', NULL),
(135, 'imgnews135.png', 'http://bioafrica.net/workshops/SATuRNCAPRISAHIVTBClinicalCareWorkshop.html', 'Report on the SATuRN & CAPRISA HIV & TB Advanced Clinical Care Workshop', 'SATuRN & CAPRISA', NULL, '2015-04-13', '<p>The Southern Africa Treatment and Resistance Network (SATuRN) and the Centre for the AIDS Programme of Research in South Africa (CAPRISA) organized a HIV & TB Advanced Clinical Care Workshop. This workshop is funded by the Centers for Disease Control and Prevention (CDC) & PEPFAR program in South Africa.</p>', NULL, 3, '<p><center><img src=\"imagesBIO/SATuRNCAPRISA1.png\"></center></p>\n\n<p>The second workshop was presented at Markaranga Garden Lodge in Durban South Africa. In total 62 participants were selected from 108 applicants. The great majority of the participants (> 80%) were clinicians that are dealing with complex HIV & TB clinical cases in KwaZulu-Natal.</p>\n\n<p>The workshop had 11 presenters, including some of the most respected physicians and scientists of the HIV and TB drug resistance field in the country. The workshop generated great discussion and the highlight was the discussion of clinical cases that involved both HIV & TB drug resistance infections.  </p>\n\n<p>The workshop ended with a questions and answers sections. As part of this a hot-line was created at CAPRISA, for which any clinician facing a difficult HIV & TB case can phone to get advice on how to manage it. </p>\n\n<p>In summary, this was SATuRN first successful workshop with CAPRISA. We will be also presenting another specialized workshop on the 8 and 9 of May 2015 with them, which we will blog about it. This collaboration is funded by the Centers for Disease Control and Prevention (CDC) & PEPFAR program in South Africa.</p>\n', 'SATuRN, CAPRISA, HIV, TB, drug resistance, workshop, Durban, 2015, clinical management, training programme, advanced clinical care, CDC, South Africa, southern african treatment resistance network, clinical cases, SATuRN, CAPRISA, HIV, TB, drug resistance, workshop, Durban, 2015, clinical management, training programme, advanced clinical care, CDC, South Africa, southern african treatment resistance network, clinical cases, SATuRN, CAPRISA, HIV, TB, drug resistance, workshop, Durban, 2015, clinical management, training programme, advanced clinical care, CDC, South Africa, southern african treatment resistance network, clinical cases, SATuRN, CAPRISA, HIV, TB, drug resistance, workshop, Durban, 2015, clinical management, training programme, advanced clinical care, CDC, South Africa, southern african treatment resistance network, clinical cases', 'The Southern Africa Treatment and Resistance Network (SATuRN) and the Centre for the AIDS Programme of Research in South Africa (CAPRISA) organized a HIV & TB Advanced Clinical Care Workshop. This workshop is funded by the Centers for Disease Control and Prevention (CDC) & PEPFAR program in South Africa.', NULL),
(136, 'imgnews105.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipApril2015KRITH.pdf', 'Seminar: Near Full Length Sequencing to Understand HIV & TB Epidemics In Africa In Real Time', 'KRISP Talks', NULL, '2015-04-30', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Tulio de Oliveira, 30 April 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipApril2015KRITH.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipApril2015KRITH.png\"></a></center></p>\n<p><b>by Prof. Tulio de Oliveira\n</b>, (Africa Centre for Health and Population Studies, & College of Health Sciences, University of KwaZulu-Natal)</p>\n<p>Date: 30 April 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K2 Seminar room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'seminar, nelson Mandela school of medicine, Full Length, Sequencing, Understand, HIV, TB, Epidemics, Africa, Real Time. Tulio de Oliveira, April 2015, K-RITH, UKZN, lecture, bioinformatics, genomics, seminar, nelson Mandela school of medicine, Full Length, Sequencing, Understand, HIV, TB, Epidemics, Africa, Real Time. Tulio de Oliveira, April 2015, K-RITH, UKZN, lecture, bioinformatics, genomics, seminar, nelson Mandela school of medicine, Full Length, Sequencing, Understand, HIV, TB, Epidemics, Africa, Real Time. Tulio de Oliveira, April 2015, K-RITH, UKZN, lecture, bioinformatics, genomics, seminar, nelson Mandela school of medicine, Full Length, Sequencing, Understand, HIV, TB, Epidemics, Africa, Real Time. Tulio de Oliveira, April 2015, K-RITH, UKZN, lecture, bioinformatics, genomics', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Tulio de Oliveira, 30 April 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>', NULL),
(137, 'imgnews137.png', 'http://ndabaonline.ukzn.ac.za/UkzndabaStory/Vol3-Issue15-College-of-Health-Sciences/Ground%20breaking%20PhD%20Study%20helps%20Rural%20Doctors%20monitor%20HIV%20Drug%20Resistance#', 'Ground-breaking PhD Study helps Rural Doctors monitor HIV Drug Resistance', 'UKZN', NULL, '2015-04-17', '<p>Dr Justen Manasa graduated with a PhD after completing ground-breaking research in the Hlabisa District of KwaZulu-Natal that resulted in a low cost genotyping method envisaged to help doctors monitor and evaluate drug resistance among HIV-infected patients in resource-limited settings.</p>\n', NULL, 3, '<p><center><img src=\"imagesBIO/Africa-Centres-Professor-Tulio-de-Oliveira-congratulates-Dr-Justen-Manasa.jpg\"></p>\n<p><i>Africa Centres Professor Tulio de Oliveira congratulates Dr Justen Manasa.</i></p></center>\n\n<p>Supervised by the prolific Programme Director for Genomics at the Wellcome Trust Africa Centre for Health and Population, Professor Tulio de Oliveira, Manasa\'s study demonstrated a low cost and open access method for HIV drug resistance genotyping which follows a four-stage protocol consisting of RNA extraction, reverse transcription and PCR, sequencing and bioinformatics.</p>\n\n<p>Because HIV drug resistance has the potential to derail the progress made in the efforts to control the epidemic, Manasa said it was important to continuously survey and monitor drug resistance in naive patients and patients failing therapy.</p>\n\n<p><b><i>\'Unfortunately most of the methods used are expensive to implement, especially in the context of the magnitude of the HIV epidemic in sub-Saharan Africa\'</b></i>, said Manasa.</p>\n\n<p>He said the numbers of patients accessing HIV-1 antiretroviral (ARV) treatment in resource-limited settings had increased exponentially over the past decade. This was accompanied by significant improvements in the quality of life and life expectancy of the patients who are already infected, however, the emergence and spread of HIV-1 drug resistance had the potential to reverse all the efforts made by scientists thus far.</p>\n\n<p>His study involved monitoring the temporal changes in HIV drug resistance in patients failing their first line ARV therapy (acquired drug resistance) and those not yet on treatment (transmitted drug resistance) in a rapidly expanding and decentralized public ARV treatment programme between the Department of Health and the Africa Centre for Health and Population in the rural district of Hlabisa.</p>\n\n<p>Manasa said: <b><i>\'High levels of acquired resistance were observed among patients failing therapy and almost 10 years after the roll out of the national treatment programme in South Africa, transmitted drug resistance was still less than five percent. However, latest data on transmitted drug resistance indicated an upward trend in the proportions of newly infected patients that have evidence of drug resistance.\'</b></i></p>\n\n<p>His study resulted in the development of a free and open source bioinformatics drug resistance database and a low cost HIV drug resistance genotyping method for resource-limited settings, which he says are freely available on the website: www.bioafrica.net</p>\n\n<p><b><i>\'The genotyping method and database are currently being used in ARV treatment and scientific research programmes in Botswana, South Africa and Zimbabwe.\'</b></i></p>\n\n<p>His PhD resulted in the publication of eight manuscripts in peer-reviewed journals, of which five were first author publications. He says he was also fortunate to present some of the work in a plenary session at the International AIDS Conference in Washington, D.C. in 2012.</p>\n\n<p><b><i>\'I really enjoyed the study\'s multidisciplinary nature encompassing molecular virology, bioinformatics and epidemiology. I was also happy the results could be translated to better management of patients failing antiretroviral therapy and that it addressed policy relevant research questions in the African fight against HIV and AIDS.\'</b></i></p>\n\n<p>He is a Fellow of the Salzburg Seminar series and a member of the Southern African Society for Human Genetics; the African Society for Laboratory Medicine; the American Society for Microbiology; the International AIDS Society and the Southern Africa Treatment and Resistance Network.</p>\n\n<p>Born in Zimbabwe, Manasa said he was very passionate about science and would like to better understand the causes and consequences of HIV drug resistance at individual and population levels in Africa.</p>\n\n<p><b><i>\'UKZN provides a unique environment of scholarship that enables one to answer policy relevant research questions using the most advanced tools under the mentorship of world leading researchers. At the moment I am excited about the new research hub at the Nelson R Mandela School of Medicine comprising K-RITH, HPP, CAPRISA and the Africa Centre.\'</b></i></p>\n', 'PhD, graduation, UKZN, Ndaba, 2015, Justen Manasa, Tulio de Oliveira, drug resistance, Africa Centre, Hlabisa, HIV, open source, bioinformatics tools, news, University of KwaZulu-Natal, doctorate, PhD, graduation, UKZN, Ndaba, 2015, Justen Manasa, Tulio de Oliveira, drug resistance, Africa Centre, Hlabisa, HIV, open source, bioinformatics tools, news, University of KwaZulu-Natal, doctorate, PhD, graduation, UKZN, Ndaba, 2015, Justen Manasa, Tulio de Oliveira, drug resistance, Africa Centre, Hlabisa, HIV, open source, bioinformatics tools, news, University of KwaZulu-Natal, doctorate, PhD, graduation, UKZN, Ndaba, 2015, Justen Manasa, Tulio de Oliveira, drug resistance, Africa Centre, Hlabisa, HIV, open source, bioinformatics tools, news, University of KwaZulu-Natal, doctorate, PhD, graduation, UKZN, Ndaba, 2015, Justen Manasa, Tulio de Oliveira, drug resistance, Africa Centre, Hlabisa, HIV, open source, bioinformatics tools, news, University of KwaZulu-Natal, doctorate', 'PhD graduation 2015, Durban, South Africa. Dr Justen Manasa graduated with a PhD after completing ground-breaking research in the Hlabisa District of KwaZulu-Natal that resulted in a low cost genotyping method envisaged to help doctors monitor and evaluate drug resistance among HIV-infected patients in resource-limited settings', NULL),
(138, 'imgnews138.png', 'http://www.nyas.org/Events/Detail.aspx?cid=1db34692-7883-4ea0-9231-39386e6a9948', 'HIV 2015: Using Phylogenetics to Enhance the HIV Response, New York, June 4, 2015', 'New York Academy of Sciences', NULL, '2015-06-04', '<p>A discussion meeting presented by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Microbiology & Infectious Diseases Discussion Group at the New York Academy of Sciences on the use of phylogenetics to enhance HIV response.</p>\n', NULL, 3, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/NYAS_HIV_Phylogenetics_2015_Flyer.pdf\"><img src=\"imagesBIO/NYAS_HIV_Phylogenetics_2015_Flyer.png\"></a></center></p>\n<p>Rapid advances in molecular genetics and bio-informatics allow more and better data on the phylogeny of HIV to be collected. The genetic diversity among HIV strains within individual patients, communities and globally allows the dynamics of transmission and evolution of the virus to be studied in ever greater detail. The implications for drug resistance, vaccine development, transmission networks and evaluation of prevention interventions are beginning to be understood. The challenge is to translate the new science into more effective ways to prioritize the HIV response and to monitor the impact of different intervention approaches. This meeting brings together scientists, policy makers, and international organizations dedicated to advancing our scientific knowledge of HIV and translating that information into the most effective programs for reducing transmission of the virus.</p>\n\n\n<p><b>Organizers</b></p>\n<p><b><i>Tulio De Oliveira</b></i>, PhD, Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa</p>\n\n<p><b><i>Ade Fakoya, BA, MB BS, DTM&H, FRCP(UK)</b></i>, The Global Fund to Fight AIDS, Tuberculosis and Malaria</p>\n\n<p><b><i>Morgane Rolland, PhD</b></i>,United States Military HIV Research Program</p>\n\n<p><b><i>Sonya Dougal</b></i>, PhD,The New York Academy of Sciences</p>\n\n<p><b><i>Peter Godfrey-Faussett</b></i>, BA, MBBS, DTM&H, FRCP(UK), UNAIDS, Geneva, Switzerland</p>\n\n<br><p><b>Speakers</b></p>\n<p><b><i>William A. Blattner</b></i>,, MD, MS, University of Maryland, College Park</p>\n\n<p><b><i>Jonathan M. Carlson</b></i>, PhD, Microsoft Research</p>\n\n<p><b><i>Tulio De Oliveira</b></i>, PhD, Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa</p>\n\n<p><b><i>Ade Fakoya</b></i>, MB, BS, DTM&H, FRCP (UK), The Global Fund to Fight AIDS, Tuberculosis and Malaria</p>\n\n<p><b><i>Christophe Fraser</b></i>, PhD, Imperial College</p>\n\n<p><b><i>Ayesha BM Kharsany</b></i>, PhD, Center for the AIDS Program of Research in South Africa (CAPRISA)</p>\n\n<p><b><i>Alexa Oster</b></i>, MD, Centers for Disease Control and Prevention</p>\n\n<p><b><i>Thomas Quinn</b></i>, MD, Johns Hopkins University</p>\n\n<p><b><i>Morgane Rolland</b></i>, PhD. US Military HIV Research Program</p>\n\n<br><p><b>Panelist</b></p>\n<p><b><i>Ralf Jurgens</b></i>, LLM, PhD, Open Society Foundations</p>\n<br><p><b>Press coverage:</b></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=141\"> - <b>Science</b>, 12 June 2015, by John Cohen - Molecular Epidemiology: HIV family trees reveal viral spread</a>.</p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=140\"> - <b>UNAIDS</b>, 8 June 2015, Feature story: Understanding HIV through phylogenetic research</a>.</p>\n\n', NULL, NULL, 'Y'),
(139, 'imgnews63.png', 'http://www.bioafrica.net/manuscripts/Seminar_MRCFlagship_June2015.pdf', 'Seminar: Clinical Impressions of HIV Pathogenesis & Vaccine Research', 'KRISP Talks', NULL, '2015-06-19', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr Nigel Garrett from CAPRISA, 19 June 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipJune2015.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipJune2015.png\"></a></center></p>\n<p><b>by Dr Nigel Garrett\n</b>, (Head of Pathogenesis and Vaccine Research: Centre for AIDS Programme of Research in South Africa - CAPRISA)</p>\n<p>Date: 19 June 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K2 Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'Seminar, CAPRISA, hiv, pathogenesis, vaccine, clinical, Africa Centre, Nigel Garrett, Wellcome Trust, Nelson R Mandela School of Medicine, South Africa, UKZN, MRC Flagship, Tulio de Oliveira, bioinformatics, june, 2015, Seminar, CAPRISA, hiv, pathogenesis, vaccine, clinical, Africa Centre, Nigel Garrett, Wellcome Trust, Nelson R Mandela School of Medicine, South Africa, UKZN, MRC Flagship, Tulio de Oliveira, bioinformatics, june, 2015, Seminar, CAPRISA, hiv, pathogenesis, vaccine, clinical, Africa Centre, Nigel Garrett, Wellcome Trust, Nelson R Mandela School of Medicine, South Africa, UKZN, MRC Flagship, Tulio de Oliveira, bioinformatics, june, 2015, Seminar, CAPRISA, hiv, pathogenesis, vaccine, clinical, Africa Centre, Nigel Garrett, Wellcome Trust, Nelson R Mandela School of Medicine, South Africa, UKZN, MRC Flagship, Tulio de Oliveira, bioinformatics, june, 2015, Seminar, CAPRISA, hiv, pathogenesis, vaccine, clinical, Africa Centre, Nigel Garrett, Wellcome Trust, Nelson R Mandela School of Medicine, South Africa, UKZN, MRC Flagship, Tulio de Oliveira, bioinformatics, june, 2015', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar and lecture presented by Dr Nigel Garrett from CAPRISA in June 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban</p>', ''),
(140, 'unaids_eng.png', 'http://www.unaids.org/en/resources/presscentre/featurestories/2015/june/20150608_phylogenetics', 'Feature story: Understanding HIV through phylogenetic research', 'UNAIDS', NULL, '2015-06-08', '<p>Phylogenetic research \'the analysis of molecular sequencing data to study evolutionary relationships among groups and organisms\' needs to be scaled up to end the AIDS epidemic, according to the participants at a symposium held on 4 June at the New York Academy of Sciences called HIV 2015: Using Phylogenetics to Enhance the HIV Response.</p>', NULL, 3, '<p><center><img src=\"imagesBIO/unaids_phylogenetics.jpg\"></center></p>\n<p>Speaking at the symposium, UNAIDS Deputy Executive Director Luiz Loures said that an evidence-driven, focused and rights-based approach is needed to Fast-Track the HIV response in the next five years and end the AIDS epidemic by 2030. <b><i>\'Science has been the major component of the progress we have made so far. Advancing phylogenetics will help us sharpen our focus on the most vulnerable groups, their locations and the progression of the HIV virus,\'</b></i> said <b><i>Mr Loures</b></i>.  </p>\n\n<p>Molecular genetics and biodata will provide high-quality information on the diversity of HIV strains among people living with HIV and their evolution and on the dynamics of HIV transmission. <b><i>\'A molecular clock study enables us to identify important characteristics of people transmitting HIV and understand how to reduce high incidence among vulnerable groups, for example young women in Africa,\'</b></i> said <b><i><a href=\"http://bioafrica.net/people.php?peopleid=1\">Tulio De Oliveira</b></i></a> from the Africa Centre and the University of KwaZulu-Natal in Durban, South Africa. <b><i>\'Recent advances in phylogenetic methods and molecular evolution show that data that combine genetic, spatial, immunological and social information can transform our understanding of epidemic dynamics.\'</b></i></p>\n\n<p>In the past few years, scientists have been closely researching the effectiveness of available antiretroviral medicines and the implications of drug resistance to tailor treatment programmes for specific populations. A phylogenetic study on HIV transmission and drug resistance in 27 areas representing 72% of new diagnosis in the United States of America, among many other findings, showed that 18.9% of men who have sex with men living with HIV transmitted drug resistance mutations between 2010 and 2012. The study also showed higher transmission rates among African-American men who have sex with men and young men who have sex with men. <b><i>\'There is a great opportunity to incorporate phylogenetics and molecular epidemiology into HIV prevention and treatment programmes to improve sustainability,\'</b></i> said <b><i>Alexa Oster</b></i>, Lead, Molecular HIV Surveillance at the Division of HIV/AIDS Prevention, Centres for Disease Control and Prevention.  </p>\n\n<p>However, the participants agreed that the significant challenges around genetics and HIV research among key populations, including ethics and human rights issues, will need to be addressed to fully benefit from the potential of phylogenetics.</p>\n\n<p>The annual symposiums convened by the New York Academy of Sciences and UNAIDS bring together scientists, activists, human rights defenders and policy-makers to discuss emerging advances in science relevant to accelerating the HIV response. </p> \n\n<br><p><b>Press coverage & flyer:</b></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=141\"> - <b>Science</b>, 12 June 2015, by John Cohen - Molecular Epidemiology: HIV family trees reveal viral spread</a>.</p>\n\n<p><a href=\"http://www.bioafrica.net/news.php?id=138\"> - <b>New York Academy of Science</b> HIV 2015: Using Phylogenetics to Enhance the HIV Response, New York, June 4, 2015</a>.</p>', NULL, NULL, NULL),
(141, 'science_logo.png', 'http://www.bioafrica.net/manuscripts/Science-2015-Cohen-1188-9.pdf', 'MOLECULAR EPIDEMIOLOGY: HIV family trees reveal viral spread.', 'Science', NULL, '2015-06-12', '<p>By John Cohen, Science, 12 June 2015. New studies could aid public health efforts. Last week at the New York Academy of Sciences in New York City, researchers, public health specialists, and HIV/AIDS advocates discussed how to exploit the potential of the technique, called phylogenetic analysis - and the thorny ethical and legal issues it raises...</p>', NULL, 3, '<p>The very trait that makes HIV so good at dodging the immune system and at thwarting efforts to develop an effective vaccine might also turn out to be an Achilles\' heel.</p>\n<p><center><a href=\"http://www.bioafrica.net/manuscripts/Science-2015-Cohen-1188-9.pdf\"><img src=\"imagesBIO/Science-2015-Cohen-1188-9.png\"></center></a></p>\n<p>HIV evades immune attack by copying itself at breakneck speed, regularly mutating so that each progeny differs slightly from the parent virus. The pace of change means that the more closely two isolates resemble each other, the more recently they shared a common host\' making it possible to track the spread of the virus and design precise interventions to block it. Last week at the New York Academy of Sciences in New York City, researchers, public health specialists, and HIV/AIDS advocates discussed how to exploit the potential of the technique, called phylogenetic analysis\'and the thorny ethical and legal issues it raises.</p>\n<p><b><i>\'This is a methodological breakthrough,\'</b></i> says epidemiologist William Blattner of the University of Maryland School of Medicine\'s Institute of Human Virology in Baltimore. The plummeting costs of DNA and RNA sequencing are now allowing it to be applied on a large scale, and early efforts are yielding some surprises about how HIV spreads and when it can most effectively be controlled.</p>\n<p>At the heart of the technique is the assumption that if the HIV sequences found in two people differ by less than 1.5%, then they are in a <b><i>\'transmission cluster.\'</b></i> This does not prove that one person infected the other\'there could have been intermediaries but their infections are closely linked. Because HIV mutates at a constant rate, researchers can also construct a molecular clock to estimate when the transmission took place. Combining the information from many HIV-infected people in a limited geographical area creates diagrams that resemble airline routing maps, allowing researchers to infer the direction and speed of spread.</p>\n<p>One study, by a group led by epidemiologist Alexa Oster of the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, takes advantage of a CDC recommendation that before starting antiretroviral (ARV) treatment, every newly infected person be tested for drug-resistant virus. That requires sequencing HIV, which has enabled CDC to build an anonymized database that includes information such as likely mode of transmission and age.</p>\n<p>With researchers from the University of California, San Diego, Oster\'s team mined HIV sequences from 27 sites around the country. They found that in men who report having sex with men (MSM), that explains the transmission 88% of the time. But surprisingly, Oster said, among men and women who inject drugs, the most common source of infection is not needle sharing but sex involving MSM. Also unexpected: Infections in heterosexual women were more frequently linked to MSM than to heterosexual men.</p>\n<p>CDC is now tracking transmission networks of 30 or more people to project whether they will grow by 2020. <b><i>\'If we were able to predict which clusters are going to grow, we would know where we might want to focus prevention efforts,\'</b></i> Oster said.</p>\n<p>Christophe Fraser, an epidemiologist at Imperial College London, and his colleagues hope to bolster prevention efforts in the Netherlands with their analysis of more than 13,000 HIV sequences from a cohort of predominantly MSM. They identified 106 distinct transmission networks and 883 probable transmitters, 69.2% of whom had undiagnosed infections; diagnosed people on ARV treatment, in contrast, rarely transmitted. What\'s more, 40% of the probable transmitters had just recently become infected, a time when they are most infectious. Models suggest that treating high-risk people who test negative for HIV with ARVs, a strategy called preexposure prophylaxis, could lead to <b><i>\'substantial reductions in transmission\'</b></i> in the Netherlands, Fraser said.</p>\n<p>An ambitious new consortium, the Phylogenetics and Networks for Generalised HIV Epidemics in Africa (PANGEA_HIV), plans to sequence 20,000 full HIV genomes from people who are already participating in other research studies in four subSaharan countries. PANGEA_HIV aims to see whether phylogenetics can accurately assess new infection rates. That, in turn, could reveal whether a prevention intervention worked. <b><i>\'If you can use genetic data to see the effect of interventions, it may be much cheaper\'</b></i> than the current method of following an uninfected cohort over time, said PANGEA_HIV collaborator <b><i><a href=\"people.php\'peopleid=1\">Tulio de Oliveira</b></i></a>, a bioinformatics specialist at the Wellcome Trust Africa Centre for Health and Population Studies in Mtubatuba, South Africa.</p>\n<p>Speakers stressed the limits of phylogenetic analyses and cautioned that data could potentially be misused. Gay men could be <b><i>\'blamed\'</b></i> for infecting heterosexual women, for example. Several countries criminalize HIV transmission and homosexuality, and some speakers worry that governments could try to acquire confidential information to identify individuals in the studies. <b><i>\'Using this technology does not prove who infected whom: It proves that people were involved in a temporally related transmission cluster,\'</b></i> stressed Mark Harrington of Treatment Action Group in New York City. <b><i>\'We don\'t want to have a bunch of court cases where people are suing because they have biologically similar strains.\'</b></i></p>\n<br><p><b>Press coverage & flyer:</b></p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=140\"> - <b>UNAIDS</b>, 8 June 2015, Feature story: Understanding HIV through phylogenetic research</a>.</p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=138\"> - <b>New York Academy of Science</b> HIV 2015: Using Phylogenetics to Enhance the HIV Response, New York, June 4, 2015</a>.</p>\n\n', NULL, NULL, 'Y'),
(142, 'imgnews142.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipJul2015KRITHposter.pdf', 'Seminar:  The Molecular Epidemiology of HIV in Rakai Uganda\r', 'KRISP Talks', NULL, '2015-07-17', '<p>The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Oliver Laeyendecker Assistant Professor of Medicine,  Johns Hopkins University,19 June 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipJul2015KRITHposter.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipJul2015KRITHposter.png\"></a></center></p>\n<p><b>by Prof. Oliver Laeyendecker \n</b>, (Assistant Professor of Medicine,  Johns Hopkins University and Assistant Professor of Epidemiology ,  Johns Hopkins School of Public Health, USA)</p>\n<p>Date: 17 July 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K2 Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'Seminar, john hopkins, RAKAI, Africa Centre, 2015, Oliver Laeyendecker, Molecular, Epidemiology, HIV, Rakai, Uganda, Genomics, Africa Centre, Tulio de Oliveira, MRC Flagship, Seminar, john hopkins, RAKAI, Africa Centre, 2015, Oliver Laeyendecker, Molecular, Epidemiology, HIV, Rakai, Uganda, Genomics, Africa Centre, Tulio de Oliveira, MRC Flagship, Seminar, john hopkins, RAKAI, Africa Centre, 2015, Oliver Laeyendecker, Molecular, Epidemiology, HIV, Rakai, Uganda, Genomics, Africa Centre, Tulio de Oliveira, MRC Flagship, Seminar, john hopkins, RAKAI, Africa Centre, 2015, Oliver Laeyendecker, Molecular, Epidemiology, HIV, Rakai, Uganda, Genomics, Africa Centre, Tulio de Oliveira, MRC Flagship', 'The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Oliver Laeyendecker Assistant Professor of Medicine,  Johns Hopkins University,19 June 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', ''),
(143, 'imgpostdoc.png', 'http://www.bioafrica.net/manuscripts/PosterTravelFellowship.pdf', 'Research travel grants: Doctoral or post-doctoral students to Wellcome Trust Africa Centre, South Africa', 'WTAC & MRC Flagship UKZN', NULL, '2015-08-15', '<p>Introduction: This is an excellent opportunity for outstanding and motivated individuals to access one of the most comprehensive population-based HIV surveillance and genomics datasets in the world at the Wellcome Trust Africa Centre for Health and Population Studies based in KwaZulu-Natal, South Africa. </p>\n\n', NULL, 3, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/PosterTravelFellowship.pdf\"><img src=\"imagesBIO/PosterTravelFellowship.png\"></a></center></p>\n<p>We are offering 10 research collaborative travel grants, which will fund 12 weeks travel and accommodation in South Africa. At the end of 12 weeks, the candidate should have produced a body of work to give rise to a high-profile publication.  They also need to give a two-day seminar to other PhD and masters students based at the centre on a subject of their choice.  </p>\n\n<p>Candidates interested in the following broad area of research should apply:</p>\n<b>\n<p>1)	Role of population mobility in sustaining the HIV epidemic.</p>\n<p>2)	Use of phylogenetics to understand HIV transmission dynamics.</p>\n<p>3)	Development of phylogenetic and bioinformatics software to next generation sequencing.</p>\n<p>4)	Use of innovative spatial and molecular epidemiological techniques to assess the role of targeted HIV prevention strategies.</p>\n<p>5)	Use of innovative spatial and molecular epidemiological techniques to assess the role of targeted HIV prevention strategies</p>\n<p>6)	Application of statistical and bioinformatics methods to drug resistance analysis.</p></b>\n\n<p>The topics are not comprehensive and other topics in line with the research agenda of the Africa Centre will be considered. </p>\n\n<p><b>Datasets and scientific output:</b> The Africa Centre boasts state-of-the-art data collection facilities and has been collecting detailed longitudinal information on a population of 90,000 since 2000. All this longitudinal information is linked to a comprehensive geographical information system and next generation sequencing datasets, including over 500 HIV-1 whole genomes. </p>\n\n<p>Researchers at Africa Centre had used this data to produce over 600 publications, including a number of high-profile publications in Science, Nature, NEJM, Lancet and PLoS Medicine (see a list at the end of this email). </p>\n\n<p><b>Location:</b>The study site is located near the town of Mtubatuba in one of the most scenic parts of South Africa. The site is in close proximity to the world renowned Hluhluwe-Umfozozi game reserve (home to the largest concentration of white Rhino in the word) and Isamgaliso Wetland Park  (listed as South Africa?s first World Heritage Site in December 1999 in recognition of its superlative natural beauty and unique global values). Candidates can choose whether to be stationed at the study site itself or to be based at the Africa Centre state-of-the-art genomics and bioinformatics laboratories in the city of Durban, which is a sub-tropical city in the Indian Ocean coast. Africa Centre will provide high-quality and very safe accommodation during the stay.</p>\n\n<p><b>Renew:</b> Successful candidates who produce high impact publications after the initial visit can apply to have the travel grant renewed for another 12 weeks.  They will also be supported to apply for fellowships to forge long-term collaborative research links. </p>\n\n<p><b>Application:</b> Prospective candidates should send their CV and covering letter stating their research interest to Mrs Xolile Kineri (xkineri@africacentre.ac.za).</p>\n<p><b>Deadline:</b> 15 August 2015 & 15 September 2015.  </p>\n\n<p><b>Evaluation process:</b> Candidates will be evaluated based on their CV, motivation letter and the scientific question proposed. </p>\n\n<p><b>Outcome:</b> The outcome of the application will be provided by 10 days from application deadline. Travel fellowship can start any time between the 1 September 2015 and 31 March 2016.</p>\n\n<p>Funding will be provided by the South African MRC Flagship program at Africa Centre and UKZN. All publications arising from this travel fellowship should acknowledge the funding source.</p>\n\n<p>More about the Africa Centre can be found at www.africacentre.com and www.bioafrica.net. Examples of recent publications from the Africa Centre can be found below:</p>\n\n<p>-Tanser F, Barnighausen T, Cooke G, Newell ML. Localised spatial clustering of HIV infections in a widely-disseminated rural South African epidemic. Int J Epidemiol 2009; 38(4):1008-16</p>\n<p>- Tanser F, Hosegood V, Barnighausen T, Herbst K, Nyirenda M, Muhwava W, Newell C, Viljoen J, Mutevedzi T, Newell ML. Cohort Profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 2008;37(5):956-62.</p>\n<p>- Pillay D et al.  <a href=\"http://www.bioafrica.net/publications.php?pubid=109\">PANGEA-HIV: phylogenetics for generalised epidemics in Africa. Lancet Infect Dis. (2015), 15(3):259-61. </a></p>\n<p>- Tanser F. et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (2013), 339(6122):966-971. </p>\n<p>- Chevenet F et al. <a href=\"http://www.bioafrica.net/publications.php?pubid=63\">Searching for Virus Phylotypes. Bioinformatics (2013), 29 (5):561-570. </a></p>\n<p>- Goedhals D et al.  <a href=\"http://www.bioafrica.net/publications.php?pubid=58\">The tainted milk of human kindness. Lancet (2012), 380:702. </a></p>\n<p>- de Oliveira T et al.  <a href=\"http://www.bioafrica.net/publications.php?pubid=1\">Public Database for HIV Drug Resistance in southern Africa. Nature (2010), 464(7289):673.</a></p>\n<p>- de Oliveira T et al.  <a href=\"http://www.bioafrica.net/publications.php?pubid=22\">Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak. Nature (2006), 444(7121):836-7.</a></p>\n\n', 'travel, fellowships, science, phylogenetics, bioinformatics, south africa, wellcome trust, africa centre, hiv, evoution, incidence, molecular epidemiology, transmission, dynamics, next generation sequencing, drug ressitance, prevention, strategies, tulio de oliveira, frank tanser, medical research council, durban, KZN, UKZN,travel, fellowships, science, phylogenetics, bioinformatics, south africa, wellcome trust, africa centre, hiv, evoution, incidence, molecular epidemiology, transmission, dynamics, next generation sequencing, drug ressitance, prevention, strategies, tulio de oliveira, frank tanser, medical research council, durban, KZN, UKZN,travel, fellowships, science, phylogenetics, bioinformatics, south africa, wellcome trust, africa centre, hiv, evoution, incidence, molecular epidemiology, transmission, dynamics, next generation sequencing, drug ressitance, prevention, strategies, tulio de oliveira, frank tanser, medical research council, durban, KZN, UKZN,travel, fellowships, science, phylogenetics, bioinformatics, south africa, wellcome trust, africa centre, hiv, evoution, incidence, molecular epidemiology, transmission, dynamics, next generation sequencing, drug ressitance, prevention, strategies, tulio de oliveira, frank tanser, medical research council, durban, KZN, UKZN,travel, fellowships, science, phylogenetics, bioinformatics, south africa, wellcome trust, africa centre, hiv, evoution, incidence, molecular epidemiology, transmission, dynamics, next generation sequencing, drug ressitance, prevention, strategies, tulio de oliveira, frank tanser, medical research council, durban, KZN, UKZN', 'e are offering 10 research collaborative travel grants, which will fund 12 weeks travel and accommodation in South Africa to do research on the causes and consequences of HIV transmission and drug resistance. At the end of 12 weeks, the candidate should have produced a body of work to give rise to a high-profile publication', 'Y'),
(144, 'imgnews92.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipAug2015KRITHposter.pdf', 'Seminar: Is HIV-1 subtype C more pathogenic than other subtypes?', 'KRISP Talks', 0, '2015-08-21', '<p>We cordially invites you to a seminar presented by Prof Thumbi Ndungu from K-RITH and HPP/UKZN, 21 August 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipAug2015KRITHposter.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipAug2015KRITHposter.png\"></a></center></p>\n<p><b>by Prof Thumbi Ndungu\n</b>, (Investigator at Max Planck Institute for Infection Biology Research, Group Leader at the KwaZulu-Natal Research Institute for Tuberculosis and HIV, and Research Director, HIV Pathogenesis Programme)</p>\n<p>Date: 21 August 2015</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'Thumbi, Ndungu, talk, south africa, Is HIV-1 subtype C more pathogenic than other subtypes?, seminar, MRC, Wellcome Trust, Durban, HIV-1, subtype C, pathogenic, bioafrica, tulio de oliveira, Thumbi, Ndungu, talk, south africa, Is HIV-1 subtype C more pathogenic than other subtypes?, seminar, MRC, Wellcome Trust, Durban, HIV-1, subtype C, pathogenic, bioafrica, tulio de oliveira, Thumbi, Ndungu, talk, south africa, Is HIV-1 subtype C more pathogenic than other subtypes?, seminar, MRC, Wellcome Trust, Durban, HIV-1, subtype C, pathogenic, bioafrica, tulio de oliveira, Thumbi, Ndungu, talk, south africa, Is HIV-1 subtype C more pathogenic than other subtypes?, seminar, MRC, Wellcome Trust, Durban, HIV-1, subtype C, pathogenic, bioafrica, tulio de oliveira, Thumbi, Ndungu, talk, south africa, Is HIV-1 subtype C more pathogenic than other subtypes?, seminar, MRC, Wellcome Trust, Durban, HIV-1, subtype C, pathogenic, bioafrica, tulio de oliveira', 'We cordially invites you to a seminar presented by Prof Thumbi Ndungu from K-RITH and HPP/UKZN, 21 August 2015, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', NULL),
(145, 'imgnews101.png', 'http://www.awacc.org', 'SATuRN & AWACC workshop - 19-20 November 2015, Durban, South Africa', 'SATuRN & AWACC', 0, '2015-11-19', '<p>The SATuRN 10th Southern African HIV & TB Drug Resistance and Treatment Monitoring Workshop will be run together with the Annual Workshop on Advanced Clinical Care - AIDS (AWACC) - Durban, South Africa, 19 to 20 November 2015</p>', NULL, 3, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/AWACC2015Program.pdf\"><img src=\"imagesBIO/imgAWACC.png\"></a></center></p>\n<p>The AWACC annual workshop which started in 2007 has been held yearly. The first workshop was a joint effort of the Centre for AIDS research (CFAR) of Harvard Medical school and McCord Hospital (MH) ,Durban South Africa. Since 2014, the Southern African Treatment Resistance Network had joined and co-organize this annual workshop.</p>\n\n<p>The workshop receives approximately 400 delegates for its relevance to the growing ART and anti-TB roll out programme in South Africa.</p>\n<p> The two-day interactive workshop will translate the latest evidence-based research and apply best practice models of care into good clinical practice, specifically for resource constrained areas.</p>\n<p><b><i>Speakers</b></i></p>\nAll major local institutions involved in HIV care and research over the last 6 years : UKZN Health Sciences department, Centre for programme in AIDS research South Africa (CAPRISA), Africa Centre for Health and Population Studies, Southern African Treatment Resistance Network (SATuRN), Hospice Palliative Care Society (HPCS-SA), University of Wits and Cape Town, Right to Care, Kwa Zulu Natal Research Institute of HIV and TB (K-RITH). Several speakers have participated from leading US universities yearly...\n\n<p><center><a href=\"http://www.bioafrica.net/manuscripts/AWACC2015Program.pdf\">Download the program in PDF of this year workshop.</a></center></p>\n', NULL, NULL, 'Y');
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(146, 'imgnews146.png', 'http://www.bioafrica.net/manuscripts/SoftwareManagerBioinformatics.pdf', 'Positions open! Bioinformatics Software Developer & Scientific Manager', 'Africa Centre', 0, '2015-09-15', 'Africa Centre through its European Commission Virogenesis Project & MRC Flagship Programmer wish to recruit a 1) Software Developer & 2) Bioinformatics Scientific Manager.', NULL, 3, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SoftwareManagerBioinformatics.pdf\"><img src=\"imagesBIO/SoftwareManagerBioinformatics.png\"></a></center></p><br><hr>\n<p><b><center>SOFTWARE DEVELOPER:</center></b></p>\r<p>Africa Centre through its European Commission Virogenesis Project wish to recruit a Software Developer. This position will be responsible for the development of an open source bioinformatics software application. This project will further develop the popular Rega HIV and Oxford HCV subtyping tools, which are the first ever bioinformatics pipeline for automatic typing of pathogens using phylogenetics. The software application is developed as open source software with multiple programmers in some of the top academic institutions in Europe and United States of America.</p>\n\r<p>The qualifications, experience and skills required:</p><p><br>- MSc or PhD in Computer Science, Bioinformatics, Engineer or Phylogenetics <br>- Strong computer programming and software development skills.\rPersonal attributes required: <br>- Mathematical aptitude and strong problem-solving skills<br>- Excellent IT and programming skills in JAVA; PERL; Phyton or C++ <br>- Previous experience in the development of open source software applications.</p>\n<hr>\n<p><b><center>BIOINFORMATICS SCIENTIFIC MANAGER:</center></b></p>\r<p>Africa Centre through its MRC Flagship programme wishes to recruit a Bioinformatics Scientific Manager. This position will be responsible for the overall management of the day-to-day activities of a number of HIV & TB scientific projects of Africa Centre\'s bioinformatics research group. This individual will be responsible for: </p><p><br>-  Writing grant reports <br>-  Supporting new grants applications <br>-  Managing scientific communication with collaborative research groups <br>-  Proving computer and IT support in the group <br>-  Managing the group website and web-based bioinformatics tools <br>-  Drafting manuscripts <br>-  Interacting with other admin teams at Africa Centre and UKZN.</p>\n<p>Qualifications and experience required:</p><p> <br>-  Degree in a scientific discipline in line with the research topic (such as virology, microbiology, bioinformatics or biochemistry) <br>-  Quality management and health and safety certified <br>-  IT Project Management certified; project managing various IT systems and software <br>-  Experience in quality control, quality assurance and management of different projects <br>-  Experience in writing policies, procedures and reports.\nPersonal attributes and skills required: <br>-  Scientific aptitude <br>-  Excellent report-writing skills <br>-  Excellent IT and programming skills <br>-  Project management skills <br>-  Excellent organisational time and management skills <br>-  Good coordination and collaboration with the informatics team and laboratory personnel <br>-  Ability to lead cross-functional and cross-divisional efforts.</p>\n<hr><p><center><b>Deadline:</b></center> Applicants are required to submit a covering letter, Curriculum Vitae with certified copies of qualifications and details of three (3) contactable referees to: The Human Resources Office, Africa Centre, Box 198, Mtubatuba 3935 or e-mail: acemployment@africacentre.ac.za</p>', 'bioinformatics, software, developer, manager, position, south africa, africa centre, european commission, MRC Flagship, bioinformatics, software, developer, manager, position, south africa, africa centre, european commission, MRC Flagship, bioinformatics, software, developer, manager, position, south africa, africa centre, european commission, MRC Flagship, bioinformatics, software, developer, manager, position, south africa, africa centre, european commission, MRC Flagship, bioinformatics, software, developer, manager, position, south africa, africa centre, european commission, MRC Flagship', 'Bioinformatics software developer and scientific manager positions at Wellcome Trust Africa Centre, Durban, South Africa. Deadline 13 Sept. 2015', 'Y'),
(147, 'imgnews77.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipMarch2016KRITHposter.pdf', 'Seminar: A phylodynamic view of the HIV epidemic in KwaZulu-Natal', 'KRISP Talks', 0, '2016-03-11', '<p>KRISP Talks by <b>Dr David Rasmussen</b>, Postdoc Research Fellow, ETH Zurich, 11 March 2016, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p> ', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipMarch2016KRITHposter.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipMarch2016KRITHposter.png\"></a></center></p>\n<p><b>by Dr David Rasmussen\r</b>, (Postdoc Research Fellow, ETH Zurich & MRC UKZN Flagship Fellow)</p>\n<p>Date: 11 March 2016</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'seminar, Durban, ETH, Zurich, Swistzerland, Swiss, MRC UKZN Flagship Fellow,  Dr David Rasmussen, A phylodynamic view of the HIV epidemic in KwaZulu-Natal, 2016, March, KRITH, talk, public lecture, 11 March, Tulio de Oliveira, MRC, Flagship, South Africa, seminar, Durban, ETH, Zurich, Swistzerland, Swiss, MRC UKZN Flagship Fellow,  Dr David Rasmussen, A phylodynamic view of the HIV epidemic in KwaZulu-Natal, 2016, March, KRITH, talk, public lecture, 11 March, Tulio de Oliveira, MRC, Flagship, South Africa, seminar, Durban, ETH, Zurich, Swistzerland, Swiss, MRC UKZN Flagship Fellow,  Dr David Rasmussen, A phylodynamic view of the HIV epidemic in KwaZulu-Natal, 2016, March, KRITH, talk, public lecture, 11 March, Tulio de Oliveira, MRC, Flagship, South Africa', 'The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr David Rasmussen,Postdoc Research Fellow, ETH Zurich, 11 March 2016, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', ''),
(148, 'imgnews86.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipFeb2016KRITHposter.pdf', 'Seminar: Sources of HIV infection among men having sex with men and implications for prevention', 'KRISP Talks', 0, '2016-02-05', '<p>KRISP Talks by <b>Oliver Ratmann</b>, Research Fellow, Department Infectious Disease Epidemiology, Imperial College of London & UKZN MRC Research Fellow, 06 February 2016, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipFeb2016KRITHposter.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipFeb2016KRITHposter.png\"></a></center></p>\n<p><b>by Dr Oliver Ratmann\r</b>, (Research Fellow, Department Infectious Disease Epidemiology, Imperial College of London & MRC UKZN Flagship Fellow)</p>\n<p>Date: 06 February 2016</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'seminar, Durban, Oliver Ratmann, Imperial, Science translational medicine, men who has sex with men, Nelson Mandela School of Medicine, UKZN, Flagship, MRC, Tulio de Oliveira, bioafrica, phylogenetics, February, 2016, seminar, Durban, Oliver Ratmann, Imperial, Science translational medicine, men who has sex with men, Nelson Mandela School of Medicine, UKZN, Flagship, MRC, Tulio de Oliveira, bioafrica, phylogenetics, February, 2016, seminar, Durban, Oliver Ratmann, Imperial, Science translational medicine, men who has sex with men, Nelson Mandela School of Medicine, UKZN, Flagship, MRC, Tulio de Oliveira, bioafrica, phylogenetics, February, 2016, seminar, Durban, Oliver Ratmann, Imperial, Science translational medicine, men who has sex with men, Nelson Mandela School of Medicine, UKZN, Flagship, MRC, Tulio de Oliveira, bioafrica, phylogenetics, February, 2016, seminar, Durban, Oliver Ratmann, Imperial, Science translational medicine, men who has sex with men, Nelson Mandela School of Medicine, UKZN, Flagship, MRC, Tulio de Oliveira, bioafrica, phylogenetics, February, 2016', 'The Wellcome Trust Africa Centre Genomics & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr Oliver Ratmann, Research Fellow, Department Infectious Disease Epidemiology, Imperial College of London & UKZN MRC FLagship Fellow, 06 February 2016, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', ''),
(183, 'news183.png', 'http://www.awacc.org', '11th Annual Workshop on Advanced Clinical Care - AIDS (AWACC), Durban, South Africa, 6-7 Sep 2017', 'KRISP Training', NULL, '2017-09-06', '<p>The workshop is targeted at 400 clinicians, clinical virologists and nurses working in the public sector who are currently involved in the treatment of patients with HIV and TB in KwaZulu-Natal, South Africa. </p>', NULL, 4, '<p>This annual workshop attracts clinicians (nurses and doctors and pharmacists) from the private sector and public sector.</p>\n\n<p>Krisp, the Southern African Treatment and Resistance Network (SATuRN) in partnership with CAPRISA ACC will present a full day programme on HIV & TB Drug Resistance and Clinical Management.</p>\n\n<p><center><a href=\"http://www.awacc.org\"><img src=\"imagesBIO/news183feature.png\"></a></center> </p>\n \n<p><b><i>Organising Committee</b></i></p>\n<p><b><i>Dr Henry Sunpath (chairperson)</b></i>	KZN Department of Health and University of KwaZulu-Natal, South Africa </p>\n<p><b><i>Prof. Raj Gandhi </b></i>	Mass General Hospital (MGH), Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. Yunus Moosa</b></i>	University of KwaZulu-Natal, South Africa </p>\n<p><b><i>Prof. Tulio de Oliveira</b></i>	SATuRN & Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n<br>\n<p><b><i>Speakers</b></i></p>\n<p><b><i>Dr. M. Archary</b></i>	University of KwaZulu-Natal, South Africa</p>\n<p><b><i>Prof. K. Ard</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. Linda G. Bekker</b></i>	University of Cape Town, South Africa </p>\n<p><b><i>Dr. Francesca Conradie </b></i>	WHRI, South Africa</p>\n<p><b><i>Prof. Tulio de Oliveira</b></i>	SATuRN & Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n<p><b><i>Prof. Raj Gandhi </b></i>	Mass General Hospital (MGH), Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. R. Goldstein</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Dr. Richard Lessells</b></i>	London School of Hygiene and Tropical Medicine, U.K.</p>\n<p><b><i>Prof. V.C. Marconi</b></i>	Emory University, U.S.A</p>\n<p><b><i>Prof. I. Master</b></i>	Department of Health and King George V Hospital, South Africa</p>\n<p><b><i>Prof. S. Mukerji</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Dr. Z. Mthembu</b></i>	DREAMS program and MatCH, South Africa</p>\n<p><b><i>Prof. R. Murphy</b></i>	University of California Los Angeles, U.S.A.</p>\n<p><b><i>Dr. Kogie Naidoo</b></i>	CAPRISA, South Africa</p>\n<p><b><i>Prof. Catherine Orrell</b></i>	University of Cape Town, South Africa</p>\n<p><b><i>Dr. Nesri Padayatchi</b></i>	CAPRISA, South Africa</p>\n<p><b><i>Prof. M. Siedner</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. Francois Venter</b></i>	WHRI, South Africa </p>\n\n<br>\n <p>One of the main objectives of Krisp, AWACC SATuRN and CAPRISA is to support the NDoH and build capacity among clinicians to manage patients who still present in advanced HIV and TB clinical disease. In addition, we aim to build capacity as part of the CAPRISA ACC to manage patients who fail virologically and those who may need third line ART.</p>\n\n<p><b><i>More information on the joint conference, please visit the website below</b></i></p>\n', 'AWACC, Krisp Training, workshop, HIV, TB, clinical management, drug resistance, genotype, resistance, NDoH, national department of Health, Advanced, workshop, clinical, care, AIDS, Tulio de Oliveira, Havard, Durban, South Africa, 2017, AWACC, Krisp Training, workshop, HIV, TB, clinical management, drug resistance, genotype, resistance, NDoH, national department of Health, Advanced, workshop, clinical, care, AIDS, Tulio de Oliveira, Havard, Durban, South Africa, 2017, AWACC, Krisp Training, workshop, HIV, TB, clinical management, drug resistance, genotype, resistance, NDoH, national department of Health, Advanced, workshop, clinical, care, AIDS, Tulio de Oliveira, Havard, Durban, South Africa, 2017, AWACC, Krisp Training, workshop, HIV, TB, clinical management, drug resistance, genotype, resistance, NDoH, national department of Health, Advanced, workshop, clinical, care, AIDS, Tulio de Oliveira, Havard, Durban, South Africa, 2017, AWACC, Krisp Training, workshop, HIV, TB, clinical management, drug resistance, genotype, resistance, NDoH, national department of Health, Advanced, workshop, clinical, care, AIDS, Tulio de Oliveira, Havard, Durban, South Africa, 2017', 'This annual workshop in Durban, South Africa, attracts clinicians (nurses and doctors and pharmacists) from the private sector and public sector. Krisp, the Southern African Treatment and Resistance Network (SATuRN) in partnership with CAPRISA ACC will present a full day programme on HIV & TB Drug Resistance and Clinical Management', ''),
(149, 'imgnews149.png', 'https://rega.kuleuven.be/cev/veme-workshop/2016/', '21st International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology (VEME)', 'Rega Institute & Korea University College of Medicine', 0, '2016-03-15', '<p>The 21st International Workshop on Virus Evolution and Molecular Epidemiology (VEME2016) will be hosted by the Korea University College of Medicine, 14-19 August, Seoul, Republic of Korea. <b>Abstract deadline: 15 March 2016</b></p>', NULL, 4, '<p><center><a href=\"https://rega.kuleuven.be/cev/veme-workshop/2016/\"><img src=\"imagesBIO/VEME2016.png\"></a></center></p>\n<p><b><center>\n<a href=\"https://rega.kuleuven.be/cev/veme-workshop/2016/\">VEME 2016 workshop website</a></center></b></p>\n<p><b><center><a href=\"https://rega.kuleuven.be/cev/veme-workshop/2016/inschrijving\">Deadline for abstract submission: 15 March 2016</a></center></b></p>\n<p><b><center>Workshop Dates: 14 to 19 August 2016</center></b></p>\n<p><b><center>Organising Committee:</b> Anne-Mieke Vandamme, Tulio de Oliveira, Philippe Lemey, Mattia Prosperi, Man-Seong Park, Jin Il Kim & Soo-Yon Rhee</center></p>\n\n<p>The VEME workshop provides both theoretical and practical training in phylogenetic inference and evolutionary hypothesis testing as applied in virology and molecular epidemiology. It is recognized as one of the best international virus bioinformatics courses. It covers sequence analysis, phylogenetics, phylodynamics methods, and large scale methods for next-generation sequencing (NGS) analytics.</p>\n\n<p><b><i>Speakers</b></i></p>\n<p><b><i>Luiz Alcantara</b></i>	University of Fiocruz, Salvador de Bahia, Brazil</p>\n<p><b><i>Andre Altmann</b></i>	Translational Imaging Group, UCL, London</p>\n<p><b><i>Guy Baele</b></i>	University of Leuven, Belgium</p>\n<p><b><i>Tulio de Oliveira</b></i>	Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n<p><b><i>Nuno Faria</b></i>	University of Oxford, UK</p>\n<p><b><i>Olga Golosova</b></i>	UGENE team, Novosibirsk, Russia</p>\n<p><b><i>German Grekhov</b></i>	UGENE team, Novosibirsk, Russia</p>\n<p><b><i>Jin Il Kim</b></i>	Korea University, College of Medicine, Seoul, Republic of Korea</p>\n<p><b><i>Philippe Lemey</b></i>	University of Leuven, Belgium</p>\n<p><b><i>Darren Martin</b></i>	University of Cape Town, South Africa</p>\n<p><b><i>Jae Min</b></i> Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA</p>\n<p><b><i>Sergei Kosakovsky-Pond</b></i>	University of California, San Diego, USA</p>\n<p><b><i>Ludmila Prokunina-Olsson</b></i>	National Cancer Institute, Bethesda, USA</p>\n<p><b><i>Mattia Prosperi</b></i>	University of Florida, Gainesville, USA</p>\n<p><b><i>Andrew Rambaut</b></i>	Institute of Evolutionary Biology, Edinburgh, UK</p>\n<p><b><i>Soo-Yon Rhee</b></i>	Stanford University, USA</p>\n<p><b><i>Brittany Rife</b></i>	University of Florida, Gainesville, USA</p>\n<p><b><i>Richard Scheuermann</b></i>	J. Craig Venter Institute (JCVI), Rockville, USA</p>\n<p><b><i>Heiko Schmidt</b></i>	University of Vienna, Austria</p>\n<p><b><i>Marc Suchard</b></i>	University of California, Los Angeles, USA</p>\n<p><b><i>Anne-Mieke Vandamme</b></i>	University of Leuven, Belgium</p>\n<p><b><i>Ewout Vanden Eynden</b></i>	University of Leuven, Belgium</p>\n<p><b><i>Filip Bielejec</b></i>	University of Leuven, Belgium</p>\n<p><b><i>Yuriy Fofanov</b></i>	University of Texas Medical Branch (Galveston), USA</p>\n<p><b>Introduction:</b> Combating viral spread and their associated disease burden is a tremendous challenge requiring significant research efforts and dedicated measures, in public health, veterinary care, and agriculture strategies. Viral sequence data is a major asset in the characterization of pathogens. Understanding the processes that generate genetic diversity assists in the struggle against viral infections and enhances our understanding of past evolutionary and epidemiological events.  It can also help in the identification of the origins of new epidemics, in monitoring the effectiveness of therapeutic strategies, and eventually in predicting the behavior of viral epidemics. Advances in bioinformatics have led to improved approaches to investigating viral outbreaks that ave been successfully applied to viruses including the Human immunodeficiency viruses (HIV), the Ebola virus, the Dengue viruses, the Chikungunya virus and the Influenza virus.</p>\n\n\n', NULL, NULL, 'Y'),
(150, 'imgnews134.png', 'http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2016A4.pdf', 'SATuRN Newsletter, 2016: SATuRN/CAPRISA, Increase transmitted resistance, TDF global resistance', 'SATuRN', 0, '2016-04-01', '<p>The concept behind this newsletter is that anyone with  15 minutes to spare can learn about the work of SATuRN. In this first 2016 issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.<p>', NULL, 4, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2016A4.pdf\"><img src=\"imagesBIO/imgnews150.png\"></a></center> </p>\n\n<br><p><b><i>In this issue our highlights are:</b></i></p>\n \n<p> - <a href=\"Http://bioafrica.net/workshops/SATuRNCAPRISAHIVTBClinicalCareWorkshop2016.html\">SATuRN and CAPRISA Advanced Clinical Care Workshop, 7-8 July 2016.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=123\n\">PUBLICATION Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection.</a></p> \n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=120\">Publication: Understanding Specific Contexts of Antiretroviral Therapy Adherence in Rural South Africa: A Thematic Analysis of Digital Stories from a Community with High HIV Prevalence.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=122\">Publication: Increasing HIV-1 drug resistance in adults participating in population-based HIV surveillance in rural KwaZulu-Natal South Africa.\n</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=149\">Workshop: The 21st International Workshop on Virus Evolution and Molecular Epidemiology (VEME2016) </a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/proteomics/HIVproteome.html\">Web Resource: BioAfrica and ViralZone HIV-1 proteome resource: summarizes all HIV protein functions and drug resistance mutations.</a></p>\n\n<br>\n<p><a href=\"http://www.bioafrica.net/seminars.php\">Our active and well attended seminar series!</a></p>\n<p>The newsletter is open accessible at:</p>\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2016A4.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2016A4.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>\n', 'SATuRN, newsletter, Southern African treatment resistance network, 2016, publications, increase transmitted resistance, South Africa, tenofovir resistance, adherence, videos, workshops, CAPRISA, de Oliveira, SATuRN, newsletter, Southern African treatment resistance network, 2016, publications, increase transmitted resistance, South Africa, tenofovir resistance, adherence, videos, workshops, CAPRISA, de Oliveira, SATuRN, newsletter, Southern African treatment resistance network, 2016, publications, increase transmitted resistance, South Africa, tenofovir resistance, adherence, videos, workshops, CAPRISA, de Oliveira, SATuRN, newsletter, Southern African treatment resistance network, 2016, publications, increase transmitted resistance, South Africa, tenofovir resistance, adherence, videos, workshops, CAPRISA, de Oliveira', 'The concept behind this newsletter is that anyone with  15 minutes to spare can learn about the work of SATuRN. In this first 2016 issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.', 'Y'),
(151, 'imgblog43sm.png', 'http://www.bioafrica.net/blogs.php', 'First two South African MSc students graduate from the MRC Flagship Program: Inspiring blogs about their experiences and achievements', 'UKZN MRC Flagship', 0, '2016-04-15', '<p>Megan Druce and Sthembiso Msweli are two very bright South Africans who have successfully completed their MSc as part of the UKZN Flagship program at the MRC. They both wrote inspiring blogs, the first is about a Cum Laude degree which allowed the award of a scholarship for a PhD in Germany, the second is about the history of a laboratory technologist from rural KZN, who after graduating was promoted to laboratory manager... </p>', NULL, 4, '<p><center><img src=\"imagesBIO/imgblog43.png\"></a></center> </p>\n\n<br><p><b><i>Blogs:</b></i></p>\n \n<p> - <a href=\"http://www.bioafrica.net/blogs.php?id=42\"> Megan Druce: from Cum Laude MSc to a Scholarship for a PhD in Germany...</a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/blogs.php?id=43\">\nSthembiso Msweli: from Hlabisa to MSc and Further Promoted to Laboratory Manager...</a></p> \n', NULL, NULL, ''),
(152, 'imgpostdoc.png', 'http://bioafrica.net/manuscripts/CAPRISA2650_PDP_Adverts_3_1.pdf', 'PhD Fellowship I: Genomics, Bioinformatics & Drug Resistance', 'CAPRISA, UKZN & MRC Flagship', 0, '2016-08-23', '<p>The Professional Development Programme (PDP) at CAPRISA aims to develop and retain South African scientists and professionals of the highest calibre. The genomics and bioinformatics project in HIV-1 drug resistance is inter-disciplinary in nature and involves collaboration between the CAPRISA\'s MRC HIV-TB Pathogenesis and Treatment Research Unit and the\rFlagship Program of the MRC, which are two of the most prestigious research programs in South Africa.</p>\n', NULL, 4, '<p><centre><a href=\"http://bioafrica.net/manuscripts/CAPRISA2650_PDP_Adverts_3_1.pdf\"><img src=\"imagesBIO/CAPRISA_PhD_Advert1.gif\"></center></a></p>\n<br>\n<p><b><i>Mentors:</b></i></p>\n<p><a href=\"people.php?peopleid=1\">Prof. Tulio de Oliveira</a>: Research Associate CAPRISA, Professor UKZN</p>\n<p>Dr Kogie Naidoo: Head Treatment Research Programme, CAPRISA</p>\n\n<p>This PhD programme optimally exemplies how genomics, clinical and bioinformatics information can\ndirectly and immediately impact human health in Africa. The project aims to identify factors associated\nwith HIV-1 drug resistance in patients failing antiretroviral therapy (ART). By focusing on the application\nof Next Generation Sequencing (NGS) to produce whole genomes of the virus, researchers aim to identify\nnew viral mutations associated with drug resistance. This could guide future drug regimens and provide\nfurther insight into patients failing ART-based therapy.</p>\n<p><b></i>The PhD fellow will be awarded a fellowship stipend of ZAR 180,000 per annum. Applications are invited from South African or permanent resident students. Please submit a CV and a letter of motivation (max. 500 words) by 20 October 2016 to sma.mzobe@caprisa.org</b></i></p>\n\n\n', 'PhD, professional development program, PDP, NRF, DST, drug resistance, HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Kogie Naidoo, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN, PhD, professional development program, PDP, NRF, DST, drug resistance, HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Kogie Naidoo, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN, PhD, professional development program, PDP, NRF, DST, drug resistance, HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Kogie Naidoo, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN, PhD, professional development program, PDP, NRF, DST, drug resistance, HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Kogie Naidoo, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN', 'The Professional Development Programme (PDP) at CAPRISA aims to develop and retain South African scientists and professionals of the highest calibre. The genomics and bioinformatics project in HIV-1 drug resistance is inter-disciplinary in nature and involves collaboration between the CAPRISA\'s MRC HIV-TB Pathogenesis and Treatment Research Unit and the\rFlagship Program of the MRC, which are two of the most prestigious research programs in South Africa.', ''),
(153, 'imgpostdoc.png', 'http://bioafrica.net/manuscripts/CAPRISA2650_PDP_Adverts_3_2.pdf', 'PhD Fellowship II: Genomics, Bioinformatics, Epidemioloy and Phylogenetics', 'CAPRISA, UKZN & MRC Flagship', 0, '2016-08-23', '<p>The Professional Development Programme (PDP) at CAPRISA aims to develop and retain South African scientists and professionals of the highest calibre. The genomics and bioinformatics project in HIV-1 phylogenetics and molecular epidemiology is inter-disciplinary in nature and involves collaboration between the CAPRISA\'s MRC HIV-TB Pathogenesis and Treatment Research Unit and the Flagship Program of the MRC, which are two of the most prestigious research programs in South Africa.</p>\n', NULL, 4, '<p><centre><a href=\"http://bioafrica.net/manuscripts/CAPRISA2650_PDP_Adverts_3_2.pdf\"><img src=\"imagesBIO/CAPRISA_PhD_Advert2.gif\"></center></a></p>\n<br>\n<p><b><i>Mentors:</b></i></p>\n<p><a href=\"people.php?peopleid=1\">Prof. Tulio de Oliveira</a>: Research Associate CAPRISA, Professor UKZN</p>\n<p>Prof. Ayesha Kharsany: Senior Scientist, CAPRISA</p>\n\n<p>This PhD project aims to generate HIV genomic data and apply molecular epidemiology techniques to\rdescribe the characteristics of HIV transmission and drug resistance networks in the study population.\rThese results will be combined with detailed demographic information in order to identify patterns of\rinter- and intra-community transmission of HIV in the study population.</p>\n<p><b></i>The PhD fellow will be awarded a fellowship stipend of ZAR 180,000 per annum. Applications are invited from South African or permanent resident students. Please submit a CV and a letter of motivation (max. 500 words) by 20 October 2016 to sma.mzobe@caprisa.org</b></i></p>\n\n', 'PhD, professional development program, PDP, NRF, DST, evolution, phylogenetics, trees, molecular epidemiology, HIPPS, NIH,  HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Ayesha, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN, PhD, professioal development program, PDP, NRF, DST, evolution, phylogenetics, trees, molecular epidemiology, HIPPS, NIH,  HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Ayesha, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN, PhD, professional development program, PDP, NRF, DST, evolution, phylogenetics, trees, molecular epidemiology, HIPPS, NIH,  HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Ayesha, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN, PhD, professional development program, PDP, NRF, DST, evolution, phylogenetics, trees, molecular epidemiology, HIPPS, NIH,  HIV, HIV-1, AIDS, Durban, CAPRISA, Tulio de Oliveira, Ayesha, South Africa, fellowship, well paid, genomics, bioinformatics, post-graduate, UKZN', 'The Professional Development Programme (PDP) at CAPRISA aims to develop and retain South African scientists and professionals of the highest calibre. The genomics and bioinformatics project in HIV-1 phylogenetics is inter-disciplinary in nature and involves collaboration between the CAPRISA\'s MRC HIV-TB Pathogenesis and Treatment Research Unit and the\rFlagship Program of the MRC, which are two of the most prestigious research programs in South Africa.', ''),
(154, 'imgpostdoc.png', 'http://bioafrica.net/manuscripts/CAPRISA2650_PDP_PhD_Adverts.pdf', 'PhD Fellowships: 2x postions at CAPRISA on Genomics, Bioinformatics, HIV-1 Drug resistance and/or Phylogenetics', 'CAPRISA, UKZN & MRC Flagship', 0, '2016-08-24', '<p>The Professional Development Programme (PDP) of the Department of Science and Technology (DST) and the National Research Foundation (NRF) at CAPRISA aims to develop and retain South African scientists and professionals of the highest calibre. </p>\n', NULL, 4, '<p>The PhD fellow will be awarded a fellowship stipend of ZAR 180,000 per annum. Applications are invited from South African or permanent resident students. Please submit a CV and a letter of motivation (max. 500 words) by 20 October 2016 to sma.mzobe@caprisa.org</p>\n\n<p><b><i>Detailed information on PhD fellowships:</b></i></p>\n<p><b><a href=\"http://www.bioafrica.net/news.php?id=152\">PhD Fellowship I: Genomics, Bioinformatics & Drug Resistance</p>\n<p><a href=\"http://www.bioafrica.net/news.php?id=153\">PhD Fellowship II: Genomics, Bioinformatics, Molecular Epidemiology & Phylogenetics</p></b><br>\n\n', NULL, NULL, 'Y'),
(155, 'science_logo.png', NULL, 'South Africa\'s bid to end AIDS', 'Science', 139, '2016-06-29', '<p> Science magazine (Vol. 353, Issue 6294, pp. 18-21, 2016). This issue was published before the AIDS conference in Durban 2016 and highlights some of our research, including our treatment as prevention trial (TasP) as well our phylogenetic analysis <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">(de Oliveira et al. Lancet HIV 2016)</a>.</p>\n', NULL, NULL, '<p>By Jon Cohen, Jun. 29, 2016 , 11:00 AM</p>\n\n<p>On a Wednesday morning in April, a line of 600 HIV-infected people snakes through the hallways to the first waiting room of the Themba Lethu Clinic, a wing of the Helen Joseph Hospital in Johannesburg, South Africa. In most places in the country, where clinics are overtaxed, this would presage a wait of up to 10 hours. But here something different is happening. Staffers at computer monitors swiftly log in people and dispatch them for triage or, if they have tuberculosis, a special area away from others. Those who only need their antiretroviral (ARV) drugs walk directly to the pharmacists, who retrieve each patient\'s electronic medical record and use a robotic system to pull drugs from shelves and fill orders. The average wait time is 30 minutes to 2 hours to complete a doctor or nurse visit and 15 minutes at the pharmacy. A prototype ATM promises to further speed visits by directly dispensing ARV pills; one day, it is hoped, similar pill machines in shopping malls could make some clinic visits unnecessary.</p>\n\n<p><center><img src=\"imagesBIO/imagescience.jpg\"></center></p>\n\n<p>\'This is an awesomely efficient place,\' says Ian Sanne, who heads Right to Care, a nongovernmental organization that runs this and several other clinics in collaboration with the health department. In developed countries, where patients complain about much shorter waits, this boast might seem absurd. But in South Africa, the Themba Lethu Clinic is celebrated as an example of what can be done to care for large numbers of HIV-infected people. This is at once a compliment to the clinic and a hint of the country\'s overwhelming HIV/AIDS challenge.</p>\n\n<p>South Africa has pledged to ramp up efforts to end its massive HIV/AIDS epidemic, the world\'s largest. Come September, it will offer every infected person ARVs, which both stave off disease and make people less infectious. The immediate goal is to reach what is known as 90-90-90 by 2020: to have 90% of infected people aware of their status, 90% of known positives start ARVs, and 90% of that group drive the amount of virus in their bloodstream down to un-detectable levels. The theory is that as viral levels drop, transmission will, too, leading the epidemic to spiral downward. This 90-90-90 target is the cornerstone of a grand campaign, articulated by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and widely embraced by world leaders, to end the AIDS epidemic \'as a global public health threat\' by 2030. </p>\n\n<p>In a nation estimated to have at least 6.6 million HIV-infected people\'18% of the world\'s total\'the drive to hit 90-90-90 by 2020 seems overly ambitious to many experts. And the obstacles faced by South Africa provide a sobering reality check to the lofty, laudable aspiration of ending AIDS, a topic that promises to occupy center stage later this month in Durban at the biannual International AIDS Conference.</p>\n\n<p>Models and reality</p>\n\n<p>A model predicts how different HIV/AIDS response scenarios would affect new infection rates, or incidence. As seen on the map, some areas of the country have far more HIV than others.</p>\n\n<p><center><img src=\"imagesBIO/AIDS_map.png\"></center></p>\n<p>South African HIV and TB Investment Case, SANAC and National Department of Health</p>\n\n<p>South Africa has already made enormous gains against its HIV/AIDS epidemic. When it last hosted this international gathering in 2000, then-President Thabo Mbeki and his health minister questioned whether HIV even causes AIDS, triggering widespread outrage. At the time, only the wealthiest South Africans had access to ARVs, which cost about $5000 per person for an annual supply. But by the end of 2015, the price had dropped to $100, and 3.4 million HIV-infected South Africans were receiving ARVs\'more than in any other country in the world. South Africa, in fact, consumes the same amount of the life-saving drugs as Asia and the Pacific, North America, and western and central Europe combined. </p>\n\n<p>As a result, life expectancy jumped 9 years between 2005, when ARVs started to become widely available, and 2014. The country has pioneered innovative ways to deliver the drugs and help people stay on them. And South Africa\'s strong cadre of HIV/AIDS investigators has made the country a hub of cutting-edge basic research and clinical trials. \'Given our resources, we\'ve done amazing things,\' says Glenda Gray, an HIV/AIDS researcher who heads South Africa\'s Medical Research Council in Cape Town.</p>\n\n<p>This family tree is derived from the DNA of thousands of HIV isolates from South Africa and it shows how the virus has evolved in 5 year periods. The darkest blue dots represent sequences from 2010-15 and the lightest dots are from 1989.</p>\n\n<p>This family tree is derived from the genetic material of thousands of HIV isolates from South Africa and it shows how the virus has evolved in 5-year periods. The darkest blue dots represent sequences from 2010 to 2015 and the lightest dots are from 1989.</p>\n<p><center><img src=\"imagesBIO/400x380_africa_hiv_drupal_02.jpg\"></center></p>\n<p>Andrew Rambaut, Univ. of Edinburgh, and Tulio de Oliveira, Africa Centre for Population Health</p>\n\n<p>Yet almost half the infected population today is still untreated. Some have not suffered enough immune damage from the virus to merit ARVs under current government policy. Many other infected people don\'t know their status or never seek care, and still others who start treatment have difficulty taking their daily pills for years on end. Estimates suggest that because of failures in this \'care continuum,\' only about one in four HIV-infected South Africans has fully suppressed the virus. \'We have to ride two horses at the same time,\' says Fareed Abdullah, who heads the quasi-governmental South African National AIDS Council (SANAC) in Pretoria. \'One is to improve our system so that the more than 3 million on treatment are retained in care and properly managed, and we also have to expand to a group that is largely asymptomatic and well.\'</p>\n<p>Adding to those challenges is South Africa\'s alarming HIV incidence\'the percentage of the population that becomes infected each year. The government reports that HIV incidence has dropped from a high of 1.67% in adults in 2005 to 1.22% last year, but that still translates into 330,000 new infections a year. The rate is shockingly high in women under 25, especially in the hardest hit province, KwaZulu-Natal, where incidence tops 6% in some communities.</p>\n\n<p>Health Minister Aaron Motsoaledi, who acknowledges that the country\'s aggressive HIV/AIDS program got off to a late start because of Mbeki, is confident that South Africa has the willpower and the money to hit 90-90-90. \'Can we afford not to treat people\'\' Motsoaledi asks. \'Surely, we\'re going to pay much more dearly socially, politically, and economically if you can\'t.\' To that end, the government, which already spends $1.2 billion a year on HIV/AIDS and receives another $300 million in foreign aid, is adding $65 million annually through 2019.</p>\n\n<p>But a new report concludes that meeting the UNAIDS target will require an additional $8 billion over the next 5 years. \'UNAIDS is pushing very hard on our health ministry, which doesn\'t want to be caughtshort again and wants to make the case that we can reach 90-90-90,\' says Linda-Gail Bekker, who co-runs the Desmond Tutu HIV Foundation (DTHF) in Cape Town and is one of the co-authors of the report. The cost of drugs is just one part of the equation, she says. Reaching the target will also require massive HIV testing and the costly delivery of ARVs to patients who must be monitored and then helped if they\'re not suppressing the virus. \'I\'m really, really anxious about the resources it\'s going to take.\' </p>\n<p>There are scientific questions, too. The assumption that reaching the 90-90-90 target will end AIDS is based on mathematical models that factor in ARV \'coverage\' in combination with other proven prevention strategies like male circumcision, condom promotion, and behavior change efforts. Researchers note that in large epidemics like the one in South Africa, which has spread far beyond \'concentrated\' populations such as men who have sex with men and sex workers, such strategies could prove less effective than expected, allowing HIV to continue spreading at high rates even after the country reaches 90-90-90.</p>\n\n<p>Epidemiologist Salim Abdool Karim, who runs the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban, points to recent data from Botswana that call into question the model\'s assumptions. Botswana, which is relatively wealthy and has a tiny population of 2 million, has nearly reached 90-90-90, as shown in a study published online on 23 March in The Lancet. But incidence has barely budged, in part because the missing 10-10-10 continue to spread the virus. \'For a country that\'s close to 90-90-90, the incidence is ridiculously high,\' Karim says. \'It\'s scandalous.\' A report published by SANAC and the health department further questions the 90-90-90 mathematical modeling. Even if 90-90-90 leads to big declines in new infections by 2030, that report suggests that incidence in South Africa\'s population of 53 million will not quite drop below 0.1%\'the level that UNAIDS says it must reach for an epidemic to end. </p>\n\n<p>The bottom line is that it remains an open question whether the 90-90-90 treatment goal really can stop the spread of HIV in South Africa. Some of the world\'s largest controlled trials of treatment as prevention (TasP) are underway in the country to try to answer it.</p>\n\n<p>The bottom line is that it remains an open question whether the 90-90-90 treatment goal really can stop the spread of HIV in South Africa. Some of the world\'s largest controlled trials of treatment as prevention (TasP) are underway in the country to try to answer it.</p>\n\n<p>In an area known as Mfekayi in rural KwaZulu-Natal, two dozen people are sitting on the shaded porch of a plywood shack waiting their turn to see a counselor. The shack is the Egedeni Clinic, and the people are participants in a 28,000-person, multisite clinical trial that will assess the precise relationship between increased levels of HIV suppression in a community and drops in incidence. At Egedeni and 10 other clinics across the province, the TasP study offers ARVs to all infected participants. Another 11 TasP clinics instead offer treatment in keeping with current government recommendations, meaning that people start ARVs only after their immune systems show signs of damage.</p>\n\n<p>One by one, the participants hand bottles of ARVs they received a month earlier to the counselors, who count the remaining pills. This ritual, which is a crude way to monitor adherence, underscores an obvious limitation of the underlying strategy: Even if ARVs make people less infectious, TasP relies on the fickle relationship humans have with taking daily medications. </p>\n\n<p>Run by the Africa Centre for Population Health in nearby Mtubatuba, TasP is the furthest along of four similar large trials in sub-Saharan Africa that are examining the care continuum and the real-world outcome of \'universal treatment.\' Early analysis of TasP results found that fewer than 40% of the people who tested positive sought care within 3 months, as recommended. This first step still has remained a major stumbling block on the road to 90-90-90.</p>\n\n<p>At the International AIDS Conference later this month, the researchers plan to reveal whether their intervention has reduced incidence. \'This will be the first opportunity to assess whether, in fact, the bio-logical rationale is actually true in practice,\' says Deenan Pillay, a clinical virologist who heads the Africa Centre. But Pillay says the study already has made clear that ending AIDS is not simply a matter of \'let\'s just treat everyone and everything will be OK.\' In the final analysis, he says, the power of TasP depends as much on human behavior as it does on biology.</p>\n\n<p>Jacqualine Ncube, a 19-year-old restaurant worker, first took an HIV test when she was in high school. At the time, Ncube spent many hours after school hanging out at DTHF\'s Youth Centre, which abuts the struggling township of Masiphumelele outside of Cape Town. The Youth Centre offers teens internet access, holds soccer matches, loans surfboards, and provides care at a health clinic. Kids also earn \'Tutus,\' good for shopping vouchers or food, for every-thing from helping the community to taking an HIV test. When Ncube got her first results, she was overwhelmed. \'I really screamed,\' she says. She was negative.  </p>\n\n<p>Ncube has repeatedly tested negative, and in April 2015 she joined the Youth Centre\'s Pillsplus, a study of what\'s known as pre-exposure prophylaxis, or PrEP, in 150 teens. With PrEP, uninfected people take daily ARV pills to prevent infection. Although PrEP is a proven strategy, South Africa recommends its use only in sex workers, and Ncube is one of the first hetero-sexual teens in the world to take ARVs for prevention. She still uses condoms with her boyfriend, but says she wanted to try PrEP because \'no protection is 100%.\'</p>\n\n<p>DTHF\'s Bekker, who is heading Pillsplus to assess PrEP\'s acceptability in teens, contends that PrEP should be provided to all people at high risk of infection. \'When I sit opposite a 17-year-old young woman, I have nothing to offer her,\' Bekker says. </p>\n\n<p>CAPRISA\'s Karim says using PrEP in young women could be key to breaking the epidemic\'s back. About 30% of new infections in South Africa occur in young women between 15 and 24 years of age. The new infection rate in men in the same age bracket is more than four times lower. In some districts of KwaZulu-Natal, a woman has a 60% chance of becoming infected by age 34.</p>\n\n<p>Sex and age</p>\n\n<p>HIV infects far more girls and young women than boys and men of the same age in South Africa. The sex difference shrinks by age 35, then prevalence drops.</p>\n\n<p><center><img src=\"imagesBIO/AIDS_prevalence_0.png\"></center></p>\n<p><center><img src=\"imagesBIO/AIDS_cycle_0.png\"></center></p>\n\n<p>To understand the pattern of viral spread, CAPRISA and the Africa Centre mapped out the infection cycle between men and women of different ages in KwaZulu-Natal. The study analyzed the genetic sequences of HIV isolated from 858 men and women, all between 16 and 35 years old, who belonged to the same sexual networks. The viral genetics linked different isolates and indicated which ones were older, allowing the researchers to infer who infected whom. Teenage girls were infected by men who were, on average, 8 years older. After the age of 24, people typically became infected by partners their own age, with transmission more frequently moving from woman to man. \'They are trying to find lifetime partners at this age,\' Karim says. These older men are the same group having sex with the youngest women. \'We have to break the chain between men in their late 20s and teen girls,\' he says. </p>\n\n<p>PrEP can help address shortcomings of TasP, Karim says. In the infection-cycle study, men who infected younger women had extremely high HIV levels, indicating they recently acquired the virus and thus would not appear infected on standard antibody-based tests. \'If your strategy is to test and treat these people, you\'re not going to catch them,\' Karim says. Men are also less connected to the health care system and often migrate for work, he adds, making it more difficult to help those who know they are infected fully suppress the virus. Giving PrEP to young women sidesteps the male dilemma. \'We just have to protect girls for 5 years in that critical risk period until they find their partners,\' he says.</p>\n\n<p>Karim says new biomedical interventions on the horizon may bolster prevention efforts. His group plans to report at the Durban meeting that it has identified an unusual microbe linked to vaginal inflammation in women in KwaZulu-Natal. Treating it could potentially lower their risk of HIV infection. Injectable ARVs that last for 2 months are also being tested in South Africa and elsewhere, and those could eliminate the challenge of taking daily pills\'a key problem for both treatment and PrEP. Next fall, South Africa plans to launch the world\'s only efficacy trial of an AIDS vaccine\'the strongest preventive medicine of all.</p>\n\n<p>For now, 90-90-90 is the most powerful tool available to South Africa in its quest to end its epidemic, even if PrEP and other new strategies ultimately are needed. SANAC\'s Abdullah takes a pragmatic view of meeting the UNAIDS deadline. \'I think we should plan for it, because if we don\'t hit it by 2020, we\'ll do it by 2022,\' he predicts. \'What we\'re really after is bringing down new infections to low levels,\' along with getting as many HIV-infected people as possible on treatment and living longer lives. The virus itself, Abdullah says, \'will be with us for the next 100 years.\'</p>\n', NULL, NULL, 'Y');
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(156, 'nature_logo.png', 'http://bioafrica.net/manuscripts/SocialCycleHIVNature2016.pdf', 'Social cycle aids HIV spread', 'Nature', 139, '2016-07-21', '<p> Nature (Vol. 535,  pp. 335, 2016) report our recent results on the use of genetic sequences to uncover HIV-1 transmission patterns in young woman in South Africa <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">(de Oliveira et al. Lancet HIV 2016)</a>. The paper was presented as a Keynote at AIDS 2016 conference.</p>\n', NULL, NULL, '<p><center><img src=\"imagesBIO/NatureGeneticsHIV.jpg\"></center></p>\n<p>By Amy Maxem, Nature, Vol 535, page 335, 21 July 2016</p>\n<p>Sex between young women and older men is no secret in South Africa. The name \'blesser\' is commonly used to describe a man who may at first pay for a teenager\'s bus fare to high school, then buy school supplies she cannot afford, and perhaps lunch at a decent cafe. Over time, the adolescent sleeps with her provider.</p>\n<p>A genetic analysis, lead by Prof. Tulio de Oliveira, now suggests how this social phenomenon plays into the cycle of HIV transmission in the country, which has the world\'s largest HIV epidemic. By analysing the similarity of viral genetic sequences from nearly 1,600 people with HIV in one community in KwaZulu-Natal, the study shows that adolescent girls and women in their early 20s tend to pick up the virus from men aged around 30. When the women grow older, they go on to infect their long-term partners, who in turn may pass the virus on through affairs with younger women.</p>\n<p><b><i>This is the engine driving high rates of HIV,</b></i> says epidemiologist Salim Abdool Karim, senior author of the unpublished study and director of the Centre for the AIDS</p>\n<p>Program of Research in South Africa (CAPRISA). He presents the work this week at the International AIDS Conference in Durban.</p>\n<p>Karim thinks that the study adds to growing evidence that HIV-free young women in regions with very high rates of HIV should be encouraged to take antiretroviral medications regularly to prevent infection. The World Health Organization also recommends that people at substantial risk of HIV be offered what is known as PrEP (pre-exposure prophylaxis). But, owing in part to disappointing results in clinical trials, the South African government has not yet recommended PrEP for young women.</p>\n<p>Karim\'s study also shows the importance of making broader social changes, adds <b><i>Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS)</b></i>. In parts of South Africa, 8 times as many teenage girls have HIV as do teenage boys, and in some communities in KwaZulu-Natal, a 15-year-old girl has an 80% risk of getting HIV in her lifetime.\' <b><i>Something that underlies the study is how common it is for older men to have sex with young girls. Pills are useful, but how can we break this silence around the lack of enforcement of laws that protect young women\' How can we invest in the capacity of people to claim their rights and reduce this kind of violence\'\'</b></i></p>\n<p><b><i>VICIOUS CYCLE</b></i></p>\n<b><i>\'This is the engine driving high rates of HIV.\'</b></i>\n<p>Researchers have long known of the high burden of HIV infections in young South African women, and that they get infected by older men, says <b><i>Thomas Quinn, an epidemiologist at Johns Hopkins Bloomberg School of Public Health</b></i>  in Baltimore, Maryland, who was not involved in the study. But, he says, <b><i>\'it is very exciting to use molecular genetic information to actually show how the virus spreads among people\'</b></i>  \' and to pinpoint the ages of women and men at key points in the cycle of HIV transmission.</p>\n<p>Karim has tracked HIV genetic data for the past couple of years, and his work has already affected how governments and international organizations tackle the virus. He has been sharing results regularly with Deborah Birx, the US Global AIDS Coordinator who oversees the US President\'s Emergency Plan for AIDS Relief (PEPFAR), the largest federal funder of HIV-prevention research.</p>\n<p>In 2014, PEPFAR launched an initiative called DREAMS to protect young women from HIV, in response to the finding that more than 1,000 women aged 16\'24 become infected every day in southern and eastern Africa. When Birx heard details of Karim\'s results last year, she convinced PEPFAR to target particular demographic groups. For example, she says, half of the recipients of the US$85-million DREAMS Innovation Challenge, announced on 18 July, are 15- to 19-year-old girls.</p>\n<p>Despite the results, health officials remain reluctant to recommend PrEP for adolescent girls and young women. In June, the South African government endorsed PrEP for sex workers \' but not for other high-risk groups, such as gay men and young women. One reason for its hesitancy is that the treatments have not proved effective in clinical trials, and blood tests have suggested that is because women in these trials did not consistently take their medications (either daily pills or a vaginal gel).</p>\n<p>But at the conference, the CAPRISA team announced another as-yet-unpublished finding that suggests a woman\'s vaginal microbiome may be in part responsible for the inefficacy of PrEP. A study of women who used the gel tenofovir to prevent HIV infection suggests that it was less effective in those who had Gardnerella vaginalis bacteria in their vaginal lining. The researchers found that G. vaginalis absorbed the PrEP drugs, reducing the amount of medication in the blood.</p>\n<p>This hints that more women may actually have taken their medications than the disappointing blood tests from earlier trials suggested, Karim says \' and also that treatment for an imbalance in vaginal bacteria might help PrEP to work better in some young women.</p>', NULL, NULL, 'Y'),
(157, 'imgnews157sm.png', 'http://bioafrica.net/manuscripts/SATuRNnewsletter_3_2016A4.pdf', 'SATuRN Newsletter, 3rd quarter, 2016: SATuRN/CAPRISA, Rural vs Urban resistance levels, PhD fellowships, AWACC workshop', 'SATuRN', 0, '2016-10-01', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN. In this third 2016 issue of our newsletter we have included interesting news, blogs, reports, tweets, publications and training information produced by our network. We hope you enjoy it and find it informative. We welcome any feedback about content or format.<p>', NULL, 4, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_3_2016A4.pdf\"><img src=\"imagesBIO/imgnews157.png\"></a></center> </p>\n\n<br><p><b><i>In this issue our highlights are:</b></i></p>\n\n\n<p> - <a href=\"http://www.awacc.org\">Upcoming event: Annual Workshop on Advanced Clinical Care, Durban ICC, 6-7 Oct 2016</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=154\">PhD positions: DST Professional development program (PDP) PhD Fellowship at CAPRISA and SATuRN</a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/news.php?id=152\">PhD position I: HIV-1 Drug Resistance </a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/news.php?id=153\">PhD position II: HIV-1 Genomics, Bioinformatics and Phylogenetics</a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/publications.php?pubid=136\">Publication: Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy, Antimicrob Agents Chemotherapy, 2016</a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/publications.php?pubid=126\">Publication: HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa, HIV Medicine, 2016</a></p>\n\n<p> - <a href=\"http://www.bioafrica.net/news.php?id=155\">News: South Africa\'s bid to end AIDS & The cycle of infection in South Africa, Science 2016 coverage of our phylogenetics results.</a></p>\n\n \n<p>The newsletter is open accessible at:</p>\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_3_2016A4.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_3_2016A4.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>\n', 'SATuRN, newsletter, september, drug resistance, urban, rural, protease resistance, pediatric, workshop, training, Prof. Tulio de Oliveira, president, SASBI, South Africa Bioinformatics Society, AWACC, 2016, HIV-1, drug resistance, news, blogs, SATuRN, newsletter, september, drug resistance, urban, rural, protease resistance, pediatric, workshop, training, Prof. Tulio de Oliveira, president, SASBI, South Africa Bioinformatics Society, AWACC, 2016, HIV-1, drug resistance, news, blogs, SATuRN, newsletter, september, drug resistance, urban, rural, protease resistance, pediatric, workshop, training, Prof. Tulio de Oliveira, president, SASBI, South Africa Bioinformatics Society, AWACC, 2016, HIV-1, drug resistance, news, blogs, SATuRN, newsletter, september, drug resistance, urban, rural, protease resistance, pediatric, workshop, training, Prof. Tulio de Oliveira, president, SASBI, South Africa Bioinformatics Society, AWACC, 2016, HIV-1, drug resistance, news, blogs', 'The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN and our Biofrica research group. The newsletter is presented as a PDF document with links to complete articles at bioafrica.net.  In our third issue of 2064, we would like to bring attention to our participation in the AIDS 2016 conference and our AWACC and CAPRISA clinical care training program in KwaZulu-Natal.', ''),
(158, 'imgnews75.png', 'http://www.sasbi-sags.co.za/conference-info/', '4th Joint Congress of the South African Society for Bioinformatics (SASBi) and the South African Genetics Society (SAGS)', 'SASBi & SAGS', 0, '2016-09-23', '<p>The biennial SASBi and SAGS congresses are the premier national scientific meetings on bioinformatics and genetics in South Africa. In total, 187 participats delivered 40 oral presentations and 65 posters in SASBi-SAGS-2016. This congress provided an exciting opportunity to learn about cutting-edge research in both disciplines, and to network with members of the two societies and with leading international scientists.</p>', NULL, 4, '<p><center><img src=\"imagesBIO/SAGS_people_0022.png\"></center> </p>\n\n<br><p>We have been delighted to host the 4th Joint Congress of the South African Society for Bioinformatics (SASBi) and the South African Genetics Society (SAGS), which was held from 20 to 23 September 2016 at the Nelson R Mandela School of Medicine, University of KwaZulu-Natal (UKZN), Durban.</p>\n\n<p>The theme of the congress was <b><i>\'Bridging the gap: Decoding genetics for integration and application\'</b></i> with an emphasis on the integration of diverse biological data to understand the function and evolution of biological systems from single gene to whole-genome levels towards an application across diverse fields. We are at the doorway to a promising future for bioinformatics and genomics research in South Africa. Both fields are accelerating and gaining momentum due to the flood of biological data being produced and exciting breakthroughs are awaiting us at the level of genes, genomes, and beyond.</p>\n\n<br>\n<p><b><i>Keynote and Invited Speakers</b></i></p>\n<p><b><i>Stephen J. O\'Brien </b></i>Theodosius Dobzhansky Center for Genome Bioinformatics, Russia & National Institutes of Health (NIH), U.S.A. </p>\n<p><b><i>Jason Williams</b></i>	Cold Spring Harbor Laboratory, U.S.A.</p>\n<p><b><i>Carsten Kulheim </b></i>	Australian National University, Australia</p>\n<p><b><i>Tulio de Oliveira</b></i>	Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n<p><b><i>Alexander Herbig</b></i> Max Planck Institute, Germany</p>\n<p><b><i>Eduard Venter</b></i>	Vice-President SAGS, University of Pretoria, South Africa</p>\n<p><b><i>Fourie JoubertSAGS</b></i>	Previous President SASBi, University of Pretoria, South Africa </p>\n<p><b><i>Nicola Mulder</b></i>	University of Cape Town, South Africa</p>\n<p><b><i>Che Pillay</b></i>University of KwaZulu-Natal, South Africa</p>\n<p><b><i>Zander Myburg</b></i>	Department of Genetics at the University of Pretoria, South Africa</p>\n<p><b><i>Robyn Jacob</b></i>	South African Sugarcane Research Institute, South Africa</p>\n<p><b><i>Sanushka Naidoo</b></i>	University of Pretoria, South Africa</p>\n<p><b><i>Gerard Tromp </b></i>	Stellenbosch University, South Africa</p>\n<br>\n<p>In the 4th Joint Congress. The  South African Society for Bioinformatics (SASBi) and the South African Genetics Society (SAGS) also elect their new presidents. <b><i>Prof. Tulio de Oliveira</b></i> Nelson R Mandela School of Medicine, UKZN was elected the president of SASBi (2016-2018) and <b><i>Dr. Sanushka Naidoo</b></i> was elected the new president of SAGS (2016-2018). Interestingly, Both Tulio and Sanushka were colleagues during their BSc Honours at UKZN in 1998. They  look forward to continue the successful collaboration of SASBi and SAGS.</p>\n<p><b><i>More information on the joint conference, please visit the website below</b></i></p> \n\n\n\n', NULL, NULL, 'Y'),
(159, 'news158sm.png', 'http://www.awacc.org', '10th Annual Workshop on Advanced Clinical Care - AIDS (AWACC)', 'AWACC', 0, '2016-10-06', '<p>This AWACC annual workshop is in the 10th edition and it is organized as a joint effort of the Centre for AIDS research (CFAR) of Harvard Medical School, SATuRN, CAPRISA, UKZN and the KwaZulu-Natal Department of Health. AWACC objecitve is to translate the latest evidence-based research and apply best practice models of care into good clinical practice, specifically for resource constrained areas.</p>', NULL, 4, '<p><center><img src=\"imagesBIO/ICC_AWACC_0023.jpg\"></center> </p>\n<p>The conference has attracted clinicians (nurses and doctors and pharmacists) from the private sector and public sector. This year, 458 delegates have attended. In addition, many medical aid administrators, pharmaceutical reps, health department officials and paraclinical workers have also been part of the workshop.</p>\n\n<p>The Southern African Treatment and Resistance Network (SATuRN) in partnership with CAPRISA have presented a full day programme on HIV & TB Drug Resistance and Clinical Management.</p>\n\n<p><center><img src=\"imagesBIO/ICC_AWACC_0024.jpg\"></center> </p>\n<p><small>Prof. Linda Grail Bekker and Prof. Francois Venter were some of the keynote speakers in AWACC.</small></p>\n\n<p><b><i>Organising Committee</b></i></p>\n<p><b><i>Dr Henry Sunpath (chairperson)</b></i>	KZN Department of Health and University of KwaZulu-Natal, South Africa </p>\n<p><b><i>Prof. Raj Gandhi </b></i>	Mass General Hospital (MGH), Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. Yunus Moosa</b></i>	University of KwaZulu-Natal, South Africa </p>\n<p><b><i>Prof. Tulio de Oliveira</b></i>	SATuRN & Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n<br>\n<p><b><i>Speakers</b></i></p>\n<p><b><i>Dr. M. Archary</b></i>	University of KwaZulu-Natal, South Africa</p>\n<p><b><i>Prof. K. Ard</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. Linda G. Bekker</b></i>	University of Cape Town, South Africa </p>\n<p><b><i>Dr. Francesca Conradie </b></i>	WHRI, South Africa</p>\n<p><b><i>Prof. Tulio de Oliveira</b></i>	SATuRN & Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n<p><b><i>Prof. Raj Gandhi </b></i>	Mass General Hospital (MGH), Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. R. Goldstein</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Dr. Richard Lessells</b></i>	London School of Hygiene and Tropical Medicine, U.K.</p>\n<p><b><i>Prof. V.C. Marconi</b></i>	Emory University, U.S.A</p>\n<p><b><i>Prof. I. Master</b></i>	Department of Health and King George V Hospital, South Africa</p>\n<p><b><i>Prof. S. Mukerji</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Dr. Z. Mthembu</b></i>	DREAMS program and MatCH, South Africa</p>\n<p><b><i>Prof. R. Murphy</b></i>	University of California Los Angeles, U.S.A.</p>\n<p><b><i>Dr. Kogie Naidoo</b></i>	CAPRISA, South Africa</p>\n<p><b><i>Prof. Catherine Orrell</b></i>	University of Cape Town, South Africa</p>\n<p><b><i>Dr. Nesri Padayatchi</b></i>	CAPRISA, South Africa</p>\n<p><b><i>Prof. M. Siedner</b></i>	Harvard Medical School, U.S.A.</p>\n<p><b><i>Prof. Francois Venter</b></i>	WHRI, South Africa </p>\n\n<br>\n <p>One of the main objectives of AWACC, SATuRN and CAPRISA is to support the NDoH and build capacity among clinicians to manage patients who still present in advanced HIV and TB clinical disease. In addition, we aim to build capacity as part of the CAPRISA ACC to manage patients who fail virologically and those who may need third line ART.</p>\n\n<p><b><i>More information on the joint conference, please visit the website below</b></i></p> ', NULL, NULL, 'Y'),
(160, 'unaids_eng.png', 'http://www.unaids.org/en/resources/documents/2016/get-on-the-fast-track', 'UNAIDS Report 2016 - Get on the Fast-Track - The life-cycle approach to HIV', 'UNAIDS', 139, '2016-11-22', '<p>In this report, UNAIDS is announcing that 18.2 million people now have access to HIV treatment. The Fast-Track response is working. Increasing treatment coverage is reducing AIDS-related deaths among adults and children. But the life-cycle approach, which highlight our phylogenetics manuscript <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">(de Oliveira et al. Lancet HIV 2016)</a>, has to include more than just treatment.</p>', NULL, 4, '<p><center><a href=\"manuscripts/UNAIDS2016_Get_on_the_Fast_Track_en.pdf\"><img src=\"imagesBIO/UNAIDS_cycle_transmission_phylogenetic_deOliveira.jpg\"></a></center> </p>\n<p><i>Download the full report, which review our HIV-1 phylogenetic results with CAPRISA.</i></p>\n<p>WINDHOEK/GENEVA, 21 November 2016 A new report by UNAIDS shows that countries are getting on the Fast-Track, with an additional one million people accessing treatment in just six months (January to June 2016). By June 2016, around 18.2 million [16.1 million 19.0 million] people had access to the life-saving medicines, including 910 000 children, double the number five years earlier. If these efforts are sustained and increased, the world will be on track to achieve the target of 30 million people on treatment by 2020.</p>\n<p>Get on the Fast-Track: the life-cycle approach to HIV was launched today in Windhoek, Namibia, by the President of Namibia, Hage Geingob and the Executive Director of UNAIDS, Michel Sidibe.  <b><i>\'Just under two years ago, 15 million people were accessing antiretroviral treatment today more than 18 million are on treatment and new HIV infections among children continue to fall,\'</b></i> said President Geingob. <b><i>\'Now, we must ensure that the world stays on the Fast-Track to end the AIDS epidemic by 2030 in Namibia, in Africa and across the world.\'</b></i>  </p>\n<p>The report contains detailed data on the complexities of HIV and reveals that girls  transition to womanhood is a very dangerous time, particularly in sub-Saharan Africa. <b><i>\'Young women are facing a triple threat,\'</b></i> said Mr Sidibe. <b><i>\'They are at high risk of HIV infection, have low rates of HIV testing, and have poor adherence to treatment. The world is failing young women and we urgently need to do more.\'</b></i></p>\n<p>HIV prevention is key to ending the AIDS epidemic among young women and the cycle of HIV infection needs to be broken. Recent data from South-Africa shows that young women are acquiring HIV from adult men, while men acquire HIV much later in life after they transition into adulthood and continue the cycle of new infections.  </p>\n<p>The report also shows that the life-extending impact of treatment is working. In 2015, there were more people over the age of 50 living with HIV than ever before 5.8 million. The report highlights that if treatment targets are reached, that number is expected to soar to 8.5 million by 2020. Older people living with HIV, however, have up to five times the risk of chronic disease and a comprehensive strategy is needed to respond to increasing long-term health-care costs.    </p>\n<p>The report also warns of the risk of drug resistance and the need to reduce the costs of second- and third-line treatments. It also highlights the need for more synergies with tuberculosis (TB), human papillomavirus (HPV) and cervical cancer, and hepatitis C programmes in order to reduce the major causes of illness and death among people living with HIV. In 2015, 440 000 of the 1.1 million people who died from an AIDS-related illness died from TB, including 40 000 children.</p>\n<p><b><i>\'The progress we have made is remarkable, particularly around treatment, but it is also incredibly fragile,\'</b></i> said Mr Sidibe. <b><i>\'New threats are emerging and if we do not act now we risk resurgence and resistance. We have seen this with TB. We must not make the same mistakes again.\'</b></i></p>\n<p>Get on the Fast-Track: the life-cycle approach to HIV outlines that large numbers of people at higher-risk of HIV infection and people living in high-burden areas are being left without access to HIV services at critical points in their lives, opening the door to new HIV infections and increasing the risk of dying from AIDS-related illnesses. The report examines the gaps and approaches needed in HIV programming across the life cycle and offers tailored HIV prevention and treatment solutions for every stage of life.</p>\n<p>\"Ending AIDS is possible only if we join hands by each doing what is within our scope, creatively and aggressively embracing the 90 90 90 targets,\" said Eunice Makena Henguva, Youth Economic Empowerment Project Officer for the Namibian Women\'s Health Network.</p>\n<p><b><i>From birth</b></i></p>\n<p>Globally, access to HIV medicines to prevent mother-to-child transmission of HIV has increased to 77% in 2015 (up from 50% in 2010). As a result, new HIV infections among children have declined by 51% since 2010.</p>\n<p>The report highlights that of the 150 000 children who were newly infected with HIV in 2015, around half were infected through breastfeeding. It stresses that infection through breastfeeding can be avoided if mothers living with HIV are supported to continue taking antiretroviral medicines, allowing them to breastfeed safely and ensure that their children receive the important protective benefits of breastmilk.</p>\n<p>Testing also remains a major issue. The report shows that only four of 21 priority countries in Africa provided HIV testing for more than half the babies exposed to HIV within their first weeks of life. It also shows that in Nigeria, which accounts for more than a quarter of all new HIV infections among children globally, only half of pregnant women living with HIV are tested for HIV.</p>\n<p>Get on the Fast-Track: the life-cycle approach to HIV stresses that more efforts are needed to expand HIV testing for pregnant women, expand treatment for children and improve and expand early infant diagnosis by using new diagnostic tools and innovative methods, such as SMS reminders, to retain mothers living with HIV and their babies in care.</p>\n<p>The report also encourages countries to adopt the targets of the Start Free, Stay Free, AIDS Free framework led by UNAIDS and the United States President s Emergency Plan for AIDS Relief to reduce the number of new HIV infections among children, adolescents and young women, and ensure lifelong access to antiretroviral therapy if they are living with HIV.</p>\n<p><b><i>Through adolescence</b></i></p>\n<p>The report shows that the ages between 15 and 24 years are an incredibly dangerous time for young women. In 2015, around 7500 young women became newly infected with HIV every week. Data from studies in six locations within eastern and southern Africa reveal that in southern Africa girls aged between 15 and 19 years accounted for 90% of all new HIV infections among 10 19-year-olds, and more than 74% in eastern Africa. </p>\n<p>Globally, between 2010 and 2015, the number of new HIV infections among young women aged between 15 and 24 years was reduced by just 6%, from 420 000 to 390 000. To reach the target of less than 100 000 new HIV infections among adolescent girls and young women by 2020 will require a 74% reduction in the four years between 2016 and 2020.</p>\n<p>Many children who were born with HIV and survived are now entering adulthood. Studies from 25 countries in 2015 show that 40% of young people aged between 15 and 19 years became infected through mother-to-child transmission of HIV. This transition is also magnifying another major challenge high numbers of AIDS-related deaths among adolescents. Adolescents living with HIV have the highest rates of poor medication adherence and treatment failure.</p>\n<p>A range of solutions are needed to respond to the specific needs of adolescents, including increased HIV prevention efforts, keeping girls and boys in school, increasing HIV testing and voluntary medical male circumcision, pre-exposure prophylaxis and immediate access to antiretroviral therapy.   </p>\n<p><b><i>Key populations</b></i></p>\n<p>In 2014, an estimated 45% of all new HIV infections globally were among members of key populations and their sexual partners. The report warns that new HIV infections are continuing to rise among people who inject drugs (by 36% from 2010 to 2015) and among gay men and other men who have sex with men (by 12% from 2010 to 2015) and are not declining among sex workers or transgender people.</p>\n<p>The report outlines the critical need to reach key populations with HIV prevention and treatment programmes that meet their specific needs throughout their lives; however, total funding levels are far below what is needed for HIV programmes to reach key populations, particularly funding from domestic sources.</p>\n<p><b><i>Adulthood</b></i></p>\n<p>In July 2016, in the HIV prevention gap report, UNAIDS warned that HIV prevention efforts are not working for adults and that new HIV infections among adults have failed to decline for at least five years. Get on the Fast-Track: the life-cycle approach to HIV cites concerns that western and central Africa is off-track in responding to HIV. The region accounts for 18% of people living with HIV, but a serious lack of access to treatment means that the region accounts for 30% of all AIDS-related deaths globally. </p>\n<p>The report sheds new light on HIV infection and treatment among adult men, showing that men are much less likely to know their HIV status and access treatment than women. One study in KwaZulu-Natal, South Africa, showed that just 26% of men were aware of their HIV status, only 5% were on treatment and that the viral load among men living with HIV was extremely high, making onward transmission of the virus much more likely.</p>\n<p><b><i>Into later life</b></i></p>\n<p>The report shows that antiretroviral therapy is allowing people living with HIV to live longer. In 2015, people more than 50 years old accounted for around 17% of the adult population (15 years and older) living with HIV. In high-income countries, 31% of people living with HIV were over the age of 50 years.</p>\n<p>Get on the Fast-Track: the life-cycle approach also shows that around 100 000 people in low- and middle-income countries aged 50 years and over are estimated to newly acquire HIV every year, confirming the need to include older people in HIV prevention, as well as treatment, programming.</p>\n<p>As people living with HIV grow older, they are also at risk of developing long-term side-effects from HIV treatment, developing drug resistance and requiring treatment of co-morbidities, such as TB and hepatitis C, which can also interact with antiretroviral therapy. Continued research and investment is needed to discover simpler, more tolerable treatments for HIV and co-morbidities and to discover an HIV vaccine and cure.</p>\n<p>Finding solutions for everyone at every stage of life</p>\n<p>The report concludes that investments must be made wisely across the life cycle, using a location population approach to ensure that evidence-informed, high-impact programmes are available in the geographical areas and among the populations in greatest need.</p>\n<p>It strongly urges countries to continue to Fast-Track HIV prevention, testing and treatment in order to end the AIDS epidemic as a public health threat by 2030 and ensure that future generations are free from HIV.</p>\n<p>New phylogenetic data from South Africa (de Oliveira et al. Lancet HIV 2016) reveal a vicious cycle of HIV infection among older and younger people that may be at play in many high-prevalence settings: young women are acquiring HIV from adult men\'as these young women grow older, they tend to transmit HIV to adult men, and the cycle repeats. Data from other studies suggest that gender inequalities and harmful masculinities underpin this cycle. Lower access to education, lower levels of economic independence and intimate partner violence erode the ability of young women to negotiate safer sex and retain control of their bodies. Men, meanwhile, tend to be ignored by health policies and HIV strategies, they seek services infrequently, and they tend to be diagnosed with HIV and initiate treatment very late - often with deadly consequences.</p>\n\n', 'UNAIDS, report 2016, phylogenetic, de oliveira, young woman, transmission, cycle of infection, CAPRISA, South Africa, UNAIDS, report 2016, phylogenetic, de oliveira, young woman, transmission, cycle of infection, CAPRISA, South Africa, UNAIDS, report 2016, phylogenetic, de oliveira, young woman, transmission, cycle of infection, CAPRISA, South Africa, UNAIDS, report 2016, phylogenetic, de oliveira, young woman, transmission, cycle of infection, CAPRISA, South Africa, UNAIDS, report 2016, phylogenetic, de oliveira, young woman, transmission, cycle of infection, CAPRISA, South Africa', 'UNAIDS 2016 report show that our new phylogenetic data from South Africa reveal a vicious cycle of HIV infection among older and younger people that may be at play in many high-prevalence settings: young women are acquiring HIV from adult men?as these young women grow older, they tend to transmit HIV to adult men, and the cycle repeats', 'Y'),
(161, 'imgreuters.jpg', 'http://www.reuters.com/article/us-health-aids-idUSKBN13G17V', 'More than 18 million on HIV treatment, a million more than 2015: UNAIDS 2016 Report', 'Reuters', 139, '2016-11-22', '<p>More than 18 million people now have access to life-saving AIDS treatment, 1.2 million more than at the end of last year, the United Nations said on Monday. With detailed data showing some of the many complexities of the HIV epidemic, the report found that people are particularly vulnerable to HIV at certain points in their lives <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">(de Oliveira et al. Lancet HIV 2016)</a>. It called for \'life-cycle; approach to offer help and prevention measures for everyone at every stage of life.</p>', NULL, 4, '<p><center><img src=\"imagesBIO/reuters_UNAIDS2016.jpg\"></center> </p><p> By Kate Kelland, LONDON, Nov 21 - More than 18 million people now have access to life-saving AIDS treatment, 1.2 million more than at the end of last year, the United Nations said on Monday.</p>\n<p>In a report on the AIDS pandemic, which has infected 78 million people and killed 35 million since it began in the 1980s, UNAIDS said the consistently strong scale-up of treatment has seen annual AIDS-related deaths drop by 45 percent to 1.1 million in 2015 from a peak of about 2 million in 2005.</p>\n<p>But, as more HIV-positive people live longer, the challenges of caring for them as they get older, of preventing the virus spreading and of reducing new infections are tough, UNAIDS said, even though drugs can reduce virus levels in a patient\'s blood to near zero and significantly reduce the risk of passing it on.</p>\n<p><b><i>\'The progress we have made is remarkable, particularly around treatment, but it is also incredibly fragile\'</b></i>, UNAIDS\' executive director Michel Sidibe said as the report was published.</p><p>With detailed data showing some of the many complexities of the HIV epidemic, the report found that people are particularly vulnerable to HIV at certain points in their lives.</p><p>It called for <b><i>\'life-cycle\'</b></i> approach to offer help and prevention measures for everyone at every stage of life.</p><p>As people with HIV grow older, they are at risk of developing long-term side-effects from HIV treatment, developing drug resistance and requiring treatment for other illnesses such as tuberculosis and hepatitis C.</p><p>The report also cited de Oliveira\'s phylogenetics data from South Africa showing that young women who become infected with HIV often catch the virus from older men. It said prevention is vital to ending the epidemic in young women and the cycle of HIV infection needs to be broken.</p><p><b><i>\'Young women are facing a triple threat\'</b></i>, said Sidibe. <b><i>\'They are at high risk of HIV infection, have low rates of HIV testing, and have poor adherence to treatment.\'</b></i></p><p>The report, saying the number of people with HIV getting life-saving drugs was 18.2 million, also showed that the rapid progress in getting AIDS drugs to those who need them is having a significant life-extending impact. </p>\n<p>In 2015, there were 5.8 million people aged over 50 living with HIV - more than ever before.</p>\n<p>UNAIDS said that if treatment targets are reached - the U.N. is aiming to have 30 million HIV positive people on treatment by 2020 - that number will soar.</p>', 'Reuters, UNAIDS, report, 2016, hiv phylogenetics, south africa, young women, paper, de Oliveira, news, AIDS day 2016, cycle of HIV infection, Reuters, UNAIDS, report, 2016, hiv phylogenetics, south africa, young women, paper, de Oliveira, news, AIDS day 2016, cycle of HIV infection, Reuters, UNAIDS, report, 2016, hiv phylogenetics, south africa, young women, paper, de Oliveira, news, AIDS day 2016, cycle of HIV infection, Reuters, UNAIDS, report, 2016, hiv phylogenetics, south africa, young women, paper, de Oliveira, news, AIDS day 2016, cycle of HIV infection', 'More than 18 million people now have access to life-saving AIDS treatment, 1.2 million more than at the end of last year, the United Nations said on Monday. With detailed data showing some of the many complexities of the HIV epidemic, the report found that people are particularly vulnerable to HIV at certain points in their lives. It called for \'life-cycle; approach to offer help and prevention measures for everyone at every stage of life.', ''),
(162, 'imgWSJ.jpg', 'http://www.wsj.com/articles/studies-offer-fresh-hope-in-fight-against-hiv-aids-in-south-africa-1468839605', 'Studies Offer Fresh Hope in Fight Against\rHIV/AIDS in South Africa.', 'Wall Street Journal', 139, '2016-07-18', '<p>Researchers with the Centre for the AIDS Programme of Research in South Africa, or CAPRISA, a consortium of South African and North American scientists, analyzed genetic codes  <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">(de Oliveira et al. Lancet HIV 2016)</a> from study subjects in South Africa to try to pinpoint biological factors that may contribute, along with behavioral factors, to the large number of infections.</p>', NULL, 4, '<p><center><img src=\"imagesBIO/HIVWallStreetJournal.jpg\"></center></p><p><i> A march against the rise in HIV infection in Cape Town, South Africa. Adolescent girls and young women account for one in four new HIV infections in sub-Saharan Africa, according to the Joint United Nations Programme on HIV/AIDS. Photo: Reuters</i></p> \n\n\n\n<p> By Betsy McKay, NEW YORK, July 18, 2016 7:10 a.m. The findings were striking, and could help chart a path to reduce the number of new infections in young women and girls?one of the greatest challenges for health officials combating HIV in southern Africa, the epicenter of the global epidemic, according to Salim Abdool Karim, director of the consortium and leader of the research team. <b><i>\'These three studies give us new insight and new evidence in how to improve our HIV prevention program for women in southern Africa,\'</b></i> he said in an interview.</p>\n\n<p>The findings were striking, and could help chart a path to reduce the number of new infections in young women and girls - one of the greatest challenges for health officials combating HIV in southern Africa, the epicenter of the global epidemic, according to Salim Abdool Karim, director of the consortium and leader of the research team. <b><i>\'These three studies give us new insight and new evidence in how to improve our HIV prevention program for women in southern Africa,\'</b></i> he said in an interview.</p>\n<p>The research will be presented at the 21st International AIDS Conference in Durban, South Africa, on Tuesday.</p>\n<p>Adolescent girls and young women account for one in four new HIV infections in sub-Saharan Africa, according to the Joint United Nations Programme on HIV/AIDS. Nearly three quarters of new HIV infections in adolescents in sub-Saharan Africa are in females. But the need for more prevention programs comes after funding for HIV efforts from donor governments to low- and middle-income countries globally fell in 2015 for the first time in five years, according to the Kaiser Family Foundation and UNAIDS.</p>\n<p>Results from a separate study, also to be presented Tuesday, offered new hope for preventing HIV infection. The analysis found that a vaginal ring that continuously releases the HIV drug dapivirine reduced the risk of HIV infection in women by at least 56%.</p>\n<p>In one study of a South African community, the CAPRISA researchers analyzed the genetic code of HIV from each of 1,589 HIV-positive people, tracing an unrelenting cycle of HIV transmission in which women under the age of 25 are routinely infected by men who are on average 8.7 years older than they are. The researchers found that girls between ages 16 and 20 are infected by men 11.5 years older than they are. <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">Open access publication (de Oliveira et al. Lancet HIV 2016)</a> </p>\n<p>The men in turn are infected by women their own age?many of whom were given the virus by older men when they were younger. Nearly 62% of women in the study ages 25 to 40 were HIV positive. <b><i>\'This cycle is the engine that ensures you have continuing high rates of HIV,\'</b></i> Dr. Abdool Karim said.</p>\n<p>The researchers then showed how an abundance of certain bacteria in the vagina put women at greater risk of HIV infection and make a preventive drug less effective. Analyzing more than 3 million genetic sequences from 120 South African women, the CAPRISA researchers found that those with large amounts of a particular bacterium, Prevotella bivia, had a 19.2 times greater chance of inflammation and HIV infection than those who had low levels or none of this bacteria. The bacteria may release a molecule linked to HIV infection, the researchers found.</p>\n<p>The CAPRISA researchers then analyzed genital bacterial proteins in 688 women. They discovered that a microbicide?a compound to prevent the transmission of sexually transmitted infections?containing the drug tenofovir was effective in the 61% of women who had predominantly <b><i>\'healthy\'</b></i> bacteria in their vaginas. But it had little effect in the remaining women, who had large amounts of gardnerella bacteria. The bacteria absorbed much of the drug, rather than leaving it to fight off HIV.</p>\n<p>The findings provide evidence that young women should be tested regularly for bacterial infections and treated if they have them, Dr. Abdool Karim said. They should also be offered HIV drugs for pre-exposure prophylaxis, or known as PrEP, to prevent infection, he said.</p>\n<p><b><i>\'PrEP is not promoted in this younger population and this series should make people rethink whether it should be offered to them,\'</b></i> said Thomas Quinn, an HIV/AIDS expert at the U.S. National Institute of Allergy and Infectious Diseases and professor of medicine at Johns Hopkins University, who was briefed on, but not involved in, the research. <b><i>\'These young women have superhigh infection rates.\'</b></i></p>\n<p>He called the research <b><i>\'a nice blending of behavioral with biological sciences.\'</b></i></p>\n<p>The research is particularly important because sub-Saharan Africa is experiencing a boom in its youth population, as mortality rates have dropped, according to Deborah Birx, the U.S. global AIDS coordinator. It also helps to explain why microbicides have appeared in studies to be less effective among young women than other age groups, said Dr. Birx, describing the work as <b><i>\'groundbreaking.\'</b></i></p>\n<p>Scientists had concluded that the women weren?t using the microbicides regularly, because they couldn?t find evidence of the drug in their bodies. More studies should be done urgently, she said. <b><i>\'This is really quite extraordinary,\'</b></i> she said. <b><i>\'We were making the assumption that the women were noncompliant when it may have been biological,\'</b></i> she said.</p>\n<p>The U.S. government was a funder of the research, through several agencies, and its key global AIDS program, the President?s Emergency Plan for AIDS Relief, funds efforts to address the epidemic in young women.</p>\n<p>Dr. Abdool Karim said that he hopes that researchers undertake similar studies in other countries in southern Africa, to see if their findings match. He said that he would be <b><i>\'surprised\'</b></i> if the CAPRISA findings don?t apply there too.</p>', 'wall street journal, new york, press, USA, CAPRISA, young woman, phylogenetics, de Oliveira, AIDS 2016, Durban, news, teenage girls, south africa, kwaZulu-Natal, infection, transmission, older men, wall street journal, new york, press, USA, CAPRISA, young woman, phylogenetics, de Oliveira, AIDS 2016, Durban, news, teenage girls, south africa, kwaZulu-Natal, infection, transmission, older men, wall street journal, new york, press, USA, CAPRISA, young woman, phylogenetics, de Oliveira, AIDS 2016, Durban, news, teenage girls, south africa, kwaZulu-Natal, infection, transmission, older men, wall street journal, new york, press, USA, CAPRISA, young woman, phylogenetics, de Oliveira, AIDS 2016, Durban, news, teenage girls, south africa, kwaZulu-Natal, infection, transmission, older men, wall street journal, new york, press, USA, CAPRISA, young woman, phylogenetics, de Oliveira, AIDS 2016, Durban, news, teenage girls, south africa, kwaZulu-Natal, infection, transmission, older men', 'Researchers with the Centre for the AIDS Programme of Research in South Africa, or CAPRISA, a consortium of South African and North American scientists, analyzed genetic codes and produce phylogenetic analysis  (de Oliveira et al. Lancet HIV 2016 from study subjects in South Africa to try to pinpoint biological factors that may contribute, along with behavioral factors, to the large number of infections.', ''),
(168, 'imgnews86.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipJan2017poster.pdf', 'Seminar: Differential HLA-A Expression Levels and the Effect on HIV', 'KRISP Talks', NULL, '2017-01-27', '<p><p>KRISP Talks by <b>Dr Veron Ramsuran</b>, Senior Lecturer: College of Health Sciences, UKZN, 27 January 2017, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipJan2017poster.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipJan2017poster.png\"></a></center></p>\n<p><b>Dr Veron Ramsuran \r</b>, (Senior Lecturer: College of Health Sciences, UKZN)</p>\n<p>Date: 27 January 2017</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: K1 Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'seminar, Differential, HLA-A, Expression, Levels, Effect, HIV, MRC Flaghip, UKZN, Dr Veron Ramsuran, Senior Lecturer, College of Health Sciences, UKZN, Durban, South Africa, seminar, Differential, HLA-A, Expression, Levels, Effect, HIV, MRC Flaghip, UKZN, Dr Veron Ramsuran, Senior Lecturer, College of Health Sciences, UKZN, Durban, South Africa, seminar, Differential, HLA-A, Expression, Levels, Effect, HIV, MRC Flaghip, UKZN, Dr Veron Ramsuran, Senior Lecturer, College of Health Sciences, UKZN, Durban, South Africa, seminar, Differential, HLA-A, Expression, Levels, Effect, HIV, MRC Flaghip, UKZN, Dr Veron Ramsuran, Senior Lecturer, College of Health Sciences, UKZN, Durban, South Africa, immunology, genomics, human genemics', 'The Genomics, Epidemiology & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Dr Veron Ramsuran, Senior Lecturer: College of Health Sciences, UKZN, entitled: Differential HLA-A Expression Levels and the Effect on HIV, 27 January 2017, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', '');
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(163, 'themercury.jpg', 'http://bioafrica.net/manuscripts/HIVAIDSDayMercury2016.pdf', 'Unrelenting spread of HIV amongst Adolescent girls and young women in rural and urban KwaZulu-Natal', 'Mercury', 139, '2016-12-01', '<p>By Professor Ayesha Kharsany, December 1, 2016, Durban - Globally, over 1.6 billion people are in the age group 12-24 years, the largest generation of adolescents and young people.  However, almost 42% of new HIV infections occur in this age group, nearly 80% of these live in sub-Saharan Africa and more than 70% of these infections occur in adolescent girls and young women.  Not only do these adolescent girls and young women have higher rates of HIV, they also acquire infection 5-7 years earlier than their male peers. </p>', NULL, 4, '<p><center><img src=\"imagesBIO/HIVMercuryPrinceHarryDurban.jpg\"></center></p><p><i> Britain\'s Prince Harry meets HIV youth activists at the 2016 International Aids Conference at the Durban International Conference Centre, in July. Studies suggest that age-disparate heterosexual relationships may play a role in the prevalence of HIV among teenage girls and young women.</i></p> \n<p>Worldwide there are some declining trends in HIV infections in the 15-24 year age group with simultaneous behaviour changes such as waiting longer to become sexually active, having fewer multiple sex partners and an increased use of condoms in multiple partnerships.   However, in South Africa the declines in the number of HIV positive young women are too slow and too little, with similarly low levels of behaviour change. For example the results from the National South African Household HIV Survey conducted in 2012 showed 11.4% of young women compared to 2.9% of boys in the 15-24 year age group were HIV positive, whilst in the 2008 survey, 13.9% of young women compared to 3.6% of young boys were HIV positive. These differences are minor.  </p>\n<p>Despite high levels of knowledge on HIV prevention and transmission, adolescent girls and young women are a key population who remain highly vulnerable to HIV.  A key gateway to HIV prevention and treatment is knowledge of HIV status and this remains low in South Africa.  This disconnect is related to the low risk perception,  perpetuates vulnerability to HIV within challenging environments of high levels of household poverty and unemployment that are complexly linked to embedded gender inequalities, gender based violence, harmful gender norms, patriarchy and premature attrition from schools that limit young women and girls from reaching their full potential.  </p>\n<p>The persistently high gender imbalance of HIV amongst young people has led to an increase in research to better understand the disparate burden and associated risks facing adolescent girls and young women.  Increasing attention has been paid to the role that age-disparate heterosexual relationships may play in this gender imbalance. Several studies across a variety of settings have shown that larger age differences among sex partners are associated with lower condom use and higher rates of sexually transmitted infections among adolescent girls and young women.   Recent data from the third National HIV Communication Survey conducted in 2012 suggest that women aged 16-24 years in age-disparate partnerships were more likely to report unprotected sex, amplifying transmission risk. In contrast another study from the same region, however, found that age-disparate partnerships did not predict HIV acquisition among young women in KwaZulu-Natal, South Africa.</p>\n<p>The study from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) provides new evidence and sheds light on why young women in South Africa are at high risk of HIV infection <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">(de Oliveira et al. Lancet HIV 2016)</a>. A large study undertaken between 2014 and 2015 involved nearly 10 000 randomly sampled people within two districts in the province KwaZulu-Natal between 2014 and 2015.  The overall HIV prevalence among 15-49 year olds in these districts was 36% and as high as 66% among women in their thirties. The difference in HIV prevalence among men and women was greatest in the young age groups, reinforcing that women in this community on average acquire HIV at a younger age than men.  The genetic sequences of the viruses from the HIV blood samples were analysed and this information was used to map the sexual partnerships among the people living with HIV to better understand the relentless spread of HIV in this community.  A total of 90 clusters of probable male?female transmission were identified, and within those clusters were 123 women and 103 men. Among the women aged under 25 years, their sexual partners were on average 8.7 years older, with 62% of these men aged 25-40 years. Among the women aged 25-40 years, their sexual partners were on average just 1 year older. Among the men aged 25-40 years linked to a woman aged under 25 years, 39% were linked simultaneously to a woman aged 25-40 years. The most probable direction of transmission among these individuals was inferred by the levels of HIV prevalence within this community.  HIV transmission was most likely to occur from high to low prevalence. Together, these data suggest that any men aged 25-40 years living with HIV may have acquired HIV from a woman aged 25-40 years, and that most of the younger women aged under 25 years living with HIV may have acquired HIV from a man aged 25-40 years. Over time, as the younger women grow older, this cycle is expected to continue.  Greater understanding of the sexual networks driving HIV transmission could help in the design of programmes to reduce HIV infection in adolescent girls and young women.</p>\n<p>This study revealed that the \'cycle of HIV transmission\' heightening the vulnerability of adolescent girls and young women\'s to HIV is driven by high rates of new HIV infections from men, on average 8 years older. Many of these men were also partners of similarly aged women who have HIV prevalence rates exceeding 60%.   </p>\n<p>Young women are uniquely vulnerable to infection, and understanding the cycle of HIV transmission for this key population is a public health imperative, despite South Africa\'s substantial progress in the large scale roll-out of HIV prevention and treatment programmes.  Several programmes such as DREAMS (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe Women) Partnership, Global Fund, Adolescent Girls and Young Women\'s Programme, Girl Effect and SheConquers are comprehensive evidence based programmes for adolescent girls and young women that aim to provide sexuality education, increase and retain girls in school, reduce teenage pregnancies and gender-based violence, increase economic opportunities for young people and most importantly interrupt the cycle of transmission and decrease new HIV infections. </p>\n<p>This study provides scientific evidence, using state-of-the-art research technologies, to guide targeted HIV prevention interventions to break the cycle of HIV transmission and impact the course for HIV in South Africa and potentially in other high burden settings.</p>', 'Mercury, news, durban, hiv, infection, young woman, ', NULL, ''),
(164, 'lancet.jpg', 'http://www.thelancet.com/', 'Two manuscripts featured in the Lancet website front webpage on AIDS day.', 'The Lancet', 139, '2016-12-01', '<p>Two of our recently published manuscripts (de Oliveira et al. Lancet HIV 2016 & Gregson et al Lancet Infectious Diseases 2016) are highlighed in the Lancet website front webpage...</p>', NULL, 4, '<br><p><center><img src=\"imagesBIO/frontpageLancet2PapersDec2016.jpg\"></center></p><br> \n<p><b><i>Publications:</b></i></p>\n<p> - <b>Lancet HIV</b> - <a href=\"http://www.bioafrica.net/publications.php?pubid=139\">Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. de Oliveira T, Kharsany ABM, Graf T, Cawood C, Khanyile D, Grobler A, Puren A, Madurai S, Baxter C, Karim QA, Karim SSA, Lancet HIV (2016), http://dx.doi.org/10.1016/S2352-3018(16)30186-2.</a></p><br>\n<p> - <b>Lancet Infectious Diseases</b> - <a href=\"http://www.bioafrica.net/publications.php?pubid=140\"> Occult HIV-1 drug resistance to thymidine analogues\nfollowing failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Gregson et al. Lancet Infectious Diseases (2016), http://dx.doi.org/10.1016/S1473-3099(16)30469-8.</p><br> \n', NULL, NULL, ''),
(165, 'lancet.jpg', 'http://www.bioafrica.net/manuscripts/CommentHIVdrugresistance_NRTI_SouthAfrica_LancetID2016.pdf', 'Time to get serious with HIV-1 resistance in sub-Saharan Africa', 'The Lancet Infectious Diseases', 140, '2016-12-02', '<p>In The Lancet Infectious Diseases, <a href=\"http://bioafrica.net/publications.php?pubid=140\">John Gregson and colleagues report the results of a meta-analysis investigating HIV-1 drug resistance</a> in 20 studies from sub-Saharan Africa.</p>', NULL, 4, '<p>Gregson and colleagues included patients with failure of first-line tenofovir disproxil fumarate (TDF)-containing antiretroviral treatment (ART) regimens that also included first generation (nevirapine and efavirenz) non-nucleoside reverse transcriptase inhibitors (NNRTI) and a cytosine analogue (lamivudine or emtricitabine) - the WHO-recommended first-line ART regimen.2 They found a substantial prevalence of thymidine-analogue mutations (TAMs) among patients who had treatment failure (115 [16%] of 712 patients), which was a somewhat unexpected fi nding, and TAMs were signifi cantly associated with the presence of resistance to TDF, NNRTIs, and cytosine analogues.</p>\n<p>TAMs are selected for by zidovudine and stavudine, drugs that were replaced by TDF in the WHO guidelines in June, 2013. However, more than 3.5 million people are estimated to be still using zidovudine, often switching to TDF without plasma HIV-1 RNA monitoring if their CD4 cell counts remain stable. Furthermore, stavudine can select for the Lys65Arg mutation in HIV-1 reverse transcriptase, which aff ects subsequent TDF activity.</p>\n<p>Gregson and colleagues\' study builds on an important previous report, the results of which showed an alarmingly high prevalence of drug resistance in people who had treatment failure on TDF-containing first-line regimens, with the highest proportion of resistance (up to 57%) identifi ed in sub-Saharan Africa.3 People who have treatment failure on first-line ART with either efavirenz or nevirapine in Africa typically have high prevalence of resistance against nucleoside reverse transcriptase inhibitors and NNRTIs, including more than 70% of patients with at least one mutation and 50% with dual-class resistance.4</p>\n<p>Previously undisclosed ART exposure and failure with NNRTIs could be the major driver of TAM selection and associated resistance in these apparently first-line cases of treatment failure. Patients with TAMs had signifi cantly lower CD4 cell counts at baseline than did patients without TAMs, the presence of TAMs was unrelated to HIV-1 subtype (most patients had subtype C), and the prevalence of NNRTI resistance was not signifi cantly increased in women who received single-dose nevirapine for the prevention of mother-tochild transmission of HIV.</p>\n<p>Transmitted HIV-1 resistance is not routinely screened for in sub-Saharan Africa, whereas screening is specifi cally recommended in well-resourced countries.5 In the absence of pretreatment resistance screening, the recommendation is to avoid use of NNRTIs. Nonetheless, NNRTIs are actually the preferred and so far only initial regimens available in most countries in the region.2</p>\n<p>Gregson and colleagues claim that doing resistance testing could mitigate the emergence and spread of such resistant viruses. Early detection of failure helps to limit the accumulation of resistance. Although implementation of point-of-care routine viral load measurements and resistance tests would obviously be welcome, they would only partly mitigate the emergence of these dual-class resistant strains that jeopardise the eff ectiveness of standard second-line ART. Implementation of these essential measures will need extra budgets and time, but time to prevent the spread of these resistant strains might be limited.</p>\n<p>Strategies to prevent HIV-1 resistance are a global priority. After the scale-up of ART in Africa, increasing numbers of patients have pretreatment drug resistance. However, networks monitoring this issue face challenges in the form of funding limitations, constraints on human resources, vulnerable health infrastructure, and drug stock-outs.6 Furthermore, individual-level resistance testing before ART initiation is generally considered not to be cost-eff ective, irrespective of the cost-eff ectiveness threshold used.7 Although optimum resource allocation to reduce HIV-1 incidence, mainly through treatment-as-prevention, is being fi ne-tuned, local prevalence of HIV-1 resistance could reverse all these benefi ts. Needless to say, concern over resistance should not stop the expansion of ART availability, but the prevalence of resistance is projected to increase substantially.8</p>\n<p>The lessons learned from tuberculosis cannot be allowed to fall into oblivion. In the African region, which has the highest burden of HIV-associated tuberculosis, the selection of resistant tuberculosis has achieved alarming rates. Some countries report multidrug-resistant tuberculosis in 5% of new cases and 25% among previously treated patients.9 The HIV-1 epidemic has the potential to resemble tuberculosis in this region. Transmission of HIV-1 resistance has been limited in the fi rst years of ART scale-up, but the prevalence of resistance is heterogeneous (1.1-12.3%), failure of fi rst-line ART ranges from 15-35% at 48 weeks,10 and development of resistance after failure is high.1,11 The odds ratio for HIV-1 resistance associated with each additional year since the start of ART roll-out in this region is 1.38 (95% CI 1.13-1.68).11 Resistance surveillance and prevention is therefore a priority.</p>\n<p>WHO still recommends efavirenz plus TDF plus lamivudine (or emtricitabine) as the preferred fi rst-line regimen. However, dolutegravir has been introduced for the fi rst time as part of alternative regimens.2 This new integrase inhibitor has superior effi cacy to efavirenz and low toxicity, making it a preferred option worldwide.5 Dolutegravir has a unique feature of particular interest in Africa: in triple-drug regimens it does not select for resistance at the failure of initial ART. So far, none of 1366 patients included in phase 2/3 studies for 48-144 weeks has developed resistance to either the integrase or the reverse transcriptase.12 This high barrier against the development of resistance in initial therapy could be live-saving in sub-Saharan Africa if properly used. Generic dolutegravir received tentative approval from the US Food and Drug Administration in September, 2016, allowing the product to be launched in the US President\'s Emergency Plan for AIDS Relief market. This is a one-of-a-kind agreement between innovator and generic companies whereby the generic version has been launched only about 3 years after the original product. While stakeholders are escalating the implementation of human and infrastructure networks in sub-Saharan Africa, a straightforward and cost-eff ective measure to limit new HIV-1 resistance would be to scale up the substitution of efavirenz for generic dolutegravir in initial ART.</p>\n\n\n<p><center><a href=\"http://www.bioafrica.net/manuscripts/CommentHIVdrugresistance_NRTI_SouthAfrica_LancetID2016.pdf\"><img src=\"imagesBIO/lancetIDDrugResistance2016.jpg\"></center></p><br>\n\n', 'comment, lancet id, hiv drug resistance paper, bioafrica, de oliveira, sub-saharan africa, Lancet, HIV-1, tenofovir, paper, commentary, bioafrica,comment, lancet id, hiv drug resistance paper, bioafrica, de oliveira, sub-saharan africa, Lancet, HIV-1, tenofovir, paper, commentary, bioafrica,comment, lancet id, hiv drug resistance paper, bioafrica, de oliveira, sub-saharan africa, Lancet, HIV-1, tenofovir, paper, commentary, bioafrica,comment, lancet id, hiv drug resistance paper, bioafrica, de oliveira, sub-saharan africa, Lancet, HIV-1, tenofovir, paper, commentary, bioafrica,comment, lancet id, hiv drug resistance paper, bioafrica, de oliveira, sub-saharan africa, Lancet, HIV-1, tenofovir, paper, commentary, bioafrica', NULL, ''),
(166, 'imgnews105.png', 'http://www.bioafrica.net/manuscripts/ethics_viral_genomicsPhylogeneticsWorkshop2016.pdf', 'Ethics and Viral Genomics: An Exploration of Ethical Issues Associated with HIV Phylogenetics', 'Nelson Mandela School of Medicine, UKZN', NULL, '2016-12-09', '<p>This is a half-day interactive workshop, which seeks to explore and deliberate on key ethical issues associated with HIV phylogenetic analysis as applied in our understanding of HIV transmission dynamics, particularly in African settings. Keynote presentations will be followed by plenary discussions led by the speakers.</p>', NULL, 4, '<br><p><center><a href=\"manuscripts/ethics_viral_genomicsPhylogeneticsWorkshop2016.pdf\"><img src=\"imagesBIO/ethics_viral_genomicsPhylogeneticsWorkshop2016.png\"></center></a></p><br> \n', NULL, NULL, ''),
(167, 'imgnews167.png', 'http://bioafrica.net/manuscripts/SATuRNnewsletter_4_2016.pdf', 'Newsletter, Dec 2016: Ethics & phylogenetics, HIV transmission cycle, UNAIDS Report, Drug resistance increases in Africa', 'BioAfrica & SATuRN', 139, '2016-12-15', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about our research work. In this December 2016 issue of our newsletter, we have included interesting news, blogs, reports, tweets, publications and training information produced by our group. <p>', NULL, 4, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_4_2016.pdf\"><img src=\"imagesBIO/SATuRNnewsletter_4_2016.png\"></a></center> </p>\n\n<br><p><b><i>In this issue our highlights are:</b></i></p>\n\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=139\">Publication - Lancet HIV: Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=160\">UNAIDS Report 2016 - Get on the Fast-Track: Cover our phylogenetic results and the life-cycle approach to HIV</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=138\">Publication - Nature Reviews Genetics: Microbial genome-wide association studies: lessons from human GWAS</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=140\">Publication ? Lancet Infectious Diseases: Occult HIV-1 drug resistance following failure of 1stline Tenofovir in sub Saharan Africa: a retrospective multi-centre cohort study.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=165\">Commentary - Lancet Infectious Diseases: Time to get serious with HIV-1 resistance in sub-Saharan Africa</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=166\">Workshop: Ethics and Viral Genomics: An Exploration of Ethical Issues Associated with HIV Phylogenetics, Durban, 9 December 2016</a></p>\n\n \n<br><p><b><i>The newsletter is open accessible at:</b></i></p>\n\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_4_2016.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_4_2016.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>\n<p> Produced by <a href=\"http://www.bioafrica.net/people.php?peopleid=1\">Prof. Tulio de Oliveira</a> (Nelson R Mandela School of Medicine, UKZN & CAPRISA, South Africa)</p>', 'newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa, newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa, newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa, newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa', 'The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN and our Bioafrica research group. The newsletter is presented as a PDF document with links to complete articles at bioafrica.net.  In our forth issue of 2064, we would like to bring attention to our HIV-1 phylogenetics paper at Lancet HIV, our GWAS manuscript at Nature Reviews Genetics and drug resistance publication in Lancet Infectious Diseases. We also present an ethics workshop on HIV-1 phylogenetics.', 'Y'),
(169, 'imgnews169.png', 'http://bioafrica.net/workshops/SATuRNCAPRISAHIVTBClinicalCareWorkshop2017.html', 'KRISP/SATuRN & CAPRISA 2017: HIV & TB Drug Resistance and Advanced Care Workshop', 'KRISP & CAPRISA', NULL, '2017-03-30', '<p>The workshop is targeted at clinicians, clinical virologists and nurses working in the public sector who are currently involved in the treatment of patients with HIV and TB in KwaZulu-Natal, South Africa.</p>', NULL, 4, '<p><center>Click on the image below to access the website of the workshop.</p><p><a href=\"http://bioafrica.net/workshops/SATuRNCAPRISAHIVTBClinicalCareWorkshop2017.html\"><img src=\"imagesBIO/news169link.jpg\"></a></center></p><br>\n<p>Organizers: Kogie Naidoo, Nesri Padayachi, Moherndran Archary & Tulio de Oliveira.</p>\n\n<p>Sponsors: CDC/PEPFAR Advanced Clinical Care Program at CAPRISA.</p>\n\n<p>The workshop is organized by: CAPRISA, KRISP - KwaZulu-Natal Research Innovation and Sequencing Platform and the Southern African Treatment Resistance Network (SATuRN) and University of KwaZulu-Natal (UKZN).</p>\n', 'CAPRISA, SATuRN, workshop, HIV, TB, drug resistance, clinical management, 2017, south Africa, Drakensberg, Tulio de Oliveira, KZN, KwaZulu-Natal, clinical, advanced care, training, CAPRISA, SATuRN, workshop, HIV, TB, drug resistance, clinical management, 2017, south Africa, Drakensberg, Tulio de Oliveira, KZN, KwaZulu-Natal, clinical, advanced care, training, CAPRISA, SATuRN, workshop, HIV, TB, drug resistance, clinical management, 2017, south Africa, Drakensberg, Tulio de Oliveira, KZN, KwaZulu-Natal, clinical, advanced care, training, CAPRISA, SATuRN, workshop, HIV, TB, drug resistance, clinical management, 2017, south Africa, Drakensberg, Tulio de Oliveira, KZN, KwaZulu-Natal, clinical, advanced care, training', 'The workshop program will follow and expand on the successful format of previous SATuRN and CAPRISA workshops and will include presentations of anti-retroviral (ARV) and anti-TB treatment programs and clinical case management of HIV and TB patients. Emphasis will be put on how to manage HIV & drug resistance as well as advert effects of treatment', 'Y'),
(170, 'imgnews119.png', 'http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipMarch2017poster.pdf', 'Seminar: Microbial genome-wide association studies: lessons from human GWAS\r', 'KRISP Talks', NULL, '2017-03-17', '<p>KRISP Talks by <b> Prof. Tulio de Oliveira</b>, College of Health Sciences, UKZN & CAPRISA Research Associate, 17 March 2017, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa</p>\n', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipMarch2017poster.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipMarch2017poster.png\"></a></center></p>\n<p><b>Professor Tulio de Oliveira\r</b>, College of Health Sciences, UKZN & CAPRISA Research Associate</p>\n<p>Date: 17 March 2017</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'seminar, microbial, gwas, human, de oliveira, durban, south africa, Nelson R Mandela School of Medicine, Genomics, Bioinformatics, seminar, microbial, gwas, human, de oliveira, durban, south africa, Nelson R Mandela School of Medicine, Genomics, Bioinformatics, seminar, microbial, gwas, human, de oliveira, durban, south africa, Nelson R Mandela School of Medicine, Genomics, Bioinformatics, seminar, microbial, gwas, human, de oliveira, durban, south africa, Nelson R Mandela School of Medicine, Genomics, Bioinformatics', 'The Genomics, Epidemiology & Bioinformatics Programme & UKZN MRC Flagship project cordially invites you to a seminar presented by Prof. Tulio de Oliveira, College of Health Sciences, UKZN, entitled: Microbial genome-wide association studies: lessons from human GWAS, 17 March 2017, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa', ''),
(171, 'imgnews171.png', 'http://www.bioafrica.net/manuscripts/SwissSASymposiumpathogengenomics.pdf', 'Swiss South African Symposium on Pathogen Genomics', 'Swiss National Science Foundation & SA NRF', NULL, '2017-02-23', '<p>The National Research Foundation and Swiss National Science Foundation through their Swiss-South Africa\rprogramme, have funded a project entitled: A context-based knowledge resource integrating HIV and Mtb\rmolecular biology with host-pathogen and drug-resistance data. As part of the project, the University of Cape Town Computational Biology Division and our research group at UKZN are hosting a symposium on pathogen genomics.</p>', NULL, 4, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SwissSASymposiumpathogengenomics.pdf\"><img src=\"imagesBIO/SwissSASymposiumpathogengenomics.png\"></a></center></p>\n<p>The aim of the symposium is to provide the opportunity for\rshort talks from the Swiss Institute of Bioinformatics trainers and local researchers to showcase their work in\rthe genomics (and other \'omics\') of pathogens, with a particular focus on Mycobacterium tuberculosis.</p>\r<p>Date: 23 February 2017</p>\n<p>Time: 9:00-17:00</p>\n<p>Venue: Lecture Theatre 1 Kramer building, UCT Middle Campus, Cape Town, South Africa</p>\n<p>Organizers and Chairs: Ioannis Xenarious, Swiss Institute of Bioinformatics (SIB), Tulio de Oliveira (UKZN) and Nicola Mulder (UCT)</p>\n, ', 'symposyum, swiss, south africa, genomics, omics, pathogen, UCT, cape Town, Nicola Mulder, Tulio de Oliveira, SIB, UKZN, 2017, tuberculosis, MTB, symposyum, swiss, south africa, genomics, omics, pathogen, UCT, cape Town, Nicola Mulder, Tulio de Oliveira, SIB, UKZN, 2017, tuberculosis, MTB, symposyum, swiss, south africa, genomics, omics, pathogen, UCT, cape Town, Nicola Mulder, Tulio de Oliveira, SIB, UKZN, 2017, tuberculosis, MTB, symposyum, swiss, south africa, genomics, omics, pathogen, UCT, cape Town, Nicola Mulder, Tulio de Oliveira, SIB, UKZN, 2017, tuberculosis, MTB', 'The National Research Foundation and Swiss National Science Foundation through their Swiss-South Africa\rprogramme, have funded a project entitled: A context-based knowledge resource integrating HIV and Mtb\rmolecular biology with host-pathogen and drug-resistance data. The collaborative project includes joint\rworkshops and meetings. As part of the project, the University of Cape Town Computational Biology Division\ris hosting a symposium on pathogen genomics. The aim of the symposium is to provide the opportunity for\rshort talks from the Swiss Institute of Bioinformatics trainers and local researchers to showcase their work in\rthe genomics (and other omics) of pathogens, with a particular focus on Mycobacterium tuberculosis.', ''),
(172, 'santhelogo.png', 'http://www.santheafrica.org/news/santhe-awards-337-579-collaborative-grants', 'We have been awarded a collaborative grant from SANTHE/Wellcome Trust programme in Africa', 'SANTHE', NULL, '2017-02-28', '<p>The Wellcome Trust DELTAS funded SANTHE program awarded seven  grants to develop collaborative research projects to address critical challenges to African capacity in HIV and/or TB clinical, social/behavioural, and biomedical science. </p>', NULL, 4, '<br><p><center><img src=\"imagesBIO/santheinfo.png\"></center></p><br> \n<p><b><i>Grant title: Full Length Sequencing and Biological Characterisation of Early Divergent HIV-1 Lineages from Cameroon</b></i></p>\n<p><b><i>Principal Investigator:</b></i> Dr Marcel Tongo, University of KwaZulu-Natal (UKZN)</p>    \n<p><b><i>Collaborating Principal Investigators:</b></i> Prof. Tulio De Oliveira, University of KwaZulu-Natal (UKZN), Professor Thumbi Ndung\'u, HIV Pathogenesis Programme (HPP), Dr Jaclyn Mann, HIV Pathogenesis Programme (HPP)</p>\n', NULL, NULL, ''),
(173, 'curacaosm.png', 'http://www.healio.com/infectious-disease/hiv-aids/news/in-the-journals/%7B17e947c4-87d8-488d-a874-b58d9a0bfb27%7D/prevalence-of-drug-resistant-hiv-reaches-alarming-levels-in-aruba', 'Prevalence of drug-resistant HIV reaches \'alarming levels\' in Aruba', 'Healio News', 161, '2017-03-17', '<p>The prevalence of resistance to nonnucleoside reverse transcriptase inhibitors among HIV-infected individuals has increased to \'alarming levels\' in Aruba, reaching 45% in 2015, see our recent <a herf=\"http://bioafrica.net/publications.php?pubid=161\">publication at CID</a>.</p>', NULL, 4, '<p><center><a href=\"http://bioafrica.net/publications.php?pubid=161\"><img src=\"imagesBIO/curacao.png\"><br><i>Click on the image to access our publication at Clinical Infectious Diseases, 2017.\'</a></i></center></p>\n\n<p>L. Marije Hofstra, MD, of the department of medical microbiology at the University Medical Center Utrecht, the Netherlands, and colleagues discovered that the increase in resistance is due to a rise in the nonnucleoside reverse transcriptase inhibitor (NNRTI) mutation K103N. The mutation has a detrimental effect against Sustiva (efavirenz, Bristol-Myers Squibb) and nevirapine, which are commonly used in first-line combination ART (cART) regimens in highly endemic countries.</p>\n\n<p><p><b><i>\'Emergence of HIV drug resistance during cART use has tremendously decreased in Western countries, and transmission of drug resistance has merely stabilized in recent years, as a result of close laboratory monitoring, the use of regimens with a higher genetic barrier to resistance, and surveillance,\'</b></i> Hofstra, who also is from the department of infection and immunity at Luxembourg Institute of Health, and colleagues wrote in Clinical Infectious Diseases. <b><i>\'However, our data demonstrate that in a setting without adequate surveillance, the prevalence of infections with NNRTI resistant HIV can increase to worrisome levels, compromising the efficacy of the standard first-line NNRTI-based regimen.\'</b></i></p>\n<p>The researchers examined data on 104 treatment-naive participants who underwent HIV drug-resistance testing from 2010 to 2015 in Aruba. Among them, 86% were men, 39% were foreign-born and 22% had AIDS at diagnosis.</p>\n<p>Results showed that 33% (95% CI, 24-42) of participants were infected with a drug-resistant strain of HIV. While resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) was rare, (2%; 95% CI, 0-5), the prevalence of NNRTI resistance was 32% (95% CI, 23-41), increasing to 45% (95% CI, 27-64) in 2015. According to the researchers, all NNRTI resistance was due to the K103N mutation. An additional analysis of 28 participants who experienced treatment failure showed that 54% of participants had virus with a K103N mutation.</p>\n<p>All patients who received HIV drug resistance testing at baseline were infected with an HIV-1 subtype B virus, the researchers said. Those infected with a K103N strain were more often men who have sex with men and were more likely to experience virologic failure with NNRTI-based regimens.</p>\n<p>Hofstra and colleagues performed a phylogenetic analysis of 688 sequences to determine the source of K103N transmission. They found that K103N-harboring strains were introduced into treatment-naive populations through at least six independent transmissions involving the surrounding countries, including Venezuela, the Dominican Republic and Curacao.</p>\n<p>The researchers reported that previous research has shown that resistant variants may revert to wild-type after transmission to attain viral fitness, limiting further potential spread of the resistant variant. In this cohort, however, K103N persisted at high frequencies despite the long duration of infection in some participants. A next generation sequencing analysis did not show evidence of reverted minority K103N variants compared with population sequencing.</p>\n<p><b><i>\'The long-term persistence of variants with K103N after transmission underlines their threatening potential to spread widely among therapy-naive individuals,\'</b></i> Hofstra and colleagues wrote. </p>\n<p>Following these results, the researchers notified local and regional public health authorities, and local guidelines reinforced baseline resistance testing and replaced the WHO-recommended first-line ART regimen with an integrase inhibitor-based regimen.</p>\n<p><b><i>\'Our data indicate that it is crucial to combine the scale up of cART in low- and middle-income countries with adequate surveillance for resistance as recommended by the WHO, to guard the efficacy of our current public health approach and to prevent jeopardizing the potential benefit of treatment as prevention,\'</b></i> Hofstra and colleagues concluded. <b><i>\'If strengthened surveillance would show that these NNRTI-resistant viruses are more widespread in the region, a change of the current first-line NNRTI-based regimen to a regimen with a higher genetic barrier to resistance should be strongly considered, despite its major implications for resources and logistics.\'</b></i> by Stephanie Viguers</p>\n', 'aruba, high-level, drug resistance, phylogenetic analysis, tulio de oliveira, clinical infectious diseases, paper, online, news, HIV, HIV-1, antiretroviral, NNRTI, WHO, Caribeean, aruba, high-level, drug resistance, phylogenetic analysis, tulio de oliveira, clinical infectious diseases, paper, online, news, HIV, HIV-1, antiretroviral, NNRTI, WHO, Caribeean, aruba, high-level, drug resistance, phylogenetic analysis, tulio de oliveira, clinical infectious diseases, paper, online, news, HIV, HIV-1, antiretroviral, NNRTI, WHO, Caribeean, aruba, high-level, drug resistance, phylogenetic analysis, tulio de oliveira, clinical infectious diseases, paper, online, news, HIV, HIV-1, antiretroviral, NNRTI, WHO, Caribeean, aruba, high-level, drug resistance, phylogenetic analysis, tulio de oliveira, clinical infectious diseases, paper, online, news, HIV, HIV-1, antiretroviral, NNRTI, WHO, Caribeean', 'The prevalence of resistance to nonnucleoside reverse transcriptase inhibitors among HIV?infected individuals has increased to alarming levels in Aruba, reaching 45% in 2015, researchers reported. L. Marije Hofstra, MD, of the department of medical microbiology at the University Medical Center Utrecht, the Netherlands, Prof. Tulio de Oliveira, UKZN, South Africa and colleagues discovered that the increase in resistance is due to a rise in the nonnucleoside reverse transcriptase inhibitor (NNRTI) mutation K103N. The mutation has a detrimental effect against Sustiva (efavirenz, Bristol-Myers Squibb) and nevirapine, which are commonly used in first-line combination ART (cART) regimens in highly endemic countries', ''),
(174, 'arubasm.png', 'http://www.healio.com/infectious-disease/hiv-aids/news/in-the-journals/%7B17e947c4-87d8-488d-a874-b58d9a0bfb27%7D/prevalence-of-drug-resistant-hiv-reaches-alarming-levels-in-aruba', 'Perspective: Extreme high-level of drug resistance in Aruba: We need ITI-based regimens available globally now!', 'Healio News: IAS Perspective', 161, '2017-03-17', '<p>Perspective by Carlos del Rio, MD Professor of medicine, division of infectious diseases, Emory University School of Medicine on our recent CID manuscript on high-level transmitted resistance epidemic in Aruba.</p>', NULL, 4, '<p><center><a href=\"http://bioafrica.net/publications.php?pubid=161\"><img src=\"imagesBIO/aruba.png\"><br><i>Click on the image to access our CID publication</a></i></center></p>\n<p>The major issue related to drug resistance in most of the world is that the most commonly used regimen contains efavirenz, and in many places (especially in Los Angeles), it is not available as a fixed dose combination, so people may not take their efavirenz. The findings in this study in Aruba show a large increase in the prevalence of K103N mutations from 2010 to 2015.  But even the prevalence at 26% in 2010 is alarmingly high, so my question is, what did they do then? How did they act based on these data? The study sample is small and I suspect that all new diagnoses did not get baseline resistance testing (which is the case in most of the world). A major implication is that if we lose EFV, we are in trouble starting an EFV?containing regimen in most of the world where genotypic testing is not routinely available. Bottom line: we need ITI-based regimens available globally now.</p>\n<p>Carlos del Rio, MD</p>\n<p>Professor of medicine, division of infectious diseases, Emory University School of Medicine</p>\n<p>Immediate past chair, HIV Medicine Association</p>\n<p>Disclosure: del Rio reports being a member of the board of the HIV Medicine Association and International Antiviral Society-USA, and chair of the PEPFAR Scientific Advisory Board.  </p>', 'drug resistance, EFV, genotypic, testing, not, routinely, available, need, integrase,  ITI-based, regimens, available, globally, now, CID, de Oliveira, Drug resistance, Aruba, extreme, high-level, ARV, antiretroviral, HIV, epidemic, phylogenetics, drug resistance, EFV, genotypic, testing, not, routinely, available, need, integrase,  ITI-based, regimens, available, globally, now, CID, de Oliveira, Drug resistance, Aruba, extreme, high-level, ARV, antiretroviral, HIV, epidemic, phylogenetics, drug resistance, EFV, genotypic, testing, not, routinely, available, need, integrase,  ITI-based, regimens, available, globally, now, CID, de Oliveira, Drug resistance, Aruba, extreme, high-level, ARV, antiretroviral, HIV, epidemic, phylogenetics', 'The major issue related to drug resistance in most of the world is that the most commonly used regimen contains efavirenz, and in many places (especially in Los Angeles), it is not available as a fixed dose combination, so people may not take their efavirenz. The findings in this study in Aruba show a large increase in the prevalence of K103N mutations from 2010 to 2015.  But even the prevalence at 26% in 2010 is alarmingly high, so my question is, what did they do then? How did they act based on these data? The study sample is small and I suspect that all new diagnoses did not get baseline resistance testing (which is the case in most of the world). ', ''),
(175, 'cd4sm.png', 'https://www.eurekalert.org/pub_releases/2017-03/bsp-ctc031717.php', 'CD4+ T-cell count useful to assess antiretroviral therapy response in HTLV-1/HIV patients?', 'EurekaAlert!', 158, '2017-03-17', '<p>News coverage and clinical management implication of our recent <a href=\"http://bioafrica.net/publications.php?pubid=158\">HIV/HTLV co-infection manuscript, Current HIV Research, 2017</a></a>', NULL, 4, '<p><center><a href=\"http://bioafrica.net/publications.php?pubid=158\"><img src=\"imagesBIO/cd4.png\"><br><i>Click on the CD4 image to access our publication</a></i></center></p>\n<p>The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. Any differences in the CD4+ T-cell counts were expected to disappear once the co-infected and mono-infected patients began to fail their antiretroviral therapy (ART) regimens.</p>\n\n<p>Instead, the authors found that HTLV-1/HIVco-infected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/uL higher than their HIV mono-infected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients.</p>\n\n<p>HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient\'s response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences.</p>\n\n<p>Against this background, recent scientific research has begun to show that HIV viral load testing can be both an accurate and cost-effective treatment monitoring strategy. The present study was based in the KwaZulu-Natal province of South Africa and used patient data from a poor and rural community at the epicentre of the global HIV epidemic. </p>\n<p>This article by <a href=\"http://bioafrica.net/publications.php?pubid=158\">Dr. Alain Vandormael et al has been published in Current HIV Research, Volume 15, 2017</a></p>', 'HTLV-1/HIV, hiv, htlv, co-infected, patients, continued, elevated, CD4+, T-cell, counts, Fiocruz, UKZN, Vandormel, de oliveira, KwaZulu-Natal, South Africa, epidemic, levels, clinical management, high, HTLV-1/HIV, hiv, htlv, co-infected, patients, continued, elevated, CD4+, T-cell, counts, Fiocruz, UKZN, Vandormel, de oliveira, KwaZulu-Natal, South Africa, epidemic, levels, clinical management, high, HTLV-1/HIV, hiv, htlv, co-infected, patients, continued, elevated, CD4+, T-cell, counts, Fiocruz, UKZN, Vandormel, de oliveira, KwaZulu-Natal, South Africa, epidemic, levels, clinical management, high, HTLV-1/HIV, hiv, htlv, co-infected, patients, continued, elevated, CD4+, T-cell, counts, Fiocruz, UKZN, Vandormel, de oliveira, KwaZulu-Natal, South Africa, epidemic, levels, clinical management, high', 'The authors compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either mono-infected with HIV or co-infected with HTLV-1/HIV. They confirmed that co-infected patients were more likely to have higher CD4+ T-cell counts prior to treatment initiation with no immunologic benefit--a result that has been well documented in scholarly literature. HIV viral load testing is currently recommended by the World Health Organization (WHO) as an accurate strategy for monitoring a patient\'s response to ART. Nevertheless, CD4+ T-cell testing is often used in resource-limited settings because it is perceived to be more affordable. The continued use of CD4+ T-cell testing has implications for the clinical management of HIV-positive patients. Results from the present study suggest that HTLV-1/HIV co-infection could delay the identification of patients who are failing ART with adverse consequences', ''),
(176, 'idse.png', 'http://www.idse.net/HIV-AIDS--STIs/Article/03-17/CD4-Count-Not-Useful-to-Assess-ART-Response-in-HTLV-1-HIV-Coinfection/40733', 'CD4+ Count Not Useful to Assess ART Response in HTLV-1/HIV Coinfection', 'IDSE Infectious Diseases', 158, '2017-03-21', '<p>Patients coinfected with human T-cell lymphotropic virus 1 (HTLV-1) and HIV continue to have elevated CD4+ T-cell counts, even though there is no difference in their HIV viral load levels after antiretroviral therapy when compared with patients who just have HIV <a href=\"http://www.bioafrica.net/publications.php?pubid=158\">(Curr HIV Res 2017)</a>.</p>', NULL, 4, '<p><b><i>Our results indicate that CD4+ T-cell count testing may not be a useful strategy to monitor ART response in the presence of HTLV-1 infection,</b></i> the researchers said.</p> <p>Alain Vandormael, PhD, of the Wellcome Trust Africa Centre for Population Health and University of KwaZulu-Natal, South Africa, and his colleagues compared the CD4+ T-cell counts and HIV-1 RNA viral loads of 383 patients who were either monoinfected with HIV or coinfected with HTLV-1/HIV. They looked at patient data from a poor and rural community in the KwaZulu-Natal province of South Africa, at the epicenter of the global HIV epidemic.</p> <p>Coinfected patients were more likely to have higher CD4+ T-cell counts before the initiation of ART with no immunologic benefit. However, the researchers expected any differences in the CD4+ T-cell counts to disappear once the coinfected and monoinfected patients began to fail their ART regimens.</p> <p>Instead, the researchers found that HTLV-1/HIV-coinfected patients continued to have elevated CD4+ T-cell counts, on average 115 cells/mcL higher than their HIV-monoinfected counterparts, over the two-year study period. But when the authors compared the HIV viral loads over the same period, they could not find any statistically significant difference between the two groups of patients.</p> <p>The World Health Organization recommends HIV viral load testing as an accurate strategy for monitoring a patient\\\'s respo', 'patients, coinfected, human T-cell lymphotropic virus 1, HTLV-1, HIV, continue, elevated, CD4+, T-cell counts, even though, no difference, HIV, viral load, after, antiretroviral, therapy, ARV, Vandormel, de Oliveira, UKZN, FioCruz, KZN, South Africa,patients, coinfected, human T-cell lymphotropic virus 1, HTLV-1, HIV, continue, elevated, CD4+, T-cell counts, even though, no difference, HIV, viral load, after, antiretroviral, therapy, ARV, Vandormel, de Oliveira, UKZN, FioCruz, KZN, South Africa,patients, coinfected, human T-cell lymphotropic virus 1, HTLV-1, HIV, continue, elevated, CD4+, T-cell counts, even though, no difference, HIV, viral load, after, antiretroviral, therapy, ARV, Vandormel, de Oliveira, UKZN, FioCruz, KZN, South Africa,patients, coinfected, human T-cell lymphotropic virus 1, HTLV-1, HIV, continue, elevated, CD4+, T-cell counts, even though, no difference, HIV, viral load, after, antiretroviral, therapy, ARV, Vandormel, de Oliveira, UKZN, FioCruz, KZN, South Africa', 'atients coinfected with human T-cell lymphotropic virus 1 (HTLV-1) and HIV continue to have elevated CD4+ T-cell counts, even though there is no difference in their HIV viral load levels after antiretroviral therapy when compared with patients who just have HIV', '');
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(177, 'news177.png', 'http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2017.pdf', 'Newsletter, Jan-Mar 2017: \'Alarming\' drug resistance levels, novel next generation sequencing method and the origin of HIV, SATuRN & CAPRISA workshop', 'KRISP Newsletter', NULL, '2017-03-31', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about our research work. In this Jan-Mar 2017 issue of our newsletter, we have included interesting open access publications, news, blogs, reports, tweets,  and training information produced by our group. <p>', NULL, 4, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SATuRNnewsletter_1_2017.pdf\"><img src=\"imagesBIO/SATuRNnewsletter_1_2017.jpg\"></a></center> </p>\n\n<br><p><b><i>In this issue our highlights are:</b></i></p>\n\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=161\">News & Publication - Prevalence of drug resistant HIV at \'alarming levels\' in Aruba.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=174\">Commentary: Extreme High-level of Drug Resistance in Aruba: We need Integrase-Based Regimens Available Globally NoW!</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=158\">News & Publication - CD4+ Count Not Useful to Assess ART Response in HTLV-1/HIV Coinfection.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=144\">Publication - Sensitive next generation sequencing method reveals deep genetic diversity of HIV-1 in the Democratic Republic of the Congo</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=156\">Publication Sequence & Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=159\">Publication: Virological Outcomes of 2nd line Protease Inhibitor-Based Treatment HIV-1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=146\">Publication: Primary HIV-1 Drug Resistant Minority Variants</a></p>\n\n<p> - <a href=\"http://bioafrica.net/publications.php?pubid=157\">Publication: Social disequilibrium and the risk of HIV acquisition: A multilevel study in rural KwaZulu-Natal Province, South Africa.</a></p>\n\n<p> - <a href=\"http://bioafrica.net/news.php?id=166\">Workshop: SATuRN & CAPRISA 2017: HIV & TB Drug Resistance and Advanced Care Workshop</a></p>\n\n<br><p><b><i>The newsletter is open accessible at:</b></i></p>\n\n<p>(<a href=\"http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2017.pdf\">http://bioafrica.net/manuscripts/SATuRNnewsletter_1_2017.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>\n<p> Produced by <a href=\"http://www.bioafrica.net/people.php?surname=de Oliveira\">Prof. Tulio de Oliveira</a> (Nelson R Mandela School of Medicine, UKZN & CAPRISA, South Africa)</p>', 'newsletter, 2017, congo, HIV, origin, next generation sequencing, aruba, alarming levels, drug reisistance, newsletter, 2017, congo, HIV, origin, next generation sequencing, aruba, alarming levels, drug reisistance, newsletter, 2017, congo, HIV, origin, next generation sequencing, aruba, alarming levels, drug reisistance, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa, newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa, newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa, newsletter, saturn, southern africa, drug resistance, network, de oliveira, bioafrica, hiv-1, aids, phylogenetics, news, nelson R Mandela School of Medicine, Tulio de Oliveira, South Africa', 'The concept behind this newsletter is that anyone with 15 minutes to spare can learn about the work of SATuRN and our Bioafrica research group. The newsletter is presented as a PDF document with links to complete articles at bioafrica.net.  In our first issue of 2017, we would like to bring attention to our next generation sequencing and HIV-1 phylogenetics paper at journal of virology, our alarming drug resistance transmission level paper in Aruba published the clinical infectious diseases, our paper that show that CD4+ is not a good clinical marker. We also present an HIV & TB drug resistance and clinical management workshop with CAPRISA.', 'Y'),
(178, 'imgnews86.png', 'http://www.krisp.org.za/manuscripts/SeminarMRCFlagshipJune2017poster.pdf', 'Seminar: Can the type of jeans you wear determine your treatment response?\n\n', 'KRISP Talks', NULL, '2017-06-23', '<p>KRISP Talks by <b>Professor Bonga Chiliza</b>, Discipline of Psychiatry: College of Health Sciences, UKZN, 23 June 2017, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa. All welcome!</p>', NULL, 5, '<p><center><a href=\"http://www.bioafrica.net/manuscripts/SeminarMRCFlagshipJune2017poster.pdf\"><img src=\"imagesBIO/SeminarMRCFlagshipJune2017poster.png\"></a></center></p>\n<p><b>Professor Bonga Chiliza\n</b>, Discipline of Psychiatry: College of Health Sciences, UKZN</p>\n<p>Date: Friday, 23 June 2017</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'seminar, durban, June, 2017, MRC Flagship, UKZN, Professor Bonga Chiliza, Discipline of Psychiatry: College of Health Sciences, psychiatry, genetics, South Africa, bioafrica, krist, K-RITH, Nelson R Mandela School of Medicine, seminar, durban, June, 2017, MRC Flagship, UKZN, Professor Bonga Chiliza, Discipline of Psychiatry: College of Health Sciences, psychiatry, genetics, South Africa, bioafrica, krist, K-RITH, Nelson R Mandela School of Medicine, seminar, durban, June, 2017, MRC Flagship, UKZN, Professor Bonga Chiliza, Discipline of Psychiatry: College of Health Sciences, psychiatry, genetics, South Africa, bioafrica, krist, K-RITH, Nelson R Mandela School of Medicine, seminar, durban, June, 2017, MRC Flagship, UKZN, Professor Bonga Chiliza, Discipline of Psychiatry: College of Health Sciences, psychiatry, genetics, South Africa, bioafrica, krist, K-RITH, Nelson R Mandela School of Medicine', 'We cordially invites you to a seminar presented by Professor Bonga Chiliza, Discipline of Psychiatry: College of Health Sciences, UKZN, 23 June 2017, K-RITH building, Nelson R Mandela School of Medicine, Durban, South Africa. The seminar is sponsored by the South African Medical Research Council (MRC) programme.', ''),
(179, 'imgnews96.png', 'http://www.krisp.org.za/manuscripts/UKZN_KRISP_TIA_NdabaOnline.pdf', 'KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP) Established', 'KRISP News', NULL, '2017-07-12', '<p>The Technology Innovation Agency (TIA) and UKZN have signed an agreement for the establishment of KRISP - the KwaZulu-Natal Research and Innovation Sequencing Platform.</p>', NULL, 4, '<p><center><img src=\"imagesBIO/KRISP_deOliveiraJuly2017.jpg\" alt=\"Professor Tulio de Oliveira and right is the view from Vital-IT and the Swiss Institute of Bioinformatics campus in Lausanne, Switzerland, which KRISP team recently to visited to set-up collaborations and learn more about their successful business plan\"><i>Professor Tulio de Oliveira and right is the view from Vital-IT and the Swiss Institute of Bioinformatics campus in Lausanne, Switzerland, which KRISP team recently to visited to set-up collaborations and learn more about their successful business plan.</i></center></p>\n\n<p>This signed agreement with TIA takes the omics/informatics facility to new levels.</p>\n\n<p>KRISP, the result of hard work by, among others, Professor Tulio de Oliveira, Professor Deresh Ramjugernath and Professor Salim Abdool Karim, was previously known as the Genomics and Bioinformatics Centre.</p>\n\n<p>Deputy Vice-Chancellor and Head of the College of Health Sciences, Professor Rob Slotow, said KRISP is one of many exciting research projects driven by de Oliviera.</p>\n\n<p>De Oliveira is a full Professor at the Nelson R. Mandela School of Medicine at UKZN and a Research Associate at the Centre for the AIDS Programme of Research in South Africa (CAPRISA). Recognised as an expert on HIV genetic data and bioinformatics software development, he received his PhD at the Nelson R. Mandela School of Medicine in 2003, was a Marie Curie Fellow at the University of Oxford in the United Kingdom in 2006, and has recently been awarded a Royal Society Newton Advanced Fellowship.</p>\n\n<p>In total, he has published more than 100 manuscripts, and developed dozens of bioinformatics software applications and databases. De Oliveira leads a group of 18 researchers and/or postgraduate students.</p>\n\n<p>The concept for KRISP started in discussions with the executives of UKZN, CAPRISA, TIA and the Department of Science and Technology, funded by the South African Research Infrastructure Roadmap (SARIR) DIPLOMICS programme.</p>\n\n<p><b><i>\'We decided that it was wise to build KRISP on our strength in genomics, epidemiology and bioinformatics and to use our existing facilities at the School of Laboratory Medicine and Medical Sciences in the College of Health Sciences to host it,\'</i></b> said de Oliveira.</p>\n\n<p>The vision of KRISP is to produce and analyse omics data at the same speed and quality as the top genomics centres in the world. This will produce cutting-edge research, support industrial development and capacitate the next generation of scientists in South Africa.</p>\n\n<p>A critical function of KRISP will be to enable and facilitate access to genomics, epigenetics and bioinformatics technology to a broader community of users who might not otherwise pursue these technologies or use alternative international resources.  KRISP aims at creating, in collaboration with TIA, a professionally run and accredited service component that is available for academic, commercial and industrial clients.</p>\n\n<p>This agreement will see TIA providing R5 million a year for the core of the facility, but there is now opportunity to leverage additional funding for flagship projects, including a flagship programme from the South African Medical Research Council (SAMRC). The SAMRC Flagship programme has been very successful - it has published 60 manuscripts, graduated nine MScs and PhD students and trained 1 150 participants as part of capacity building workshops in the last three years. KRISP is now looking for opportunities to collaborate with key stakeholders and funders to identify new flagship programmes that can generate similar scientific and capacity building output.</p>\n\n<p><b><i>\'We are very passionate about training and capacity building. For example, in the last three years, we have organised 16 workshops during which 1 150 individuals were trained. As part of KRISP, we will continue and expand our training programme.  We also expect to graduate more PhDs and MScs in order to create the scientific leaders of tomorrow,\'</i></b> said de Oliviera.</p>\n\n<p>Director of CAPRISA Professor Salim Abdool Karim has been crucial in the planning processes and will act as chair of the board.</p>\n\n<p>KRISP has thanked SAMRC for its support and look forward to a very positive interaction in the future.</p>\n\n<p><b><i>\'A big thank you to everyone who worked hard towards the establishment of KRISP. I am very glad to see this has happened and we will work very hard to become a success history,\'</i></b> added de Oliveira</p>\n\n<p>In order to transform our plans in reality, we had the support of many individuals and organizations in South Africa and abroad. </p>\n\n<p>We would like to acknowledge the great support received from UKZN Executives. Prof. Rob Slotow (DVC of CHS), Prof. Deresh Ramjugernath (DVC Research), Prof. Musa Mabandla (Dean LMMS) and Prof. Albert Van Jaarsveld (VC). </p>\n\n<p>We also would like to acknowledge the TIA executives, Dr. Barlow Manilal (CEO), Dr. Tim Newman and Dr. Mohohlo Molatudi, who have met with us in many occasions and provided a critical review of our plans and vision. </p>\n\n<p>Prof. Salim Abdool Karim (Director CAPRISA) has also been crucial in the planning processes. We are also very honored that Prof. Karim has also accepted to chair our advisory board. Many other members of CAPRISA have also supported our plans, we would like to thank Prof. Quarraisha Abdool Karim, Dr. Kogie Naidoo, Prof. Ayesha Kharsany, Prof. Lynn Morris, Dr. Nesri Padayatchi, Dr. Nigel Garrett, Dr. Cheryl Baxter, Mr. Nasrin Amla, Ms Natasha Samsunder and Ms. Norma Hatcher.</p>\n\n<p>The CPGR and the DST DIPLOMICS team (Dr. Reinhard Hiller, Dr. Judith Hornby, Dr. Dries Oelofse, Dr. Busiswa Kekana and Dr. Lindsay Petersen) have also been very important in our planning and, now, will be also very important for our implementation plans. It is important to note that Dr. Hiller is also taking a position in our governance board.</p>\n\n<p>The SAMRC, in addition to funding our Flagship programme, have also officially accepted to take a position in our board of governance, we would like to really thank the SAMRC for all of their support in the past and we look forward to a very positive interaction in the future. We would like to acknowledge the support of Prof. Glenda Gray, Dr. Niresh Bhagwandin, Ms. Arlene Smith and Dr. Rizwana Mia. </p>\n\n<p>We also have a special thanks to Global Labs (Dr. Lorna Madurai) and NHLS (Prof. Pravi Moodley and Dr. Reshmi Samuel). They are very important partners and provide some of our best models for running a well-functioning and accredited laboratory.</p>\n\n<p>We also got support from AHRI, including Prof. Deenan Pillay, Prof. Alan Aderem, Prof. Thumbi Ndung\'u  and Mr. Brendan Gilbert. We look forward for a continuing and positive partnership.</p>\n\n<p>We also received key support and guidance from Prof. Nicola Mulder and Prof. Carolyn Williamson from UCT.</p>\n\n<p>Other key supporters from UKZN, some who will be faculty in KRISP, included, Prof. Fernando Albericio, Prof. Sabiha Yusuf Essack, Dr. Michelle Gordon, Dr. Veron Ramsuran, Prof. Beatriz Garcia De La Torre, Dr. Richard Lessells, Prof. Frank Tanser, Ms. Keshni Hiramen and Prof. Yunus Moosa. We cannot forget our very hard working Researchers and Post-doctoral fellow, Dr.  Alain Vandormael, Dr. Andrew Tomita, Dr. Tiago Graft, Dr. Marcel Tongo Passo, Dr. Eduan Wilkinson, Dr. Jennifer Giandhari, Dr. Werner Smidt, without you keeping the science going we would never have been so productive! </p>\n<p>We also want to thank to our fantastic financial and operational support group, including Ms. Nicolette Croizer, Ms. Suzette Grobler, Mr. Helgaard Holtzhausen, Mr. Bonginhlanhla Ernest Mbambo, Prof. Fanie Botha, Dr. Mark Tufts and Ms Metse Serumula. Lastly but not the least, we would like to thank all of our UKZN students and staff for the patience and encouragement during this process.</p>\n\n<p>Our main international partners that supported this initiative were: Prof. Ioannis Xenarios (Member of our advisory board and director of the Swiss Institute of Bioinformatics (SIB) and Vital-IT), Prof. Anne-Mieke Vandamme (Leuven Kathoelic University, Belgium), Prof. Robert Shafer (Stanford University), Prof. Mary Carrington (NIH), Prof. Jim Mullins and Dr. Josh Herbeck (University of Washington), Prof. Luiz Alcantara (FioCruz, Brazil) and Prof. Per I. Arvidsson (SciLifeLab, Sweden). </p>\n\n\n<p>Words by: Lihle Sosibo</p>', 'Technology Innovation Agency, TIA, UKZN, signed, agreement, establishment, KRISP, KwaZulu-Natal Research and Innovation Sequencing Platform, KwaZulu-Natal, Research, Innovation, Sequencing, Platform, CAPRISA, South African Medical Research council, SAMRC, DNA, sequencing, genomics, centre, bioinformatics, Tulio de Oliveira, Durban, South Africa,Technology Innovation Agency, TIA, UKZN, signed, agreement, establishment, KRISP, KwaZulu-Natal Research and Innovation Sequencing Platform, KwaZulu-Natal, Research, Innovation, Sequencing, Platform, CAPRISA, South African Medical Research council, SAMRC, DNA, sequencing, genomics, centre, bioinformatics, Tulio de Oliveira, Durban, South Africa,Technology Innovation Agency, TIA, UKZN, signed, agreement, establishment, KRISP, KwaZulu-Natal Research and Innovation Sequencing Platform, KwaZulu-Natal, Research, Innovation, Sequencing, Platform, CAPRISA, South African Medical Research council, SAMRC, DNA, sequencing, genomics, centre, bioinformatics, Tulio de Oliveira, Durban, South Africa', 'The Technology Innovation Agency (TIA) and the University of KwaZulu-Natal (UKZN) have signed an agreement for the establishment of KRISP ? the KwaZulu-Natal Research and Innovation Sequencing Platform. KRISP, the result of hard work by, among others, Professor Tulio de Oliveira, Professor Deresh Ramjugernath and Professor Salim Abdool Karim, was previously known as the Genomics and Bioinformatics Centre', 'Y'),
(180, 'imgindependent.png', 'http://www.krisp.org.za/manuscripts/Independent_KRISP_July2017.pdf', 'Durban at the forefront of DNA research - KwaZulu-Natal Research and Innovation Sequencing Platform - KRISP', 'KRISP News', NULL, '2017-07-15', '<p> By Arthi Gopi, Independent on Saturday Newspaper - KRISP atrracts the brightest - Durban is leading the way in DNA research, having attracted some of the brightest minds in the science field, in a new state-of-the-art lab in the city. </p>', NULL, 4, '<p><center><img src=\'imagesBIO/KRISP_team.jpg\' alt=\'DPhD fellows Zandile Sibisi, from left, Benjamin Chimukangara, Mlungisi Dlamini and Dr Tongo Marcel work on the state-of-the-art DNA sequencing machines at the KZN Research and Innovation Sequencing Platform (KRISP) centre, based at UKZN\'s medical school\'><i>DPhD fellows Zandile Sibisi, from left, Benjamin Chimukangara, Mlungisi Dlamini and Dr Tongo Marcel work on the state-of-the-art DNA sequencing machines at the KZN Research and Innovation Sequencing Platform (KRISP) centre, based at UKZN?s medical school. Picture: S\'bonelo Ngcobo</i></center></p>\n<p>Durban - Durban is leading the way in DNA research, having attracted some of the brightest minds in the science field, in a new state-of-the-art lab in the city.</p>\n\n<p>With cutting-edge technology, such as the next generation DNA sequencing machines, the scientists at the centre, called the KZN Research and Innovation Sequencing Platform (KRISP), are forging ahead in DNA research, with the data collated eventually being able to influence government health policies.</p>\n\n<p>Based at the Nelson Mandela School of Medicine, the centre will be officially launched later this year but scientists are already hard at work analysing data.</p>\n\n<p>Professor Tulio de Oliveira, of KRISP, an HIV genetic data and bioinformatics software development expert, said the Technology Innovation Agency (TIA) and UKZN signed an agreement for the establishment of KRISP, paving the way for KZN to join a national group of state-of-the-art DNA centres.</p>\n\n<p><b><i>\'Right here in Durban, South Africa, we can now produce some of the best, high quality data in DNA sequencing, without having to send it out of KZN or even out of the country for analysis,\'</b></i> he said.</p>\n\n<p>DNA sequencing was important because it allowed scientists to see the makeup of a DNA molecule of, for example, HIV in a patient, which allowed them to see how it was transmitted.</p>\n\n<p>DNA sequencing also gave scientists a better understanding of how a particular virus, or disease, was affecting a patient, so treatment could be <b><i>\'tailor-made\'</b></i> for the patient. The facility will allow DNA testing for diseases such as cancer, cases of paternity, and Alzheimer\'s.</p>\n\n<p><b><i>\'The good thing about this centre is that it not only allows researchers and the academic field a space for research, but it can be contracted to businesses, which may use the facilities and technology and expertise here, for work in veterinary, agriculture, pharmaceutical and food industries.\'</b></i></p>\n\n<p><b><i>\'The work we do here is very relevant to communities. As an example, there is a lot of work going into antibiotic resistance because in 10 to 20 years\' time, we may not have any antibiotics, for which drug resistance has not developed\'</b></i> said De Oliveira.</p>\n\n<p>The centre has attracted academics, who left the country, to come back to SA, and specifically Durban, in what De Oliveira called a <b><i>\'reverse brain drain\'</b></i>.</p>\n\n<p>One such scientist, Dr Veron Ramsuran, an expert in genetics, was at Harvard in the US when he was lured to Durban.</p>\n\n<p><b><i>\'I\'ve been looking at HIV from a host perspective and we found surprising results that will soon be published in a medical journal. In effect, we can analyse a host and analyse the virus and determine what kind of treatment would work, it allows us to be very specific in treatment,\'</b></i> he said. ', 'Durban , leading , way, DNA, research, attracted, brightest, minds, science, field, , state-of-the-art, lab, ,city, next generation sequencing, KRISP, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP, Tulio de Oliveira, TIA, UKZN, Nelson R Mandela School of Medicine, genomics, bioinformatics, HIV, antibiotics, resistance, centre, omics, Durban , leading , way, DNA, research, attracted, brightest, minds, science, field, , state-of-the-art, lab, ,city, next generation sequencing, KRISP, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP, Tulio de Oliveira, TIA, UKZN, Nelson R Mandela School of Medicine, genomics, bioinformatics, HIV, antibiotics, resistance, centre, omics, Durban , leading , way, DNA, research, attracted, brightest, minds, science, field, , state-of-the-art, lab, ,city, next generation sequencing, KRISP, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP, Tulio de Oliveira, TIA, UKZN, Nelson R Mandela School of Medicine, genomics, bioinformatics, HIV, antibiotics, resistance, centre, omics, Durban , leading , way, DNA, research, attracted, brightest, minds, science, field, , state-of-the-art, lab, ,city, next generation sequencing, KRISP, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP, Tulio de Oliveira, TIA, UKZN, Nelson R Mandela School of Medicine, genomics, bioinformatics, HIV, antibiotics, resistance, centre, omics', 'cutting-edge technology, such as the next generation DNA sequencing machines, the scientists at the centre, called the KZN Research and Innovation Sequencing Platform (KRISP), are forging ahead in DNA research, with the data collated eventually being able to influence government health policies. KRISP is Based at the Nelson Mandela School of Medicine. Professor Tulio de Oliveira, of KRISP, an HIV genetic data and bioinformatics software development expert, said the Technology Innovation Agency (TIA) and UKZN signed an agreement for the establishment of KRISP', 'Y'),
(181, 'news181.png', 'https://www.santheafrica.org/news/santhe-trainee-wins-best-abstract-deltas-africa-meeting', 'KRISP & SANTHE trainee  wins Best Abstract at DELTAS Africa meeting', 'KRISP News', NULL, '2017-07-20', '<p>Friday, 7 July, 2017, Dr Marcel Tongo Passo, a SANTHE Post-doctoral trainee, has won a \"Best Abstract\" award at the DELTAS (Developing Excellence in Leadership, Training and Science) Africa Annual Grantees Meeting 2017, held in Accra, Ghana, between 3 to 5 July. Passo is based at <b>KRISP (KwaZulu-Natal Research and Innovation Sequencing Platform)</b> and HPP (HIV Pathogenesis Programme) at the University of KwaZulu-Natal, South Africa.<p>\n', NULL, 4, '<p><center><img src=\'imagesBIO/marcel2.jpg\' alt=\'Dr Marcel Tongo Passo won the best abstract at Wellcome Trust DELTAS meeting in  Ghana, 2017\'></center></p>\n<p><center><b><i>Dr Marcel Tongo Passo, KRISP, won the best abstract at Wellcome Trust DELTAS meeting in  Ghana, 2017</i></b></center></p>\n<p>Out of 500 fellows from 11 cutting edge, public health related, research programmes - including 54 institutions in 21 African countries - Passo was selected to present at the meeting and ended up winning this prestigious award. He said he felt deeply honoured and grateful for the recognition.</p>\n<br>\n<p><center><b>ABSTRACT</b></center></p>\n<p><b>Determining the distribution of HIV-1M subtypes genomic sites within recombinants sequences</b></p>\n \n <p><b>Authors:</b> Marcel Tongo<sup>1,2</sup>, Tulio de Oliveira<sup>1</sup> and Darren P. Martin<sup>3</sup></p>\n<sup> <p>1 - KwaZulu-Natal Research Innovation and Sequencing Platform, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa</p> \n <p>2 - Institute of Medical Research and Study of Medicinal Plants, Yaounde, Cameroon</p>\n <p>3 - Division of Computational Biology, Department of Integrated Biology Sciences and Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa</p></sup>\n<p>HIV-1M uses recombination as mechanism for generating genetic diversity. However, it remains unclear whether inter-subtype recombinants tend to randomly inherit particular genome regions from their parental genomes, or whether some genomic regions from particular subtypes tend to occur more frequently in recombinants than what would be expected under random recombination in the absence of selection.</p> \n<p>To differentiate between these two possibilities, we analysed the distribution within 79 circulating and 229 unique recombinant forms of genome fragments derived from subtype A, B, C, D, F, G and CRF01_AE viruses. We used a permutation-based test to identify genome regions that tended to be more frequently inherited from particular subtypes than could be accounted for by chance under random recombination. </p> \n<p>While genome fragments derived from each of the subtypes were scattered throughout the analysed recombinant genomes, statistically significant hot-spots of subtypes A and 01_AE derived sequences was detected in gp120, in RT for subtypes B and D, in vif for subtype C, in p24 for subtype F and in prot for subtype G. Conversely, statistically significant cold-spots were identified in vpu for subtype A derived sequences, in p24 and vif for subtype B, in RT for subtype C, in Nef for subtype D, in p17 and vpu for subtype F, in RT and p15 for subtype G and in RT for CRF01_AE. </p> \n<p>The apparent non-randomness in the frequencies which different subtypes have contributed particular genome regions to known HIV-1M recombinants suggests that selection may either favour or disfavour the survival of inter-subtype recombinants. </p> \n\n<p>Corresponding Author:<br>\nMarcel Tongo Passo, PhD<br>\nKRISP. College of Health Sciences, University of KwaZulu-Natal <br>\n719, Umbilo Road<br>\nDurban, 4001, Kwazulu-Natal, South Africa<br>\nTel: +27 31 260 3744</p>', 'KRISP, best, abstract, Ghana, Deltas, Marcel, Tongo, Passo, HIV-1, Subtype A, KRISP, KwaZulu-Natal, Research, Innovation, Sequencing, Platform, HPP, HIV, Pathogenesis, Programme, KRISP, best, abstract, Ghana, Deltas, Marcel, Tongo, Passo, HIV-1, Subtype A, KRISP, KwaZulu-Natal, Research, Innovation, Sequencing, Platform, HPP, HIV, Pathogenesis, Programme, KRISP, best, abstract, Ghana, Deltas, Marcel, Tongo, Passo, HIV-1, Subtype A, KRISP, KwaZulu-Natal, Research, Innovation, Sequencing, Platform, HPP, HIV, Pathogenesis, Programme, bioinformatics, phylogenetics', 'Dr Marcel Tongo Passo, a SANTHE Post-doctoral trainee, has won a \"Best Abstract\" award at the DELTAS (Developing Excellence in Leadership, Training and Science) Africa Annual Grantees Meeting 2017, held in Accra, Ghana, between 3 to 5 July. Passo is based at KRISP (KwaZulu-Natal Research and Innovation Sequencing Platform) and HPP (HIV Pathogenesis Programme) at the University of KwaZulu-Natal, South Africa.', 'Y'),
(182, 'imgnews133.png', 'http://www.krisp.org.za/manuscripts/UKZN_MRCFlagship_Seminar_August2017.pdf', 'A multi-centre analysis of internal migration and AIDS/TB and NCD-related mortality in Kenya and South Africa', 'KRISP Talks', NULL, '2017-08-23', '<p>KRISP Talks by <b>Dr Carren Ginsburg</b>, SAMRC/Wits  Rural Public Health \r& Health Transitions Research Unit (Agincourt), <b>23 August 2017 (11am - midday)</b>, K-RITH building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa. All welcome!</p>', NULL, 5, '<p><center><a href=\"http://www.krisp.org.za/manuscripts/UKZN_MRCFlagship_Seminar_August2017.pdf\"><img src=\"imagesBIO/KRISP_MRCFlagship_Seminar_August2017.jpg\" alt=\"krisp monthly seminar series present  Dr Carren Ginsburg, Medical Research Council/Wits Rural Public Health and Health Transitions Research Unit, Agincourt, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand\"></a></center></p>\n<p><b>Dr Carren Ginsburg\n</b>, Medical Research Council/Wits Rural Public Health and Health Transitions Research Unit, Agincourt, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand</p>\n<p>Date: Wednesday, 23 August 2017</p>\n<p>Time: 11:00-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', NULL, NULL, ''),
(184, 'news184.png', 'https://rega.kuleuven.be/cev/veme-workshop/2017', '22nd International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology (VEME), Lisbon, Portugal', 'KRISP Training', NULL, '2017-08-27', '<p>The workshop provides both theoretical and practical training in phylogenetic inference and evolutionary hypothesis testing. It is recognized as one of the best international virus bioinformatics courses. It covers sequence analysis, phylogenetics, phylodynamics methods and large scale methods for next-generation sequencing (NGS) analytics</p>', NULL, 4, '<p>This annual workshop will provide 90 virologists with intensive training in the mathematical principles and computer applications used in the study of virus evolution and for conducting detailed molecular epidemiological investigations.</p>\n\n<p>The 22nd International Workshop on Virus Evolution and Molecular Epidemiology (VEME2017) will be hosted by the Instituto de Higiene e Medicina Tropical.</p>\n\n<p><center><a href=\"https://rega.kuleuven.be/cev/veme-workshop/2017\"><img src=\"imagesBIO/news184feature.png\"></a></center> </p>\n \n<p><b><i>Organising Committee</b></i></p>\n<p>Anne-Mieke Vandamme (KU Leuven - University of Leuven, Belgium)</p><p> Tulio de Oliveira (Krisp, University of KwaZulu-Natal, South Africa)</p><p> Philippe Lemey (KU Leuven - University of Leuven, Belgium)</p><p> Mattia Prosperi (University of Florida, USA)</p><p>Ana Abecasis (Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Portugal)</p><p> Pedro Fernandes (Instituto Gulbenkian de Cienca, Oeiras, Portugal)</p><p> Nuno Taveira (Instituto Superior de Ciencias da Saude Egas Moniz, Monte de Caparica, Portugal)</p>\n<br>\n <p>Combating viral spread and their associated disease burden is a tremendous challenge requiring significant research efforts and dedicated measures, in public health, veterinary care, and agriculture strategies. Viral sequence data is a major asset in the characterization of pathogens. Understanding the processes that generate genetic diversity assists in the struggle against viral infections and enhances our understanding of past evolutionary and epidemiological events.  It can also help in the identification of the origins of new epidemics, in monitoring the effectiveness of therapeutic strategies, and eventually in predicting the behavior of viral epidemics. Advances in bioinformatics have led to improved approaches to investigating viral outbreaks that ave been successfully applied to viruses including the Human immunodeficiency viruses (HIV), the Ebola virus, the Dengue viruses, the Chikungunya virus and the Influenza virus.</p>\n\n<p><b><i>More information on the VEME workshop, please visit the website below</b></i></p>\n', 'bioinformatics, training, krisp training, NGS, next generation sequencing, phylogenetics, tulio de oliveira, Anne-Mieke Vandamme, Portugal, VEME, molecular epidemiology, workshop, annual, virus evolution, bioinformatics, training, krisp training, NGS, next generation sequencing, phylogenetics, tulio de oliveira, Anne-Mieke Vandamme, Portugal, VEME, molecular epidemiology, workshop, annual, virus evolution, bioinformatics, training, krisp training, NGS, next generation sequencing, phylogenetics, tulio de oliveira, Anne-Mieke Vandamme, Portugal, VEME, molecular epidemiology, workshop, annual, virus evolution, bioinformatics, training, krisp training, NGS, next generation sequencing, phylogenetics, tulio de oliveira, Anne-Mieke Vandamme, Portugal, VEME, molecular epidemiology, workshop, annual, virus evolution, bioinformatics, training, krisp training, NGS, next generation sequencing, phylogenetics, tulio de oliveira, Anne-Mieke Vandamme, Portugal, VEME, molecular epidemiology, workshop, annual, virus evolution, 2017', 'The 22nd International Workshop on Virus Evolution and Molecular Epidemiology (VEME2017) will be hosted by the Instituto de Higiene e Medicina Tropical, August & september 2017. The VEME workshop provides both theoretical and practical training in phylogenetic inference and evolutionary hypothesis testing as applied in virology and molecular epidemiology. It is recognized as one of the best international virus bioinformatics courses. It covers sequence analysis, phylogenetics, phylodynamics methods, and large scale methods for next-generation sequencing (NGS) analytics.', ''),
(186, 'imgnews186.png', 'https://news.it.ufl.edu/research/enabling-infectious-disease-transmission-research/', 'Enabling Infectious Disease Transmission Research', 'KRISP News', NULL, '2017-07-27', '<p>KRISP Researcher and Fulbright scholar Dr. Eduan Wilkinson news from the US: HiPerGator supercomputer is enabling infectious disease transmission research in UF\'s Emerging Pathogens Institute. </p>', NULL, 4, '<p>Among the research underway at the EPI are two studies by graduate students: Taylor Paisie is studying Cholera in Haiti and Fulbright scholar Eduan Wilkinson is analyzing factors generating HIV transmission in South Africa. Paisie, originally from Ohio, says HiPerGator is integral to her work:</p> \n<p><b><i>\'I look at disease patterns of the past in order to understand the global clinical and epidemiological patterns of the disease,\'</b></i> said Paisie. <b><i>\'I can\'t analyze samples without HiPerGator. Its power allows us to sequence whole genome samples and continue working while the data is being analyzed on our computers.\'</b></i></p>\n<p><center><img src=\"imagesBIO/EduanWilkinsonFloridaUniv2.jpg\" alt=\"Taylor Paisie is studying Cholera in Haiti and Fulbright scholar at University of Florida Eduan Wilkinson is analyzing factors generating HIV transmission in South Africa\"></a></center></p>\n<p><i>Taylor Paisie and Eduan Wilkinson sequencing Cholera whole genomes in Prof. Marco Salemi\'s laboratory, University of Florida.</i></p>\n<p>In addition to researching Cholera, the Salemi Lab also includes Eduan Wilkinson, a postdoc studying HIV transmission in his native South Africa. Wilkinson is able to run 16,000 very large sequences on HiPerGator in one week, thanks to UFIT\'s ability to optimize job scripts and provide exceptional software.</p>\n<p></p>\n<p><b><i>\'The methods that we use to look at viral strains are extremely powerful,\'</b></i> said Wilkinson. <b><i>\'By analyzing sequences we can construct relationships between pathogens so we can see what\'s driving the transmission. We can also use these methods to evaluate how public health interventions are impacting the epidemic.\'</b></i></p>\n<p><center><img src=\"imagesBIO/EduanWilkinsonFloridaUniv.jpg\" alt=\"Eduan Wilkinson, FulBright Scholar using HiPerGator supercomputer to HIV data from South Africa\"></a></center></p>\n<p><i>Dr. Eduan Wilkinson using HiPerGator supercomputer in Florida to analyze large HIV datasets from South Africa.</i></p>\n<p></p>\n<p>Faculty and affiliated staff and students interested in utilizing HiPerGator may attend a Research Computing walk-in session, held each Wednesday at the Informatics Institute. <a href=\"https://www.rc.ufl.edu/wp-content/uploads/2013/09/2017-2018-Research-Computing-Flyer.pdf\">A list of consulting and training services provided by Research Computing is available in the HiPerGator 2017-2018 brochure.</a></p>\n', NULL, NULL, ''),
(185, 'news185.png', 'http://www.x-meeting.com/events/2017', 'X-meeting - 13th International Conference of the AB3C, Sao Pedro, Brazil, Oct 4-6, 2017', 'KRISP Training', NULL, '2017-10-04', '<p>Bioinformatics is now a strategic area for Brazil and all Latin America and, therefore, it is also strategic to the development of Science, Technology and Economy. The X-Meeting is a Brazilian event with international reach which has an average of 400 participants. </p>', NULL, 4, '<p>The scientific program of the X-Meeting 2017 will feature a variety of sessions, including keynote lectures, panel sessions, theoretical and hand-on courses, short talks and poster sessions. As in previous meetings we will have a great team of speakers!</p>\n\n<p>The X-meeting 2017 - 13th International Conference of the AB3C  will be hosted at a farm hotel in the beautiful Mantiqueira Mountains in Brazil</p>\n\n<p><center><a href=\"http://www.x-meeting.com/events/2017\"><img src=\"imagesBIO/news185feature.png\"></a></center> </p>\n \n<p><b><i>Organising Committee</b></i></p>\n<p>AB3C President: Alan Mitchell Durham (USP)</p>\n\n<p>AB3C Vice President: Ney Lemke (Unesp)</p>\n\n<p>AB3C Secretaries: Marcelo Brandao (Unicamp) and Fabricio Martins Lopes (UTFPR)</p>\n\n<p>AB3C Financial Department: Priscila Grynberg (Embrapa) and Nicole de Miranda Scherer (INCA)</p>\n\n <p>Many international speakers will be presenting in this workshop. <a href=\"http://www.x-meeting.com/events/speakers/panel\">Prof. Tulio de Oliveira will be giving an oral presentation and leading a panel session discussion on the use of genomics and bioinformatics in infectious diseases.</a></p>\n\n<p><b><i>More information on the X-meeting conference, please visit the website below</b></i></p>\n', 'X-meeting, Brazil, bioinformatics, genomics, workshop, tulio de oliveira, winston hide, international conference, 2017, Krisp, panel discussion, infectious disases, HIV, next generation sequencing, NGS, X-meeting, Brazil, bioinformatics, genomics, workshop, tulio de oliveira, winston hide, international conference, 2017, Krisp, panel discussion, infectious disases, HIV, next generation sequencing, NGS, X-meeting, Brazil, bioinformatics, genomics, workshop, tulio de oliveira, winston hide, international conference, 2017, Krisp, panel discussion, infectious disases, HIV, next generation sequencing, NGS, X-meeting, Brazil, bioinformatics, genomics, workshop, tulio de oliveira, winston hide, international conference, 2017, Krisp, panel discussion, infectious disases, HIV, next generation sequencing, NGS', 'X-meeting brings internationa and Brazilian experts to discuss genomics and bioinformatics in 2017. Bioinformatics is now a strategic area for Brazil and all Latin America and, therefore, it is also strategic to the development of Science, Technology and Economy. The X-Meeting is a Brazilian event with international reach which has an average of 400 participants. The Conference is an opportunity for students, researchers and companies to interact and diffuse knowledge.', 'Y'),
(187, 'imgsundaytribune.png', NULL, 'State-of-art lab for DNA sequencing a boost for KZN', 'KRISP News', NULL, '2017-07-30', '<p>By Siboniso Mngadi, Sunday Tribune. WITH a new, state-of-the-art laboratory at the University of KwaZulu-Natal\'s (UKZN) medical school, Durban can now produce some of the best, high-quality data in DNA sequencing without having to send it out of the province or to other countries. </p>', NULL, 4, '<p><center><img src=\"imagesBIO/TulioZandile_KRISP.jpg\" alt=\"Professor Tulio de Oliveira and PhD fellow Zandile Sibisi work at the DNA sequencing machine at the KZN Research and Innovation Sequencing Platform (Krisp) centre. Picture: ZANELE ZULU \"></a></center></p>\n<p><center><i>Professor Tulio de Oliveira and PhD fellow Zandile Sibisi work at the DNA sequencing machine at the KZN Research and Innovation Sequencing Platform (Krisp) centre. Picture: ZANELE ZULU</i></center></p>\n\n<p>UKZN and Technology Innovation Agency signed an agreement for the establishment of the KwaZulu-Natal Research and Innovation Sequencing Platform (Krisp) led by Professor Tulio de Oliveira, who is an expert on HIV genetic data and bioinformatics software development.</p>\n\n<p>De Oliveira said the vision of Krisp was to produce and analyse omics (genomics, proteomics or metabolomics) data at the same speed and quality as the top centres in the world.</p>\n\n<p>The facility would produce cutting-edge research, support industrial development and capacitate the next generation of scientists, he said.</p>\n\n<p>The laboratory has about 35 scientists working in it. In terms of the agreement, Technology Innovation Agency is providing R5 million a year for the facility.</p>\n\n<p>The centre will assist in overcoming a backlog in DNA testing for pathogens, such as HIV and TB, and diseases, such as cancer and Alzheimer\'s.</p>\n\n\n<p>De Oliveira said a critical function of Krisp would be to enable and facilitate access to genomics, epigenetics and bioinformatics technology to a broader community of users who might not otherwise pursue these technologies or use alternative international resources.</p>\n\n<p>Local funding was the way to drive a scientific agenda that benefited the country, he said, adding that foreign countries had their own scientific agendas which might not be suitable for South Africa.</p>\n\n<p><b><i>\'It was important for the country to build this cutting-edge scientific structure because now we can find scientific solutions that would have biggest impact on our economy, health and well-being of people.\'</b></i></p>\n\n<p>Krisp was also looking for opportunities to collaborate with key stakeholders and funders to identify new flagship programmes that could generate similar scientific and capacity building output, he said.</p>\n\n<p><b><i>\'We want to create a professionally run and accredited service component that is available for academic, commercial and industrial clients..\'</b></i></p>\n\n<p><b><i>\'We are passionate about training and capacity building. For example, in the past three years, we have organised 16 workshops during which 1150 individuals were trained. As part of Krisp, we will continue and expand our training programme. I am glad to see this has happened and we will work hard to become a success story.\'</b></i></p>\n\n<p>Among those who were part of Krisp was postgraduate student Zandile Sibisi, 29, from KwaMashu. Sibisi is studying towards her PhD in virology after completing several qualifications in health sciences.</p>\n\n<p><b><i>\'When I completed matric my parents had no money to support my studies. I had to pay my way through working at the retail shops where I was paid on commission,\'</b></i> she said.</p>\n\n<p>Pursuing her postgraduate studies at UKZN was unique and afforded her an exclusive opportunity compared to other institutions, she said.</p>\n\n<p>She was inspired by working with experts such as De Oliviera. <b><i>\'With Krisp facilities, we have enough space to do research because you can\'t do it in a vacuum lab. We have advanced resources here. I have mastered all the specia- lities, I can do the DNA test from blood extraction to analysis of result.\'</b></i></p>\n\n<p>The centre has attracted scientists from other provinces and academics who had left Durban but returned to the city. One is Dr Veron Ramsuran, an expert in genetics, who was at the National Institutes of Health and Harvard in the US. He said the centre was world-class.</p>\n\n<p><b><i>\'We have similar facilities and equipment; basically the stuff we did there can be done here. We have an added advantage, we have access to samples more easily than in the US,\'</b></i> Ramsuran said.</p>', NULL, NULL, 'Y'),
(188, 'KRISPnewsletter.png', 'http://www.krisp.org.za/manuscripts/KRISPnewsletter_1_2017A4small.pdf', 'KRISP Newsletter - July 2017:  news, videos, blogs, publications and training events', 'KRISP Newsletter', NULL, '2017-08-01', '<p>The concept behind this newsletter is that anyone with 15 minutes to spare can learn about KRISP  work. In this July 2017 issue of our newsletter, we have included interesting news, videos, blogs, reports, tweets, publications and training events of KRISP<p>', NULL, 4, '<p><center><a href=\"http://www.krisp.org.za/manuscripts/KRISPnewsletter_1_2017A4small.pdf\"><img src=\"imagesBIO/KRISPnewsletter_1_2017A4.png\"></a></center> </p>\n\n<br><p><b><i>In this issue our highlights are:</b></i></p>\n\n\n<p> - <a href=\"http://www.krisp.org.za/news.php?id=179\">News: KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP) Established</a></p>\n\n<p> - <a href=\"http://www.krisp.org.za/news.php?id=181\">News: KRISP & SANTHE trainee wins Best Abstract at DELTAS Africa meeting</a></p>\n\n<p> - <a href=\"http://www.krisp.org.za/videos.php\">Video: Durban at the forefront of DNA research - eTV news</a></p>\n\n<p> - <a href=\"http://www.krisp.org.za/blogs.php?id=45\">Blog: Bioinformaticians are pioneering the future of science</a></p>\n\n<p> - <a href=\"http://www.krisp.org.za/blogs.php?id=44\">Blog: Meeting of the Swiss, Swedes and South Africans minds</a></p>\n\n<p> - <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28540766\">Publication: HIV-1 full-genome phylogenetics of generalized epidemics in sub-Saharan Africa: impact of missing nucleotide characters in next-generation sequences.</a></p>\n\n<p> - <a href=\"http://www.krisp.org.za/news.php?id=183\">Workshop: 11th Annual Workshop on Advanced Clinical Care - AIDS (AWACC), Durban, South Africa, 6-7 Sep 2017.</a></p>\n \n<br><p><b><i>The newsletter is open accessible at:</b></i></p>\n\n<p>(<a href=\"http://www.krisp.org.za/manuscripts/KRISPnewsletter_1_2017A4small.pdff\">http://www.krisp.org.za/manuscripts/KRISPnewsletter_1_2017A4small.pdf)</a></p>\n \n<p>We hope that you enjoy our newsletters. We think that they are truly interesting and we really have enjoyed producing it!</p>\n<p> Produced by <a href=\"http://www.bioafrica.net/people.php?peopleid=1\">Prof. Tulio de Oliveira</a> (Nelson R Mandela School of Medicine, UKZN & CAPRISA, South Africa)</p>', 'KRISP. first. newsletter, 2017, bioinformatics, genomics, DNA research, award, DELTAS, wellcome trust, AWACC, training, videos, blots, pioneering the future of science, KwaZulu-Natal Research Innovation and Sequencing Platform, Tulio de Oliveira, Yumna Moosa, Veron Ransuram, Zandile Sibisi, phylogenetics, papers, July, CAPRISA, KRISP. first. newsletter, 2017, bioinformatics, genomics, DNA research, award, DELTAS, wellcome trust, AWACC, training, videos, blots, pioneering the future of science, KwaZulu-Natal Research Innovation and Sequencing Platform, Tulio de Oliveira, Yumna Moosa, Veron Ransuram, Zandile Sibisi, phylogenetics, papers, KRISP. first. newsletter, 2017, bioinformatics, genomics, DNA research, award, DELTAS, wellcome trust, AWACC, training, videos, blots, pioneering the future of science, KwaZulu-Natal Research Innovation and Sequencing Platform, Tulio de Oliveira, Yumna Moosa, Veron Ransuram, Zandile Sibisi, phylogenetics, papers, KRISP. first. newsletter, 2017, bioinformatics, genomics, DNA research, award, DELTAS, wellcome trust, AWACC, training, videos, blots, pioneering the future of science, KwaZulu-Natal Research Innovation and Sequencing Platform, Tulio de Oliveira, Yumna Moosa, Veron Ransuram, Zandile Sibisi, phylogenetics, papers', 'KRISP newsletter present our work on bioinformatics, genomics in SOuth Africa In this July 2017 issue of our newsletter, we have included interesting news, videos, blogs, reports, tweets, publications and training events of KRISP', '');
INSERT INTO `b_news` (`id`, `image`, `webpage`, `title`, `journal`, `pubid`, `date`, `summary`, `file`, `bioafricaSATuRN`, `summary2`, `keywords`, `topdescription`, `feature`) VALUES
(189, 'imgnews86.png', 'http://www.krisp.org.za/manuscripts/KRISP_Talks_September2017_edited.pdf', 'Paediatric HIV Infection: Elite Control, Remission and Cure', 'KRISP Talks', NULL, '2017-09-20', '<p>KRISP Talks by <b>Prof. Philip Goulder, Oxford University, 20 September 2017 (14:00 - 15:00)</b>, K-RITH building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa. All welcome!</p>', NULL, 5, '<p><center><a href=\"http://www.krisp.org.za/manuscripts/KRISP_Talks_September2017_edited.pdf\"><img src=\"imagesBIO/KRISP_Talks_September2017.jpg\" alt=\"KRISP Talks by Prof Philip Goulder, Oxford University September 2017, Paediatric HIV Infection: Elite Control, Remission and Cure\"></a></center></p>\n<p><b>Prof. Philip Goulder\r\n</b>, Professor of Immunology, Oxford University, U.K.</p>\n<p>Date: Wednesday, 20 September 2017</p>\n<p>Time: 14:00-15:00</p>\n<p>Venue: K1 Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'KRISP Talks, September, 2017, montly, scientific, talk, Durban, South Africa, Philip Goulder, Oxford, Oxford University, Nelson R Mandela School of Medicine, HIV, pediatric, paediatric, elite, controlers, HIV cure, cure, immunology, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP Talks, September, 2017, montly, scientific, talk, Durban, South Africa, Philip Goulder, Oxford, Oxford University, Nelson R Mandela School of Medicine, HIV, pediatric, paediatric, elite, controlers, HIV cure, cure, immunology, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP Talks, September, 2017, montly, scientific, talk, Durban, South Africa, Philip Goulder, Oxford, Oxford University, Nelson R Mandela School of Medicine, HIV, pediatric, paediatric, elite, controlers, HIV cure, cure, immunology, KwaZulu-Natal Research Innovation and Sequencing Platform, KRISP Talks, September, 2017, montly, scientific, talk, Durban, South Africa, Philip Goulder, Oxford, Oxford University, Nelson R Mandela School of Medicine, HIV, pediatric, paediatric, elite, controlers, HIV cure, cure, immunology, KwaZulu-Natal Research Innovation and Sequencing Platform', 'KRISP Talks by Prof. Philip Goulder, Oxford University, U.K. 20 September 2017 (13:00 - 14:00), K-RITH building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa talk title Paediatric HIV Infection: Elite Control, Remission and Cure\r', ''),
(190, 'imgnews86.png', 'http://www.krisp.org.za/manuscripts/KRISP_Talks_October2017.pdf', 'Improving the estimation of temporal trends in HIV incidence by calibrating agent-based simulation models to multiple data sources', 'KRISP Talks', NULL, '2017-10-23', '<p>KRISP Talks by <b>Dr. Wim Delma, SACEMA (Stellenbosch), 23 October 2017 (11:00am - 12:00)</b>, K-RITH building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa. All welcome!</p>', NULL, 5, '<p><center><a href=\"http://www.krisp.org.za/manuscripts/KRISP_Talks_October2017.pdf\"><img src=\"imagesBIO/KRISP_Talks_October2017.jpg\" alt=\"KRISP Talks by Dr Wim Delma, SACEMA, Stellenbosch, Ghent, Hasselt & KU Leuven October 2017, Improving the estimation of temporal trends in HIV incidence by calibrating agent-based simulation models to multiple data sources\"></a></center></p>\n<p><b>Dr. Wim Delma\r\n</b>, SACEMA (Stellenbosch University, South Africa), Hasselt, Ghent University and KU Leuven Universities, Belgium</p>\n<p>Date: Monday, 23 October 2017</p>\n<p>Time: 11:00am-12:00</p>\n<p>Venue: Susser and Stein Seminar Room, K-RITH Tower Building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa</p>\n', 'KRISP Talks, October, 2017, montly, scientific, talk, Durban, South Africa, Wim Delma, Delma, SACEMA, Ghent, KU Leuven, Belgium, South Africa, Improving,  estimation, temporal, trends, HIV, incidence, calibrating, agent-based, simulation, models, multiple, data sources, KRISP Talks, October, 2017, montly, scientific, talk, Durban, South Africa, Wim Delma, Delma, SACEMA, Ghent, KU Leuven, Belgium, South Africa, Improving,  estimation, temporal, trends, HIV, incidence, calibrating, agent-based, simulation, models, multiple, data sources, KRISP Talks, October, 2017, montly, scientific, talk, Durban, South Africa, Wim Delma, Delma, SACEMA, Ghent, KU Leuven, Belgium, South Africa, Improving,  estimation, temporal, trends, HIV, incidence, calibrating, agent-based, simulation, models, multiple, data sources', 'KRISP Talks by Dr. Wim Delma, SACEMA, Ghent, KU Leuven, 23 October 2017 (11:00am - 12:00), K-RITH building, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa talk title Improving the estimation of temporal trends in HIV incidence by calibrating agent-based simulation models to multiple data sources', ''),
(191, 'imgnews104.png', 'http://www.krisp.org.za/manuscripts/KRISP_five_positions_2017.pdf', 'Five (5) KRISP positions open in Durban! Grants Manager, Office Admin, Molecular Technologist, DNA Data & Laboraroty Quality administrators.', 'KRISP Jobs', NULL, '2017-11-04', 'KRISP wants to challenge the status quo and create a scientific environment in (South) Africa that drives innovations in global health, reverses the brain drain and benefits the economy. KRISP staff are based in a state of the art building in Durban and have access to fast advancing technologies such as genomics, epigenetics, bioinformatics and epidemiology. ', NULL, 5, '<p><center><a href=\"manuscripts/KRISP_five_positions_2017.pdf\"><img src=\"imagesBIO/KRISP_jobs_grants_technical_finantial_data_quality.jpg\" alt=\"KRISP Jobs - Manager, Office admin, Technologist, DNA Data & Laboraroty Quality administrator, Durban, South Africa, 2017 \"></a></center></p>\n<br><p><center><b><a href=\"http://vacancies.ukzn.ac.za/VacanciesPostedSept2017/September-2017-Support.aspx\">For full details of these positions and other exciting academic and professional services opportunities at our University, visit our careers webpage: http://vacancies.ukzn.ac.za</a></p>\n<p>Closing dates for applications: 04 October 2017.</p></b></center>\n\n', 'krisp, jobs, positions, 2017, grants and contracts manager, office administrator, molecular laboratory data administrator, molecular laboratory technologist, laboratory quality assistant officer, durban, south africa, kwazulu-natal research innovation and sequencing platform, tia, samrc, KRISP, Tulio de Oliveira, reverse brain drain, DNA sequencing, krisp, jobs, positions, 2017, grants and contracts manager, office administrator, molecular laboratory data administrator, molecular laboratory technologist, laboratory quality assistant officer, durban, south africa, kwazulu-natal research innovation and sequencing platform, tia, samrc, KRISP, Tulio de Oliveira, reverse brain drain, DNA sequencing, krisp, jobs, positions, 2017, grants and contracts manager, office administrator, molecular laboratory data administrator, molecular laboratory technologist, laboratory quality assistant officer, durban, south africa, kwazulu-natal research innovation and sequencing platform, tia, samrc, KRISP, Tulio de Oliveira, reverse brain drain, DNA sequencing, krisp, jobs, positions, 2017, grants and contracts manager, office administrator, molecular laboratory data administrator, molecular laboratory technologist, laboratory quality assistant officer, durban, south africa, kwazulu-natal research innovation and sequencing platform, tia, samrc, KRISP, Tulio de Oliveira, reverse brain drain, DNA sequencing, krisp, jobs, positions, 2017, grants and contracts manager, office administrator, molecular laboratory data administrator, molecular laboratory technologist, laboratory quality assistant officer, durban, south africa, kwazulu-natal research innovation and sequencing platform, tia, samrc, KRISP, Tulio de Oliveira, reverse brain drain, DNA sequencing', 'Five Positions open! Grants Manager, Office admin, Molecular Technologist, DNA Data & Laboraroty Quality administrators. Please join us in order to extend the frontiers of scientific research, drive innovation and solve some of the biggest global health problems, such as HIV & TB epidemics and the increase of drug resistance. All positions advertised are ?xed term (3 year) appointments and are externally funded. KRISP is funded by TIA, SAMRC and a number of international funders', '');

-- --------------------------------------------------------

--
-- Table structure for table `b_people`
--

CREATE TABLE `b_people` (
  `id` int(11) NOT NULL,
  `name` char(50) DEFAULT NULL,
  `email` char(50) DEFAULT NULL,
  `telephone` char(50) DEFAULT NULL,
  `fax` char(50) DEFAULT NULL,
  `summary` longtext,
  `image` char(40) DEFAULT NULL,
  `summary2` longtext,
  `surname` char(50) DEFAULT NULL,
  `initials` char(10) DEFAULT NULL,
  `photo2` tinytext,
  `bioafricaSATuRN` int(11) DEFAULT NULL,
  `member` tinytext NOT NULL,
  `category` text
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_people`
--

INSERT INTO `b_people` (`id`, `name`, `email`, `telephone`, `fax`, `summary`, `image`, `summary2`, `surname`, `initials`, `photo2`, `bioafricaSATuRN`, `member`, `category`) VALUES
(1, 'Prof. Tulio', 'tuliodna@gmail.com & deoliveira@ukzn.ac.za', '+27 (0) 31 260 4898', '+27 35 550 75 65', 'My research interests concentrates on viral evolution under selection pressure created in the transmission, acquisition and drug escape processes. A particular point of interest is on the study of virus\' origins and the effect of network of transmissions in the spread of epidemics in Africa and other continents. I also enjoy developing bioinformatics software applications and running a next generation sequencing (NGS) laboratory. \n', 'mojizu1.png', '<p><b>Background:</b></p>\n<p>Prof. Tulio de Oliveira is a bioinformatician that has been working with HIV research since 1997. He has received his PhD at the Nelson R Mandela School of Medicine, UKZN, South Africa. He was a <a href=\"manuscripts/deOliveira_Marie_Curie_inspiring_researchers_European_Commission.pdf\">Marie Curie research fellow at the University of Oxford, U.K. from 2004 to 2006</a>, where he received in depth training on virus genetic analysis and molecular evolution. He is recognized as an expert on HIV genetic data and bioinformatics and has published some high-impact articles including the one that presents the Rega Subtyping tools (<a href=\"http://www.bioafrica.net/publications.php?pubid=26\">de Oliveira et al. Bioinformatics 2005</a>), one that proof the innocence of the six foreign medical personnel condemned to death for infecting with HIV 438 children in a hospital in Libya (<a href=\"publications.php?pubid=22\">de Oliveira et al. Nature 2006</a>), open access and public HIV drug resistance databases in Africa (<a href=\"publications.php?pubid=1\">de Oliveira et al. Nature 2010</a>) and the first case of proven HIV surrogate transmission in South Africa (<a href=\"publications.php?pubid=58\">Goedhals et al. Lancet 2012</a>).</p> \n<br><p><b>Current Affiliations:</b>\n<p>Director: KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa.</p> \n<p>Professor (Research): College of Health Sciences, University of KwaZulu-Natal (UKZN), Durban, South Africa.</p>\n<p>Professor and Research Associate, Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, South Africa.</p>\n<p>Director: Southern African Treatment Research Network (SATuRN).</p>\n<p>President: South African Society for Bioinformatics (SASBi).</p>\n<p>Royal Society Newton Fellow at Wellcome Trust Sanger Institute, U.K.</p>', 'de Oliveira', 'T', 'deOliveira_photo.jpg', 3, 'current', NULL),
(3, 'Dr. Justen', 'jmanasa@africacentre.ac.za', '+27 (0) 31 260 3744', '+27 (0) 31 260 4015', 'Completed PhD in 2015. Current at Stanford University.', 'mojizu3.jpg', '<p><b>Background</b></p>My research interests are in translational medicine. Currently I have been working on HIV drug resistance from both epidemiological and clinical management perspectives. I am interested in the optimal use of the currently available tools and new innovative algorithms to monitor the emergence and spread of HIV drug resistance as the antiretroviral treatment programs in Sub-Saharan Africa expand. I am also interested in the development of more affordable diagnostic methods or monitoring algorithms that will enable the integration of HIV drug resistance monitoring in routine clinical care so as to provide optimal care to patients on antiretroviral therapy. </p>', 'Manasa', 'J', 'imgJusten.jpg', 3, 'departed', NULL),
(19, 'Dr. Tiago', 'tiago@gmail.com', '+27 (0)31 260 1925', NULL, 'Research interests in phylogenetics and molecular evolution. ', 'mojizu19.png', '<p><b>Background:</b></p>\n<p>Interested in molecular evolution analysis of virus data. I am specially interested in the application and development of phylogeographic methods. </p>\n\n<p><b>Education:</b></p>\n<p>Ph.D. Biotechnology and Biosciences, Federal University of Santa Catarina, Brazil, 2015</p>\n<p>Ph.D. Fellow, Leuven Catholic University, Belgium, 2014</p>', 'Graf', 'T', 'Tiago_photo.jpg', 3, 'current', 'researcher'),
(2, 'Dr. Siva', 'sdanaviah@africacentre.ac.za', '+27 (0) 31 260 3744', '+27 (0) 31 260 4015', 'Laboratory specialist at Africa Health Research Institute (AHRI)', 'mojizu8.jpg', '<p><b>Background</b></p>\n<p>Siva Danaviah received a PhD from University of KwaZulu-Natal in 2009 with training in Molecular Virolgy and Bioinformatics. My doctoral research on the Immunopathogenesis of TB Spondylitis in HIV-Infected and -uninfected patients, suggested viral compartmentalization in the isolated spinal TB granuloma, which was a novel finding. The study also highlighted the need for a more sensitive, broad-range molecular diagnostic tool for pauci-bacillary diseases such as spinal TB. My investigation of T-cell proliferation in spinal TB granulomas of HIV-infected and -uninfected patients indicated a greater role of CD8 T-cells in the site specific immune response in CD4 depleted / immunosuppressed patients.  </p>', 'Danaviah', 'S', 'Danaviah.jpg', 3, 'departed', NULL),
(5, 'Sureshnee', 'spillay@africacentre.ac.za', '+27 (0) 31 260 4654', '+27 (0) 31 260 4015', 'Completed her MSc in 2014. Currently at Africa Centre for Health and Population Studies.', 'mojizu5.jpg', '<p><b>Background</b></p>\n<p>I am currently studying towards my Masters degree at the Africa Centre Virology Laboratory. My research involves investigating the virologic failure and the spectrum of drug resistance mutations in a paediatric ART programme in Rural KZN, SA. We used the open access Southern African Treatment Resistance Network (SATuRN) drug resistance genotyping system in this study to show that genotyping to assess resistance patterns and to guide treatment switches can be done affordably in resource limited settings such as ours.</p>', 'Pillay', 'S', 'SureshneePillayphoto.jpg', 3, 'departed', NULL),
(4, 'Dr. Eduan', 'ewilkinson83@gmail.com', '+27 (0) 35 550 7500', '+27 (0) 35 550 7565', 'My main area of interest is the molecular epidemiology of HIV-1 in the Southern African region. ', 'mojizu4.png', '<p><b>Background</b></p>\n<p>I recently completed my PhD at Stellenbosch University, which focused on uncovering the history and macro-dynamic aspects of the heterosexual HIV-1 subtype C epidemic in the Southern African region. I recently joined the Africa Centre for Health and Population Studies as a post-doctoral research fellow under the supervision of Prof. Tulio de Oliveira. My post-doctoral research focuses on the identification and characterization of transmission events of HIV-1 in a small rural community in KwaZulu-Natal, South Africa, in order to obtain a better understanding of the factors driving transmission of the virus in this rural community, and to develop better targeted HIV-1 prevention strategies. </p>', 'Wilkinson', 'E', 'Eduan.jpg', 1, 'current', NULL),
(6, 'Dr. Phetole', 'thakgalo03@gmail.com', '+27 (0)12 319 2', '+27 (0)12 323 7', 'Completed his PhD in 2014', 'mojizu10.jpg', NULL, 'Walter Mahasha', 'P', NULL, 1, 'departed', NULL),
(7, 'Lavanya', 'singhl@ukzn.ac.za', '+27 (0)31 240 2', '+27 (0)31 240 2', 'Completed her MSc (Cum Laude) in 2014. ', 'mojizu13.jpg', NULL, 'Singh', 'L', NULL, 3, 'departed', NULL),
(8, 'Pascal', 'pascal@jembi.org', '+27 (0) 21 701', ' +27 (0) 21 701', 'Completed MSc in 2014. Current at Stanford University', 'mojizu11.jpg', NULL, 'Brandt', 'P', NULL, 3, 'departed', NULL),
(13, 'Dr. Richard', 'rjlessells@gmail.com', '+27 31 260 4898', '+27 35 550 7565', 'Completed a Wellcome Trust Clinical Research Fellowship and PhD at LSHTM, U.K. Clinical Infectious Diseases Specialist with interests in HIV & TB drug resistance, epidemiology and clinical management', 'KiltedSmurf.png', '<p><b>Background</b></p>\n<p>I am a Clinical Research PhD Graduate from the London School of Hygiene and Tropical Medicine and am currently based at the Africa Centre for Health and Population Studies. I was funded by a fellowship from the Wellcome Trust and my research is focused on evaluation of TB and HIV diagnostics, with a particular interest in drug resistance. </p>\n<p><b>Affiliations: </b></p>\n<p>Group Leader: KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa.</p> \n<p>Associate: Centre for the AIDS Programme of Research in South Africa Advanced Clinical Care (CAPRISA ACC), Durban, South Africa.</p> \n<p>Associate: Infectious Diseases Department, Nelson R Mandela School of Medicine, UKZN, Durban, South Africa.</p> \n\n\n', 'Lessells', 'R', 'Richard.jpg', 3, 'current', NULL),
(9, 'Dr. Filipe', 'filipefar@hotmail.com', '+27 (0) 31 260 4654', '+27 (0) 31 260 4015', 'Completed his PhD in 2014. Current a researcher at Bahian School of Medicine.', 'mojizu5.jpg', NULL, 'Rego', 'F', NULL, NULL, 'departed', NULL),
(10, 'Jaffer', 'jaffer_mz@hotmail.com', '+27 35 550 7500', '+27 35 550 7565', 'Completed his research fellowship in 2014. Currently doing a PhD at Harvard University', 'mojizu2.jpg', '<p><b>Background</b></p>\n<p>I am a statistician, helping virologists and bioinformaticians with their data analysis.  My research interests are both theoretical and applied: I interested in the associations between HIV drug resistance and clinical/demographic variables.  On the theoretical side, I have recently become interested phylogenetic tree construction and the underlying mathematical properties of such trees.  </p>', 'Zaidi', 'J', 'jafferphoto.jpg', NULL, 'departed', NULL),
(16, 'Rachael', 'rachael.dellar@gmail.com', '+25 (0) 31 260 3744', '+27 (0) 35 550 7565', 'Completed research fellowship in 2015. Current at Oxford University', NULL, '<p><b>Background</b></p>\n<p>I currently work as a research fellow at the Africa Centre for Health and Population Studies. Under the supervision of <a href=\"people.php?peopleid=1\">Prof. Tulio de Oliveira</a> and Prof. Frank Tanser, I am investigating the transmission of HIV to adolescent girls and young women in rural KwaZulu-Natal using phylogenetic and epidemiological methods.  More specifically, I am trying to characterise men most likely to infect adolescent women (in terms of age, residence, stage in HIV care cascade etc.) in order to inform the targeting of prevention interventions toward these men. </p>\n<br><p><b>Education:</b> <p>\nMaster of Biochemistry, Oxford University, Oxford, U.K.</p>', 'Dellar', NULL, 'Dellar_photo.jpg', NULL, 'departed', NULL),
(14, 'Dr. Glen', 'glen.malherbe@tuks.co.za', NULL, NULL, 'Completed his PhD in 2014. ', NULL, NULL, 'Malherbe', NULL, NULL, NULL, 'departed', NULL),
(15, 'Dr. Ben', 'murrellb@gmail.com', NULL, NULL, 'Completed his MSc in 2013. Research Fellow at University of San Diego.', NULL, '', 'Murrell', NULL, NULL, NULL, 'departed', NULL),
(18, 'Nicolette', 'croziern@ukzn.ac.za', '+27 (0) 31 260 1925', '+27 (0) 35 550 7565', 'I currently work as a Bioinformatics Science Manager for BioAfrica at Nelson Mandela School of Medicine for Prof. Tulio de Oliveira and Prof. Frank Tanser ', 'mojizu18.png', '<p><b>Background</b></p><p>Working with Prof. Tulio de Oliveira and Prof. Frank Tanser as a Bioinformatics Science manager managing all sectors of the department. Previously been involved in the corporate environment for the last 15 years. Qualified in a Bachelor of Science - majoring in Microbiology and Biochemistry, computer science, quality management, financial and project management, as well as health and safety. Currently busy with Honors through Unisa and to progress into Masters in Virology thereafter.</p>\n<p><b>Education</b></p><p>\nBSc. In Microbiology and Biochemistry, Unisa, South Africa.</p>\n', 'Crozier', 'N', 'nicolette.png', 3, 'current', 'management'),
(17, 'Farirai', 'mutenherwaf@gmail.com', '+27 (0) 31 260 3744', '+27 (0) 35 550 7565', 'My PhD focuses on the social, ethical and legal issues associated with using pathogen data to link infections, in particular, using phylogenetic analysis results as evidence to prove HIV transmission', 'mojizu17.jpg', '<p><b>Background</b></p>\n<p>PhD student under the supervision of <a href=\"people.php?peopleid=1\">Professor Tulio de Oliveira</a> and Professor Douglass Wassenaar. My PhD focuses on the social, ethical and legal issues associated with using pathogen data to link infections, in particular, using phylogenetic analysis results as evidence to prove HIV transmission.  My previous work has focused on the quality of the informed consent process and the review and oversight of social and behavioural research in a Zimbabwean context.</p>\n<p><b>Fellowship:</b></p>\n<p>Wellcome Trust Ethics Bursary Fellow at the Global Health Bioethics Network (GHBN) with project title: <i>\"Ethical issues in the use of molecular epidemiological techniques - a literature review and expert opinion analysis.</i> Link to <a href=\"http://e-mops.ning.com/page/featured-project-ethical-issues-in-the-use-of-molecular-epidemiol\">Farirai fellowship at GHBN website.</a></p>\n<p><b>Education:</b></p>', 'Mutenherwa', NULL, 'Mutenherwa_photo.png', NULL, 'current', NULL),
(20, 'Dr. Andrew', 'atomita@africacentre.ac.za', '+27 (0) 31 260 3744', NULL, 'Post-doctoral researcher fellow with interests in BIG DATA analysis. ', 'mojizu20.png', '<p><b>Background:</b></p>\n<p>Interested in BIG data analysis and social determinates of health. Epidemiology of HIV transmission. Mental health intervention in sub-Saharan Africa</p>\n\n<p><b>Education:</b></p>\n<p>Ph.D. Columbia University School of Social Work, 2011</p>\n<p>Master of Public Administration, Columbia University School of International and Public Affairs, 2006</p>\n<p>Bachelor of Science in Business Administration, Boston University School of Management, 2000</p>\n', 'Tomita', 'A', 'Tomita_photo.png', NULL, 'current', NULL),
(21, 'Dr. Alain', 'avandormael@africacentre.ac.za', '+27 (0) 31 260 3744', NULL, 'Post-doctoral researcher fellow. Multi-disciplinary research interests, including sociology, epidemiology, statistics, and demography.', 'mojizu21.png', '<p><b>Background:</b></p>\n<p>As a social epidemiologist, I am interested in identifying the set of demographic, institutional, and clinic level factors that may limit the efficacy of HIV prevention strategies in the South African context. These factors are likely to be associated with distinct and identifiable risk groups that continue to drive the high levels of new HIV infections within rural communities. I have experience in the statistical analysis of surveillance, longitudinal, and cross-sectional survey data using Stata and R. I have also partnered in academic and government settings; collaborated on multidisciplinary research projects, reports and publications; and acquired experience in the planning and management of research-related projects.\n</p>\n\n<p><b>Education:</b></p>\n<p>Ph.D. Sociology University of Minnesota, Twin Cities, Sept. 2014</p>\n<p>M.S. Statistics University of Minnesota, Twin Cities, February 2014</p>\n<p>M.A. Sociology University of Pretoria, South Africa, May 2005</p>\n<p>B.A. Psychology University of Pretoria, South Africa, January 2003</p>\n', 'Vandormael', 'A', 'Vandormael_photo.jpg', NULL, 'current', NULL),
(22, 'Dr. Jennifer', 'jennifer.giandhari@gmail.com', '+27 (0) 31 260 3744', NULL, 'Post-doctoral researcher fellow. Research interests in HIV-1 genomics and drug resistance.', 'mojizu22.png', '<p><B>Background</b></p>\n<p>Jennifer Giandhari  joined our group studies as a postdoctoral researcher under the supervision of Prof. Tulio de Oliveira. Her postdoctoral research focuses on identifying new drug resistance mutations to protease inhibitors outside of the protease gene by using a genomics and bioinformatics approach. This will assist in the management of patients failing second-line therapy and help guide effective third line options. The project forms part of the Southern African Treatment Resistance Network (SATuRN) and will provide the largest sample dataset of patients failing protease inhibitors in South Africa. </p>\n<br><p><b>Current Affiliations:</b> </p>\n<p>NGS Platform Manager: KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa.</p> \n<p>Post-Doctoral fellow: College of Health Sciences, University of KwaZulu-Natal (UKZN), Durban, South Africa.</p>\n<p>DST-NRF PDP felllow, Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, South Africa.</p>\n\n<p><b>Education:</b></p>\n<p>PhD in Virology from the University of Witwatersrand in 2015. </p>\n<p>MSc in Virology from the Nelson R Mandela School of Medicine, UKZN, in 2012.</p>\n\n', 'Giandhari', 'J', 'Giandhari_photo.png', NULL, 'current', NULL),
(23, 'Benjamin', 'benjiechim@yahoo.com', '+27 (0) 31 260 3744', NULL, 'PhD student. Research interests on genomics, bioinformatics and drug resistance. PhD in collaboration with CAPRISA, NHLS and Stanford University.', 'mojizu23.png', '<p><b>Background:</b></p>\r<p>PhD student in Virology at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa. My research interests are in understanding levels of primary HIV-1 drug resistant minority variants and their impact on antiretroviral treatment (ART). I would specifically want to determine how drug resistant minority variants detected using next generation sequencing platforms can be used to inform use of antiretroviral drugs in clinical practice, when initiating patients on ART. I am also interested in the use of bioinformatics for large scale data analysis in the field of molecular biology. </p>\r\r<p><b>Affiliations:</b></p>\n<p>KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa.</p> \r<p>Department of Virology, National Health Laboratory Service (NHLS), Durban, South Africa (PhD student).</p>\r<p>Centre for AIDS Programme of Research (CAPRISA), South Africa (Research fellow).</p>\r<p>Letten Foundation, Oslo University, Norway (Research fellow).</p>\r', 'Chimukangara', 'B', 'Chimukangara_photo.png', NULL, 'current', NULL),
(24, 'Dr. Yumna', 'yumbilina@gmail.com', '+27 (0) 31 260 3744', NULL, 'PhD/MSc student. Research interests in viromics, bioinformatics and mathematics. ', 'mojizu24.jpg', '<p><b>Background:</b></p>\n<p>Interested in the use of next generation sequencing (NGS) technology and bioinformatics methods to survey the microbiome and virome present in a clinical sample. </p>\n\n<br><p><b>Current Affiliations:</b> \n<p>MSC/PhD student, University of KwaZulu-Natal (UKZN), Durban, South Africa.</p>\n<p>Fellow, Centre for the Aids Programme of Research in South Africa (CAPRISA), Durban, South Africa.</p>\n<p>Student Council President: South African Society for Bioinformatics (SASBi).</p>\n\n\n<p><b>Education:</b></p>\n<p>Pure mathematics, University of South Africa, 2015</p>\n<p>Bachelor of Medicine and Surgery (MBChB), University of Cape Town, 2012</p>\n<p>Top 10 (silver medalist) in the South African Mathematics Olympiad, 2005</p>\n', 'Moosa', 'Y', 'Moosa_photo.png', NULL, 'current', NULL),
(25, 'Dr. Sikhulile', NULL, NULL, NULL, 'Completed his PhD in 2016. Current at Botswana Harvard Partnership (BHP)', NULL, '', 'Moyo', 'S', NULL, NULL, 'departed', NULL),
(26, 'Megan', NULL, NULL, NULL, 'Completed her MSc (Cum Laude) in 2016. Awareded a PhD fellowship at the German Cancer Research Institute (DKFZ)', NULL, NULL, 'Druce', 'M', NULL, NULL, 'departed', NULL),
(27, 'Sthembiso', NULL, NULL, NULL, 'Completed his MSc in 2016. Lab manager at National Healh Laboratories (NHLS)', NULL, NULL, 'Msweli', 'S', NULL, NULL, 'departed', NULL),
(28, 'Phiwokuhle', NULL, NULL, NULL, 'Completed MSc in 2016. ', NULL, NULL, 'Mjoli', 'P', NULL, NULL, 'departed', NULL),
(29, 'Dr. Veron', 'Veron.ramsuran@gmail.com', '+27 (0) 31 260 4898', NULL, 'My work focus on host factors associating with HIV disease, with special interest on the Human Leukocyte Antigen (HLA) genes. I am also very interested epigenetics techniques such as CRISPR and DNA methylation.', 'mojizu29.png', '<p><b><i>Background:</b></i></p> \n<p>Dr. Veron Ramsuran graduated with a PhD from the University of KwaZulu-Natal where he examined host factors associating with HIV disease. He spent almost 70% of his PhD in two international laboratories, i.e. Fred Hutchinson Cancer Research Center and The University of Texas Health Science Center at San Antonio. After completion of his PhD he was recruited to join the Ragon Institute of MGH, MIT and Harvard as a post-doctoral research fellow, he had a joint affiliation with a contractor to the NIH and NCI. His appointment was under the mentorship of Dr. Mary Carrington. His work continued to focus on host factors associating with HIV disease, with special interest on the Human Leukocyte Antigen (HLA) genes. After completing 5 years in these institutes Dr. Ramsuran returned to South Africa where he is currently a Senior Lecturer within the University of KwaZulu-Natal.</p>\n\n<p><b><i>Current Affiliations:</b></i></p>\n<p>Group leader: KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa.</p> \n<p> - Senior Lecturer: School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa.</p>\n\n<p><b><i>Education:</b></i></p>\n<p> - Post Doctorate: Ragon Institute of MGH, MIT and Harvard and National Cancer Institute (NCI) a division of the National Institute of Health (NIH) (2012-2016).</p>\n<p> - PhD in Genetics: HIV Pathogenesis Programme and University of KwaZulu-Natal (2007-2011).</p>\n<p> - MSc in Genetics: School of Life Sciences, University of KwaZulu-Natal (2006).</p>', 'Ramsuran', 'V', 'veron.jpg', NULL, 'current', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `b_projects`
--

CREATE TABLE `b_projects` (
  `id` int(11) UNSIGNED NOT NULL,
  `title` longtext,
  `short` char(50) DEFAULT NULL,
  `webpage` mediumtext,
  `date` int(4) DEFAULT NULL,
  `image` text,
  `summary` longtext,
  `people` mediumtext,
  `funder` mediumtext,
  `expertise` longtext,
  `externalPI` mediumtext
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_projects`
--

INSERT INTO `b_projects` (`id`, `title`, `short`, `webpage`, `date`, `image`, `summary`, `people`, `funder`, `expertise`, `externalPI`) VALUES
(1, 'Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention.', 'HIV & HCV Genomics', NULL, 2017, 'news177.png', 'This is the NIH grant R01 (PIs: Herbeck & ) from the University of Washington to identify the causes and consequences of HIV & HCV transmission in key populations in Kenya.  ', 'Tulio de Oliveira', 'National Institute of Health (NIH)', 'Phylogenetics, Population Genetics, Epidemiology, Genomics, NGS data processing, Variant calling,  Sequence analysis, Statistics, Virology', NULL),
(2, 'Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study', 'HIV Phylogenetics', NULL, 2017, 'imgcaprisa.png', 'This is the CAPRISA HIPPS phylogenetic project (PI: Kharsany) that aims to identify the source of HIV-1 infection to young woman in a hyper-epidemic setting in South Africa.', 'Tulio de Oliveira', 'SAMRC & US CDC', 'Phylogenetics, Population Genetics, Epidemiology, Genomics, Sanger data processing, Sequence analysis, Statistics, Virology', NULL),
(3, 'Full length sequencing and biological characterisation of early divergent HIV-1 lineages from Cameroon', 'HIV origin', NULL, 2017, 'imgnews77.png', 'This is a collaborative SANTHE research project (PIs: Tongo & de Oliveira) that aims to produce new whole genome strains of HIV strains sampled in Cameroon. ', 'Marcel Aime Togo', 'Wellcome Trust SANTHE programme', 'Phylogenetics, Population Genetics, Epidemiology, Genomics, PCR optimisation, NGS data processing, Variant calling,  Sequence analysis, Statistics, Virology', NULL),
(4, 'Validation of HIV-1 dried blood splots (DBS) sequencing for phylogenetic analysis', 'DBS sequencing', NULL, 2017, 'imgnews120sm.png', 'This is a validation project that aims to use of dried blood spot (DBS) to generate HIV-1 drug resistance genotypes. This validation project includes quality control and externally evaluation panels.', 'Benjamin Chimukangara', 'South African Medical Research Council (SAMRC)', 'DBS RNA extraction, PCR optimisation, Sanger data processing, Sequence analysis, Clinical bioinformatics, Virology', NULL),
(5, 'VIROGENESIS', 'VIROGENESIS', NULL, 2017, 'imgnews119.png', 'This is a EC H2020 research and development programme (PI: Vandamme). The objective of this programme is to develop the next generation of bioinformatics software application to analyze virus genomes', 'Tulio de Oliveira & Vagner Fonseca', 'European Commission (EC) H2020 framework', 'Software optimization, Software development, NGS data processing, Genomics, Phylogenetics, Population Genetics, Clinical bioinformatics, Virology ', NULL),
(6, 'MHC HLA expression levels and HIV-1', 'HLA expression', NULL, 2017, 'imgnews75.png', 'This is a collaborative project with the National Institute of Health (PI: Mary Carrington). The objective of this project is to determine how HLA variation and expression impact on HIV-1 transmission and disease progression.', 'Veron Ransuram', 'National Instiute of Health (NIH)', 'Genetics, Genomics, Population Genetics, Genome-wide association studies, HLA expression, DNA sequencing, Virology, Immunology', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `b_publications`
--

CREATE TABLE `b_publications` (
  `id` int(11) NOT NULL,
  `title` longtext,
  `authors` longtext,
  `abstract` longtext,
  `journal` char(50) DEFAULT NULL,
  `volume` longtext,
  `citations` int(11) DEFAULT NULL,
  `link` longtext,
  `file` char(50) DEFAULT NULL,
  `keywords` longtext,
  `topdescription` longtext,
  `pages` tinytext,
  `datafile` tinytext,
  `date` int(4) DEFAULT NULL,
  `doi` tinytext,
  `impact` float DEFAULT NULL,
  `bioafricaSATuRN` int(1) DEFAULT NULL,
  `video` int(11) DEFAULT NULL,
  `shorttitle` longtext,
  `feature` char(1) DEFAULT '',
  `projectid` int(11) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_publications`
--

INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(1, 'Public Database for HIV Drug Resistance in southern Africa', 'de Oliveira T, Shafer WR, Seebregts C, for SATuRN', '<p>The Opinion article by S. Karim\rand Q. Karim laments the lack of\ran effective conduit between\rSouth Africa\'s AIDS research and\rits prevention and treatment\rpolicies and programmes (Nature\r463, 733?734; 2010). We would\rlike to draw attention to an HIV-1\rdrug-resistance database, a\rscientific resource for regional and\rglobal HIV research that will\renhance surveillance programmes\rin southern Africa.\r</p><p>The database was established\rby investigators from the\rSouthern African Treatment and\rResistance Network (SATuRN),\rin collaboration with researchers\rfrom the United States and Europe.\rSATuRN will provide national\rdepartments of health with highquality,\rup-to-date information\rto guide delivery of antiretroviral\rtherapy, helping to ensure the\rlong-term success of antiretroviral\rtreatment programmes.\rAs part of this network, we have\rinstalled a South African mirror of\rthe Stanford HIV Drug Resistance\rDatabase (HIVDB). This mirror\r(www.bioafrica.net/saturn) will\rbe continuously updated and\rreleased to local investigators in\ra curated and readily analysable\rform, in the context of more than\r120,000 sequences already in the\rStanford HIVDB. Neighbouring\rcountries that share subtype C as\rthe predominant virus (the strain\rfuelling southern Africa\'sAIDS\repidemic) are also providing data.\r</p><p>The mirror will ensure that\rsubtype-C sequences are\ranalysed according to standard\rstate-of-the-art technologies\rdeveloped by Stanford HIVDB.\rIt will help patient management,\rallowing quick identification of\rresistant strains and systematic\rtracking both of resistance\rpatterns and of prevalence\rand distribution of resistance\rmutations within different\rpopulation groups. It will inform\rdecisions about new drugs,\rdiagnostics and treatment\rstrategies in southern Africa.\r</p><p>Already, the data show that\rresistance in newly infected\rindividuals is still very low (under\r5%), as is the accumulation of\rthymidine-analogue mutations\rthat can limit the effectiveness of\rsecond-line antiretroviral therapy.\rInvestigators, clinicians and\rlaboratories wishing to take part in\rthe collaboration should contact\rthe authors.', 'Nature', '464(7289)', 27, 'www.bioafrica.net/saturn/', 'deOliveiraHIVDRNature', 'database, hiv, drug resistance, ARV, resistance, Africa, SATuRN, bioinformatics, tulio, oliveira, sequence', 'HIV-1\rdrug-resistance database, a\rscientific resource for regional and\rglobal HIV research that will\renhance surveillance programmes\rin southern Africa. The database was established\rby the\rSouthern African Treatment and\rResistance Network (SATuRN),\rin collaboration with researchers\rfrom the United States and Europe.', '673', NULL, 2010, NULL, 34.48, 3, NULL, NULL, NULL, NULL),
(2, 'The HIV-1 Subtype C Epidemic in South America is Linked to the United Kingdom', 'de Oliveira T, Pillay D, Gifford RJ; for the UK Collaborative Group on HIV Drug Resistance', '<p><i>Background:</i> The global spread of HIV-1 has been accompanied by the emergence of genetically distinct viral strains. Over \nthe past two decades subtype C viruses, which predominate in Southern and Eastern Africa, have spread rapidly throughout \nparts of South America. Phylogenetic studies indicate that subtype C viruses were introduced to South America through a \nsingle founder event that occurred in Southern Brazil. However, the external route via which subtype C viruses spread to the \nSouth American continent has remained unclear. </p><p>\n<i>Methodology/Principal Findings: </i>We used automated genotyping to screen 8,309 HIV-1 subtype C pol gene sequences \nsampled within the UK for isolates genetically linked to the subtype C epidemic in South America. Maximum likelihood and \nBayesian approaches were used to explore the phylogenetic relationships between 54 sequences identified in this screen, \nand a set of globally sampled subtype C reference sequences. Phylogenetic trees disclosed a robustly supported \nrelationship between sequences from Brazil, the UK and East Africa. A monophyletic cluster comprised exclusively of \nsequences from the UK and Brazil was identified and dated to approximately the early 1980s using a Bayesian coalescent- \nbased method. A sub-cluster of 27 sequences isolated from homosexual men of UK origin was also identified and dated to \nthe early 1990s. </p><p>\n<i>Conclusions:</i> Phylogenetic, demographic and temporal data support the conclusion that the UK was a crucial staging post \nin the spread of subtype C from East Africa to South America. This unexpected finding demonstrates the role of diffuse \ninternational networks in the global spread of HIV-1 infection, and the utility of globally sampled viral sequence data in \nrevealing these networks. Additionally, we show that subtype C viruses are spreading within the UK amongst men who have \nsex with men. </p>\n', 'PLoS One', '19;5(2)', 47, '', 'deOliveiraBrazilsubC', 'Brazil, HIV-1 subtype C, South America, U.K., United Kingdom, England, Africa, C, sequence, phylogeny, history, tulio, oliveira, robert, gifford', NULL, 'e9311', NULL, 2010, NULL, 4.411, 1, NULL, NULL, NULL, NULL),
(3, 'Evolution and Molecular Epidemiology of Subtype C HIV-1 in Zimbabwe', 'Dalai SC, de Oliveira T, Harkins GH, Kassaye SG, Lint J, Manasa J, Johnston E, Katzenstein D', '<p><i>Objective:</i> To investigate the origins and evolutionary history of subtype C HIV-1 in\rZimbabwe in a context of regional conflict and migration.\r</p><p><i>Design:</i> HIV-1C pol sequence datasets were generated from four sequential cohorts of\rantenatal women in Harare, Zimbabwe sampled over 15 years (1991-2006).\r</p><p><i>Methods: </i>One hundred and seventy-seven HIV-1C pol sequences were obtained from\rfour successive cohorts in Zimbabwe. Maximum-likelihood methods were used to\rexplore phylogenetic relationships between Zimbabwean HIV-1C sequences and\rsubtype C strains from other regions. A Bayesian coalescent-based framework was\rused to estimate evolutionary parameters for HIV-1C in Zimbabwe, including origin\rand demographic growth patterns.\r</p><p><i>Results:</i> Zimbabwe HIV-1C pol demonstrated increasing sequence divergence\rover the 15-year period. Nearly all Zimbabwe sequences clustered phylogenetically\rwith subtype C strains from neighboring countries. Bayesian evolutionary analysis\rindicated a most recent common ancestor date of 1973 with three epidemic\rgrowth phases: an initial slow phase (1970s) followed by exponential growth\r(1980s), and a linearly expanding epidemic to the present. Bayesian trees provided\revidence for multiple HIV-1C introductions into Zimbabwe during 1979-1981, corresponding\rwith Zimbabwean national independence following a period of socio-political\rinstability.\r</p><p><i>Conclusion:</i> The Zimbabwean HIV-1C epidemic likely originated from multiple introductions\rin the late 1970s and grew exponentially during the 1980s, corresponding to\rchanging political boundaries and rapid population influx from neighboring countries.\rThe timing and phylogenetic clustering of the Zimbabwean sequences is consistent with\ran origin in southern Africa and subsequent expansion. HIV-1 sequence data contain\rimportant epidemiological information, which can help focus treatment and prevention\rstrategies in light of more recent political volatility in Zimbabwe', 'AIDS', '23(18)', 40, '', 'DalaiZimbabwe', 'epidemiology, evolutionary, history, HIV-1, origin, subtype C, Zimbabwe, Africa, tulio, oliveira, sudeb, dalai, david, katzenstein, phylogeny, phylogenetic, C, virus', 'Using a combination of molecular clock\ranalysis, to estimate the timescale of the epidemic, and\ra Bayesian coalescent-based approach, to infer demographic\rparameters of virus transmission, we present new\rinformation on the origins, timing, and epidemic growth\rpatterns of subtype C HIV-1 during a period of inmigration\rand political change in Zimbabwe.', '2523-32', 'DalaiZim.fasta', 2009, NULL, 5.46, 3, NULL, NULL, NULL, NULL),
(5, 'Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa.', 'Huang KH, Goedhals D, Fryer H, van Vuuren C, Katzourakis A, De Oliveira T, Brown H, Cassol S, Seebregts C, McLean A, Klenerman P, Phillips R, Frater J; Bloemfontein-Oxford Collaborative Group.', '<p><i>BACKGROUND: </i>We aimed to characterize the molecular epidemiology of HIV type-1 (HIV-1) and the prevalence of drug-associated mutations prior to initiating highly active antiretroviral therapy (HAART) in the Free State province, South Africa. The Free State has a population of 3 million, an antenatal HIV prevalence of approximately 34% and a well established infrastucture for antiretroviral (ARV) provision.\n\n</p><p><i>METHODS: </i>HIV-1 polymerase genes were sequenced from 425 HAART-naive HIV-1-positive patients at voluntary primary healthcare HIV testing centres, who were subsequently attending district centres for assessment for commencing ARVs. Patients (>18 years) were sampled randomly with no exclusion for gender or clinical criteria. Sequences were analysed according to phylogeny and drug resistance.\n\n</p><p><i>RESULTS: </i>Phylogenetic clustering within the cohort was suggestive of multiple introductions of subtype C virus into the region. Drug resistance mutations (according to the International AIDS Society-USA classification) were distributed randomly across the cohort phylogeny with an overall prevalence of 2.3% in the sampled patients. When stratified according to CD4(+) T-cell count, the prevalence of resistance was 3.6%, 0.9% and 1.2% for CD4(+) T-cell counts <100, 200-350 and >500 cells/microl, respectively, and was most common for non-nucleoside reverse transcriptase inhibitor resistance (3.1% in patients with CD4(+) T-cell count <100 cells/microl). We surveyed all drug-selected mutations and found further significant clustering among patients with low CD4(+) T-cell counts (P=0.003), suggesting unrecognized exposure to ARVs.\n\n</p><p><i>CONCLUSIONS: </i> In the Free State population, there was a statistical association between low CD4(+) T-cell counts and drug-associated viral polymorphisms. Our data advocate the benefit of detailed history taking from patients starting HAART at low CD4(+) T-cell counts with close follow-up of the virological response.</p>', 'Antivir Ther.', '14(7)', 19, 'www.bioafrica.net/saturn/', 'HuangAntiviral', 'Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Drug Resistance, Multiple, Viral/genetics, Prevalence,\nRNA, Viral/analysis, RNA, Viral/genetics,South Africa, epidemiology, free, state, bloemfontein,  tulio, oliveira, chris, seebregts, cloete van vuuren, phylogeny, phylogenetic, C, virus', NULL, '975-84', NULL, 2009, NULL, 4.32, 3, NULL, NULL, NULL, NULL),
(6, 'Comparative performance of the REGA subtyping tool version 2 versus version 1', 'Abecasis AB, Wang Y, Libin P, Imbrechts S, de Oliveira T, Camacho RJ, Vandamme AM', '<p>The REGA HIV-1 subtyping tool is a phylogenetic-based method for subtyping HIV-1 genomic sequences that was published in 2005. The subtyping tool combines phylogenetic approaches with recombination detection methods. Recently, version 2 was released (http://www.bioafrica.net/rega-genotype/html/index.html) as an improvement of version 1. Version 2 implements a Decision-Tree-based algorithm that was not implemented in version 1. \n</p><p>We wanted to compare the two versions on a large sequence dataset to assess the improvements of version 2 and to verify whether features lost during updating the tool needed to be recovered. We analysed the results of the two versions in the genotyping of 4676 HIV-1 pol sequences. We compared those results to a manual approach, used in previous studies. Our results show that version 2 has an overall better sensitivity but especially for the detection of subtypes A, B, D, F, G and CRF14_BG and CRF06_CPX. For the other subtypes, no significant differences were observed in the sensitivity of versions 1 and 2. The overall increase in sensitivity was however accompanied by a decrease in the specificity for the detection of subtype B. This is the main limitation of version 2. However, while the number of false negatives decreased by 53 samples, the number of false positives increased only by 5 samples from version 1 to 2. \n</p><p>The performance of the REGA HIV-1 subtyping tool was considerably improved from one version to the other. Our results are very valuable and allow us to make suggestions for further improvement of the tool for a version 3 release.</p>', 'Infect Genet Evol.', '10(3)', 14, 'www.bioafrica.net/rega-genotype/html/', 'abecasis07.pdf', 'REGA, subtyping, tool, abecasis, version 2, comparison, bioinformatics, software, genotyping, hiv, HIV-1, tulio, oliveira, ', NULL, '380-5', NULL, 2010, NULL, 3.223, 1, NULL, NULL, NULL, NULL),
(7, 'A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences', 'Alcantara LC, Cassol S, Libin P, Deforche K, Pybus OG, Van Ranst M, Galvao-Castro B, Vandamme AM, de Oliveira T', '<p>Human immunodeficiency virus type-1 (HIV-1), hepatitis B (HBV) and C (HCV) and other rapidly evolving viruses are characterized by extremely high levels of genetic diversity. \n</p><p>To facilitate diagnosis and the development of prevention and treatment strategies that efficiently target the diversity of these viruses, and other pathogens such as human T-lymphotropic virus type-1 (HTLV-1), human herpes virus type-8 (HHV8) and human papillomavirus (HPV), we developed a rapid high-throughput-genotyping system. \n</p><p>The method involves the alignment of a query sequence with a carefully selected set of pre-defined reference strains, followed by phylogenetic analysis of multiple overlapping segments of the alignment using a sliding window. Each segment of the query sequence is assigned the genotype and sub-genotype of the reference strain with the highest bootstrap (>70%) and bootscanning (>90%) scores. \n</p><p>Results from all windows are combined and displayed graphically using color-coded genotypes. The new Virus-Genotyping Tools provide accurate classification of recombinant and non-recombinant viruses and are currently being assessed for their diagnostic utility. They have incorporated into several HIV drug resistance algorithms including the Stanford (http://hivdb.stanford.edu) and two European databases (http://www.umcutrecht.nl/subsite/spread-programme/ and http://www.hivrdb.org.uk/) and have been successfully used to genotype a large number of sequences in these and other databases. \n</p><p>The tools are a PHP/JAVA web application and are freely accessible on a number of servers including: http://bioafrica.mrc.ac.za/rega-genotype/html/, http://lasp.cpqgm.fiocruz.br/virus-genotype/html/, http://jose.med.kuleuven.be/genotypetool/html/</p>', 'Nucleic Acids Res', '37(Web Server issue)', 92, 'www.bioafrica.net/rega-genotype/html/', 'AlcantaraVirusGenotyping', 'Rega Version 2, HTLV-1, HPV, HCV, HBV, Subtyping, genotyping, tools, citation, Alcantara, bioinformatics, Luiz Carlos, tulio, oliveira, HIV, ', 'Citation for the usage of Rega Subtyping tools, including the Oxford HCV Subtyping Tool, Oxford HBV Subtyping Tool, LASP HTLV-1 Subtyping Tool, Rega HPV Subtyping Tool, HIV-1 Rega Subtyping tool version 2.0', 'W634-42', NULL, 2009, NULL, 7.479, 1, NULL, NULL, NULL, NULL),
(8, 'Functional characteristics of HIV-1 subtype C compatible with increased heterosexual transmissibility', 'Walter BL, Armitage AE, Graham SC, de Oliveira T, Skinhoj P, Jones EY, Stuart DI, McMichael AJ, Chesebro B, Iversen AK', '<p><i>BACKGROUND:</i> Despite the existence of over 50 subtypes and circulating recombinant forms of HIV-1, subtype C dominates the heterosexual pandemic causing approximately 56% of all infections.\n\n</p><p><i>OBJECTIVE:</i> To evaluate whether viral genetic factors may contribute to the observed subtype-C predominance.\n\n</p><p><i>METHODS:</i> Chimeric viruses were generated using V1-V3 envelope fragments from a subtype-A/C dually infected woman with preferential genital replication of subtype C. Viral adaptation, spread and cell fusion ability were evaluated in vitro using peripheral blood mononuclear cells and HeLa-CD4-CCR5 cell lines, sequencing and cloning. Structural modeling was performed using a crystal structure of gp120-CD4-X5. Phylogenetic analysis was done using subtype-A, subtype-B and subtype-C sequences from blood and cervix of 37 infected women and database sequences.\n\n</p><p><i>RESULTS:</i> We identified two envelope motifs, compact V1-V2 loops and V3-316T, which are found at high frequency throughout subtype-C evolution and affect gp120 interactions with CD4 and CCR5, respectively. When a V1-Delta5 deletion or V3-A316T was incorporated into subtype A, each increased viral fusion and spread several fold in peripheral blood mononuclear cell and cell lines with low CCR5 expression. Structural modeling suggested the formation of an additional hydrogen bond between V3 and CCR5. Moreover, we found preferential selection of HIV with 316T and/or extremely short V1-V2 loops in cervices of three women infected with subtypes A/C, B or C.\n\n</p><p><i>CONCLUSION: </i>As CD4-CCR5-T cells are key targets for genital HIV infection and cervical selection can favor compact V1-V2 loops and 316T, which increase viral infectivity, we propose that these conserved subtype-C motifs may contribute to transmission and spread of this subtype.</p>', 'AIDS', '23(9)', 16, NULL, 'WalterCHetero', 'HIV Envelope Protein gp120/genetics, HIV Infections, virology, subtype C, Heterosexuality,Humans, Immunohistochemistry, Sequence Analysis, Sexually Transmitted Diseases,  Virus Replication/genetics, tulio, oliveira, Astrid Iversen,', NULL, '1047-57', NULL, 2009, NULL, 5.46, 1, NULL, NULL, NULL, NULL),
(9, 'Extensive HIV-1 intra-host recombination is common in tissues with abnormal histopathology', 'Lamers SL, Salemi M, Galligan DC, de Oliveira T, Fogel GB, Granier SC, Zhao L, Brown JN, Morris A, Masliah E, McGrath MS', '<p>There is evidence that immune-activated macrophages infected with the Human Immunodeficiency Virus (HIV) are associated with tissue damage and serve as a long-lived viral reservoir during therapy. In this study, we analyzed 780 HIV genetic sequences generated from 53 tissues displaying normal and abnormal histopathology. \n</p><p>We found up to 50% of the sequences from abnormal lymphoid and macrophage rich non-lymphoid tissues were intra-host viral recombinants. The presence of extensive recombination, especially in non-lymphoid tissues, implies that HIV-1 infected macrophages may significantly contribute to the generation of elusive viral genotypes in vivo. Because recombination has been implicated in immune evasion, the acquisition of drug-resistance mutations, and alterations of viral co-receptor usage, any attempt towards the successful eradication of HIV-1 requires therapeutic approaches targeting tissue macrophages.</p>', 'PLoS One', '4(3)', 35, NULL, 'LamersRecombination', ' tulio, oliveira, susanna, lamers, marco, salemi, HIV, recombination, tissue, sequence, analysis, genetics', NULL, 'e5065', NULL, 2009, NULL, 4.411, 1, NULL, NULL, NULL, NULL),
(10, 'Genetic variability of human immunodeficiency virus-1 in Bahia state, Northeast, Brazil: high diversity of HIV genotypes', 'Monteiro JP, Alcantara LC, de Oliveira T, Oliveira AM, Melo MA, Brites C, Galvao-Castro B', '<p>The HIV-1 genetic variability in Bahia state, Brazil, was investigated. DNA samples from 229 and 213 HIV-1-infected individuals were analyzed using the heteroduplex mobility assay (HMA) in gag and env fragments, respectively. One hundred seventy-five samples were characterized in both genes. Thirty-two subtype F and BF recombinant viruses were sequenced and analyzed by phylogenetic methods. \n</p><p>The combination of HMA and sequencing results showed that seven different HIV-1 genotypes comprised this sample: 147 (84%) B/B, 4 (2.3%) F/F, 3 (1.7%) B/F, 1 (0.6%) F/B, 1 (0.6%) F/D, 1 (0.6%) BF/F, and 18 (10.3%) BF/B. A significant divergence was observed between these two techniques results (84.4%). This is explained by the low accuracy of the HMA for detecting recombinant viruses. These recombinants were unrelated to CRF12, while two sequences were related to CRF28 and CRF29. Nineteen BF mosaics shared the same gag breakpoint. In conclusion, the use of HMA may be inappropriate in regions where different subtypes are co-circulating. \n</p><p>Subtype B is the most common genotype, however, an increased prevalence (13.1%) of different BF variants and a potentially new CRF suggest that recombination is occurring frequently in Bahia. These viruses were associated with women infected heterosexually. Finally, this study identified the presence of an F/D recombinant HIV-1 in Brazil.</p>', 'J Med Virol', '81(3)', 21, NULL, 'HIVsubCJoana', 'brazil, hiv, subtype, c, tulio, oliveira, joana, luiz carlos, alcantara, bahia, salvador, HIV-1, genetics', NULL, '391-9', NULL, 2009, NULL, 2.867, 1, NULL, NULL, NULL, NULL),
(11, 'The RNA virus database', 'Belshaw R, de Oliveira T, Markowitz S, Rambaut A', '<p>The RNA Virus Database is a database and web application describing the genome organization and providing analytical tools for the 938 known species of RNA virus. It can identify submitted nucleotide sequences, can place them into multiple whole-genome alignments (in species where more than one isolate has been fully sequenced) and contains translated genome sequences for all species. \n</p><p>It has been created for two main purposes: to facilitate the comparative analysis of RNA viruses and to become a hub for other, more specialised virus Web sites. It is available at the following four mirrored sites. http://virus.zoo.ox.ac.uk/rnavirusdb; <a href=\"http://bioafrica.mrc.ac.za/rnavirusdb/\">http://bioafrica.mrc.ac.za/rnavirusdb/</a></p>', 'Nucleic Acids Res', '37(Database issue)', 12, 'bioafrica.mrc.ac.za/rnavirusdb/', 'BelshawRNAdb', 'RNA, virus, database, oxford, bioafrica, citation, genetic, tulio, oliveira, robert, belshaw, andrew, rambaut, bioinformatics, software, retrovirus,', NULL, 'D431-5', NULL, 2009, NULL, 7.479, 1, NULL, NULL, NULL, NULL),
(12, 'Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences', 'Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK', '<p>The human polynucleotide cytidine deaminases APOBEC3G (hA3G) and APOBEC3F (hA3F) are antiviral restriction factors capable of inducing extensive plus-strand guanine-to-adenine (G-to-A) hypermutation in a variety of retroviruses and retroelements, including human immunodeficiency virus type 1 (HIV-1). They differ in target specificity, favoring plus-strand 5\'GG and 5\'GA dinucleotide motifs, respectively. \n</p><p>To characterize their mutational preferences in detail, we analyzed single-copy, near-full-length HIV-1 proviruses which had been hypermutated in vitro by hA3G or hA3F. hA3-induced G-to-A mutation rates were significantly influenced by the wider sequence context of the target G. Moreover, hA3G, and to a lesser extent hA3F, displayed clear tetranucleotide preference hierarchies, irrespective of the genomic region examined and overall hypermutation rate. \n</p><p>We similarly analyzed patient-derived hypermutated HIV-1 genomes using a new method for estimating reference sequences. The majority of these, regardless of subtype, carried signatures of hypermutation that strongly correlated with those induced in vitro by hA3G. Analysis of genome-wide hA3-induced mutational profiles confirmed that hypermutation levels were reduced downstream of the polypurine tracts. Additionally, while hA3G mutations were found throughout the genome, hA3F often intensely mutated shorter regions, the locations of which varied between proviruses. </p><p>We extended our analysis to human endogenous retroviruses (HERVs) from the HERV-K(HML2) family, finding two elements that carried clear footprints of hA3G activity. This constitutes the most direct evidence to date for hA3G activity in the context of natural HERV infections, demonstrating the involvement of this restriction factor in defense against retroviral attacks over millions of years of human evolution.</p>', 'J Virol', '82(17)', 69, NULL, 'ArmitageAPOBEC', 'APOBEC, HIV, APOBEC3G, APOBEC3F, hypermutation, retrovirus, evolution, tulio, oliveira, astrid, iversen, hiv-1, sequence analysis, genetics', NULL, '8743-61', NULL, 2008, NULL, 5.15, 1, NULL, NULL, NULL, NULL),
(13, 'The HIV type 1 epidemic in Bulgaria involves multiple subtypes and is sustained by continuous viral inflow from West and East European countries', 'Salemi M, Goodenow MM, Montieri S, de Oliveira T, Santoro MM, Beshkov D, Alexiev I, Elenkov I, Elenkov I, Yakimova T, Varleva T, Rezza G, Ciccozzi M', '<p>Little is known about the HIV-1 epidemic in Balkan countries. To fill the gap, we investigated the viral genetic diversity in Bulgaria, by sequencing and phylogenetic characterization of 86 plasma samples collected between 2002 and 2006 from seropositive individuals diagnosed within 1986-2006. \n</p><p>Analysis of pol gene sequences assigned 51% of the samples to HIV-1 subtype B and 27% to subtype A1. HIV-1 subtype C, F, G, H, and a few putative recombinant forms were also found. Phylogenetic and molecular clock analysis showed a continuous exchange of subtype A and B between Bulgaria and Western as well as other Eastern European countries. At least three separate introductions of HIV-1 subtype A and four of HIV-1 subtype B have occurred within the past 25 years in Bulgaria. \n</p><p>The central geographic location of Bulgaria, the substantial genetic heterogeneity of the epidemic with multiple subtypes, and the significant viral flow observed to and from the Balkan countries have the potential to modify the current HIV-1 epidemiological structure in Europe and highlight the importance of more extensive and continuous monitoring of the epidemic in the Balkans.</p>', 'AIDS Res Hum Retroviruses', '24(6)', 34, NULL, NULL, 'hiv, bulgaria, genetics, marco, salemi, tulio, oliveira, molecular, epidemiology, origin, history', NULL, '771-9', NULL, 2008, NULL, 2.178, 1, NULL, NULL, NULL, NULL),
(14, 'Mapping the molecular characteristics of Brazilian human T-cell lymphotropic virus type 1 Env (gp46) and Pol amino acid sequences for vaccine design', 'Mota-Miranda AC, de Oliveira T, Moreau DR, Bomfim C, Galvao-Castro B, Alcantara LC Jr', '<p>This study was carried out to evaluate the molecular pattern of all available Brazilian human T-cell lymphotropic virus type 1 Env (n = 15) and Pol (n = 43) nucleotide sequences via epitope prediction, physico-chemical analysis, and protein potential sites identification, giving support to the Brazilian AIDS vaccine program. In 12 previously described peptides of the Env sequences we found 12 epitopes, while in 4 peptides of the Pol sequences we found 4 epitopes. \n</p><p>The total variation on the amino acid composition was 9 and 17% for human leukocyte antigen (HLA) class I and class II Env epitopes, respectively. After analyzing the Pol sequences, results revealed a total amino acid variation of 0.75% for HLA-I and HLA-II epitopes. In 5 of the 12 Env epitopes the physico-chemical analysis demonstrated that the mutations magnified the antigenicity profile. \n</p><p>The potential protein domain analysis of Env sequences showed the loss of a CK-2 phosphorylation site caused by D197N mutation in one epitope, and a N-glycosylation site caused by S246Y and V247I mutations in another epitope. Besides, the analysis of selection pressure have found 8 positive selected sites (w = 9.59) using the codon-based substitution models and maximum-likelihood methods. These studies underscore the importance of this Env region for the virus fitness, for the host immune response and, therefore, for the development of vaccine candidates.', 'Mem Inst Oswaldo Cruz', '102(6)', 3, NULL, 'AlineHTLV', 'Human T-lymphotropic virus 1, genetics,immunology, Humans, brazil, salvador, fiocruz, luiz carlos alcantara, tulio, oliveira, bernardo galvao, htlv, HTLV,Retroviridae Proteins, Oncogenic, immunology, Viral Vaccines', NULL, '741-9', NULL, 2007, NULL, 2.1, 1, NULL, NULL, NULL, NULL),
(15, 'High-resolution molecular epidemiology and evolutionary history of HIV-1 subtypes in Albania', 'Salemi M, de Oliveira T, Ciccozzi M, Rezza G, Goodenow MM', '<p><i>BACKGROUND: </i>HIV-1 epidemic in Western Europe is largely due to subtype B. Little is known about the HIV-1 in Eastern Europe, but a few studies have shown that non-B subtypes are quite common. In Albania, where a recent study estimated a ten-fold increase of AIDS incidence during the last six years, subtype A and B account for 90% of the know infections.\n\n</p><p><i>METHODOLOGY/PRINCIPAL FINDINGS: </i>We investigated the demographic history of HIV-1 subtype A and B in Albania by using a statistical framework based on coalescent theory and phylogeography. High-resolution phylogenetic and molecular clock analysis showed a limited introduction to the Balkan country of subtype A during the late 1980s followed by an epidemic outburst in the early 1990 s. In contrast, subtype B was apparently introduced multiple times between the mid-1970s and mid-1980s. Both subtypes are growing exponentially, although the HIV-1A epidemic displays a faster growth rate, and a significantly higher basic reproductive number R(0). HIV-1A gene flow occurs primarily from the capital Tirane, in the center of the country, to the periphery, while HIV-1B flow is characterized by a balanced exchange between center and periphery. Finally, we calculated that the actual number of infections in Albania is at least two orders of magnitude higher than previously thought.\n\n</p><p><i>CONCLUSIONS/SIGNIFICANCE:</i> Our analysis demonstrates the power of recently developed computational tools to investigate molecular epidemiology of pathogens, and emphasize the complex factors involved in the establishment of HIV-1 epidemics. We suggest that a significant correlation exists between HIV-1 exponential spread and the socio-political changes occurred during the Balkan wars. The fast growth of a relatively new non-B epidemic in the Balkans may have significant consequences for the evolution of HIV-1 epidemiology in neighboring countries in Eastern and Western Europe.</p>', 'PLoS One', '3(1)', 66, NULL, 'PlLoSSalemiAlbania', 'Albania, Evolution, Molecular, Geography, HIV-1/classification, genetics, Molecular Epidemiology, Phylogeny, eastern, europe, tulio, oliveira, marco, salemi, beast, molecular, clock BEAST,s equence, analysis', NULL, 'e1390', NULL, 2008, NULL, 4.411, 1, NULL, NULL, NULL, NULL),
(16, 'Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1', 'Gifford RJ, de Oliveira T, Rambaut A, Pybus OG, Dunn D, Vandamme AM, Kellam P, Pillay D; UK Collaborative Group on HIV Drug Resistance', '<p>With ongoing generation of viral genetic diversity and increasing levels of migration, the global human immunodeficiency virus type 1 (HIV-1) epidemic is becoming increasingly heterogeneous. In this study, we investigate the epidemiological characteristics of 5,675 HIV-1 pol gene sequences sampled from distinct infections in the United Kingdom. These sequences were phylogenetically analyzed in conjunction with 976 complete-genome and 3,201 pol gene reference sequences sampled globally and representing the broad range of HIV-1 genetic diversity, allowing us to estimate the probable geographic origins of the various strains present in the United Kingdom. \n</p><p>A statistical analysis of phylogenetic clustering in this data set identified several independent transmission chains within the United Kingdom involving recently introduced strains and indicated that strains more commonly associated with infections acquired heterosexually in East Africa are spreading among men who have sex with men. Coalescent approaches were also used and indicated that the transmission chains that we identify originated in the late 1980s to early 1990s. Similar changes in the epidemiological structuring of HIV epidemics are likely to be taking in place in other industrialized nations with large immigrant populations. \n</p><p>The framework implemented here takes advantage of the vast amount of routinely generated HIV-1 sequence data and can provide epidemiological insights not readily obtainable through standard surveillance methods.</p>', 'J Virol', '81(23)', 74, NULL, 'GiffordJVirol07', 'Cluster Analysis, Evolution, Molecular,  Great Britain, epidemiology, HIV Infections, HIV-1 classification,  Molecular Epidemiology, Phylogeny, Sequence Analysis, DNA, tulio, oliveira, robert, gifford, U.K., UK, england, london, ', NULL, '13050-6', NULL, 2007, NULL, 5.15, 1, NULL, NULL, NULL, NULL),
(17, 'Libya should stop denying scientific evidence on HIV', 'Colizzi V, de Oliveira T, Roberts RJ', NULL, 'Nature', '448(7157)', 4, NULL, 'ColliziLetterNature', 'Child, Equipment Contamination, HIV Infections, transmission,  Hospitals,  Libya, epidemiology, Nurses, legislation, jurisprudence, Physicians, Benghazi, tulio, oliveira, collizi, robert, richards, Bulgaria, children, nosocomial, innocence', NULL, '992', NULL, 2007, NULL, 34.48, 1, NULL, NULL, NULL, NULL),
(18, 'Recombination confounds the early evolutionary history of human immunodeficiency virus type 1: subtype G is a circulating recombinant form', 'Abecasis AB, Lemey P, Vidal N, de Oliveira T, Peeters M, Camacho R, Shapiro B, Rambaut A, Vandamme AM', '<p>Human immunodeficiency virus type 1 (HIV-1) is classified in nine subtypes (A to D, F, G, H, J, and K), a number of subsubtypes, and several circulating recombinant forms (CRFs). Due to the high level of genetic diversity within HIV-1 and to its worldwide distribution, this classification system is widely used in fields as diverse as vaccine development, evolution, epidemiology, viral fitness, and drug resistance. \n</p><p>Here, we demonstrate how the high recombination rates of HIV-1 may confound the study of its evolutionary history and classification. Our data show that subtype G, currently classified as a pure subtype, has in fact a recombinant history, having evolved following recombination between subtypes A and J and a putative subtype G parent. In addition, we find no evidence for recombination within one of the lineages currently classified as a CRF, CRF02_AG. Our analysis indicates that CRF02_AG was the parent of the recombinant subtype G, rather than the two having the opposite evolutionary relationship, as is currently proposed. \n</p><p>Our results imply that the current classification of HIV-1 subtypes and CRFs is an artifact of sampling history, rather than reflecting the evolutionary history of the virus. We suggest a reanalysis of all pure subtypes and CRFs in order to better understand how high rates of recombination have influenced HIV-1 evolutionary history</p>', 'J Virol', '81(16)', 101, NULL, 'AbecasisJVirCRF02', 'Base Sequence, Evolution, Molecular, Genome, Viral/genetics, HIV-1 classification, Phylogeny, Recombination, Genetics, Sequence Analysis, RNA, CRF02, west, africa, western, tulio, oliveira, ana abecasis, REGA, subtyping', NULL, '8543-51', NULL, 2007, NULL, 5.15, 1, NULL, NULL, NULL, NULL),
(19, 'An outbreak of HIV-1 subtype G among Italian injecting drug users', 'Ciccozzi M, Montieri S, Salemi M, De Oliveira T, Dorrucci M, Sinicco A, De Luca A, Giuliani M, Balotta C, Rezza G', '<p>We describe an outbreak of subtype G among injecting drug users (IDU) in northern Italy newly infected with HIV. We analysed pol gene sequences from samples of 139 individuals from different risk groups. Non-B subtypes were more frequently detected among IDU than in homosexual or heterosexual contacts. All G subtypes but one were found among IDU. The phylogenetic analysis indicated that the outbreak was of monophyletic origin and was caused by HIV-1 strains similar to those from western Africa.</p>', 'AIDS', '21(9)', 24, NULL, 'CiccoziAIDS', 'CRF02, HIV-1, Subtype G, Genes, pol, genetics, Italy, epidemiology, Phylogeny Substance Abuse, Intravenous, epidemiology, genetics, Nigeria, west, africa, western, africa, tulio, oliveira, marco, salemi', NULL, '1213-5', NULL, 2007, NULL, 5.46, 1, NULL, NULL, NULL, NULL),
(20, 'Evidence for recombination in natural populations of porcine circovirus type 2 in Hong Kong and mainland China', 'Ma CM, Hon CC, Lam TY, Li VY, Wong CK, de Oliveira T, Leung FC', '<p>Porcine circovirus type 2 (PCV2) belongs to the family Circoviridae, and is the causative agent of post-weaning multisystemic wasting syndrome (PMWS) in pigs. \n</p><p>In this study, phylogenetic analyses of three complete PCV2 genomic sequences from Hong Kong suggest that natural recombination happened among different lineages of PCV2. A preliminary investigation of the parental strains of these potential recombinants was carried out using bootscanning. Statistical significance of this recombination event was tested and positions of the potential recombination breakpoints were estimated in a maximum-likelihood framework. The recombinant breakpoints were estimated to be located within the origin of replication (ori) and replicase (rep) gene of PCV2.\n</p><p> Interestingly, several GenBank sequences of PCV2 in mainland China were found to have a recombination pattern similar to that of the potential PCV2 recombinants from Hong Kong, implying that this recombinant genotype might already be widespread within mainland China</p>', 'J Gen Virol', '88(Pt 6)', 59, NULL, 'PCV2', 'Animals, Base Sequence, China, Circoviridae, Circovirus, genetics, Genome, Viral, Hong Kong, Molecular Epidemiology, Molecular Sequence Data, Phylogeny, Recombination, Genetic, Swine, Swine Diseases, virology, tulio, oliveira', NULL, '1733-7', NULL, 2007, NULL, 3.26, 1, NULL, NULL, NULL, NULL),
(21, 'Re-mapping the molecular features of the human immunodeficiency virus type 1 and human T-cell lymphotropic virus type 1 Brazilian sequences using a bioinformatics unit established in Salvador, Bahia, Brazil, to give support to the viral epidemiology studies', 'de Queiroz AT, Mota-Miranda AC, de Oliveira T, Moreau DR, Urpia Cde C, Carvalho CM, Galvao-Castro B, Alcantara LC', '<p>The analysis of genetic data for human immunodeficiency virus type 1 (HIV-1) and human T-cell lymphotropic virus type 1 (HTLV-1) is essential to improve treatment and public health strategies as well as to select strains for vaccine programs. However, the analysis of large quantities of genetic data requires collaborative efforts in bioinformatics, computer biology, molecular biology, evolution, and medical science. \n</p><p>The objective of this study was to review and improve the molecular epidemiology of HIV-1 and HTLV-1 viruses isolated in Brazil using bioinformatic tools available in the Laboratorio Avancado de Saude Publica (Lasp) bioinformatics unit. The analysis of HIV-1 isolates confirmed a heterogeneous distribution of the viral genotypes circulating in the country. The Brazilian HIV-1 epidemic is characterized by the presence of multiple subtypes (B, F1, C) and B/F1 recombinant virus while, on the other hand, most of the HTLV-1 sequences were classified as Transcontinental subgroup of the Cosmopolitan subtype. Despite the high variation among HIV-1 subtypes, protein glycosylation and phosphorylation domains were conserved in the pol, gag, and env genes of the Brazilian HIV-1 strains suggesting constraints in the HIV-1 evolution process. \n</p><p>As expected, the functional protein sites were highly conservative in the HTLV-1 env gene sequences. Furthermore, the presence of these functional sites in HIV-1 and HTLV-1 strains could help in the development of vaccines that pre-empt the viral escape process</p>', 'Mem Inst Oswaldo Cruz', '102(2)', 10, NULL, 'ArturHTLV', 'Amino Acid Sequence, Brazil, Computational Biology, Genotype, Glycosylation, HTLV-1,human, HIV-1, classification, genetics, Molecular Epidemiology, Molecular Sequence Data, Phosphorylation, Bahia, Salvador, Luiz carlos alcantara, tulio, oliveira, htlv,', NULL, '133-9', NULL, 2007, NULL, 2.1, 1, NULL, NULL, NULL, NULL),
(22, 'Molecular epidemiology: HIV-1 and HCV sequences from Libyan outbreak', 'de Oliveira T, Pybus OG, Rambaut A, Salemi M, Cassol S, Ciccozzi M, Rezza G, Gattinara GC, D\'Arrigo R, Amicosante M, Perrin L, Colizzi V, Perno CF; Benghazi Study Group', '<p>In 1998, outbreaks of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) infection were reported in children attending Al-Fateh Hospital in Benghazi, Libya. Here we use molecular phylogenetic techniques to analyse new virus sequences from these outbreaks.\n</p><p> We find that the HIV-1 and HCV strains were already circulating and prevalent in this hospital and its environs before the arrival in March 1998 of the foreign medical staff (five Bulgarian nurses and a Palestinian doctor) who stand accused of transmitting the HIV strain to the children</p>', 'Nature', '444(7121)', 114, NULL, 'HIVLybiapaper', 'Child, HIV Infections, epidemiology, transmission, Benghazi, Libya, nurses, physicians, human rights, HIV, HCV, AIDS, phylogeny, molecular, jurisprudence, tulio, oliveira, nature, oliver pybus, andrew rambaut, nosocomial, inocence\n', NULL, '836-7', NULL, 2006, NULL, 34.48, 1, NULL, NULL, NULL, NULL),
(23, 'Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity', 'Gifford R, de Oliveira T, Rambaut A, Myers RE, Gale CV, Dunn D, Shafer R, Vandamme AM, Kellam P, Pillay D; UK Collaborative Group on HIV Drug Resistance', '<p><i>BACKGROUND:</i> The routine use of drug resistance testing provides an abundant source of HIV-1 sequence data. However, it is not clear how reliable standard genotyping of these sequences is for describing HIV-1 genetic variation and for detecting novel genetic variants and epidemiological trends.\n\n</p><p><i>OBJECTIVES: </i>To compare assignment of HIV-1 resistance test sequences to reference strains across commonly used genotyping protocols.\n\n</p><p><i>METHODS: </i>Subtype assignments were compared across three standard genotyping protocols for 10 537 resistance test sequences, representing approximately one-fifth of all reported infections in the United Kingdom. Sequences that were inconsistently genotyped across methods, or that were unassigned by at least one method, were examined for evidence of recombination using sliding-window-based approaches.\n\n</p><p><i>RESULTS: </i>Although agreement across methods was high for subtypes B, C and H, it was generally much lower (< 50%) for other subtypes. Disagreement between methods typically involved closely related, but epidemiologically distinct, groups or involved a significant proportion ( approximately 12%) of divergent sequences in which analysis revealed widespread evidence of recombination and a remarkable diversity of unusual recombinant forms.\n\n</p><p><i>CONCLUSIONS:</i> With frequent long-distance transfer of viral strains and widespread recombination between them, genetic and epidemiological relationships within HIV-1 are becoming increasingly complex. Current methods of subtype assignment vary in their ability to identify novel genetic variants and to distinguish epidemiologically distinct strains. Capturing meaningful epidemiological information from resistance test data will require a critical understanding of the methodologies used in order to appreciate the possible sources of error and misclassification.</p>', 'AIDS', '20(11)', 33, NULL, 'GiffordAIDS', 'Databases, Genetic, Drug Resistance, Viral, Genetic Variation,  Genotype, subtyping tool, Rega, STAR, Stanford, HIV-1 classification, Phylogeny, Recombination, tulio, bioinformatics, oliveira, REGA subtyping tool, comparison, software', NULL, '1521-9', NULL, 2006, NULL, 5.46, 3, NULL, NULL, NULL, NULL),
(24, 'Tracing the origin of Brazilian HTLV-1 as determined by analysis of host and viral genes', 'Alcantara LC, de Oliveira T, Gordon M, Pybus O, Mascarenhas RE, Seixas MO, Goncalves M, Hlela C, Cassol S, Galvao-Castro B', '<p>We compared the genetic diversity of the Brazilian human T-cell lymphotropic virus type 1 isolates with those found in KwaZulu-Natal (KZN), South Africa, and with the genetic background of the hosts. The seroprevalence rate in KZN was 1.7%. All sequences belonged to the A subgroup. \n</p><p>The presence of South African sequences in two different clusters from Brazil, and the finding of the beta-globin haplotype in infected hosts are consistent with the transmission of this virus from southern Africa to Brazil</p>', 'AIDS', '20(5)', 39, NULL, 'AlcantaraHTLVAIDS', 'Brazil/epidemiology, Evolution, Molecular Genes, Viral, Genetic Variation, HTLV-I Infections, epidemiology, HTLV-I genetics,  Human T-lymphotropic virus 1, Molecular Epidemiology,  Phylogeny, luiz, carlos, alcantara, tulio, oliveira, salvador, bahia, brazil', NULL, '780-2', NULL, 2006, NULL, 5.46, 1, NULL, NULL, NULL, NULL),
(25, 'Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS', 'Salemi M, Lamers SL, Yu S, de Oliveira T, Fitch WM, McGrath MS', '<p>\"Phylodynamic\" analysis combines various statistical procedures that can be used to correlate the epidemiological and evolutionary behavior of viral pathogens with the immune system of the host. \n</p><p>We utilized this approach to examine human immunodeficiency virus type 1 (HIV-1) gp120 envelope DNA sequences (V1, V2, and V3) isolated from different brain compartments of a T-cell-depleted patient diagnosed with severe HIV-associated dementia at the time of death. In agreement with previous reports, phylogenetic analysis showed distinct virodemes but also revealed a significant amount of viral gene flow among different brain compartments. Local-molecular-clock analysis showed that HIV-1 meninges and temporal lobe subpopulations evolve about 30 and 100 times faster, respectively, than the other viral populations in the brain.\n</p><p> However, maximum likelihood codon-based substitution models did not detect any site under significant positive selective pressure, and the main cause of HIV-1 genetic variation appeared to be random genetic drift. Therefore, the higher evolutionary rate in the meninges and temporal lobe could be due to an enhanced infection/expansion rate of macrophages as a consequence of the immune system failure. In conclusion, in this case study, viral infection in the brain progressed with a nonspecific genetic evolution, recurrent migration events, and an expansion of macrophage-tropic sequences. \n</p><p>The data suggest that after immune failure newly produced viral variants, which would be rapidly cleared under normal conditions, begin to productively infect macrophages in a \"self-amplifying\" cycle of infection/inflammatory response that could be at the origin of HIV-associated dementia</p>', 'J Virol', '79(17)', 72, NULL, 'HIVbrainSalemi', 'AIDS Dementia Complex, immunology, Amino Acid Sequence, Brain, virology, genetics, HIV,  Lymph Nodes, Meninges, Organ Specificity, Phylogeny, Sequence Alignment, tulio, oliveira, marco, salemi', NULL, '11343-52', NULL, 2005, NULL, 5.15, 1, NULL, NULL, NULL, NULL),
(26, 'An automated genotyping system for analysis of HIV-1 and other microbial sequences', 'de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, Snoeck J, van Rensburg EJ, Wensing AM, van de Vijver DA, Boucher CA, Camacho R, Vandamme AM', '<p>MOTIVATION: Genetic analysis of HIV-1 is important not only for vaccine development, but also to guide treatment strategies, track the emergence of new viral variants and ensure that diagnostic assays are contemporary and fully optimized. However, most genotyping methods are laborious and complex, and involve the use of multiple software applications. Here, we describe the development of an automated genotyping system that can be easily applied to HIV-1 and other rapidly evolving viral pathogens. \n</p><p>RESULTS: The new REGA subtyping tool, developed using Java programming and PERL scripts, combines phylogenetic analyses with boot-scanning methods for the genetic subtyping of full-length and subgenomic fragments of HIV-1. When used to investigate the subtype of previously published reference datasets that were analysed using manual phylogenetic methods, the automated method correctly identified 97.5-100% of non-recombinant and circulating recombinant forms of HIV-1, including 108 full-length, 108 gag and 221 env sequences downloaded from the Los Alamos database</p>\n', 'Bioinformatics', '21(19)', 435, NULL, 'deOliveiraBioinformatics', 'Algorithms, Artificial Intelligence, DNA, Viral analysis, Genotype, subtype, Rega subtyping tools,  Phylogeny, Sequence Alignment methods,  Sequence Analysis, software, bioinformatics, software, tulio, oliveira, ', NULL, '3797-800', NULL, 2005, NULL, 5.468, 1, NULL, NULL, NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(27, 'Different epidemic potentials of the HIV-1B and C subtypes', 'Salemi M, de Oliveira T, Soares MA, Pybus O, Dumans AT, Vandamme AM, Tanuri A, Cassol S, Fitch WM', '<p>HIV, the cause of AIDS in humans, is characterized by great genetic heterogeneity. In particular, HIV-1 group M subtypes are responsible for most of the infections worldwide. We investigate the demographic history of HIV-1B and HIV-1C subtypes in South Africa and Brazil using both a parametric and a nonparametric approach based on coalescent theory. \n</p><p>Our results show that although both subtypes are spreading exponentially in Brazil, the HIV-1C growth rate is about twice that of Brazilian HIV-1B or South African HIV-1C, providing evidence, for the first time, of a different epidemic potential between two HIV-1 subtypes.\n</p><p>The present study not only may have important consequences for devising future vaccination and therapeutic strategies, but also offers additional evidence that skyline plots are indeed a simple and powerful tool for monitoring and predicting the behavior of viral epidemics</p>', 'J Mol Evol', '60(5)', 89, NULL, 'SalemisubBandCdynamics', 'Demography, Evolution, Molecular,  Genetic Variation,  HIV-1, genetics, Human, Models, Biological, Models, Genetic,\nPhylogeny, Population Dynamics, brazil, subtype C, C, tulio, oliveira, marco, salemi, walter fitch, South Africa, epidemiology, South America, subtype', NULL, '598-605', NULL, 2005, NULL, 2.32, 1, NULL, NULL, NULL, NULL),
(28, 'Genetic Characteristics, Coreceptor Usage Potential and Evolution of Nigerian HIV-1 Subtype G and CRF02_AG Isolate', 'Ajoge HO, Gordon ML, de Oliveira T, Green TN, Ibrahim S,  Shittu OS, Olonitola SO, Ahmad AA, Ndung\'u T', '<p>HIV-1 CRF02_AG and subtype G (HIV-1G) account for most HIV infections in Nigeria, but their evolutionary trends have not been well documented. To better elucidate the dynamics of the epidemic in Nigeria we characterised the gag and env genes of North-Central Nigerian HIV-1 isolates from pregnant women. \n</p><p>Of 28 samples sequenced in both genes, the predominant clades were CRF02_AG (39%) and HIV-1G (32%). Higher predicted proportion of CXCR4-tropic (X4) HIV-1G isolates was noted compared to CRF02_AG (p = 0.007, Fisher\'s exact test). Phylogenetic and Bayesian analysis conducted on our sequences and all the dated available Nigerian sequences on the Los Alamos data base showed that CRF02_AG and HIV-1G entered into Nigeria through multiple entries, with presence of HIV-1G dating back to early 1980s. \n</p><p>This study underlines the genetic complexity of the HIV-1 epidemic in Nigeria, possible subtype-specific differences in co-receptor usage, and the evolutionary trends of the predominant HIV-1 strains in Nigeria, which may have implications for the design of biomedical interventions and better understanding of the epidemic</p>', 'PLoS One', '6(3)', 11, NULL, 'AjoleCRF02Nigeria', 'CRF02AG, AG, recombinant, Nigeria, West-Africa, demographic, history, molecular epidemiology, phylogeny, subtype, evolution, genetics, tulio, oliveira, western, africa, HIV, BEAST, molecular, clock', NULL, 'e17865', NULL, 2011, 'doi:10.1371/journal.pone.0017865', 4.411, 1, NULL, NULL, NULL, NULL),
(29, 'BioAfrica\'s HIV-1 proteomics resource: combining protein data with bioinformatics tools', 'Doherty RS, de Oliveira T, Seebregts C, Danaviah S, Gordon M, Cassol S', '<p>Most Internet online resources for investigating HIV biology contain either bioinformatics tools, protein information or sequence data. The objective of this study was to develop a comprehensive online proteomics resource that integrates bioinformatics with the latest information on HIV-1 protein structure, gene expression, post-transcriptional/post-translational modification, functional activity, and protein-macromolecule interactions. \n</p><p>The BioAfrica HIV-1 Proteomics Resource http://bioafrica.mrc.ac.za/proteomics/index.html is a website that contains detailed information about the HIV-1 proteome and protease cleavage sites, as well as data-mining tools that can be used to manipulate and query protein sequence data, a BLAST tool for initiating structural analyses of HIV-1 proteins, and a proteomics tools directory. The Proteome section contains extensive data on each of 19 HIV-1 proteins, including their functional properties, a sample analysis of HIV-1HXB2, structural models and links to other online resources. The HIV-1 Protease Cleavage Sites section provides information on the position, subtype variation and genetic evolution of Gag, Gag-Pol and Nef cleavage sites. \n</p><p>The HIV-1 Protein Data-mining Tool includes a set of 27 group M (subtypes A through K) reference sequences that can be used to assess the influence of genetic variation on immunological and functional domains of the protein. The BLAST Structure Tool identifies proteins with similar, experimentally determined topologies, and the Tools Directory provides a categorized list of websites and relevant software programs. \n</p><p>This combined database and software repository is designed to facilitate the capture, retrieval and analysis of HIV-1 protein data, and to convert it into clinically useful information relating to the pathogenesis, transmission and therapeutic response of different HIV-1 variants. The HIV-1 Proteomics Resource is readily accessible through the BioAfrica website at: <a href=\"http://www.bioafrica.net/proteomics/HIVproteome.html\">http://bioafrica.mrc.ac.za/proteomics/index.html</p>', 'Retrovirology', '2', 14, NULL, 'RyanProteomics', 'HIV, proteomics, proteome, proteins, data mining, swissprot, bioafrica, tulio, oliveira, hiv, protein, bioinformatics, software', NULL, '18', NULL, 2005, NULL, 5.24, 1, NULL, NULL, NULL, NULL),
(30, 'Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness?', 'de Oliveira T, Engelbrecht S, Janse van Rensburg E, Gordon M, Bishop K, zur Megede J, Barnett SW, Cassol S', '<p>Naturally occurring polymorphisms in the protease of human immunodeficiency virus type 1 (HIV-1) subtype C would be expected to lead to adaptive (compensatory) changes in protease cleavage sites. To test this hypothesis, we examined the prevalences and patterns of cleavage site polymorphisms in the Gag, Gag-Pol, and Nef cleavage sites of C compared to those in non-C subtypes. \n</p><p>Codon-based maximum-likelihood methods were used to assess the natural selection and evolutionary history of individual cleavage sites. Seven cleavage sites (p17/p24, p24/p2, NC/p1, NC/TFP, PR/RT, RT/p66, and p66/IN) were well conserved over time and in all HIV-1 subtypes. One site (p1/p6(gag)) exhibited moderate variation, and four sites (p2/NC, TFP/p6(pol), p6(pol)/PR, and Nef) were highly variable, both within and between subtypes. Three of the variable sites are known to be major determinants of polyprotein processing and virion production. P2/NC controls the rate and order of cleavage, p6(gag) is an important phosphoprotein required for virion release, and TFP/p6(pol), a novel cleavage site in the transframe domain, influences the specificity of Gag-Pol processing and the activation of protease. Overall, 58.3% of the 12 HIV-1 cleavage sites were significantly more diverse in C than in B viruses. \n</p><p>When analyzed as a single concatenated fragment of 360 bp, 96.0% of group M cleavage site sequences fell into subtype-specific phylogenetic clusters, suggesting that they coevolved with the virus. Natural variation at C cleavage sites may play an important role, not only in regulation of the viral cycle but also in disease progression and response to therapy</p>', 'J Virol', '77(17)', 62, NULL, 'deOliveiraProtease', 'HIV, protease, cleavage, site, fitness, gag, pol, nef, HIV-1, tulio, oliveira', NULL, '9422-30', NULL, 2003, NULL, 5.15, 3, NULL, NULL, NULL, NULL),
(31, 'Mosaic genomes of the six major primate lentivirus lineages revealed by phylogenetic analyses', 'Salemi M, De Oliveira T, Courgnaud V, Moulton V, Holland B, Cassol S, Switzer WM, Vandamme AM', '<p>To clarify the origin and evolution of the primate lentiviruses (PLVs), which include human immunodeficiency virus types 1 and 2 as well as their simian relatives, simian immunodeficiency viruses (SIVs), isolated from several host species, we investigated the phylogenetic relationships among the six supposedly nonrecombinant PLV lineages for which the full genome sequences are available. \n</p><p>Employing bootscanning as an exploratory tool, we located several regions in the PLV genome that seem to have uncertain or conflicting phylogenetic histories. Phylogeny reconstruction based on distance and maximum-likelihood algorithms followed by a number of statistical tests confirms the existence of at least five putative recombinant fragments in the PLV genome with different clustering patterns. Split decomposition analysis also shows that phylogenetic relationships among PLVs may be better represented by network-based graphs, such as the ones produced by SplitsTree. </p><p>Our findings not only imply that the six so-called pure PLV lineages have in fact mosaic genomes but also make more unlikely the hypothesis of cospeciation of SIVs and their simian hosts</p>', 'J Virol', '77(13)', 42, NULL, 'SalemiSIVrec', 'Algorithms, SIV, simian, immunodeficiency, Genome, Viral,  Likelihood Functions, Models, Genetic, Mosaicism, Phylogeny, tulio, oliveira, marco, salemi, hiv, origin, date, origin', NULL, '7202-13', NULL, 2003, NULL, 5.15, 1, NULL, NULL, NULL, NULL),
(32, 'Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies', 'Gordon M, De Oliveira T, Bishop K, Coovadia HM, Madurai L, Engelbrecht S, Janse van Rensburg E, Mosam A, Smith A, Cassol S', '<p>The KwaZulu-Natal region of South Africa is experiencing an explosive outbreak of human immunodeficiency virus type 1 (HIV-1) subtype C infections. Understanding the genetic diversity of C viruses and the biological consequences of this diversity is important for the design of effective control strategies. We analyzed the protease gene, the first 935 nucleotides of reverse transcriptase, and the C2V5 envelope region of a representative set of 72 treatment-nave patients from KwaZulu-Natal and correlated the results with amino acid signature and resistance patterns. \n</p><p>Phylogenetic analysis revealed multiple clusters or \"lineages\" of HIV-1 subtype C that segregated with other C viruses from southern Africa. The same pattern was observed for both black and Indian subgroups and for retrospective specimens collected prior to 1990, indicating that multiple sublineages of HIV-1 C have been present in KwaZulu-Natal since the early stages of the epidemic. With the exception of three nonnucleoside reverse transcriptase inhibitor mutations, no primary resistance mutations were identified. \n</p><p>Numerous accessory polymorphisms were present in the protease, but none were located at drug-binding or active sites of the enzyme. One frequent polymorphism, I93L, was located near the protease/reverse transcriptase cleavage site. In the envelope, disruption of the glycosylation motif at the beginning of V3 was associated with the presence of an extra protein kinase C phosphorylation site at codon 11. \n</p><p>Many polymorphisms were embedded within cytotoxic T lymphocyte or overlapping cytotoxic T-lymphocyte/T-helper epitopes, as defined for subtype B. This work forms a baseline for future studies aimed at understanding the impact of genetic diversity on vaccine efficacy and on natural susceptibility to antiretroviral drugs</p>', 'J Virol', '77(4)', 78, NULL, 'GordonHIVKZN', 'Genes, env/genetics, Genetic Variation,  HIV Infections, drug therapy, HIV Protease, genetics, HIV Reverse Transcriptase, Molecular Sequence Data, Phylogeny, subtype C, Sequence Analysis, DNA, South Africa, africa centre, tulio, oliveira, resistance, KZN, KwaZulu-Natal, sharon, cassol', NULL, '2587-99', NULL, 2003, NULL, 5.15, 3, NULL, NULL, NULL, NULL),
(33, 'An integrated genetic data environment (GDE)-based LINUX interface for analysis of HIV-1 and other microbial sequences', 'De Oliveira T, Miller R, Tarin M, Cassol S', '<p><i>MOTIVATION:</i> Sequence databases encode a wealth of information needed to develop improved vaccination and treatment strategies for the control of HIV and other important pathogens. To facilitate effective utilization of these datasets, we developed a user-friendly GDE-based LINUX interface that reduces input/output file formatting.\n\n</p><p><i>DESIGN AND RESULTS:</i> GDE was adapted to the Linux operating system, bioinformatics tools were integrated with microbe-specific databases, and up-to-date GDE menus were developed for several clinically important viral, bacterial and parasitic genomes. Each microbial interface was designed for local access and contains Genbank, BLAST-formatted and phylogenetic databases.\n\n</p><p><i>AVAILABILITY: </i> GDE-Linux is available for research purposes by direct application to the corresponding author. Application-specific menus and support files can be downloaded from (http://www.bioafrica.net)</p>', 'Bioinformatics', '19(1)', 12, NULL, 'GDEdeOliveiraBioinformatics', 'Database Management Systems, Databases, Genetic,  Genetics, Microbial, HIV-1, Information Storage and Retrieval/methods, Sequence Alignment, Sequence Analysis, Software, User-Computer Interface, bioinformatics, GDE, software, application, tulio, oliveira, sharon, cassol', NULL, '153-4', NULL, 2003, NULL, 5.468, 1, NULL, NULL, NULL, NULL),
(34, 'Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa', 'zur Megede J, Engelbrecht S, de Oliveira T, Cassol S, Scriba TJ, van Rensburg EJ, Barnett SW', '<p>Understanding the origin, distribution, and evolving dominance of HIV-1 subtype C strains is an important component in the design and evaluation of a globally effective AIDS vaccine. \n</p><p>To better understand subtype C viruses, we constructed complete molecular clones of primary, CCR-5-using isolates from South Africa and analyzed the molecular phylogenies of these clones using best fitting evolutionary substitution models. Analyses were performed on three full-length sequences, and on the individual genes. All clones were nonrecombinant, and although two of three had open reading frames and intact splice sites, they were not infectious. \n</p><p>At the genomic level, the models demonstrated the increasing variability of subtype C in South Africa. At the subgenomic level, they revealed marked differences in the evolutionary patterns of individual genes, a finding that suggests that the genes are under different selective pressures and constraints. These data underscore the dynamic nature of the subtype C epidemic and emphasize the need for continuous monitoring of local strains</p>', 'AIDS Res Hum Retroviruses', '18(17)', 16, NULL, 'ZurMegede', 'HIV-1, complete genome, genetics, Humans, Molecular Sequence Data, Phylogeny, South Africa, cape town, tulio, oliveira, sharon, cassol', NULL, '1327-32', NULL, 2002, NULL, 2.178, 1, NULL, NULL, NULL, NULL),
(35, 'A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil', 'Soares MA, De Oliveira T, Brindeiro RM, Diaz RS, Sabino EC, Brigido L, Pires IL, Morgado MG, Dantas MC, Barreira D, Teixeira PR, Cassol S, Tanuri A; Brazilian Network for Drug Resistance Surveillance', '<p><i>OBJECTIVE: </i>To characterize the subtype C strains of HIV type 1 that circulate in Brazil, especially those originated from the southern part of the country.\n\n</p><p><i>DESIGN AND METHODS:</i> One hundred and twelve HIV-1-positive subjects had their plasma viral RNA extracted. Protease (PR) and reverse transcriptase (RT) genomic regions were polymerase chain reaction-amplified and sequenced for subtype determination. Subtype C strains were selected and compared to other strains of this subtype from the database, and specific amino acid signature patterns were searched.\n\n</p><p><i>RESULTS: </i>Brazilian subtype C viruses form a very strong monophyletic group when compared to subtype C viruses from other countries and presented specific signature amino acids. Recombinants between subtype C and B viruses have been documented in areas of co-circulation. The incidence of primary PR and RT inhibitor resistance mutations in drug-nave subjects was observed. An increasing number of secondary resistance mutations was also seen, some of which are characteristic of subtype C-related sequences.\n\n</p><p><i>CONCLUSIONS: </i>Introduction of subtype C of HIV-1 in Brazil was likely a single event of one or a mixture of similarly related strains. Recombination between subtype C and B viruses is an ongoing process in the country. Primary and secondary drug resistance mutations were observed, although some of the secondary mutations could be associated with subtype C molecular signatures. Subtype-specific polymorphisms of PR and RT sequences found in this subtype C Brazilian variant might influence this emergence and have an impact on HIV treatment and on vaccine development in the country</p>', 'AIDS', '17(1)', 121, NULL, 'SoaresAIDS', 'hiv-1, subtype C, Brazil, phylogeny, origin, bioinformatics, molecular epidemiology, cluster, HIV, tulio, oliveira, marcelo, soares, origin, sequence, analysis', NULL, '11-21', NULL, 2003, NULL, 5.46, 1, NULL, NULL, NULL, NULL),
(36, 'Molecular cloning and functional analysis of three type D endogenous retroviruses of sheep reveal a different cell tropism from that of the highly related exogenous jaagsiekte sheep retrovirus', 'Palmarini M, Hallwirth C, York D, Murgia C, de Oliveira T, Spencer T, Fan H', '<p>Integrated into the sheep genome are 15 to 20 copies of type D endogenous loci that are highly related to two exogenous oncogenic viruses, jaagsiekte sheep retrovirus (JSRV) and enzootic nasal tumor virus (ENTV). The exogenous viruses cause infectious neoplasms of the respiratory tract in small ruminants. \n</p><p>In this study, we molecularly cloned three intact type D endogenous retroviruses of sheep (enJS56A1, enJS5F16, and enJS59A1; collectively called enJRSVs) and analyzed their genomic structures, their phylogenies with respect to their exogenous counterparts, their capacity to form viral particles, and the expression specificities of their long terminal repeats (LTRs). In addition, the pattern of expression of enJSRVs in vivo was studied by in situ hybridization. All of the three enJSRV proviruses had open reading frames for at least one of the structural genes. In particular, enJS56A1 had open reading frames for all structural genes, but it could not assemble viral particles when highly expressed in human 293T cells. \n</p><p>We localized the defect for viral assembly in the first two-thirds of the gag gene by making a series of chimeras between enJS56A1 and the exogenous infectious molecular clone JSRV(21). Phylogenetic analysis distinguished five ovine type D retroviruses: enJSRV groups A and B, ENTV, and two exogenous JSRV groups (African versus United Kingdom/North America isolates). Transient transfection assays indicated that the LTRs of the three enJSRVs were not preferentially active in differentiated lung epithelial cells. \n</p><p>This suggests that the pulmonary tropic JSRV developed from a type D retrovirus that did not have lung specificity. Consistent with this, in situ hybridization of a panel of normal ovine tissues revealed high expression of enJSRV mRNA in the luminal epithelium and glandular epithelium of the uterus; lower expression was localized in the lamina propria of the gut and in the bronchiolar epithelium of the lungs</p>', 'J Virol', '74(17)', 131, NULL, 'PalmariniJSRV', 'Mice, Molecular Sequence Data, Organ Specificity, Phylogeny, Pulmonary Adenomatosis, Ovine, virology, Sequence Alignment, retrovirus, Sequence Analysis, DNA, Sheep, genetics, tulio, oliveira, ', NULL, '8065-76', NULL, 2000, NULL, 5.15, 1, NULL, NULL, NULL, NULL),
(37, 'Sequence of the env gene of some KwaZulu-Natal, South African strains of HTLV type I', 'Bhigjee AI, Tarin ML, Bill PL, De Oliveira T, York D', '<p>Phylogenetic analysis of HTLV-I suggests three main subtypes, namely, cosmopolitan, Central African, and Australo-Melanesian. HTLV-I is endemic in KwaZulu-Natal, South Africa. However, sequence data on the local strains are limited to the LTR region. The env gene of the local strain was amplified and sequenced from the peripheral blood of five seropositive individuals. Four had HTLV-I-associated myelopathy and one had infective eczema. \n</p><p>The sequence analysis of the env gene showed a greater then 99% homology of the local strains. They were closely related to the North American strains (99.3%), followed by the Japanese strains (98.3-98.9%). Phylogenetic studies linked the local strains to the cosmopolitan subtype. This study provides new sequence data on the env gene of the local HTLV-I strain</p>', 'AIDS Res Hum Retroviruses', '15(13)', 7, NULL, 'BhigjeeHTLV', 'HTLV-1, south africa, KwaZulu-Natal, Durban, sequence analysis, phylogeny, south africa, tulio, oliveira, htlv', NULL, '1229-33', NULL, 1999, NULL, 2.178, 1, NULL, NULL, NULL, NULL),
(38, 'Scourge of a Continent: The BioAfrica Website', 'de Oliveira T, Cassol S (edited by M. Leslie)', '<p>HIV is hammering Africa, with infection rates of more than 30%\rin countries such as Botswana. Researchers will find tools for\ranalyzing HIV molecular data and information on the main\rAfrican strain at BioAfrica, created by virologists at Oxford University\rand the University of Pretoria in South Africa. \n</p><p>BioAfrica\rcomplements other HIV sites, such as the sequence bank at Los\rAlamos National Lab in New Mexico (Science,NetWatch, 23 August\r2002, p. 1243), by spotlighting\rHIV?s subtype\rC, the viral variant that\rpredominates in the\rsouthern part of the\rcontinent. \n</p><p>Users can\rdownload free software\rfor determining a virus\rsubtype or visit a new\rproteomics section that\rprobes the sequences\rand structures of HIV\r19 proteins.The site also includes plenty of background on subtype\rC, including charts that follow its spread starting in the\rearly 1980s. Website: <a href=\"http://www.bioafrica.net\">bioafrica.net</a></p>\n<p><a href=\"http://www.sciencemag.org/content/310/5756/netwatch.full\">Science Volume 310, Number 5756, Issue of 23 December 2005 </a></p>', 'Science', '310', 2, 'www.bioafrica.net', 'BioAfricaScience', 'bioafrica, science, website, bioinformatics, africa, tulio de oliveira, sharon cassol, bioafrica.net', NULL, '1877', NULL, 2005, NULL, 29.747, 1, NULL, NULL, NULL, NULL),
(39, 'Out of Africa: The BioAfrica website', 'de Oliveira T', '<p>Originally developed as a part of Dr.\rTulio de Oliveira?s Ph.D. thesis at the\rNelson R Mandela School of Medicine, BioAfrica has a\rmission??to organize and distribute\rinformation on the HIV/AIDS subtype\rC epidemic in Africa.\n</p><p>Numerous resources\rsupport this effort, including\repidemiological information, countryby-\rcountry fact sheets, a phylogenetic\rtree of 116 sequences, software\rfor BLASTing, and miscellaneous\rpieces of information relating to the\rserotype?s prevalence and infection\rrate. \n</p><p>Visitors can download software\rproducts, perform proteomics analyses,\rand get miscellaneous information\ron workshops, maps, and reports.\rLike a one-stop shop, BioAfrica has\rsomething for everyone</p>', 'BioTechniques', '41', NULL, 'www.bioafrica.net', 'BioTechniquesBioAfrica', 'bioafrica, biotechniques, website, bioinformatics, tulio de oliveira, africa, sharon, cassol, bioafrica.net', NULL, '129', NULL, 2006, NULL, 2.305, 1, NULL, NULL, NULL, NULL),
(40, 'Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape', 'Karlsson AC, Iversen AK, Chapman JM, de Oliveira T, Spotts G, McMichael AJ, Davenport MP, Hecht FM, Nixon DF', '<p><i>BACKGROUND:</i> Antigen-specific CTL responses are thought to play a central role in containment of HIV-1 infection, but no consistent correlation has been found between the magnitude and/or breadth of response and viral load changes during disease progression.\n\n<p><i>METHODS AND FINDINGS:</i> We undertook a detailed investigation of longitudinal CTL responses and HIV-1 evolution beginning with primary infection in 11 untreated HLA-A2 positive individuals. A subset of patients developed broad responses, which selected for consensus B epitope variants in Gag, Pol, and Nef, suggesting CTL-induced adaptation of HIV-1 at the population level. The patients who developed viral escape mutations and broad autologous CTL responses over time had a significantly higher increase in viral load during the first year of infection compared to those who did not develop viral escape mutations.\n\n<p><i>CONCLUSIONS:</i> A continuous dynamic development of CTL responses was associated with viral escape from temporarily effective immune responses. Our results suggest that broad CTL responses often represent footprints left by viral CTL escape rather than effective immune control, and help explain earlier findings that fail to show an association between breadth of CTL responses and viral load. Our results also demonstrate that CTL pressures help to maintain certain elements of consensus viral sequence, which likely represent viral escape from common HLA-restricted CTL responses. The ability of HIV to evolve to escape CTL responses restricted by a common HLA type highlights the challenges posed to development of an effective CTL-based vaccine</p>', 'PLos One', '2(2)', 68, NULL, 'AnnikaPLOSONE', 'Molecular Sequence Data, Phylogeny, HIV,  Sequence Alignment, Sequence Homology, Nucleic Acid, T-Lymphocytes, Cytotoxic, immunology, Tumor Necrosis Factor-alpha/analysis, tulio, oliveira, immunology, immuno, ', NULL, 'e225', NULL, 2007, NULL, 4.411, 1, NULL, NULL, NULL, NULL),
(41, 'Primary drug resistance in South Africa - data from 10 years of surveys', 'Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T', '<p><b><i>Background:</p></b></i>\n<p>HIV-1 transmitted drug resistance (TDR) could reverse the gains of antiretroviral rollout. To ensure that current 1st line therapies remain effective, TDR levels in recently infected treatment-naive patients need to be monitored.</p>\n<p><b><i>Methods: </p></b></i>\n<p>A literature review and data mining exercise was carried out to determine the temporal trends in TDR in South Africa. In addition, 72 sequences from seroconvertors identified from Africa Centre\'s 2010 HIV surveillance round were also examined for TDR. Publicly available data on TDR were retrieved from Genbank, curated in RegaDB and analyzed using the Calibrated Population Resistance Program. </p>\n<p><b><i>Results: </p></b></i>\n<p>There was no evidence of TDR from the 2010 rural KwaZulu Natal samples. Ten datasets with a total of 1618 sequences collected between 2000 and 2010 were pooled to provide a temporal analysis of TDR. The year with the highest TDR rate was 2002 (6.67%, 95% confidence interval (CI): 3.09-13.79%; n: 6/90). After 2002, TDR levels returned to <5% (WHO low-level threshold) and showed no statistically significant increase in the interval between 2002 and 2010. The most common mutations were associated with NNRTI resistance, K103N, followed by Y181C and Y188C/L. Five sequences had multiple resistance mutations associated with NNRTI resistance.</p><p><b><i> \nConclusions: </b></p></i>\n<p>There is no evidence of TDR in rural KwaZulu-Natal. TDR levels in South Africa have remained low following a downward trend since 2003. Continuous vigilance in monitoring of TDR is needed as more patients are initiated and maintained onto antiretroviral therapy.</p>\n', 'AIDS Res Hum Retroviruses', '28(6)', 45, NULL, 'ManasaHIVDRprimarySA', 'Primary, HIV, drug, resistance , South Africa, 10 years, surveys', 'Primary drug resistance in South Africa - data from 10 years of surveys', '558-565', NULL, 2012, NULL, 2.178, 1, NULL, NULL, NULL, NULL),
(42, 'Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact', 'Lessells RJ, Cooke GS, Newell ML, Godfrey-Faussett P', '<p>The limitations of existing tuberculosis diagnostic tools are significantly hampering tuberculosis control\refforts, most noticeably in areas with high prevalence of human immunodeficiency virus (HIV) infection and\rantituberculosis drug resistance. However, renewed global interest in tuberculosis research has begun to bear\rfruit, with several new diagnostic technologies progressing through the development pipeline. There are\rsignificant challenges in building a sound evidence base to inform public health policies because most\rdiagnostic research focuses on the accuracy of individual tests, with often significant limitations in the design,\rconduct, and reporting of diagnostic accuracy studies.</p>\n<p> Diagnostic accuracy studies may not be appropriate to\rguide public health policies, and clinical trials may increasingly be required to determine the incremental value\rand cost-effectiveness of new tools. The urgent need for new diagnostics should not distract from pursuing\rrigorous scientific evaluation focused on public health impact.</p>', 'J Infect Dis', '204', NULL, NULL, 'Lessells_2011_JID_diagnostic evaluation', 'Evaluation, tuberculosis, diagnostics, evidence, base, around, public, health, impact', 'Evaluation of tuberculosis diagnostics: establishing an evidence base around the public health impact', 'S1187-95', NULL, 2011, NULL, 6.288, 1, NULL, NULL, NULL, NULL),
(43, 'International spread of multidrug-resistant tuberculosis from Tugela Ferry, South Africa', 'Cooke GS, Beaton RK, Lessells RJ, John L, Ashworth S, Kon OM, Williams OM, Supply P, Moodley P, Pym AS', '<p>We describe a death associated with multidrugresistant\rtuberculosis and HIV infection outside Africa that\rcan be linked to Tugela Ferry (KwaZulu-Natal, South Africa),\rthe town most closely associated with the regional epidemic\rof drug-resistant tuberculosis. This case underscores the\rinternational relevance of this regional epidemic, particularly\ramong health care workers.</p>', 'Emerg Infect Dis', '17', NULL, NULL, 'Cooke_2011_EID_MDR spread', 'International, sprea, multidrug-resistant, tuberculosis, Tugela Ferry, South Africa', 'International spread of multidrug-resistant tuberculosis from Tugela Ferry, South Africa', '2035-2037', NULL, 2011, NULL, 6.859, 1, NULL, NULL, NULL, NULL),
(44, 'Poor long-term outcomes for cryptococcal meningitis in rural South Africa', 'Lessells RJ, Mutevedzi PC, Heller T, Newell ML', '<p><b><i>Objectives.</b></i> To explore linkage to and retention in HIV care after an\repisode of cryptococcal meningitis (CM) in rural South Africa.</p>\r<p><b><i>Design.</b></i> A retrospective case series of adult individuals (?16 years\rold) with laboratory-confirmed CM from January - December\r2007 at Hlabisa Hospital ? a district hospital in northern KwaZulu-\rNatal.</p>\r<p><b><i>Outcome measures.</b></i> Inpatient mortality and associated risk factors\rwere analysed. The proportion alive and on antiretroviral therapy\r(ART) at 2 years was determined by linkage to the HIV treatment\rprogramme.</p>\r<p><b><i>Results.</b></i> One hundred and four individuals were identified with\rlaboratory diagnosis of CM; 74/104 (71.2%) with complete records\rwere included in the analysis. Inpatient mortality was high (40.5%)\rand was significantly associated with reduced conscious level (aHR\r3.09, 95% CI 1.30 - 7.33) and absence of headache (aHR 0.33 for\rheadache, 95% CI 0.13 - 0.87). Only 8 individuals (10.8% of all\rstudy subjects) were alive and receiving ART 2 years after the CM\repisode.</p>\r<p><b><i>Conclusions.</b></i> Long-term outcomes of CM are poor in routine\rpractice. Interventions to strengthen linkage to HIV treatment and\rcare and continuation of secondary fluconazole prophylaxis are\rcritical.</p>', 'S Afr Med', '101', 7, NULL, 'Lessells_2011_SAMJ_crypto', 'Poor, long-term, outcomes, cryptococcal, meningitis, rural, South Africa', 'Poor long-term outcomes for cryptococcal meningitis in rural South Africa', '251-2', NULL, 2011, NULL, 1.676, 1, NULL, NULL, NULL, NULL),
(45, 'Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults', 'Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML', '<p><b><i>Objective:</b></i> To assess whether treatment outcomes vary with age for adults receiving antiretroviral therapy (ART) in a large\rrural HIV treatment cohort.</p>\r<p><b><i>Design: </b></i>Retrospective cohort analysis using data from a public HIV Treatment & Care Programme.\rMethods: Adults initiating ART 1st August 2004 - 31st October 2009 were stratified by age at initiation: young adults (16?24\ryears) mid-age adults (25?49 years) and older ($50 years) adults. Kaplan-Meier survival analysis was used to estimate\rmortality rates and age and person-time stratified Cox regression to determine factors associated with mortality. Changes in\rCD4 cell counts were quantified using a piecewise linear model based on follow-up CD4 cell counts measured at sixmonthly\rtime points.</p>\r<p><b><i>Results:</b></i> 8846 adults were included, 808 (9.1%) young adults; 7119 (80.5%) mid-age adults and 919 (10.4%) older adults, with\r997 deaths over 14,778 person-years of follow-up. Adjusting for baseline characteristics, older adults had 32% excess\rmortality (p = 0.004) compared to those aged 25?49 years. Overall mortality rates (MR) per 100 person-years were 6.18 (95%\rCI 4.90?7.78); 6.55 (95% CI 6.11?7.02) and 8.69 (95% CI 7.34?10.28) for young, mid-age and older adults respectively. In the\rfirst year on ART, for older compared to both young and mid-aged adults, MR per 100 person-years were significantly\rhigher; 0?3 months (MR: 27.1 vs 17.17 and 21.36) and 3?12 months (MR: 9.5 vs 4.02 and 6.02) respectively. CD4 count\rreconstitution was lower, despite better virological response in the older adults. There were no significant differences in MR\rafter 1year of ART. Baseline markers of advanced disease were independently associated with very early mortality (0?3\rmonths) whilst immunological and virological responses were associated with mortality after 12months.</p>\r<p><b><i>Conclusions:</b></i> Early ART initiation and improving clinical care of older adults are required to reduce high early mortality and\renhance immunologic recovery, particularly in the initial phases of ART.</p>', 'PLoS ONE', '6(7)', 9, NULL, 'Mutevedzi_2011_PLoS ONE_elderly outcomes', 'Association, age, mortalit,  virologica,  immunological, respons,  antiretroviral, ARV, therapy, rural, South African, adults', 'Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults', 'e21795', NULL, 2011, 'doi:10.1371/journal.pone.0021795', 4.411, 1, NULL, NULL, NULL, NULL),
(46, 'Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa', 'Lessells RJ, Mutevedzi PC, Cooke GS, Newell ML.', '<p><b><i>Objectives:</b></i> To determine retention in HIV care for individuals not\ryet eligible for antiretroviral therapy (ART) and to explore factors\rassociated with retention in a rural public health HIV program.</p>\r<p><b><i>Methods:</b></i> HIV-infected adults ($16 years) not yet eligible for ART,\rwith CD4 cell count .200 cells per microliter from January 2007 to\rDecember 2007 were included in the analysis. Retention was defined by\rrepeat CD4 count within 13 months. Factors associated with retention\rwere assessed using logistic regression with clustering at clinic level.</p>\r<p><b><i>Results:</b></i> Four thousand two hundred twenty-three were included in\rthe analysis (83.9% female). Overall retention was 44.9% with\rmedian time to return 201 days [interquartile range (IQR): 127?274].\rRetention by initial CD4 count 201?350, 351?500, and .500 cells\rper microliter was 51.6% [95% confidence interval (CI): 49.1 to\r54.0], 43.2% (95% CI: 40.5 to 45.9), and 34.9% (95% CI: 32.4 to\r37.4), respectively. Compared with CD4 201?350 cells per microliter,\rhigher initial CD4 count was significantly associated with lower\rodds of retention [CD4: 351?500 cells/mL adjusted odds ratio (aOR):\r0.72, 95% CI: 0.62 to 0.84; CD4.500 cells/mL aOR: 0.51, 95% CI: 0.44\rto 0.60]. Male sex was independently associated with lower odds (aOR:\r0.80, 95% CI: 0.67 to 0.96), and older age with higher odds of retention\r(for each additional year of age aOR: 1.03, 95% CI: 1.03 to 1.04).</p>\r<p><b><i>Conclusions:</b></i> Retention in HIV care before eligibility for ART is\rpoor, particularly for younger individuals and those at an earlier stage.</p>', 'J Acquir Immune Defic Syndr', '56(3)', 32, NULL, 'Lessells_2011_JAIDS_preART retention', 'Retentio, HIV care, individuals, not yet eligible, antiretroviral, ARV, therapy, rural, KwaZulu-Natal, South Africa', 'Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa', 'e79-86', NULL, 2011, NULL, 4.262, 1, NULL, NULL, NULL, NULL),
(47, 'Scale-up of a decentralised HIV treatment programme in rural KwaZulu- Natal, South Africa: does rapid expansion affect patient outcomes?', 'Mutevedzi P, Lessells RJ, Heller T, Barnighausen T, Cooke G, Newell ML', '<p><b><i>Objective</b></i> To describe the scale-up of a decentralized HIV treatment programme delivered through the primary health care system in rural KwaZulu-Natal, South Africa, and to assess trends in baseline characteristics and outcomes in the study population.</p>\r<p><b><i>Methods</b></i> The programme started delivery of antiretroviral therapy (ART) in October 2004. Information on all patients initiated on ART was captured in the programme database and follow-up status was updated monthly. All adult patients (? 16 years) who initiated ART between October 2004 and September 2008 were included and stratified into 6-month groups. Clinical and sociodemographic characteristics were compared between the groups. Retention in care, mortality, loss to follow-up and virological outcomes were assessed at 12 months post-ART initiation.</p>\r<p><b><i>Findings</b></i> A total of 5719 adults initiated on ART were included (67.9% female). Median baseline CD4+ lymphocyte count was 116 cells/?l (interquartile range, IQR: 53?173). There was an increase in the proportion of women who initiated ART while pregnant but no change in other baseline characteristics over time. Overall retention in care at 12 months was 84.0% (95% confidence interval, CI: 82.6?85.3); 10.9% died (95% CI: 9.8?12.0); 3.7% were lost to follow-up (95% CI: 3.0?4.4). Mortality was highest in the first 3 months after ART initiation: 30.1 deaths per 100 person?years (95% CI: 26.3?34.5). At 12 months 23.0% had a detectable viral load (> 25 copies/ml) (95% CI: 19.5?25.5).</p>\r<p><b><i>Conclusion</b></i> Outcomes were not affected by rapid expansion of this decentralized HIV treatment programme. The relatively high rates of detectable viral load highlight the need for further efforts to improve the quality of services.</p>', 'Bull WHO', '88', 31, NULL, 'Mutevedzi_2010_Bull WHO', 'Scale-up, decentralised, HIV, treatment, programme, rural, KwaZulu- Natal, South Africa, rapid, expansion, affect, patient outcomes', 'Scale-up of a decentralised HIV treatment programme in rural KwaZulu- Natal, South Africa: does rapid expansion affect patient outcomes?', '593-600', NULL, 2010, NULL, 5.459, 1, NULL, NULL, NULL, NULL),
(48, 'The TB challenge in a rural South African HIV programme', 'Houlihan C, Mutevedzi P, Lessells R, Cooke G, Tanser F, Newell ML', '<p><b><i>Background:</b></i> South Africa remains the country with the greatest burden of HIV-infected individuals and the\rsecond highest estimated TB incidence per capita worldwide. Within South Africa, KwaZulu-Natal has one of the\rhighest rates of TB incidence and an emerging epidemic of drug-resistant tuberculosis.</p>\r<p><b><i>Methods:</b></i> Review of records of consecutive HIV-infected people initiated onto ART between 1st January 2005 and\r31st March 2006. Patients were screened for TB at initiation and incident episodes recorded. CD4 counts, viral loads\rand follow-up status were recorded; data was censored on 5th August 2008. Geographic cluster analysis was\rperformed using spatial scanning.</p>\r<p><b><i>Results:</b></i> 801 patients were initiated. TB prevalence was 25.3%, associated with lower CD4 (AHR 2.61 p = 0.01 for\rCD4 <50 cells/?l) and prior TB (AHR 1.58 p = 0.02). Incidence was 6.89 per 100 person-years from 81 cases over\r1175 person-years analysis time and was highest in the first 3 months after ART initiation; associated with male sex\rand higher log HIV RNA. Prevalent and incident TB were significantly associated with mortality (OR 1.81 p = 0.01\rand 2.02 p = 0.01 respectively). Incident TB was associated with a non-significant trend towards viral load >25\rcopies/ml (OR 1.75 p = 0.11). A low-risk cluster for incident TB was identified for patients living near the local\rhospital in the geospatial analysis.</p>\r<p><b><i>Conclusion:</b></i> There is a large burden of TB in this population. Rate of incident TB stabilises at a rate higher than\rthat of the overall population. These data highlight the need for greater research on strategies for active case\rfinding in rural settings and the need to focus on strengthening primary health care.</p>', 'BMC Infect Dis', '10', 16, NULL, 'Houlihan_BMC ID_2010', 'TB, challenge,  rural, South African, HIV, programme, KwaZulu-Natal, Hlabisa', 'The TB challenge in a rural South African HIV programme in KwaZulu-Natal', '23', NULL, 2010, NULL, 2.83, 1, NULL, NULL, NULL, NULL),
(49, 'Cohort profile: Hlabisa HIV Treatment and Care Programme', 'Houlihan C, Bland R, Mutevedzi P, Lessells R, Ndirangu J, Thulare H, Newell ML', '<p><b><i> No abstract</b></i> as this is a detailed cohort paper</p>', 'Int J Epidemiol', '40', 34, NULL, 'Houlihan_2010_IJE_cohort', 'Cohort, profile, Hlabisa, HIV, Treatment, Care, Programme, KwaZulu-Natal', 'Cohort profile: Hlabisa HIV Treatment and Care Programme', '318-26', NULL, 2011, NULL, 5.759, 1, NULL, NULL, NULL, NULL),
(50, 'Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa', 'Heller T, Lessells RJ, Wallrauch C, Barnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML', '<p><b><i>SETTING:</b></i> Hlabisa health sub-district, KwaZulu-Natal,\rSouth Africa.</p>\r<p><b><i>OBJECTIVE:</b></i> To describe the establishment of a\rc ommunity-based multidrug-resistant tuberculosis\r(MDR-TB) treatment programme embedded in the district\rTB control programme and to evaluate whether\rearly outcomes are comparable to those in the traditional\rhospital-based model of care.</p>\r<p><b><i>DESIGN: </b></i>Cases who initiated community-based MDRTB\rtreatment (CM) between March and December 2008\rwere compared with patients who initiated MDR-TB\rtreatment under the traditional hospital-based model of\rcare (TM) between January 2001 and February 2008.\rTime to initiation of treatment and time to sputum smear\rand culture conversion were compared for the two groups\rin Kaplan-Meier survival curves using the Mantel-Cox\rlog-rank test.</p>\r<p><b><i>RESULTS:</b></i> Overall, 50 CM cases and 57 TM cases were\rincluded; 39 of the 50 CM cases (78.0%) were human\rimmunodefi ciency virus positive. The median time to initiation\rof treatment was 84 days for CM and 106.5 days\rfor TM (P = 0.002). Median time to sputum smear conversion\rwas shorter for CM than TM (59 vs. 92 days,\rP = 0.055), as was time to sputum culture conversion\r(85 vs. 119 days, P = 0.002).</p>\r<p><b><i>CONCLUSION:</b></i> Community-based treatment for MDRTB\rcan be implemented within the existing TB control\rprogramme in rural South Africa and should be scaled\rup where resources allow.</p>\r', 'Int J TB Lung Dis', '14', 27, NULL, 'Heller_2010_IJTLD_MDR', 'Community-based, treatment , multidrug-resistant, tuberculosis, rural, KwaZulu-Natal, South Africa', 'Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa', '420-426', NULL, 2010, NULL, 2.557, 1, NULL, NULL, NULL, NULL),
(51, 'Effect of the HIV epidemic on liver cancer in Africa', 'Lessells RJ, Cooke GS', '<p>The timely Comment by Pierre Hainaut\rand Peter Boyle (Feb 2, p 367)1 makes\rsurprisingly little mention of the\rpotential eff ect of the HIV epidemic\ron the future burden of liver cancer in\rAfrica, particularly the leading cause in\rsub-Saharan Africa, chronic hepatitis B\rvirus (HBV) infection.</p>\r<p>With the HIV epidemic still rampant,\rsuch cancer is likely to become more\rcommon. Just one reason for this is that\rHIV/HBV co-infected individuals exhibit\rhigher HBV DNA levels and higher rates\rof HBeAg carriage than those who\rare HIV negative; both variables are\rpredictors of hepatocellular carcinoma\rrisk.</p>\r<p>Vaccination is the cornerstone of\rplans for global control of HBV, yet HIV\rinfection also threatens to diminish\rthe eff ect of vaccination programmes:\rblunted response to hepatitis B vaccine\ris evident among HIV-infected children3\rand adults, and vaccine-escape viral\rmutants have been detected among\rpeople receiving long-term antiviral\rtherapy. Widespread transmission of\rvaccine-escape mutants could threaten\rthe eff ectiveness of vaccination.</p>\r<p>Beyond vaccination, the inclusion\rof HBV suppressive agents in anti retroviral\rrollout programmes (lami vudine,\remtri citabine, and tenofovir) has the\rpotential to have a positive eff ect on the\rincidence of HBV-related liver cancer.</p>\r<p>However, with only lamivudine widely\ravailable in Africa, it is possible that as\rrollout of antiretroviral therapy reduces\rAIDS deaths, chronic liver disease including\rhepatocellular carcinoma will\rbecome increasingly common, as has\rbeen seen in cohorts from developed\rnations. Greater understanding of\rHBV/HIV interactions in Africa should\rbe a high priority.</p>', 'Lancet', '371', 4, NULL, 'Lessells_2008_Lancet_LiverCancer', 'Effect, HIV, epidemic, liver, cancer, Africa', 'Effect of the HIV epidemic on liver cancer in Africa', '1504', NULL, 2008, NULL, 33.633, 1, NULL, NULL, NULL, NULL),
(52, 'HIV and hepatitis B co-infection in Africa', 'Lessells RJ, Main J, Cooke GS', '<p>The Review by Christopher Hoff mann and Chloe Thio1\rbrings to the fore the issue of HIV and hepatitis B virus\r(HBV) co-infection in resource-poor settings. We\rsupport their call for further research in this fi eld.\rThe management of HIV/HBV co-infection in highincome\rsettings involves individualised therapy usually\rfrom an expert provider with the support of an array of\rdiagnostic tests. The primary goal of this treatment is to\rreduce the risk of cirrhosis and hepatocellular carcinoma.</p>\r<p>However, the public-health approach to antiretroviral\rtherapy (ART) aims to maximise survival at the\rpopulation level.2 ART programmes in Africa and other\rresource-poor settings involve standardised treatment\rprotocols and simplifi ed monitoring to achieve best\rpossible use of available resources. The treatment of\rhepatitis B is already entwined with the roll-out of\rART since lamivudine, a key drug in most fi rst-line HIV\rtreatment combinations, is also active against HBV.</p>', 'Lancet Infectious Diseases', '8', 8, '', 'Lessells_2008_LancetID_HBVHIV', 'HIV, hepatitis B, HepB, HBV, co-infection, Africa', 'HIV and hepatitis B co-infection in Africa', '210-11', NULL, 2008, NULL, 16.144, 1, NULL, NULL, NULL, NULL),
(53, 'Management of hepatitis B co-infection in human immunodeficiency virus infected subjects', 'Lessells R, Leen CLS', '<p>The human immunodeficiency virus (HIV) and\rthe hepatitis B virus share common routes of transmission,\rand hence, coinfection with these two viruses is common.\rChronic hepatitis B does not influence the progression of\rHIV disease or the response to highly active antiretroviral\rtherapy. It is clear, however, that HIV infection does\rimpact the course of hepatitis B, as higher rates of chronic\rcarriage, lower seroconversion rates, and accelerated\rprogression towards cirrhosis have been observed. Vaccination\ragainst hepatitis B is less effective in HIV-infected\rindividuals. </p>\n<p>Coinfected subjects have a poor response to\rinterferon therapy. Lamivudine is more effective in\rcoinfected subjects but must not be used as monotherapy\rbecause of the risk of resistance developing. Combination\rtherapy with lamivudine and tenofovir has shown promise\rand is currently being investigated in clinical trials, while\rnew drugs and other combinations are in development.</p>', 'Eur J Clin Micro ID', '23(5)', NULL, NULL, 'Lessells_2004_EurJClinMicroID_HBVHIV', 'Managemen, hepatitis B, HBV, HepB, co-infectio, human, immunodeficiency, virus, HIV, infected, subjects', 'Management of hepatitis B co-infection in human immunodeficiency virus infected subjects', '366-374', NULL, 2004, NULL, 2.631, 1, NULL, NULL, NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(54, 'Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe.', 'Tshabalala M, Manasa J, Zijenah LS, Rusakaniko S, Kadzirange G, Mucheche M, Kassaye S, Johnston E, Katzenstein D', '<p>The rapid scale-up of highly active antiretroviral therapy (HAART) and use of single dose Nevirapine (SD NVP) for prevention of mother-to-child transmission (pMTCT) have raised fears about the emergence of resistance to the first line antiretroviral drug regimens. A cross-sectional study was conducted to determine the prevalence of primary drug resistance (PDR) in a cohort of young (<25 yrs) HAART-naive HIV pregnant women attending antenatal clinics in Chitungwiza, Zimbabwe. Whole blood was collected in EDTA for CD4 counts, viral load, serological estimation of duration of infection using the BED Calypte assay and genotyping for drug resistance. Four hundred and seventy-one women, mean age 21 years; SD: 2.1 were enrolled into the study between 2006 and 2007. Their median CD4 count was 371cells/uL; IQR: 255-511 cells/uL. Two hundred and thirty-six samples were genotyped for drug resistance. </p>\r<p>Based on the BED assay, 27% were recently infected (RI) whilst 73% had long-term infection (LTI). Median CD4 count was higher (p<0.05) in RI than in women with LTI. Only 2 women had drug resistance mutations; protease I85V and reverse transcriptase Y181C. Prevalence of PDR in Chitungwiza, 4 years after commencement of the national ART program remained below WHO threshold limit (5%). Frequency of recent infection BED testing is consistent with high HIV acquisition during pregnancy. With the scale-up of long-term ART programs, maintenance of proper prescribing practices, continuous monitoring of patients and reinforcement of adherence may prevent the acquisition and transmission of PDR.</p>', 'PLoS ONE', '6(6)', 11, NULL, 'Manasa_2011_Zimbabwe', 'Surveillanc, transmitted, antiretroviral, drug resistance, HIV-1, infected, women, attending, antenatal, clinic, Chitungwiza, Zimbabwe', 'Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe.', 'e21241', NULL, 2011, NULL, 4.411, 1, NULL, NULL, NULL, NULL),
(55, 'Evaluation of the Partec flow cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe', 'Manasa J, Musabaike H, Masimirembwa C, Burke E, Luthy R, Mudzori J', '<p>A single-platform volumetric flow cytometer, the Partec Cyflow SL_3, was evaluated against a BD FACSCalibur/\rSysmex XT1800i dual platform for measuring CD4 lymphocytes, total lymphocytes, and the percentage of CD4\rlymphocytes in whole-blood samples for monitoring the immune systems of human immunodeficiency virus\r(HIV)/AIDS patients. Statistical analyses for precision, correlation, and agreement were performed. Coefficients\rof variation (CV) of 5.8, 4.6, and 3.9% were obtained for low, medium, and high CD4 cell counts,\rrespectively, using the SL_3, and CV of 3.7, 4.0, and 0.94 were obtained for the same categories, using the BD\rFACSCalibur. Significant correlations (P < 0.005) between the two assays for CD4 counts, total lymphocyte\rcounts, and percentages of CD4 were obtained, with correlation coefficients of 0.99, 0.96, and 0.99, respectively\r(n  229). Using the Bland-Altman plot, mean biases of 18 cell/l (95% confidence interval (CI); 91 to 54\rcells/l), 0.8% (95% CI; 3.6 to 2%), and 36.8 cells/l (95% CI; 477 to 404 cells/l) were obtained for\rcomparisons of CD4 counts, percentages of CD4 cells, and total lymphocyte counts, respectively.</p> \r<p>The effects of\rthe age of the samples on the three parameters were also analyzed by comparing results from the same samples\ranalyzed at 6, 24, and 48 h after collection. The correlation coefficients for comparisons among different time\rpoints for the same machine and among all the time points for the two different machines were greater than\r0.90. These data showed that the Partec Cyflow SL_3 assay is comparable to the BD FACSCalibur_Sysmex\rXT1800i dual-platform method for measuring the amount of CD4 cells and total lymphocytes and the\rpercentages of CD4 cells in blood samples for the purpose of monitoring HIV/AIDS patients.</p>', 'Clin Vaccine Immunol', '14(3)', 32, NULL, 'Manasa_cBED_2007', 'Evaluation, Partec, flow, cytometer, BD FACSCalibur system, monitoring, immune, responses, human immunodeficiency virus, HIV, infected, patients ,Zimbabwe', 'Evaluation of the Partec flow cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe', '293-8', NULL, 2007, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(56, 'Modeling HIV-1 Drug Resistance as Episodic Directional Selection', 'Murrell B, de Oliveira T, Seebregts C, Kosakovsky-Pond SL, Scheffler K, on behalf SATuRN', '<p>The evolution of substitutions conferring drug resistance to HIV-1 is both episodic, occurring when patients are on antiretroviral therapy, and strongly directional, with site-specific resistant residues increasing in frequency over time. While methods exist to detect episodic diversifying selection and continuous directional selection, no evolutionary model combining these two properties has been proposed. We present two models of episodic directional selection (MEDS and EDEPS) which allow the a priori specification of lineages expected to have undergone directional selection.</p> \n<p>The models infer the sites and target residues that were likely subject to directional selection, using either codon or protein sequences. Compared to its null model of episodic diversifying selection, MEDS provides a superior fit to most sites known to be involved in drug resistance, and neither one test for episodic diversifying selection nor another for constant directional selection are able to detect as many true positives as MEDS and EDEPS while maintaining acceptable levels of false positives. This suggests that episodic directional selection is a better description of the process driving the evolution of drug resistance.</p>\n<p><b>Author Summary</b></p>\n<p>When exposed to treatment, HIV-1 and other rapidly evolving viruses have the capacity to acquire drug resistance mutations (DRAMs), which limit the efficacy of antivirals. There are a number of experimentally well characterized HIV-1 DRAMs, but many mutations whose roles are not fully understood have also been reported. In this manuscript we construct evolutionary models that identify the locations and targets of mutations conferring resistance to antiretrovirals from viral sequences sampled from treated and untreated individuals. While the evolution of drug resistance is a classic example of natural selection, existing analyses fail to detect the majority of DRAMs. We show that, in order to identify resistance mutations from sequence data, it is necessary to recognize that in this case natural selection is both episodic (it only operates when the virus is exposed to the drugs) and directional (only mutations to a particular amino-acid confer resistance while allowing the virus to continue replicating). The new class of models that allow for the episodic and directional nature of adaptive evolution performs very well at recovering known DRAMs, can be useful at identifying unknown resistance-associated mutations, and is generally applicable to a variety of biological scenarios where similar selective forces are at play.</p>', 'PLoS Comput Biol', ' 8(5)', 10, NULL, 'Murrell_Direction_Selection_HIVDR_2012', 'Modeling, HIV-1, Drug, Resistance , Episodic, positive, darwinian, Directional, Selection', 'Modeling HIV-1 Drug Resistance as Episodic Directional Selection. Plos Computational biology, Murrell, de Oliveira and colleagues for the Southern African Treatment and Resistance Network 2012 open access publication', 'e1002507', NULL, 2012, 'doi:10.1371', 5.759, 1, NULL, NULL, NULL, NULL),
(57, 'WHO HIV drug resistance report 2012', 'WHO ResNet, including - Jordan MR, Barcarolo J, Parkin N, de Oliveira T (analysis support), Bertagnolio S', '<p>This report assesses the general levels of transmitted and acquired drug resistance in select geographical areas of low- and middle-income countries. It is based on two distinct data sources: surveys performed to assess transmitted and acquired drug resistance using standardized WHO methods (WHO surveys) and a broad systematic review of the published literature on transmitted and acquired drug resistance. Findings from the monitoring of early warning indicators of HIV drug resistance are also presented and discussed.</p>\n<p>This report is organized as follows.</p>\n<p>		Chapter 1 outlines the objectives of the report, discusses the determinants of HIV drug resistance, and describes the WHO global HIV drug resistance surveillance and monitoring strategy.</p>\n<p>		Chapter 2 provides an overview of HIV drug resistance in high-income countries.</p>\n<p>		Chapter 3 discusses a systematic review and meta-analysis of the published literature on levels and trends of transmitted drug resistance in select areas of low- and middle-income countries and presents data from surveys of transmitted drug resistance conducted according to standardized WHO methods.</p>\n<p>		Chapter 4 discusses a systematic review of levels of acquired drug resistance in patients failing first-line antiretroviral therapy in select low- and middle-income countries, and presents data from surveys of acquired drug resistance conducted according to standardized WHO methods.</p>\n<p>		Chapter 5 presents findings from the monitoring of early warning indicators of HIV drug resistance.\n<p>		Chapter 6 discusses overall conclusions.</p>\n		\n<p><a href=\"http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html\">http://www.who.int/hiv/pub/drugresistance/report2012/en/index.html</a></p>', 'WHO report', 'ISBN 978 92 4 150393 8', NULL, NULL, 'WHOdrugresistance2012report', 'hiv, drug, resistance, world health organization, who, report, 2012, primary, acquired, treatment,hiv, drug, resistance, world health organization, who, report, 2012, primary, acquired, treatment', 'This report assesses the general levels of transmitted and acquired drug resistance in select geographical areas of low- and middle-income countries. It is based on two distinct data sources: surveys performed to assess transmitted and acquired drug resistance using standardized WHO method', NULL, NULL, 2012, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(58, 'The tainted milk of human kindness', 'Goedhals D, Rossouw I, Hallbauer U, Mamabolo M, de Oliveira T', '<p>In September, 2009, a 74-day-old infant presented to a local hospital in Bloemfontein, South Africa, in broncho- pneumonia related respiratory distress. She appeared pale, cyanosed, and had palpable axillary lymph nodes, hepatomegaly, and oropharyngeal candidosis. She had received all scheduled vaccinations and had been exclusively breastfed. Cytomegalovirus was isolated from a respiratory sample by shell vial culture, and a paired blood sample showed a cytomegalovirus viral load of 12 600 copies per mL. She was positive for HIV by ELISA and DNA PCR. However, the baby?s mother said that she tested HIV negative during pregnancy, which was confirmed by fourth generation ELISA test. The baby?s CD4 cell count was 2189 cells per mL (40% lymphocytes) and antiretroviral therapy was started. The mother reported that her sister had breastfed the baby inter- mittently from 6 weeks of age. The sister and her 5-month-old child were subsequently found to be HIV positive by ELISA and DNA PCR. Laboratory records confirmed the sister\'s positive HIV status in February, 2008, excluding recent seroconversion. At final follow-up in April, 2010, our patient was well with an undetectable HIV viral load.</p>\n<p>Plasma samples from the sister and both infants were used for partial sequencing of the HIV pol gene with the TRUGENE HIV-1 genotyping kit (Siemens Healthcare Diagnostics, Tarrytown, NY, USA). We analysed the data with the same approach used to identify the source of the nosocomial HIV-1 CRFO2_AG outbreak in the Al-Fateh Hospital, Libya.1 We collated 100 HIV-1 reference strains from the Free State Province, South Africa, closely related to the three case sequences, and then estimated and assessed phylogenies using algorithmic, Bayesian, and maximum-likelihood methods. The case sequences form a well-supported monophyletic cluster within the HIV-1 subtype C clade. The linkage is supported with 100% bootstrap in the algorithm and maximum-likelihood methods and with 100% posterior probability in the Bayesian phylogenies.</p>\n', 'Lancet', '380', 5, NULL, 'LancetHIVsurrogate2012', 'hiv, transmission, surrogate, pmtct, mother-to-child-transmission, phylogeny, aunt, baby, phylogeny, lancet, de oliveira', 'This is the first proven HIV-1 surrogate transmission case in the world. It uses DNA sequencing and it is been published this week in one of the most respected medical journals in the world, the Lancet. This case highlights the need of implementation of safe and appropriate infant feeding practices in Africa, including HIV testing of all breastfeeding surrogates and mothers', '702', NULL, 2012, NULL, 33.633, 1, NULL, NULL, NULL, NULL),
(59, 'Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study', 'Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L For IeDEA-SA', '<p><b><i>Background</b></i></p>\n<p>Increased mortality among men on antiretroviral therapy (ART) has been documented but remains poorly understood. We examined the magnitude of and risk factors for gender differences in mortality on ART.</p>\n<p><b><i>Methods and Findings</b></i></p>\n<p>Analyses included 46,201 ART-naive adults starting ART between January 2002 and December 2009 in eight ART programmes across South Africa (SA). Patients were followed from initiation of ART to outcome or analysis closure. The primary outcome was mortality; secondary outcomes were loss to follow-up (LTF), virologic suppression, and CD4+ cell count responses. Survival analyses were used to examine the hazard of death on ART by gender. Sensitivity analyses were limited to patients who were virologically suppressed and patients whose CD4+ cell count reached >200 cells/ul. We compared gender differences in mortality among HIV+ patients on ART with mortality in an age-standardised HIV-negative population.</p>\n\n<p>Among 46,201 adults (65% female, median age 35 years), during 77,578 person-years of follow-up, men had lower median CD4+ cell counts than women (85 versus 110 cells/ul, p<0.001), were more likely to be classified WHO stage III/IV (86 versus 77%, p<0.001), and had higher mortality in crude (8.5 versus 5.7 deaths/100 person-years, p<0.001) and adjusted analyses (adjusted hazard ratio [AHR] 1.31, 95% CI 1.22?1.41). After 36 months on ART, men were more likely than women to be truly LTF (AHR 1.20, 95% CI 1.12?1.28) but not to die after LTF (AHR 1.04, 95% CI 0.86?1.25). Findings were consistent across all eight programmes. Virologic suppression was similar by gender; women had slightly better immunologic responses than men. Notably, the observed gender differences in mortality on ART were smaller than gender differences in age-standardised death rates in the HIV-negative South African population. Over time, non-HIV mortality appeared to account for an increasing proportion of observed mortality. The analysis was limited by missing data on baseline HIV disease characteristics, and we did not observe directly mortality in HIV-negative populations where the participating cohorts were located.</p>\n\n<p><b><i>Conclusions</b></i></p>\n<p>HIV-infected men have higher mortality on ART than women in South African programmes, but these differences are only partly explained by more advanced HIV disease at the time of ART initiation, differential LTF and subsequent mortality, and differences in responses to treatment. The observed differences in mortality on ART may be best explained by background differences in mortality between men and women in the South African population unrelated to the HIV/AIDS epidemic.</p>', 'PLoS Medicine', '9(9)', NULL, NULL, 'PLosMed_gender_ARV_2012', 'Gender, Differences, Survival, Adult, Patients, Starting, Antiretroviral, Therapy, South Africa', 'Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study\r\n', 'e1001304', NULL, 2012, NULL, 13.05, 1, NULL, NULL, NULL, NULL),
(60, 'Are subtype differences important in HIV drug resistance?', 'Lessells RJ, Katzenstein DK, de Oliveira T', '<p>The diversity of human immunodeficiency virus type 1 (HIV-1)\rhas given rise to multiple subtypes and recombinant strains.\rThe majority of research into antiretroviral agents and drug\rresistance has been performed on subtype B viruses, yet nonsubtype\rB strains are responsible for 90% of global infections.\rAlthough it seems that combination antiretroviral regimens are\reffective against all HIV-1 subtypes, there is emerging evidence\rof subtype differences in drug resistance, relevant to\rantiretroviral strategies in different parts of the world. For this\rpurpose, extensive sampling of HIV genetic diversity, curation\rand analyses are required to inform antiretroviral strategies in\rdifferent parts of the world.</p>\n<p><b><i>Summary of main concepts:</b></i></p>\n<p>- HIV-1 diversity has given rise to numerous subtypes and recombinant forms.</p>\n<p>- New subtyping tools (e.g. Rega HIV-1 Subtyping Tool version 3, SCUEL and COMET) can accurately identify the most important HIV-1 variants.</p>\n<p>- National and international public drug resistance databases are useful resources to trace the evolution of drug resistance in different subtypes.</p>\n<p>- HIV-1 subtype genetic variation can influence the development of drug resistance and the susceptibility to certain antiretroviral drugs.</p>\n<p>- K65R is an example of a clinically relevant mutation that emerges more frequently and more rapidly in subtype C viruses compared to subtype B; this has been shown to be related to the different template nucleotide sequence.</p>\n<p>- Evidence from recent clinical trials and cohort studies suggests that response to combination antiretroviral regimens does not differ substantially by HIV-1 subtype.</p>\n<p>- Appreciation of subtype differences is important in the development of new drugs and in the formulation of antiretroviral strategies.\n', 'Current Opinion Virology', '2(5)', 35, NULL, 'CurrOpVirol_2012_SubtypeResistance', 'subtypes, HIV, resistance, drug resistance, mutations, k65R, subtyping tools, review,  subtype C, SATuRN, de Oliveira, Katzenstein, Lessells', 'The diversity of human immunodeficiency virus type 1 (HIV-1)\rhas given rise to multiple subtypes and recombinant strains.\rThe majority of research into antiretroviral agents and drug\rresistance has been performed on subtype B viruses, yet nonsubtype\rB strains are responsible for 90% of global infections.\rAlthough it seems that combination antiretroviral regimens are\reffective against all HIV-1 subtypes, there is emerging evidence\rof subtype differences in drug resistance, relevant to\rantiretroviral strategies in different parts of the world. For this\rpurpose, extensive sampling of HIV genetic diversity, curation\rand analyses are required to inform antiretroviral strategies in\rdifferent parts of the world', '636-43', NULL, 2012, NULL, 9.15, 1, 2, NULL, NULL, NULL),
(61, 'The 2012 southern African ARV drug resistance testing guidelines', 'Conradie F, Wilson D, Basson A, de Oliveira T, Hunt G, Joel D, Papathanasopoulos M, Preiser W, Klausner J, Spencer D, Stevens W, Venter F, van Vuuren C', '<p>Following the rapid scale-up of the programme for universal access to antiretroviral therapy (ART) in southern Africa, resistance to antiretroviral medications will occur. A detectable viral load must be treated as an emergency and should trigger intensive patient tracking and adherence counselling. </p>\n<p>In contrast to the developed world, the incidence of transmitted resistance is still low in most areas in the region. Therefore, in this consensus statement we do not recommend resistance testing in HIV-infected adults upon diagnosis or ART initiation. </p>\n<p>However, baseline resistance testing is recommended for children who have been exposed to ART for prevention of mother-to-child-transmission therapy and subsequently become HIV-infected. Resistance testing is also recommended after virological failure of first- and second-line ART regimens.</p>', 'S Afr J HIV Med', '13(4)', 23, NULL, 'SouthernAfricanARVdrugresistanceguidelines_2012', 'guidelines, southern africa, south africa, southern african, hiv, drug resistance, antiretroviral, guideline, national, ARV, resistance, HIVDR,guidelines, southern africa, south africa, southern african, hiv, drug resistance, antiretroviral, guideline, national, ARV, resistance, HIVDR,guidelines, southern africa, south africa, southern african, hiv, drug resistance, antiretroviral, guideline, national, ARV, resistance, HIVDR', 'The 2012 southern African antiretroviral ARV drug resistance testing guidelines by the Southern African HIV Clinicians Society. Tulio de Oliveira, Francesca Conradie, Wendy Stevens, Dough Wilson, etc', '162-167', NULL, 2012, 'DOI:10.7196/SAJHIVMED.874', NULL, 1, NULL, NULL, NULL, NULL),
(62, 'Principles of HIV drug resistance for clinical management in South Africa', 'Stott K, Michel J, de Oliveira T', '<p>The rapid scale-up of antiretroviral therapy (ART) during the past decade has led to dramatic reductions in HIVrelated morbidity and mortality. Efforts are now focused on maintaining virological suppression of patients on first line ART, detecting treatment failure and switching to second-line regimens where necessary. </p>\n<p>A major threat to sustaining the positive impacts of ART is the increasing issue of drug resistance. Drug resistance may be primary (transmitted), whereby a person is infected by a strain of HIV that is not fully susceptible to antiretroviral medications (ARVs), or secondary (acquired), whereby a person develops resistance to ARVs over time. In South Africa, the level of primary resistance has been below 5% for the last decade and so this article will focus on the more pressing problem of secondary resistance. </p>\n<p>In Southern Africa, routine viral-load monitoring is recommended to identify treatment failure but it is often not done with sufficient frequency, nor reacted to appropriately. There can be a reluctance to switch patients to second-line therapy, in spite of clear guidelines. This is in part because of a lack of certainty regarding the reason for treatment failure ? whether it is due to poor patient adherence, the development of drug resistance, or a combination of these issues. Nonetheless, patients who continue taking a failing ART regimen are at risk of developing resistance to those medications. This article reviews the South African guidelines for viral load monitoring and regimen switch and introduces basic concepts of drug resistance for nurses and health care workers. The information presented here is useful to practitioners throughout Southern Africa as most HIV epidemics in the region are dominated by the same HIV subtype (HIV-1 subtype C), and drug resistance develops by similar mechanisms.</p>', 'HIV Nursing Matters', '3(4)', NULL, NULL, 'HIVdrugResistance_Nurses2012', 'principles, drug resistance, HIV-1, nurses, health care workers, south africa, HIV Nursing matters, de Oliveira, nurse, resistance, treatment resistance, HIV, SATuRN, genotype, clinical, management, principles, drug resistance, HIV-1, nurses, health care workers, south africa, HIV Nursing matters, de Oliveira, nurse, resistance, treatment resistance, HIV, SATuRN, genotype, clinical, management, principles, drug resistance, HIV-1, nurses, health care workers, south africa, HIV Nursing matters, de Oliveira, nurse, resistance, treatment resistance, HIV, SATuRN, genotype, clinical, management', 'Principles of HIV drug resistance for clinical management in South Africa. This publication introduces HIV drug resistance to nurses and health care workers. Stott, Michel, de Oliveira publication on HIV drug resistance at HIV Nursing Matters journal from the Southern African HIV Clinicians Society', '46-51', NULL, 2012, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(63, 'Searching for Virus Phylotypes', 'surname=de OliveiraChevenet F, Jung M, Peeters M, <a href=\"http://www.bioafrica.net/people.php?surname=de Oliveira\">de Oliveira T</a>, Gascuel O', '<p><b><i>Motivation:</b></i> Very large phylogenies are being built today in order to study virus evolution, trace the origin of epidemics, establish the mode of transmission, and survey the appearance of drug resistance. However, no tool is available to quickly inspect these phylogenies and combine them with extrinsic traits (e.g. geographic location, risk group, presence of a given resistance mutation), seeking to extract strain groups of specific interest or requiring surveillance.</p>\n\n<p><b><i>Results:</b></i> We propose a new method for obtaining such groups, which we call phylotypes, from a phylogeny having taxa (strains) annotated with extrinsic traits. Phylotypes are subsets of taxa with close phylogenetic relationships and common trait values. The method combines ancestral trait reconstruction using parsimony, with combinatorial and numerical criteria measuring tree shape characteristics and the diversity and separation of the potential phylotypes. A shuffling procedure is used to assess the statistical significance of phylotypes. All algorithms have linear time complexity. This results in very low computing times, typically a few minutes for the larger data sets with a number of shuffling steps. Two HIV-1 data sets are analyzed, one of which is very large, containing more than 3,000 strains of HIV-1 subtype C collected worldwide, where the method shows its ability to recover known clusters and transmission routes, and to detect new ones.</p>\n\n<p><b><i>Availability:</b></i> This method and companion tools are implemented in an interactive Web interface (<a href=\"http://www.phylotype.org\">www.phylotype.org</a>), which provides a wide choice of graphical views and output formats, and allows for exploratory analyses of very large data sets.</p>\n', 'Bioinformatics', '29 (5)', 10, NULL, 'Phylotypes_Bioinformatics_2013', 'virus, phylotype, phylotype.org, HIV phylotyping, de Oliveira, Gascuel, large phylogenies, bioinformatics, bioafrica.net, large datasets, phylotyping, tulio, virus, phylotype, phylotype.org, HIV phylotyping, de Oliveira, Gascuel, large phylogenies, bioinformatics, bioafrica.net, large datasets, phylotyping, tulio, virus, phylotype, phylotype.org, HIV phylotyping, de Oliveira, Gascuel, large phylogenies, bioinformatics, bioafrica.net, large datasets, phylotyping, tulio, virus, phylotype, phylotype.org, HIV phylotyping, de Oliveira, Gascuel, large phylogenies, bioinformatics, bioafrica.net, large datasets, phylotyping, tulio', 'Searching for Virus Phylotypes. Bioinformatics 2013, Very large phylogenies are being built today in order to study virus evolution, trace the origin of epidemics, establish the mode of transmission, and survey the appearance of drug resistance. However, no tool is available to quickly inspect these phylogenies and combine them with extrinsic traits (e.g. geographic location, risk group, presence of a given resistance mutation), seeking to extract strain groups of specific interest or requiring surveillance.', '561-570', NULL, 2013, '10.1093/bioinformatics/btt010', 5.468, 1, NULL, NULL, NULL, NULL),
(64, 'HIV & TB Drug Resistance & Clinical Management Case Book', 'Rossouw T, Lessells RJ, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p>The twin epidemics of HIV and TB continue to cause untold damage to individuals, families and communities in sub-Saharan Africa. The massive scale up of antiretroviral therapy (ART) in this region has begun to reverse some of the trends in morbidity and mortality caused by these twin epidemics. Drug resistance appears as an inevitable consequence of the widespread use of antimicrobial agents. The past two decades has seen the emergence of drug-resistant strains of Mycobacterium tuberculosis which threaten basic TB control. Resistance to antiretroviral drugs is now an escalating threat in this region as we end the first decade of ART roll-out in Africa with over five million people receiving ART. </p>\n<p></p>\n<p>In order to confront this challenge we need to learn how to prevent and manage drug resistance, both at an individual and at a programmatic level. The aim of this book is to equip health care workers with the knowledge and skills to diagnose and manage cases of drug-resistant HIV and TB but also to learn how drug resistance might be prevented. The focus is on the interpretation of diagnostic tests related to drug resistance. The book is aimed primarily at doctors, nurses, and pharmacists but other readers might find information that is relevant for their own circumstances. The focus throughout most of the cases is on practice in the public health sector but there is also information relevant to private practitioners.</p>\n<p></p>\n<p>The book is equally suited to learning on your own or learning within a group - the cases could, for example, be used as teaching material for Nurse Initiation and Management of ART (NIM-ART) nurses at your clinic or hospital. The cases are also available online (<a href=\"http:/www.bioafrica.net/saturn\">www.bioafrica.net/saturn</a>) - new cases will be added regularly to the online site and updated information about existing cases will also be added. We aim to compile a second edition of this book in the future as more cases are added to the website.</p>\n<p> </p>\n<p>It has been a great pleasure putting together this book and we hope that you also enjoy the experience of reading and learning from the material. We ask that readers send us any feedback and comments so that we can improve the book in future editions. You can send your comments to us using our email addresses.</p>\n<p></p>\n<p>Theresa Rossouw MBChB, PhD, MPH</p>\n\n<p><a href=\"people.php?peopleid=13\">Richard J Lessells</a> BSc(MedSci), MBChB, MRCP(UK), DTM&H, DipHIVMed</p>\n<p><a href=\"people.php?peopleid=1\">Tulio de Oliveira</a> BSc, BSc (Hon), PhD</p>\n<p><center><a href=\"http://www.bioafrica.net/cases.php\"><img src=\"imagesBIO/OpenAccesslogoGREEN.png\" align=\"center\"><h3>The HIV & TB Drug Resistance Clinical Management Case Book is free for download at our website</h3></p><br>\n', 'South African Medical Research Council Press', 'ISBN 978-1-920014-91-9', NULL, NULL, '', 'HIV, TB, Drug, Resistance, Clinical, Management, Case, Book, saturn, south africa, casebook, tuberculosis, MDR, XDR, HIVDR, de Oliveira, Lessells, Rossouw, HIV, TB, Drug, Resistance, Clinical, Management, Case, Book, saturn, south africa, casebook, tuberculosis, MDR, XDR, HIVDR, de Oliveira, Lessells, Rossouw, HIV, TB, Drug, Resistance, Clinical, Management, Case, Book, saturn, south africa, casebook, tuberculosis, MDR, XDR, HIVDR, de Oliveira, Lessells, Rossouw, open access, free, MRC, EC', 'The aim of this openly accessible book is to equip health care workers with the knowledge and skills to diagnose and manage cases of drug-resistant HIV and TB but also to learn how drug resistance might be prevented. The focus is on the interpretation of diagnostic tests related to drug resistance. T', '', NULL, 2013, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(65, 'RegaDB: Community-driven data management and analysis for infectious diseases', 'Libin P, Beheydt G, Deforche K, Imbrechts S, Ferreira F, Van Laethem K, Theys K, Carvalho AP, Cavaco Silva J, Lapadula G, Torti P, Assel M, Wesner S, Snoeck J, Ruelle J, De Bel A, Lacor P, De Munter P, Van Wijngaerden E, Zazzi M, Kaiser R, Ayouba A, Peeters M, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Alcantara L, Grossman Z, Sloot P, Otelea D, Paraschiv S, Boucher C, Camacho R, and Vandamme AM', '<p><b><i>Summary:</b></i> RegaDB is a free and open source data management and analysis environment for infectious diseases. RegaDB allows clinicians to store, manage and analyze patient data, including viral genetic sequences. Moreover, RegaDB provides researchers with a mechanism to collect data in a uniform format and offers them a canvas to make newly developed bioinformatics tools available to clinicians and virologists through a user friendly interface. </p>\n<p><b><i>Availability and implementation:</b></i> Source code, binaries and documentation are available on http://regaweb.med.kuleuven.be/software/regadb/ RegaDB is written in the Java programming language, using a web-service oriented architecture.</p>\n<p><b><i>Opportunities for researchers:</b></i>  Another example of the utility of RegaDB is the collaborative database used within the Southern African Treatment and Resistance Network (SATuRN). This network has 24 member institutions working in Southern Africa, the region at the epicenter of the HIV epidemic. Currently there are more than ten institutions using the SATuRN RegaDB for patient data management, data curation and research. Under SATuRN, more than 7,000 genotypes with treatment and monitoring data has been collected. Using the built-in customized report and query functionality, data of specific attributes is selected, analyzed and used to answer specific clinical and research questions (<a href=\"publications.php?pubid=41\">Manasa et al. 2012</a>, <a href=\"publications.php?pubid=1\">de Oliveira et al. 2010</a>). In addition, members of the SATuRN project recently published a book (<a href=\"publications.php?pubid=64\">Rossouw, Lessells & de Oliveira 2013</a>) containing a series of case studies used for training. More than 1,450 physicians and nurses have been trained through conferences, workshops and online web-tutorials  RegaDB: Community-driven data management and analysis for infectious diseases.</p>', 'Bioinformatics', '29 (11)', 14, NULL, 'RegaDB_Bioinformatics_2013_Libin', 'regaDB, bioinformatics, database, drug resistance, open source, community, saturn, hiv, clinical management, de oliveira, Rega, regaDB, bioinformatics, database, drug resistance, open source, community, saturn, hiv, clinical management, de oliveira, Rega, regaDB, bioinformatics, database, drug resistance, open source, community, saturn, hiv, clinical management, de oliveira, Rega', 'egaDB is a free and open source data management and analysis environment for infectious diseases. RegaDB allows clinicians to store, manage and analyze patient data, including viral genetic sequences. Moreover, RegaDB provides researchers with a mechanism to collect data in a uniform format and offers them a canvas to make newly developed bioinformatics tools available to clinicians and virologists through a user friendly interface.', '1477-1480, doi: 10.1093/bioinformatics/btst162\n', NULL, 2013, NULL, 5.468, 3, NULL, NULL, NULL, NULL),
(66, 'Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.', 'Aitken SC, Kliphuis A, Bronze M, Wallis CL, Kityo C, Balinda S, Stevens WS, Spieker N, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Rinke de Wit TF, Schuurman R.', '<p>Virological failure (VF) has been identified as the earliest, most predictive determinant of HIV-1 antiretroviral treatment (ART) failure. Due to high costs and complexity of virological monitoring, VF assays are rarely performed in resource-limited settings (RLS). Rather, ART failure is determined by clinical monitoring and to a large extent immunological monitoring. This paper describes the development and evaluation of a low-cost, dried blood spot (DBS)-compatible qualitative assay to determine VF, in accordance with current WHO guideline recommendations for therapy-switching in RLS.  </p>\n<p>The described assay is an internally-controlled qualitative real-time PCR targeting the conserved long terminal repeat domain of HIV-1. This assay was applied with HIV-1 subtypes A-H and further evaluated on HIV-1 clinical plasma samples from South Africa (n=191) and Tanzania (n=42). Field evaluation was performed in Uganda using local clinical plasma samples (n=176). Furthermore, assay performance was evaluated for DBS.  </p>\n<p>The described assay is able to identify VF for all major HIV-1 group-M subtypes with equal specificity, and lower detection limit of 1.00E+03 copies/ml for plasma and 5.00E+03 copies/ml for DBS. Comparative testing yielded accurate VF determination for therapy-switching in 89%-96% of samples compared to gold standards.  </p>\n<p>The assay is robust and flexible, allowing for \"open platform\" applications and producing comparable results to commercial assays. Assay design enables application in laboratories that can accommodate real-time PCR equipment, allowing decentralization of testing to some extent. Compatibility with DBS extends access of sampling and thus access to this test to remote settings.</p>', 'J Clin Microbiol', '29 (11)', 10, NULL, 'Aitken_ViralLoad_2013', 'affordable, real-time, qulitatitve, assay, hiv-1, virological failure, plasma, dried blood spots, ARTA, SATuRN, de Oliveira, Rinke de Wit Tobias,affordable, real-time, qulitatitve, assay, hiv-1, virological failure, plasma, dried blood spots, ARTA, SATuRN, de Oliveira, Rinke de Wit Tobias,affordable, real-time, qulitatitve, assay, hiv-1, virological failure, plasma, dried blood spots, ARTA, SATuRN, de Oliveira, Rinke de Wit Tobias', 'Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.Virological failure (VF) has been identified as the earliest, most predictive determinant of HIV-1 antiretroviral treatment (ART) failure. Due to high costs and complexity of virological monitoring, VF assays are rarely performed in resource-limited settings (RLS). Rather, ART failure is determined by clinical monitoring and to a large extent immunological monitoring. This paper describes the development and evaluation of a low-cost, dried blood spot (DBS)-compatible qualitative assay to determine VF, in accordance with current WHO guideline recommendations for therapy-switching in RLS. ', 'JCM.03305-12', NULL, 2013, NULL, 4.399, 3, NULL, NULL, NULL, NULL),
(67, 'Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: Performance evaluation of the new REGA version 3 and seven other tools', 'Pena ACP, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, Gomez A, Camacho RJ, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Vandamme A-M', '<p><b><i>Background:</b></i> To investigate differences in pathogenesis, diagnosis and resistance pathways between HIV-1 subtypes, an accurate subtyping tool for large datasets is needed. We aimed to evaluate the performance of automated subtyping tools to classify the different subtypes and circulating recombinant forms using pol, the most sequenced region in clinical practice. We also present the upgraded version 3 of the Rega HIV subtyping tool (REGAv3).</p>\n<p><b><i>Methodology:</b></i> HIV-1 pol sequences (PR + RT) for 4674 patients retrieved from the Portuguese HIV Drug Resistance Database, and 1872 pol sequences trimmed from full-length genomes retrieved from theLos Alamos database were classified with statistical-based tools such as COMET, jpHMM and STAR; similarity-based tools such as NCBI and Stanford; and phylogenetic-based tools such as REGA version 2(REGAv2), REGAv3, and SCUEAL. The performance of these tools, for pol, and for PR and RT separately, was compared in terms of reproducibility, sensitivity and specificity with respect to the gold standard which was manual phylogenetic analysis of the pol region.</p>\n<p><b><i>Results:</b></i> The sensitivity and specificity for subtypes B and C was more than 96% for seven tools, but was variable for other subtypes such as A, D, F and G. With regard to the most common circulating recombinant forms (CRFs), the sensitivity and specificity for CRF01_AE was  approximately 99% with statistical-based tools, with phylogenetic-based tools and with Stanford, one of the similarity based tools. CRF02_AG was correctly identified for more than 96% by COMET, REGAv3, Stanford and STAR. All the tools reached a specificity of more than 97% for most of the subtypes and the two main CRFs (CRF01_AE and CRF02_AG).Other CRFs were identified only by COMET, REGAv2, REGAv3, and SCUEAL and with variable sensitivity. When analyzing sequences for PR and RT separately, the performance for PR was generally lower and variable between the tools. Similarity and statistical-based tools were 100% reproducible, but this was lower for phylogenetic-based tools such as REGA (approximately 99%) and SCUEAL (approximately 96%).</p>\n<p><b><i>Conclusions:</b></i> REGAv3 had an improved performance for subtype B and CRF02_AG compared to REGAv2 and is now able to also identify all epidemiologically relevant CRFs. In general the best performing tools, in alphabetical order, were COMET, jpHMM, REGAv3, and SCUEAL when analyzing pure subtypes in the pol region, and COMET and REGAv3 when analyzing most of the CRFs. Based on this study, we recommend to confirm subtyping with 2 well performing tools, and be cautious with the interpretation of short sequences.</p>\n', 'Infectious Genetics and Evolution', ' in press ', 65, NULL, 'Pineda_SubtypingTools2013', 'hiv-1, subtyping, tool, comparison, surveillance, rega, regav3, version 3, other tools, scuel, rip, jpmhh, altomated, subtyping, hiv, genetic sequences, clinical, de oliveira, vandamme, REGA,hiv-1, subtyping, tool, comparison, surveillance, rega, regav3, version 3, other tools, scuel, rip, jpmhh, altomated, subtyping, hiv, genetic sequences, clinical, de oliveira, vandamme, REGA,hiv-1, subtyping, tool, comparison, surveillance, rega, regav3, version 3, other tools, scuel, rip, jpmhh, altomated, subtyping, hiv, genetic sequences, clinical, de oliveira, vandamme, REGA', 'REGAv3 had an improved performance for hiv-1 subtype B and CRF02_AG compared to REGAv2 and is nowable to also identify all epidemiologically relevant CRFs. In general the best performing tools, in alphabetical order, were COMET, jpHMM, REGAv3, and SCUEAL when analyzing pure subtypes in the pol region, and COMET and REGAv3 when analyzingmost of the CRFs.', NULL, NULL, 2013, NULL, 3.223, 1, NULL, NULL, NULL, NULL),
(68, 'Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens', 'Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Preiser W, Wood NT, Travers S, Shafer RW', '<p><b><i>Objectives:</b></i> South Africa\'s national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the associated changes in genotypic drug resistance patterns in patients with first-line ARV treatment failure since the introduction of these drugs, and protease inhibitor (PI) resistance patterns in patients who received ritonavir-boosted lopinavir (LPV/r)-containing therapy.</p>\n<p><b><i>Methods:</b></i> We analysed ARV treatment histories and HIV-1 RT and protease mutations in plasma samples submitted to the Tygerberg Academic Hospital National Health Service Laboratory.</p>\n<p><b><i>Results:</b></i> Between 2006 and 2012, 1,667 plasma samples from 1,416 ARV-treated patients, including 588 children and infants, were submitted for genotypic resistance testing. Compared with 720 recipients of a d4T or AZT-containing first-line regimen, the 153 recipients of a TDF-containing first-line regimen were more likely to have the RT mutations K65R (46% vs 4.0%; p,0.001), Y115F (10% vs. 0.6%; p,0.001), L74VI (8.5% vs. 1.8%; p,0.001), and K70EGQ (7.8% vs. 0.4%) and recipients of an ABC-containing first-line regimen were more likely to have K65R (17% vs 4.0%; p,0.001), Y115F (30% vs 0.6%; p,0.001), and L74VI (56% vs 1.8%; p,0.001). Among the 490 LPV/r recipients, 55 (11%) had $1 LPV-resistance mutations including 45 (9.6%) with intermediate or high-level LPV resistance. Low (20 patients) and intermediate (3 patients) darunavir (DRV) cross resistance was present in 23 (4.6%) patients.</p>\n<p><b><i>Conclusions:</b></i> Among patients experiencing virological failure on a first-line regimen containing two NRTI plus one NNRTI, the use of TDF in adults and ABC in children was associated with an increase in four major non- thymidine analogue mutations. In a minority of patients, LPV/r-use was associated with intermediate or high-level LPV resistance with predominantly low-level DRV cross-resistance.</p>\n', 'PLoS One', '8(6)', 36, NULL, 'VanZylPLoSOne_HIVDR_2013', 'hiv-1, drug resistance, south africa, TDF, tenofovir, Gert Van Zyl, Bob Shafer, Tulio de Oliveira, SATuRN, public database, ABC, large dataset, department of health,hiv-1, drug resistance, south africa, TDF, tenofovir, Gert Van Zyl, Bob Shafer, Tulio de Oliveira, SATuRN, public database, ABC, large dataset, department of health, antiretroviral, ARVs, hiv-1, drug resistance, south africa, TDF, tenofovir, Gert Van Zyl, Bob Shafer, Tulio de Oliveira, SATuRN, public database, ABC, large dataset, department of health,hiv-1, drug resistance, south africa, TDF, tenofovir, Gert Van Zyl, Bob Shafer, Tulio de Oliveira, SATuRN, public database, ABC, large dataset, department of health', 'uth Africa\'s national antiretroviral (ARV) treatment program expanded in 2010 to include the nucleoside reverse transcriptase (RT) inhibitors (NRTI) tenofovir (TDF) for adults and abacavir (ABC) for children. We investigated the associated changes in genotypic drug resistance patterns in patients with first-line ARV treatment failure since the introduction of these drugs, and protease inhibitor (PI) resistance patterns in patients who received ritonavir-boosted lopinavir.', 'e67188', NULL, 2013, 'doi:10.1371/journal.pone.0067188', 4.411, 3, NULL, NULL, NULL, NULL),
(69, 'High Level of HIV-2 False Positivity in KwaZulu-Natal Province: A Region of South Africa With a Very High HIV-1 Subtype C Prevalence', ' Singh L, Parboosing R, Manasa J, Moodley P,  <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>Human immunodeficiency virus 2 (HIV-2) is found predominantly in West Africa. It is not unlikely, however, that HIV-2 may also be found in South Africa, due to the influx of immigrants into this country. </p>\n<p>It is important to distinguish between HIV-1 and HIV-2 since the clinical courses and treatment responses of these viruses are different. Routine serological methods for diagnosing HIV do not differentiate between HIV-1 and -2 infections, while rapid tests, viral load quantification and PCR are HIV-type specific. </p>\n<p>The objective of this study was to describe the seroprevalence and molecular epidemiology of HIV-2 in KwaZulu- Natal, one of the regions with the highest HIV prevalence in the world and home of the two largest harbors in South Africa. HIV-1 positive samples were screened for antibodies against HIV-2, using a rapid test. </p>\n<p>The confirmation of HIV-2 positive samples was done by PCR. Of the 2,123 samples screened, 319 (15%) were identified as positive by the rapid test. None of these samples were confirmed positive by PCR. To explore this discrepancy in the results, a subset (n = 52) of the rapid HIV-2 positive samples was subjected to Western blotting. Thirty-seven (71%) of these were positive, yielding an overall HIV-2 seroprevalence of 10.6%. Three out of 28 (10.7%) Western blot positive samples were positive by a Pepti-LAV assay. </p>\n<p>This discrepancy between serological and molecular confirmation may be attributed to non-specific or cross-reacting antibodies. The use of rapid tests and Western blots for HIV-2 diagnosis in South Africa should be interpreted with caution.</p>', 'Journal of Medical Virology', 'Advanced Access', 5, NULL, 'Lavanya_Singh_HIV2MSCpaper_JMedViro2013', 'hiv-2, False Positivity, KZN, rapid test, KwaZulu-Natal, South Africa, de Oliveira, Lavanya Singh, SD Bioline HIV-1/2, WHO, rapid test, hiv-2, False Positivity, KZN, rapid test, KwaZulu-Natal, South Africa, de Oliveira, Lavanya Singh, SD Bioline HIV-1/2, WHO, rapid test, hiv-2, False Positivity, KZN, rapid test, KwaZulu-Natal, South Africa, de Oliveira, Lavanya Singh, SD Bioline HIV-1/2, WHO, rapid test, hiv-2, False Positivity, KZN, rapid test, KwaZulu-Natal, South Africa, de Oliveira, Lavanya Singh, SD Bioline HIV-1/2, WHO, rapid test', 'High Level of HIV-2 False Positivity in KwaZulu-Natal Province: A Region of South Africa With a Very High HIV-1 Subtype C Prevalence. Journal of Medical Virology 2013', 'doi: 10.1002/jmv.23716', NULL, 2013, NULL, 2.373, 3, NULL, NULL, NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(70, 'High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa', '<a href=\"people.php?peopleid=3\">Manasa J</a>, <a href=\"people.php?peopleid=13\">Lessells RJ</a>, Skingsley A, Naidu KK, Newell M-L, McGrath N, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p><b><i>Objective</b></i></p>\n<p>To determine the frequency and patterns of acquired antiretroviral drug resistance in a rural primary health care programme in South Africa.</p>\n<p><b><i>Design</b></i></p>\n<p>Cross-sectional study nested within HIV treatment programme.</p>\n<p><b><i>Methods</b></i></p>\n<p>Adult (>=18 years) HIV-infected individuals initially treated with a first-line stavudine- or zidovudine-based antiretroviral therapy (ART) regimen and with evidence of virological failure (one viral load >1000 copies/ml) were enrolled from 17 rural primary health care clinics. Genotypic resistance testing was performed using the in-house SATuRN/Life Technologies system. Sequences were analysed and genotypic susceptibility scores (GSS) for standard second-line regimens were calculated using the Stanford HIVDB 6.0.5 algorithms.</p>\n<p><b><i>Results</b></i></p>\n<p>A total of 222 adults were successfully genotyped for HIV drug resistance between December 2010 and March 2012. The most common regimens at time of genotype were stavudine, lamivudine and efavirenz (51%); and stavudine, lamivudine and nevirapine (24%). Median duration of ART was 42 months (interquartile range (IQR) 32-53) and median duration of antiretroviral failure was 27 months (IQR 17-40). One hundred and ninety one (86%) had at least one drug resistance mutation. For 34 individuals (15%), the GSS for the standard second-line regimen was <2, suggesting a significantly compromised regimen. In univariate analysis, individuals with a prior nucleoside reverse-transcriptase inhibitor (NRTI) substitution were more likely to have a GSS <2 than those on the same NRTIs throughout (odds ratio (OR) 5.70, 95% confidence interval (CI) 2.60-12.49).</p>\n<p><b><i>Conclusions</b></i></p>\n<p>There are high levels of drug resistance in adults with failure of first-line antiretroviral therapy in this rural primary health care programme. Standard second-line regimens could potentially have had reduced efficacy in about one in seven adults involved.</p>', 'PLoS One', '8(8)', 27, NULL, 'Manasa_pone_HighHIVDR_rural_Africa_0072152_2013', 'hiv-1, rural, south africa, africa, drug resistance, adult, acquired, SATuRN, high-level, failing, ARV, antiretroviral, first-line, HIV, treatment, de Oliveira, Manasa, Lessells, hiv-1, rural, south africa, africa, drug resistance, adult, acquired, SATuRN, high-level, failing, ARV, antiretroviral, first-line, HIV, treatment, de Oliveira, Manasa, Lessells, hiv-1, rural, south africa, africa, drug resistance, adult, acquired, SATuRN, high-level, failing, ARV, antiretroviral, first-line, HIV, treatment, de Oliveira, Manasa, Lessells, hiv-1, rural, south africa, africa, drug resistance, adult, acquired, SATuRN, high-level, failing, ARV, antiretroviral, first-line, HIV, treatment, de Oliveira, Manasa, Lessells', 'Open Access Publication PLoS One 2013, High-Levels of Acquired Drug Resistance in Adult Patients Failing First-Line Antiretroviral Therapy in a Rural HIV Treatment Programme in KwaZulu-Natal, South Africa. Manasa, Lessells, de Oliveira for SATuRN', 'e72152', NULL, 2013, 'doi:10.1371/journal.pone.0072152', 4.411, 1, NULL, NULL, NULL, NULL),
(71, 'Human Retrovirus Codon Usage from tRNA Point of View: Therapeutic Insights', 'Frias D, Monteiro-Cunha JP, Mota-Miranda AC, Fonseca VS, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Galvao-Castro B Alcantara LCJ', '<p>The purpose of this study was to investigate the balance between transfer ribonucleic acid (tRNA) supply and demand in retrovirus-infected cells, seeking the best targets for antiretroviral therapy based on the hypothetical tRNA Inhibition Therapy (TRIT). Codon usage and tRNA gene data were retrieved from public databases. </p><p>Based on logistic principles, a therapeutic score (T-score) was calculated for all sense codons, in each retrovirus-host system. Codons that are critical for viral protein translation, but not as critical for the host, have the highest T-score values. Theoretically, inactivating the cognate tRNA species should imply a severe reduction of the elongation rate during viral mRNA translation. We developed a method to predict tRNA species critical for retroviral protein synthesis. Four of the best TRIT targets in HIV-1 and HIV-2 encode Large Hydrophobic Residues (LHR), which have a central role in protein folding. One of them, codon CUA, is also a TRIT target in both HTLV-1 and HTLV-2. </p><p>Therefore, a drug designed for inactivating or reducing the cytoplasmatic concentration of tRNA species with anticodon TAG could attenuate significantly both HIV and HTLV protein synthesis rates. Inversely, replacing codons ending in UA by synonymous codons should increase the expression, which is relevant for DNA vaccine design.</p>', 'Bioinformatics and Biology Insights', '7', 2, NULL, 'HIVHTLV_codonUsage_Bioinformatics', 'hiv, htlv-1, codon, usage, tRNA, bioinformatics, therapy, Therapeutic, human retroviruses, hiv, htlv-1, codon, usage, tRNA, bioinformatics, therapy, Therapeutic, human retroviruses, hiv, htlv-1, codon, usage, tRNA, bioinformatics, therapy, Therapeutic, human retroviruses, hiv, htlv-1, codon, usage, tRNA, bioinformatics, therapy, Therapeutic, human retroviruses, manuscript, open access', 'Open access publication Human Retrovirus Codon Usage from tRNA Point of View: Therapeutic Insights. The purpose of this study was to investigate the balance between transfer ribonucleic acid (tRNA) supply and demand in retrovirus-infected cells (i.e. HIV, and HTLV), seeking the best targets for antiretroviral therapy based on the hypothetical tRNA Inhibition Therapy (TRIT). Codon usage and tRNA gene data were retrieved from public databases.', '1-11', NULL, 2013, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(72, 'Combined antiretroviral and antituberculosis drug resistance following incarceration', 'Stott KE, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, <a href=\"people.php?peopleid=13\">Lessells RJ</a>', '<p>We describe a case of HIV/tuberculosis (TB) co-infection from KwaZulu-Natal, South Africa, characterised by drug resistance\rin both pathogens. The development of drug resistance was linked temporally to two periods of incarceration. This highlights\rthe urgent need for improved integration of HIV/TB control strategies within prison health systems and within the broader\rpublic health framework.</p>', 'S Afr J HIV Med', '14(3)', 3, NULL, 'Lessells_SAJHIVMED_HIV_TB_prison', 'case, report, prison, HIV-1, TB, drug resistance, south africa, KwaZulu-Natal, Tulio de Oliveira, Richard Lessells, public heath, MDR, HIVDR, case, report, prison, HIV-1, TB, drug resistance, south africa, KwaZulu-Natal, Tulio de Oliveira, Richard Lessells, public heath, MDR, HIVDR, case, report, prison, HIV-1, TB, drug resistance, south africa, KwaZulu-Natal, Tulio de Oliveira, Richard Lessells, public heath, MDR, HIVDR, SAfr J HIV Med', 'Open Access publication on dual HIV/TB drug resistance from a prisoner. We describe a case of HIV/tuberculosis (TB) co-infection from KwaZulu-Natal, South Africa, characterised by drug resistance\rin both pathogens. The development of drug resistance was linked temporally to two periods of incarceration. This highlights\rthe urgent need for improved integration of HIV/TB control strategies within prison health systems and within the broader\rpublic health framework.', '135-137', NULL, 2013, 'DOI:10.7196/SAJHIVMED.957', NULL, 1, NULL, NULL, NULL, NULL),
(73, 'Pili contribute to biofilm formation in vitro in Mycobacterium tuberculosis', 'Ramsugit S, Guma S, Pillay B, Jain P, Larsen MH, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Pillay M.', '<p>Organized bacterial communities, or biofilms, provide an important reservoir for persistent cells that are inaccessible or tolerant to antibiotics. Curli pili are cell-surface structures produced by certain bacteria and have been implicated in biofilm formation in these species. In order to determine whether these structures, which were suggested to be encoded by the Rv3312A (mtp) gene, have a similar role in Mycobacterium tuberculosis, we generated a Dmtp mutant and a mtp-complemented strain of a clinical isolate of M. tuberculosis and analyzed these strains for their ability to produce pili in comparison to the wild-type strain.</p><p> Phenotypic analysis by transmission electron microscopy proved the essentiality of mtp for piliation in M. tuberculosis. We then compared biofilm formation of the derived strains in detergentfree Sauton?s media. Biofilm mass was quantified spectrophotometrically using crystal violet. Furthermore, we examined mtp gene expression by quantitative real-time PCR in wild-type cells grown under biofilm versus planktonic growth conditions. We found a 68.4 % reduction in biofilm mass in the mutant compared to the wild-type strain (P = 0.002). Complementation of the mutant resulted in a restoration of the wild-type biofilm phenotype (P = 0.022). </p><p> We, however, found no significant difference between mtp expression in cells of the biofilm to those growing planktonically. Our findings highlight a crucial, but non-specific, role of pili in the biofilm lifestyle of M. tuberculosis and indicate that they may represent an important target for the development of therapeutics to attenuate biofilm formation, thereby potentially reducing persistence.</p>', 'Antonie Van Leeuwenhoek', '104(2)', NULL, NULL, 'Ramsugit_etal_2013', NULL, NULL, 'DOI 10.1007/s10482-013-9981-6', NULL, 2013, 'DOI 10.1007/s10482-013-9981-6', 2.072, 1, NULL, NULL, NULL, NULL),
(74, 'A qualitative and quantitative histopathological analysis of the host immune response to TB of the spine in HIV-positive and negative patients', '<a href=\"people.php?peopleid=2\">Danaviah S</a>, Sacks J, Taylor L, Govender S, Fallows D, Kumar KPS, Ndung\'u T, Kaplan G.   ', '<p>Tuberculosis (TB) is mainly a disease of the lungs, but Mycobacterium tuberculosis (Mtb) can establish\rinfection in virtually any organ in the body. Rising rates of extrapulmonary (EP) TB have been largely\rassociated with the HIV epidemic, as patients co-infected with HIV show a four-fold higher risk of EPTB.\rSpinal TB (Pott?s Disease), one of the most debilitating extrapulmonary forms of disease, is difficult to\rdiagnose and can cause deformity and/or neurological deficits.</p><p> This study examined the histopathology\rand distribution of immune cells within spinal TB lesions and the impact of HIV on pathogenesis.\rThe overall structure of the spinal granulomas resembled that seen in lung lesions from patients with\rpulmonary TB. Evidence of efficient macrophage activation and differentiation were detectable within\rorganized structures in the spinal tissue, irrespective of HIV status. Interestingly, the granulomatous\rarchitecture and macroscopic features were similar in all samples examined, despite a reversal in the\rratio of infiltrating CD4 to CD8 T cells in the lesions from HIV-infected patients. </p><p> This study provides a\rfoundation to understand the mechanism of tissue destruction and disease progression in Spinal TB,\renabling the future development of novel therapeutic strategies and diagnostic approaches for this\rdevastating disease.</p>', 'Tuberculosis', '93(4)', NULL, NULL, 'danaviah_etal_2013', NULL, NULL, '432-41', NULL, 2013, NULL, 3.036, 1, NULL, NULL, NULL, NULL),
(75, 'Use of dried blood spots for the determination of genetic variation of IL-10, Killer Immunoglobulin-like Receptor and HLA Class I genes', 'Ndlovu BG, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Moodley E, Ghebremichael M, Bland R, Viljoen J, Newell M-L, Ndung\'u T, and Carr WH', '<p>Optimal methods for using dried blood spots (DBSs) for population genetics-based\rstudies have not been well established. Using DBS stored for 8 years from 21\rpregnant South African women, we evaluated three methods of gDNA extraction\rwith and without whole-genome amplification (WGA) to characterize immune-related\rgenes: interleukin-10 (IL-10 ), killer immunoglobulin-like receptors (KIRs) and human\rleukocyte antigen (HLA) class I. </p><p>We found that the QIAamp DNA mini kit yielded the\rhighest gDNA quality (P< 0.05; Wilcoxon signed rank test) with sufficient yield for\rsubsequent analyses. In contrast, we found that WGA was not reliable for sequencespecific\rprimer polymerase chain reaction (SSP-PCR) analysis of KIR2DL1, KIR2DS1,\rKIR2DL5 and KIR2DL3 or high-resolution HLA genotyping using a sequence-based\rapproach. We speculate that unequal template amplification by WGA underrepresents\rgene repertoires determined by sequence-based approaches.</p>', 'Tissue Antigens', '79(2)', NULL, NULL, 'Bongiwe_etal_2011', NULL, NULL, '114-22', NULL, 2011, NULL, 2.934, 1, NULL, NULL, NULL, NULL),
(76, 'Cumulative exposure to cell-free HIV in breast milk, rather than feeding pattern per se, identifies postnatally infected infants', 'Neveu D, Viljoen J, Bland RM, Nagot N, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Coutsoudis A, Rollins NC, Coovadia HM, Van de Perre P, Newell ML. ', '<p><b><i>Background</b></i>. We quantified the relationship between human immunodeficiency virus (HIV) RNA shedding in\nbreast milk, cumulative RNA exposure, and postnatal transmission, relating timing of infection in the infant to\nestimated total volume of milk exposure.</p>\n<p><b><i>Methods</b></i>. Nested case-control study of 36 infants of HIV-infected mothers. Case patients were infants who\nacquired HIV infection through breastfeeding from age 6 through 28 weeks, and control subjects were uninfected\ninfants matched on age at obtainment of a breast milk sample. Mothers and infants received peripartum single-dose\nnevirapine prophylaxis. Feeding data were collected daily; breast milk samples were collected and infant\nanthropometry was performed at 6 weeks and monthly thereafter. Volume of milk ingested was estimated using\ninfant weight and feeding pattern.</p>\n<p><b><i>Results</b></i>. Before HIV acquisition in case patients, feeding pattern (exclusive breastfeeding; median duration, 65\nvs 70 days; P 5 .6) and daily milk intake (mean volume, 638 vs 637 mL; P 5 .97) did not differ significantly between\ncase patients and control subjects. Case mothers were more likely to shed virus (64% vs 9% always, 22% vs 20.5%\nintermittently, 14% vs 70.5% never shed; overall, P .001). Case patients ingested 15 times more HIV-1 RNA\nparticles than did control subjects (196.5 vs 13 3 106 copies; P .001). Allowing for maternal antenatal CD4 cell\ncount and plasma HIV-1 load, child sex and duration of mixed breastfeeding, the association between HIV RNA\nexposure and infection remained statistically significant (P .001).</p>\n<p><b><i>Conclusions</b></i>. Postnatal acquisition of HIV-1 is more strongly associated with cumulative exposure to cell-free\nparticles in breast milk than with feeding mode. Reducing breast milk viral load through antiretroviral therapy to\nmother or child can further decrease postnatal transmission in exclusively breastfed infants.</p>', 'Clin Infect Dis', '52(6)', NULL, NULL, 'Neveu_CID_2011', NULL, NULL, '819-25', NULL, 2011, NULL, 9.374, 1, NULL, NULL, NULL, NULL),
(77, 'Dried Blood Spot HIV-1 RNA Quantification Using Open Real-Time Systems in South Africa and Burkina Faso', 'Viljoen J, Gampini S, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Valea D, Pillay S, Kania D, Meda N, Newell ML, Van de Perre P, Rouet F; for the World Health Organization/ANRS 1289 Kesho Bora Study Group', '<p>There is an urgent need to assess the accuracy/feasibility\nof using dried blood spots (DBS) for monitoring of HIV-1 viral load\nin resource-limited settings. A total of 892 DBS from HIV-1?positive\npregnant women and their neonates enrolled in the Kesho Bora\nprevention of mother-to-child transmission trial conducted in Durban\n(South Africa) and Bobo-Dioulasso (Burkina Faso) between May\n2005 and July 2008 were tested for HIV-1 RNA. The combination\nNuclisens extraction method (BioMetrieux)/Generic HIV Viral Load\nassay (Biocentric) was performed using one DBS (in Durban) versus\n2 DBS (in Bobo-Dioulasso) on 2 distinct open real-time polymerase\nchain reaction instruments.</p><p> DBS HIV-1 RNA results were compared\nwith plasma HIV-1 RNA and HIV serology results used as the\ngold standards. The limits of detection of assays on DBS were 3100\nand 1550 copies per milliliter in Durban and Bobo-Dioulasso,\nrespectively. DBS HIV-1 RNA values correlated significantly with\nplasma levels (n = 327; R = 0.7351) and were uniformly distributed\naccording to duration of DBS storage at 220C (median duration,\n280 days). For early infant diagnosis, the sensitivity and specificity\nwere 100% (95% confidence interval: 97.2 to 100.0 and 96.5 to\n100.0, respectively). </p><p>HIV-1 viral load kinetics in DNase-pretreated\nDBS were similar to those obtained in plasma specimens among 13\npatients receiving antiretroviral treatment. HIV-1 RNA findings from\nserial infant DBS collected prospectively (n = 164) showed 100%\nconcordance with HIV serology at 18 months of life. Our findings\nstrongly advocate the implementation of DBS HIV-1 RNA testing in\nremote areas from low-income and middle-income countries.</p>', 'Acquir Immune Defic Syndr', '55(3)', NULL, NULL, 'viljoen_etal_2010', NULL, NULL, '290-8', NULL, 2010, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(78, 'Comparison of the Generic HIV Viral Load assay with the Amplicor HIV-1 monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. ', 'Rouet F, Foulongne V, Viljoen J, Steegen K, Becquart P, Valea D, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Segondy M, Verhofstede C, Van de Perre P; WHO/ANRS 1289 Kesho Bora Study Group', '<p>The implementation of cost effective HIV-1 RNA quantitation assays in resource-poor settings is of\nparamount importance for monitoring HV-1 infection. A study comparing the analytical performance\nof three HIV-1 RNA assays (Generic HIV Viral Load, AmplicorTM v1.5 and Nuclisens EasyQ v1.2) was\nperformed on 160 plasma samples from 160 consecutive antiretroviral treatment naive HIV-1-infected\npregnant women assessed for eligibility in the Kesho Bora trial aimed at prevention of mother-to-child\ntransmission of HIV-1 in three African countries (Burkina Faso, Kenya and South Africa). Correlation and\nagreement of results of the three assays were assessed for plasma HIV-1 RNA quantitation in specimens\nharbouring mainly sub-subtype A1, subtype C, and circulating recombinant form (CRF) 02 AG and\nCRF06 cpx.</p><p>\nGood degrees of correlation and agreement were observed between these HIV-1 RNA assays. However,\nnine (9/160, 5.6%) strains detectable with the Generic HIV Viral Load assay were not detected by\neither the AmplicorTM (n = 7) or EasyQ (n = 2) test. One strain (0.6%) was missed with the Generic HIV\nViral Load assay. Further, concordantly positive plasma samples harbouring CRF02 AG and CRF06 cpx\nyielded significantly higher HIV-1 RNA concentrations when tested by Generic HIV Viral Load, as compared\nto AmplicorTM v1.5 (mean differences, +0.33 and +0.67 log10 copies/ml; P = 0.0004 and P = 0.002,\nrespectively). The Generic HIV Viral Load assay accurately quantified the majority of the non-B HIV-1\nsubtypes assessed in this study. Due to its low cost (?10 US $/test), this assay performed with open realtime\nPCR instruments is now used routinely in the Kesho Bora trial and may be recommended in other\nAfrican settings.</p>', 'Virol Methods', '163(2)', NULL, NULL, 'rouet_etal_2010', NULL, NULL, '253-7', NULL, 2010, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(79, 'In-house HIV-1 RNA real-time reverse transcription PCR assays: principle, available tests and usefulness in developing countries', 'Rouet F, Menan H, Viljoen J, Ngo Giang Huong N, Mandaliya K, Valea D, Xuan L, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Rousset D, Ganon A and Nerrienet E', '<p>The principle of currently available licensed HIV-1 RNA assays is based on real-time technologies that continuously monitor the fluorescence emitted by the amplification products. Besides these assays, in-house quantitative (q) real-time reverse transcription (RT)-PCR (RT-qPCR) tests have been developed and evaluated particularly in developing countries, for two main reasons.</p><p> First, affordable and generalized access to HIV-1 RNA viral load is urgently needed in the context of expected universal access to prevention and antiretroviral treatment programs in these settings. Second, since many non-B subtypes, circulating recombinant forms and unique recombinant forms circulate in these areas, in-house HIV-1 RNA RT-qPCR assays are ideal academic tools to thoroughly evaluate the impact of HIV-1 genetic diversity on the accuracy of HIV-1 RNA quantification, as compared with licensed techniques. </p><p>To date, at least 15 distinct in-house assays have been designed. They differ by their chemistry and the HIV-1 target sequence (located in gag, Pol-IN or LTR gene). Analytical performances of the tests that have been extensively evaluated appear at least as good as (or even better than) those of approved assays, with regard to HIV-1 strain diversity. Their clinical usefulness has been clearly demonstrated for early diagnosis of pediatric HIV-1 infection and monitoring of highly active antiretroviral therapy efficacy. </p><p>The LTR-based HIV-1 RNA RT-qPCR assay has been evaluated by several groups under the auspices of the Agence Nationale de Recherches sur le SIDA et les hpatites virales B et C. It exists now as a complete standardized commercial test.</p>', 'Expert Review of Molecular Diagnostics', '8(5)', 22, NULL, NULL, NULL, NULL, '635-650', NULL, 2008, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(80, 'Cervical spine tuberculosis in children', 'Govender S, Ramnarain A, <a href=\"peopple.php?peopleid=2\">Danaviah S</a>', '<p>The presentation and outcome of pediatric cervical spine tuberculosis are different from those of adult cervical spine tuberculosis. We retrospectively reviewed the clinical and radiographic outcome of 58 children with cervical spine tuberculosis treated nonoperatively and operatively between 1996 and 2004. The mean age was 3.7 years (range, 1.9-14 years). The cervicodorsal junction was affected in 27 children, the atlantoaxial complex in 19 children, and the mid-cervical spine in 12 children.</p><p> Multifocal noncontiguous spinal lesions were observed in 21 patients. Surgery was performed in 25 children for: neurologic deficit (14); drainage of retropharyngeal abscesses (four); atlantoaxial fusion for late C1-C2 instability (three); and progressive deformity and pain (four). Neurologic recovery occurred in all patients. Seven patients were lost to followup within 2 years. The minimum followup was 2.4 years (mean, 3.5 years; range, 2.4-10 years). We attributed the improved functional outcome after anti-TB chemotherapy alone to the remodeling potential of the pediatric cervical spine. </p><p>Surgery was performed only for neurologic deficit, an atlantodental interval greater than 5 mm on flexion/extension view, and progressive deformity. Four patients developed superficial wound infection, two patients had graft repositioning for a slipped graft, and seven children developed a grade 1 pressure sore over the scalp while on traction.</p>', 'Clin Orthop Relat Res.', '460', 13, NULL, NULL, NULL, NULL, '50-5', NULL, 2007, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(81, 'Atypical mycobacterial spondylitis in HIV-negative patients identified by 16S rDNA genotyping', '<a href=\"people.php?peopleid=2\">Danaviah S</a>, Govender S, Gordon ML, Cassol S.  ', '<p>Non-tuberculous mycobacterial infections pose a significant diagnostic and therapeutic challenge. We report two cases of such infection of the spine in HIV-negative patients who presented with deformity and neurological deficit. The histopathological features in both specimens were diagnostic of tuberculosis. The isolates were identified as Mycobacterium intracellulare and M. fortuitum by genotyping (MicroSeq 16S rDNA Full Gene assay) and as M. tuberculosis and a mycobacterium other than tuberculosis, respectively, by culture. There is a growing need for molecular diagnostic tools that can differentiate accurately between M. tuberculosis and atypical mycobacteria, especially in regions of the developing world which are experiencing an increase in non-tuberculous mycobacterial infections.</p>', 'J Bone Joint Surg Br.', '89(3)\n', 3, NULL, 'danaviah_etal_2007', NULL, NULL, '346-348', NULL, 2007, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(82, 'A report of 3 unusual opportunistic bacterial infections of the spine', '<a href=\"people.php?peopleid=2\">Danaviah S</a>, Govender S, Gordon M, Cassol S', NULL, 'SAOJ', '5(3)', NULL, NULL, NULL, NULL, NULL, '12-16', NULL, 2006, NULL, NULL, 1, NULL, NULL, NULL, NULL),
(83, 'Prevalence, incidence and mother-to-child transmission of HIV-1 in rural South Africa', 'Rollins NC, Dedicoat M, <a href=\"people.php?peopleid=2\">Danaviah S</a>, Page T, Bishop K, Kleinschmidt I, Coovadia HM, Cassol SA', '<p>Simple, robust approaches are needed to monitor prevalence, incidence, and mother-to-child transmission of HIV-1 in rural Africa. We have designed a method that uses antibody and viral RNA testing of dried blood spots obtained from mother-infant pairs attending routine immunisation clinics. In our study, prevalence and incidence of HIV-1 was highest in young women in their late teens and early twenties. In children born to infected mothers, prevalence increased from 14% in infants younger than 6 weeks of age to 24% at 3-6 months. The blood-spot approach is an effective method for surveillance of HIV-1 in women and children, and for early identification of incidence of this infection in women of child-bearing age.</p>', 'Lancet', '360(9330)', 48, NULL, NULL, NULL, NULL, '389', NULL, 2002, NULL, 33.633, 1, NULL, NULL, NULL, NULL),
(84, 'Molecular characterization of non-subtype C and recombinant HIV-1 viruses from Cape Town, South Africa', '<a href=\"people.php?peopleid=4\">Wilkinson E</a>, Engelbrecht S', '<p>HIV was first diagnosed within South Africa in 1982. Homosexual transmission of HIV-1 dominated the epidemic within the country in the early stages of the 1980s. Currently heterosexual transmission of HIV-1 is responsible for themajority of HIV cases in South Africa with subtype C HIV-1 being responsible for an estimated 95% of infections. Only a few papers have been published on non-subtype C HIV-1 detection within South Africa.</p><p> This study characterized subgenomic and near full-length sequences of non-subtype C HIV-1 viruses from the Cape Town area. Amplification and direct sequencing characterized partial gene fragments of 11 samples. Phylogenetic analysis of the sequenced data, with online subtyping tools (REGA and jpHMM) and the drawing of NJ-trees revealed the presence of subtypes A1, B, and F1 as well as recombinant viral forms such as AD, AG and AC. </p><p>Near full-length genome characterization of 4 of the 11 samples was performed. Analysis of sequenced data with the use of subtyping, recombination identification, and tree drawing tools revealed one subtype B and one A1 isolate. The other two isolates were identified as AC and AD recombinants. The data that was gathered will greatly improve our knowledge of non-subtype C isolates circulating within South Africa.</p>', 'Infectious Genetics and Evolution', '9', 17, NULL, 'Wilkinson_HIV_CapeTown2009', NULL, NULL, '840-846', NULL, 2009, NULL, 3.223, 1, NULL, NULL, NULL, NULL),
(85, 'High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa', 'Tanser F, Barnighausen T, Grapsa E, <a href=\"people.php?peopleid=10\">Zaidi J</a>, Newell M-L.', '<p>The landmark HIV Prevention Trials Network (HPTN) 052 trial in HIV-discordant couples demonstrated unequivocally that treatment with antiretroviral therapy (ART) substantially lowers the probability of HIV transmission to the HIV-uninfected partner. However, it has been vigorously debated whether substantial population-level reductions in the rate of new HIV infections could be achieved in \"real-world\" sub-Saharan African settings where stable, cohabiting couples are often not the norm and where considerable operational challenges exist to the successful and sustainable delivery of treatment and care to large numbers of patients.</p><p> We used data from one of Africa\'s largest population-based prospective cohort studies (in rural KwaZulu-Natal, South Africa) to follow up a total of 16,667 individuals who were HIV-uninfected at baseline, observing individual HIV seroconversions over the period 2004 to 2011. Holding other key HIV risk factors constant, individual HIV acquisition risk declined significantly with increasing ART coverage in the surrounding local community. For example, an HIV-uninfected individual living in a community with high ART coverage (30 to 40% of all HIV-infected individuals on ART) was 38% less likely to acquire HIV than someone living in a community where ART coverage was low (<10% of all HIV-infected individuals on ART).</p>', 'Science', '339(6122)', 49, NULL, NULL, NULL, NULL, '966-971', NULL, 2013, NULL, 29.747, 1, NULL, NULL, NULL, NULL),
(86, 'Dramatic increases in HIV prevalence after scale-up of antiretroviral treatment: a longitudinal population-based HIV surveillance study in rural Kwazulu-Natal', '<a href=\"people.php?peopleid=10\">Zaidi J</a>, Grapsa E, Tanser F, Newell M-L, Barnighausen T', '<p><b><i>OBJECTIVES:</b></i></p>\n<p> To investigate HIV prevalence trends in a rural South African community after the scale-up of antiretroviral treatment (ART) in 2004.</p>\n<p><b><i>METHODS:</b></i></p>\n<p>We estimated adult HIV prevalence (ages 15-49 years) using data from a large, longitudinal, population-based HIV surveillance in rural KwaZulu-Natal, South Africa, over the period from 2004 (the year when the public-sector ART scale-up started) to 2011. We control for selection effects due to surveillance nonparticipation using multiple imputation. We further linked the surveillance data to patient records from the local HIV treatment program to estimate ART coverage.</p>\n<p><b><i>RESULTS:</b></i></p>\n<p>ART coverage of all HIV-infected people in this community increased from 0% in 2004 to 31% in 2011. Over the same observation period adult HIV prevalence increased steadily from 21 to 29%. The change in overall HIV prevalence is nearly completely explained by an increase of HIV-infected people receiving ART, and it is largely driven by increases in HIV prevalence in women and men older than 24 years.</p>\n<p><b><i>CONCLUSION:</b></i></p>\n<p>The observed dramatic increase in adult HIV prevalence can most likely be explained by increased survival of HIV-infected people due to ART. Future studies should decompose HIV prevalence trends into HIV incidence and HIV-specific mortality changes to further improve the causal attribution of prevalence increases to treatment success rather than prevention failure.</p>', 'AIDS', '27(14)', 4, NULL, NULL, NULL, NULL, '2301-2305', NULL, 2013, NULL, 5.76, 1, NULL, NULL, NULL, NULL),
(87, 'Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004', 'Pillay V, Ledwaba J, Hunt G, Rakgotho M, Singh B, Makubalo L, Bennett D E, Puren A, Morris L ', NULL, 'Antivir Ther', '13 Suppl 2', 72, NULL, NULL, NULL, NULL, '101-107', NULL, 2008, NULL, 3.07, 4, NULL, 'NICD protocol', NULL, NULL),
(100, 'An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings', 'Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Seebregts C, Rinke De Wit TF, Viljoen J, Katzenstein D,  De Oliveira T ', '<p>HIV-1 drug resistance has the potential to seriously compromise the effectiveness and impact of antiretroviral therapy (ART). As ART programs in sub-Saharan Africa continue to expand, individuals on ART should be closely monitored for the emergence of drug resistance. Surveillance of transmitted drug resistance to track transmission of viral strains already resistant to ART is also critical. </p><p>Unfortunately, drug resistance testing is still not readily accessible in resource limited settings, because genotyping is expensive and requires sophisticated laboratory and data management infrastructure. An open access genotypic drug resistance monitoring method to manage individuals and assess transmitted drug resistance is described. </p><p>The method uses free open source software for the interpretation of drug resistance patterns and the generation of individual patient reports. The genotyping protocol has an amplification rate of greater than 95% for plasma samples with a viral load >1,000 HIV-1 RNA copies/ml. The sensitivity decreases significantly for viral loads <1,000 HIV-1 RNA copies/ml. The method described here was validated against a method of HIV-1 drug resistance testing approved by the United States Food and Drug Administration (FDA), the Viroseq genotyping method. </p><p>Limitations of the method described here include the fact that it is not automated and that it also failed to amplify the circulating recombinant form CRF02_AG from a validation panel of samples, although it amplified subtypes A and B from the same panel.</p>\n<p><b>The video component of this article can be found at <a href=\"http://www.jove.com/video/51242/\">http://www.jove.com/video/51242/</a></b></p>', 'Journal of Visualized Experiments (JoVE)', '(85)', 11, NULL, 'Manasa_JOVE2014', 'affordable, hiv, HIV-1, HIV Infections, Viremia, Nucleic Acids, genetics, antiretroviral therapy, drug\rresistance, genotyping, affordable, HIV-1, HIV Infections, Viremia, Nucleic Acids, genetics, antiretroviral therapy, drug\rresistance, genotyping, affordable, HIV-1, HIV Infections, Viremia, Nucleic Acids, genetics, antiretroviral therapy, drug\rresistance, genotyping, affordable, Manasa, SATuRN, southern african treatment resistance network, paper, JOVE, JOVE, 2014', 'Video Article. Journal of Visualized Experiments www.jove.  An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings. Tulio de Oliveira & Justen for SATuRN', 'e51242, doi:10.3791/51242', NULL, 2014, NULL, 1.2, 5, 0, 'SATuRN/Life Techonologies protocol', NULL, NULL),
(88, 'A Pragmatic Approach to HIV-1 Drug Resistance Determination in Resource-Limited Settings by Use of a Novel Genotyping Assay Targeting the Reverse Transcriptase-Encoding Region Only', 'Aitken SC, Bronze M, Wallis CL, Stuyver L, Steegen K, Balinda S, Kityo C, Stevens W, Rinke De Wit TF & Schuurman R.', NULL, 'J Clin Microbiol', '51', 3, NULL, 'ARTAHIVDRultralightAitken2013', NULL, NULL, '1757-1761', NULL, 2013, NULL, 4.068, 4, NULL, 'Paser Ultra-light', NULL, NULL),
(89, 'Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.', 'Zhou Z, Wagar N, Devos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O, Ugbena R, Wadonda-Kabondo N, Mcconnell MS, Zulu I, Chilima B, Nkengasong J, Yang C ', NULL, 'PLoS One', '6', 11, NULL, 'ZHOU_CDC', NULL, NULL, 'e28184', NULL, 2011, NULL, 4.411, 4, NULL, 'CDC protocol', NULL, NULL),
(90, 'Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1', 'Wallis CL, Papathanasopoulos MA, Lakhi S, Karita E, Kamali A, Kaleebu P, Sanders E, Anzala O, Bekker LG, Stevens G, De Wit TF, Stevens W ', NULL, 'J Virol Methods', '163', 31, NULL, 'Waliis_etal', NULL, NULL, '505-508', NULL, 2010, NULL, 2.065, 4, NULL, 'Wallis and colleagues protocol', NULL, NULL),
(91, 'In-house human immunodeficiency virus-1 genotype resistance testing to determine highly active antiretroviral therapy resistance mutations in Hong Kong', 'Chen JH, Wong KH, Li PC, Chan KK, Lee MP, To SW, Yam WC ', NULL, 'Hong Kong Med J', '18', 1, NULL, 'chen_jbiochem2004', NULL, NULL, '20-24', NULL, 2012, NULL, 0.26, 4, NULL, 'Chen and colleagues protocol', NULL, NULL),
(93, 'An Investigation of Classification Algorithms for Predicting HIV Drug Resistance without Genotype Resistance Testing', 'Brandt P, Moodley D, Pillay AW, Seebregts CJ, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>The development of drug resistance is a major factor impeding the efficacy of antiretroviral treatment of South Africa?s HIV infected population. While genotype resistance testing is the standard method to determine resistance, access to these tests is limited in low-resource settings.</p> \n<p>In this paper we investigate machine learning techniques for drug resistance prediction from routine treatment and laboratory data to help clinicians select patients for confirmatory genotype testing. The techniques, including binary relevance, HOMER, MLkNN, predictive clustering trees (PCT), RAkEL and ensemble of classifier chains were tested on a dataset of 252 medical records of patients enrolled in an HIV treatment failure clinic in rural KwaZulu-Natal in South Africa. </p> \n<p>The PCT method performed best with a discriminant power of 1.56 for two drugs, above 1.0 for three others and a mean true positive rate of 0.68. These methods show potential for application where access to genotyping is limited.</p>', 'Lecture Notes in Computer Science (LNCS)', '8315', 1, NULL, 'Brandt_Moodley_Pillay_Seebregts_deOliveira_FHIES13', NULL, NULL, '236-253', NULL, 2013, NULL, 1.2, 3, NULL, NULL, NULL, NULL),
(94, 'Implementing HIV-1 Genotypic Resistance Testing in Antiretroviral Therapy Programs in Africa: Needs, Opportunities, and Challenges', '<a href=\"people.php?peopleid=13\">Lessells RJ</a>, Avalos A, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>Tremendous progress has been made with the scale-up of antiretroviral therapy in Africa, with an es- timated seven million people now receiving antiretroviral therapy in the region. The long-term success of antiretroviral therapy programs depends on appropriate strategies to deal with potential threats, one of which is the emergence and spread of antiretroviral drug resistance.</p><p> Whilst public health surveillance forms the mainstay of the World Health Organization approach to antiretroviral drug resistance, there is likely to be increasing demand for access to drug resistance testing as programs mature and as HIV clinical management becomes more complex. African-owned research initiatives have helped to develop affordable resistance testing appropriate for use in the region, and have developed delivery models for resistance testing at different levels of the public health system.</p><p> Some upper-middle-income countries such as Botswana and South Africa have introduced drug resistance testing for selected patient groups to guide clinical management. The scale-up of resistance testing will require substantial expansion of clinical and laboratory capacity in the region, but the expertise and resources exist in Africa to support this. The long-term population health impact and cost-effectiveness of resistance testing in the region will also require further investigation. </p>', 'AIDS Reviews', '15', 14, NULL, 'Lessells_2013_AIDSReviews', 'HIV-1, Drug resistance,  Antiretroviral therapy, Treatment failure, genotyping, resistance, testing, africa, review, clinical management, surveillance, de oliveira, SATURN, lessells,HIV-1, Drug resistance,  Antiretroviral therapy, Treatment failure, genotyping, resistance, testing, africa, review, clinical management, surveillance, de oliveira, SATURN, lessells,HIV-1, Drug resistance,  Antiretroviral therapy, Treatment failure, genotyping, resistance, testing, africa, review, clinical management, surveillance, de oliveira, SATURN, lessells,HIV-1, Drug resistance,  Antiretroviral therapy, Treatment failure, genotyping, resistance, testing, africa, review, clinical management, surveillance, de oliveira, SATURN, lessells', 'This is a AIDS Reviews on the implementation of HIV-1 resistance testing for clinical management and surveillance in Africa. Whilst public health surveillance forms the mainstay of the World Health Organization approach to antiretroviral drug resistance, there is likely to be increasing demand for access to drug resistance testing as programs mature and as HIV clinical management becomes more complex.', '221-229', NULL, 2013, NULL, 4.075, 3, NULL, NULL, NULL, NULL),
(95, 'Concentrated HIV subepidemics in generalized epidemic settings', 'Tanser F, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Maheu-Giroux M, Barnighausen T', '<p><b><i>PURPOSE OF REVIEW:</p></b></i>\n<p>A relatively neglected topic to date has been the occurrence of concentrated epidemics within generalized epidemic settings and the potential role of targeted interventions in such settings. We review recent studies in high-risk groups as well as findings relating to geographical heterogeneity and the potential for targeting \'high-transmission zones\' in the 10 countries with highest HIV prevalence.</p>\n<p><b><i>RECENT FINDINGS:</p></b></i>\n<p>Our review of recent studies confirmed earlier findings that, even in the context of generalized epidemics, MSM have a substantially higher prevalence than the general population. Estimates of prevalence of HIV among people who inject drugs (PWID) in sub-Saharan African countries are rarely available and, when they are, often outdated. We identified recent studies of sex workers in Kenya and Uganda. </p>\n<p>In all three cases - MSM, PWID, and sex workers - HIV prevalence estimates are mostly based on convenience. Moreover, good estimates of the total size of these populations are not available. Our review of recent studies of high-risk populations defined on the basis of geography showed high levels of both new and existing infections in Kenya (slums), South Africa (peri-urban communities), and Uganda (fishing villages).</p>\n<p><b><i>SUMMARY:</p></b></i>\n<p>Recent empirical findings combined with evidence from phylogenetic studies and supported by mathematical models provide a clear rationale for testing the feasibility, acceptability, and effectiveness of targeted HIV prevention approaches in hyperendemic populations to supplement measures aimed at the general population.</p>', 'Curr Opin HIV AIDS', '9(2)', 37, NULL, 'Tanser_HIVsubepidemics_CurrentOpinion2013', 'hiv, phylogeny, epidemics, current, opinion, HIV & AIDS, Tulio de Oliveira, review, Concentrated, HIV, subepidemics, generalized epidemic settings, africa, southg africa, uganda, malawi, phylonetics, evolutionary, molecular, epidemiology, hiv, phylogeny, epidemics, current, opinion, HIV & AIDS, Tulio de Oliveira, review, Concentrated, HIV, subepidemics, generalized epidemic settings, africa, southg africa, uganda, malawi, phylonetics, evolutionary, molecular, epidemiology, hiv, phylogeny, epidemics, current, opinion, HIV & AIDS, Tulio de Oliveira, review, Concentrated, HIV, subepidemics, generalized epidemic settings, africa, southg africa, uganda, malawi, phylonetics, evolutionary, molecular, epidemiology, hiv, phylogeny, epidemics, current, opinion, HIV & AIDS, Tulio de Oliveira, review, Concentrated, HIV, subepidemics, generalized epidemic settings, africa, southg africa, uganda, malawi, phylonetics, evolutionary, molecular, epidemiology, hiv, phylogeny, epidemics, current, opinion, HIV & AIDS, Tulio de Oliveira, review, Concentrated, HIV, subepidemics, generalized epidemic settings, africa, southg africa, uganda, malawi, phylonetics, evolutionary, molecular, epidemiology', 'this is an review in empirical findings combined with evidence from phylogenetic studies and supported by mathematical models provide a clear rationale for testing the feasibility, acceptability, and effectiveness of targeted HIV prevention approaches in hyperendemic populations to supplement measures aimed at the general population by Frank Tanser, Tulio de Oliveira and colleagues. Current Opinion in HIV and AIDS, 2013.', '115-125', NULL, 2014, '', 4.704, 1, NULL, NULL, NULL, NULL),
(96, 'Drug resistance in children at virological failure in a rural KwaZulu-Natal, South Africa, cohort', '<a href=\"people.php?peopleid=5\">Pillay S</a>, Bland RM, <a href=\"people.php?peopleid=13\">Lessells RJ</a>, <a href=\"people.php?peopleid=3\">Manasa J</a>, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, <a href=\"people.php?peopleid=2\">Danaviah S</a>.', '<p><b><i>BACKGROUND:</b></i></p>\n<p>Better understanding of drug resistance patterns in HIV-infected children on antiretroviral therapy (ART) is required to inform public health policies in high prevalence settings. The aim of this study was to characterise the acquired drug resistance in HIV-infected children failing first-line ART in a decentralised rural HIV programme.</p>\n\n<p><b><i>METHODS:</b></i></p>\n<p>Plasma samples were collected from 101 paediatric patients (<15 yrs of age) identified as failing ART. RNA was extracted from the plasma, reverse transcribed and a 1.3 kb region of the pol gene was amplified and sequenced using Sanger sequencing protocols. Sequences were edited in Geneious and drug resistance mutations were identified using the RegaDB and the Stanford resistance algorithms. The prevalence and frequency of mutations were analysed together with selected clinical and demographic data in STATA v11.</p>\n\n<p><b><i>RESULTS:</b></i></p>\n<p>A total of 101 children were enrolled and 89 (88%) were successfully genotyped; 73 on a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen and 16 on a protease inhibitor (PI)-based regimen at the time of genotyping. The majority of patients on an NNRTI regimen (80%) had both nucleoside reverse-transcriptase inhibitor (NRTI) and NNRTI resistance mutations. M184V and K103N were the most common mutations amongst children on NNRTI-based and M184V among children on PI-based regimens. 30.1% had one or more thymidine analogue mutation (TAM) and 6% had > 3 TAMs. Only one child on a PI-based regimen harboured a major PI resistance mutation.</p>\n\n<p><b><i>CONCLUSIONS:</b></i></p>\n<p>Whilst the patterns of resistance were largely predictable, the few complex resistance patterns seen with NNRTI-based regimens and the absence of major PI mutations in children failing PI-based regimens suggest the need for wider access to genotypic resistance testing in this setting.</p>\n', 'AIDS Res Ther.', '11(1)', 10, NULL, 'Pillay_Pediatrics_HIV_DrugResistance2014', 'Antiretroviral therapy, ARV, Drug resistance, mutations, HIV, Protease inhibitors, NTRTI, NRTI, rural, South Africa, Africa Centre, SATuRN, Southern AfricanTreatment Resistance Network, pediatrics, children, adolescents, HIVDR, DR, acquired, second line, therapy, Antiretroviral therapy, ARV, Drug resistance, mutations, HIV, Protease inhibitors, NTRTI, NRTI, rural, South Africa, Africa Centre, SATuRN, Southern AfricanTreatment Resistance Network, pediatrics, children, adolescents, HIVDR, DR, acquired, second line, therapy, Antiretroviral therapy, ARV, Drug resistance, mutations, HIV, Protease inhibitors, NTRTI, NRTI, rural, South Africa, Africa Centre, SATuRN, Southern AfricanTreatment Resistance Network, pediatrics, children, adolescents, HIVDR, DR, acquired, second line, therapy', 'This is a peer-review publication on drug resistance in children at virological failure in a rural south african cohort. In this study, the Authors show drug resistance levels in children failing first and second line therapy.', '3. doi: 10.1186/1742-6405-11-3', NULL, 2014, NULL, 1.78, 3, NULL, NULL, NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(97, 'Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa', '<a href=\"people.php?peopleid=3\">Manasa J</a>, <a href=\"people.php?peopleid=13\">Lessells R</a>, Rossouw T, Naidu K, Van Vuuren C, Goedhals D, van Zyl G, Bester A, Skingsley A, Stott K, <a href=\"people.php?peopleid=2>Danaviah S</a>, Chetty T, Singh L, Moodley P, Iwuji C, McGrath N, Seebregts CJ, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>Substantial amounts of data have been generated from patient management and academic exercises designed to better understand the human immunodeficiency virus (HIV) epidemic and design interventions to control it. A number of specialized databases have been designed to manage huge data sets from HIV cohort, vaccine, host genomic and drug resistance studies. Besides databases from cohort studies, most of the online databases contain limited curated data and are thus sequence repositories.</p> \n<p>HIV drug resistance has been shown to have a great potential to derail the progress made thus far through antiretroviral therapy. Thus, a lot of resources have been invested in generating drug resistance data for patient management and surveillance purposes. Unfortunately, most of the data currently available relate to subtype B even though >60% of the epidemic is caused by HIV-1 subtype C. </p>\n<p>A consortium of clinicians, scientists, public health experts and policy markers working in southern Africa came together and formed a network, the Southern African Treatment and Resistance Network (SATuRN), with the aim of increasing curated HIV-1 subtype C and tuberculosis drug resistance data. This article describes the HIV-1 data curation process using the SATuRN Rega database. The data curation is a manual and time-consuming process done by clinical, laboratory and data curation specialists. Access to the highly curated data sets is through applications that are reviewed by the SATuRN executive committee.</p>\n<p>Examples of research outputs from the analysis of the curated data include trends in the level of transmitted drug resistance in South Africa, analysis of the levels of acquired resistance among patients failing therapy and factors associated with the absence of genotypic evidence of drug resistance among patients failing therapy. All these studies have been important for informing first- and second-line therapy. This database is a free password-protected open source database available on www.bioafrica.net </p><p> Database URL: <a href=\"http://www.bioafrica.net/regadb/\">http://www.bioafrica.net/regadb/</a></p>', 'Database (Oxford)', 'Vol. 2014 ', 5, NULL, 'Manasa_SATuRN_Database2014', 'database, saturn, regadb, south africa, southern africa, southern african treatment resistance network, tulio de oliveira, public, sequence, drug resistance, oxford, 2014, curation, open access, bioinformatics, genomics, HIV-1, HIV, antiretroviral therapy, ARVs, database, saturn, regadb, south africa, southern africa, southern african treatment resistance network, tulio de oliveira, public, sequence, drug resistance, oxford, 2014, curation, open access, bioinformatics, genomics, HIV-1, HIV, antiretroviral therapy, ARVs, database, saturn, regadb, south africa, southern africa, southern african treatment resistance network, tulio de oliveira, public, sequence, drug resistance, oxford, 2014, curation, open access, bioinformatics, genomics, HIV-1, HIV, antiretroviral therapy, ARVs, database, saturn, regadb, south africa, southern africa, southern african treatment resistance network, tulio de oliveira, public, sequence, drug resistance, oxford, 2014, curation, open access, bioinformatics, genomics, HIV-1, HIV, antiretroviral therapy, ARVs', 'This is an orignal peer-review article that describes the data curation process and data stored at the RegaDB SATURN database. This database is mantained at the South Africa Medical Research Council as a public access database for clinicians and researchers in Africa. Many 1000s of sequences and detailed clinical data is accessible and interested collabroators should submit a proposal to submit the data to the SATuRN steering commitee at http://www.bioafrica.net/saturn/', 'bat082. doi: 10.1093/database/bat082', NULL, 2014, NULL, 4.2, 3, NULL, NULL, NULL, NULL),
(98, 'Implementing antiretroviral resistance testing in a primary health care HIV treatment programme in rural KwaZulu-Natal, South Africa: early experiences, achievements and challenges', '<a href=\"people.php?peopleid=13\">Lessells RJ</a>, Stott KE, <a href=\"people.php?peopleid=3\">Manasa J</a>, Naidu KK, Skingsley A, Rossouw T, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p><b><i>Background</i></b></p>\n<p>Antiretroviral drug resistance is becoming increasingly common with the expansion of human immunodeficiency virus (HIV) treatment programmes in high prevalence settings. Genotypic resistance testing could have benefit in guiding individual-level treatment decisions but successful models for delivering resistance testing in low- and middle-income countries have not been reported.</p>\n\n<p><b><i>Methods</i></b></p>\n<p>An HIV Treatment Failure Clinic model was implemented within a large primary health care HIV treatment programme in northern KwaZulu-Natal, South Africa. Genotypic resistance testing was offered to adults (>=16 years) with virological failure on first-line antiretroviral therapy (one viral load >1000 copies/ml after at least 12 months on a standard first-line regimen). A genotypic resistance test report was generated with treatment recommendations from a specialist HIV clinician and sent to medical officers at the clinics who were responsible for patient management. A quantitative process evaluation was conducted to determine how the model was implemented and to provide feedback regarding barriers and challenges to delivery.</p>\n\n<p><b><i>Results</i></b></p>\n<p>A total of 508 specimens were submitted for genotyping between 8 April 2011 and 31 January 2013; in 438 cases (86.2%) a complete genotype report with recommendations from the specialist clinician was sent to the medical officer. The median turnaround time from specimen collection to receipt of final report was 18 days (interquartile range (IQR) 13-29). In 114 (26.0%) cases the recommended treatment differed from what would be given in the absence of drug resistance testing. In the majority of cases (n = 315, 71.9%), the subsequent treatment prescribed was in line with the recommendations of the report.</p>\n\n<p><b><i>Conclusions</i></b></p>\n<p>Genotypic resistance testing was successfully implemented in this large primary health care HIV programme and the system functioned well enough for the results to influence clinical management decisions in real time. Further research will explore the impact and cost-effectiveness of different implementation models in different settings.</p>', 'BMC Health Services Research', '14:116', 6, NULL, 'Lessels_BMC_Health_Services_2014', 'BMC, health, services, research, saturn, hiv, treatment, failure clinic, model, evaluation, rural, south africa, anteretorviral, resistance, drug resistance, HIV-1, Africa, southern african treatment resistance network, Tulio de Oliveira, Richard Lessells, BMC, health, services, research, saturn, hiv, treatment, failure clinic, model, evaluation, rural, south africa, anteretorviral, resistance, drug resistance, HIV-1, Africa, southern african treatment resistance network, Tulio de Oliveira, Richard Lessells, BMC, health, services, research, saturn, hiv, treatment, failure clinic, model, evaluation, rural, south africa, anteretorviral, resistance, drug resistance, HIV-1, Africa, southern african treatment resistance network, Tulio de Oliveira, Richard Lessells', 'This is a peer-review manuscript that describe the experiences of the SATuRN HIV Treatment Failure Clinic model was implemented within a large primary health care HIV treatment programme in northern KwaZulu-Natal, South Africa. Conclusions were that genotypic resistance testing was successfully implemented in this large primary health care HIV programme and the system functioned well enough for the results to influence clinical management decisions in real time.', 'doi:10.1186/1472-6963-14-116', NULL, 2014, NULL, 1.77, 3, NULL, NULL, NULL, NULL),
(99, 'HIV-1 Subtypes B and C Unique Recombinant Forms (URFs) and Transmitted Drug Resistance Identified in the Western Cape Province, South Africa', 'Jacobs GB, <a href=\"people.php?peopleid=4\">Wilkinson E</a>, Isaacs S, Spies G, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Seedat S, Engelbrecht S ', '<p>South Africa has the largest worldwide HIV/AIDS population with 5.6 million people infected and at least 2 million people on antiretroviral therapy. The majority of these infections are caused by HIV-1 subtype C. Using genotyping methods we characterized HIV-1 subtypes of the gag p24 and pol PR and RT fragments, from a cohort of female participants in the Western Cape Province, South Africa. These participants were recruited as part of a study to assess the combined brain and behavioural effects of HIV and early childhood trauma. The partial HIV-1 gag and pol fragments of 84 participants were amplified by PCR and sequenced. </p>\n<p>Different online tools and manual phylogenetic analysis were used for HIV-1 subtyping. Online tools included: REGA HIV Subtyping tool version 3; Recombinant Identification Program (RIP); Context-based Modeling for Expeditious Typing (COMET); jumping profile Hidden Markov Models (jpHMM) webserver; and subtype classification using evolutionary algorithms (SCUEAL). </p>\n<p>HIV-1 subtype C predominates within the cohort with a prevalence of 93.8%. We also show, for the first time, the presence of circulating BC strains in at least 4.6% of our study cohort. In addition, we detected transmitted resistance associated mutations in 4.6% of analysed sequences. With tourism and migration rates to South Africa currently very high, we are detecting more and more HIV-1 URFs within our study populations.</p> \n<p>It is stil unclear what role these unique strains will play in terms of long term antiretroviral treatment and what challenges they will pose to vaccine development. Nevertheless, it remains vitally important to monitor the HIV-1 diversity in South Africa and worldwide as the face of the epidemic is continually changing.</p>', 'PLoS One', '9(3)', 8, NULL, 'Jacobs_URFsCapeTown_PLoSOne_2014', 'Plos One, Cape Town, HIV-1, recombinants, unique recombinant forms, URFs, South Africa, drug resistance, western cape, Africa, Eduan Wilkinson, Tulio de Oliveira, manuscript, 2014, Plos One, Cape Town, HIV-1, recombinants, unique recombinant forms, URFs, South Africa, drug resistance, western cape, Africa, Eduan Wilkinson, Tulio de Oliveira, manuscript, 2014, Plos One, Cape Town, HIV-1, recombinants, unique recombinant forms, URFs, South Africa, drug resistance, western cape, Africa, Eduan Wilkinson, Tulio de Oliveira, manuscript, 2014', 'This is a peer-review paper that shows that HIV-1 subtype C predominates within Cape Town area with a prevalence of 93.8%. We also show, for the first time, the presence of circulating BC strains in at least 4.6% of our study cohort. In addition, we detected transmitted resistance associated mutations in 4.6% of analysed sequences. With tourism and migration rates to South Africa currently very high, we are detecting more and more HIV-1 URFs within our study populations.', 'e90845. doi:10.1371/journal.pone.0090845', NULL, 2014, NULL, 4.411, 1, NULL, NULL, NULL, NULL),
(101, 'Circulating Biomarkers of Immune Activation Distinguish Viral Suppression from Nonsuppression in HAART-Treated Patients with Advanced HIV-1 Subtype C Infection', 'Malherbe G, Steel HC, Cassol S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Seebregts CJ, Anderson R, Cassol E, Rossouw TM.', '<p>Few studies have examined immune activation profiles in patients with advanced HIV-1 subtype C infection or assessed their potential to predict responsiveness to HAART. BioPlex, ELISA, and nephelometric procedures were used to measure plasma levels of inflammatory biomarkers in HIV-1 subtype C-infected patients sampled before and after 6 months of successful HAART (n = 20); in patients failing HAART (n = 30); and in uninfected controls (n = 8).</p>\n<p>Prior to HAART, CXCL9, CXCL10, Beta-2M, sTNF-R1, TGF-Beta1, IFN-Alpha, IL-6, TNF, and sCD14 were significantly elevated in HIV-1-infected patients compared to controls (P < 0.01). All of these markers, with the exception of sTNF-R1, were also elevated in patients failing HAART (P < 0.05).</p>\n<p> The persistently elevated levels of CXCL9, CXCL10, and Beta-2M in patients failing therapy in the setting of a marked reduction in these markers in patients on successful HAART suggest that they may be useful not only to monitor immune activation during HAART, but also to distinguish between good and poor responders. In the case of sCD14 and TGF- Beta1, the levels of these biomarkers remained persistently elevated despite HAART-induced virological suppression, a finding that is consistent with ongoing monocyte-macrophage activation, underscoring a potential role for adjuvant anti-inflammatory therapy.</p>', 'Mediators Inflamm.', '2014:198413', 11, NULL, 'MalherbeBioMarkers2014', 'Immune, biomarkers, activator, HIV-1, subtype C, ARV, HAART, South Africa, African, activation, viral supression, non-responders, treated, CXCL9, CXCL10, ??2M, sTNF-R1, TGF-??1, IFN-??, IL-6, TNF, sCD14, 2014, paper, manuscript, open access, Immune, biomarkers, activator, HIV-1, subtype C, ARV, HAART, South Africa, African, activation, viral supression, non-responders, treated, CXCL9, CXCL10, ??2M, sTNF-R1, TGF-??1, IFN-??, IL-6, TNF, sCD14, 2014, paper, manuscript, open access, Immune, biomarkers, activator, HIV-1, subtype C, ARV, HAART, South Africa, African, activation, viral supression, non-responders, treated, CXCL9, CXCL10, ??2M, sTNF-R1, TGF-??1, IFN-??, IL-6, TNF, sCD14, 2014, paper, manuscript, open access, Immune, biomarkers, activator, HIV-1, subtype C, ARV, HAART, South Africa, African, activation, viral supression, non-responders, treated, CXCL9, CXCL10, ??2M, sTNF-R1, TGF-??1, IFN-??, IL-6, TNF, sCD14, 2014, paper, manuscript, open access', 'Prior to HAART, CXCL9, CXCL10, ? 2M, sTNF-R1, TGF- ? 1, IFN- ? , IL-6, TNF, and sCD14 were significantly elevated in HIV-1-infected patients compared to controls. The persistently elevated levels of CXCL9, CXCL10, and ? 2M in patients failing therapy in the setting of a marked reduction in these markers in patients on successful ARV therapy.', 'doi: 10.1155/2014/198413', NULL, 2014, NULL, 3.882, 3, NULL, NULL, NULL, NULL),
(102, 'HIV-1 adaptation to antigen processing results in population-level immune evasion and affects subtype diversification', 'Tenzer S, Crawford H, Pymm P, Gifford R, Sreenu VB, Weimershaus M, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Burgevin A, Gerstoft J, Akkad N, Lunn D, Fugger L, Bell J, Schild H, van Endert P, Iversen AK.', '<p>The recent HIV-1 vaccine failures highlight the need to better understand virus-host interactions. One key question is why CD8(+) T cell responses to two HIV-Gag regions are uniquely associated with delayed disease progression only in patients expressing a few rare HLA class I variants when these regions encode epitopes presented by ~30 more common HLA variants.</p>\n<p> By combining epitope processing and computational analyses of the two HIV subtypes responsible for ~60% of worldwide infections, we identified a hitherto unrecognized adaptation to the antigen-processing machinery through substitutions at subtype-specific motifs. Multiple HLA variants presenting epitopes situated next to a given subtype-specific motif drive selection at this subtype-specific position, and epitope abundances correlate inversely with the HLA frequency distribution in affected populations.</p>\n<p> This adaptation reflects the sum of intrapatient adaptations, is predictable, facilitates viral subtype diversification, and increases global HIV diversity. Because low epitope abundance is associated with infrequent and weak T cell responses, this most likely results in both population-level immune evasion and inadequate responses in most people vaccinated with natural HIV-1 sequence constructs. Our results suggest that artificial sequence modifications at subtype-specific positions in vitro could refocus and reverse the poor immunogenicity of HIV proteins.</p>', 'Cell Reports', '7', 5, NULL, 'IversenHIVAdaptationCellPress2014', 'HIV-1, adaptation, antigen, processing, population-level, immune, evasion, subtype diversification, genomics, bioinformatics, cell, reports, iversen, de oliveira, HIV-1, adaptation, antigen, processing, population-level, immune, evasion, subtype diversification, genomics, bioinformatics, cell, reports, iversen, de oliveira, HIV-1, adaptation, antigen, processing, population-level, immune, evasion, subtype diversification, genomics, bioinformatics, cell, reports, iversen, de oliveira', ' By combining epitope processing, HLA typing and computational analyses of the two HIV subtypes responsible for ~60% of worldwide infections, we identified a hitherto unrecognized adaptation to the antigen-processing machinery through substitutions at subtype-specific motifs', 'doi: 10.1016/j.celrep.2014.03.031', NULL, 2014, NULL, 10.5, 1, NULL, NULL, NULL, NULL),
(103, 'Phylogenetic studies of transmission dynamics in generalized HIV epidemics: An essential tool where\rthe burden is greatest?', 'Dennis AM, Herbeck JT, Brown AL, Kellam P, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Pillay D, Fraser C, Cohen MS', '<p>Efficient and effective HIV prevention measures for generalized epidemics in sub-Saharan Africa have not yet\nbeen validated at the population-level. Design and impact evaluation of such measures requires fine-scale\nunderstanding of local HIV transmission dynamics.</p><p> The novel tools of HIV phylogenetics and molecular\nepidemiology may elucidate these transmission dynamics. Such methods have been incorporated into studies\nof concentrated HIV epidemics to identify proximate and determinant traits associated with ongoing\ntransmission. However, applying similar phylogenetic analyses to generalized epidemics, including the design\nand evaluation of prevention trials, presents additional challenges. </p><p>Here we review the scope of these methods\nand present examples of their use in concentrated epidemics in the context of prevention. Next, we describe\nthe current uses for phylogenetics in generalized epidemics, and discuss their promise for elucidating\ntransmission patterns and informing prevention trials. Finally, we review logistic and technical challenges\ninherent to large-scale molecular epidemiological studies of generalized epidemics, and suggest potential\nsolutions.</p>', 'J Acquir Immune Defic Syndr.', 'in press', 15, NULL, 'Dennis_PANGEA1', 'HIV-1, molecular epidemiology, phylogenetic, transmission networks, Sub-Saharan Africa, publication, review, PANGEA, phylogenetics, networks, generalized, epidemics, africa, de Oliveira, HIV-1, molecular epidemiology, phylogenetic, transmission networks, Sub-Saharan Africa, publication, review, PANGEA, phylogenetics, networks, generalized, epidemics, africa, de Oliveira, HIV-1, molecular epidemiology, phylogenetic, transmission networks, Sub-Saharan Africa, publication, review, PANGEA, phylogenetics, networks, generalized, epidemics, africa, de Oliveira, HIV-1, molecular epidemiology, phylogenetic, transmission networks, Sub-Saharan Africa, publication, review, PANGEA, phylogenetics, networks, generalized, epidemics, africa, de Oliveira', 'Review of phylogenetic methods and present examples of their use in concentrated epidemics in the context of prevention. Next, we describe the current uses for phylogenetics in generalized epidemics, and discuss their promise for elucidating transmission patterns and informing prevention trials. Finally, we review logistic and technical challenges\rinherent to large-scale molecular epidemiological studies of generalized epidemics, and suggest potential solutions', NULL, NULL, 2014, NULL, 4.262, 1, NULL, NULL, NULL, NULL),
(104, 'HIV Drug Resistance Patterns at the Epicentre of the HIV-1 Epidemic in Kwazulu-Natal, South Africa 2003-2013', 'Kiepiela P, Manasa J, Moosa M-Y, Moodley P, Gordon M, Parikh UM, Sunpath H, de Oliveira T, Ramjee G', '<p>South Africa has the highest number of individuals with HIV-1 infection worldwide with the epicentre of the epidemic in the province of KwaZulu-Natal (KZN). Currently South Africa has the largest antiretroviral treatment (ART) programme with KZN and Gauteng provinces accounting for 56% of all patients on ART. In order to understand transmission dynamics and temporal trends in drug resistance, we performed a comprehensive literature review of primary and acquired drug resistance in adults and children in KZN over a ten year period, 2003-2013.</p><p> Transmitted drug resistance (TDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) in adults is increasing to moderate levels (5-15%). Acquired drug resistance to first line drug regimens in adults was associated with at least one mutation to nucleoside reverse transcriptase inhibitors (NRTI) or NNRTIs or both, with M184V and K103N the most common mutations. Prevalence of thymidine analogues (TAMs) was low to moderate. There was no published data on acquired drug resistance to second line agents. Children failing first line drug regimens harboured drug resistance mutations to NRTI (M184V and TAMs), NNRTI (V106M and K103N) and protease inhibitors (PIs) (V82A). Concerns have been raised about the high levels of the K65R mutation associated with tenofovir regimens in adults and children.</p><p> Continued vigilance is needed for ART failure in both adults and children, so as not to compromise second line treatment options. Drug resistance genotyping is now cost effective and should be considered for inclusion in regional surveillance studies and during routine care.</p>\n', 'J AIDS Clin Res', '5', 1, NULL, 'Kiepela_2014', 'hiv-1, drug resistance, south africa, kwazulu-natal, KZN, review, levels, acquired, transmitted, pediatrics, SATuRN, hiv-1, drug resistance, south africa, kwazulu-natal, KZN, review, levels, acquired, transmitted, pediatrics, SATuRN, hiv-1, drug resistance, south africa, kwazulu-natal, KZN, review, levels, acquired, transmitted, pediatrics, SATuRN, hiv-1, drug resistance, south africa, kwazulu-natal, KZN, review, levels, acquired, transmitted, pediatrics, SATuRN, hiv-1, drug resistance, south africa, kwazulu-natal, KZN, review, levels, acquired, transmitted, pediatrics, SATuRN, hiv-1, drug resistance, south africa, kwazulu-natal, KZN, review, levels, acquired, transmitted, pediatrics, SATuRN, ', 'Review paper on HIV drug resistance in KwaZulu-Natal show that ransmitted drug resistance (TDR) to non-nucleoside reverse transcriptase inhibitors (NNRTIs) in adults is increasing to moderate levels (5-15%). Acquired drug resistance to first line drug regimens in adults was associated with at least one mutation to nucleoside reverse transcriptase inhibitors (NRTI) or NNRTIs or both, with M184V and K103N the most common mutations. Prevalence of thymidine analogues (TAMs) was low to moderate. There was no published data on acquired drug resistance to second line agents. Children failing first line drug regimens harboured drug resistance mutations to NRTI (M184V and TAMs), NNRTI (V106M and K103N) and protease inhibitors (PIs) (V82A).', 'doi: 10.4172/2155-6113.1000299', NULL, 2014, NULL, 1.2, 3, NULL, NULL, NULL, NULL),
(105, 'Detection of Transmission Clusters of HIV-1 Subtype C over a 21-Year Period in Cape Town, South Africa', '<a href=\"people.php?peopleid=4\">Wilkinson E</a>, Engelbrecht S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p><b><i>Introduction</b></i></p>\n<p>Despite recent breakthroughs in the fight against the HIV/AIDS epidemic within South Africa, the transmission of the virus continues at alarmingly high rates. It is possible, with the use of phylogenetic methods, to uncover transmission events of HIV amongst local communities in order to identify factors that may contribute to the sustained transmission of the virus. The aim of this study was to uncover transmission events of HIV amongst the infected population of Cape Town.</p>\n<p><b><i>Methods and Results</b></i></p>\n<p>We analysed gag p24 and RT-pol sequences which were generated from samples spanning over 21-years with advanced phylogenetic techniques. We identified two transmission clusters over a 21-year period amongst randomly sampled patients from Cape Town and the surrounding areas. We also estimated the origin of each of the identified transmission clusters with the oldest cluster dating back, on average, 30 years and the youngest dating back roughly 20 years.</p>\n<p><b><i>Discussion and Conclusion</b></i></p>\n<p>These transmission clusters represent the first identified transmission events among the heterosexual population in Cape Town. By increasing the number of randomly sampled specimens within a dataset over time, it is possible to start to uncover transmission events of HIV amongst local communities in generalized epidemics. This information can be used to produce targeted interventions to decrease transmission of HIV in Africa.</p>\n', 'PLoS One', '9(10)', 3, NULL, 'WilkinsonCT_2014', 'hiv-1, Detection, Transmission, Clusters, HIV-1, Subtype C, old sequences, Cape Town, South Africa, phylogeny, phylotype, de oliveira, africa centre, stellenbosch, eduan wilkinson, evolutionary, biology, hiv-1, Detection, Transmission, Clusters, HIV-1, Subtype C, old sequences, Cape Town, South Africa, phylogeny, phylotype, de oliveira, africa centre, stellenbosch, eduan wilkinson, evolutionary, biology, hiv-1, Detection, Transmission, Clusters, HIV-1, Subtype C, old sequences, Cape Town, South Africa, phylogeny, phylotype, de oliveira, africa centre, stellenbosch, eduan wilkinson, evolutionary, biology, hiv-1, Detection, Transmission, Clusters, HIV-1, Subtype C, old sequences, Cape Town, South Africa, phylogeny, phylotype, de oliveira, africa centre, stellenbosch, eduan wilkinson, evolutionary, biology, hiv-1, Detection, Transmission, Clusters, HIV-1, Subtype C, old sequences, Cape Town, South Africa, phylogeny, phylotype, de oliveira, africa centre, stellenbosch, eduan wilkinson, evolutionary, biology', 'Peer reivew publication describing Detection of Transmission Clusters of HIV-1 Subtype C over a 21-Year Period in Cape Town, South Africa using phylogenetic analysis. This is the first transmission chains of HIV-1 to be described in South Africa.', 'doi:10.1371/journal.pone.0109296', NULL, 2014, NULL, 4.441, 3, NULL, NULL, NULL, NULL),
(106, 'Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors', 'Basson AE, Rhee SY, Parry CM, El-Khatib Z, Charalambous S, <a href=\"people.php?peopleid=1\">De Oliveira T</a>, Pillay D, Hoffmann C, Katzenstein D, Shafer RW, Morris L', '<p><b><i>OBJECTIVE:</b></i></p>\n<p>To assess the phenotypic susceptibility of NNRTI resistance associated amino acid changes to newer NNRTIs in HIV-1 subtype C.</p>\n<p><b><i>METHODS:</b></i></p>\n<p>A panel of 52 site-directed mutants and 38 clinically derived HIV-1 subtype C clones were created and assessed for phenotypic susceptibility to etravirine (ETR), rilpivirine (RPV), efavirenz (EFV) and nevirapine (NVP) in an in vitro single-cycle phenotypic assay.</p>\n<p><b><i>RESULTS:</b></i></p>\n<p>Amino acid substitutions E138Q/R, Y181I/V and M230L conferred high-level resistance to ETR while K101P and Y181I/V conferred high-level resistance to RPV. Y181C, a major NNRTI resistance-associated amino acid substitution caused decreased susceptibility to ETR and to a lesser extent RPV when combined with other mutations. This included N348I and T369I, amino acid changes in the connection domain that are not generally assessed during resistance testing. However, the prevalence of these genotypes among subtype C sequences was in most cases <1%. The more common EFV/NVP resistance substitutions, such as K103N, V106M, and G190A, had no major impact on ETR or RPV susceptibility. Low-level resistance to RPV and ETR conferred by the RPV-specific amino acid substitution E138K was not significantly enhanced in the presence of the common NRTI substitution M184V/I, unlike for EFV and NVP. Among patient samples, 97% were resistant to EFV and/or NVP while only 24% and 16% were resistant to ETR and RPV, respectively.</p>\n<p><b><i>CONCLUSION:</b></i></p>\n<p>Only a few, relatively rare, NNRTI resistance-associated amino acid substitutions caused resistance to ETR and/or RPV in an HIV-1 subtype C background suggesting that these newer NNRTI would be effective in NVP/EFV-experienced HIV-1 subtype C-infected patients.</p>', 'Antimicrob Agents Chemother', 'pii: AAC.04215-14', 12, NULL, 'Antimicrob_Basson2013_NNRTI_NRTI', 'impact, drug resistance, HIV-1 subtype C, susceptibility, NNRTI, etravirine, ETR, rilpivirine, PCV, efavirenz, EFV, nevirapine, NVP, south africa, impact, drug resistance, HIV-1 subtype C, susceptibility, NNRTI, etravirine, ETR, rilpivirine, PCV, efavirenz, EFV, nevirapine, NVP, south africa, impact, drug resistance, HIV-1 subtype C, susceptibility, NNRTI, etravirine, ETR, rilpivirine, PCV, efavirenz, EFV, nevirapine, NVP, south africa, impact, drug resistance, HIV-1 subtype C, susceptibility, NNRTI, etravirine, ETR, rilpivirine, PCV, efavirenz, EFV, nevirapine, NVP, south africa', 'Impact of resistance on subtype C NNRTI new generation. This included drug resistance to etravirine (ETR), rilpivirine (RPV), efavirenz (EFV) and nevirapine (NVP) in an in vitro single-cycle phenotypic assay. This is a South African research project focusing on subtype C. Lynn Morris, Tulio de Oliveira, Robert Shafer.', 'pii: AAC.04215-14', NULL, 2015, NULL, 4.598, 3, NULL, NULL, NULL, NULL),
(107, 'Sequencing and phylogenetic analysis of near full-length HIV-1 subtypes A, B, G and unique recombinant AC and AD viral strains identified in South Africa', 'Wilkinson E, Holzmayer V, Jacobs G, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Brennan C, Hackett J Jr, Janse van Rensburg E, Engelbrecht S.', '<p>By the end of 2012, more than 6.1 million people were infected with HIV-1 in South Africa. Subtype C was responsible for the majority of these infections and more than 300 near full-length genomes (NFLGs) have been published. Currently very few non-subtype C isolates have been identified and characterized within the country, particularly full-genome non-C isolates. Seven patients from the Tygerberg Virology (TV) cohort were previously identified as possible non-C subtypes and were selected for further analyses. RNA was isolated from five individuals (TV047, TV096, TV101, TV218, TV546), and DNA from TV016 and TV1057. </p>\n\n<p>The NFLGs of these samples were amplified in overlapping fragments and sequenced. Online subtyping tools, REGA version 3 and jpHMM were used to screen for subtypes and recombinants. Maximum Likelihood (ML) phylogenetic analysis (PhyML) was used to infer subtypes and SimPlot was used to confirm possible inter-subtype recombinants. We identified three subtype B (TV016, TV047 and TV1057) isolates, one subtype A1 (TV096), one subtype G (TV546), one unique AD (TV101) and one unique AC (TV218) recombinant form. This is the first NFLG of subtype G that has been described in South Africa.</p>\n<p>The subtype B sequences described also increased the NFLG subtype B sequences in Africa from three to six. There is a need for more NFLG sequences, as partial HIV-1 sequences may under represent viral recombinant forms. It is also necessary to continue monitoring the evolution and spread of HIV-1 in South Africa, because understanding viral diversity may play an important role in HIV-1 prevention strategies.</p>\n\n', 'AIDS Research and Human Retroviruses', 'in press', 1, NULL, NULL, 'HIV-1, complete genomes, south africa, sutype A, subtype B, subtype G, unique recombinats, AC recombinants, AD recombinants, viral strains, near full lenght genome, Stellenbosch, HIV, genomes, near full lenght genome, NFLG, HIV-1, complete genomes, south africa, sutype A, subtype B, subtype G, unique recombinats, AC recombinants, AD recombinants, viral strains, near full lenght genome, Stellenbosch, HIV, genomes, HIV-1, complete genomes, south africa, sutype A, subtype B, subtype G, unique recombinats, AC recombinants, AD recombinants, viral strains, near full lenght genome, Stellenbosch, HIV, genomes, HIV-1, complete genomes, south africa, sutype A, subtype B, subtype G, unique recombinats, AC recombinants, AD recombinants, viral strains, near full lenght genome, Stellenbosch, HIV, genomes', 'Seven complete genomes from non-subtype C virus were sequenced in South Africa from Cape Town, South Africa. These are the first near full lenght genomes of non-subtype C sequenced in South Africa. It is also necessary to continue monitoring the evolution and spread of HIV-1 in South Africa, because understanding viral diversity may play an important role in HIV-1 prevention strategies.', NULL, NULL, 2015, NULL, 2.457, 3, NULL, NULL, NULL, NULL),
(108, 'Evidence of Long-Lived Founder Virus in Mother-to-Child HIV Transmission', '<a href=\"people.php?peopleid=2\">Danaviah S</a>, <a href=\"people.php?peopleid=1\"> de Oliveira T</a>, Bland R, Viljoen J, Pillay S, Tuaillon E, Van de Perre P, Newell ML', '<p>Exposure of the infant\'s gut to cell-associated and cell-free HIV-1 trafficking in breast milk (BM) remains a primary cause of mother-to-child transmission (MTCT). The mammary gland represents a unique environment for HIV-1 replication and host-virus interplay. We aimed to explore the origin of the virus transmitted during breastfeeding, and the link with quasi-species found in acellular and cellular fractions of breast-milk (BM) and in maternal plasma. The C2-V5 region of the env gene was amplified, cloned and sequenced from the RNA and DNA of BM, the RNA from the mother\'s plasma (PLA) and the DNA from infant\'s dried blood spot (DBS) in 11 post-natal mother-infant pairs.</p>\n<p> Sequences were assembled in Geneious, aligned in ClustalX, manually edited in SeAL and phylogenetic reconstruction was undertaken in PhyML and MrBayes. We estimated the timing of transmission (ETT) and reconstructed the time for the most recent common ancestor (TMRCA) of the infant in BEAST.</p>\n<p> Transmission of single quasi-species was observed in 9 of 11 cases. Phylogenetic analysis illustrated a BM transmission event by cell-free virus in 4 cases, and by cell-associated virus in 2 cases but could not be identified in the remaining 5 cases. Molecular clock estimates, of the infant ETT and TMRCA, corresponded well with the timing of transmission estimated by sequential infant DNA PCR in 10 of 11 children. The TMRCA of BM variants were estimated to emerge during gestation in 8 cases. We hypothesize that in the remaining cases, the breast was seeded with a long-lived lineage latently infecting resting T-cells. Our analysis illustrated the role of DNA and RNA virus in MTCT. We postulate that DNA archived viruses stem from latently infected quiescent T-cells within breast tissue and MTCT can be expected to continue, albeit at low levels, should interventions not effectively target these cells.</p>', 'PLoS One', '10(3)', 2, NULL, 'DanaviahMotherChildPLoSOne2015', 'hiv-1, mother-to-child, transmission, founder virus, phylogenetics, beast, molecular clock, breast milk, vertical, hiv transmission, babies, mother, south africa, rural, KwaZulu-Natal, Africa Centre, bioinformatics, hiv-1, mother-to-child, transmission, founder virus, phylogenetics, beast, molecular clock, breast milk, vertical, hiv transmission, babies, mother, south africa, rural, KwaZulu-Natal, Africa Centre, bioinformatics, hiv-1, mother-to-child, transmission, founder virus, phylogenetics, beast, molecular clock, breast milk, vertical, hiv transmission, babies, mother, south africa, rural, KwaZulu-Natal, Africa Centre, bioinformatics, hiv-1, mother-to-child, transmission, founder virus, phylogenetics, beast, molecular clock, breast milk, vertical, hiv transmission, babies, mother, south africa, rural, KwaZulu-Natal, Africa Centre, bioinformatics', 'Exposure of the infant\'s gut to cell-associated and cell-free HIV-1 trafficking in breast milk (BM) remains a primary cause of mother-to-child transmission (MTCT). T ransmission of single quasi-species was observed in 9 of 11 cases. Phylogenetic analysis illustrated a BM transmission event by cell-free virus in 4 cases, and by cell-associated virus in 2 cases but could not be identified in the remaining 5 cases. We postulate that DNA archived viruses stem from latently infected quiescent T-cells within breast tissue and MTCT can be expected to continue, albeit at low levels, should interventions not effectively target these cells. PLoS One 2015', 'e0120389', NULL, 2015, 'doi: 10.1371/journal.pone.012038', 4.441, 1, NULL, NULL, NULL, NULL),
(109, 'PANGEA-HIV: phylogenetics for generalised epidemics in Africa', 'Pillay D, Herbeck J, Cohen MS, <a href=\"people.php?peopleid=1\"> de Oliveira T</a>, Fraser C, Ratmann O, Brown A-L, Kellam P, on behalf of the PANGEA-HIV Consortium', '<p>The Phylogenetics and Networks for Generalized HIV Epidemics in Africa consortium (PANGEA-HIV) is an international partnership to use viral sequence analyses to assess the transmission of HIV in Africa. The aims of PANGEA-HIV include to sequence 20 000 total HIV genomes from several African study sites, with every genome sequence linked to clinical, demographic, and epidemiological data; and to direct the development of phylogenetic methods to address key challenges and opportunities in measuring, understanding, and controlling HIV transmission in generalised epidemics.</p>', 'Lancet Infect Dis.', '15(3)', 9, NULL, 'Pillay2015PANGEALancetID', 'Phylogenetics, Networks, Generalized, HIV, Epidemics, Africa, consortium, PANGEA-HIV,  international, partnership, viral sequence, analyses, assess, transmission, Africa, Bill and Melinda Gates Foundation, BMGF, Africa Centre, Tulio de Oliveira, bioafrica, pangea, saturn, bioinformatics, Phylogenetics and Networks for Generalized HIV Epidemics in Africa, Phylogenetics, Networks, Generalized, HIV, Epidemics, Africa, consortium, PANGEA-HIV,  international, partnership, viral sequence, analyses, assess, transmission, Africa, Bill and Melinda Gates Foundation, BMGF, Africa Centre, Tulio de Oliveira, bioafrica, pangea, saturn, bioinformatics, Phylogenetics and Networks for Generalized HIV Epidemics in Africa, Phylogenetics, Networks, Generalized, HIV, Epidemics, Africa, consortium, PANGEA-HIV,  international, partnership, viral sequence, analyses, assess, transmission, Africa, Bill and Melinda Gates Foundation, BMGF, Africa Centre, Tulio de Oliveira, bioafrica, pangea, saturn, bioinformatics, Phylogenetics and Networks for Generalized HIV Epidemics in Africa, Phylogenetics, Networks, Generalized, HIV, Epidemics, Africa, consortium, PANGEA-HIV,  international, partnership, viral sequence, analyses, assess, transmission, Africa, Bill and Melinda Gates Foundation, BMGF, Africa Centre, Tulio de Oliveira, bioafrica, pangea, saturn, bioinformatics, Phylogenetics and Networks for Generalized HIV Epidemics in Africa', 'he Phylogenetics and Networks for Generalized HIV Epidemics in Africa consortium (PANGEA-HIV) is an international partnership to use viral sequence analyses to assess the transmission of HIV in Africa. The aims of PANGEA-HIV include to sequence 20 000 total HIV genomes from several African study sites, with every genome sequence linked to clinical, demographic, and epidemiological data; and to direct the development of phylogenetic methods to address key challenges and opportunities in measuring, understanding, and controlling HIV transmission in generalised epidemics', '259-61', NULL, 2015, 'doi: 10.1016/S1473-3099(15)70036-8', 16.144, 3, NULL, NULL, NULL, NULL),
(110, 'The origin of HTLV-1 in southern Bahia by phylogenetic, mtDNA and Beta-globin analysis', 'Aleluia MM, Mello MAG,Alcantara LCJ, Rego FFA, Santos LPS, Galvao-Castro B, Goncalves MS, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Marin LJ, Sousa SMB, Gadelha SR', '<p>Different hypotheses have been elaborated to explain how the HTLV spread throughout the world. It has been proposed that the virus was introduced in Bahia, during the slave-trade period from the 16th century to 19th century. However, there is no information about the HTLV evolutionary history in southern Bahia. The phylogeny is fundamental in order to clarify its introduction and dispersion.</p>\n<p> The DNA of 29 samples was extracted, followed by nested-PCR assay for the LTR and DNA sequencing. These sequences were analyzed by phylogenic methods. The mtDNA ancestry markers and BetaA-globin haplotypes were analyzed by PCR/RFLP. In relation to HTLV subtyping, all samples were classified as cosmopolitan subtype and transcontinental subgroup. Results suggest an ancient post-Columbian introduction of HTLV-1a-A associated with the slave trade between the XVI and late XIX centuries in southern Bahia.</p>\n<p> As regards the ethnicity of HTLV-infected women, the haplotype characterization of Beta-globin gene and the mtDNA ethnicity of HTLV-infected women, we have detected a major African contribution, with a predominance of Benin and Bantu types. HTLV-1 infection is spread in Bahia and the point of origin was possibly Salvador.</p>', 'Virology Reports', NULL, 1, NULL, 'Aleluia_Viruses_HTLV1_2005', 'HTLV-1a-A, HTLV-1, Brazil, Ancestry, Phylogeny, Africa, Viral spread, tulio de oliveira, Luiz Alcantara, HTLV-1a-A, HTLV-1, Brazil, Ancestry, Phylogeny, Africa, Viral spread, tulio de oliveira, Luiz Alcantara, HTLV-1a-A, HTLV-1, Brazil, Ancestry, Phylogeny, Africa, Viral spread, tulio de oliveira, Luiz Alcantara, HTLV-1a-A, HTLV-1, Brazil, Ancestry, Phylogeny, Africa, Viral spread, tulio de oliveira, Luiz Alcantara', 'Results suggest an ancient post-Columbian introduction of HTLV-1a-A associated with the slave trade between the XVI and late XIX centuries in southern Bahia. As regards the ethnicity of HTLV-infected women, the haplotype characterization of ?-globin gene and the mtDNA ethnicity of HTLV-infected women.', 'dx.doi.org/10.1016/j.virep.2015.05.002', NULL, 2015, 'dx.doi.org/10.1016/j.virep.2015.05.002', 2.5, 1, NULL, NULL, NULL, NULL),
(111, 'Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes', 'Gall A, Ferns B, Morris C, Watson S, Cotten M, Robinson M, Berry N, Pillay D, Kellam P', '<p>Whole HIV-1 genome sequences are pivotal for large-scale studies of interand intrahost evolution, including the acquisition of drug resistance mutations. The ability to rapidly and cost-effectively generate large numbers of HIV-1 genome sequences from different populations and geographical locations and determine the effect of minority genetic variants is, however, a limiting factor. Next-generation sequencing promises to bridge this gap but is hindered by the lack of methods for the enrichment of virus genomes across the phylogenetic breadth of HIV-1 and methods for the robust assembly of the virus genomes from shortread data. </p>\n<p>Here we report a method for the amplification, next-generation sequencing, and unbiased de novo assembly of HIV-1 genomes of groups M, N, and O, as well as recombinants, that does not require prior knowledge of the sequence or subtype. A sensitivity of at least 3,000 copies/ml was determined by using plasma virus samples of known copy numbers. We applied our novel method to compare the genome diversities of HIV-1 groups, subtypes, and genes. The highest level of diversity was found in the env, nef, vpr, tat, and rev genes and parts of the gag gene. Furthermore, we used our method to investigate mutations associated with HIV-1 drug resistance in clinical samples at the level of the complete genome. Drug resistance mutations were detected as both major variant and minor species. In conclusion, we demonstrate the feasibility of our method for large-scale HIV-1 genome sequencing. This will enable the phylogenetic and phylodynamic resolution of the ongoing pandemic and efficient monitoring of complex HIV-1 drug resistance genotypes.</p>', 'Journal of Clinical Microbiology', '50(12)', 20, NULL, 'PaulKellam_NGS', NULL, NULL, 'doi:10.1128/JCM.01516-12', NULL, 2012, 'doi:10.1128/JCM.01516-12', 3.993, 4, NULL, 'Universal whole HIV-1 genome WT Sanger', NULL, NULL),
(112, 'Long-range HIV genotyping using viral RNA and proviral DNA for analysis of HIV drug-resistance and HIV clustering', 'Novitsky V, Zahralban-Steele M, McLane MF, Moyo S, Widenfelt E, Gaseitsiwe S, Makhema J, Essex M', '<p>The goal of the study was to improve the methodology of HIV genotyping for analysis of HIV drug resistance and HIV clustering. Using the protocol of Gall et al. (J Clin Microbiol 50:3838?44, 2012), we developed a robust methodology for amplification of two large fragments of viral genome covering about 80% of the unique HIV-1 genome sequence. Importantly, this method can be applied to both viral RNA and proviral DNA amplification templates, allowing genotyping in HIVinfected subjects with suppressed viral load (e.g., subjects on ART).</p><p> The two amplicons cover critical regions across the HIV-1 genome (including pol and env), allowing analysis of mutations associated with resistance to protease inhibitors, reverse transcriptase inhibitors (NRTIs and NNRTIs), integrase strand transfer inhibitors, and virus entry inhibitors. The two amplicons generated span 7,124 bp, providing substantial sequence length and number of informative sites for comprehensive phylogenic analysis and greater refinement of viral linkage analyses in HIV prevention studies.</p><p> The long-range HIV genotyping from proviral DNA was successful in about 90% of 212 targeted blood specimens collected in a cohort where the majority of patients had suppressed viral load, including 65% of patients with undetectable levels of HIV-1 RNA load. The generated amplicons could be sequenced by different methods, such as population Sanger sequencing, single-genome sequencing, or next-generation ultra-deep sequencing. The developed method is cost-effective ? the cost of the long-range.</p>', 'Journal of Clinical Microbiology', 'in press', 1, NULL, 'NovitskyJCM2015', NULL, NULL, 'in press\n', NULL, 2015, NULL, 3.993, 4, NULL, 'DNA and RNA Long-range HIV genotyping Harvard-Botswana', NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(113, 'Identifying Recent HIV Infections: From Serological Assays to Genomics', 'Moyo S, Wilkinson E, Novitsky V, Vandormael A, Gaseitsiwe S, Essex M, Engelbrecht S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>\n', '<p>In this paper, we review serological and molecular based methods to identify HIV infection recency. The accurate identification of recent HIV infection continues to be an important research area and has implications for HIV prevention and treatment interventions. Longitudinal cohorts that follow HIV negative individuals over time are the current gold standard approach, but they are logistically challenging, time consuming and an expensive enterprise.</p><p>Methods that utilize cross-sectional testing and biomarker information have become an affordable alternative to the longitudinal approach. These methods use well-characterized biological makers to differentiate between recent and established HIV infections. However, recent results have identified a number of limitations in serological based assays that are sensitive to the variability in immune responses modulated by HIV subtypes, viral load and antiretroviral therapy. </p><p>Molecular methods that explore the dynamics between the timing of infection and viral evolution are now emerging as a promising approach. The combination of serological and molecular methods may provide a good solution to identify recent HIV infection in cross-sectional data. As part of this review, we present the advantages and limitations of serological and molecular based methods and their potential complementary role for the identification of HIV infection recency.</p', 'Viruses', '7', 7, NULL, 'Moyo_2015_viruses_recent_infection', 'recent HIV infection, viral diversity, serology-based assays, molecular-based assays, sequencing, LIPA, viral load, subtypes, incidence cases, genomics, serological, assaysrecent HIV infection, viral diversity, serology-based assays, molecular-based assays, sequencing, LIPA, viral load, subtypes, incidence cases, genomics, serological, assaysrecent HIV infection, viral diversity, serology-based assays, molecular-based assays, sequencing, LIPA, viral load, subtypes, incidence cases, genomics, serological, assaysrecent HIV infection, viral diversity, serology-based assays, molecular-based assays, sequencing, LIPA, viral load, subtypes, incidence cases, genomics, serological, assaysrecent HIV infection, viral diversity, serology-based assays, molecular-based assays, sequencing, LIPA, viral load, subtypes, incidence cases, genomics, serological, assays', 'In this paper, we review serological and molecular based methods to identify HIV infection recency. The accurate identification of recent HIV infection continues to be an important research area and has implications for HIV prevention and treatment interventions. Longitudinal cohorts that follow HIV negative individuals over time are the current gold standard approach, but they are logistically challenging, time consuming and an expensive enterprise. Methods that utilize cross-sectional testing and biomarker information have become an affordable alternative to the longitudinal approach', '5508-5524; doi:10.3390/v7102887', NULL, 2015, 'doi:10.3390/v7102887', 3.8, 3, NULL, NULL, NULL, NULL),
(114, 'Deep Sequencing Analysis of Human T Cell Lymphotropic Virus Type 1 Long Terminal Repeat 5\' Region from Patients with Tropical Spastic Paraparesis/Human T Cell Lymphotropic Virus Type 1-Associated Myelopathy and Asymptomatic Carriers.', 'Rego FF, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Giovanetti M, Galvao-Castro B, Goncalves MS, Alcantara LC.', '<p>The aim of this study was to analyze patients by deep sequencing the HTLV-1 LTR region in order to determine if minor and/or major mutations in this promoter region might be associated with TSP/HAM outcome or proviral load or HTLV-1 expression. This study is a cross-sectional analyze of 29 HTLV-1 infected patients with TSP/HAM or asymptomatic carriers. Proviral DNA from those subjects was submitted to a nested-PCR for the HTLV-1 LTR 5\' region. The HTLV-1 LTR5\' purified products were submitted to deep sequencing using the Ion Torrent? sequencing technology (Life Technologies, Carlsbad, CA). </p><p>We found that samples with low proviral load showed more detected minor than the samples with high proviral load. Mutations in 136 positions were found over the 520 bp analyzed fragment of HTLV-1 LTR 5\' with at least 1% frequency. Eleven mutations were present in the previously determined major TFBS and in more than a patient, indicating that might be a differential HTLV-1 expression comparing individuals or in different cells from the same individual. </p><p>Three mutations were statistically significant using the Fisher non-parametric test between the groups but were not present in previously determined TFBS (G126C/T, G306C and C479T). Those mutations that were not present in previously determined TFBS were statistically significant in this study and most frequent in patients with low proviral load or in asymptomatic carriers. Despite those mutations being not present in previously determined TFBS, one of those mutations (G306C/A) was present in a Sp-1 binding site determined by in silico analyze, and its presence abrogated the site for Sp-1 binding and created a new possible ATF binding site.</p>', 'AIDS Research and Human Retroviruses', '32(3)', 1, NULL, NULL, 'HTLV, deep sequencing, ion torrent, TSP, HAM, LTR, bioinformatics, fiocruz, brazil, tulio de oliveira, HTLV, deep sequencing, ion torrent, TSP, HAM, LTR, bioinformatics, fiocruz, brazil, tulio de oliveira, HTLV, deep sequencing, ion torrent, TSP, HAM, LTR, bioinformatics, fiocruz, brazil, tulio de oliveira, HTLV, deep sequencing, ion torrent, TSP, HAM, LTR, bioinformatics, fiocruz, brazil, tulio de oliveira, HTLV, deep sequencing, ion torrent, TSP, HAM, LTR, bioinformatics, fiocruz, brazil, tulio de oliveira, HTLV, deep sequencing, ion torrent, TSP, HAM, LTR, bioinformatics, fiocruz, brazil, tulio de oliveira', 'The aim of this study was to analyze patients by deep sequencing the HTLV-1 LTR region in order to determine if minor and/or major mutations in this promoter region might be associated with TSP/HAM outcome or proviral load or HTLV-1 expression. This study is a cross-sectional analyze of 29 HTLV-1 infected patients with TSP/HAM or asymptomatic carriers. Proviral DNA from those subjects was submitted to a nested-PCR for the HTLV-1 LTR 5\' region. ', '279-83', NULL, 2016, 'doi: 10.1089/AID.2015.0273', 2.457, 1, NULL, NULL, NULL, NULL),
(115, 'Brief Report: Virologic Monitoring Can Be a Cost-Effective Strategy to Diagnose Treatment Failure on First-Line ART', 'Vandormael AM, Boulware DR, Tanser FC, Barnighuasen TW, Stott KE, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>CD4 count testing is perceived to be an affordable strategy to diagnose treatment failure on first-line ART. We hypothesize that the superior accuracy of viral load (VL) testing will result in less patients being incorrectly switched to more expensive and toxic second-line regimens. Using data from a drug resistance cohort, we show that CD4 testing is approximately double the cost to make one correct regimen switch under certain diagnostic thresholds (CD4=US$499 vs. VL=US$186 or CD4=US$3,031 vs. VL=US$1,828). In line with World Health Organization guidelines, our findings show that VL testing can be both an accurate and cost-effective treatment monitoring strategy.</p>', 'J Acquir Immune Defic Syndr.', '71(4)', 1, NULL, 'Vandormael_JAIDS_viralLoad_costEffective_2016', 'Virologic, monitoring, cost-effective, strategy,  diagnose, treatment , failure ,first-line, antiretroviral therapy, ARV, South Africa, viral load, Virologic, monitoring, cost-effective, strategy,  diagnose, treatment , failure ,first-line, antiretroviral therapy, ARV, South Africa, viral load, Virologic, monitoring, cost-effective, strategy,  diagnose, treatment , failure ,first-line, antiretroviral therapy, ARV, South Africa, viral load, Virologic, monitoring, cost-effective, strategy,  diagnose, treatment , failure ,first-line, antiretroviral therapy, ARV, South Africa, viral load, Virologic, monitoring, cost-effective, strategy,  diagnose, treatment , failure ,first-line, antiretroviral therapy, ARV, South Africa, viral load, CD4', 'CD4 count testing is perceived to be an affordable strategy to diagnose treatment failure on first-line ART. We hypothesize that the superior accuracy of viral load (VL) testing will result in less patients being incorrectly switched to more expensive and toxic second-line regimens. Using data from a drug resistance cohort, we show that CD4 testing is approximately double the cost to make one correct regimen switch under certain diagnostic thresholds (CD4=US$499 vs. VL=US$186 or CD4=US$3,031 vs. VL=US$1,828). In line with World Health Organization guidelines, our findings show that VL testing can be both an accurate and cost-effective treatment monitoring strategy.', '462?466', NULL, 2016, 'doi:  10.1097/QAI.0000000000000870', 5.4, 3, NULL, NULL, NULL, NULL),
(116, 'The Art of HIV Elimination: Past and Present Science', 'Iwuji CC, McGrath N, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Porter K, Pillay D, Fisher M, Newport M, Newell M-L', '<p><b><i>Introduction:</b></i> Remarkable strides have been made in controlling the HIV epidemic, although not enough to achieve epidemic control. More recently, interest in biomedical HIV control approaches has increased, but substantial challenges with the HIV cascade of care hinder successful implementation. We summarise all available HIV prevention methods and make recommendations on how to address current challenges.</p>\r<p><b><i>Discussion: </b></i>In the early days of the epidemic, behavioural approaches to control the HIV dominated, and the few available evidence-based interventions demonstrated to reduce HIV transmission were applied independently from one another. More recently, it has become clear that combination prevention strategies targeted to high transmission geographies and people at most risk of infections are required to achieve epidemic control. Biomedical strategies such as male medical circumcision and antiretroviral therapy for treatment in HIV-positive individuals and as pre- exposure prophylaxis in HIV-negative individuals provide immense promise for the future of HIV control. In resource- rich settings, the threat of HIV treatment optimism resulting in increased sexual risk taking has been observed and there are concerns that as ART roll-out matures in resource-poor settings and the benefits of ART become clearly visible, behavioural disinhibition may also become a challenge in those settings. Unfortunately, an efficacious vaccine, a strategy which could potentially halt the HIV epidemic, remains elusive.</p>\r<p><b><i>Conclusion: </b></i>Combination HIV prevention offers a logical approach to HIV control, although what and how the available options should be combined is contextual. Therefore, knowledge of the local or national drivers of HIV infection is paramount. Problems with the HIV care continuum remain of concern, hindering progress towards the UNAIDS target of 90-90-90 by 2020. Research is needed on combination interventions that address all the steps of the cascade as the steps are not independent of each other. Until these issues are addressed, HIV elimination may remain an unattainable goal.</p>', 'AIDS & Clinical Research', '6', 7, NULL, 'Iwuji_hiv_elimination_review_2015', 'art, hiv, elimination, review, treatment as prevention, TasP, test and treat, science, antiretroviral, therapy, combination prevention, UNAIDS target, 2020, 2015, Tulio de Oliveira, Vollins Iwuji, AIDS & Clinical Research, paper, art, hiv, elimination, review, treatment as prevention, TasP, test and treat, science, antiretroviral, therapy, combination prevention, UNAIDS target, 2020, 2015, Tulio de Oliveira, Vollins Iwuji, AIDS & Clinical Research, paper, art, hiv, elimination, review, treatment as prevention, TasP, test and treat, science, antiretroviral, therapy, combination prevention, UNAIDS target, 2020, 2015, Tulio de Oliveira, Vollins Iwuji, AIDS & Clinical Research, paper, art, hiv, elimination, review, treatment as prevention, TasP, test and treat, science, antiretroviral, therapy, combination prevention, UNAIDS target, 2020, 2015, Tulio de Oliveira, Vollins Iwuji, AIDS & Clinical Research, paper', 'In this paper, we summarise all available HIV prevention methods and make recommendations on how to address current challenges. Combination HIV prevention offers a logical approach to HIV control, although what and how the available options should be combined is contextual. Therefore, knowledge of the local or national drivers of HIV infection is paramount. Problems with the HIV care continuum remain of concern, hindering progress towards the UNAIDS target of 90-90-90 by 2020. Research is needed on combination interventions that address all the steps of the cascade as the steps are not independent of each other. ', ' 525. doi:10.4172/2155-6113.1000525\r', NULL, 2015, 'doi:10.4172/2155-6113.1000525\r', 6.88, 3, NULL, NULL, NULL, NULL),
(117, 'HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing', 'Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.', '<p>The increasing prevalence of acquired and transmitted HIV-1 drug resistance is an obstacle to successful antiretroviral therapy (ART) in the low- and middle-income countries (LMICs) hardest hit by the HIV-1 pandemic. Genotypic drug resistance testing could facilitate the choice of initial ART in areas with rising transmitted drug resistance (TDR) and enable care-providers to determine which individuals with virological failure (VF) on a first- or second-line ART regimen require a change in treatment.</p><p> An inexpensive near point-of-care (POC) genotypic resistance test would be useful in settings where the resources, capacity, and infrastructure to perform standard genotypic drug resistance testing are limited. Such a test would be particularly useful in conjunction with the POC HIV-1 viral load tests that are currently being introduced in LMICs. A POC genotypic resistance test is likely to involve the use of allele-specific point mutation assays for detecting drug-resistance mutations (DRMs). </p><p>This study proposes that two major nucleoside reverse transcriptase inhibitor (NRTI)-associated DRMs (M184V and K65R) and four major NNRTI-associated DRMs (K103N, Y181C, G190A, and V106M) would be the most useful for POC genotypic resistance testing in LMIC settings. One or more of these six DRMs was present in 61.2% of analyzed virus sequences from ART-naive individuals with intermediate or high-level TDR and 98.8% of analyzed virus sequences from individuals on a first-line NRTI/NNRTI-containing regimen with intermediate or high-level acquired drug resistance. </p><p>The detection of one or more of these DRMs in an ART-naive individual or in a individual with VF on a first-line NRTI/NNRTI-containing regimen may be considered an indication for a protease inhibitor (PI)-containing regimen or closer virological monitoring based on cost-effectiveness or country policy.</p>', 'PLoS One', '10(12)', 7, NULL, NULL, 'HIV, drug resistance, point-of-care, POC, genotypic, resistance, testing, HIV-1, limited, resource settings, antiretroviral therapy, 2015, Stanford HIVDB, Robert Shafer, Tulio de Oliveira, transmitted resistance, HIV, drug resistance, point-of-care, POC, genotypic, resistance, testing, HIV-1, limited, resource settings, antiretroviral therapy, 2015, Stanford HIVDB, Robert Shafer, Tulio de Oliveira, transmitted resistance, HIV, drug resistance, point-of-care, POC, genotypic, resistance, testing, HIV-1, limited, resource settings, antiretroviral therapy, 2015, Stanford HIVDB, Robert Shafer, Tulio de Oliveira, transmitted resistance, HIV, drug resistance, point-of-care, POC, genotypic, resistance, testing, HIV-1, limited, resource settings, antiretroviral therapy, 2015, Stanford HIVDB, Robert Shafer, Tulio de Oliveira, transmitted resistance', 'Genotypic drug resistance testing could facilitate the choice of initial ART in areas with rising transmitted drug resistance (TDR) and enable care-providers to determine which individuals with virological failure (VF) on a first- or second-line ART regimen require a change in treatment. An inexpensive near point-of-care (POC) genotypic resistance test would be useful in settings where the resources, capacity, and infrastructure to perform standard genotypic drug resistance testing are limited.The detection of one or more of these DRMs in an ART-nave individual or in a individual with VF on a first-line NRTI/NNRTI-containing regimen may be considered an indication for a protease inhibitor (PI)-containing regimen or closer virological monitoring based on cost-effectiveness or country policy.', 'e0145772. doi: 10.1371/journal.pone.0145772', NULL, 2015, 'doi: 10.1371/journal.pone.0145772', 4.441, 3, NULL, NULL, NULL, NULL),
(118, 'History and origin of the HIV-1 subtype C epidemic in South Africa and the greater southern African region', 'Wilkinson E, Engelbrecht S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>HIV has spread at an alarming rate in South Africa, making it the country with the highest number of HIV infections. Several studies have investigated the histories of HIV-1 subtype C epidemics but none have done so in the context of social and political transformation in southern Africa. There is a need to understand how these processes affects epidemics, as socio-political transformation is a common and on-going process in Africa. </p><p>Here, we genotyped strains from the start of the epidemic and applied phylodynamic techniques to determine the history of the southern Africa and South African epidemic from longitudinal sampled data. The southern African epidemic\'s estimated dates of origin was placed around 1960 (95% HPD 1956-64), while dynamic reconstruction revealed strong growth during the 1970s and 80s. </p><p>The South African epidemic has a similar origin, caused by multiple introductions from neighbouring countries, and grew exponentially during the 1980s and 90s, coinciding with socio-political changes in South Africa. These findings provide an indication as to when the epidemic started and how it has grown, while the inclusion of sequence data from the start of the epidemic provided better estimates. The epidemic have stabilized in recent years with the expansion of antiretroviral therapy.</p>', 'Scientific Reports', '5', 3, NULL, 'Wilkinson_HIV_subtypeC_origin_SouthAfrica', 'history, origin, HIV-1, subtype C, south Africa, Southern Africa, Apartheith, socio-political, changes, dynamic reconstruction, growth, 1990s, 1980s, 1970s, epidemic, expansion, ART, tulio de oliveira, phylodynamics, phylogenetic, history, origin, HIV-1, subtype C, south Africa, Southern Africa, Apartheith, socio-political, changes, dynamic reconstruction, growth, 1990s, 1980s, 1970s, epidemic, expansion, ART, tulio de oliveira, phylodynamics, phylogenetic, history, origin, HIV-1, subtype C, south Africa, Southern Africa, Apartheith, socio-political, changes, dynamic reconstruction, growth, 1990s, 1980s, 1970s, epidemic, expansion, ART, tulio de oliveira, phylodynamics, phylogenetic, history, origin, HIV-1, subtype C, south Africa, Southern Africa, Apartheith, socio-political, changes, dynamic reconstruction, growth, 1990s, 1980s, 1970s, epidemic, expansion, ART, tulio de oliveira, phylodynamics, phylogenetic', 'HIV has spread at an alarming rate in South Africa, making it the country with the highest number of HIV infections. Several studies have investigated the histories of HIV-1 subtype C epidemics but none have done so in the context of social and political transformation in southern Africa. There is a need to understand how these processes affects epidemics, as socio-political transformation is a common and on-going process in Africa. Here, we genotyped strains from the start of the epidemic and applied phylodynamic techniques to determine the history of the southern Africa and South African epidemic from longitudinal sampled data. The southern African epidemic\'s estimated dates of origin was placed around 1960 (95% HPD 1956-64), while dynamic reconstruction revealed strong growth during the 1970s and 80s. The South African epidemic has a similar origin, caused by multiple introductions from neighbouring countries, and grew exponentially during the 1980s and 90s, coinciding with socio-political changes in South Africa. These findings provide an indication as to when the epidemic started and how it has grown, while the inclusion of sequence data from the start of the epidemic provided better estimates. The epidemic have stabilized in recent years with the expansion of antiretroviral therapy.', '16897. doi: 10.1038/srep16897', NULL, 2015, '16897. doi: 10.1038/srep16897.', 5.578, 3, NULL, NULL, NULL, NULL),
(119, 'Analysis of Dominant HIV Quasispecies Suggests Independent Viral Evolution Within Spinal Granulomas Coinfected with Mycobacterium tuberculosis and HIV-1 Subtype C', 'Danaviah S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Gordon M, Govender S, Chelule P, Pillay S, Naicker T, Cassol S, Ndung\'u T', '<p>Extrapulmonary tuberculosis (TB) is a significant public health challenge in South Africa and worldwide, largely fuelled by the HIV epidemic. In spinal TB, Mycobacteria infect the spinal column without dissemination to the spinal cord. The immune microenvironment, target cell characteristics, and other evolutionary forces within granulomas during HIV/TB coinfection are poorly characterized. </p><p>We investigated whether spinal TB granulomas represent a sequestered anatomical site where independent HIV evolution occurs, and assessed the role of macrophages as a target cell for both HIV and mycobacteria. RNA was extracted from plasma and granulomatous tissue from six antiretroviral-naive HIV-1/spinal TB-coinfected patients, RT-PCR amplified, and the C2-V5 env segment was cloned and sequenced. Analysis of genetic diversity, phylogeny and coalescence patterns was performed on clonal sequences. To investigate their role in HIV sequestration, macrophages and the HIV-1 p24 protein were immune localized and ultrastructural features were studied. </p><p>Intercompartment diversity measurements and phylogenetic reconstruction revealed anatomically distinct monophyletic HIV-1 clusters in four of six patients. Genotypic CCR5-tropic variants were predominant (98.9%) with conservation of putative N-linked glycosylation sites in both compartments. CD68+ reactivity was associated with higher tissue viral load (r=1.0; p<0.01) but not greater intrapatient diversity (r=0.60; p>0.05). Ultrastructural imaging revealed the presence of bacterial and virus-like particles within membrane-bound intracellular compartments of macrophages. Spinal tuberculosis granulomas may form anatomically discreet sites of divergent viral evolution. Macrophages in these granulomas harbored both pathogens, suggesting that they may facilitate the process of viral sequestration within this compartment.</p>', 'AIDS Research and Human Retroviruses', '', 1, NULL, NULL, 'Dominant, HIV, Quasispecies, Independent, Viral, Evolution, Spinal Granulomas, Coinfected, Mycobacterium,  tuberculosis, MTB, TB, HIV-1, Subtype C, phylogenetic, phylodynamics, Dominant, HIV, Quasispecies, Independent, Viral, Evolution, Spinal Granulomas, Coinfected, Mycobacterium,  tuberculosis, MTB, TB, HIV-1, Subtype C, phylogenetic, phylodynamics, Dominant, HIV, Quasispecies, Independent, Viral, Evolution, Spinal Granulomas, Coinfected, Mycobacterium,  tuberculosis, MTB, TB, HIV-1, Subtype C, phylogenetic, phylodynamics', 'Extrapulmonary tuberculosis (TB) is a significant public health challenge in South Africa and worldwide, largely fuelled by the HIV epidemic. Intercompartment diversity measurements and phylogenetic reconstruction revealed anatomically distinct monophyletic HIV-1 clusters in four of six patients. Genotypic CCR5-tropic variants were predominant (98.9%) with conservation of putative N-linked glycosylation sites in both compartments. CD68+ reactivity was associated with higher tissue viral load but not greater intrapatient diversity. Ultrastructural imaging revealed the presence of bacterial and virus-like particles within membrane-bound intracellular compartments of macrophages. Spinal tuberculosis granulomas may form anatomically discreet sites of divergent viral evolution. Macrophages in these granulomas harbored both pathogens, suggesting that they may facilitate the process of viral sequestration within this compartment.', 'doi:10.1089/aid.2015.0189', NULL, 2016, 'doi:10.1089/aid.2015.0189', 2.457, 1, NULL, NULL, NULL, NULL),
(120, 'Understanding Specific Contexts of Antiretroviral Therapy Adherence in Rural South Africa: A Thematic Analysis of Digital Stories from a Community with High HIV Prevalence', 'Treffry-Goatley A, Lessells R, Sykes P, Barnighausen T, <a href=\"people.php?surname=de Oliveira\">de Oliveira T<a/>, Moletsane R, Seeley J.', '<p>Near-perfect adherence to antiretroviral therapy (ART) is required to achieve the best possible prevention and treatment outcomes. Yet, there have been particular concerns about the challenges of adherence among patients living in resource-limited settings in sub-Saharan Africa. The primary objective of this study was to explore adherence in a low-resourced, rural community of high HIV prevalence in South Africa and to identify specific individual and structural factors that can either challenge or support adherence in this context. We applied digital stories as a qualitative research tool to gain insights into personal contexts of HIV and ART adherence. Through an inductive thematic analysis of twenty story texts, soundtracks and drawings, we explored experiences, understandings, and contexts of the participants and identified potential barriers and facilitators for those on lifelong treatment.</p><p> We found that many of the stories reflected a growing confidence in the effectiveness of ART, which should be viewed as a key facilitator to successful adherence since this attitude can promote disclosure and boost access to social support. Nevertheless, stories also highlighted the complexity of the issues that individuals and households face as they deal with HIV and ART in this setting and it is clear that an overburdened local healthcare system has often struggled to meet the demands of a rapidly expanding epidemic and to provide the necessary medical and emotional support.</p><p> Our analysis suggests several opportunities for further research and the design of novel health interventions to support optimal adherence. Firstly, future health promotion campaigns should encourage individuals to test together, or at least accompany each other for testing, to encourage social support from the outset. Additionally, home-based testing and ART club interventions might be recommended to make it easier for individuals to adhere to their treatment regimens and to provide a sense of support and solidarity.</p>', 'PLoS One', '11(2)', 1, NULL, 'treffrygoatleyHIVAdherence2016', 'HIV, adherance, art, science, wellcome trust, South Africa, antiretroviral therapy, story telling, Stories, Community, High, HIV\rPrevalence, treffygoatley, de oliveira, Africa Centre, rural, Africa, HIV, adherance, art, science, wellcome trust, South Africa, antiretroviral therapy, story telling, Stories, Community, High, HIV\rPrevalence, treffygoatley, de oliveira, Africa Centre, rural, Africa, HIV, adherance, art, science, wellcome trust, South Africa, antiretroviral therapy, story telling, Stories, Community, High, HIV\rPrevalence, treffygoatley, de oliveira, Africa Centre, rural, Africa, HIV, adherance, art, science, wellcome trust, South Africa, antiretroviral therapy, story telling, Stories, Community, High, HIV\rPrevalence, treffygoatley, de oliveira, Africa Centre, rural, Africa, HIV, adherance, art, science, wellcome trust, South Africa, antiretroviral therapy, story telling, Stories, Community, High, HIV\rPrevalence, treffygoatley, de oliveira, Africa Centre, rural, Africa', 'Our manuscript suggests several opportunities for further research and the design of novel health interventions to support optimal adherence. Firstly, future health promotion campaigns should encourage individuals to test together, or at least accompany each other for testing, to encourage social support from the outset. Additionally, home-based testing and ART club interventions might be recommended to make it easier for individuals to adhere to their treatment regimens and to provide a sense of support and solidarity.', 'doi: 10.1371/journal.pone.0148801', NULL, 2016, 'doi: 10.1371/journal.pone.0148801', 4.441, 3, NULL, NULL, NULL, NULL),
(121, 'The Development of Computational Biology in South Africa: Successes Achieved and Lessons Learnt', 'Mulder NJ, Christoffels A, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Gamieldien J, Hazelhurst S, Joubert F, Kumuthini J, Pillay CS, Snoep JL, Tastan Bishop O, Tiffin N', '<p>Bioinformatics is now a critical skill in many research and commercial environments as biological data are increasing in both size and complexity. South African researchers recognized this need in the mid-1990s and responded by working with the government as well as international bodies to develop initiatives to build bioinformatics capacity in the country. Significant injections of support from these bodies provided a springboard for the establishment of computational biology units at multiple universities throughout the country, which took on teaching, basic research and support roles. Several challenges were encountered, for example with unreliability of funding, lack of skills, and lack of infrastructure. However, the bioinformatics community worked together to overcome these, and South Africa is now arguably the leading country in bioinformatics on the African continent. Here we discuss how the discipline developed in the country, highlighting the challenges, successes, and lessons learnt.</p>', 'PLoS Comput Biol', '12(2)', 1, NULL, 'MulderBioinformaticsSouthAfricaPLoSComputBio2016', 'bioinformatics, south africa, computational biology, 2016, africa, review, summary, drug resistance databases, tulio de oliveira, bioafrica, training, capacity building,bioinformatics, south africa, computational biology, 2016, africa, review, summary, drug resistance databases, tulio de oliveira, bioafrica, training, capacity building,bioinformatics, south africa, computational biology, 2016, africa, review, summary, drug resistance databases, tulio de oliveira, bioafrica, training, capacity building,bioinformatics, south africa, computational biology, 2016, africa, review, summary, drug resistance databases, tulio de oliveira, bioafrica, training, capacity building', 'Bioinformatics is now a critical skill in many research and commercial environments as biological\rdata are increasing in both size and complexity. South African researchers recognized\rthis need in the mid-1990s and responded by working with the government as well as\rinternational bodies to develop initiatives to build bioinformatics capacity in the country. Significant\rinjections of support from these bodies provided a springboard for the establishment\rof computational biology units at multiple universities throughout the country, which took on\rteaching, basic research and support roles. Several challenges were encountered, for\rexample with unreliability of funding, lack of skills, and lack of infrastructure. However, the\rbioinformatics community worked together to overcome these, and South Africa is now\rarguably the leading country in bioinformatics on the African continent. Here we discuss\rhow the discipline developed in the country, highlighting the challenges, successes, and\rlessons learnt.	', 'e1004395', NULL, 2016, 'doi: 10.1371/journal.pcbi.1004395', 5.62, 3, NULL, NULL, NULL, NULL),
(123, 'Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study', 'The TenoRes Study Group* Gregson J, Tang M, Ndembi N, Hamers RL, ..., <a href=\"people.php?peopleid=1\">de Oliveira T</a>, ..., Shafer RW, Gupta KR', '<p><b><i>Background</b></i> Antiretroviral therapy (ART) is crucial for controlling HIV-1 infection through wide-scale treatment as\nprevention and pre-exposure prophylaxis (PrEP). Potent tenofovir disoproxil fumarate-containing regimens are\nincreasingly used to treat and prevent HIV, although few data exist for frequency and risk factors of acquired drug\nresistance in regions hardest hit by the HIV pandemic. We aimed to do a global assessment of drug resistance after\nvirological failure with first-line tenofovir-containing ART.</p>\n<p><b><i>Methods</b></i> The TenoRes collaboration comprises adult HIV treatment cohorts and clinical trials of HIV drug resistance\ntesting in Europe, Latin and North America, sub-Saharan Africa, and Asia. We extracted and harmonised data for\npatients undergoing genotypic resistance testing after virological failure with a first-line regimen containing tenofovir\nplus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleotide reverse-transcriptase inhibitor (NNRTI;\nefavirenz or nevirapine). We used an individual participant-level meta-analysis and multiple logistic regression to\nidentify covariates associated with drug resistance. Our primary outcome was tenofovir resistance, defi ned as presence\nof K65R/N or K70E/G/Q mutations in the reverse transcriptase (RT) gene.</p>\n<p><b><i>Findings</b></i> We included 1926 patients from 36 countries with treatment failure between 1998 and 2015. Prevalence of\ntenofovir resistance was highest in sub-Saharan Africa (370/654 [57%]). Pre-ART CD4 cell count was the covariate\nmost strongly associated with the development of tenofovir resistance (odds ratio [OR] 1.50, 95% CI 1.27-1.77 for\nCD4 cell count <100 cells per ?L). Use of lamivudine versus emtricitabine increased the risk of tenofovir resistance\nacross regions (OR 1.48, 95% CI 1.20-1.82). Of 700 individuals with tenofovir resistance, 578 (83%) had cytosine\nanalogue resistance (M184V/I mutation), 543 (78%) had major NNRTI resistance, and 457 (65%) had both. The mean\nplasma viral load at virological failure was similar in individuals with and without tenofovir resistance (145 700 copies\nper mL [SE 12 480] versus 133 900 copies per mL [SE 16 650; p=0.626]).</p>\n<p><b><i>Interpretation</b></i> We recorded drug resistance in a high proportion of patients after virological failure on a tenofovircontaining first-line regimen across low-income and middle-income regions. Effective surveillance for transmission\nof drug resistance is crucial.</p>', 'Lancet Infect Dis.', '15', 20, NULL, 'TenoResLancetInfDis2016', 'tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, 2016, africa centre, tulio de oliveira, lancet, publication, open access, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, 2016, africa centre, tulio de oliveira, lancet, publication, open access, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, 2016, africa centre, tulio de oliveira, lancet, publication, open access, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, tenofovir, TDF, resistance, mutation, high-level, subtype C, africa, first line regimen, 2016, africa centre, tulio de oliveira, lancet, publication, open access, ', 'We recorded drug resistance in a high proportion of patients after virological failure on a tenofovir containing\rfirst-line regimen across low-income and middle-income regions in Africa. Effective surveillance for transmission\rof drug resistance is crucial', 'http://dx.doi.org/10.1016/S1473-3099(15)00536-8', NULL, 2016, 'http://dx.doi.org/10.1016/S1473-3099(15)00536-8', 16.144, 3, NULL, NULL, NULL, NULL),
(122, 'Increasing HIV-1 drug resistance between 2010 and 2012 in adults participating in population-based HIV surveillance in rural KwaZulu-Natal South Africa', 'Manasa J, Danaviah S, Lessells RJ, Elshareef M, Tanser F, Wilkinson E, Pillay S, Mthiyane H, Mwambi H, Pillay D,  <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p><b><i>Background</b></i> As more HIV-infected patients access combination antiretroviral therapy (cART), higher proportions of newly infected patients may be infected with drug-resistant viruses. Regular surveillance of transmitted drug resistance (TDR) is required in southern Africa where high rates of transmission persist despite rapid expansion of ART.</p>\n\n\n<p><b><i>Methods</b></i>Dried blood spot (DBS) samples from cART-naive participants from two rounds of an annual population based HIV surveillance programme in rural KwaZulu-Natal underwent HIV RNA testing and samples with HIV RNA >10 000 copies/ml were genotyped for drug resistance. The 2009 Surveillance of drug resistance mutations (SDRM) list was used for drug resistance interpretation. The data was added to previously published data from the same programme and the Chi-square (?2) test for trend was used to test for trend in estimated prevalence of any transmitted drug resistance.</p>\n\n\n<p><b><i>Results</b></i>701 participant\'s data were analyzed: 67 (2010), 381(2011), and 253 (2012). No TDR was detected in 2010. 2011 and 2012 both had 18 participants with SDRMs, 4.7% and 7.1% respectively (p = 0.02, X2 test for trend). The non-nucleoside reverse-transcriptase inhibitor mutation, K103N was the most common mutation, occurring in 27 (3.8%) while nucleoside reverse-transcriptase inhibitor (NRTI) SDRMs were detected in ten (1.4%) of the participants, of whom eight had only a single NRTI SDRM.</p>\n\n<p><b><i>Conclusions</b></i>The increase in levels of drug resistance observed in this population could be a signal of increasing transmission of drug-resistant HIV. Thus continued surveillance is critical to inform public health policies around HIV treatment and prevention.</p>\n', 'AIDS Res Hum Retroviruses', '32(8)', 2, NULL, 'Manasa_IncreasingDrugResistanceSouthAfricaARHR2016', 'drug resistance, transmission, TDR, Increasing, HIV-1, drug, resistance, 2010, 2012, adults, population-based, population,  HIV, surveillance, rural, KwaZulu-Natal, South Africa, africa, drug resistance, transmission, TDR, Increasing, HIV-1, drug, resistance, 2010, 2012, adults, population-based, population,  HIV, surveillance, rural, KwaZulu-Natal, South Africa, africa, drug resistance, transmission, TDR, Increasing, HIV-1, drug, resistance, 2010, 2012, adults, population-based, population,  HIV, surveillance, rural, KwaZulu-Natal, South Africa, africa, drug resistance, transmission, TDR, Increasing, HIV-1, drug, resistance, 2010, 2012, adults, population-based, population,  HIV, surveillance, rural, KwaZulu-Natal, South Africa, africa, de oliveira, manasa, 2016, TDR', 'The increasing levels of transmitted drug resistance in South Africa was observed in this population in KwaZulu-Natal and suggest high transmission of drug-resistant HIV. Thus continued surveillance is critical to inform public health policies around HIV treatment and prevention.', '763-769', NULL, 2016, 'doi:10.1089/aid.2015.0225', 2.705, 3, NULL, NULL, NULL, NULL),
(124, 'Improving HIV proteome annotation: new features of BioAfrica HIV Proteomics Resource ', 'Druce Megan, Hulo C, Masson P, Sommer P, Xenarios I, Le Mercier P, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p>The Human Immunodeficiency Virus (HIV) is one of the pathogens that cause the greatest global concern, with approximately 35 million people currently infected with HIV. Extensive HIV research has been performed, generating a large amount of HIV and host genomic data. However, no effective vaccine that protects the host from HIV infection is available and HIV is still spreading at an alarming rate, despite effective antiretroviral (ARV) treatment.</p> \n<p>In order to develop effective therapies, we need to expand our knowledge of the interaction between HIV and host proteins. In contrast to virus proteins, which often rapidly evolve drug resistance mutations, the host proteins are essentially invariant within all humans. Thus, if we can identify the host proteins needed for virus replication, such as those involved in transporting viral proteins to the cell surface, we have a chance of interrupting viral replication. There is no proteome resource that summarizes this interaction, making research on this subject a difficult enterprise. In order to fill this gap in knowledge, we curated a resource presents detailed annotation on the interaction between the HIV proteome and host proteins.</p>\n<p> Our resource was produced in collaboration with ViralZone and used manual curation techniques developed by UniProtKB/Swiss-Prot. Our new website also used previous annotations of the BioAfrica HIV-1 Proteome Resource, which has been accessed by approximately 10 000 unique users a year since its inception in 2005.</p><p> The novel features include a dedicated new page for each HIV protein, a graphic display of its function and a section on its interaction with host proteins. Our new webpages also add information on the genomic location of each HIV protein and the position of ARV drug resistance mutations. Our improved BioAfrica HIV-1 Proteome Resource fills a gap in the current knowledge of biocuration. </p>\n<p>Database URL: <a href=\"http://www.bioafrica.net/proteomics/HIVproteome.html\">http://www.bioafrica.net/proteomics/HIVproteome.html</a>', 'Database', '2016', 1, NULL, 'bioafricaHIVproteome2016', 'hiv, proteome, database, hiv-1, proteins, bioafrica, function, structure, information, life-cycle, host interaction, host, proteomics, drug resistance, CCR5, TRIM, CD4, genes, de oliveira, viralzone, swiss institute of bioinformatics, South Africa, Switzerland, hiv, proteome, database, hiv-1, proteins, bioafrica, function, structure, information, life-cycle, host interaction, host, proteomics, drug resistance, CCR5, TRIM, CD4, genes, de oliveira, viralzone, swiss institute of bioinformatics, South Africa, Switzerland, hiv, proteome, database, hiv-1, proteins, bioafrica, function, structure, information, life-cycle, host interaction, host, proteomics, drug resistance, CCR5, TRIM, CD4, genes, de oliveira, viralzone, swiss institute of bioinformatics, South Africa, Switzerland, hiv, proteome, database, hiv-1, proteins, bioafrica, function, structure, information, life-cycle, host interaction, host, proteomics, drug resistance, CCR5, TRIM, CD4, genes, de oliveira, viralzone, swiss institute of bioinformatics, South Africa, Switzerland', 'Our new website also used previous annotations of the BioAfrica HIV-1 Proteome Resource, which has been accessed by approximately 10 000 unique users a year since its inception in 2005. The novel features include a dedicated new page for each HIV protein, a graphic display of its function and a section on its interaction with host proteins. Our new webpages also add information on the genomic location of each HIV protein and the position of ARV drug resistance mutations. Our improved BioAfrica HIV-1 Proteome Resource fills a gap in the current knowledge of biocuration. ', 'doi:10.1093/database/baw045', NULL, 2016, 'doi:10.1093/database/baw045', 4.5, 3, NULL, NULL, NULL, NULL),
(125, 'Zika virus complete genome from Salvador, Bahia, Brazil', 'surname=de OliveiraGiovanetti M, Faria NR, Nunes MR, de Vasconcelos JM, Lourenco J, Rodrigues SG, Vianez JL Jr, da Silva SP, Lemos PS, Tavares FN, Martin DP, do Rosario MS, Siqueira IC, Ciccozzi M, Pybus OG, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>,  Alcantara LC Junior', '<p>In May 2015 the first autochthonous Zika virus infection was reported in Brazil. Rapid and urgent measures are needed to contain the ongoing outbreak. Here we report the full-length ZIKV coding sequence from Bahia. Genetic analysis of outbreak sequences will be essential for characterizing the diversity of circulating strains, identifying hotspots of virus transmission and guiding public health control. Rapid and urgent measures are needed to contain the ongoing outbreak.</p>\n \n<p><b><i> Highlights:</b></i></p>\n<p> - Phylogeny of Zika Virus was investigated by analyzing the complete genome sequence from Salvador Bahia, Brazil.</p>\n\n<p> - Evolutionary analysis was investigated considering the Envelope, NS3, NS5 proteins of Zika Virus.</p>\n\n<p> - This study reinforces the need to monitor the spread of the still ongoing outbreak of Zika Virus.</p>', 'Infection, Genetics and Evolution', '41', 8, NULL, 'ZikavirusCompleteGenomeBrazil_Giovanetti2016.pdf', 'zika, brazil, complete genome, salvador, brasil, phylogenetic analysis, outbreak, 2015, 2016, genes, NS3, NS5, Envelope, phylogeny, tree, ZIKV, Fiocruz, bioafrica, zika, brazil, complete genome, salvador, brasil, phylogenetic analysis, outbreak, 2015, 2016, genes, NS3, NS5, Envelope, phylogeny, tree, ZIKV, Fiocruz, bioafrica, zika, brazil, complete genome, salvador, brasil, phylogenetic analysis, outbreak, 2015, 2016, genes, NS3, NS5, Envelope, phylogeny, tree, ZIKV, Fiocruz, bioafrica, zika, brazil, complete genome, salvador, brasil, phylogenetic analysis, outbreak, 2015, 2016, genes, NS3, NS5, Envelope, phylogeny, tree, ZIKV, Fiocruz, bioafrica', 'In May 2015 the first autochthonous Zika virus infection was reported in Brazil. Rapid and urgent measures are needed to contain the ongoing outbreak. Here we report the full-length ZIKV coding sequence from Bahia. Genetic analysis of outbreak sequences will be essential for characterizing the diversity of circulating strains, identifying hotspots of virus transmission and guiding public health control. Rapid and urgent measures are needed to contain the ongoing outbreak', '142-145', NULL, 2016, 'doi: 10.1016/j.meegid.2016.03.030', 3.015, 1, NULL, NULL, NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(126, 'HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South Africa', 'Rossouw TM, Nieuwoudt M, Manasa J, Malherbe G, Lessells RJ, Pillay S, Danaviah S, Mahasha P, van Dyk G, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p><b><i>OBJECTIVES:</b></i></p>\n<p>Urban and rural HIV treatment programmes face different challenges in the long-term management of patients. There are few studies comparing drug resistance profiles in patients accessing treatment through these programmes. The aim of this study was to perform such a comparison.</p>\n<p><b><i>METHODS:</b></i></p>\n<p>HIV drug resistance data and associated treatment and monitoring information for adult patients failing first-line therapy in an urban and a rural programme were collected. Data were curated and managed in SATuRN RegaDB before statistical analysis using Microsoft Excel 2013 and stata Ver14, in which clinical parameters, resistance profiles and predicted treatment responses were compared.</p>\n<p><b><i>RESULTS:</b></i></p>\n<p>Data for 595 patients were analysed: 492 patients from a rural setting and 103 patients from an urban setting. The urban group had lower CD4 counts at treatment initiation than the rural group (98 vs. 126 cells/?L, respectively; P = 0.05), had more viral load measurements performed per year (median 3 vs. 1.4, respectively; P < 0.01) and were more likely to have no drug resistance mutations detected (35.9% vs. 11.2%, respectively; P < 0.01). Patients in the rural group were more likely to have been on first-line treatment for a longer period, to have failed for longer, and to have thymidine analogue mutations. Notwithstanding these differences, the two groups had comparable predicted responses to the standard second-line regimen, based on the genotypic susceptibility score. Mutations accumulated in a sigmoidal fashion over failure duration.</p>\n<p><b><i>CONCLUSIONS:</b></i></p>\n<p>The frequency and patterns of drug resistance, as well the intensity of virological monitoring, in adults with first-line therapy failure differed between the urban and rural sites. Despite these differences, based on the genotypic susceptibility scores, the majority of patients across the two sites would be expected to respond well to the standard second-line regimen.</p>', 'HIV Med.', '2016 ', 1, NULL, 'Rossouw2016_HIVDrugResistanceUrbanRuralSouthAfrica', 'drug resistance, rural, urban, south africa, programatic factor, viral failure, HIV-1, resistance, SATuRN, de Oliveira, Pretoria, KwaZulu-Natal, increase trends, drug resistance, rural, urban, south africa, programatic factor, viral failure, HIV-1, resistance, SATuRN, de Oliveira, Pretoria, KwaZulu-Natal, increase trends, drug resistance, rural, urban, south africa, programatic factor, viral failure, HIV-1, resistance, SATuRN, de Oliveira, Pretoria, KwaZulu-Natal, increase trends, drug resistance, rural, urban, south africa, programatic factor, viral failure, HIV-1, resistance, SATuRN, de Oliveira, Pretoria, KwaZulu-Natal, increase trends, drug resistance, rural, urban, south africa, programatic factor, viral failure, HIV-1, resistance, SATuRN, de Oliveira, Pretoria, KwaZulu-Natal, increase trends', 'Urban and rural HIV treatment programmes face different challenges in the long-term management of patients. There are few studies comparing drug resistance profiles in patients accessing treatment through these programmes. The urban group had lower CD4 counts at treatment initiation than the rural group and were more likely to have no drug resistance mutations detected. The frequency and patterns of drug resistance, as well the intensity of virological monitoring, in adults with first-line therapy failure differed between the urban and rural sites. Despite these differences, based on the genotypic susceptibility scores, the majority of patients across the two sites would be expected to respond well to the standard second-line regimen.', 'doi: 10.1111/hiv.12400', NULL, 2016, 'doi: 10.1111/hiv.12400', 3.341, 3, NULL, NULL, NULL, NULL),
(127, 'Origin, imports and exports of HIV-1 subtype C in South Africa: A historical perspective', '<a href=\"people.php?surname=Wilkinson\">Wilkinson E</a>, Rasmussen D, Ratmann O, Stadler T, Engelbrecht S, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p><b><i>BACKGROUND:</p></b></i>\n<p>While the HIV epidemic in South Africa had a later onset than epidemics in other southern African countries, prevalence grew rapidly during the 1990\'s when the country was going through socio-political changes with the end of Apartheid. South Africa currently has the largest number of people living with HIV in the world and the epidemic is dominated by a unique subtype, HIV-1 subtype C. This large epidemic is also characterized by high level of genetic diversity. We hypothesize that this diversity is due to multiple introductions of the virus during the period of change. In this paper, we apply novel phylogeographic methods to estimate the number of viral imports and exportsfrom the start of the epidemic to the present.</p>\n<p><b><i>METHODS:</p></b></i>\n<p>We assembled 11,289 unique subtype C pol sequences from southern Africa. These represent one of the largest sequence datasets ever analyzed in the region. Sequences were stratified based on country of sampling and levels of genetic diversity were estimated for each country. Sequences were aligned and a maximum-likelihood evolutionary tree was inferred. Least-Squares Dating was then used to obtain a dated phylogeny from which we estimated the number of introductions into and exports out of South Africa using parsimony-based ancestral location reconstructions.</p>\n<p><b><i>RESULTS:</p></b></i>\n<p>Our results identified 189 viral introductions into South Africa with the largest number of introductions attributed to Zambia (n=109), Botswana (n=32), Malawi (n=26) and Zimbabwe (n=13). South Africa also exported many viral lineages to its neighbours. The bulk viral imports and exports appear to have occurred between 1985 and 2000, coincident with the period of socio-political transition.</p>\n<p><b><i>CONCLUSION:</p></b></i>\n<p>The high level of subtype C genetic diversity in South Africa is related to multiple introductions of the virus to the country. While the number of viral imports and exports we identified was highly sensitive to the number of samples included from each country, they mostly clustered around the period of rapid political and socio-economic change in South Africa.</p>', 'Infection, Genetics and Evolution', 'S1567-1348(16)30298-2', 2, NULL, 'WilkinsonHIVintroductionExportEvolutionSouthAfrica', 'HIV, introduction, subtype C, south africa, history, evolution, politica, socio-economic, change, South Africa, Eduan Wilkinson, Tanja Stadler, Oliver Ratmann, Tulio de Oliveira, manuscript, open access, HIV, introduction, subtype C, south africa, history, evolution, politica, socio-economic, change, South Africa, Eduan Wilkinson, Tanja Stadler, Oliver Ratmann, Tulio de Oliveira, manuscript, open access, phylogeny, phylogenetics,HIV, introduction, subtype C, south africa, history, evolution, politica, socio-economic, change, South Africa, Eduan Wilkinson, Tanja Stadler, Oliver Ratmann, Tulio de Oliveira, manuscript, open access, HIV, introduction, subtype C, south africa, history, evolution, politica, socio-economic, change, South Africa, Eduan Wilkinson, Tanja Stadler, Oliver Ratmann, Tulio de Oliveira, manuscript, open access, phylogeny, phylogenetics', 'Open access manuscript on Origin, imports and exports of HIV-1 subtype C in South Africa: A historical perspective. The high level of subtype C genetic diversity in South Africa is related to multiple introductions of the virus to the country. While the number of viral imports and exports we identified was highly sensitive to the number of samples included from each country, they mostly clustered around the period of rapid political and socio-economic change in South Africa. Infection Genetics Evolution 2016', 'doi: 10.1016/j.meegid.2016.07.008', NULL, 2016, 'doi: 10.1016/j.meegid.2016.07.008', 3.015, 3, NULL, NULL, NULL, NULL),
(128, 'Substance use and duration of untreated psychosis in KwaZulu-Natal, South Africa', 'Davis GP, <a href=\"people.php?peopleid=20\">Tomita A</a>, Baumgartner JN, Mtshemla S, Nene S, King H, Susser E and Burns JK', '<p><b><i>Background:</b></i> Substance use and psychiatric disorders cause significant burden of disease in low- and middle-income countries. Co-morbid psychopathology and longer duration of untreated psychosis (DUP) can negatively affect treatment outcomes. </p>\n<p><b><i>Objectives:</b></i> The study assessed substance use amongst adults with severe mental illness receiving services at a regional psychiatric hospital in KwaZulu-Natal (South Africa). We describe the prevalence and correlates of lifetime substance use and examine the association between substance use and DUP. </p>\n<p><b><i>Methods:</b></i> A cross-sectional survey recruited adults diagnosed with severe mental illness and assessed lifetime and past 3-month substance use using the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test. Regression analyses were conducted to determine associations between lifetime substance use (other than alcohol and tobacco) and DUP as measured by the World Health Organization Encounter Form. </p>\n<p><b><i>Results:</b></i> Amongst 87 participants, alcohol (81.6%), tobacco (75.6%) and cannabis (49.4%) were the most common substances reported for lifetime use. Risk of health-related problems (health, social, financial, legal and relationship) of cannabis use was associated with younger age, single marital status and lower education. Adjusted regression analyses indicated that use of amphetamines and methaqualone is associated with longer DUP. </p>\n<p><b><i>Conclusions:</b></i> Substance use is prevalent amongst psychiatric patients in KwaZulu-Natal and may contribute to longer DUP. Mental health services in this region should address co-morbid substance use and psychiatric disorders.</p>', 'South African Journal of Psychiatry', '22(1)', 3, NULL, 'Tomita_SubstanceUse_2016', 'Substance, use, duration, untreated, psychosis, KwaZulu-Natal, South Africa, Tomita, Psycology, Psychology, Substance, use, duration, untreated, psychosis, KwaZulu-Natal, South Africa, Tomita, Substance, use, duration, untreated, psychosis, KwaZulu-Natal, South Africa, Tomita, Substance, use, duration, untreated, psychosis, KwaZulu-Natal, South Africa, Tomita', 'Substance use is prevalent amongst psychiatric patients in KwaZulu-Natal and may contribute to longer duration of untreated psychosis. Mental health services in this region should address co-morbid substance use and psychiatric disorders.', 'p. 7', NULL, 2016, NULL, 2, 1, NULL, NULL, NULL, NULL),
(129, 'Relationship between HIV serostatus, CD4 count and rehospitalisation: Potential implications for health systems strengthening in South Africa', 'Moodley Y, <a href=\"people.php?peopleid=20\">Tomita A</a>', '<p><b><i>Background:</b></i> Despite three decades of scientific response to HIV/AIDS, the generalised HIV epidemic continues to persist in South Africa. There is growing acknowledgement that health system strengthening will be critical in tackling HIV/AIDS. Patient rehospitalisation is an important quality benchmark of health service delivery, but there is currently limited data on rehospitalisation of patients with HIV/AIDS in South Africa, a setting with a high burden of HIV disease. </p>\n<p><b><i>Objectives:</b></i> To determine the relationship between combined HIV serostatus and CD4 count, and rehospitalisation in South Africa. </p>\n<p><b><i>Methods:</b></i> This study was a retrospective analysis of data from 11,362 non-surgical adult patients who attended the Hlabisa Hospital in South Africa. Data related to patient age, gender, HIV serostatus, CD4 count (for HIV-positive patients) and comorbidity were analysed through univariate (Fisher?s Exact or ?2 tests) and multivariate (Cox regression) statistical methods to determine associations with rehospitalisation within 1 month (acute rehospitalisation) or 12 months (long term rehospitalisation).</p> \n<p><b><i>Results:</b></i> An HIV-positive serostatus with CD4 count < 350 cells/mm3 or an HIV-positive serostatus with an unknown CD4 count were independently associated with a higher risk of acute (p = 0.010 and p = 0.003) and long term rehospitalisation (p < 0.001 for both categories) when compared with an HIV-negative serostatus group. </p>\n<p><b><i>Conclusions:</b></i> HIV-positive individuals with immune deficiency, or lacking a CD4 count measurement are at risk of rehospitalisation. Strengthening primary healthcare service delivery of these key affected inpatient populations should be a priority.</p>', 'Southern African Journal of Infectious Diseases', '1(1)', 1, NULL, 'Tomita_CD4_HIV_2016', 'CD4 count, HIV, patient re-admission, rehospitalisation, serostatus, HIV-1, South Africa, KwaZulu-Natal, CD4 count, HIV, patient re-admission, rehospitalisation, serostatus, HIV-1, South Africa, KwaZulu-Natal, CD4 count, HIV, patient re-admission, rehospitalisation, serostatus, HIV-1, South Africa, KwaZulu-Natal, CD4 count, HIV, patient re-admission, rehospitalisation, serostatus, HIV-1, South Africa, KwaZulu-Natal, CD4 count, HIV, patient re-admission, rehospitalisation, serostatus, HIV-1, South Africa, KwaZulu-Natal', 'HIV-positive individuals with immune deficiency, or lacking a CD4 count measurement are at risk of rehospitalisation. Strengthening primary healthcare service delivery of these key affected inpatient populations should be a priority', '1-6', NULL, 2016, NULL, 1.8, 1, NULL, NULL, NULL, NULL),
(130, 'Analysis of Viral Diversity in Relation to the Recency of HIV-1C Infection in Botswana', 'Moyo S, <a href=\"people.php?peopleid=21\">Vandormael A</a>, <a href=\"people.php/peopleid=4\">Wilkinson E</a>, Engelbrecht S, Gaseitsiwe S, Kotokwe, KP, Musonda R, Tanser F, Essex M, Novitsky V, <a href=\"people.php/peopleid=1\">de Oliveira T</a>', '<p><b><i>Background</b></i> Cross-sectional, biomarker methods to determine HIV infection recency present a promising and cost-effective alternative to the repeated testing of uninfected individuals. We evaluate a viral-based assay that uses a measure of pairwise distances (PwD) to identify HIV infection recency, and compare its performance with two serologic incidence assays, BED and LAg. In addition, we assess whether combination BED plus PwD or LAg plus PwD screening can improve predictive accuracy by reducing the likelihood of a false-recent result. </p>\n<p><b><i>Methods</b></i> The data comes from 854 time-points and 42 participants enrolled in a primary HIV-1C infection study in Botswana. Time points after treatment initiation or with evidence of multiplicity of infection were excluded from the final analysis. PwD was calculated from quasispecies generated using single genome amplification and sequencing.We evaluated the ability of PwD to correctly classify HIV infection recency within <130, <180 and <360 days postseroconversion using Receiver Operator Characteristics (ROC) methods. Following a secondary PwD screening, we quantified the reduction in the relative false-recency rate (rFRR) of the BED and LAg assays while maintaining a sensitivity of either 75, 80, 85 or 90%. </p>\n<p><b><i>Results</b></i> The final analytic sample consisted of 758 time-points from 40 participants. The PwD assay was more accurate in classifying infection recency for the 130 and 180-day cut-offs when compared with the recommended LAg and BED thresholds. A higher AUC statistic confirmed the superior predictive performance of the PwD assay for the three cut-offs. When used for combination screening, the PwD assay reduced the rFRR of the LAg assay by 52% and the BED assay by 57.8% while maintaining a 90% sensitivity for the 130 and 180-day cut-offs respectively.</p> \n<p><b><i>Conclusion</b></i> PwD can accurately determine HIV infection recency. A secondary PwD screening reduces misclassification and increases the accuracy of serologic-based assays.</p>', 'PLoS One', '11(8)', 3, NULL, 'Moyo_viral_diversity_recent_infection', 'Analysis,viral,Diversity,Relation,Recency,HIV-1C,Infection,Botswana,AIDS, HIV, HIV-1, incidence, Africa, genomics, Analysis,viral,Diversity,Relation,Recency,HIV-1C,Infection,Botswana,AIDS, HIV, HIV-1, incidence, Africa, genomics,Analysis,viral,Diversity,Relation,Recency,HIV-1C,Infection,Botswana,AIDS, HIV, HIV-1, incidence, Africa, genomics,Analysis,viral,Diversity,Relation,Recency,HIV-1C,Infection,Botswana,AIDS, HIV, HIV-1, incidence, Africa, genomics,Analysis,viral,Diversity,Relation,Recency,HIV-1C,Infection,Botswana,AIDS, HIV, HIV-1, incidence, Africa, genomics,', 'pair wise diversity (pairwise diversity PwD) can accurately determine HIV infection recency. A secondary PwD screening reduces misclassification and increases the accuracy of serologic-based assays.', 'DOI:10.1371/journal.pone.0160649', NULL, 2016, NULL, 4.441, 3, NULL, NULL, NULL, NULL),
(131, 'Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe', 'Makadzange AT, Higgins-Biddle M, <a href=\"people.php?peopleid=23\">Chimukangara B</a>, Birri R, Gordon M, Mahlanza T, McHugh G, van Dijk JH, Bwakura-Dangarembizi M, Ndung\'u T, Masimirembwa C, Phelps B, Amzel A, Ojikutu BO, Walker BD, Ndhlovu CE', '<p><b><i>OBJECTIVE:</b></i> To determine immunologic, virologic outcomes and drug resistance among children and adolescents receiving care during routine programmatic implementation in a low-income country.</p>\n<p><b><i>METHODS:</b></i> A cross-sectional evaluation with collection of clinical and laboratory data for children (0-<10 years) and adolescents (10-19 years) attending a public ART program in Harare providing care for pediatric patients since 2004, was conducted. Longitudinal data for each participant was obtained from the clinic based medical record.</p>\n<p><b><i>RESULTS:</b></i> Data from 599 children and adolescents was evaluated. The participants presented to care with low CD4 cell count and CD4%, median baseline CD4% was lower in adolescents compared with children (11.0% vs. 15.0%, p<0.0001). The median age at ART initiation was 8.0 years (IQR 3.0, 12.0); median time on ART was 2.9 years (IQR 1.7, 4.5). On ART, median CD4% improved for all age groups but remained below 25%. Older age (? 5 years) at ART initiation was associated with severe stunting (HAZ <-2: 53.3% vs. 28.4%, p<0.0001). Virologic failure rate was 30.6% and associated with age at ART initiation. In children, nevirapine based ART regimen was associated with a 3-fold increased risk of failure (AOR: 3.5; 95% CI: 1.3, 9.1, p = 0.0180). Children (<10 y) on ART for ?4 years had higher failure rates than those on ART for <4 years (39.6% vs. 23.9%, p = 0.0239). In those initiating ART as adolescents, each additional year in age above 10 years at the time of ART initiation (AOR 0.4 95%CI: 0.1, 0.9, p = 0.0324), and each additional year on ART (AOR 0.4, 95%CI 0.2, 0.9, p = 0.0379) were associated with decreased risk of virologic failure. Drug resistance was evident in 67.6% of sequenced virus isolates.</p>\n<p><b><i>CONCLUSIONS:</b></i> During routine programmatic implementation of HIV care for children and adolescents, delayed age at ART initiation has long-term implications on immunologic recovery, growth and virologic outcomes.</p>', 'PLoS One', '10(12)', NULL, NULL, 'Zimbabwe_HIV_resistance_2015', 'Clinical,Virologic,Immunologic,Outcomes,Emerging,HIV,Drug,Resistance,Patterns,Children,Adolescents,Public,ART,Care,ZimbabweClinical,Virologic,Immunologic,Outcomes,Emerging,HIV,Drug,Resistance,Patterns,Children,Adolescents,Public,ART,Care,ZimbabweClinical,Virologic,Immunologic,Outcomes,Emerging,HIV,Drug,Resistance,Patterns,Children,Adolescents,Public,ART,Care,ZimbabweClinical,Virologic,Immunologic,Outcomes,Emerging,HIV,Drug,Resistance,Patterns,Children,Adolescents,Public,ART,Care,Zimbabwe', 'During routine programmatic implementation of HIV care for children and adolescents, delayed age at ART initiation has long-term implications on immunologic recovery, growth and virologic outcomes', 'DOI: 10.1371/journal.pone.0144057\n', NULL, 2015, NULL, 4.441, 3, NULL, NULL, NULL, NULL),
(132, 'Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe', ' <a href=\"people.php?peopleid=23\">Chimukangara B</a>, Gwanzura G, Mitchell R, Katzenstein D, Masimirembwa C ', '<p><b><i>INTRODUCTION: </b></i> There are more than 500 000 HIV-infected people on antiretroviral treatment (ART) in Zimbabwe with very limited laboratory monitoring. To ensure effective treatment and prevent transmission of drug resistance, affordable treatment monitoring is needed to guide individual treatment.</p>\n<p><b><i>METHODS:</b></i> 125 whole blood samples from patients on first-line ART were investigated for drug resistance mutations using an in-house genotypic testing method. Patients had been on HIV reverse transcriptase inhibitors only, with some having been on both HIV and TB treatment. DNA was extracted from whole blood; amplicons were generated by nested PCR and sequenced. Drug resistance mutations were determined using the Stanford HIV drug resistance database. Exact statistics were used to investigate relationships between drug resistance and predisposing factors.</p>\n<p><b><i>RESULTS:</b></i> From 125 samples, 108 were successfully analyzed for drug resistance mutations. 11 of the 108 sequences had drug resistance mutations; predominantly M184V and Y181C. For a 100-cell increase in CD4 count, the odds of being resistant were 61% lower than those with the baseline CD4 count (p = 0.04, CI: 0.34-0.98). There was no association between concurrent HIV/TB treatment and drug resistance (p = 0.41).</p>\n<p><b><i>DISCUSSION AND CONCLUSION:</b></i> Although plasma samples are recommended for genotypic testing, the cost of analyzing plasma RNA makes it less feasible in resource limited settings. Lower cost DNA drug resistance testing from whole blood samples was assessed as a treatment-monitoring tool among patients followed by CD4 and clinical monitoring only. The infrequent detection of resistance and higher CD4 is consistent with effective first-line treatment. Further investigation of proviral DNA as a tool to identify drug resistance mutations is warranted.</p>', 'Curr HIV Res', '12(5)', 3, NULL, 'Chimukangara_HIV_resistance_2014', 'Drug,resistance,mutations,whole,blood,proviral,DNA,among,patients,antiretroviral,drugs, Zimbabwe,Drug,resistance,mutations,whole,blood,proviral,DNA,among,patients,antiretroviral,drugs, Zimbabwe,Drug,resistance,mutations,whole,blood,proviral,DNA,among,patients,antiretroviral,drugs, Zimbabwe', 'Although plasma samples are recommended for genotypic testing, the cost of analyzing plasma RNA makes it less feasible in resource limited settings. Lower cost DNA drug resistance testing from whole blood samples was assessed as a treatment-monitoring tool among patients followed by CD4 and clinical monitoring only. The infrequent detection of resistance and higher CD4 is consistent with effective first-line treatment. Further investigation of proviral DNA as a tool to identify drug resistance mutations is warranted', '309-16', NULL, 2014, NULL, 1.8, 3, NULL, NULL, NULL, NULL),
(133, 'Comprehensive Characterization of HIV-1 Molecular Epidemiology and Demographic History in the Brazilian Region Most Heavily Affected by AIDS', ' <a href=\"people.php?peopleid=19\">Graf T</a>, Fritsch HM, de Medeiros RM, Junqueira DM, Almeida SEM, Pinto AR ', '<p>The high incidence of AIDS cases and the dominance of HIV-1 subtype C infections are two features that distinguish the HIV-1 epidemic in the two southernmost Brazilian states (Rio Grande do Sul [RS] and Santa Catarina [SC]) from the epidemic in other parts of the country. Nevertheless, previous studies on HIV molecular epidemiology were conducted mainly in capital cities, and a more comprehensive understanding of factors driving this unique epidemic in Brazil is necessary.</p>\n<p>Blood samples were collected from individuals in 13 municipalities in the Brazilian southern region. HIV-1 env and pol genes were submitted to phylogenetic analyses for assignment of subtype, and viral population phylodynamics were reconstructed by applying Skygrid and logistic coalescent models in a Bayesian analysis. </p>\n<p>A high prevalence of subtype C was observed in all sampled locations; however, an increased frequency of recombinant strains was found in RS, with evidence for new circulating forms (CRFs). In the SC state, subtype B and C epidemics were associated with distinct exposure groups. Although logistic models estimated similar growth rates for HIV-1 subtype C (HIV-1C) and HIV-1B, a Skygrid plot reveals that the former epidemic has been expanding for a longer time. </p>\n<p>Our results highlight a consistent expansion of HIV-1C in south Brazil, and we also discuss how heterosexual and men who have sex with men (MSM) transmission chains might have impacted the current prevalence of HIV-1 subtypes in this region. </p>\n<p><b><i>IMPORTANCE</b></i> The AIDS epidemic in south Brazil is expanding rapidly, but the circumstances driving this condition are not well known. A high prevalence of HIV-1 subtype C was reported in the capital cities of this region, in contrast to the subtype B dominance in the rest of the country. This study sought to comparatively investigate the HIV-1 subtype B and C epidemics by sampling individuals from several cities in the two states with the highest AIDS incidences in Brazil. Our analyses showed distinct epidemic growth curves for the two epidemics, and we also found evidence suggesting that separate transmission chains may be impacting the viral phylodynamics and the emergence of new recombinant form.</p>', 'Journal of Virology', '90(18)', 3, NULL, 'Graft_HIV_subtC_Brazil_2016', 'hiv, subtype C, origin, Brazil, recombination, Tiago, rio grande do Sul, expansive epidemic, AIDS, high-prevalence, evolution, phylogenetics,hiv, subtype C, origin, Brazil, recombination, Tiago, rio grande do Sul, expansive epidemic, AIDS, high-prevalence, evolution, phylogenetics,hiv, subtype C, origin, Brazil, recombination, Tiago, rio grande do Sul, expansive epidemic, AIDS, high-prevalence, evolution, phylogenetics,hiv, subtype C, origin, Brazil, recombination, Tiago, rio grande do Sul, expansive epidemic, AIDS, high-prevalence, evolution, phylogenetics', 'The AIDS epidemic in south Brazil is expanding rapidly, but the circumstances driving this condition are not well known. A high\rprevalence of HIV-1 subtype C was reported in the capital cities of this region, in contrast to the subtype B dominance in the rest\rof the country. This study sought to comparatively investigate the HIV-1 subtype B and C epidemics by sampling individuals\rfrom several cities in the two states with the highest AIDS incidences in Brazil. Our analyses showed distinct epidemic growth\rcurves for the two epidemics, and we also found evidence suggesting that separate transmission chains may be impacting the\rviral phylodynamics and the emergence of new recombinant forms', '8160-8168', NULL, 2016, NULL, 5.15, 3, NULL, NULL, NULL, NULL),
(134, 'Use of antiretroviral therapy in households and risk of HIV acquisition in rural KwaZulu-Natal, South Africa, 2004-12: a prospective cohort study', '<a href=\"people.php?peopleid=21\">Vandormael A</a>, Newell ML, Barnighausen T, Tanser F', '<p><b><i>Background </b></i> Studies of HIV-serodiscordant couples in stable sexual relationships have provided convincing evidence that antiretroviral therapy can prevent the transmission of HIV. We aimed to quantify the preventive eff ect of a publicsector HIV treatment and care programme based in a community with poor knowledge and disclosure of HIV status, frequent migration, late marriage, and multiple partnerships. Specifically, we assessed whether an individual\'s hazard of HIV acquisition was associated with antiretroviral therapy coverage among household members of the opposite sex. </p>\n<p><b><i>Methods</b></i> In this prospective cohort study, we linked patients\' records from a public-sector HIV treatment programme in rural KwaZulu-Natal, South Africa, with population-based HIV surveillance data collected between 2004 and 2012. We used information about coresidence to construct estimates of HIV prevalence and antiretroviral therapy coverage for each household. We then regressed the time to HIV seroconversion for 14 505 individuals, who were HIV-uninfected at baseline and individually followed up over time regarding their HIV status, on opposite-sex household antiretroviral therapy coverage, controlling for household HIV prevalence and a range of other potential confounders. </p>\n<p><b><i>Findings</b></i> 2037 individual HIV seroconversions were recorded during 54 845 person-years of follow-up. For each increase of ten percentage points in opposite-sex household antiretroviral therapy coverage, the HIV acquisition hazard was reduced by 6% (95% CI 2\'9), after controlling for other factors. This eff ect size translates into large reductions in HIV acquisition hazards when household antiretroviral therapy coverage is substantially increased. For example, an increase of 50 percentage points in household antiretroviral therapy coverage (eg, from 20% to 70%) reduced the hazard of HIV acquisition by 26% (95% CI 9\'39). </p>\n<p><b><i>Interpretation</b></i> Our findings provide further evidence that antiretroviral therapy signifi cantly reduces the risk of onward transmission of HIV in a real-world setting in sub-Saharan Africa. Awareness that antiretroviral therapy can prevent transmission to coresident sexual partners could be a powerful motivator for HIV testing and antiretroviral treatment uptake, retention, and adherence.</p>', 'Lancet Global Health', '2', 12, NULL, 'Vandormael_LancetGH_2014', 'antiretroviral, therapy, ARV, ART, households, risk, HIV, acquisition, rural, KwaZulu-Natal, South Africa, 2004?12, prospective, cohort, study, UKZN, antiretroviral, therapy, ARV, ART, households, risk, HIV, acquisition, rural, KwaZulu-Natal, South Africa, 2004?12, prospective, cohort, study, UKZN, antiretroviral, therapy, ARV, ART, households, risk, HIV, acquisition, rural, KwaZulu-Natal, South Africa, 2004?12, prospective, cohort, study, UKZN, antiretroviral, therapy, ARV, ART, households, risk, HIV, acquisition, rural, KwaZulu-Natal, South Africa, 2004?12, prospective, cohort, study, UKZN', 'Our findings provide further evidence that antiretroviral therapy signifi cantly reduces the risk of\ronward transmission of HIV in a real-world setting in sub-Saharan Africa. Awareness that antiretroviral therapy can\rprevent transmission to coresident sexual partners could be a powerful motivator for HIV testing and antiretroviral\rtreatment uptake, retention, and adherence', 'e209-215', NULL, 2014, NULL, 12, 3, NULL, NULL, NULL, NULL),
(135, 'Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients', '<a href=\"people.php?peopleid=22\">Giandhari J</a>,  Basson AE, Coovadia A, Kuhn L, Abrams AJ, Strehlau R, Morris L, Hunt GM', '<p>Studies have shown a low frequency of HIV-1 protease drug resistance mutations in patients failing protease\rinhibitor (PI)-based therapy. Recent studies have identified mutations in Gag as an alternate pathway for PI drug\rresistance in subtype B viruses.</p>\n<p> We therefore genotyped the Gag and protease genes from 20 HIV-1 subtype Cinfected pediatric patients failing a PI-based regimen. Major protease resistance mutations (M46I, I54V, and V82A) were identified in eight (40%) patients, as well as Gag cleavage site (CS) mutations (at codons 373, 374, 378, 428, 431, 449, 451, and 453) in nine (45%) patients. Four of these Gag CS mutations occurred in the absence of major protease mutations at PI failure. </p>\n<p>In addition, amino acid changes were noted at Gag non-CS with some predicted to be under HLA/KIR immune-mediated pressure and/or drug selection pressure. Changes in Gag during PI failure therefore warrant further investigation of the Gag gene and its role in PI failure in\rHIV-1 subtype C infection.</p>', 'AIDS Res Hum Retroviruses', '31(8)', 3, NULL, 'Genetic_Changes_HIV_Gag_Protease_resistance_peads', 'gag, protease, drug resistance, pediatric, patients, south africa, protease inhibitor, PI, ART, antiretroviral therapy, ARV, Africa, HIV-1, HIV, gag, protease, drug resistance, pediatric, patients, south africa, protease inhibitor, PI, ART, antiretroviral therapy, ARV, Africa, HIV-1, HIV, gag, protease, drug resistance, pediatric, patients, south africa, protease inhibitor, PI, ART, antiretroviral therapy, ARV, Africa, HIV-1, HIV, gag, protease, drug resistance, pediatric, patients, south africa, protease inhibitor, PI, ART, antiretroviral therapy, ARV, Africa, HIV-1, HIV', 'Studies have shown a low frequency of HIV-1 protease drug resistance mutations in patients failing protease\rinhibitor (PI)-based therapy. Recent studies have identified mutations in Gag as an alternate pathway for PI drug\rresistance in subtype B viruses. We therefore genotyped the Gag and protease genes from 20 HIV-1 subtype Cinfected\rpediatric patients failing a PI-based regimen. Major protease resistance mutations (M46I, I54V, and\rV82A) were identified in eight (40%) patients, as well as Gag cleavage site (CS) mutations (at codons 373, 374,\r378, 428, 431, 449, 451, and 453) in nine (45%) patients', '776-82', NULL, 2015, 'doi: 10.1089/AID.2014.0349', 2.457, 3, NULL, NULL, NULL, NULL),
(136, 'Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy', '<a href=\"people.php?peopleid=22\">Giandhari J</a>, Basson AE, Sutherland K, Parry CM, Cane PA, Coovadia A, Kuhn L, Hunt G, Morris L', '<p>Protease inhibitors (PIs) are used as a first-line regimen in HIV-1-infected children. Here we investigated the phenotypic consequences of amino acid changes in Gag and protease on lopinavir (LPV) and ritonavir (RTV) susceptibility among pediatric patients failing PI therapy. </p>\n<p>The Gag-protease from isolates from 20 HIV-1 subtype C-infected pediatric patients failing an LPV and/or RTV-based regimen was phenotyped using a nonreplicativein vitroassay. Changes in sensitivity to LPV and RTV relative to that of the matched baseline (pretherapy) sample were calculated. Gag and protease amino acid substitutions associated with PI failure were created in a reference clone by site-directed mutagenesis and assessed. Predicted phenotypes were determined using the Stanford drug resistance algorithm. </p>\n<p>Phenotypic resistance or reduced susceptibility to RTV and/or LPV was observed in isolates from 10 (50%) patients, all of whom had been treated with RTV. In most cases, this was associated with protease resistance mutations, but substitutions at Gag cleavage and noncleavage sites were also detected. Gag amino acid substitutions were also found in isolates from three patients with reduced drug susceptibilities who had wild-type protease. Site-directed mutagenesis confirmed that some amino acid changes in Gag contributed to PI resistance but only in the presence of major protease resistance-associated substitutions. The isolates from all patients who received LPV exclusively were phenotypically susceptible. Baseline isolates from the 20 patients showed a large (47-fold) range in the 50% effective concentration of LPV, which accounted for most of the discordance seen between the experimentally determined and the predicted phenotypes. </p>\n<p>Overall, the inclusion of thegaggene and the use of matched baseline samples provided a more comprehensive assessment of the effect of PI-induced amino acid changes on PI resistance. The lack of phenotypic resistance to LPV supports the continued use of this drug in pediatric patients.</p>', 'Antimicrob Agents Chemother.', '60(4)', 5, NULL, 'Gag_Protease_HIVPhenotypicDrugResistance_Giandhari', 'gag, protease, phenotipic, resistance, genotypic, pediatric, paeds, protease inhibitor, PIS, antiretroviral therapy, ARV, ART, south africa, HIV-1, drug resistance, resistance, NICD, sequence,gag, protease, phenotipic, resistance, genotypic, pediatric, paeds, protease inhibitor, PIS, antiretroviral therapy, ARV, ART, south africa, HIV-1, drug resistance, resistance, NICD, sequence,gag, protease, phenotipic, resistance, genotypic, pediatric, paeds, protease inhibitor, PIS, antiretroviral therapy, ARV, ART, south africa, HIV-1, drug resistance, resistance, NICD, sequence,gag, protease, phenotipic, resistance, genotypic, pediatric, paeds, protease inhibitor, PIS, antiretroviral therapy, ARV, ART, south africa, HIV-1, drug resistance, resistance, NICD, sequence, mutation', 'the inclusion of\rthe gag gene and the use of matched baseline samples provided a more comprehensive assessment of the effect of PI-induced\ramino acid changes on PI resistance. The lack of phenotypic resistance to LPV supports the continued use of this drug in pediatric\rpatients', '2248-56', NULL, 2016, 'doi: 10.1128/AAC.02682-15', 4.598, 3, NULL, NULL, NULL, NULL),
(137, 'Genome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug Resistance', 'Power RA, Davaniah S, Derache A, <a href=\"people.php?peopleid=3\">Wilkinson E</a>, Tanser F, Gupta RK, Pillay D, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p><b><i>BACKGROUND:</b></i> Genome-wide association studies (GWAS) have considerably advanced our understanding of human traits and diseases. With the increasing availability of whole genome sequences (WGS) for pathogens, it is important to establish whether GWAS of viral genomes could reveal important biological insights. Here we perform the first proof of concept viral GWAS examining drug resistance (DR), a phenotype with well understood genetics.\n</p><p><b><i>METHOD:</b></i> We performed a GWAS of DR in a sample of 343 HIV subtype C patients failing 1st line antiretroviral treatment in rural KwaZulu-Natal, South Africa. The majority and minority variants within each sequence were called using PILON, and GWAS was performed within PLINK. HIV WGS from patients failing on different antiretroviral treatments were compared to sequences derived from individuals nave to the respective treatment.\n</p><p><b><i>RESULTS:</b></i> GWAS methodology was validated by identifying five associations on a genetic level that led to amino acid changes known to cause DR. Further, we highlighted the ability of GWAS to identify epistatic effects, identifying two replicable variants within amino acid 68 of the reverse transcriptase protein previously described as potential fitness compensatory mutations. A possible additional DR variant within amino acid 91 of the matrix region of the Gag protein was associated with tenofovir failure, highlighting GWAS\'s ability to identify variants outside classical candidate genes. Our results also suggest a polygenic component to DR.\n</p><p><b><i>CONCLUSIONS:</b></i> These results validate the applicability of GWAS to HIV WGS data even in relative small samples, and emphasise how high throughput sequencing can provide novel and clinically relevant insights. Further they suggested that for viruses like HIV, population structure was only minor concern compared to that seen in bacteria or parasite GWAS. Given the small genome length and reduced burden for multiple testing, this makes HIV an ideal candidate for GWAS.</p>\n', 'PLoS One', '11(9)', 3, NULL, 'HIV_drug_resistance_GWAS_PLosOne_Rob_Power_2016', 'Genome-Wide, Association, Study, GWAS, HIV, Whole, Genome, Sequences, Drug, Resistance, HIVDR, HIV-1, genome wide association study, subtype C, Rob Power, Tulio de Oliveira, microbial, GWAS,Genome-Wide, Association, Study, GWAS, HIV, Whole, Genome, Sequences, Drug, Resistance, HIVDR, HIV-1, genome wide association study, subtype C, Rob Power, Tulio de Oliveira, microbial, GWAS,Genome-Wide, Association, Study, GWAS, HIV, Whole, Genome, Sequences, Drug, Resistance, HIVDR, HIV-1, genome wide association study, subtype C, Rob Power, Tulio de Oliveira, microbial, GWAS,Genome-Wide, Association, Study, GWAS, HIV, Whole, Genome, Sequences, Drug, Resistance, HIVDR, HIV-1, genome wide association study, subtype C, Rob Power, Tulio de Oliveira, microbial, GWAS,Genome-Wide, Association, Study, GWAS, HIV, Whole, Genome, Sequences, Drug, Resistance, HIVDR, HIV-1, genome wide association study, subtype C, Rob Power, Tulio de Oliveira, microbial, GWAS,', 'Genome-wide association studies (GWAS)results validate the applicability of GWAS to HIV WGS data even in relative small samples, and emphasise how high throughput sequencing can provide novel and clinically relevant insights. Further they suggested that for viruses like HIV, population structure was only minor concern compared to that seen in bacteria or parasite GWAS', 'e0163746', NULL, 2016, 'doi: 10.1371/journal.pone.0163746', 4.441, 3, NULL, NULL, NULL, NULL),
(138, 'Microbial genome-wide association studies: lessons from human GWAS', 'Power RA, Parkhill J,  <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>The reduced costs of sequencing have led to whole-genome sequences for a large number of microorganisms, enabling the application of microbial genome-wide association studies (GWAS). Given the successes of human GWAS in understanding disease aetiology and identifying potential drug targets, microbial GWAS are likely to further advance our understanding of infectious diseases. These advances include insights into pressing global health problems, such as antibiotic resistance and disease transmission. </p><p>In this Review, we outline the methodologies of GWAS, the current state of the field of microbial GWAS, and how lessons from human GWAS can direct the future of the field.</p>', 'Nature Reviews Genetics', 'nrg.2016.132', 3, NULL, 'Microbial_GWAS_Nature_Reviews_Genetics_2016', 'GWAS, reduced, costs, sequencing, whole-genome, sequences, large, number, microorganisms, enabling, application, microbial, genome-wide, association, studies, GWAS, disease, aetiology, identifying, potential, drug targets, microbial GWAS, advance, understanding, infectious diseases, HIV, TB, micobacterium, tuberculosis, malaria, plasmodium falciparum, Nature, reviews, review, Tulio de Oliveira, Rob Power, Wellcome trust sanger institute, Jullian Parkhill, Nature Reviews Genetics, genetics, bioinformatics, reduced, costs, sequencing, whole-genome, sequences, large, number, microorganisms, enabling, application, microbial, genome-wide, association, studies, GWAS, disease, aetiology, identifying, potential, drug targets, microbial GWAS, advance, understanding, infectious diseases, HIV, TB, micobacterium, tuberculosis, malaria, plasmodium falciparum, Nature, reviews, review, Tulio de Oliveira, Rob Power, Wellcome trust sanger institute, Jullian Parkhill, Nature Reviews Genetics, genetics, bioinformatics', 'The reduced costs of sequencing have led to whole-genome sequences for a large number of microorganisms, enabling the application of microbial genome-wide association studies (GWAS). Given the successes of human GWAS in understanding disease aetiology and identifying potential drug targets, microbial GWAS are likely to further advance our understanding of infectious diseases. These advances include insights into pressing global health problems, such as antibiotic resistance and disease transmission. In this Review, we outline the methodologies of GWAS, the current state of the field of microbial GWAS, and how lessons from human GWAS can direct the future of the field', 'doi:10.1038/nrg.2016.132', NULL, 2017, 'doi:10.1038/nrg.2016.132', 35.989, 3, NULL, NULL, 'Y', NULL),
(139, 'Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study', '<a href=\"people.php?peopleid=1\">de Oliveira T</a>, Kharsany ABM, Graf T, Cawood C, Khanyile D, Grobler A, Puren A, Madurai S, Baxter C, Karim QA, Karim SSA', '<p><b><i>Background</b></i> The incidence of HIV infection in young women in Africa is very high. We did a large-scale community-wide phylogenetic study to examine the underlying HIV transmission dynamics and the source and consequences of high rates of HIV infection in young women in South Africa. </p>\n<p><b><i>Methods</b></i> We did a cross-sectional household survey of randomly selected individuals aged 15-49 years in two neighbouring subdistricts (one urban and one rural) with a high burden of HIV infection in KwaZulu-Natal, South Africa. Participants completed structured questionnaires that captured general demographic, socioeconomic, psychosocial, and behavioural data. Peripheral blood samples were obtained for HIV antibody testing. Samples with HIV RNA viral load greater than 1000 copies per mL were selected for genotyping. We constructed a phylogenetic tree to identify clusters of linked infections (defi ned as two or more sequences with bootstrap or posterior support >90% and genetic distance <4.5%). </p>\n<p><b><i>Findings</b></i> From June 11, 2014, to June 22, 2015, we enrolled 9812 participants, 3969 of whom tested HIV positive. HIV prevalence (weighted) was 59.8% in 2835 women aged 25-40 years, 40.3% in 1548 men aged 25-40 years, 22.3% in 2224 women younger than 25 years, and 7.6% in 1472 men younger than 25 years. HIV genotyping was done in 1589 individuals with a viral load of more than 1000 copies per mL. In 90 transmission clusters, 123 women were linked to 103 men. Of 60 possible phylogenetically linked pairings with the 43 women younger than 25 years, 18 (30.0%) probable male partners were younger than 25 years, 37 (61.7%) were aged 25-40 years, and fi ve (8.3%) were aged 41-49 years: mean age diff erence 8.7 years (95% CI 6.8-10.6; p<0.0001). For the 92 possible phylogenetically linked pairings with the 56 women aged 25-40 years, the age diff erence dropped to 1.1 years (95% CI -0.6 to 2.8; p=0.111). 16 (39.0%) of 41 probable male partners linked to women younger than 25 years were also linked to women aged 25-40 years. Of 79 men (mean age 31.5 years) linked to women younger than 40 years, 62 (78.5%) were unaware of their HIV-positive status, 76 (96.2%) were not on antiretroviral therapy, and 29 (36.7%) had viral loads of more than 50 000 copies per mL. </p>\n<p><b><i>Interpretation</b></i> Sexual partnering between young women and older men, who might have acquired HIV from women of similar age, is a key feature of the sexual networks driving transmission. Expansion of treatment and combination prevention strategies that include interventions to address age-disparate sexual partnering is crucial to reducing HIV incidence and enabling Africa to reach the goal of ending AIDS as a public health threat. </p>\n<p><b><i>Funding</b></i> President\'s Emergency Program for AIDS Relief, US Centers for Disease Control and Prevention, South African Medical Research Council, and MAC AIDS Fund.</p>', 'Lancet HIV', 'http://dx.doi.org/10.1016/S2352-3018(16)30186-2', 5, NULL, 'deOliveira_phylogenetics_youngWoman_LancetHIV2016', 'Transmission, networks, risk, HIV, infection, KwaZulu-Natal, South Africa, community-wide, community, phylogenetic, study, phylogeny, young woman, older men, men, adolescent, CAPRISA, de Oliveira, Lancet, HIV-1, Lancet HIV, AIDS, Transmission, networks, risk, HIV, infection, KwaZulu-Natal, South Africa, community-wide, community, phylogenetic, study, phylogeny, young woman, older men, men, adolescent, CAPRISA, de Oliveira, Lancet, HIV-1, Lancet HIV, AIDS, Transmission, networks, risk, HIV, infection, KwaZulu-Natal, South Africa, community-wide, community, phylogenetic, study, phylogeny, young woman, older men, men, adolescent, CAPRISA, de Oliveira, Lancet, HIV-1, Lancet HIV, AIDS, Transmission, networks, risk, HIV, infection, KwaZulu-Natal, South Africa, community-wide, community, phylogenetic, study, phylogeny, young woman, older men, men, adolescent, CAPRISA, de Oliveira, Lancet, HIV-1, Lancet HIV, AIDS, Transmission, networks, risk, HIV, infection, KwaZulu-Natal, South Africa, community-wide, community, phylogenetic, study, phylogeny, young woman, older men, men, adolescent, CAPRISA, de Oliveira, Lancet, HIV-1, Lancet HIV, AIDS, Salim Abdool Karim', 'The incidence of HIV infection in young women in Africa is very high. We did a large-scale community-wide phylogenetic study to examine the underlying HIV transmission dynamics and the source and consequences of high rates of HIV infection in young women in South Africa.Sexual partnering between young women and older men, who might have acquired HIV from women of similar age, is a key feature of the sexual networks driving transmission', '', NULL, 2017, NULL, 11, 3, NULL, NULL, 'Y', 2);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(140, 'Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study', 'Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK', '<p><b><i>BACKGROUND:</b></i> HIV-1 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identified in sub-Saharan Africa in patients with virological failure of first-line combination antiretroviral therapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir. We aimed to investigate the prevalence and correlates of thymidine analogue mutations (TAM) in patients with virological failure of first-line tenofovir-containing ART.</p>\n<p><b><i>METHODS:</b></i> We retrospectively analysed patients from 20 studies within the TenoRes collaboration who had locally defined viral failure on first-line therapy with tenofovir plus a cytosine analogue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa. Baseline visits in these studies occurred between 2005 and 2013. To assess between-study and within-study associations, we used meta-regression and meta-analyses to compare patients with and without TAMs for the presence of resistance to tenofovir, cytosine analogue, or NNRTIs.</p>\n<p><b><i>FINDINGS:</b></i> Of 712 individuals with failure of first-line tenofovir-containing regimens, 115 (16%) had at least one TAM. In crude comparisons, patients with TAMs had lower CD4 counts at treatment initiation than did patients without TAMs (60.5 cells per ?L [IQR 21.0-128.0] in patients with TAMS vs 95.0 cells per ?L [37.0-177.0] in patients without TAMs; p=0.007) and were more likely to have tenofovir resistance (93 [81%] of 115 patients with TAMs vs 352 [59%] of 597 patients without TAMs; p<0.0001), NNRTI resistance (107 [93%] vs 462 [77%]; p<0.0001), and cytosine analogue resistance (100 [87%] vs 378 [63%]; p=0.0002). We detected associations between TAMs and drug resistance mutations both between and within studies; the correlation between the study-level proportion of patients with tenofovir resistance and TAMs was 0.64 (p<0.0001), and the odds ratio for tenofovir resistance comparing patients with and without TAMs was 1.29 (1.13-1.47; p<0.0001) </p>\n<p><b><i>INTERPRETATION:</b></i> TAMs are common in patients who have failure of first-line tenofovir-containing regimens in sub-Saharan Africa, and are associated with multidrug resistant HIV-1. Effective viral load monitoring and point-of-care resistance tests could help to mitigate the emergence and spread of such strains.</p>\n<p><b><i>', 'Lancet Infectious Diseases', 'pii: S1473-3099(16)30469-8', 5, NULL, 'HIVdrugresistance_NRTI_SouthAfrica_LancetID2016', 'HIV-1, drug, resistance, older, thymidine, analogue, nucleoside, reverse, transcriptase, inhibitor, drugs, sub-Saharan, patients, virological, failure, first-line, combination, antiretroviral, therapy, ART, Tenofovir, TDF, Africa, HIV, de Oliveira, SATURN, MRC, HIV-1, drug, resistance, older, thymidine, analogue, nucleoside, reverse, transcriptase, inhibitor, drugs, sub-Saharan, patients, virological, failure, first-line, combination, antiretroviral, therapy, ART, Tenofovir, TDF, Africa, HIV, de Oliveira, SATURN, MRC, HIV-1, drug, resistance, older, thymidine, analogue, nucleoside, reverse, transcriptase, inhibitor, drugs, sub-Saharan, patients, virological, failure, first-line, combination, antiretroviral, therapy, ART, Tenofovir, TDF, Africa, HIV, de Oliveira, SATURN, MRC', 'Lancet Infectious Diseases publication 2016 that show that TAMs are common in patients who have failure of first-line tenofovir-containing regimens in sub-Saharan Africa, and are associated with multidrug resistant HIV-1. Effective viral load monitoring and point-of-care resistance tests could help to mitigate the emergence and spread of such strains', 'http://dx.doi.org/10.1016/S1473-3099(16)30447-9', NULL, 2017, 'http://dx.doi.org/10.1016/S1473-3099(16)30447-9', 16.144, 3, NULL, NULL, NULL, NULL),
(141, 'Spread of yellow fever virus outbreak in Angola and the Democratic Republic of the Congo 2015-16: a modelling study', 'Kraemer MUG, Faria NR, Reiner Jr RC, Golding N, Nikolay B, Stasse S, Johansson MA, Salje H, Faye O, Wint GRW, Niedrig M, Shearer FM, Hill SC, Thompson RN, Bisanzio D, Taveira N, Nax HH, Pradelski BSR, Nsoesie EO, Murphy NR, Bogoch II, Khan K, Brownstein JS, Tatem AJ, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Smith DL, Sall AA, Pybus OG, Hay SI, Cauchemez S', '<p><b><i>Background</b></i> Since late 2015, an epidemic of yellow fever has caused more than 7334 suspected cases in Angola and the Democratic Republic of the Congo, including 393 deaths. We sought to understand the spatial spread of this outbreak to optimise the use of the limited available vaccine stock. \n</p><p><b><i>Methods</b></i> We jointly analysed datasets describing the epidemic of yellow fever, vector suitability, human demography, and mobility in central Africa to understand and predict the spread of yellow fever virus. We used a standard logistic model to infer the district-specific yellow fever virus infection risk during the course of the epidemic in the region. \n</p><p><b><i>Findings</b></i> The early spread of yellow fever virus was characterised by fast exponential growth (doubling time of 5-7 days) and fast spatial expansion (49 districts reported cases after only 3 months) from Luanda, the capital of Angola. Early invasion was positively correlated with high population density (Pearson\'s r 0.52, 95% CI 0.34-0.66). The further away locations were from Luanda, the later the date of invasion (Pearson\'s r 0.60, 95% CI 0.52-0.66). In a Cox model, we noted that districts with higher population densities also had higher risks of sustained transmission (the hazard ratio for cases ceasing was 0.74, 95% CI 0.13-0.92 per log-unit increase in the population size of a district). A model that captured human mobility and vector suitability successfully discriminated districts with high risk of invasion from others with a lower risk (area under the curve 0.94, 95% CI 0.92-0.97). If at the start of the epidemic, sufficient vaccines had been available to target 50 out of 313 districts in the area, our model would have correctly identified 27 (84%) of the 32 districts that were eventually affected. </p><p><b><i>Interpretation</b></i> Our findings show the contributions of ecological and demographic factors to the ongoing spread of the yellow fever outbreak and provide estimates of the areas that could be prioritised for vaccination, although other constraints such as vaccine supply and delivery need to be accounted for before such insights can be translated into policy.</p>', 'Lancet Infectious Diseases', 'http://dx.doi.org/10.1016/S1473-3099(16)30513-8', 3, NULL, 'Kraemer_LID_YellowFever_DRC_Africa_2016', 'yellow fever, africa, YFV, virus, spread, Angola, DRC, democratic republic of congo, viral spread, geography, lancet, Faria, de Oliveira, Moritz  Kraemer, Oliver Pybus, Lancegt infectious diseases, 2016, yellow fever, africa, YFV, virus, spread, Angola, DRC, democratic republic of congo, viral spread, geography, lancet, Faria, de Oliveira, Moritz  Kraemer, Oliver Pybus, Lancegt infectious diseases, 2016, yellow fever, africa, YFV, virus, spread, Angola, DRC, democratic republic of congo, viral spread, geography, lancet, Faria, de Oliveira, Moritz  Kraemer, Oliver Pybus, Lancegt infectious diseases, 2016, yellow fever, africa, YFV, virus, spread, Angola, DRC, democratic republic of congo, viral spread, geography, lancet, Faria, de Oliveira, Moritz  Kraemer, Oliver Pybus, Lancegt infectious diseases, 2016', 'Lancet Infectious Diseases publication on Yellow fever spread in 2016. Since late 2015, an epidemic of yellow fever has caused more than 7334 suspected cases in Angola and the Democratic Republic of the Congo, including 393 deaths. We sought to understand the spatial spread of this outbreak to optimise the use of the limited available vaccine stock.', NULL, NULL, 2017, 'http://dx.doi.org/10.1016/S1473-3099(16)30513-8', 16.144, 3, NULL, NULL, NULL, NULL),
(142, 'HTLV-1aA introduction into Brazil and its association with the trans-Atlantic slave trade', 'Amoussa AE, Wilkinson E, Giovanetti M, de Almeida Rego FF, Araujo TH, de Souza Goncalves M, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Alcantara LC', '<p><b><i>INTRODUCTION:</b></i> Human T-lymphotropic virus (HTLV) is an endemic virus in some parts of the world, with Africa being home to most of the viral genetic diversity. In Brazil, HTLV-1 is endemic amongst Japanese and African immigrant populations. Multiple introductions of the virus in Brazil from other epidemic foci were hypothesized. The long terminal repeat (LTR) region of HTLV-1 was used to infer the origin of the virus in Brazil, using phylogenetic analysis.\n</p><p><b><i>METHODS:</b></i> LTR sequences were obtained from the HTLV-1 database (http://htlv1db.bahia.fiocruz.br). Sequences were aligned and maximum-likelihood and Bayesian tree topologies were inferred. Brazilian specific clusters were identified and molecular-clock and coalescent models were used to estimate each cluster\'s time to the most recent common ancestor (tMRCA).\n</p><p><b><i>RESULTS:</b></i> Three Brazilian clusters were identified with a posterior probability ranged from 0.61 to 0.99. Molecular clock analysis of these three clusters dated back their respective tMRCAs between the year 1499 and the year 1668. Additional analysis also identified a close association between Brazilian sequences and new sequences from South Africa.\n</p><p><b><i>CONCLUSION:</b></i> Our results support the hypothesis of a multiple introductions of HTLV-1 into Brazil, with the majority of introductions occurring in the post-Colombian period. Our results further suggest that HTLV-1 introduction into Brazil was facilitated by the trans-Atlantic slave trade from endemic areas of Africa. The close association between southern African and Brazilian sequences also suggested that greater numbers of the southern African Bantu population might also have been part of the slave trade than previously thought.</p>\n\n', 'Infection, Genetics and Evolution', '48', 2, NULL, NULL, 'HTLV-1, Brazil, HTLV, Southern Africa, Trans-Atlantic slave trade, BEAST, tMRCA, most recent common ancestor, molecular clock, FioCruz, Alcantara, de Oliveira, Eduan Wilkinson, HTLV-1, Brazil, HTLV, Southern Africa, Trans-Atlantic slave trade, BEAST, tMRCA, most recent common ancestor, molecular clock, FioCruz, Alcantara, de Oliveira, Eduan Wilkinson, HTLV-1, Brazil, HTLV, Southern Africa, Trans-Atlantic slave trade, BEAST, tMRCA, most recent common ancestor, molecular clock, FioCruz, Alcantara, de Oliveira, Eduan Wilkinson, HTLV-1, Brazil, HTLV, Southern Africa, Trans-Atlantic slave trade, BEAST, tMRCA, most recent common ancestor, molecular clock, FioCruz, Alcantara, de Oliveira, Eduan Wilkinson', 'Human T-lymphotropic virus (HTLV) is an endemic virus in some parts of the world, with Africa being home to most of the viral genetic diversity. Our results support the hypothesis of a multiple introductions of HTLV-1 into Brazil, with the majority of introductions occurring in the post-Colombian period. Our results further suggest that HTLV-1 introduction into Brazil was facilitated by the trans-Atlantic slave trade from endemic areas of Africa. The close association between southern African and Brazilian sequences also suggested that greater numbers of the southern African Bantu population might also have been part of the slave trade than previously thought', 'doi: 10.1016/j.meegid.2016.12.005', NULL, 2016, ' doi: 10.1016/j.meegid.2016.12.005', 3.015, 3, NULL, NULL, NULL, NULL),
(143, 'Complex subtype diversity of HIV-1 among drug users in major Kenyan cities', 'Gounder K, Oyaro M, Padayachi N, Zulu TM,<a href=\"people.php?peopleid=1\">de Oliveira T</a>, Wylie J, Ndung\'u T', '<p>Drug users are increasingly recognized as a key population driving HIV spread in sub-Saharan Africa. To determine HIV-1 subtypes circulating in this population group and explore possible geographic differences, we analyzed HIV-1 sequences among drug users from Nairobi, Mombasa and Kisumu in Kenya.</p><p> We sequenced gag and env from 55 drug users. Subtype analysis from 220 gag clonal sequences from 54/55 participants (median=4/participant) showed that 44.4% were A, 16.7% were C, 3.7% were D and 35.2% were intersubtype recombinants. Of 156 env clonal sequences from 48/55 subjects (median=3/participant), 45.8% were subtype A, 14.6% were C, 6.3% were D and 33.3% were recombinants. Comparative analysis of both genes showed that 30 (63.8%) participants had concordant subtypes while 17 (36.2%) were discordant. </p><p>We identified one genetically-linked transmission pair and 2 cases of dual infection. These data are indicative of extensive HIV-1 intersubtype recombination in Kenya and suggest decline in subtype D prevalence.</p>\n', 'AIDS Res Hum Retroviruses', NULL, 2, NULL, NULL, 'Complex, subtype, diversity, HIV-1, drug users, Kenyan, cities, key population, driving, HIV spread,sub-Saharan Africa, extensive, HIV-1, intersubtype, recombination, Kenya, decline, subtype D, prevalence\n', 'Drug users are increasingly recognized as a key population driving HIV spread in sub-Saharan Africa. To determine HIV-1 subtypes circulating in this population group and explore possible geographic differences, we analyzed HIV-1 sequences among drug users from Nairobi, Mombasa and Kisumu in Kenya. We sequenced gag and env from 55 drug users. We identified one genetically-linked transmission pair and 2 cases of dual infection. These data are indicative of extensive HIV-1 intersubtype recombination in Kenya and suggest decline in subtype D prevalence.', '10.1089/AID.2016.0321', NULL, 2017, 'doi: 10.1089/AID.2016.0321', 2.457, 3, NULL, NULL, NULL, NULL),
(144, 'Sensitive next generation sequencing method reveals deep genetic diversity of HIV-1 in the Democratic Republic of the Congo', 'Rodgers MA, Wilkerson E, Vallari A, McArthur C, Sthreshley L, Brennan CA, Cloherty G, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>As the epidemiological epicentre of the human immunodeficiency virus (HIV) pandemic, the Democratic Republic of the Congo (DRC) is a reservoir of circulating HIV strains exhibiting high levels of diversity and recombination. In this study, we characterized HIV specimens collected in two rural areas of the DRC between 2001 and 2003 to identify rare strains of HIV.</p><p> The env gp41 region was sequenced and characterized for 172 HIV-positive specimens. The env sequences were predominantly subtype A (43.02%), but 7 other subtypes (33.14%), 20 circulating recombinant forms (CRFs: 11.63%), and 20 unclassified (11.63%) sequences were also found. Of the rare and unclassified subtypes, 18 specimens were selected for next generation sequencing (NGS) by a modified HIV-SMART method to obtain full genome sequences. NGS produced 14 new complete genomes, which included pure subtypes C (n=2), D (n=1), F1 (n=1), H (n=3), and J (n=1). </p><p>The two Cs and one of the H genomes branched basal to their respective subtype branches but had no evidence of recombination. The remaining 6 genomes were complex recombinants of 2 or more subtypes, including A1, F, G, H, J, K, and unclassified fragments, including one CRF25 isolate, which branched basal to all CRF25 references. Notably, all recombinant H fragments branched basal to the H clade. </p><p>Spatial-geographical analysis indicated that the diverse sequences identified here did not expand globally. The full- and sub-genomic sequences identified in our study population significantly increase the documented diversity of the continually evolving HIV-1 pandemic.</p><p>\n\n<b><i>IMPORTANCE:</b></i></p>\n\n<p>Very little is known about the ancestral HIV-1 strains that founded the global pandemic, and very few complete genome sequences are available from patients in the Congo Basin where HIV-1 expanded early in the global pandemic. By sequencing a sub-genomic fragment of the HIV-1 envelope from study participants in the DRC, we identified rare variants for complete genome sequencing. The basal branching of some of the complete genome sequences we recovered suggests that these strains are more closely related to ancestral HIV-1 sequences than to previously reported strains and is evidence that the local diversification of HIV in the DRC continues to outpace the diversity of global strains decades after the emergence of the pandemic.</p>', 'Journal of Virology', 'JVI.01841-16', 10, NULL, 'Rodgers_Sensitive_NGS_Whole_GenomeHIV_NGS_DRC', 'Sensitive, next generation sequencing, NGS, method, reveals, deep, genetic, diversity, HIV-1, Democratic Republic of the Congo, Congo Basin, Spatial-geographical, globally, subtype C, origin, basal, emergency, pandemic, de Oliveira, Abbott, DNA, sequencing, method,Sensitive, next generation sequencing, NGS, method, reveals, deep, genetic, diversity, HIV-1, Democratic Republic of the Congo, Congo Basin, Spatial-geographical, globally, subtype C, origin, basal, emergency, pandemic, de Oliveira, Abbott, DNA, sequencing, method,Sensitive, next generation sequencing, NGS, method, reveals, deep, genetic, diversity, HIV-1, Democratic Republic of the Congo, Congo Basin, Spatial-geographical, globally, subtype C, origin, basal, emergency, pandemic, de Oliveira, Abbott, DNA, sequencing, method,Sensitive, next generation sequencing, NGS, method, reveals, deep, genetic, diversity, HIV-1, Democratic Republic of the Congo, Congo Basin, Spatial-geographical, globally, subtype C, origin, basal, emergency, pandemic, de Oliveira, Abbott, DNA, sequencing, method', 'Sensitive next generation sequencing method reveals deep genetic diversity of HIV-1 in the Democratic Republic of the Congo. Spatial-geographical analysis indicated that the diverse sequences identified here did not expand globally. The full- and sub-genomic sequences identified in our study population significantly increase the documented diversity of the continually evolving HIV-1 pandemic', 'doi: 10.1128/JVI.01841-16', NULL, 2017, 'doi: 10.1128/JVI.01841-16', 5.15, 3, NULL, NULL, '', NULL),
(145, 'Pairwise diversity and tMRCA as potential markers for HIV infection recency', 'Moyo S,<a href=\"people.php?peopleid=4\"> Wilkinson E</a>, <a href=\"people.php?peopleid=21\">Vandormael A</a>, Wang R, Weng J, Kotokwe KP, Gaseitsiwe S, Musonda R, Makhema J, Essex M, Engelbrecht S, <a href=\"people.php?peopleid=1\">de Oliveira T</a>, Novitsky V\n', '<p>Intrahost human immunodeficiency virus (HIV)-1 diversity increases linearly over time. We assessed the extent to which mean pairwise distances and the time to the most recent common ancestor (tMRCA) inferred from intrahost HIV-1C env sequences were associated with the estimated time of HIV infection. </p><p>Data from a primary HIV-1C infection study in Botswana were used for this analysis (N?=?42). A total of 2540 HIV-1C env gp120 variable loop region 1 to conserved region 5 (V1C5) of the HIV-1 envelope gp120 viral sequences were generated by single genome amplification and sequencing, with an average of 61 viral sequences per participant and 11 sequences per time point per participant. Raw pairwise distances were calculated for each time point and participant using the ape package in R software. The tMRCA was estimated using phylogenetic inference implemented in Bayesian Evolutionary Analysis by Sampling Trees v1.8.2. </p><p>Pairwise distances and tMRCA were significantly associated with the estimated time since HIV infection (both P?<?0.001). Taking into account multiplicity of HIV infection strengthened these associations. HIV-1C env-based pairwise distances and tMRCA can be used as potential markers for HIV recency. However, the tMRCA estimates demonstrated no advantage over the pairwise distances estimates.</p>', 'Medicine (Baltimore)', '96', 1, NULL, 'Moyo_Pairwise_diversity_tMRCA_recency_markers2017', 'Pairwise, diversity, tMRCA, time to most common recent ancestor, potential, markers, HIV, HIV-1, infection, recency, time to sero convertion,Botswana, harvard, UKZN, de Oliveira, Moyo, Wilkinson, paper, open access, sequence, phylogeny, Africa, Pairwise, diversity, tMRCA, time to most common recent ancestor, potential, markers, HIV, HIV-1, infection, recency, time to sero convertion,Botswana, harvard, UKZN, de Oliveira, Moyo, Wilkinson, paper, open access, sequence, phylogeny, Africa, Pairwise, diversity, tMRCA, time to most common recent ancestor, potential, markers, HIV, HIV-1, infection, recency, time to sero convertion,Botswana, harvard, UKZN, de Oliveira, Moyo, Wilkinson, paper, open access, sequence, phylogeny, Africa, Pairwise, diversity, tMRCA, time to most common recent ancestor, potential, markers, HIV, HIV-1, infection, recency, time to sero convertion,Botswana, harvard, UKZN, de Oliveira, Moyo, Wilkinson, paper, open access, sequence, phylogeny, Africa', 'Intrahost human immunodeficiency virus (HIV)-1 diversity increases linearly over time. We assessed the extent to which mean pairwise distances and the time to the most recent common ancestor (tMRCA) inferred from intrahost HIV-1C env sequences were associated with the estimated time of HIV infection. ', 'doi: 10.1097/MD.0000000000006041', NULL, 2017, 'doi: 10.1097/MD.0000000000006041', 2.133, 3, NULL, NULL, NULL, NULL),
(146, 'Primary HIV-1 Drug Resistant Minority Variants', '<a href=\"people.php?peopleid=23\">Chimukangara B</a>, Samuel R, Naidoo K, <a href=\"people.php?peopleid=1\">de Oliveira T</a>', '<p>Primary HIV drug resistant mutations are mutations that occur in an HIV-infected individual prior to the initiation of antiretroviral therapy (ART). These mutations may arise by de novo mutagenesis or result from transmission. Drug resistant mutations (DRMs) may reduce the effectiveness of ART leading to inadequate virological outcomes. </p><p>Currently, Sanger sequencing is the standard method for detection of DRMs to inform treatment decisions, but does not detect minor variant mutations. Drug resistant minority variants (DRMVs) can be detected by next generation sequencing (NGS). However, several challenges including cost of infrastructure and the need for complex data analysis bioinformatics tools remain major setbacks for NGS use. </p><p>More importantly, the clinical impact of DRMVs on ART is not well understood, underscoring the importance for understanding whether the levels of primary DRMVs for different mutations impact on the effectiveness of ART and the rationale for inclusion in routine diagnostics. Understanding the impact of primary DRMVs will help inform how NGS may be utilized in the future for pre-emptive clinical ART decision making.</p>', 'AIDS Reviews', '19(2)', 5, NULL, NULL, 'AIDS, reviews, review, next generation sequencing, NGS, Sanger, sequences, DNA, Primary, HIV-1,  Drug, Resistant, Minority, Variants, clinical impact, drug resistance, HIV, de Oliveira, minor, Chimukangara, Benjamin, Tulio, Open access, Durban, South Africa, AIDS, reviews, review, next generation sequencing, NGS, Sanger, sequences, DNA, Primary, HIV-1,  Drug, Resistant, Minority, Variants, clinical impact, drug resistance, HIV, de Oliveira, minor, Chimukangara, Benjamin, Tulio, Open access, Durban, South Africa, AIDS, reviews, review, next generation sequencing, NGS, Sanger, sequences, DNA, Primary, HIV-1,  Drug, Resistant, Minority, Variants, clinical impact, drug resistance, HIV, de Oliveira, minor, Chimukangara, Benjamin, Tulio, Open access, Durban, South Africa, AIDS, reviews, review, next generation sequencing, NGS, Sanger, sequences, DNA, Primary, HIV-1,  Drug, Resistant, Minority, Variants, clinical impact, drug resistance, HIV, de Oliveira, minor, Chimukangara, Benjamin, Tulio, Open access, Durban, South Africa, AIDS, reviews, review, next generation sequencing, NGS, Sanger, sequences, DNA, Primary, HIV-1,  Drug, Resistant, Minority, Variants, clinical impact, drug resistance, HIV, de Oliveira, minor, Chimukangara, Benjamin, Tulio, Open access, Durban, South Africa', 'Primary HIV drug resistant mutations are mutations that occur in an HIV-infected individual prior to the initiation of antiretroviral therapy (ART). These mutations may arise by de novo mutagenesis or result from transmission. Drug resistant mutations (DRMs) may reduce the effectiveness of ART leading to inadequate virological outcomes. The clinical impact of DRMVs on ART is not well understood, underscoring the importance for understanding whether the levels of primary DRMVs for different mutations impact on the effectiveness of ART and the rationale for inclusion in routine diagnostics. Understanding the impact of primary DRMVs will help inform how NGS may be utilized in the future for pre-emptive clinical ART decision making.', '[Epub ahead of print]', NULL, 2017, '[Epub ahead of print]', 3.787, 3, NULL, NULL, NULL, NULL),
(147, 'HIV drug resistance testing among patients failing second line antiretroviral therapy-Comparison of in-house and commercial sequencing', '<a href=\"people.php?peopleid=23\">Chimukangara B</a>, Varyani B, Shamu T, Mutsvangwa J, Manasa J, White E, Chimbetete C, Luethy R, Katzenstein D', '<p><b><i>INTRODUCTION:</b></i> HIV genotyping is often unavailable in low and middle-income countries due to infrastructure requirements and cost. We compared genotype resistance testing in patients with virologic failure, by amplification of HIV pol gene, followed by \"in-house\" sequencing and commercial sequencing.</p>\n<p><b><i>METHODS:</b></i> Remnant plasma samples from adults and children failing second-line ART were amplified and sequenced using in-house and commercial di-deoxysequencing, and analyzed in Harare, Zimbabwe and at Stanford, U.S.A, respectively. HIV drug resistance mutations were determined using the Stanford HIV drug resistance database.</p>\n<p><b><i>RESULTS:</b></i> Twenty-six of 28 samples were amplified and 25 were successfully genotyped. Comparison of average percent nucleotide and amino acid identities between 23 pairs sequenced in both laboratories were 99.51 (0.56) and 99.11 (0.95), respectively. All pairs clustered together in phylogenetic analysis. Sequencing analysis identified 6/23 pairs with mutation discordances resulting in differences in phenotype, but these did not impact future regimens.</p>\n<p><b><i>CONCLUSIONS:</b></i> The results demonstrate our ability to produce good quality drug resistance data in-house. Despite discordant mutations in some sequence pairs, the phenotypic predictions were not clinically significant.</p>\n<br><p><b><i>HIGHLIGHTS:</b></i></p>\n<p> - In-house sequencing can provide reliable genotyping information.\n</p><p> -  Low-cost sequencing achieved by adopting SATURN protocol.\n</p><p> -  In-house and commercial sequencing make testing feasible, accessible and affordable.\n</p><p> -  High quality resistance testing improves patient care.</p>\n', 'J Virol Methods', 'pii: S0166-0934(16)30289-0', 5, NULL, NULL, 'HIV, drug, resistance, testing, among, patients, failing, second, line, antiretroviral, therapy-Comparison, of, in-house, and, commercial, sequencing, DNA, SATURN, Zimbabwe, Stanford, Benjamin, Justen, southern african treatment resistance network, HIV, drug, resistance, testing, among, patients, failing, second, line, antiretroviral, therapy-Comparison, of, in-house, and, commercial, sequencing, DNA, SATURN, Zimbabwe, Stanford, Benjamin, Justen, southern african treatment resistance network, HIV, drug, resistance, testing, among, patients, failing, second, line, antiretroviral, therapy-Comparison, of, in-house, and, commercial, sequencing, DNA, SATURN, Zimbabwe, Stanford, Benjamin, Justen, southern african treatment resistance network', 'HIV genotyping is often unavailable in low and middle-income countries due to infrastructure requirements and cost. We compared genotype resistance testing in patients with virologic failure, by amplification of HIV pol gene, followed by \"in-house\" sequencing and commercial sequencing. The results demonstrate our ability to produce good quality drug resistance data in-house. Despite discordant mutations in some sequence pairs, the phenotypic predictions were not clinically significant', ' doi: 10.1016/j.jviromet.2016.11.010', NULL, 2016, ' doi: 10.1016/j.jviromet.2016.11.010', 1.781, 3, NULL, NULL, NULL, NULL),
(148, 'Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women', '<a href=\"people.php?peopleid=29\">Ramsuran V</a>, Kulkarni H, He W, Mlisana K, Wright EJ, Werner L, Castiblanco J, Dhanda R, Le T, Dolan MJ, Guan W, Weiss RA, Clark RA, Karim SS, Ahuja SK, Ndung\'u T', '<p><b><i>BACKGROUND:</b></i></p>\n<p>The Duffy-null trait and ethnic netropenia are both highly prevalent in Africa. The influence of pre-seroconversion levels of peripheral blood cell counts (PBCs) on the risk of acquiring human immunodeficiency virus (HIV)-1 infection among Africans is unknown.</p>\n<p><b><i>METHODS:</b></i></p>\n<p>The triangular relationship among pre-seroconversion PBC counts, host genotypes, and risk of HIV acquisition was determined in a prospective cohort of black South African high-risk female sex workers. Twenty-seven women had seroconversion during follow-up, and 115 remained HIV negative for 2 years, despite engaging in high-risk activity.</p>\n<p><b><i>RESULTS:</b></i></p>\n<p>Pre-seroconversion neutrophil counts in women who subsequently had seroconversion were significantly lower, whereas platelet counts were higher, compared with those who remained HIV negative. Comprising 27% of the cohort, subjects with pre-seroconversion neutrophil counts of <2500 cells/mm(3) had a 3-fold greater risk of acquiring HIV infection. In a genome-wide association analyses, an African-specific polymorphism (rs2814778) in the promoter of Duffy Antigen Receptor for Chemokines (DARC -46T > C) was significantly associated with neutrophil counts (P = 7.9 x 10(-11)). DARC -46C/C results in loss of DARC expression on erthyrocytes (Duffy-null) and resistance to Plasmodium vivax malaria, and in our cohort, only subjects with this genotype had pre-seroconversion neutrophil counts of <2500 cells/mm(3). The risk of acquiring HIV infection was 3-fold greater in those with the trait of Duffy-null-associated low neutrophil counts, compared with all other study participants.</p>\n<p><b><i>CONCLUSIONS:</b></i></p>\n<p>Pre-seroconversion neutrophil and platelet counts influence risk of HIV infection. The trait of Duffy-null-associated low neutrophil counts influences HIV susceptibility. Because of the high prevalence of this trait among persons of African ancestry, it may contribute to the dynamics of the HIV epidemic in Africa.</p>', 'Clin Infect Dis.', '52(10)', 30, NULL, 'Ramsuran_2011_Clinical_Infectious_Diseases', NULL, NULL, '1248-56', NULL, 2011, 'doi: 10.1093/cid/cir119', 8.886, 3, NULL, NULL, NULL, NULL),
(149, 'Influence of variations in CCL3L1 and CCR5 on tuberculosis in a northwestern Colombian population', 'Mamtani M, Mummidi S, <a href=\"people.php?peopleid=29\">Ramsuran V</a>, Pham MH, Maldonado R, Begum K, Valera MS, Sanchez R, Castiblanco J, Kulkarni H, Ndung\'u T, He W, Anaya JM, Ahuja SK', '<p>We investigated the association of polymorphisms in CCR5, the major human immunodeficiency virus (HIV)-1 coreceptor, and copy number of its potent ligand CCL3L1 with tuberculosis in 298 individuals from Colombia.</p><p> The CCR5-HHD haplotype, a known genetic determinant of increased susceptibility to HIV-AIDS, and a high copy number of CCL3L1, a known genetic determinant of enhanced CCL3/CCL3L1 chemokine expression, each associated with presence of tuberculosis. Furthermore, CCR5-HHD was associated with higher CCR5 gene and surface expression. </p><p>These results substantiate the strong link between the pro-inflammatory effects of CCR5 and its ligands with active tuberculosis and suggest that chemokine-chemokine receptor genetic determinants may influence tuberculosis in addition to HIV/AIDS.</p>', 'J Infect Dis', '203(11)', 17, NULL, 'Mamtani_2011_Journal_Infectious_Diseases', NULL, NULL, '1590-4', NULL, 2011, 'doi: 10.1093/infdis/jir145', 5.997, 3, NULL, NULL, NULL, NULL),
(150, 'Genetic interplay between HLA-C and MIR148A in HIV control and Crohn disease', 'Kulkarni S, Qi Y, O\'hUigin C, Pereyra F, <a href=\"people.php?peopleid=29\">Ramsuran V</a>, McLaren P, Fellay J, Nelson G, Chen H, Liao W, Bass S, Apps R, Gao X, Yuki Y, Lied A, Ganesan A, Hunt PW, Deeks SG, Wolinsky S, Walker BD, Carrington M', '<p>Variation in the 3\' untranslated region (3\'UTR) of the HLA-C locus determines binding of the microRNA Hsa-miR-148a, resulting in lower cell surface expression of alleles that bind miR-148a relative to those alleles that escape its binding.</p><p> The HLA-C 3\'UTR variant was shown to associate with HIV control, but like the vast majority of disease associations in a region dense with causal candidates, a direct effect of HLA-C expression level on HIV control was not proven. We demonstrate that a MIR148A insertion/deletion polymorphism associates with its own expression levels, affecting the extent to which HLA-C is down-regulated, the level of HIV control, and the risk of Crohn disease only among those carrying an intact miR-148a binding site in the HLA-C 3\'UTR.</p><p> These data illustrate a direct effect of HLA-C expression level on HIV control that cannot be attributed to other HLA loci in linkage disequilibrium with HLA-C and highlight the rich complexity of genetic interactions in human disease. </p>', 'Proc Natl Acad Sci U S A', '110(51)', 40, NULL, 'Kulkarni_2013_PNAS', NULL, NULL, '20705-10', NULL, 2013, 'doi: 10.1073/pnas.1312237110', 9.423, 3, NULL, NULL, NULL, NULL),
(151, 'Effect of female genital schistosomiasis and anti-schistosomal treatment on monocytes, CD4+ T-cells and CCR5 expression in the female genital tract', 'Kleppa E, <a href=\"people.php?peopleid=29\">Ramsuran V</a>, Zulu S, Karlsen GH, Bere A, Passmore JA, Ndhlovu P, Lillebo K, Holmen SD, Onsrud M, Gundersen SG, Taylor M, Kjetland EF, Ndung\'u T', '<p><b><i>BACKGROUND:</b></i> Schistosoma haematobium is a waterborne parasite that may cause female genital schistosomiasis (FGS), characterized by genital mucosal lesions. There is clinical and epidemiological evidence for a relationship between FGS and HIV. We investigated the impact of FGS on HIV target cell density and expression of the HIV co-receptor CCR5 in blood and cervical cytobrush samples. Furthermore we evaluated the effect of anti-schistosomal treatment on these cell populations.\n<p><b><i>DESIGN:</b></i> The study followed a case-control design with post treatment follow-up, nested in an on-going field study on FGS.\n<p><b><i>METHODS:</b></i> Blood and cervical cytobrush samples were collected from FGS negative and positive women for flow cytometry analyses. Urine samples were investigated for schistosome ova by microscopy and polymerase chain reaction (PCR).\n<p><b><i>RESULTS:</b></i> FGS was associated with a higher frequency of CD14+ cells (monocytes) in blood (11.5% in FGS+ vs. 2.2% in FGS-, p = 0.042). Frequencies of CD4+ cells expressing CCR5 were higher in blood samples from FGS+ than from FGS- women (4.7% vs. 1.5%, p = 0.018). The CD14+ cell population decreased significantly in both compartments after anti-schistosomal treatment (p = 0.043). Although the frequency of CD4+ cells did not change after treatment, frequencies of CCR5 expression by CD4+ cells decreased significantly in both compartments (from 3.4% to 0.5% in blood, p = 0.036; and from 42.4% to 5.6% in genital samples, p = 0.025).\n<p><b><i>CONCLUSIONS:</b></i> The results support the hypothesis that FGS may increase the risk of HIV acquisition, not only through damage of the mucosal epithelial barrier, but also by affecting HIV target cell populations, and that anti-schistosomal treatment can modify this.</p>', 'PLoS One', '9(6)', 17, NULL, 'Kleppa_2014_PLoS_One', NULL, NULL, 'e98593', NULL, 2014, 'doi: 10.1371/journal.pone.0098593', 4.441, 3, NULL, NULL, NULL, NULL),
(152, 'Expression of the CCR5 HIV co-receptor in\rwomen with genital schistosomiasis', 'Kleppa E, <a href=\"people.php?peopleid=29\">Ramsuran V</a>, Zulu S, Karlsen GH, Bere A, Passmore JA, Ndhlovu P, Lillebo K, Holmen SD, Onsrud M, Gundersen SG, Taylor M, Kjetland EF, Ndung\'u T', '<p><b><i>Background:</b></i> Female genital schistosomiasis (FGS) is characterised by genital mucosal lesions called sandy patches causing inflammation and bleeding. Epidemiological evidence of a relationship between FGS and HIV has been found, but the biological mechanism behind the association is unknown. Heterosexual transmission is the most frequent mode of HIV transmission, and increased expression of the HIV co-receptor CCR5 is likely to cause enhanced susceptibility to HIV. This study set out to explore CCR5 on CD4+ T-cells in treated and untreated women with FGS.</p>\n<p><b><i> Methods & Materials:</b></i> Participants were recruited from a large school based study in KwaZulu-Natal, South Africa. Blood and endocervical cytobrush samples were collected from 19 young women with genital sandy patches detected by colposcopy. The negative controls consisted of 25 patients without genital lesions and with no S. haematobium ova found by urine microscopy. From the FGS positive group, 14 women were seen again 8 months after antischistosomal treatment. Flow cytometry analysis was run with an activation panel including the parameters CD3, CD4 and CCR5. The Mann-Whitney U non-parametric test and the Wilcoxon signed rank test were used when comparing the groups.</p> \n<p><b><i>Results:</b></i> The expression of the co-receptor CCR5 on CD4+ cells was higher in blood samples from FGS positives than FGS negatives (4.7% vs. 1.5%, p = 0.018). No significant difference was found in the genital samples (p = 0.29). After anti-schistosomal treatment, the CCR5 expression decreased in both blood and genital samples (p = 0.036 and 0.025, respectively). </p>\n<p><b><i>Conclusion:</b></i> The results support the assumption that FGS may increase the risk of HIV acquisition, not only through damage of the mucosal epithelial barrier, but also by altering the co-receptor expression on HIV target cell populations. Anti-schistosomal treatment may modify this effect.</p>', '16th ICID Abstracts / International Journal of Inf', '21S', 1, NULL, 'Kleppa_International_Journal_Infectious_Diseases', NULL, NULL, '1-460', NULL, 2014, NULL, 2.435, 1, NULL, NULL, NULL, NULL),
(153, 'Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor', 'Gornalusse GG, Mummidi S, Gaitan AA, Jimenez F, <a href=\"people.php?peopleid=29\">Ramsuran V</a>, Picton A, Rogers K, Manoharan MS, Avadhanam N, Murthy KK, Martinez H, Molano Murillo A, Chykarenko ZA, Hutt R, Daskalakis D, Shostakovich-Koretskaya L, Abdool Karim S, Martin JN, Deeks SG, Hecht F, Sinclair E, Clark RA, Okulicz J, Valentine FT, Martinson N, Tiemessen CT, Ndung\'u T, Hunt PW, He W, Ahuja SK.', '<p>T-cell expression levels of CC chemokine receptor 5 (CCR5) are a critical determinant of HIV/AIDS susceptibility, and manifest wide variations (i) between T-cell subsets and among individuals and (ii) in T-cell activation-induced increases in expression levels.</p><p> We demonstrate that a unifying mechanism for this variation is differences in constitutive and T-cell activation-induced DNA methylation status of CCR5 cis-regulatory regions (cis-regions). Commencing at an evolutionarily conserved CpG (CpG -41), CCR5 cis-regions manifest lower vs. higher methylation in T cells with higher vs. lower CCR5 levels (memory vs. naive T cells) and in memory T cells with higher vs. lower CCR5 levels. HIV-related and in vitro induced T-cell activation is associated with demethylation of these cis-regions. CCR5 haplotypes associated with increased vs. decreased gene/surface expression levels and HIV/AIDS susceptibility magnify vs. dampen T-cell activation-associated demethylation.</p><p> Methylation status of CCR5 intron 2 explains a larger proportion of the variation in CCR5 levels than genotype or T-cell activation.</p><p> The ancestral, protective CCR5-HHA haplotype bears a polymorphism at CpG -41 that is (i) specific to southern Africa, (ii) abrogates binding of the transcription factor CREB1 to this cis-region, and (iii) exhibits a trend for overrepresentation in persons with reduced susceptibility to HIV and disease progression. Genotypes lacking the CCR5-Delta32 mutation but with hypermethylated cis-regions have CCR5 levels similar to genotypes heterozygous for CCR5-Delta32. In HIV-infected individuals, CCR5 cis-regions remain demethylated, despite restoration of CD4+ counts (>800 cells per mm(3)) with antiretroviral therapy. Thus, methylation content of CCR5 cis-regions is a central epigenetic determinant of T-cell CCR5 levels, and possibly HIV-related outcomes.</p>', 'Proc Natl Acad Sci U S A', '112(34)', 6, NULL, 'Gornalusse_2015_PNAS', NULL, NULL, 'E4762-71', NULL, 2015, 'doi: 10.1073/pnas.1423228112', 9.423, 3, NULL, NULL, NULL, NULL),
(154, 'Epigenetic regulation of differential HLA-A allelic expression levels', '<a href=\"people.php?peopleid=29\">Ramsuran V</a>, Kulkarni S, O\'huigin C, Yuki Y, Augusto DG, Gao X, Carrington M', '<p>MHC class I expression levels influence the strength of immune responses and represent another variable in determining outcome to disease beyond peptide binding alone. Identification of the HLA loci that vary in allelic expression levels and delineating the mechanism responsible for expression variation may provide the opportunity to modify their expression therapeutically.</p><p> We have examined the expression levels of allelic lineages at the HLA-A locus in a sample of 216 European Americans using a real-time polymerase chain reaction assay, which amplifies all HLA-A lineages specifically with equal efficiency, and observed a gradient of expression that associates with HLA-A allelic lineage (R = 0.6, P = 5 x 10(-25)).</p><p> DNA methylation of the HLA-A gene appears to contribute to the variation in HLA-A mRNA expression levels, as a significant inverse correlation was observed between HLA-A mRNA expression levels in untreated cells and the degree to which expression is increased after treatment of the cells with a DNA methyltransferase inhibitor (R = 0.6, P = 2.8 x 10(-6)). Further, deep-sequencing and immunoprecipitation assays revealed allelic lineage-specific methylation patterns within the HLA-A promoter region where increased DNA methylation levels correlated significantly with reduced HLA-A expression levels (R = 0.89, P = 3.7 x 10(-9)).</p><p> These data demonstrate HLA-A allelic lineage-specific variation in expression levels, and DNA methylation as a likely factor in contributing to this variation. </p>', 'Hum Mol Genet', '24(15)', 6, NULL, 'Ramsuran_2015_Human_Molecular_Genetics', NULL, NULL, '4268-75', NULL, 2015, 'doi: 10.1093/hmg/ddv158', 5.985, 3, NULL, NULL, NULL, NULL),
(155, 'HLA-C Level Is Regulated by a Polymorphic Oct1 Binding Site in the HLA-C Promoter Region', 'Vince N, Li H, <a href=\"people.php?peopleid=29\">Ramsuran V</a>, Naranbhai V, Duh FM, Fairfax BP, Saleh B, Knight JC, Anderson SK, Carrington M', '<p>Differential HLA-C levels influence several human diseases, but the mechanisms responsible are incompletely characterized. Using a validated prediction algorithm, we imputed HLA-C cell surface levels in 228 individuals from the 1000 Genomes dataset.</p><p> We tested 68,726 SNPs within the MHC for association with HLA-C level. The HLA-C promoter region variant, rs2395471, 800 bp upstream of the transcription start site, gave the most significant association with HLA-C levels (p = 4.2 x 10-66). This imputed expression quantitative trait locus, termed impeQTL, was also shown to associate with HLA-C expression in a genome-wide association study of 273 donors in which HLA-C mRNA expression levels were determined by quantitative PCR (qPCR) (p = 1.8 x 10-20) and in two cohorts where HLA-C cell surface levels were determined directly by flow cytometry (n = 369 combined, p < 10-15).</p><p> rs2395471 is located in an Oct1 transcription factor consensus binding site motif where the A allele is predicted to have higher affinity for Oct1 than the G allele. Mobility shift electrophoresis demonstrated that Oct1 binds to both alleles in vitro, but decreased HLA-C promoter activity was observed in a luciferase reporter assay for rs2395471_G relative to rs2395471_A on a fixed promoter background. The rs2395471 variant accounts for up to 36% of the explained variation of HLA-C level.</p><p> These data strengthen our understanding of HLA-C transcriptional regulation and provide a basis for understanding the potential consequences of manipulating HLA-C levels therapeutically.</p>', 'Am J Hum Genet', '99(6)', 25, NULL, 'Vince_2016_Am_J_Hu_Gen', NULL, NULL, '1353-1358', NULL, 2016, 'doi: 10.1016/j.ajhg.2016.09.023', 11.202, 3, NULL, NULL, NULL, NULL),
(156, 'Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes', '<a href=\"people.php?peopleid=29\">Ramsuran V</a>, Hernandez-Sanchez PG, O\'hUigin C, Sharma G, Spence N, Augusto DG, Gao X, Garcia-Sepulveda CA, Kaur G, Mehra NK, Carrington M,', '<p>Polymorphisms located within the MHC have been linked to many disease outcomes by mechanisms not yet fully understood in most cases. Variants located within untranslated regions of HLA genes are involved in allele-specific expression and may therefore underlie some of these disease associations.</p><p> We determined sequences extending nearly 2 kb upstream of the transcription start site for 68 alleles from 57 major lineages of classical HLA class I genes. The nucleotide diversity within this promoter segment roughly follows that seen within the coding regions, with HLA-B showing the highest (?1.9%), followed by HLA-A (?1.8%), and HLA-C showing the lowest diversity (?0.9%). Despite its greater diversity, HLA-B mRNA expression levels determined in 178 European Americans do not vary in an allele- or lineage-specific manner, unlike the differential expression levels of HLA-A or HLA-C reported previously.</p><p> Close proximity of promoter sequences in phylogenetic trees is roughly reflected by similarity of expression pattern for most HLA-A and -C loci. Although promoter sequence divergence might impact promoter activity, we observed no clear link between the phylogenetic structures as represented by pairwise nucleotide differences in the promoter regions with estimated differences in mRNA expression levels for the classical class I loci. Further, no pair of class I loci showed coordinated expression levels, suggesting that distinct mechanisms across loci determine their expression level under nonstimulated conditions. </p><p>These data serve as a foundation for more in-depth analysis of the functional consequences of promoter region variation within the classical HLA class I loci.</p>', 'J Immunol', 'pii: 1601679', 3, NULL, 'Ramsuran_2017_J_Immunol', NULL, NULL, NULL, NULL, 2017, 'doi: 10.4049/jimmunol.1601679', 4.92, 3, NULL, NULL, NULL, NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(157, 'Social disequilibrium and the risk of HIV acquisition: A multilevel study in rural KwaZulu-Natal Province, South Africa', '<a href=\"people.php?surname=Tomita\">Tomita A</a>, <a href=\"people.php?surname= Vandormael\">Vandormael AM</a>, Barnighausen T, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>, Tanser F', '<p><b><i>BACKGROUND:</b></i> \nFew population-based multilevel studies have quantified the risks that social context poses in rural communities with high HIV incidence across South Africa. We investigated the individual, social and community challenges to HIV acquisition risk in areas with high and low incidence of HIV infection (hotspots/coldspots).</p>\n<p><b><i>METHODS:</b></i> \nThe cohort (N=17,376) included all HIV-negative adults enrolled in a population-based HIV surveillance study from 2004-2015 in a rural South African community with a large labor migrancy. Multilevel survival models were fitted to examine the social determinants (i.e. neighborhood migration intensity), community traits (i.e. HIV prevalence), and individual determinants of HIV acquisition risk in identified hotspots/coldspots.</p>\n<p><b><i>RESULTS:</b></i> \nThe HIV acquisition risk (aHR=1.05, 95% CI:1.01-1.09) was greater in hotspots with a higher neighborhood migration intensity amongst men. In women, higher neighborhood migration intensity (aHR=1.02, 95% CI:1.01-1.02) was associated with a greater HIV acquisition risk, irrespective of whether they lived in hotspot/coldspot communities. HIV acquisition risk was greater in communities with a higher prevalence of HIV in both men (aHR=1.07, 95% CI:1.03-1.12) and women (aHR=1.03, 95% CI:1.01-1.05), irrespective of hotspot/coldspot locations.</p>\n<p><b><i>CONCLUSION:</b></i> \nHIV acquisition risk was strongly influenced by gender (i.e. young women), behavior (i.e. sexual debut, contraception, circumcision) and social determinants. Certain challenges (i.e. community disease prevalence) for HIV acquisition risk impacted both sexes, regardless of residence in hotspot/coldspot communities, while social determinants (i.e. neighborhood migration intensity) were pronounced in hotspots among men. Future intervention scale-up requires addressing the social context that contributes to HIV acquisition risk in rural areas with high migration.</p>', 'J Acquir Immune Defic Syndr.', NULL, 2, NULL, 'Tomita_Social_Disequilibrium_HIV_JAIDS2017', 'hot spots, cold spots, hiv, transmission, rural, KwaZulu-Natal, HIV acquisition, risk, strongly, influenced, gender,  young women, behavior, sexual debut, contraception, circumcision, social determinants, Tulio de Oliveira, Andrew Tomita, Alain Vandormel, hot spots, cold spots, hiv, transmission, rural, KwaZulu-Natal, HIV acquisition, risk, strongly, influenced, gender,  young women, behavior, sexual debut, contraception, circumcision, social determinants, Tulio de Oliveira, Andrew Tomita, Alain Vandormel, hot spots, cold spots, hiv, transmission, rural, KwaZulu-Natal, HIV acquisition, risk, strongly, influenced, gender,  young women, behavior, sexual debut, contraception, circumcision, social determinants, Tulio de Oliveira, Andrew Tomita, Alain Vandormel, hot spots, cold spots, hiv, transmission, rural, KwaZulu-Natal, HIV acquisition, risk, strongly, influenced, gender,  young women, behavior, sexual debut, contraception, circumcision, social determinants, Tulio de Oliveira, Andrew Tomita, Alain Vandormel', 'Few population-based multilevel studies have quantified the risks that social context poses in rural communities with high HIV incidence across South Africa. We investigated the individual, social and community challenges to HIV acquisition risk in areas with high and low incidence of HIV infection (hotspots/coldspots). HIV acquisition risk was strongly influenced by gender (i.e. young women), behavior (i.e. sexual debut, contraception, circumcision) and social determinants. Certain challenges (i.e. community disease prevalence) for HIV acquisition risk impacted both sexes, regardless of residence in hotspot/coldspot communities, while social determinants (i.e. neighborhood migration intensity) were pronounced in hotspots among men. Future intervention scale-up requires addressing the social context that contributes to HIV acquisition risk in rural areas with high migration.', '10.1097/QAI.0000000000001349', NULL, 2017, '10.1097/QAI.0000000000001349', 3.806, 3, NULL, NULL, NULL, NULL),
(158, 'CD4+ T-cell count may not be a useful strategy to monitor antiretroviral therapy response in HTLV-1/HIV co-infected patients', '<a href=\"people.php?surname= Vandormael\">Vandormael A</a>, Rego F, Danaviah S, Alcantara L, Boulware D, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p><b><i>BACKGROUND:</b></i> \nHTLV-1/HIV co-infection is known to elevate the CD4+ T-cell counts of treatment-naive persons. We investigated whether HTLV-1/HIV co-infected patients continued to have elevated CD4+ T-cell counts after developing virologic failure on antiretroviral therapy (ART).</p>\n<p><b><i>METHODS:</b></i> \n\nThe data comes from a drug resistance study located in the KwaZulu-Natal province of South Africa. All participants (N=383) presented for repeated CD4+ T-cell count and HIV viral load level testing between January 2006 and March 2014. We used a random-coefficient model to estimate the change in CD4+ T-cell count and HIV viral load level by HTLV-1/HIV co-infection status over time, adjusting for age, sex, and duration of virologic failure.</p>\n<p><b><i>RESULTS:</b></i> \n\nHTLV-1/HIV co-infected participants (n=8) had higher CD4+ T-cell counts, with a positive difference of 117.2 cells/uL at the ART initiation date (p-value=0.001), 114.7 cells/uL (p-value<0.001) 12 months after this date, and 112.3 cells/uL (p-value=0.005) 24 months after this date, holding all else constant. In contrast, there was no difference in the HIV viral load level by HTLV-1/HIV co-infected status throughout the observation period.</p>\n<p><b><i>CONCLUSIONS:</b></i> \n\nWe show that HTLV-1/HIV co-infected participants continued to have elevated CD4+ T-cell counts after developing virologic failure on ART, despite no difference in their HIV viral load levels when compared with HIV mono-infected participants. Our results indicate that CD4+ T-cell count testing may not be a useful strategy to monitor ART response in the presence of HTLV-1 infection.</p>', 'Current HIV Research', NULL, 2, NULL, NULL, 'HTLV-1, HIV, co-infection, elevate, CD4+, cd4, T-cell, counts, treatment-naive, persons, virologic failure,  antiretroviral therapy, ART, CD4+, T-cell, count, testing, not useful, strategy, monitor, ART, response, HTLV-1, HIV, co-infection, elevate, CD4+, cd4, T-cell, counts, treatment-naive, persons, virologic failure,  antiretroviral therapy, ART, CD4+, T-cell, count, testing, not useful, strategy, monitor, ART, response, HTLV-1, HIV, co-infection, elevate, CD4+, cd4, T-cell, counts, treatment-naive, persons, virologic failure,  antiretroviral therapy, ART, CD4+, T-cell, count, testing, not useful, strategy, monitor, ART, response', 'e show that HTLV-1/HIV co-infected participants continued to have elevated CD4+ T-cell counts after developing virologic failure on ART, despite no difference in their HIV viral load levels when compared with HIV mono-infected participants. Our results indicate that CD4+ T-cell count testing may not be a useful strategy to monitor ART response in the presence of HTLV-1 infection', 'doi: 10.2174/1570162X15666170216114917', NULL, 2017, 'doi: 10.2174/1570162X15666170216114917', 1.631, 3, NULL, NULL, NULL, NULL),
(159, 'Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis', 'Collier D, Iwuji C, Derache A, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK, for ANRS 12249 TasP Study Group', '<p><b><i>BACKGROUND:</b></i>  Second-line antiretroviral therapy (ART) based on ritonavir-boosted protease inhibitors (bPIs) represents the only available option after first-line failure for the majority of individuals living with human immunodeficiency virus (HIV) worldwide. Maximizing their effectiveness is imperative.</p> \n<p><b><i>METHODS:</b></i>  This cohort study was nested within the French National Agency for AIDS and Viral Hepatitis Research (ANRS) 12249 Treatment as Prevention (TasP) cluster-randomized trial in rural KwaZulu-Natal, South Africa. We prospectively investigated risk factors for virological failure (VF) of bPI-based ART in the combined study arms. VF was defined by a plasma viral load >1000 copies/mL ?6 months after initiating bPI-based ART. Cumulative incidence of VF was estimated and competing risk regression was used to derive the subdistribution hazard ratio (SHR) of the associations between VF and patient clinical and demographic factors, taking into account death and loss to follow-up. </p>\n<p><b><i>RESULTS:</b></i> One hundred one participants contributed 178.7 person-years of follow-up. Sixty-five percent were female; the median age was 37.4 years. Second-line ART regimens were based on ritonavir-boosted lopinavir, combined with zidovudine or tenofovir plus lamivudine or emtricitabine. The incidence of VF on second-line ART was 12.9 per 100 person-years (n = 23), and prevalence of VF at censoring was 17.8%. Thirteen of these 23 (56.5%) virologic failures resuppressed after a median of 8.0 months (interquartile range, 2.8?16.8 months) in this setting where viral load monitoring was available. Tuberculosis treatment was associated with VF (SHR, 11.50 [95% confidence interval, 3.92?33.74]; P < .001). </p>\n<p><b><i>CONCLUSIONS:</b></i>  Second-line VF was frequent in this setting. Resuppression occurred in more than half of failures, highlighting the value of viral load monitoring of second-line ART. Tuberculosis was associated with VF; therefore, novel approaches to optimize the effectiveness of PI-based ART in high-tuberculosis-burden settings are needed.</p>', 'Clinical Infectious Diseases', NULL, 3, NULL, 'Collier_HIVART_SecondLine_outcome_TasP_cix015_2017', 'HIV; antiretroviral therapy; virological failure; second line; protease inhibitorHIV, antiretroviral therapy, virological failure, second line, protease inhibitor, treatment as prevention, TB, viral suppression, drug resistance, protease, second line therapy, south africa, KwaZulu-Natal, de Oliveira, Gupta, HIV, antiretroviral therapy, virological failure, second line, protease inhibitor, treatment as prevention, TB, viral suppression, drug resistance, protease, second line therapy, south africa, KwaZulu-Natal, de Oliveira, Gupta, HIV, antiretroviral therapy, virological failure, second line, protease inhibitor, treatment as prevention, TB, viral suppression, drug resistance, protease, second line therapy, south africa, KwaZulu-Natal, de Oliveira, Gupta, ', 'Second-line viral faliure VF was frequent in this setting. Resuppression occurred in more than half of failures, highlighting the value of viral load monitoring of second-line Antiretroviral therapy ART. Tuberculosis was associated with VF; therefore, novel approaches to optimize the effectiveness of PI-based ART in high-tuberculosis-burden TB settings are needed', 'doi: 10.1093/cid/cix015', NULL, 2017, 'DOI: 10.1093/cid/cix015', 8.88, 3, NULL, NULL, NULL, NULL),
(160, 'Using nearly full-genome HIV sequence data improves phylogeny reconstruction in a simulated epidemic', 'Yebra G, Hodcroft EB1, Ragonnet-Cronin ML1, Pillay D2, Brown AJ1; <a href=people.php?surname=de Oliveira\">PANGEA_HIV Consortium de Oliveira T</a>; ICONIC Project.', 'HIV molecular epidemiology studies analyse viral pol gene sequences due to their availability, but whole genome sequencing allows to use other genes. We aimed to determine what gene(s) provide(s) the best approximation to the real phylogeny by analysing a simulated epidemic (created as part of the PANGEA_HIV project) with a known transmission tree. We sub-sampled a simulated dataset of 4662 sequences into different combinations of genes (gag-pol-env, gag-pol, gag, pol, env and partial pol) and sampling depths (100%, 60%, 20% and 5%), generating 100 replicates for each case. We built maximum-likelihood trees for each combination using RAxML (GTR?+??), and compared their topologies to the corresponding true tree\'s using CompareTree. The accuracy of the trees was significantly proportional to the length of the sequences used, with the gag-pol-env datasets showing the best performance and gag and partial pol sequences showing the worst. The lowest sampling depths (20% and 5%) greatly reduced the accuracy of tree reconstruction and showed high variability among replicates, especially when using the shortest gene datasets. In conclusion, using longer sequences derived from nearly whole genomes will improve the reliability of phylogenetic reconstruction. With low sample coverage, results can be highly variable, particularly when based on short sequences.', 'Scientific Reports', '6', 3, NULL, 'Yebra_srep39489_2017', NULL, NULL, '39489. doi: 10.1038/srep39489', NULL, 2016, '39489. doi: 10.1038/srep39489', 5.578, 3, NULL, NULL, NULL, NULL),
(161, 'High Rates of Transmission of Drug-resistant HIV in Aruba Resulting in Reduced Susceptibility to the WHO Recommended First-line Regimen in Nearly Half of Newly Diagnosed HIV-infected Patients', 'Hofstra LM, Rivas ES, Nijhuis M, Bank LEA, <a href=\"people.php?surname=Wilkinson\">Wilkinson E</a>, Kelly K, Mudrikova T, Schuurman R, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>, de Kort J, Wensing AMJ', '<p><b><i>BACKGROUND:</b></i> In Western countries emergence of human immunodeficiency virus (HIV) drug resistance has tremendously decreased, and transmission of drug resistance has merely stabilized in recent years. However, in many endemic settings with limited resources rates of emerging and transmitted drug resistance are not regularly assessed.</p>\n<p><b><i>METHODS:</b></i>  We performed a survey including all HIV-infected individuals who received resistance testing in 2010-2015 in Aruba, a highly endemic HIV area in the Caribbean. Transmitted HIV drug resistance was determined using World Health Organization (WHO) criteria. Transmission dynamics were investigated using phylogenetic analyses. In a subset, baseline samples were re-analyzed using next generation sequencing (NGS). </p>\n<p><b><i>RESULTS:</b></i>  Baseline resistance testing was performed in 104 newly diagnosed untreated individuals (54% of all newly diagnosed individuals in 2010-2015): 86% were men, 39% were foreign-born, and 22% had AIDS at diagnosis. And 33% (95% CI: 24-42%) was infected with a drug-resistant HIV variant. The prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (95% CI: 27-64%) in 2015, all based on the prevalence of mutation K103N. NGS did not demonstrate additional minority K103N-variants compared to routine resistance testing. K103N-harboring strains were introduced into the therapy-unexposed population via at least 6 independent transmissions epidemiologically linked to the surrounding countries. Virological failure of the WHO-recommended first-line NNRTI-based regimen was higher in the presence of K103N.</p>\n<p><b><i>CONCLUSIONS:</b></i>  The prevalence of resistant HIV in Aruba has increased to alarming levels, compromising the WHO-recommended first-line regimen. As adequate surveillance as advocated by the WHO is limited, the Caribbean region could face an unidentified rise of NNRTI-resistant HIV.</p>', 'Clinical Infectious Diseases', NULL, 5, NULL, 'Hofstra_Aruba_Alarming_DrugResistance_HIV_cix056', 'HIV, antiretroviral therapy, HIV-1, drug resistance, transmission, surveillance, therapy, Caribbean, half of patients with drug resistance, high prevalence, alarming rates, resistance virus, Caribbean, Aruba, phylogenetics, phylogenetic analysis, Tulio de Oliveira, Eduan Wilkinson, HIV, antiretroviral therapy, HIV-1, drug resistance, transmission, surveillance, therapy, Caribbean, half of patients with drug resistance, high prevalence, alarming rates, resistance virus, Caribbean, Aruba, phylogenetics, phylogenetic analysis, Tulio de Oliveira, Eduan Wilkinson, HIV, antiretroviral therapy, HIV-1, drug resistance, transmission, surveillance, therapy, Caribbean, half of patients with drug resistance, high prevalence, alarming rates, resistance virus, Caribbean, Aruba, phylogenetics, phylogenetic analysis, Tulio de Oliveira, Eduan Wilkinson, HIV, antiretroviral therapy, HIV-1, drug resistance, transmission, surveillance, therapy, Caribbean, half of patients with drug resistance, high prevalence, alarming rates, resistance virus, Caribbean, Aruba, phylogenetics, phylogenetic analysis, Tulio de Oliveira, Eduan Wilkinson', 'The prevalence of resistant HIV in Aruba has increased to alarming levels, compromising the WHO-recommended\rfirst-line regimen. As adequate surveillance as advocated by the WHO is limited, the Caribbean region could face an unidentified rise of NNRTI-resistant HIV. Open access publication, drug resistance levels very high, change regimen, de oliveira', 'doi: 10.1093/cid/cix056', NULL, 2017, 'doi: 10.1093/cid/cix056', 8.88, 3, NULL, NULL, 'Y', NULL),
(162, 'Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration', 'Rhee SY, Varghese V, Holmes SP, Van Zyl GU, Steegen K, Boyd MA, Cooper DA, Nsanzimana S, Saravanan S, Charpentier C, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>, Etiebet MA, Garcia F, Goedhals D, Gomes P, Gunthard HF, Hamers RL, Hoffmann CJ, Hunt G, Jiamsakul A, Kaleebu P, Kanki P, Kantor R, Kerschberger B, Marconi VC, D\'amour Ndahimana J, Ndembi N, Ngo-Giang-Huong N, Rokx C, Santoro MM, Schapiro JM, Schmidt D, Seu L, Sigaloff KCE, Sirivichayakul S, Skhosana L, Sunpath H, Tang M, Yang C, Carmona S, Gupta RK, Shafer RW.', '<p>Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-containing first-line regimen. However, the full spectrum of reverse transcriptase (RT) mutations selected in individuals with VF on such a regimen is not known.</p><p> To identify TDF regimen-associated mutations (TRAMs), we compared the proportion of each RT mutation in 2873 individuals with VF on a WHO-recommended first-line TDF-containing regimen to its proportion in a cohort of 50,803 antiretroviral-naive individuals. To identify TRAMs specifically associated with TDF-selection pressure, we compared the proportion of each TRAM to its proportion in a cohort of 5805 individuals with VF on a first-line thymidine analog-containing regimen. </p><p>We identified 83 TRAMs including 33 NRTI-associated, 40 NNRTI-associated, and 10 uncommon mutations of uncertain provenance. Of the 33 NRTI-associated TRAMs, 12 - A62V, K65R/N, S68G/N/D, K70E/Q/T, L74I, V75L, and Y115F - were more common among individuals receiving a first-line TDF-containing compared to a first-line thymidine analog-containing regimen. </p><p>These 12 TDF-selected TRAMs will be important for monitoring TDF-associated transmitted drug-resistance and for determining the extent of reduced TDF susceptibility in individuals with VF on a TDF-containing regimen.</p>', 'EBioMedicine', NULL, 3, NULL, 'Rhee_TDF_mutations_EBiomedicine2017', 'Mutational, Correlates, Virological, Failure, Individuals, Receiving, WHO-Recommended, Tenofovir, TDF, ARV, antiretroviral, drug resistance, First-Line, 1st, Regimen, line, WHO, world health organization, International, Collaboration, SATuRN, Stanford, Mutational, Correlates, Virological, Failure, Individuals, Receiving, WHO-Recommended, Tenofovir, TDF, ARV, antiretroviral, drug resistance, First-Line, 1st, Regimen, line, WHO, world health organization, International, Collaboration, SATuRN, Stanford, Mutational, Correlates, Virological, Failure, Individuals, Receiving, WHO-Recommended, Tenofovir, TDF, ARV, antiretroviral, drug resistance, First-Line, 1st, Regimen, line, WHO, world health organization, International, Collaboration, SATuRN, Stanford, Mutational, Correlates, Virological, Failure, Individuals, Receiving, WHO-Recommended, Tenofovir, TDF, ARV, antiretroviral, drug resistance, First-Line, 1st, Regimen, line, WHO, world health organization, International, Collaboration, SATuRN, Stanford', 'Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to\r60% of individuals with virological failure (VF) on aWHO-recommended TDF-containing first-line regimenOf the 33 NRTI-associated. TRAMs, 12 ? A62V, K65R/N, S68G/N/D, K70E/Q/T, L74I, V75L, and Y115F ? weremore common among individuals\rreceiving a first-line TDF-containing compared to a first-line thymidine analog-containing regimen. These 12\rTDF-selected TRAMswill be important formonitoring TDF-associated transmitted drug-resistance and for determining\rthe extent of reduced TDF susceptibility in individuals with VF on a TDF-containing regimen.', 'doi: 10.1016/j.ebiom.2017.03.024', NULL, 2017, 'doi: 10.1016/j.ebiom.2017.03.024', 2.11, 3, NULL, NULL, NULL, NULL),
(163, 'Incidence rate estimation, periodic testing and the limitations of the mid-point imputation approach', 'Vandormael A, Dobra A, Barnighausen T, de Oliveira T, Tanser F', '<p><b><i>Background:</b></i> It is common to use the mid-point between the latest-negative and earliest-positive test dates as the date of the infection event. However, the accuracy of the mid-point method has yet to be systematically quantified for incidence studies once participants start to miss their scheduled test dates.</p>\n<p><b><i>Methods:</b></i> We used a simulation-based approach to generate an infectious disease epidemic for an incidence cohort with a high (80-100%), moderate (60-79.9%), low (40-59.9%) and poor (30-39.9%) testing rate. Next, we imputed a mid-point and random-point value between the participant\'s latest-negative and earliest-positive test dates. We then compared the incidence rate derived from these imputed values with the true incidence rate generated from the simulation model.</p>\n<p><b><i>Results: </b></i>The mid-point incidence rate estimates erroneously declined towards the end of the observation period once the testing rate dropped below 80%. This decline was in error of approximately 9%, 27% and 41% for a moderate, low and poor testing rate, respectively. The random-point method did not introduce any systematic bias in the incidence rate estimate, even for testing rates as low as 30%.</p>\n<p><b><i>Conclusions: </b></i>The mid-point assumption of the infection date is unjustified and should not be used to calculate the incidence rate once participants start to miss the scheduled test dates. Under these conditions, we show an artefactual decline in the incidence rate towards the end of the observation period. Alternatively, the single random-point method is straightforward to implement and produces estimates very close to the true incidence rate.</p>', 'International Journal of Epidemiology', '', 5, NULL, 'Vandormael_HIV_Incidence_methods_IJE_2017', 'incidence, imputation, mid-point, random-point, interval censoring, periodic testing, HIV, incidence, imputation, mid-point, random-point, interval censoring, periodic testing, HIV, incidence, imputation, mid-point, random-point, interval censoring, periodic testing, HIV, South Africa, AHRI, Tulio de Oliveira, Frank Tanser, methods, alain Vandormael, incidence, imputation, mid-point, random-point, interval censoring, periodic testing, HIV, incidence, imputation, mid-point, random-point, interval censoring, periodic testing, HIV, incidence, imputation, mid-point, random-point, interval censoring, periodic testing, HIV, South Africa, AHRI, Tulio de Oliveira, Frank Tanser, methods, alain Vandormael', 'KRISP open access publication on HIV incidence estimation in South Africa. Tulio de Oliveira, Frank Tanser, Alain Vandormael  Using a simulation-based approach, we show that the infection date does not occur at the mid-point of the censored interval once participants start to miss their scheduled test dates.Under these circumstances, the mid-point method may lead epidemiologists to falsely conclude that the incidence rate is declining toward the end of the observation period.  Imputation of a random infection date within the censored interval, based on a Monte Carlo approach, is straightforward to implement and produces estimates very close to the true incidence rate.', 'doi.org/10.1093/ije/dyx134', NULL, 2017, 'doi.org/10.1093/ije/dyx134', 7.738, 3, NULL, NULL, '', NULL),
(164, 'Sexual partnership age pairings and risk of HIV acquisition in rural South Africa', 'Akulliana A, Bershteyna A, Kleina D, Vandormael A, Barnighausen T, Tanser F', '<p><b><i>Objective:</b></i> To quantify the contribution of specific sexual partner age groups to the risk of HIV acquisition in men and women in a hyperendemic region of South Africa. Design: We conducted a population-based cohort study among women (15?49 years of age) and men (15?55 years of age) between 2004 and 2015 in KwaZulu-Natal, South Africa. </p>\n<p><b><i>Methods:</b></i> Generalized additive models were used to estimate smoothed HIV incidence rates across partnership age pairings in men and women. Cox proportional hazards regression was used to estimate the relative risk of HIV acquisition by partner age group. </p>\n<p><b><i>Results:</b></i> A total of 882 HIV seroconversions were observed in 15 935 person-years for women, incidence rate 5.5 per 100 person-years [95% confidence interval (CI), 5.2- 5.9] and 270 HIV seroconversions were observed in 9372 person-years for men, incidence rate 2.9 per 100 person-years (95% CI, 2.6-3.2). HIV incidence was highest among 15-24-year-old women reporting partnerships with 30-34-year-old men, incidence rate9.7 per 100 person-years (95% CI, 7.2-13.1). Risk of HIV acquisition in women was associated with male partners aged 25-29 years (adjusted hazard ratio; aHR 1.44, 95% CI, 1.02-2.04) and 30-34 years (aHR 1.50, 95% CI, 1.08-2.09) relative to male partners aged 35 and above. Risk of HIV acquisition in men was associated with 25-29-year-old (aHR 1.72, 95% CI, 1.02-2.90) and 30-34- year-old women (aHR 2.12, 95% CI, 1.03-4.39) compared to partnerships with women aged 15-19 years. </p>\n<p><b><i>Conclusion:</b></i> Age of sexual partner is a major risk factor for HIV acquisition in both men and women, independent of one-s own age. Partner age pairings play a critical role in driving the cycle of HIV transmission.</p>', 'AIDS', NULL, 3, NULL, 'Sexual_partnership_age_pairings_and_risk_HIV2017', 'age gaps, HIV transmission, sexual behavior, South Africa, sexual partnership, young women, older men, epidemiology, Alain Vandormael, Fran Tanser, KRISP, 2017, open access, paper, age gaps, HIV transmission, sexual behavior, South Africa, sexual partnership, young women, older men, epidemiology, Alain Vandormael, Fran Tanser, KRISP, 2017, open access, paper, age gaps, HIV transmission, sexual behavior, South Africa, sexual partnership, young women, older men, epidemiology, Alain Vandormael, Fran Tanser, KRISP, 2017, open access, paper, age gaps, HIV transmission, sexual behavior, South Africa, sexual partnership, young women, older men, epidemiology, Alain Vandormael, Fran Tanser, KRISP, 2017, open access, paper', NULL, 'DOI:10.1097/QAD.0000000000001553', NULL, 2017, 'DOI:10.1097/QAD.0000000000001553', 5.554, 3, NULL, NULL, '', NULL),
(165, 'Genetic markers for protease inhibitor drug resistance in regions outside of the protease gene', 'Giandhari J, Gordon M, van Vuuren C, Moodley P,  <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p>There are currently 6.8 million individuals infected with HIV-1 in South Africa. Nearly half of these individuals are on antiretroviral therapy. Protease inhibitors (PIs) form part of the South African national treatment guidelines as a first-line regimen for paediatric patients and a second-line regimen for adults. However, successful treatment is often hindered by the development of drug resistance. \n</p><p>Resistance to PIs is characterised by a stepwise accumulation of mutations in the protease gene. However, studies have shown a low frequency of mutations in patients failing PIs. Regions outside of the protease, such as gag and more recently env, have been associated with PI drug resistance in the absence of protease mutations. \n</p><p>We aim to identify genetic markers in the gag and envelope genes which are associated with PI treatment failure. Stored plasma samples from HIV-1-infected patients failing PI-based therapy (n =>500) will be collected from collaborators in South Africa and whole genome sequences from PI-naive patients will be downloaded from the Los Alamos Sequence Database. Failure will be defined as having two consecutive viral loads=>1,000 cpm after being on a PI-based regimen for > 6 months. The whole HIV-1 genome will be amplified from the PI failures and sequenced using Illumina Miseq. Sequences will be aligned to a reference and analysed for single nucleotide polymorphisms (SNPs) in all HIV genes using Geneious v 8.1.8 and GATK software application. \n</p><p>Genome wide association analysis using PLINK will be performed to identify SNPs in PI treated patients that are associated with treatment failure. Episodic directional selection model such as MEDS and IFEL will be used to identify mutations that occur at specific amino acid positions and confer resistance to PIs. The previously mentioned methods allow the identification of drug resistance mutations without the need of baseline samples. Preliminary data from GWAS analysis on 26 patients failing PI-based therapy has identified codons in envelope and gag which are significantly associated with PI failure. Further examination of these sites in the viral minority population has shown that they are present at?>2% of the viral population. By increasing our sample size we will obtain a more comprehensive and robust analysis of the role of regions outside the protease gene in PI resistance. Analysis of the control samples is currently being performed.</p>', 'Virus Evolution', NULL, 1, NULL, 'GiandhariVirusEvolutionProteaseAbstract2017', 'Genetic, markers, protease, inhibitor, drug, resistance, regions , outside, protease, gene, HIV, South Africa, Subtype C, Tulio de Oliveira, Giadhari, VEME, South Korea, Abstract, 2016, Genetic, markers, protease, inhibitor, drug, resistance, regions , outside, protease, gene, HIV, South Africa, Subtype C, Tulio de Oliveira, Giadhari, VEME, South Korea, Abstract, 2016, Genetic, markers, protease, inhibitor, drug, resistance, regions , outside, protease, gene, HIV, South Africa, Subtype C, Tulio de Oliveira, Giadhari, VEME, South Korea, Abstract, 2016, Genetic, markers, protease, inhibitor, drug, resistance, regions , outside, protease, gene, HIV, South Africa, Subtype C, Tulio de Oliveira, Giadhari, VEME, South Korea, Abstract, 2016', 'Virus evolution Veme workshop abstracts 2017 - Preliminary data from GWAS analysis on 26 patients failing PI-based therapy has identified codons in envelope and gag which are significantly associated with PI failure. Further examination of these sites in the viral minority population has shown that they are present at?>2% of the viral population. By increasing our sample size we will obtain a more comprehensive and robust analysis of the role of regions outside the protease gene in PI resistance. Analysis of the control samples is currently being performed.', 'doi:  10.1093/ve/vew036.018', NULL, 2017, 'doi:  10.1093/ve/vew036.018', 5, 3, NULL, NULL, '', NULL),
(166, 'Persistent circulation of highly divergent HIV-1M lineages in the Congo Basin Region', 'Tongo M, Dorfman JR, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>, Martin DP', '<p>The evolutionary processes that within a century yielded the nine major HIV-1 group M (HIV-1M) lineages and over 72 circulating recombinant forms (CRFs) remain the most important obstacles to the development of both a cure and an effective vaccine. It is still unknown how global HIV populations will respond over the long-term when confronted with efficiently protective vaccines and drug therapies.</p><p> It is entirely possible that divergent HIV variants that are presently circulating in diversity hotspots such as Cameroon and the DRC might be the source of future global multi-drug resistant or vaccine evasion re-emergence events. In an effort to discover and characterise more of these highly divergent lineages, we recently performed in-depth characterisation of HIV-1 diversity in Cameroon. </p><p>We found that 10% of gag sequences and 5% of nef sequences were not easily classifiable into any of the known HIV-1M clades. In addition, the full length characterisation of 24 unique recombinant forms (URFs) from Cameroon showed that these divergent sequences contained large tracts of sequence that could not be credibly classified as having been derived from parental viruses in the known subtypes. Furthermore, we have found that many of the sequence fragments occurring within CRF04_cpx, CRF06_cpx, CRF11_cpx, CRF18_cpx, CRF25_cpx, CRF27_cpx and CRF49_cpx are in fact likely derived from divergent unclassified parental lineages that may pre-date the current subtypes, even though they are presently identified as derived from currently defined HIV-1M subtypes. </p><p>The highly divergent sequence tracts evident within these various HIV-1M genomes might be the extant descendants of pre-epidemic HIV-1 group M lineages (i.e. they may, in a sense, be evolutionary relics). This suggests that large pools of undiscovered HIV-1M genetic diversity likely exist throughout equatorial West Africa. </p><p>We hypothesise that viruses belonging to these lineages may have gone largely undetected because of their low pathogenicity and/or transmissibility: characteristics that would be expected to result in the long-term survival of individuals that they manage to infect. This should therefore be manifested by individuals infected with these viruses displaying substantially higher degree of within-individual diversity than is usually displayed by individuals infected by viruses in the main pandemic lineages.</p>', 'Virus Evolution', NULL, 3, NULL, 'TongoVirusEvolutionHIVCongoBasinAbstract2017', 'Persistent, circulation, highly, divergent, HIV-1, HIV, group M, lineages, Congo, Basin, Congo Basin, Tulio de Oliveira, Marcel Tongo, Darren Martin, Virus Evolution, abstract, VEME 2017, Persistent, circulation, highly, divergent, HIV-1, HIV, group M, lineages, Congo, Basin, Congo Basin, Tulio de Oliveira, Marcel Tongo, Darren Martin, Virus Evolution, abstract, VEME 2017, Persistent, circulation, highly, divergent, HIV-1, HIV, group M, lineages, Congo, Basin, Congo Basin, Tulio de Oliveira, Marcel Tongo, Darren Martin, Virus Evolution, abstract, VEME 2017, Persistent, circulation, highly, divergent, HIV-1, HIV, group M, lineages, Congo, Basin, Congo Basin, Tulio de Oliveira, Marcel Tongo, Darren Martin, Virus Evolution, abstract, VEME 2017', 'Virus evolution VEME workshop abstract 2016. This paper suggests that large pools of undiscovered HIV-1M genetic diversity likely exist throughout equatorial West Africa. We hypothesise that viruses belonging to these lineages may have gone largely undetected because of their low pathogenicity and/or transmissibility: characteristics that would be expected to result in the long-term survival of individuals that they manage to infect. This should therefore be manifested by individuals infected with these viruses displaying substantially higher degree of within-individual diversity than is usually displayed by individuals infected by viruses in the main pandemic lineages.', 'doi: 10.1093/ve/vew036.039', NULL, 2017, '10.1093/ve/vew036.039', 5, 3, NULL, NULL, '', NULL),
(167, 'Automated profiling of the human virome from raw metagenomic data', 'Moosa Y, Vilsker M, Vanden Eyden E, Fonseca V, Nooij S, Deforche K, <a href=\"people.php?surname=de Oliveira\">de Oliveira T</a>', '<p>Viruses influence human health as conventional pathogens, as modulators of gene expression and through their involvement in complex host-microbiome interactions. Next generation sequencing (NGS) has enabled us to explore the role of the microbiome in human health and disease. </p><p>Metagenomic sequencing should allow us to profile all biological elements in a clinical sample in an unbiased, hypothesis-free way. However viruses display much greater variation than all other elements, and the existing tools and methods for virus identification and discovery are not effective enough. </p><p>We have developed a bioinformatics pipeline to identify and classify all known viruses present in a metagenomic sample. Viral NGS reads are identified using a protein-based alignment method, DIAMOND, which is substantially faster than the standard BLAST method, and more reliable for viruses. These reads are automatically assembled into contigs using SPAdes, a de novo assembler. The contigs are then used to classify the virus at species level using a pan-viral typing tool based on all available taxonomic reference sequences from the International Committee on Taxonomy of Viruses (ICTV) database. </p><p>This bioinformatics pipeline is Java-encoded and will include an easy-to-use web interface that is fit-for-purpose for researchers or clinicians. This tool can assemble viral contigs from paired-end reads generated by an Illumina MiSeq sequencer. So far 1865 viruses can be identified at species level resolution and 10 viruses (Chikungunya virus, Dengue virus, HBV, HCV, HHV8, HIV-1, HPV, HTLV-1, YFV, and Zika virus) at the genotype level. </p><p>A web version of the pan-viral typing tool is already available and a web version with extended NGS functionality is currently being evaluated. Eliminating the need for virus-specific laboratory techniques, or targeted sequence capture, means a virome can be profiled in the context of its non-viral microbiome. Preliminary findings suggest our tool offers greater functionality than existing alternatives, with greater sensitivity to known viruses (including bacteriophages), automatic assembly and good quality phylogenetic analyses. A systematic comparison is underway.</p>', 'Virus Evolution', NULL, 3, NULL, 'MoosaVirusEvolutionNGSViromeAbstract2017', 'virus evolution, bioinformatics, tool, Automated, profiling, human, virome, raw, metagenomic, data, de Oliveira, Koen Deforche, software, virome, virus, ICTV, NGS, next generation sequencing, virus evolution, bioinformatics, tool, Automated, profiling, human, virome, raw, metagenomic, data, de Oliveira, Koen Deforche, software, virome, virus, ICTV, NGS, next generation sequencing, virus evolution, bioinformatics, tool, Automated, profiling, human, virome, raw, metagenomic, data, de Oliveira, Koen Deforche, software, virome, virus, ICTV, NGS, next generation sequencing, VEME, 2017, 2017', 'Virus evolution VEME workshop abstracts 2017. A web version of the pan-viral typing tool is already available and a web version with extended NGS functionality is currently being evaluated. Eliminating the need for virus-specific laboratory techniques, or targeted sequence capture, means a virome can be profiled in the context of its non-viral microbiome. Preliminary findings suggest our tool offers greater functionality than existing alternatives, with greater sensitivity to known viruses (including bacteriophages), automatic assembly and good quality phylogenetic analyses. A systematic comparison is underway.', ' doi:  10.1093/ve/vew036.033', NULL, 2017, ' doi:  10.1093/ve/vew036.033', 5, 3, NULL, NULL, '', NULL),
(168, 'Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa', 'Hunt GM, Dokubo EK, Takuva S, de Oliveira T,  Ledwaba J, Dube N, Moodley P, Sabatier J, Deyde V, Morris L, Raizes E', '<p><b><i>Background:</b></i> KwaZulu-Natal (KZN) Province in South Africa has the highest HIV disease burden in the country, with an estimated population prevalence of 24.7%. A pilot sentinel surveillance project was undertaken in KZN to classify the proportion of adult patients failing first-line ART and to describe the patterns of drug resistance mutations (DRMs) in patients with virological failure (VF).</p>\n\n<p><b><i>Methods:</b></i> Cross-sectional surveillance of acquired HIV drug resistance was conducted in 15 sentinel ART clinics between August and November 2013. Two population groups were surveyed: on ART for 12-15months (Cohort A) or 24-36months (Cohort B). Plasma specimens with viral load >1000copies/mL were defined as VF and genotyped for DRMs.</p>\n\n<p><b><i>Results:</b></i> A total of 1299 adults were included in the analysis. The prevalence of VF was 4.0% (95% CI 1.8-8.8) among 540 adults in Cohort A and 7.7% (95% CI 4.4-13.0) of 759 adults in Cohort B. Treatment with efavirenz was more likely to suppress viral load in Cohort A (P<=0.005). Independent predictors of VF for Cohort B included male gender, advanced WHO stage at ART initiation and treatment with stavudine or zidovudine compared with tenofovir. DRMs were detected in 89% of 123 specimens with VF, including M184I/V, K103N/S, K65N/R, V106A/M and Y181C.</p>\n\n<p><b><i>Conclusions:</b></i> VF in adults in KZN was <8% up to 3 years post-ART initiation but was associated with a high frequency of DRMs. These data identify key groups for intensified adherence counselling and highlight the need to optimize first-line regimens to maintain viral suppression.</p>', 'Journal of Antimicrobial Chemotherapy', NULL, 10, NULL, 'Hunt_Journal_Antimicrobial_Chemotherapy2017', 'paper, de Oliveira, Hunt, hiv, mutation, drug, resistance, efavirenz, adult, counseling, male, plasma, primary, health, care, sentinel, surveillance, south, africa, stavudine, viral, load, result, world, health, organization, zidovudine, virology, tenofovir, hiv, infection, surveillance, medical, viral, suppression, paper, de Oliveira, Hunt, hiv, mutation, drug, resistance, efavirenz, adult, counseling, male, plasma, primary, health, care, sentinel, surveillance, south, africa, stavudine, viral, load, result, world, health, organization, zidovudine, virology, tenofovir, hiv, infection, surveillance, medical, viral, suppression, paper, de Oliveira, Hunt, hiv, mutation, drug, resistance, efavirenz, adult, counseling, male, plasma, primary, health, care, sentinel, surveillance, south, africa, stavudine, viral, load, result, world, health, organization, zidovudine, virology, tenofovir, hiv, infection, surveillance, medical, viral, suppression', 'KwaZulu-Natal (KZN) Province in South Africa has the highest HIV disease burden in the country, with an estimated population prevalence of 24.7%. A pilot sentinel surveillance project was undertaken in KZN to classify the proportion of adult patients failing first-line ART and to describe the patterns of drug resistance mutations (DRMs) in patients with virological failure (VF).VF in adults in KZN was <8% up to 3?years post-ART initiation but was associated with a high frequency of DRMs. These data identify key groups for intensified adherence counselling and highlight the need to optimize first-line regimens to maintain viral suppression.', 'https://doi.org/10.1093/jac/dkx252', NULL, 2017, 'https://doi.org/10.1093/jac/dkx252', 5.5, 3, NULL, NULL, '', NULL),
(169, 'Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele', 'Naidoo A, Naidoo K, <a href=\"http://krisp.org.za/people.php?surname=Ramsuran\">Ramsuran V</a>,  Reddy M, Padayatchi N', '<p> Panagopoulos et al reviewed the effects of the UGT1A1*28 polymorphism on Reyataz\r(atazanavir)-related hyperbilirubinemia in human immunodeficiency virus (HIV)-infected\rpatients that may result in increased severity and drug discontinuation in some patients.\n\r</p><p>The effects of the UGT1A1 polymorphisms on the pharmacokinetics of other antiretroviral\rdrugs such as Isentress (raltegravir) and Edurant (rilpivirine) are also discussed.\rWe respond here on the relevance of the study findings in the South African context.\r</p><p>The antiretroviral protease inhibitor (PI) atazanavir inhibits hepatic uridine diphosphate-\rglucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and\relimination of bilirubin.2 This may result in hyperbilirubinemia in >50% of patients,\rwith jaundice that can cause premature discontinuation of atazanavir in ~2%?8%\rof patients.2 Risk for bilirubin-related discontinuation of atazanavir is substantially\rincreased among individuals who carry two TAn repeat polymorphisms within the\rUGT1A1 loci: TA7 (UGT1A1*28) and TA8 (UGT1A1*37) that reduce gene transcription,\rwith reported positive predictive values for discontinuation ranging from 20%\rto 60% depending on race or ethnicity.</p>', 'Pharmacogenomics and Personalized Medicine', NULL, 1, NULL, 'Naidoo_Pharmacogenomics_Personalized_Medicine2017', 'Pharmacogenomics, Personalized, Medicine, manuscript, paper, 2017, veron, Ramsuran, HIV, TB, antiretroviral, protease, inhibitor, PI, atazanavir, south africa, genomics, genetics, open access, Pharmacogenomics, Personalized, Medicine, manuscript, paper, 2017, veron, Ramsuran, HIV, TB, antiretroviral, protease, inhibitor, PI, atazanavir, south africa, genomics, genetics, open access, Pharmacogenomics, Personalized, Medicine, manuscript, paper, 2017, veron, Ramsuran, HIV, TB, antiretroviral, protease, inhibitor, PI, atazanavir, south africa, genomics, genetics, open access, Pharmacogenomics, Personalized, Medicine, manuscript, paper, 2017, veron, Ramsuran, HIV, TB, antiretroviral, protease, inhibitor, PI, atazanavir, south africa, genomics, genetics, open access, Pharmacogenomics, Personalized, Medicine, manuscript, paper, 2017, veron, Ramsuran, HIV, TB, antiretroviral, protease, inhibitor, PI, atazanavir, south africa, genomics, genetics, open access', 'Paper on pharmakogenemics and personalized medicine, Data describing the prevalence and impact of genetic\rvariability on antiretroviral drug-metabolizing enzymes\r(DMEs) such as UGT1A1 from HIV endemic geographical\rlocations including South Africa are lacking. Investigating\rthe extent to which allelic variation of key DMEs impacts\rpharmacokinetics, drug exposures, therapeutic efficacy,\rand risk of serious adverse events is critical to ensure safe\rand sustainable virologic suppression.', 'doi: 10.2147/PGPM.S146787', NULL, 2017, 'doi: 10.2147/PGPM.S146787', 4.21, 3, NULL, NULL, '', NULL);
INSERT INTO `b_publications` (`id`, `title`, `authors`, `abstract`, `journal`, `volume`, `citations`, `link`, `file`, `keywords`, `topdescription`, `pages`, `datafile`, `date`, `doi`, `impact`, `bioafricaSATuRN`, `video`, `shorttitle`, `feature`, `projectid`) VALUES
(170, 'Impact of point-of-care Xpert MTB/RIF on tuberculosis treatment initiation: a cluster randomised trial', 'Lessells RJ, Cooke GS, McGrath N, Nicol MP, Newell ML, Godfrey-Faussett P', '<p><b><i>Rationale:</b></i> Point-of-care (POC) diagnostics have potential to reduce pre-treatment loss to follow-up and delays to initiation of appropriate TB treatment.</p>\r<p><b><i>Objective:</b></i> To evaluate the effect of a POC diagnostic strategy on initiation of appropriate TB treatment.</p>\n<p><b><i>Methods: </b></i>A cluster randomised trial of adults with cough who were HIV positive and/or at high risk of drug-resistant TB. Two-week time blocks were randomised to two strategies (i) Xpert performed at district hospital laboratory (ii) POC Xpert performed at primary health care clinic. All participants provided two sputum specimens: one for Xpert and the other for culture as reference standard. The primary outcome was the proportion of culture-positive pulmonary TB (PTB) cases initiated on appropriate TB treatment within 30 days.</p>\r<p><b><i>Measurements and Main Results:</b></i> Between August 22, 2011 and March 1, 2013, 36 two-week blocks were randomised and 1297 individuals were enrolled (646 in the laboratory arm, 651 in the POC arm); 159 (12.4%) had culture-positive PTB. The proportion of culture-positive PTB cases initiated on appropriate TB treatment within 30 days was 76.5% in the laboratory arm and 79.5% in the POC arm (odds ratio 1.13, 95% confidence interval [CI] 0.51-2.53, p = 0.76; risk difference 3.1%, 95% CI -16.2, 10.1). The median time to initiation of appropriate treatment was 7 days (laboratory) vs. 1 day (POC).</p>\r<p><b><i>Conclusions:</b></i> POC positioning of Xpert led to more rapid initiation of appropriate TB treatment. Achieving one-stop diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems.</p>', 'Am J Respir Crit Care Med', NULL, 5, NULL, 'Lessells_2017_AJRCCM_AuthorVersion', 'Tuberculosis, drug-resistant tuberculosis, molecular diagnostics, point-of-care systems, clinical trial, lessells, south africa, 2017, publication, TB, Xpert, open access, Tuberculosis, drug-resistant tuberculosis, molecular diagnostics, point-of-care systems, clinical trial, lessells, south africa, 2017, publication, TB, Xpert, open access, Tuberculosis, drug-resistant tuberculosis, molecular diagnostics, point-of-care systems, clinical trial, lessells, south africa, 2017, publication, TB, Xpert, open access, Tuberculosis, drug-resistant tuberculosis, molecular diagnostics, point-of-care systems, clinical trial, lessells, south africa, 2017, publication, TB, Xpert, open access, Tuberculosis, drug-resistant tuberculosis, molecular diagnostics, point-of-care systems, clinical trial, lessells, south africa, 2017, publication, TB, Xpert, open access', 'Paper by Lessells and colleagues that show POC positioning of Xpert led to more rapid initiation of appropriate TB treatment. Achieving one-stop diagnosis and treatment for all people with TB will require simpler, more sensitive diagnostics and broader strengthening of health systems.', 'doi: 10.1164/rccm.201702-0278OC', NULL, 2017, 'doi: 10.1164/rccm.201702-0278OC', 9.8, 3, NULL, NULL, '', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `b_reports`
--

CREATE TABLE `b_reports` (
  `id` int(11) NOT NULL,
  `title` longtext,
  `authors` longtext,
  `abstract` longtext,
  `summary` longtext,
  `journal` longtext,
  `volume` longtext,
  `link` longtext,
  `file` char(50) DEFAULT NULL,
  `keywords` longtext,
  `description` longtext,
  `pages` tinytext,
  `datafile` tinytext,
  `date` date DEFAULT NULL,
  `doi` tinytext,
  `bioafricaSATuRN` int(1) DEFAULT NULL,
  `image` tinytext,
  `pubid` int(11) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_reports`
--

INSERT INTO `b_reports` (`id`, `title`, `authors`, `abstract`, `summary`, `journal`, `volume`, `link`, `file`, `keywords`, `description`, `pages`, `datafile`, `date`, `doi`, `bioafricaSATuRN`, `image`, `pubid`) VALUES
(1, 'A survey of 10 years of primary drug resistance in South Africa', 'Manasa J, Cassol S, Seebregts C, Newell M-L, de Oliveira T\0', '<p><b><i>Methods: </p></b></i>\n<p>A literature review and data mining exercise was carried out to determine the temporal trends in TDR in South Africa. In addition, 72 sequences from seroconvertors identified from Africa Centre\'s 2010 HIV surveillance round were also examined for TDR. Publicly available data on TDR were retrieved from Genbank, curated in RegaDB and analyzed using the Calibrated Population Resistance Program. </p>\n<p><b><i>Results: </p></b></i>\n<p>There was no evidence of TDR from the 2010 rural KwaZulu Natal samples. Ten datasets with a total of 1618 sequences collected between 2000 and 2010 were pooled to provide a temporal analysis of TDR. The year with the highest TDR rate was 2002 (6.67%, 95% confidence interval (CI): 3.09-13.79%; n: 6/90). After 2002, TDR levels returned to <5% (WHO low-level threshold) and showed no statistically significant increase in the interval between 2002 and 2010. The most common mutations were associated with NNRTI resistance, K103N, followed by Y181C and Y188C/L. Five sequences had multiple resistance mutations associated with NNRTI resistance.</p><p><b><i> \nConclusions: </b></p></i>\n<p>There is no evidence of TDR in rural KwaZulu-Natal. TDR levels in South Africa have remained low following a downward trend since 2003. Continuous vigilance in monitoring of TDR is needed as more patients are initiated and maintained onto antiretroviral therapy.</p>\n<p><b><i>Reference</b></i></p>\n<p><a href=\"publications.php?pubid=41 \">Manasa J, Katzenstein D, Cassol S, Newell M.L, de Oliveira T. Primary drug resistance in South Africa - data from 10 years of surveys. AIDS Research and Human Retroviruses. Online ahead of print. doi:10.1089/AID.2011.0284. </a></p>', '<p><b><i>Background:</p></b></i>\n<p>HIV-1 transmitted drug resistance (TDR) could reverse the gains of antiretroviral rollout. To ensure that current 1st line therapies remain effective, TDR levels in recently infected treatment-naive patients need to be monitored.</p>', 'AIDS Res Hum Retroviruses', 'ahead of print. doi:10.1089/AID.2011.0284', NULL, NULL, 'hiv, drug resistance, primary, south africa, naive, ART, antiretroviral, mutations, hiv, drug resistance, primary, south africa, naive, ART, antiretroviral, mutations, hiv, drug resistance, primary, south africa, naive, ART, antiretroviral, mutations, hiv, drug resistance, primary, south africa, naive, ART, antiretroviral, mutations', 'To describe the trend in the prevalence of HIV primary transmitted drug resistance (TDR) in South Africa over the past 10 years.', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'id1HIVTDRprevalenceSouthAfrica.png', 41),
(2, 'Surveillance of Transmitted HIV-1 Drug Resistance in South African Provinces from 2005-2009', 'Hunt GM, Ledwaba J, Basson AE, Moyes J, Cohen C, Singh B, Bertagnolio S, Jordan MR, Puren A and Morris L\0', '<p><b>\0Methods: </p></b>\rAll participants were from Gauteng (GP) and KwaZulu-Natal (KZN) Provinces and were part of the 2005 to 2009 annual ante-natal HIV seroprevalence survey conducted by the National Department of Health. HIV-1 positive serum specimens were tested using the Aware BED EIA HIV-1 Incidence Test. TDR was assessed in primigravid women age <25 years. Genotyping was performed on viral RNA by sequencing the protease and reverse transcriptase genes. <br>\r<p><b>\0Results: </p></b>\rA total of 354 sequences were analyzed from 9 surveys. In GP, the levels of TDR were <5% for all drug classes while in KZN levels were <5% in 2007 but appeared to be increasing for NNRTI as these reached 5-15% in 2009. A total of 12 (3.4%) sequences had TDR including K103N and M184I/V. Use of the BED ELISA suggested that samples selected for inclusion into the study were enriched for those with incident infection. <br>\r\0<p><b>Conclusions:</p></b>\rAnalysis of the levels of TDR in 2 provinces of South Africa over 5 years suggested that in GP, TDR remains low while in KZN TDR levels may be increasing with the most recent survey showing moderate levels of resistance to the NNRTI drug class. Serological tests for incident infections may be a useful additional parameter to include in surveys of TDR. <br>\r\0', '<p><b>Background: </p></b>\rSurveillance of HIV-1 transmitted drug resistance (TDR) was conducted among pregnant women in South Africa over a 5 year period after the initiation of a large national antiretroviral treatment program.  <br>', 'CID', 'in press', NULL, NULL, 'Surveillance, transmitted, HIV-1, Drug Resistance, South African, Provinces, 2005-2009', 'Surveillance of Transmitted HIV-1 Drug Resistance in South African Provinces from 2005-2009', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'id2HIVTDRSurveillanceSouthAfrica.png', NULL),
(3, 'HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine', 'Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L and Kuhn L.\0', '<p><b>Design:</p></b> Drug resistance mutations were measured pre-treatment in 255 infants and young children under 2 years of age in South Africa exposed to sdNVP and initiating ritonavir-boosted lopinavir-based therapy.  Those who achieved viral suppression were randomized to either continue the primary regimen or to switch to a nevirapine-based regimen.  Pre-treatment samples were tested using population sequencing and real time allele-specific PCR (AS-PCR) to detect Y181C and K103N minority variants. Those with confirmed viremia >1000 copies/ml by 52 weeks post-randomization in the switch group were defined as having viral failure.<br>\r\0<p><b>Results:</p></b> Non-nucleoside reverse transcriptase inhibitor (NNRTI) mutations, predominantly Y181C, were detected by either method in 62% of infants less than 6 months of age, in 39% of children 6-12 months of age, 22% 12-18 months, and 16% 18-24 months (p=<0.0001). NNRTI mutations detected by genotyping, but not K103N or Y181C mutations detected only by AS-PCR, were associated with viral failure in the switch group.<br>\r<p><b>Conclusions: </p></b>The prevalence of mutations known to compromise primary NNRTI-based therapy is high in sdNVP-exposed children, supporting current guidelines recommending use of PI-based regimens for young children.  Standard genotyping is adequate to identify children who could benefit from switching to NNRTI-based therapy<br> \r', '<p><b>Objective:</p></b> To describe the prevalence of HIV-1 drug resistance mutations at the time of treatment initiation in a large cohort of HIV-infected children previously exposed to single dose nevirapine (sdNVP) for prevention of transmission.<br>', 'AIDS \r\n', '25(12): 1461:1469', NULL, NULL, 'HIV-1, drug resistance,  antiretroviral, treatment, initiation, children, exposed, single-dose, nevirapine\r\n\0', 'HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine\r\n', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'id3HIVDRChildrenPMTCT.png', NULL),
(4, 'Phenotypic Resistance to Etravirine in an HIV-1 Subtype-C Background', 'AE Basson, S-Y Rhee, CM Parry, T de Oliveira, D Pillay, R Shafer and L Morris\0', '<p><b>Methods:</p></b> Single and double NNRTI resistance mutations were introduced into an HIV-1 expression plasmid containing a ~3.7 kilo-base gag-pol insert from a subtype-C reference strain. The NNRTI mutation list from the International AIDS Society was used for selection of single mutants. Double mutants with significant covariation were identified by performing a Jaccard analysis on sequences from NNRTI experienced patients. Mutant plasmids were transfected into 293T-cells for the production of HIV-1 resistance vectors, and used to infect 293T-cells in serial dilutions of efavirenz, nevirapine and etravirine. Fold-change (FC) values were deduced for each virus-drug combination. Phenotypic resistance was classified by use of the Monogram PhenoSense and Virco Antivirogram cut-off values.<br>\r\0\r<p><b>Results: </p></b>Of the 30 single NNRTI mutations tested, only Y181I (FC>40) and Y181V (FC>40) caused high level resistance to etravirine. Mutations K101E/P, E138A/K, Y181C, Y188L and M230L gave a low to intermediate level of resistance. Mutations K101P, K103N, V106M, Y188L, G190S and M230L caused high-level resistance to efavirenz and nevirapine, while Y181C/I/V, Y188C/L and G190S conferred high-level resistance to nevirapine only. Mutation V179F conferred hyper-susceptibility to all three NNRTIs (FC=0.004-0.151). Mutation Y188C, although conferring high level resistance to nevirapine (FC>40), conferred hypersusceptibility to etravirine (FC=0.144). All eight double mutations caused high-level resistance to nevirapine (FC>40), and some to efavirenz. Interestingly, the combination of V179F with Y181C caused a high level of resistance to both etravirine (FC=>40) and nevirapine (FC>40). The Y181C and G190S double mutant was the only other combination that caused high-level resistance to etravirine (FC>40).<br>\r\r<p><b>Conclusion:</p></b> NNRTI resistance mutations, either singly or in combination, that arise in response to nevirapine or efavirenz rarely conferred high levels of resistance to etravirine. However, the combinations of V179F/Y181C and G190S/Y188C conferred high level resistance to ETV, as has previously been predicted. As combinations are not prevalent in currently failing individuals, etravirine is a suitable option for first-line NNRTI-based regimen salvage.<br>\r', '<p><b>Background:</p></b> South Africa has an estimated 5.7 million people infected with HIV-1 of whom 919,923 were receiving antiretroviral treatment by the end of 2009. The first-line regimen includes a non-nucleoside reverse transcriptase inhibitor (NNRTI), either efavirenz or nevirapine. Both drugs share similar mutation profiles and exhibit cross-resistance. Here we examine the phenotypic sensitivity of single and double NNRTI mutations found in patients failing either nevirapine or efavirenz, to a second generation NNRTI, etravirine which has an unrelated resistance profile.<br>', 'Poster Presentation, International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, June 7-11, 2011, Los Cabos, Mexico.', NULL, NULL, NULL, 'Phenotypic, Resistance,  Etravirine, HIV-1, Subtype-C, drug, resistance, subtype c', 'Phenotypic Resistance to Etravirine in an HIV-1 Subtype-C Background\r\n', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'id4HIVDRphenotype.png', NULL),
(5, 'In adult patients failing a second-line protease inhibitor regimen lopinavir concentration measurement in plasma or hair are helpful to exclude patients with poor adherence from unnecessary resistance testing', 'van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G.\0', '<p><b>Objective: </p></b>Therefore objective measures of drug exposure such as plasma concentration (recent drug use) or hair concentration (longer term drug use) could be helpful in identifying those patients with failure despite good adherence who would need resistance testing. In a study of patients failing this second-line regimen in 2009 conducted in two public healthcare sites, only 2 of 93 patients on this regimen had protease inhibitor resistance.<br>\r\r<p><b>Results:</p></b> A high lopinavir plasma or hair concentration had a negative predictive value of 86% and 89%, for virological failure and the use of both plasma and hair concentrations could detect all patients with inadequate drug exposure and who did not have resistance while having virological failure of the regimen.<br>\r<p><b>Conclusion: </p></b>We therefore propose that lopinavir hair and or plasma measurement should form part of the work-up of patients failing a second-line boosted protease inhibitor regimen to exclude patients with inadequate adherence from genotypic antiretroviral resistance testing. <br>\r', '<p><b>Background: </p></b>South African patients receiving a regimen of LPV/r, didanosine and zidovudine as a second regimen have a high prevalence of virological failure (30-40%). This could be due the poor tolerability of the regimen. However problems with adherence are often not disclosed.<br>', ' J Acquir Immune Defic Syndr.', '56, 333:339', NULL, NULL, 'second-line, protease, inhibitor , lopinavir , plasma,  hair , poor, adherence', 'In adult patients failing a second-line protease inhibitor regimen lopinavir concentration measurement in plasma or hair are helpful to exclude patients with poor adherence from unnecessary resistance testing\r\n\0', '333-339', NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'id5HIVDRHairLopinavir.png', NULL),
(6, 'HIV clinical management: Integrating virtually failure clinics in southern Africa', 'de Oliveira T, Rossouw T, Van Vuuren C, Naidu K, Ndwandwe L, Seebregts C\r\n\0', '<p>Data on HIV drug resistance and its impact on  the management of patients with subtype C viruses is limited. Information on resistance associated mutations at clinical outcome of patients is needed to guide treatment options and ensure that South Africas ART program is highly effective. </p>\r<p><b>Virtual Failure Clinic meetings:</b></p>\rA virtual failure clinic meeting is schedule twice a month on Wednesdays, 8am-9am. During these meetings, one clinical cases are presented together with literature on the subject. <br>\r<p><b>\0How to participate in the virtual failure clinics:</b></p>\rThese meetings are targeted at clinicians, clinical virologists, researchers and post-graduate students who are currently involved in the treatment of patients with ARVs in Southern Africa. <br>\rParticipants need to register with SATuRN in advance and will join via conference call.<br>\r<br>\r<b>Contact Information:</b><br>\r<br>\rLungani Ndwandwe<br>\rSATuRN Research Assistant<br>\rAfrica Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele -  South Africa.<br>\rTel :(035) 550 7500<br>\rFax:(035) 550 7565<br>\re-mail : lunndwandwe@africacentre.ac.za<br>\r<br>', '<p><b>Introduction: </b></p>Several years into the ART rollout program in South Africa, some patients are beginning to fail their first or second-line drug regimens.', NULL, NULL, NULL, NULL, 'HIV, clinical, management, Integrating, virtually, failure, clinics, southern, south, Africa, saturn', 'HIV clinical management: Integrating virtually failure clinics in southern Africa', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'imgwhite.png', NULL),
(7, 'Southern African HIV Drug Resistance and Clinical Management Workshop', 'de Oliveira T, Seebregts C on behalf of SATuRN', '<p><b>Successful past and promising future:</b></p>\rThe 4th and 5th workshops were presented at the University of the Free State (UFS) Medical School in 2009 and 2010. This workshop, to the best of our knowledge, is now considered the top regional meeting on HIV drug resistance and clinical management. In total we have trained nearly 1,000 physicians and nurses as part of this workshop.\r<p>For example, in 2010 we got 436 applications and 215 participants attended the workshop, representing in total 17 countries. We also had 22 presenters. These included the CDC/PEPFAR Chief of the AIDS Treatment and Care Branch in South Africa, Prof. Jeffrey Klausner, the director of the HIV resistance program from the World Health Organization, Dr. Michael Jordan and some of the top international and national HIV clinicians and researchers. </p>\r<p>In 2011, we had 345 participants in the SA AIDS Drug Resistance Satelitte Meeting, We have also presented the 6th Southern Africa HIV & TB Drug Resistance and Treatment Monitoring Workshop, Gaborone, 7-11 November 2011. This workshop was divided in two, 7-8 Nov as the SATuRN annual workshop (attended by 227) and the second part, which attended by 79 Botswana physicians that were selected and sponsored by their Ministry of Health for further training on HIV drug resistance and clinical management with SATuRN. To the best of our knowledge this is now considered to be the best regional workshop on drug resistance and treatment monitoring. </p>\n<p>This year we had 227 participants confirmed the participation of many leading international and regional scientists including: Prof. Mark Wainberg (MacGill, Canada), Prof. Vladmir Novistiky (Harvard, U.S.), Prof. Anne-Mieke Vandamme (REGA Institute, Belgium), Prof. Peter Godfrey-Faussett (LSHTM, U.K), Prof. Annatjie Peters (CDC, South Africa) and many others (complete list of the 31 presenters is seen at the  <a href=\"http://www.bioafrica.net/saturn/\">http://www.bioafrica.net/saturn/</a> website).</p>\n\n<p>Interested in training and capacity building? Please visit our annual SATuRN workshop webpage:</p>\n<p><a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\"><b>7th South African HIV & TB Drug Resistance and Treatment Monitoring Workshop</b>, Cape Town International Conference Centre, 28 to 29 November 2012, Cape Town, <b>South Africa.</b></a></p>', '<p><b>Introduction:</b></p>\rThe Southern African Drug Resistance and Clinical Management Workshop is presented every year. The workshop includes theoretical lectures and practical sessions on the usage and interpretation of HIV-1 drug resistance genotyping in the management of HIV patients on anti-retroviral (ARV) treatment. This workshop is targeted at clinicians, clinical virologists, nurses, medical students and researchers working in the public and private sector who are currently involved in the treatment of patients with ARVs in Southern Africa.', NULL, NULL, NULL, NULL, 'Southern, African, HIV, Drug, Resistance ,Clinical, Management, Workshop, saturn', 'Southern African HIV Drug Resistance and Clinical Management Workshop', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'id8HIVDRWorkshop.png', NULL),
(8, 'SATuRN and Life Technologies (ABI) partnership provide a discounted HIV resistance genotyping system', 'SATuRN / Life Technologies', '<p>Public health and patient benefit may be limited by the increase in selection and transmission of broadly ARV resistant viruses. Drug resistance viruses can currently be identified with genetic sequencing of two HIV-1 genes. However, the price of an individual test using commercial methods (ZAR 2,500 or US$ 300) makes it too expensive for public health implementation in southern Africa.</p>\r\r<p><b>SATuRN HIV Resistance Genotyping:</b></p>\rWe have developed an in-house HIV resistance genotyping system in collaboration with the Stanford HIV Drug Resistance Database team and it has been internationally validated by the French AIDS Research (French acronym: ANRS).\r\r<p>\0Our in-house sequences are generated with the Sanger ABI sequencing technology. This process involves the production of cDNA, which is reverse transcribed from the viral RNA. Our in-house genotyping test reagents currently costs around ZAR 750 (US$ 100) per sample, a great part of the cost of which ZAR560/ZAR750 (US$80/US$100) is due to the cDNA synthesis and the ABI sequencing process. SATuRN members would like to ask ABI to reduce the price of the reagents needed for HIV drug resistance genotyping for the members of our network.</p>\r\r<p><b>Life Technologies (ABI) and SATuRN partnership:</b></p>\rLife Technologies has agreed to provide a 25% discount for reagents for HIV genotyping to SATuRN members. This partnership aims to produce a discounted genotypic test kit to southern African partners that will be available soon. \n<p>For the moment, partners can request discounted reagents from ABI (Seshnee Pillay, Seshnee.Pillay@lifetech.com) and the protocol and validation samples from SATuRN partners at the UFS (Dr. Dominique Goedhals, gnvrdg@ufs.ac.za) and Africa Centre (Justen Manasa, jmanasa@africacentre.ac.za). </p>\r\0', '<p><b>Introduction:</b></p>\rAntiretroviral (ARV) drugs are becoming increasingly available to treat HIV-1 infected individuals in the developing world. The goal of many governments and non-governmental organizations is to sustain the effective ARV treatment of > 5 million people in Africa. Pharmaceutical companies are reducing both prices and international trade restrictions on patented drugs to allow more equitable access to essential medicines for AIDS, TB and Malaria. However, the widespread increase of treatment is threatened by the appearance of drug resistance. ', NULL, NULL, NULL, NULL, 'SATuRN , Life Technologies, ABI, partnership , discounted, HIV, resistance, genotyping, system', 'SATuRN and Life Technologies (ABI) partnership provide a discounted HIV resistance genotyping system', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'imgwhite.png', NULL),
(9, 'Southern African Treatment and Resistance Network (SATuRN) Executive Summary', 'Tulio de Oliveira, Justen Manasa, Lungani Ndwandwe, Richard Lessells, David Katzenstein, Chris Seebregts', '<p><h2>SATuRN</h2></p>\r<p></p>\r<p>SATuRN is a network consisting of <a href=\"saturnpartners.html\">biomedical scientists, clinicians, epidemiologists and public health experts </a> working in collaboration to monitor, evaluate and deliver Anti-retroviral (ARV) and TB therapy in Africa.  SATuRN currently includes <a href=\"saturnpartners.html\">24 research partners in Southern Africa</a>. SATuRN has collated over 7,000 resistance genotypes linked to treatment and clinical information. These datasets are open to researchers and post-graduate students through the submission of a dataset request.</p>\r<br>\r<p><h2>Problem</h2></p>\r<p></p>\r<p>With the massive scale up of HIV/AIDS antiretroviral therapy (ART), the development of HIV-1 drug resistance poses a major threat to sustaining the achievements of ART programmes in Africa. Drug resistance monitoring is limited by the lack of laboratory resources and adequately trained personnel to manage patients with drug resistance. Furthermore, Africa, particularly Southern Africa is the hardest hit, with the largest patient burden. </p>\r<br>\r<p><h2>Solution and what makes us unique</h2></p>\r<p></p>\r<p>SATuRN has developed an approach to virological failure management that ensures the  delivery of drug resistance genotyping and clinical management to remote clinics without elaborate computer systems or infectious disease specialists on site. By applying telemedicine, off site laboratories and specialists physicians from medical centers across the world can review the cases, including clinical and resistance data, and give feedback and advice to the clinician managing the patient at the primary clinic. </p>\n<p>To increase access to efficient, low cost genotyping and drug resistance testing in Africa, SATuRN has been working with a network of governments, academics and laboratories to develop and implement a cheaper resistance genotype test. SATuRN current in-house genotyping system is based on the Sanger ABI sequencing technology. Working in partnership with a key player in the field of molecular diagnostic, Life Technologies Inc, we have managed to reduce the cost of reagents for genotyping from around $250 to about $50. We are working now with the next generation DNA sequencing to further decrease the price of resistance genotyping.</p>\r<p></p>\r<p>SATuRN collaborators have produced over 7,000 drug resistance genotypes that were used for the surveillance and monitoring of drug resistance in the region. These genotypes are stored and it is publically available at the <a href=\"SaturnStanfordHIVDB.html\"> first African Public Drug Resistance in Africa</a><a href=\"../publications.php?pubid=1\"> (de Oliveira et al. Nature 2010)</a>. SATuRN distributes information to researchers, public health officials and international funding agencies in the form of <a href=\"../output.php\">open access reports and publications on the level of HIV & TB drug resistance </a>in southern Africa </p>\r<p></p>\r<p>In addition to these progressive initiatives, SATuRN also offers training to over 1,000 physicians and nurses in Southern Africa for drug resistance testing. </p>\n<p><b><i>The long-term goal being to expand clinical and laboratory training, to build research capacity and to enhance treatment throughout Africa. </b></i></p>\r', '<p><h2>Executive Summary</h2></p>\r<p>To build innovative collaborations between researchers, clinicians and public health experts focused on the monitoring, evaluation and delivery of anti-retroviral (ARV) and anti-TB therapy in Africa. </p>', 'SATuRN report 2011', NULL, NULL, 'SATURN', 'Southern, African, Treatmen, Resistance, Network, SATuRN, Executive, Summary', 'Southern African Treatment and Resistance Network (SATuRN) Executive Summary', NULL, NULL, '2011-12-01', 'SATuRN 2011 report', 3, 'imgsaturn1.png', NULL),
(10, 'A Report of the Center for Global Development\'s Drug Resistance Working Group', 'Editors: Rachel Nugent, Emma Back and Alexandra Beith', '<p>Drug resistance is an extremely serious problem that is today undermining effective health care for millions of people and threatens to grow worse, yet it doesn\'t receive serious attention. On a technical level, this is because drug efficacy is a common property resource: one that is difficult to bar people from using, but that does run out if we overuse it. We all want to believe that the drugs we rely upon will keep working no matter how much we use them or misuse them. Further, many actors make deci- sions that determine the trajectory of drug resistance that impose invisible costs to society, thereby lulling us into complacency. On a human level, it is hard to see that people are dying from drug resistance, but they are. As with climate change, we now understand the science of drug resistance well enough to act, but the policy response has eluded us.</p>\r<p>The Center for Global Development\'s global health work focuses on issues where donors can benefit from expert techni- cal advice and detailed analysis to guide decisions about resource investments. This report is an example. The Drug Resistance Working Groupi was convened in late 2007 to identify practical and feasible ways for donors, multilateral organizations, non- governmental organizations, and private companies to prevent or contain resistance to drugs for infectious diseases affecting developing countries.</p>\r<p>The highly accomplished members of the Working Group came to this task with a wide range of specialized knowledge. They acknowledged the difficulties of tackling drug resistance from a perch in Washington, Boston, London, and even Accra, but insisted that the recommendations include both global actions and local solutions that hold the potential to alter the culture of how we use medicines worldwide. In the course of their discus- sions, Working Group members carefully examined the common drivers of drug resistance that plague treatment efforts for many infectious diseases, particularly in developing countries. As a result, their recommendations emphasize common, cross-disease approaches, rather than vertical, disease-specific actions.</p>\n<p>The full report is open accessible at the <a href=\"http://www.cgdev.org/content/publications/detail/1424207\">Centre for Global Development Website</a>.\r\n\n', '<p>In an increasingly interconnected world, problems with drug resistance have moved from the patient\'s bedside to threaten global public health. Drug resistance has dramatically increased the costs of fighting tuberculosis (TB) and malaria, has slowed gains against childhood dysentery and pneumonia, and threatens to undermine the push to treat people living with HIV/AIDS effectively. Global health funders and development agencies have cause to worry about whether their investments in access to drugs, and global health programming more broadly, are being undone by the relentless advance of drug resistance.</p>', NULL, NULL, 'http://www.cgdev.org/files/1424207_file_CGD_DRWG_FINAL.pdf', NULL, 'Report, Center, Global,Development, SATuRN, bioafrica, Drug, Resistance, Working, Group, HIV', 'A Report of the Center for Global Development\'s Drug Resistance Working Group highlights the SATuRN HIV Drug Resistance Databases', NULL, NULL, '2012-01-14', 'Center for Global Development Report', 3, 'imgCGDtable.png', NULL),
(11, 'Transmited Drug Resistance data now more accessible through HIVDB GIS Tool', 'Manasa J, Hunt G and de Oliveira T for SATuRN', '<p><b><i>Transmitted Drug Resistance</b></i></p>\r<p>The transmission of viruses already resistant to the antiretrovirals currently in use poses serious challenges to the management of these recent infections. These patients start ART with a compromised arsenal of ARVs. Therefore in resource-rich settings where TDR levels are higher, it is recommended that patients are genotyped before they can be initiated onto ART. This helps the physicians personalize the regimens based on the resistance profiles identified. However, this cannot be done in resource-limited settings, which have the greatest burdens of HIV. Therefore routine surveillance programs to monitor the levels of TDR at a population level to support the public health approach to ART have been recommended. A number of publications reporting on the prevalence to TDR in different settings have sequences that are made publicly available through Genbank. </p>\r\r<p><b><i>The GIS Tool</b></i></p>\r<p>The GIS tool developed by the Stanford team generates spatial temporal data on the prevalence of TDR from studies published in different settings across the globe. The studies included had publicly available HIV-1 RT  protease sequences from well-characterized representative populations of untreated HIV-1-infected individuals for which the country and year of virus isolation were available. Studies with epidemiologically linked patients were excluded as well as studies with study populations > 25 years of age. Currently the GIS tool is generating the prevalence from sequences from more that 30,000 treatment nave patients published in more than 213 peer-reviewed articles. These studies have been published from both resource-rich and resource-limited settings. Each study included in the GIS tool is represented as a circle on the map. The size of the circle corresponds to the sample size and color to the prevalence of TDR. </p>\r\r<p><b><i>Results </b></i></p>\r<p>Data focusing on studies from Sub-Saharan Africa (SSA) and South East Asia (SEA) generated by the GIS tool was recently presented at the 19th CROI (03-08 March, 2012). 82 studies from Sub-Saharan Africa (SSA) and 39 from South / Southeast Asia (SSEA) met inclusion criteria. The 82 SSA studies included 9,179 individuals (median 71 per study). The SSA studies were most frequently conducted in South Africa (ZA; n=12), Cameroon (CM; n=7) and Uganda (UG; n=7). In 30 additional SSA countries, 1 to 3 studies were conducted. Eight studies included individuals from more than one country (Figure 1).</p>\r<p>The 39 SSEA studies included 3,189 individuals (median 57 per study). The 39 SSEA studies were conducted in China (CN; n=10), India (IN; n=10), Vietnam (VN; n=7), Thailand (TH; n=3), Cambodia (KH; n=2), and Malaysia (MY; n=2). Three studies were performed in countries of the former Soviet Union and two studies included individuals from more than one country. </p>\r\r<p>Figure 1. HIV TDR in sub-Saharan Africa</p>\r\r<p><b><i>Subtype distribution:</b></i></p>\r<p>The most common HIV-1 subtypes in SSA were subtype C, followed by CRF02_AG, A, D, and several other CRFs and URFs. The most common subtypes in SSEA were CRF01_AE, followed by subtype C, subtype B, and two B/C CRFs (CRF_07 and CRF_08), and B/01 recombinants.</p>\r\r<p>Prevalence of genotypic resistance: The median proportion of individuals per study having > 1 SDRMs was 3.2% for SSA (IQR: 1.1% to 5.7%) and 2.4% for SSEA (IQR: 0.6% to 6.1%). In both SSA and SSEA, the prevalence of NNRTI SDRM increased with year of virus sampling (OR=1.003; p<0.001 for both regions). In SSA, but not in SEA, the prevalence of NRTI SDRM increased with year of virus sampling (OR=1.003; p=0.005). There were no temporal trends in the prevalence of PI SDRM in either region .</p>\r\r<p>The collation and analysis of data collected over time and from various geographic settings provides more insight on the impact of the increased access to ART on the patterns and levels of TDR than the analysis of individual studies. Although there is an overall upward trend in the levels of TDR in both SSA and SEA, TDR levels are still low, <5%. This analysis also confirms recently published data from South Africa that also showed that TDR levels in South are still less than 5%. However, there is need for more vigilance in monitoring TDR especially in SSA as there are some individual studies that have shown levels TDR surpassing the 5% threshold. In addition, the numbers of patients on ART have been increasing exponentially during the past ten years necessitating closer monitoring of the ART programmes.</p>\r\r\r<p><b><i>Sources:</b></i></p>\r<p>1.	<a href=\"http://hivdb.stanford.edu/surveillance/map/\">http://hivdb.stanford.edu/surveillance/map/</a></p>\r<p>2.	Rhee S.Y, Blanco J.L, Liu T.F, Varghese V. Tang, M and RW Shafer, R.W. (2012). Surveillance Drug Resistance Mutation Prevalence in Untreated Populations in Sub-Saharan Africa (SSA) and South/South East Asia (SSEA): Regional Differences and Temporal Trends. Abstract presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI); 5-8 March 2012. Abstract No. 739</p>\r<p>3.	<a href=\"publications.php?pubid=41 \">Manasa J, Katzenstein D, Cassol S, Newell M.L, de Oliveira T. Primary drug resistance in South Africa - data from 10 years of surveys. AIDS Research and Human Retroviruses. Online ahead of print. doi:10.1089/AID.2011.0284. </a></p>', '<p>A new interactive Geographic Information System (GIS) displaying studies of HIV-1 Drug Resistance in ARV-Naive Populations has just been added to the ever-expanding HIV drug resistance monitoring tools developed by Stanford HIVDB group and their collaborators (Rhee et al. CROI 2012). The system uses published data to create snapshots of HIV transmitted drug resistance (TDR) levels across the globe. The data currently used is available through Genbank. </p>\r', 'SATuRN report 2012', NULL, NULL, NULL, 'Transmited, HIV, Drug, Resistance, data, accessibl, Stanford, database, HIVDB, GIS, Tool', 'Transmited Drug Resistance data now more accessible through HIVDB GIS Tool at Stanford HIV Drug Resistance Database', NULL, NULL, '2012-03-29', 'SATuRN 2012 report', 3, 'imgTDRGIS.png', NULL),
(12, '1st Nurses & Health Care Workers Drug Resistance Workshop', 'Lungani Ndwandwe, Tulio de Oliveira ', '<p>This workshop was organized by the Africa Centre and SATuRN HIV drug resistance teams, with the support of a pediatrician, dietician, and social workers and in partnership with the Department of Health (DOH). The workshop presented on 22nd May 2012 was targeted at nurses and health care workers from 17 clinics around the Hlabisa sub/district and aimed at equipping them to deal effectively with HIV drug resistance. The workshop was very well attended with 58 participants, which meant that we ran at our auditorium full capacity. The main focus of this workshop was to give nurses and health workers the necessary knowledge to handle HIV drug resistance in children. The programme ranged from the scientific background of HIV drug resistance, from nutrition and growth in children and its correlation with HIV drug resistance, to a more practical session with role-plays, where the teams produced a theater play out how to deal with drug resistance from a clinical, social and psychological point of view.  </p>\n<p>In addition, Dr. Siva Danaviah (Africa Centre, Durban) delivered a very impressive presentation on how drug resistance develops in a patient. This was followed by a series of drug resistance clinical cases presented by Prof. Ruth Bland (Pediatrician and clinical research leader of Africa Centre). The issue of disclosure ranked high in the discussions and a disclosure section was led and presented by Dr Tamsen Rochat (Psychologist) and Dumo Mkhwanazi (PhD candidate). During this section, they presented helpful steps on how one can go about disclosing the child HIV status. </p>\n<p>One of the main focuses of the workshop was to highlight that a detectable viral load result is an emergency situation and that a detectable viral load while on ARVs means that resistance is likely to develop. The workshop generated great discussion and increased awareness of this subject. <b><i>\"This workshop has been helpful to me, especially since I work closely with patients on ARVs and my task is to educate patients about the importance of taking ARVs and most importantly let them know that taking ARVs is a long term commitment\"</b></i>, said Mthunzi Mlambo, a clinic HIV counsellor. He continued on to say <b><i>\"This workshop has changed the way I will now deal with my patients, in particular on issues of disclosure and their viral load results\".</b></i></p>\n<p>This comes after a successful meeting between SATuRN and South Africa Department of Health at the end of April, where HIV drug resistance ranked as one of the highest priorities of the DOH. Consequently, the DOH is seeking to upscale HIV resistance testing and SATuRN will continue to host more workshops of this nature among the 17 clinics decentralized across the Hlabisa sub district as well as in the Free State province. The HIV drug resistance team has been working tirelessly to identify patients failing ART, organizing ART failure camps in the 17 clinics, and now hosting workshops, which will continue throughout the year. For this, the resistance team would like to thank the DOH and the DOH staff for their continued support for this initiative. The good news are that we have already seen more patients responding to treatment since this collaboration started. </p>\n<br>\n<p>Interested in training and capacity building? Please visit our annual SATuRN workshop webpage:</p>\n<p><a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\">7th South African HIV & TB Drug Resistance and Treatment Monitoring Workshop, Cape Town International Conference Centre, 28 to 29 November 2012, Cape Town, South Africa.</a></p>', '<p>One of the major challenges of any breakthrough in medical research or medical intervention is drug resistance. It should be pointed out that drug resistance in itself is complex and even more difficult to treat. HIV is no exception; SATuRN\'s research has proved the unfortunate fact that HIV drug resistance in adults and children in rural areas is very high. In order to generate awareness of this subject, we organized and hosted our first nurses and health care workers HIV & TB drug resistance workshop.</p>', 'SATuRN report 2012', NULL, NULL, NULL, 'Nurses, Health Care Workers, HCW, HIV, TB, children, Drug, Resistance, Workshop, SATuRN', 'Report on the 1st SATuRN Nurses & Health Care Workers HIV & TB Drug Resistance Workshop, Africa Centre for Health and Population Studies, KZN, 22 May 2012', NULL, NULL, '2012-06-01', 'SATuRN 2012 report', 3, 'imgNURSES.gif', NULL),
(13, 'SATuRN\'s Featured Partner: Division of Medical Virology, Stellenbosh University', 'Wolfgang Preiser, Gert van Zyl & Susan Engelbrecht', '<p>The Division of Medical Virology at Tygerberg comprises a diagnostic section which, as part of the South African National Health Laboratory Service (NHLS), provides a state-of-the-art, SANAS-accredited virological diagnostic service for the population of the Western Cape province. Its diagnostic staff perform an average of 14,000 tests per month of which almost one half are HIV-related, mostly HIV viral load, infant PCR and combined antibody-antigen tests.</p>\n<p>In addition, its academic staff pursue a number of well established research interests. These include the genomic diversity and molecular epidemiology of HIV; immunological aspects of HIV infection relevant to the development of vaccines and novel immunotherapeutic approaches; the diagnosis and monitoring of opportunistic infections, especially hepatitis B virus (HBV); and diagnostic and epidemiological aspects of emerging viral diseases. </p>\n<p>When South Africa finally embarked on its antiretroviral roll-out programme in 2004, this turned into a major success. However, from the experience of developed countries where universal antiretroviral coverage became a reality in the mid-1990s, it had to be expected that with the programme coming of age, novel challenges would emerge. One of these is antiretroviral drug resistance .</p>\n<p>Based on Prof. Susan Engelbrecht\'s longstanding interest in HIV diversity, Prof. Wolfgang Preiser\'s experience with diagnosing and managing drug resistance in the U.K. and in Germany (where resistance testing is part of routine patient management), and Dr. Gert van Zyl\'s first-hand clinical involvement and interest in epidemiology, the Division developed HIV drug resistance as a new research theme.</p>\n<p>This theme comprises a number of different aspects. Because genotypic resistance testing through sequencing is technically demanding and commercially available assays are expensive and may not perform well in our setting, an in house method which is better yet cheaper than comparable commercial tests was developed as part of a Master\'s project and is now being used routinely. </p>\n<p>Tygerberg Virology is currently one of only two NHLS laboratories performing routine diagnostic HIV drug resistance testing. It performs approximately 80 tests per month, no mean feat for a very demanding test which, in addition to the laboratory side, requires the complex task of interpreting results in the context of the individual patient\'s treatment history. The number of requests for this highly specialised service is expected to increase further once guidelines on resistance testing are released by the SA HIV Clinicians Society.</p>\n<p>The Division is conducting systematic surveillance in different groups of patients. Given that the \"public health approach\" means that patients receive standardised antiretroviral treatment regimens, the aim is to generate reliable data to inform future changes to the treatment protocol.</p>\n<p>It was found that of mothers who received a dual regimen for the prevention of mother-to-child transmission of HIV, combining short-course zidovudine with single-dose nevirapine, only half as many (17.1%) developed resistance to the latter compared to mothers not receiving the zidovudine component. This is another significant advantage of the combined regimen, in addition to reducing the risk of neonatal infection.</p>\n<p>A high rate of resistance mutations was found in pre-treatment Tanzanian patients not fulfilling the WHO criteria for transmitted resistance threshold surveys. This suggests that baseline resistance may be more common than would be expected from such surveys alone. WHO is currently considering a revision of surveillance recommendations for transmitted HIV drug resistance, to take into account these findings.</p>\n<p>Overall however the results obtained so far are encouraging, demonstrating that antiretroviral drug resistance is not yet a major problem for most South African HIV patients. However, as the South African public sector treatment programme grows and the treated cohort \"matures\", more patients will develop resistance. In parallel, a larger proportion of new infections will then be acquired from those failing therapy and harbouring resistant virus.</p>\n<p>A new publication on <a href=\"http://www.bioafrica.net/report.php?id=14\">deep sequencing shed light on low levels of PI resistance in patients with poor adherence is also featured at the SATuRN 2012 report</a>.</p> \n<p>Division of Medical Virology , Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University and National Health Laboratory Service (NHLS) Tygerberg</p>\n<p>PO Box 19063, Tygerberg 7505, SOUTH AFRICA</p>\n<p>Tel: +27 21 938 9353, Fax: +27 21 938 9361</p>\n<p>Link: <a href=\"http://www.sun.ac.za/virology\">http://www.sun.ac.za/virology</a></p>\n<p>contact: Mrs Sal van Zyl, E-mail: sal@sun.ac.za</p>\n<p><b>By Wolfgang Preiser </b>(Professor and Head),\r\n<b>Gert van Zyl</b> (Senior Specialist) & <b>Susan Engelbrecht</b> (Professor and Senior Scientist</p>\n<center><p><img src=\"imagesBIO/imgreport13people.gif\" alt=\"\"></p></center>', '', 'SATuRN report 2012', NULL, NULL, NULL, 'SATuRN, Featured, Partner, Division of Medical Virology, Stellenbosh University, Wolfgang Preiser, Gert van Zyl, Susan Engelbrecht, cape town, south africa', 'SATuRN Featured Partner, Division of Medical Virology, Stellenbosh University. HIV drug resistance and diversity research by Wolfgang Preiser, Gert van Zyl, Susan Engelbrecht, Cape Town, South Africa', NULL, NULL, '2012-07-02', 'SATuRN 2012 report', 3, 'imgreport13.gif', NULL),
(14, 'Deep sequencing shed light on low levels of PI resistance in patients with poor adherence', 'Gert van Zyl & Wolfgang Preiser', '', '<p><b>Cape Town, South Africa, 2012</b>. A team from <a href=\"http://www.bioafrica.net/report.php?id=13\">Division of Medical Virology, Stellenbosch University</a>, University of Western Cape and University of California, San Diego performed deep sequencing and analysed results from 7 South African patients who failed a second-line lopinavir/ritonavir based regimen. Standard sequencing revealed no protease inhibitor (PI) resistance, but deep sequencing revealed low abundance PI resistant HIV variants in 5 of 7 patients, which probably does not emerge to become predominant due to inadequate drug pressure, in the setting of inadequate adherence.</p>\n<p>This work may help to explain the higher probability of PI resistance in patients with intermediate to high levels of adherence. [Epublished in Journal of Virology, 28 March 2012]</p><p> <b>Link: <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/22457522\">http://www.ncbi.nlm.nih.gov/pubmed/22457522</a></b></p>\n<p><b><a href=\"http://www.bioafrica.net/report.php?id=13\">SATuRN\'s Featured Partner: The Division of Medical Virology, Stellenbosch University </a></p>', 'SATuRN report 2012', NULL, NULL, NULL, 'Deep, sequencing, low levels, PI resistance, poor, adherence, gdert Van Zyl, Journal Virology, 2012, SATuRN report ', 'Deep sequencing shed light on low levels of PI resistance in patients with poor adherence. A team from Stellenbosh that parter with SATuRN performed deep sequencing and analysed results from 7 South African patients who failed a second-line lopinavir/ritonavir based regimen. Standard sequencing revealed no protease inhibitor (PI) resistance, but deep sequencing revealed low abundance PI resistant HIV variants in 5 of 7 patients.', NULL, NULL, '2012-07-02', 'SATuRN 2012 report', 3, 'imgwhite.png', NULL),
(15, 'SATuRN\'s Featured Partner: New TB centre at the  London School of Hygiene and Tropical Medicine\r\n', 'Richard Lessells & Tulio de Oliveira', '<p>The TB Centre at the London School of Hygiene & Tropical Medicine is a unique collaborative academic centre, representing the largest collection of researchers working on TB in Europe. Our internationally-recognised experts work across all aspects of global TB research from basic science in host and pathogen biology, through to clinical research including HIV/TB, MDR-TB, TB infection control and TB diagnostics, as well as epidemiology and public health, social science, financing and policy.</p>\n<p>The TB Centre provides a focus for the School\'s long-established global research expertise in tuberculosis epidemiology, immunology, diagnosis and treatment. It will enable the development of enhanced international partnership, building on the success of 70 existing projects collaborating in more than 40 countries including the UK, South Africa, Uganda, Senegal, Malawi, India, Pakistan, China, Peru, and South Korea.</p>\n<p><b>Link: <a href=\"http://tb.lshtm.ac.uk\">http://tb.lshtm.ac.uk</a></b></p>\n<p>As can be seen on the website, the LSHTM TB Centre has scientists working and collaborating throughout Southern Africa (25 projects in South Africa alone).</p> \n<p><a href=\"http://tb.lshtm.ac.uk/projects/southern-african-treatment-resistance-network-saturn\">SATuRN  is one of the collaborating projects at the TB LSHTM site</a> and this year members of the centre will present at <a href=\"http://www.bioafrica.net/workshops/7thsaturnresitanceworkshop.html\">SATuRN annual drug resistance workshop in Cape Town 28-29 Nov 2012</a>. </p>\n<p><b>TB Centre & SATuRN collaborative project at Hlabisa</b></p>\n<center><p><img src=\"imagesBIO/imgreport15people.gif\" alt=\"\"></p><center>', NULL, NULL, NULL, NULL, NULL, 'SATuRN, Featured, Partner, New, TB, centre, London School of Hygiene and Tropical Medicine, LSHTM, UK', 'SATuRN\'s Featured Partner: New TB centre at the London School of Hygiene and Tropical Medicine.  Their internationally-recognised experts work across all aspects of global TB research from basic science in host and pathogen biology, through to clinical research including HIV/TB, MDR-TB, TB infection control and TB diagnostics, as well as epidemiology and public health, social science, financing and policy.', NULL, NULL, '2012-07-03', 'SATuRN 2012 report', 3, 'imgreport15.gif', NULL);
INSERT INTO `b_reports` (`id`, `title`, `authors`, `abstract`, `summary`, `journal`, `volume`, `link`, `file`, `keywords`, `description`, `pages`, `datafile`, `date`, `doi`, `bioafricaSATuRN`, `image`, `pubid`) VALUES
(16, '2nd Nurses and Health Care Workers Drug Resistance Training for the scale-up of resistance testing in the Free State Province, South Africa', 'Dominique Goedhals & Cloete van Vuuren', '<p>The workshop was attended by 62 health care workers from clinics and hospitals within the Motheo and Xhariep districts of the Free State.  The aim of the workshop was to provide an update on current guidelines regarding treatment failure and resistance testing, the identification and management of patients with treatment failure, and especially to highlight the factors which often contribute towards non-adherence and treatment failure.  </p>\n<p>The team of presenters was comprised of specialist physicians, a psychiatrist, pathologist, and dietician, reflecting the multi-disciplinary approach which is needed to manage these patients effectively.  Group discussions were held in which participants were asked to share the challenges and successes that they encounter in the antiretroviral treatment program.  </p>\n<p>In the final session, information was provided regarding the scale-up of the European Commission funded FIRST project in the Free State and health care workers were invited to submit samples from patients with treatment failure for HIV resistance genotyping.  The feedback from participants was overwhelmingly positive and further training workshops are planned for the remaining four health care districts in the Free State province.</p>', '<p>On 31 May 2012, the Free State Initiative on Resistance, Surveillance and Treatment (FIRST) and the Southern African Treatment Resistance Network (SATuRN) group hosted an HIV drug resistance training workshop in collaboration with the Free State Department of Health Comprehensive Care Management and Treatment of HIV and AIDS Program (CCMT).  </p>\n', 'SATuRN 2012 report', NULL, NULL, NULL, '2nd, Nurses, Health Care Workers, Drug, Resistance, HIV, Training, scale-up, testing, Free State, Province, South Africa', '2nd Nurses and Health Care Workers Drug Resistance Training for the scale-up of resistance testing in the Free State Province, South Africa. This is a project of the European Commission and the Southern African Treatment Resistance Network', NULL, NULL, '2012-07-10', 'SATuRN 2012 report', 3, 'imgreport16.png', NULL),
(17, 'Clinical Case Study: The Diagnosis and Management of First-line Antiretroviral Treatment Failure', 'Theresa Rossouw, Tulio de Oliveira & Richard Lessells', '<p>The <a href=\"http://www.sahivsoc.org/case-studies/Details/sa-hiv-clinicians-society-online-case-discuss\">Clinical Case Study: The Diagnosis and Management of First-line Antiretroviral Treatment Failure is available at the SAHIVSoc Website</a></p>', '<p>This is the first SATuRN clinical case made available at the Southern African HIV Clinicians Society (SAHIVSoc) Website. The completion of this clinical cases provides four (4) CPD credit points to physician registered at the SAHIVSoc.</p><p><b><i>Case Objective:</b></i> At the end of this case study, the reader should be able to define the criteria for antiretroviral treatment failure and for switching to second-line antiretroviral therapy. He/she should be able to interpret a genotypic resistance test in the context of the clinical history. He/she should be able to select an appropriate second-line regimen and understand how co-morbidities might affect the choice of regimen.</p> \n<p>This case is also an example of the cases presented in the HIV and TB Drug Resistance Clinical Management Book that we are publishing. All of the cases in the book are openly accessible and are available on digital book repositories, such as Google Books, and on the <a href=\"http://www.bioafrica.net/cases.php\"> Clinical Case section of the Southern African and Treatment Resistance (SATuRN) website</a></p>\n<p><b><i>Instructions:</b></i> This activity is an interactive learning activity and will give you an overview and detailed answers to the questions. Each case is separated into several sections, and only one section is visible at a time. Each section is concluded by a multiple choice question, where you will have to select the most appropriate answer. If this answer is not correct, you will be given the opportunity to re-select another answer.</p>\n<p>After all the questions have been answered, there will be a post-test questionnaire in order to qualify for CPD points. Only users registered as members of the Southern African HIV Clinicians Society may obtain CPD points. If you are not a member and would like to join, please apply online.</p>\n', 'SAHIVSoc website', NULL, NULL, NULL, 'clinical, HIV, antiretroviral, tutorial, case, study, SAHIVSoc, first line, ARV, treatment, failure, CPD points, SATuRN, de Oliveira, Lessells, clinical, HIV, antiretroviral, tutorial, case, study, SAHIVSoc, first line, ARV, treatment, failure, CPD points, SATuRN, de Oliveira, Lessells, HIV Clinicians Society, clinical, HIV, antiretroviral, tutorial, case, study, SAHIVSoc, first line, ARV, treatment, failure, CPD points, SATuRN, de Oliveira, Lessells', 'At the end of this SATuRN clinical case study, the reader should be able to define the criteria for antiretroviral treatment failure and for switching to second-line antiretroviral therapy. He/she should be able to interpret a genotypic resistance test in the context of the clinical history.', NULL, NULL, '2013-01-16', 'SATuRN 2012 report', 3, 'imgReport17.jpg', NULL),
(18, 'Bioafrica.net & SATuRN webpages received 186,746 visits in the past 12 months!', 'Tulio de Oliveira', '<p><center><img src=\"imagesBIO/webvisit1.png\"></center></p>\n<p>In the past 12 months, it has received visits from 149 countries and 2,047 cities (Source Google analytics) with a total of 186,746 pages visited. The website has also been linked from 1,024 websites and has been mentioned in many scientific journals, including <a href=\"http://www.bioafrica.net/publications.php?pubid=38\">Science</a> and <a href=\"http://www.bioafrica.net/publications.php?pubid=1\">Nature</a>.  </p>\n<p>A significant number of visitors access our website in order to use online bioinformatics tools and databases that are hosted in our Linux server at the South African Medical Research Council. Popular tools and databases of our website include <a href=\"http://bioafrica.net/rega-genotype/html/index.html\">HIV, HBV, HCV, HPV and HTLV-1 subtyping tools</a>, the <a href=\"http://bioafrica.mrc.ac.za/hivdb/\">mirror of Stanford HIVDB</a> and <a href=\"http://www.bioafrica.net/regadb/\">SATuRN RegaDB</a>.</p>\n\n<p>Another feature of our website is that distributes all of our <a href=\"publications.php\">publications as full text and open access PDF documents</a>.  At present, we are producing PowerPoint presentations and short digital videos that summarize the results of our publications.  </p>\n\n<p>Again, we would like to thank our visitors and sponsors for allowing our website to become an important source of information in Africa. Please keep visiting it so we can keep developing it!</p>', '<p>The bioafrica.net is Dr. Tulio de Oliveira research group website at the Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal. The bioafrica.net website is online for 12 years and it is one of the most popular bioinformatics and drug resistance websites in Africa. </p>', 'SATuRN 2013 report', NULL, NULL, NULL, 'bioafrica, visits, google, analytics, 2012/2013, popular, website, saturn, webpages, report, webreport, website,bioafrica, visits, google, analytics, 2012/2013, popular, website, saturn, webpages, report, webreport, website,bioafrica, visits, google, analytics, 2012/2013, popular, website, saturn, webpages, report, webreport, website', 'The bioafrica.net is Dr. Tulio de Oliveira research group website at the Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal. The bioafrica.net website is online for 12 years and it is one of the most popular bioinformatics and drug resistance websites in Africa', NULL, NULL, '2013-02-26', 'SATuRN 2013 report', NULL, 'webvisit2.png', NULL),
(19, 'Transferring knowledge and skills to frontline medical personnel fighting the HIV & TB epidemics in rural South Africa', 'Tulio de Oliveira, Justen Manasa, Richard Lessells', '<p>The workshop was also organized in order to launch the HIV & TB Drug Resistance & Clinical Management Case Book, which has just been published by the Medical Research Council (MRC). In total, 250 copies of the book were given free-of-charge to the five hospitals to be distributed to clinicians, nurses and pharmacists involved in managing HIV & TB cases at the hospitals and primary health care clinics. The book is a compilation of informative clinical cases from South Africa that together highlight some of the major challenges that clinicians face in the management of HIV and TB drug resistance and that also illustrate some of the important lessons to be learnt in trying to limit the spread of drug resistance in our programmes and communities. </p>\n<p></p>\n<p>Amongst the top challenges of the HIV & TB epidemics are issues related to patient adherence to their antiretroviral and anti-TB drug regimens and the absence of reliable tools to measure adherence. The factors that contribute to suboptimal adherence were explored in group discussion sessions and the importance of thinking beyond patient factors and thinking more broadly about health system factors and community factors was emphasized. The complexities of the management of co-infections, especially when it comes to multidrug-resistant and extensively drug-resistant TB (pulmonary and extra-pulmonary) and HIV with high-level resistance to the standard first-line regimens, were also discussed. All these challenges were explored in the context of primary health care clinics and district hospitals where there are still critical shortages of human resources and limited access to advanced diagnostic and monitoring facilities.</p>\n<p></p>\n<p>Dr Hervey Vaughan-Williams, District Family Physician at the uMkhanyakude Health District Office, said <b><i>\'I think it was a great success on a number of levels, not least the number of District staff attracted to attend... Gatherings such as these are valuable both for District staff education and bonding between institutions, which is invaluable in times of stress or crisis, as well as enriching the working environment.\'</b></i></p>\n<p></p>\n<p>One of the main aims of the workshop and the book was to create awareness and understanding of the issues related to the management of HIV and TB drug resistance, given the increasingly complex case mix facing frontline health care workers in South Africa with the rapid scale-up of antiretroviral therapy and the ongoing epidemic of drug-resistant TB. The book has been edited by Dr. Theresa Rossouw (an HIV specialist from University of Pretoria), Dr. Richard Lessells (an HIV and TB specialist from UKZN\'s Africa Centre for Health and Population Studies) and Dr. Tulio de Oliveira (a virologist and bioinformatician also from Africa Centre). </p>\n<p></p>\n<p>The book was published under an open source license and is thus freely available in print and also in electronic form at the Southern African Treatment Resistance Network (SATuRN) website (<a href=\"http://www.bioafrica.net/cases.php\">http://www.bioafrica.net/cases.php></a>. The free distribution of the book was made possible through the generous support of the European Commission, CDC and Wellcome Trust. The workshop and book launch was organized by the Africa Centre for Health and Population Studies at UKZN and SATuRN in collaboration with the uMkhanyakude Health District Office. </p>\n<p></p>\n<p>The Dean of Health Sciences at the University of Pretoria has also organized a formal book launch on the 15th March 2013. This book launch will host the ambassador of the European Union to South Africa, the head of the TB program at the CDC in South Africa, the director of the Africa Centre and Deans and directors of units of the University of Pretoria. </p>', '<p>A very successful workshop and book launch was hosted at the Ghost Mountain Inn, Mkuze, on the 7th and 8th of March 2013. In total, 52 clinicians, senior nurses and pharmacists attended from the five district hospitals within the uMkhanyakude District of northern KwaZulu-Natal. Also present were HIV and TB specialists from Africa Centre, CAPRISA, King Edward Hospital at UKZN, and Botswana. The event was organized in order to facilitate the discussion of common clinical management challenges related to the management of HIV and TB drug resistance and treatment failure within a rural district with a huge dual burden of HIV and TB.</p>', 'SATuRN 2013 report', NULL, NULL, NULL, 'workshop, hiv, tb, drug resistance, kwazulu-natal, uMkhanyakude, africa centre, book launch, rural, south africa, saturn, caprisa, workshop, hiv, tb, drug resistance, kwazulu-natal, uMkhanyakude, africa centre, book launch, rural, south africa, saturn, caprisa, workshop, hiv, tb, drug resistance, kwazulu-natal, uMkhanyakude, africa centre, book launch, rural, south africa, saturn, caprisa', 'A very successful workshop and book launch was hosted at the Ghost Mountain Inn, Mkuze, on the 7th and 8th of March 2013. In total, 52 clinicians, senior nurses and pharmacists attended from the five district hospitals within the uMkhanyakude District of northern KwaZulu-Natal. Also present were HIV and TB specialists from Africa Centre, CAPRISA, King Edward Hospital at UKZN, and Botswana. The event was organized in order to facilitate the discussion of common clinical management challenges related to the management of HIV and TB drug resistance and treatment failure within a rural district with a huge dual burden of HIV and TB', NULL, NULL, '2013-03-16', 'SATuRN 2013 report', 3, 'imgreport19.jpg', NULL),
(20, 'Major data analysis determines the trends of HIV-1 drug resistance mutations in South Africa.', 'Tulio de Oliveira', '<p>There is much debate in South Africa on the effect of changing guidelines. This is because HIV-1 subtype C may be naturally more resistant to Tenofovir, due to the K65R mutation (ref. 2). This study found that approximately 40% of patients receiving TDF had the K65R mutation. </p>\n<p></p>\n<p>This paper has also analyzed 486 sequences from patients failing second-line ART, which includes Lopinavir/ritonavir (LPV/r). The analysis found that 11% prevalence of LPV/r resistance among patients with virological failure on an LPV/r containing regimen. These results are consistent with studies from the U.K. (ref. 3) and from South Africa (ref. 4). In addition, the development of low level Darunavir (DRV) resistance in about one-half of the patients with LPV/r resistance, suggests that DRV may be a valuable component of a third-line antiretroviral regimen.</p>\n<p></p>\n<p>This paper produced one of the largest HIV-1 subtype C datasets. Very importantly, the 1,894 sequences produced were made available in the public domain. For example,  the subtype C RT sequences from 1,398 first-line (i.e. NNRTI and NRTI-based regimens) treated patients represent nearly 40% of the 3,600 patients in the Stanford HIV drug resistance database (HIVDB).  The subtype C PR sequences from 486 LPV/r-treated patients more than double the number of all subtype C-infected patients in HIVDB.</p>\n<p></p>\n<p>This manuscript concludes that although TDF and ABC are more potent and less toxic HIV-1 inhibitors than d4T and AZT, the impact of their widespread introduction into South Africa requires ongoing monitoring to ensure that the efficacy of first-line therapy is not compromised. In addition, it concludes that resistance testing to identify optimal second- and third-line regimens. Importantly, in order to inform national and international policy makers, genotypic data and its associated treatment regimen should be made available in public databases (ref 5).</p>\n<p></p>\n<p><b><i>References:</b></i></p>\n<p></p>\n<p>1 - <a href=\"http://www.bioafrica.net/publications.php?pubid=68\">Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, de Oliveira T, Preiser W, Wood NT, Travers S, Shafer RW. Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens PLoS One,8(6):e67188 (2013).</a></p>\n<p>2 - <a href=\"http://www.bioafrica.net/publications.php?pubid=60\"> Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences important in HIV drug resistance? Current Opinion Virology,2(5):636-43 (2012).</a></p>\n<p>3 -Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, et al. (2012) Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Che- mother 67: 995?1000.</p>\n<p>4 - Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W (2011) Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa. AIDS Res Treat 2011: 769627.</p>\n<p>5 - <a href=\"http://www.bioafrica.net/publications.php?pubid=1\">de Oliveira T, Shafer RW, Seebregts C (2010) Public database for HIV drug resistance in southern Africa. Nature 464: 673.</a></p>', '<p>A recent paper published in PLoS One by Gert Van Zyl and colleagues (ref. 1) determines the trends of HIV-1 drug resistance mutations in patients failing antiretroviral therapy (ART). This paper also shows the effect of changing ART national guideline regimens since 2010, which replace Stavudine (d4T) based regimens for tenofovir (TDF) in adults and Abacavir (ABC) in children. In addition, it also analyzes one of the largest datasets of patients failing second-line ART in South Africa.</p>', 'SATuRN 2013 report', NULL, NULL, NULL, 'hiv, drug resistance, TDF, LPV, tenfovir, lopinavir, south africa, Bob Shafer, Gert Van Zyl, de Oliveira, PLoS One, SATuRN report, ARV, HIV-1, hiv, drug resistance, TDF, LPV, tenfovir, lopinavir, south africa, Bob Shafer, Gert Van Zyl, de Oliveira, PLoS One, SATuRN report, ARV, hiv, drug resistance, TDF, LPV, tenfovir, lopinavir, south africa, Bob Shafer, Gert Van Zyl, de Oliveira, PLoS One, SATuRN report, ARV, hiv, drug resistance, TDF, LPV, tenfovir, lopinavir, south africa, Bob Shafer, Gert Van Zyl, de Oliveira, PLoS One, SATuRN report, ARV', 'A recent paper published in PLoS One by Gert Van Zyl and colleagues (ref. 1) determines the trends of HIV-1 drug resistance mutations in patients failing antiretroviral therapy (ART). This paper also shows the effect of changing ART national guideline regimens since 2010, which replace Stavudine (d4T) based regimens for tenofovir (TDF) in adults and Abacavir (ABC) in children. In addition, it also analyzes one of the largest datasets of patients failing second-line ART in South Africa.', NULL, NULL, '2013-07-01', 'SATuRN report 2013', NULL, 'imgreport20.png', NULL),
(21, 'SATuRN Collaborates on a Successful Molecular Diagnostics in HIV/AIDS and Tuberculosis in Zimbabwe, 6-9 Aug 2013 ', 'Justen Manasa', '<p>Thirty-one participants from various public and private academic institutions, diagnostic companies as well as the National Institute of Health Research and the National Microbiology Laboratory. The participants were drawn from various disciplines including Clinical Medicine, Biomedical Science, Public Health and Biostatistics. The aim of the workshop was to update the participants on the current trends in the application of molecular diagnostic tools in the diagnosis and monitoring of HIV/ AIDS and its co-morbidities in resource limited settings. </p>\n\n<p>The first day of the workshop started with a review of the emerging technologies in HIV and TB clinical diagnostics.  This was followed by a session in which various CD4 testing technologies in Zimbabwe were discussed as well as viral load testing in resource limited settings. Local quality assurance programmes as well as quality assurance programmes for international clinical trials were also discussed. The afternoon of the first day was dedicated to opportunistic infections. New Point of Care diagnostics for Cryptococcal infections were discussed as well as the new WHO, IDSA and CDC recommendation for the assessment and treatment of CrAg+ meningitis. The day ended with discussions on the WHO and International regional recommendations for public health TB screening and treatment as well as a review of TB drug resistance, multi-drug resistance (MDR), extreme drug resistance (XDR) and Microscopic Observation of Drug Susceptibility (MODS).</p>\n\n<p>The second day of the workshop was dedicated to HIV drug resistance. It was started with a review of molecular biology and the principles of molecular techniques (PCR and Sanger based population sequencing). This was followed by a review of the HIV replication cycle emphasizing on the targets of for the currently registered antiretroviral drugs, the mechanism of action of the drugs as well as the mechanism of resistance. The morning theoretical sessions were followed by afternoon sessions of practical sequence data analysis including sequence assembly and sequence quality assessment.</p>\n\n<p>The drug resistance discussion continued on the third day with focus on HIV drug resistance interpretation algorithms and databases (HIVDB and SATuRN) as well as sequence quality assurance tools such as phylogenetics and the sequence quality assessment tool (www.bioafrica.net). The implication of the pMTCT options adopted by Zimbabwe (B+) on drug resistance was also discussed as well as the current trends in drug resistance from the WHO ResNet Studies. This day was concluded with discussions on alternative to sequencing for drug resistance such as the OLA as well as data from the Affordable Resistance Testing for Africa (ART-A) consortium on their affordable viral load and genotyping assays.</p>\n\n<p>The last day of the workshop focused discussion of data from various implementation studies. These ranged from the implementation of rapid HIV testing and point of care test for HIV monitoring to pediatric and adolescent HIV diagnostics and management. Treatment as prevention and pre-exposure prophylaxis issues were also discussed as well as future regimens in the context of Zimbabwe\'s capability to access new drugs being developed and registered for the management of HIV. The last talk of the workshop highlighted the relationships between infectious diseases in epidemic and human security.</p>', '<p>The above-mentioned workshop was co-hosted by the Biomedical Research and Training Institute (BRTI) and the African Institute of Biomedical Research and Training (AiBST) in Harare, Zimbabwe. The two institutions organized the workshop in collaboration with scientists from the Division of Infectious Diseases at Stanford University Medical Centre, CA, USA and Southern African Treatment Resistance Network (SATuRN). </p>', 'SATURN 2013 report', NULL, NULL, NULL, 'hiv, tb, molecular, diagnostic, saturn, zimbabwe, stanford, BRTI, AiBST, Justen Manasa, 2013, Harare, AIDS, tuberculosis, genotyping, drug, resistance, hiv, tb, molecular, diagnostic, saturn, zimbabwe, stanford, BRTI, AiBST, Justen Manasa, 2013, Harare, AIDS, tuberculosis, genotyping, drug, resistance, hiv, tb, molecular, diagnostic, saturn, zimbabwe, stanford, BRTI, AiBST, Justen Manasa, 2013, Harare, AIDS, tuberculosis, genotyping, drug, resistance, hiv, tb, molecular, diagnostic, saturn, zimbabwe, stanford, BRTI, AiBST, Justen Manasa, 2013, Harare, AIDS, tuberculosis, genotyping, drug, resistance', 'A Successful Molecular Diagnostics in HIV/AIDS and Tuberculosis was co-hosted by the Biomedical Research and Training Institute (BRTI) and the African Institute of Biomedical Research and Training (AiBST) in Harare, Zimbabwe. The two institutions organized the workshop in collaboration with scientists from the Division of Infectious Diseases at Stanford University Medical Centre, CA, USA and Southern African Treatment Resistance Network (SATuRN).', NULL, NULL, '2013-08-21', 'SATuRN 2013 report', 3, 'imgreport21.png', 64),
(22, 'SATuRN and Khethimpilo HIV Drug Resistance and Clinical Management Workshop Report, Durban, 11-12 July 2013', 'Dean Solomon and Tulio de Oliveira', '<p>#Quality Nurse Mentors (QNMs) are a cadre of staff created by Kheth?Impilo to support staff on-site to ensure that all healthcare workers provide quality care. They are all professional nurses by profession. </p>\n<p></p>\n<p><b><i>Course outline</b></i> </p>\n<p>Day 1 of the workshop included: </p>\n<p>	Theory and fundamental concepts relating HIV replication, anti-retroviral drugs and drug failure (128 Power Point slides) based upon the recent publication <b><i>\'HIV & TB Drug Resistance & Clinical Management Case Book\'</b></i>  by  T Rossouw, R J Lessells & T de Oliveira.  </p>\n<p>	Case studies were also presented on Day 1 by Dr. Collins Iwuji. Presentations and discussions revolved around : </p>\n<p> - First line failure in an adult</p>\n<p> - Second line failure in an adult</p>\n<p>	- First and second line failure in an adult</p>\n<p>	A presentation on Day 1 by Dr. Kevi K Naidoo included  an overview of the model of care of patients in the primary health clinics (PHCs) and the management of drug resistance.</p>\n<p>Day 2 of the workshop included : </p>\n<p> - Dr. Kevi Naidoo First line treatment failure ? an HIV  case study in Paediatrics </p>\n<p>	- Prof Tulio de Oliveira  gave a comprehensive overview of HIV Drug resistance and model of care in the public health sector in South Africa for patients with HIV drug resistance</p>\n<p>	- Dr. Turesha Chetty covered a case study on  ARV failure in a pregnant woman exposed to sdNVP. Risks associated with PMTCT drug exposure were highlighted. </p>\n<p> - Dr. Dean A Solomon concluded the theory of HIV drug resistance development</p>\n<p>All sessions remained interactive to give participants opportunities to ask questions, obtain clarity on concepts and share clinical experiences with the audience. Participants were encouraged to bring  cases relating to patients failing treatment  from their clinics for discussions. </p>\n<p>Accreditation for CPD points applied for through the Africa Centre for Health and Population Studies and the University of KwaZulu Natal. All participants received a printed copy of a Certificate of Attendance and a a printed copy of the book entitled \'HIV & TB Drug Resistance & Clinical Management Case Book\' (130 pages)</p>', '<p>A total of 45 delegates attended the two day workshop. Four facilitators were present on each day (one from Kheth Impilo and three from the Africa Centre).  There was also an events coordinator in attendance to cover delegate registration and administration. Participants were all from KwaZulu- Natal (KZN) province from the three districts that Kheth?Impilo supports. Medical doctors (31%) and professional nurses (26.6% + 17.7%) accounted for the majority of participants, together making up a total of 75% of delegates. </p>\n', 'SATuRN 2013 report', NULL, NULL, NULL, NULL, NULL, NULL, NULL, '2013-08-01', 'SATuRN 2013 report', 3, 'imgreport22.png', 64);

-- --------------------------------------------------------

--
-- Table structure for table `b_resources_ppt`
--

CREATE TABLE `b_resources_ppt` (
  `id` int(11) NOT NULL,
  `pict` tinytext,
  `summary` longtext,
  `pubid` int(11) DEFAULT NULL,
  `feature` int(2) DEFAULT NULL,
  `pptfile` tinytext
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_resources_ppt`
--

INSERT INTO `b_resources_ppt` (`id`, `pict`, `summary`, `pubid`, `feature`, `pptfile`) VALUES
(1, 'featureStanford.jpg', 'BLASH BASLASHAU:SANS:A', 0, NULL, NULL),
(2, NULL, NULL, NULL, NULL, NULL),
(3, 'featureSalemi.jpg', 'This image shows the subtype distribution in South America and South Africa. Please cite this paper for the following information: - subtype C spreads faster than subtype B in South America.', 0, NULL, NULL),
(4, 'deOliveiraBrazilsubC.jpg', 'deOliveiraBrazilsubCtext.jpg', 0, NULL, NULL),
(5, 'DalaiZimbabwe1.jpg', 'DalaiZimbabwe1text.jpg', 0, NULL, NULL),
(6, 'DalaiZimbabwe2.jpg', 'DalaiZimbabwe2text.jpg', 0, NULL, NULL),
(7, 'HIVdrugResistance_Nurses2012.jpg', 'This summary presentation presents the tables, images and conclusions from the paper. Slides are openly accessible and can be used in other presentations, given reference details are displayed.', 62, NULL, 'HIVdrugResistance_Nurses2012.pptx'),
(8, 'ManasaHIVDRprimarySA.jpg', 'This summary presentation presents the tables, images and conclusions from the paper. Slides are openly accessible and can be used in other presentations, given reference details are displayed.', 41, NULL, 'ManasaHIVDRprimarySA.pptx'),
(9, 'SouthernAfricanARVdrugresistanceguidelines_2012\n.jpg', 'This summary presentation presents the tables, images and conclusions from the paper. Slides are openly accessible and can be used in other presentations, given reference details are displayed.', 61, NULL, 'SouthernAfricanARVdrugresistanceguidelines_2012.pptx'),
(10, 'CurrOpVirol_2012_SubtypeResistance.jpg', 'This summary presentation presents the tables, images and conclusions from the paper. Slides are openly accessible and can be used in other presentations, given reference details are displayed.', 60, NULL, 'CurrOpVirol_2012_SubtypeResistance.pptx');

-- --------------------------------------------------------

--
-- Table structure for table `b_resources_video`
--

CREATE TABLE `b_resources_video` (
  `id` int(11) NOT NULL,
  `author` mediumtext,
  `pict` tinytext,
  `summary` longtext,
  `pubid` int(11) DEFAULT NULL,
  `title` longtext,
  `feature` int(2) DEFAULT NULL,
  `youtube` tinytext,
  `file` tinytext,
  `duration` time DEFAULT NULL,
  `date` date DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_resources_video`
--

INSERT INTO `b_resources_video` (`id`, `author`, `pict`, `summary`, `pubid`, `title`, `feature`, `youtube`, `file`, `duration`, `date`) VALUES
(1, 'Tulio de Oliveira', 'imgVideo1.png', 'Short interview about our HIV & TB Drug Resistance & Clinical Management Case Book', 64, 'HIV & TB Drug Resistance & Clinical Management Case Book', NULL, 'Ozd0BIl_H0o', NULL, '00:02:45', '2013-10-06'),
(2, 'Tulio de Oliveira', 'imgVideo2.png', 'Short interview about a review paper on HIV-1 subtypes and drug resistance', 60, 'Are subtype differences important in HIV drug resistance?', NULL, 'TrZAe41RUW0', NULL, '00:03:12', '2013-10-10'),
(3, 'Justen Manasa', 'imgVideo3.png', 'Short interview about a manuscript published on antenatal HIV-1 drug resistance in Zimbabwe', 54, 'Surveillance of transmitted ARV drug resistance among HIV-1 infected women', NULL, 'fTLXq2xUeUE', NULL, '00:01:33', '2013-10-06'),
(4, 'Justen Manasa', 'imgVideo4.png', 'Interview about paper showing low level of primary (i.e. transmitted) HIV-1 drug resistance in South Africa. ', 41, 'Primary drug resistance in South Africa - data from 10 years of surveys', NULL, 'epDcrJa4Kzw', NULL, '00:01:50', '2013-10-06'),
(5, 'Justen Manasa', 'imgVideo5.png', 'Interview about a paper that show very high-level of HIV-1 drug resistance in Adults in Hlabisa, rural KZN, South Africa', 70, 'Research into Acquired HIV Drug Resistance in a Rural HIV Treatment Program', NULL, '1WYq95-12w4', NULL, '00:02:12', '2013-10-06'),
(6, 'Tobias Rinke de Wit, Raph Hamers, Justen Manasa & Sonia Boender', 'imgVideo6.png', 'A set of short interviews with PASER & SATuRN researchers about collaboration on HIV drug resistance projects in Africa. ', NULL, 'SATuRN/PASER Scientific Meeting on HIV Drug Resistance in Africa', NULL, 'QprscXTr14A', NULL, '00:03:20', '2013-09-29'),
(7, 'Tulio de Oliveira', 'imgVideo7.png', 'In this interview, Prof. Tulio de Oliveira highlights theirs plans to use new media and videos in their research.', NULL, 'Intro to BioAfrica/SATuRN Videos - Prof. Tulio de Oliveira', NULL, 'aKC4U5jG4ys', NULL, '00:02:04', '2013-09-29'),
(8, 'Eduan Wilkinson', 'imgVideo8.png', 'Dr. Eduan Wilkinson tell about his dream to use bioinformatics and molecular epidemiology to produce target intervention to curb HIV transmission in generalized epidemics in Africa', NULL, 'African Dream - Dr. Eduan Wilkinson for Southern African Treatment Resistance Network (SATuRN)', NULL, 'N80W-IswgdI', NULL, '00:00:48', '2013-08-01'),
(9, 'Justen Manasa', 'imgVideo9.png', 'Justen Manasa tell about his dream to develop affordable and open access drug resistance genotyping methods that can be used in Africa to treat drug resistance patients.\n', NULL, 'African Dream - Justen Manasa for Southern African Treatment Resistance Network (SATuRN)', NULL, 'eT7RPc2qSC0', NULL, '00:01:46', '2013-08-01'),
(10, 'Xolile Kineri', 'imgVideo10.png', 'Xolile Kineri tell about her dream to use her community educator skills to help HIV infected and affected individuals to understand and prevent drug resistance', NULL, 'African Dream - Xolile Kineri for Southern African Treatment Resistance Network (SATuRN) ', NULL, 'ZluuXrcl7uE', NULL, '00:00:52', '2013-08-01'),
(11, 'Astrid Treffry-Goatley', 'imgVideo11.png', 'Dr. Astrid Treffry-Goatley tell about her dream of using art & music to raise awareness about HIV & TB drug resistance in South Africa.\n', NULL, 'African Dream - Dr Astrid Treffry-Goatley for Southern African Treatment Resistance Network (SATuRN)', NULL, 'RBu7NTUVe4E', NULL, '00:00:36', '2013-08-01'),
(13, 'Lungani Ndwandwe', 'imgVideo13.png', 'Lungani Ndwandwe tell about his passion on the use of photography and creative writing to communicate about HIV & TB drug resistance to his Zulu community in Africa.\n', NULL, 'African Dream- Lungani Ndwandwe for Southern African Treatment Resistance Network (SATuRN)', NULL, 'fwt8cPvG0Tc', NULL, '00:00:44', '2013-08-01'),
(12, 'Zakhona Gumede', 'imgVideo12.png', 'Zakhona Gumede tell in isiZulu about her dream to become a social worker in order to curb HIV & TB drug resistance in South Africa.\n', NULL, 'African Dream - Zakhona Gumede for Southern African Treatment Resistance Network (SATuRN)', NULL, 'fGzW-r4V5BQ', NULL, '00:00:42', '2013-08-01'),
(15, 'Tulio de Oliveira', 'imgVideo15.png', 'This is the TV coverage of the HIV & TB Drug Resistance and Clinical Management Book Launch. SABC broadcast in many official languages, this is the Venda version.', NULL, 'SABC 2 - HIV & TB Drug Resistance and Clinical Management Book Launch', NULL, '7jo8P--o3DU', NULL, '00:03:12', '2013-04-02'),
(14, 'Tulio de Oliveira', 'imgVideo14.png', 'Prof Tulio de Oliveira tell about his passion of the usage of open source bioinformatics applications and open access information to curb HIV & TB drug resistance in Africa.\n', NULL, 'African Dream - Dr Tulio de Oliveira for Southern African Treatment Resistance Network (SATuRN) ', NULL, 'XqrCzLsK-yI', NULL, '00:01:04', '2013-08-01'),
(16, 'Pretty Nkosi & Nokuthula Skhosana', 'imgVideo16.png', 'Anti-retroviral (ARV) therapy workshop organized by social workers  with adolescents as part of the Hlabisa HIV and Care Treatment Program and the Southern African Treatment and Resistance Network (SATuRN)', NULL, 'Social Worker Workshop with Adolescents on ARVs in South Africa', NULL, 'U70kUepvWHA', NULL, '00:02:08', '2012-12-30'),
(17, 'Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Seebregts C, Rinke De Wit TF, Viljoen J, Katzenstein D, De Oliveira T', 'imgVideo17.png', 'SATuRN/Life Technologies open access and affordable drug resistance genotyping system. This is a video that accompain a peer-reviewed manuscript that provides detailed information on how to our affordable drug resistance testing. The paper and video are open accessible! ', 100, 'An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings', NULL, 'IMEZrJDiBh4', 'jmanasa.mov', '00:22:27', '2013-10-18'),
(18, 'Justen Manasa', 'imgVideo18.png', 'This is a 8 minutes video that summarizes the PhD thesis of Justen Manasa. This video cover the affordable and open accessible SATuRN/Life Tech genotyping method, SATuRN data curation process using RegaDB and a number of manuscripts on transmitted and acquired resistance in rural South Africa.', NULL, 'Justen Manasa PhD thesis summary', NULL, 'V-yMTju163', NULL, '00:08:10', '2013-11-29'),
(19, 'Justen Manasa', 'imgVideo19.png', 'This is a short interview about the SATuRN datacuration manuscript, which has been published at DATABASES (Oxofrd) journal. In this video Justen Manasa describe access to the database, biocuration process and highlight examples of biological discoveries done with HIV drug resistance data stored at the SATuRN RegaDB database', 97, 'SATuRN RegaDB Data Curation Process ', NULL, 'Xm9UhWyuYj4', NULL, '00:02:30', '2013-11-28'),
(20, 'Siva Danaviah', 'imgVideo20.png', 'In a short interview, Dr. Siva Danaviah describes drug resistance patterns in HIV-infected children on antiretroviral therapy (ART) and its impact to inform public health policies in high prevalence settings. The aim of this study was to characterise the acquired drug resistance in HIV-infected children failing first-line ART in a decentralised rural HIV program in South Africa', 96, 'HIV-1 Drug Resistance in Children in rural South Africa', NULL, 'gJ4GlSO38LU', NULL, '00:02:12', '2014-03-01'),
(21, 'Prevashinee Padayachee and Tulio de Oliveira', 'imgVideo21.png', 'This short video diary is the first in a series of four weekly movies that will trace the transformation of our existing laboratory into a world class DNA genomic facility. This will be one of the first facilities in the African continent that focuses on research on diseases that affect human health. The first video provides an introduction to the series, a pictorial tour of the current facilities and outlines the exciting renovation plans that are under way. The genomics facility is based at the College of Health Sciences, University of KwaZulu-Natal and funded by the Wellcome Trust Africa Centre, South Africa MRC, UKZN, NRF and BMGF', NULL, 'KRISP Genomics Laboratory Construction - Video Diary Part I', NULL, '6Xv4ZxRfAnA', NULL, '00:03:45', '2014-03-13'),
(22, 'Prevashinee Padayachee and Tulio de Oliveira', 'VideoLabDiaryPart2.jpg', 'This short video diary is the second in a series of movies that will trace the transformation of our existing laboratory into a world class DNA genomic facility. The second video provides an introduction to the robotics system and present our new bioinformatics facility. The genomics facility is based at the College of Health Sciences, University of KwaZulu-Natal and funded by the Wellcome Trust Africa Centre, South Africa MRC, UKZN, NRF and BMGF. This will be one of the first facilities in the African continent that focuses on research on diseases that affect human health. ', NULL, 'KRISP Genomics Laboratory Construction - Video Diary Part II', NULL, 'f5aFW9Xn_Tw', NULL, '00:01:52', '2014-04-05'),
(23, 'Prevashinee Padayachee and Tulio de Oliveira', 'Genomicspart3.jpg', 'This short video diary is the third in a series that traced the creation of a world class DNA genomic facility in the African continent that focuses on research on diseases that affect human health. This video shows the completion of genomics centre. It shows Illumina Miseq and Life Technologies Next Generation (NextGen) sequencing Facilities used in HIV & TB research. ', NULL, 'Completion of a world-class genomics lab at KRISP/UKZN, Durban, South Africa - Part III', NULL, '4ZwwiXPWSVc', NULL, '00:02:43', '2014-08-06'),
(24, 'Anthony Fauci, Quarraisha Abdool Karim, David Khanyile, Tulio de Oliveira, Salim Abdool Karim', 'VideoHIVCaprisa.jpg', 'This is a short video of our keynote presentation at the AIDS 2016 conference in Durban. ', 139, 'Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study -  Keynote presentation at AIDS 2016.', NULL, 'W0uDZ_Bk5NI', NULL, '00:03:41', '2016-06-20'),
(25, 'Tulio de Oliveira, Veron Ramsuran, Nicolette Crozier, Zandile Sibisi, Marcel Tongo, Benjamin Chimukangara, Thabiso Dlamini', 'Krisp_video.png', 'Krisp at South African eTV channel evenning news', NULL, 'Krisp - a next generation DNA sequencing research centre opens in Durban, South Africa - eTV news', NULL, 'nI3QsX4gGHU', NULL, '00:02:25', '2017-07-24');

-- --------------------------------------------------------

--
-- Table structure for table `b_server`
--

CREATE TABLE `b_server` (
  `svr_id` int(2) NOT NULL,
  `svr_name` varchar(25) NOT NULL,
  `svr_addr` varchar(50) NOT NULL,
  `svr_ip` varchar(15) NOT NULL,
  `instns_to_access` varchar(200) NOT NULL,
  `instns_to_req_acc` varchar(200) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_server`
--

INSERT INTO `b_server` (`svr_id`, `svr_name`, `svr_addr`, `svr_ip`, `instns_to_access`, `instns_to_req_acc`) VALUES
(1, 'KRISP', 'http://krisp.ukzn.ac.za', '146.230.170.152', 'Use the following instructions to access the server.', 'Email Tulio (tuliodna@gmail.com) to request access.'),
(2, 'KRISP2', 'http://krisp2.ukzn.ac.za', '146.230.170.151', 'Use the following instructions to access the server.', 'Email Tulio (tuliodna@gmail.com) to request access.'),
(3, 'BIOAFRICA2', 'http://bioafrica2.mrc.ac.za/', '196.21.144.176', 'Instructions to access', 'Email Tulio (tuliodna@gmail.com) to request access.');

-- --------------------------------------------------------

--
-- Table structure for table `b_software`
--

CREATE TABLE `b_software` (
  `id` int(11) NOT NULL,
  `date` date DEFAULT NULL,
  `webpage` char(100) DEFAULT NULL,
  `version` int(11) DEFAULT NULL,
  `name` char(150) DEFAULT NULL,
  `description` longtext,
  `image` char(50) DEFAULT NULL,
  `authors` longtext,
  `pubid` int(11) DEFAULT NULL,
  `summary` longtext,
  `type` mediumtext,
  `feature` char(1) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_software`
--

INSERT INTO `b_software` (`id`, `date`, `webpage`, `version`, `name`, `description`, `image`, `authors`, `pubid`, `summary`, `type`, `feature`) VALUES
(1, '2008-12-01', 'http://bioafrica.net/blast/index.html', 1, 'Blast Servers', 'for HIV, HCV and HBV numbering positioning, fast subtyping, alignment, search private and public databases.', 'log2blast.png', 'Tulio de Oliveira', NULL, 'Blast using local databases at our servers. It includes HIV Genbank, Subtype Reference Dataset and HXB2 reference sequence databases', 'online', NULL),
(2, '2008-12-01', 'http://bioafrica.net/blast/BlastAlign.html', 1, 'BlastAlign', 'BlastAlign is a program that uses blast to align nucleotide sequences that have large indels (INsertions/DELetions) or are otherwise difficult to align.', 'log2blastalign.png', 'Tulio de Oliveira', NULL, 'Online web version for BlastAlign software application', 'online', NULL),
(4, '2003-12-01', 'http://bioafrica.net/GDElinux/index.html', 1, 'GDE Linux', 'Genetic Data Environment for Linux and Mac OS X.', 'logGDE.gif', 'Tulio de Oliveira', 33, 'Genetic Data Environment (GDE) interface for HIV-1 coded in Linux Operation System', 'software', NULL),
(5, '2007-01-06', 'http://bioafrica.net/tools/HIVepiqweb.html', 1, 'HIV Epitope Analysis Tool', 'This tool is designed to determine the similarities and mutations on epitope sequences. The sequence will be searched against the HIV-1 subtypes A, B and C consensus and ancestral sequences.', 'log2epiq.png', 'Tulio de Oliveira', NULL, 'Online tools for searching for epitopes using local Blast', 'online', NULL),
(6, '2007-01-07', 'http://bioafrica.net/tools/pppweb.html', 1, 'HIV Quality Analysis Tool', 'is designed to determine the quality of a specific HIV sequence. Sequence translational problems are identified using complete genome and the proteome of the HIV-1 reference sequence HXB2.', 'log2ppp.png', 'Tulio de Oliveira', NULL, 'Tool to determine quality and contamination of sequences using local Blast', 'online', NULL),
(7, '2009-01-09', 'http://bioafrica.net/rega-genotype/html/subtypinghtlv.html', 2, 'LASP HTLV-1 Subtyping Tool', 'This bioinformatics tool uses phylogenetic methods to identify the subtype and sub-group of HTLV-1 sequences. ', 'log2LASPHTLV.png', 'Tulio de Oliveira', 7, 'Phylogenetic subtyping tool for HTLV-1', 'typing', NULL),
(8, '2003-01-09', 'http://bioafrica.mrc.ac.za/GDElinux/GDE-PAUP.html', 1, 'PAUP* Scripts', 'Contains a number of PAUP* scripts for different models of substitutions (F81, TrN, HKY, TVM and GTR). Scripts can be used to construct fine maximum likelihood and neighbour-joining phylogenetic trees.', 'logPAUP.gif', 'Tulio de Oliveira', NULL, 'Set of PAUP* scripts to contruct maximum likelihood trees', 'resource', NULL),
(9, '2009-01-10', 'http://bioafrica.net/rega-genotype/html/subtypinghcv.html', 2, 'OXFORD HCV Subtyping Tool', 'This tool uses phylogenetic methods to identify the subtype of query sequences. The recombination analysis is done either with HCV Genotypes or HCV subtypes. This version of the tool includes genotypes 1 to 6', 'log2REGAHCV.png', 'Tulio de Oliveira', 7, 'Phylogenetic subtyping tool for HCV', 'typing', NULL),
(12, '2014-03-31', 'http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/', 3, 'REGA HIV Subtyping Tool V3 - Stanford Mirror', 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 3 contains new CRFs (CRF01_AE to CRF47_BF).  Note for batch analysis: The REGA subtype tool accepts up to 1000 sequences at a time. ', 'log2REGAHIV.png', 'Tulio de Oliveira', 67, 'Phylogenetic tool to identify the HIV-1 subtypes and recombinants. Query sequences are analysed for recombination using bootscanning methods. The version 3 contains new CRFs (CRF01_AE to CRF47_BF).', 'typing', NULL),
(13, '2013-03-31', 'http://www.phylotype.org', 1, 'Searching for Virus Phylotypes: Online Tool', 'We produced a bioinformatics method for obtaining phylogenetic groups, which we call phylotypes, from a phylogeny having taxa (strains) annotated with extrinsic traits. Phylotypes are subsets of taxa with close phylogenetic relationships and common trait values. This method and companion tools are implemented in an interactive Web interface.', 'log2Phylo.png', 'Tulio de Oliveira', 63, 'Online web interface that provides an interface to identify phylotypes and allows for exploratory analyses of very large data sets.', 'online', NULL),
(14, '2013-02-01', 'http://rega.kuleuven.be/cev/regadb', 1, 'RegaDB: Community-driven data management and analysis for infectious diseases', 'RegaDB is a free and open source data management and analysis environment for infectious diseases. RegaDB allows clinicians to store, manage and analyze patient data, including viral genetic sequences. In addition, we also provide a southern African collaborative <a href=\"http://bioafrica.mrc.ac.za:8080/regadb-ui/RegaDB\">RegaDB database used within the Southern African Treatment and Resistance Network (SATuRN)</a> ', 'log2regadb.png', 'Tulio de Oliveira', 65, 'RegaDB provides researchers with a mechanism to collect data in a uniform format and offers them a canvas to make newly developed bioinformatics tools available to clinicians and virologists through a user friendly interface.', 'software', NULL),
(15, '2010-12-10', 'http://bioafrica.mrc.ac.za/hivdb/', 1, 'Southern African Mirror of the Stanford HIV Drug Resistance Database (HIVDB)', 'A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance. This is the first mirror of HIVDB outside Stanford in the world. It is available as a open access database to support the development of the antiretroviral therapy program in southern Africa', 'log2stanford.png', 'Tulio de Oliveira', 1, 'A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance', 'database', NULL),
(16, '2009-10-10', 'http://bioafrica.mrc.ac.za/rnavirusdb/', 1, 'RNA Virus Database', 'An international collaboration to create a relational database to all RNA virus genomes. The database currently has 1,062 viruses', 'log2RNAdb.png', 'Tulio de Oliveira', 11, 'The RNA Virus Database is a database and web application describing the genome organization and providing analytical tools for all known species of RNA virus.', 'database', NULL),
(17, '2015-01-14', 'http://www.bioafrica.net/proteomics/HIVproteome.html', 1, 'BioAfrica\'s HIV-1 proteomics resource: combining protein data with bioinformatics tools', 'The BioAfrica HIV-1 Proteomics Resource is a website that contains detailed information about the HIV-1 proteome and protease cleavage sites, as well as data-mining tools that can be used to manipulate and query protein sequence data, a BLAST tool for initiating structural analyses of HIV-1 proteins, and a proteomics tools directory.', 'logProteome.png', 'Tulio de Oliveira', 29, 'Contains information about each HIV-1 gene product in regard to expression, functional activities, and interactions with viral and host macromolecules', 'resource', 'Y'),
(18, '2015-01-01', 'http://www.phylotype.org', 1, 'Phylotype standalone interface', 'Download phylotype standard alone interfaces for Mac OS X, Linux and Windows system. A batch and command line version for large analysis is also available.', 'log2Phylo.png', 'Tulio de Oliveira', 63, 'Download phylotype standard alone interfaces for Mac OS X, Linux and Windows system. A batch and command line version for large analysis is also available.', 'software', NULL),
(19, '2015-01-14', 'http://bioafrica.mrc.ac.za:8080/regadb-ui/RegaDB', 2, 'SATuRN RegaDB Online tool', 'This database is a free password-protected open source database available. Access to the highly curated data sets is through applications that are reviewed by the <a http://www.bioafrica.net/saturn.php\">SATuRN executive committee</a>', 'log2regadb.png', 'Tulio de Oliveira', 65, 'This database is a free password-protected open source database available. Access to the highly curated data sets is through applications that are reviewed by the <a http://www.bioafrica.net/saturn.php\">SATuRN executive committee</a>', 'database', NULL),
(20, '2014-04-01', 'http://regatools.med.kuleuven.be/typing/v3/hiv/typingtool/', 3, 'Rega HIV Subtyping Tool V3 - Belgium mirror', 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 3 contains new CRFs (CRF01_AE to CRF47_BF). ', 'log2REGAHIV.png', 'Tulio de Oliveira', 67, 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 3 contains new CRFs (CRF01_AE to CRF47_BF). ', 'typing', 'Y'),
(21, '2014-03-12', 'http://bioafrica.net/rega-genotype/html/index.html', 2, 'REGA HIV Subtyping Tool V2 - South African mirror', 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 2 contains CRFs (CRF01_AE to CRF12_BF).', 'log2REGAHIV.png', 'Tulio de Oliveira', 26, 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 2 contains CRFs (CRF01_AE to CRF12_BF).', 'typing', NULL),
(22, '2014-02-10', 'http://bioafrica.net/rega-genotype/html/subtypinghbv.html', 2, 'Oxford HBV Subtyping Tool V2 - South African mirror', NULL, 'log2REGAHBV.png', 'Tulio de Oliveira', 7, 'Phylogenetic tool to identify the Hepatitis B Virus (HBV) subtypes and recombinants. Query sequences are analysed for recombination using bootscanning methods. ', 'typing', NULL),
(23, '2014-02-10', 'http://bioafrica.mrc.ac.za/rega-genotype/html/subtypinghhv8.html', 2, 'HHV8 Automated Subtyping Tool', NULL, 'log2REGAHHV8.png', 'Tulio de Oliveira', 7, 'Phylogenetic tool to identify the Human Herpesvirus 8 (HHV-8) subtypes and recombinants. Query sequences are analysed against the complete K1 reference sequences for HHV8 subtypes A, A5, B, C, D and E.  ', 'typing', NULL),
(24, '2014-02-09', 'http://bioafrica.mrc.ac.za/rega-genotype/html/subtypinghpv.html', 2, 'Human Papillomavirus Subtyping Tool', NULL, 'log2REGAHPV.png', 'Tulio de Oliveira', 7, 'Phylogenetic tool to identify the Human Papillomavirus (HPV) subtypes and species. Query sequences are analysed against the complete L1 reference sequences for HPV and involve the construction of a phylogenetic tree using HKY distance method with gamma distribution in PAUP* software. The HHV8 subtypes and sub-groups are identified.', 'typing', NULL),
(25, '2015-04-14', 'http://www.bioafrica.net/genomicsUKZN.php', 1, 'High-Throughput Genomics Facility at Nelson R Mandela School of Medicine, UKZN in collaboration with Africa Centre for Health and Population Studies', NULL, 'imgnews104.png', 'Tulio de Oliveira', NULL, 'The aim of the Genomics Facility is to setup one of the world\'s most advanced and respected genetic sequencing systems to UKZN in order to enable and support world-class genomics research in Africa. Our objective is to use NextGen sequencing and bioinformatics to answer scientific questions that are of local, national and international importance. Collaborators are welcome to apply for projects to generate HIV, TB, 16S and host genomic data.', 'resource', 'Y'),
(26, '2015-11-06', ' http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/dengue', 1, 'Dengue Virus Typing Tool', 'This is a beta version of our Dengue Virus Typing tool. For the mean time, this tool should be used for evaluation only. Please send feedback to <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>. ', 'logdengue.png', 'Tulio de Oliveira', 7, 'This is a beta version of our Dengue Virus Typing tool. For the mean time, this tool should be used for evaluation only. Please send feedback to <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>. ', 'typing', NULL),
(27, '2015-11-05', 'http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/htlv', 2, 'HTLV 1 & 2 Typing Tool', 'This is a beta version of our Dengue Virus Typing tool. For the mean time, this tool should be used for evaluation only. Please send feedback to <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>. ', 'log2LASPHTLV.png', 'Vagner Fonseca, Tulio de Oliveira, Luiz Carlos Alcantara', 7, 'This is a beta version of our HTLV 1 & 2 Typing tool. For the mean time, this tool should be used for evaluation only. Please send feedback to <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>. ', 'typing', NULL),
(28, '2015-11-05', 'http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/hcv', 2, 'HCV Typing Tool', 'This is a beta version of our Hepatitis C Virus Typing tool. For the mean time, this tool should be used for evaluation only. Please send feedback to <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>. ', 'log2REGAHCV.png', 'Tulio de Oliveira', 7, 'This is a beta version of our HCV Typing tool. For the mean time, this tool should be used for evaluation only. Please send feedback to <a href=\"people.php?peopleid=1\">Tulio de Oliveira</a>. ', 'typing', NULL),
(30, '2016-08-20', 'http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/zika', 1, 'Zika Typing Tool', 'This is the first version of the Zika typing tool, which uses phylogenetic analysis to identify the species and genotype of the virus.', 'logdengue.png', 'Tulio de Oliveira, Vagner Fonseca, Nuno Faria, Marcio Nunes, Luiz Carlos Alcantara, Oliver Pybus', 7, 'This is the first version of the Zika typing tool, which uses phylogenetic analysis to identify the species and genotype of the virus.', 'typing', NULL),
(29, '2016-08-20', ' http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/aedesviruses', 1, 'Arbovirus Typing Tool', 'This is the first version of our Arbovirus typing tool for Chikungunya, Dengue, Yellow Fever and Zika', 'logdengue.png', 'Tulio de Oliveira, Vagner Fonseca, Nuno Faria, Marcio Nunes, Luiz Carlos Alcantara, Oliver Pybus', 7, 'This is the first version of our Arbovirus typing tool for Chikungunya, Dengue, Yellow Fever and Zika', 'typing', NULL),
(31, '2016-08-20', 'http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/chikungunya', 1, 'Chikungunya Typing Tool', 'This is the first version of the Chikungunya typing tool, which uses phylogenetic analysis to identify the species and genotype of the virus.', 'logdengue.png', 'Tulio de Oliveira, Vagner Fonseca, Nuno Faria, Marcio Nunes, Luiz Carlos Alcantara, Oliver Pybus', 7, 'This is the first version of the Chikungunya typing tool, which uses phylogenetic analysis to identify the species and genotype of the virus.', 'typing', NULL),
(32, '2016-08-20', 'http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/yellowfevervirus', 1, 'Yellow Fever Virus Typing Tool', 'This is the first version of the Yellow Fever typing tool, which uses phylogenetic analysis to identify the species and genotype of the virus.', 'logdengue.png', 'Tulio de Oliveira, Vagner Fonseca, Nuno Faria, Marcio Nunes, Luiz Carlos Alcantara, Oliver Pybus', 7, 'This is the first version of the Yellow Fever typing tool, which uses phylogenetic analysis to identify the species and genotype of the virus.', 'typing', NULL),
(33, '2016-08-21', 'http://bioafrica2.mrc.ac.za/rega-genotype/typingtool/hiv', 3, 'REGA HIV Subtyping Tool V3 - South African mirror', 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 3 contains new CRFs (CRF01_AE to CRF47_BF). ', 'log2REGAHIV.png', 'Tulio de Oliveira, Koen Deforche, Vagner Fonseca, Anne-Mieke Vandamme', 67, 'This tool is designed to use phylogenetic methods in order to identify the HIV-1 subtype of a specific sequence. The sequence is analysed for recombination using bootscanning methods. The version 3 contains new CRFs (CRF01_AE to CRF47_BF). ', 'typing', NULL);

-- --------------------------------------------------------

--
-- Table structure for table `b_sw`
--

CREATE TABLE `b_sw` (
  `sw_id` int(4) NOT NULL,
  `sw_name` varchar(50) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_sw`
--

INSERT INTO `b_sw` (`sw_id`, `sw_name`) VALUES
(1, 'blast-2.2.26'),
(2, 'ncbi-blast-2.7.1+'),
(3, 'ncbi-blast-2.6.0+'),
(4, 'COBRApy-0.8.2'),
(5, 'coin-Clp-1.16.10'),
(6, 'blat-36'),
(7, 'ea-utils-1.1.2'),
(8, 'guidance-2.02'),
(9, 'augustus-3.2.3'),
(10, 'ESTScan2-2.1');

-- --------------------------------------------------------

--
-- Table structure for table `b_sw_cat`
--

CREATE TABLE `b_sw_cat` (
  `cat_id` int(2) NOT NULL,
  `cat_name` varchar(50) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_sw_cat`
--

INSERT INTO `b_sw_cat` (`cat_id`, `cat_name`) VALUES
(1, 'Blast'),
(2, 'Phylogeny'),
(3, 'Sequence Analysis'),
(4, 'Development'),
(6, 'UHTS'),
(7, 'Utility'),
(8, 'R-Bioconductor');

-- --------------------------------------------------------

--
-- Table structure for table `b_sw_cat_subcat`
--

CREATE TABLE `b_sw_cat_subcat` (
  `cat_id` int(3) NOT NULL,
  `subcat_id` int(3) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_sw_cat_subcat`
--

INSERT INTO `b_sw_cat_subcat` (`cat_id`, `subcat_id`) VALUES
(1, 1),
(2, 1),
(3, 1),
(3, 3),
(4, 1),
(4, 2),
(4, 4),
(6, 1),
(6, 5),
(6, 6),
(6, 7),
(6, 8),
(7, 1),
(8, 1),
(8, 4);

-- --------------------------------------------------------

--
-- Table structure for table `b_sw_cmds`
--

CREATE TABLE `b_sw_cmds` (
  `cmd_id` int(11) NOT NULL,
  `sw_id` int(11) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- --------------------------------------------------------

--
-- Table structure for table `b_sw_expert`
--

CREATE TABLE `b_sw_expert` (
  `sw_id` int(4) NOT NULL,
  `id` int(4) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

-- --------------------------------------------------------

--
-- Table structure for table `b_sw_inst_locn`
--

CREATE TABLE `b_sw_inst_locn` (
  `sw_id` smallint(3) UNSIGNED NOT NULL,
  `svr_id` smallint(3) UNSIGNED NOT NULL,
  `install_locn` varchar(200) NOT NULL,
  `install_date` date NOT NULL,
  `how_to_load` varchar(200) NOT NULL,
  `how_to_unload` varchar(200) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_sw_inst_locn`
--

INSERT INTO `b_sw_inst_locn` (`sw_id`, `svr_id`, `install_locn`, `install_date`, `how_to_load`, `how_to_unload`) VALUES
(1, 1, '/usr/local/biotools/blast-2.2.26', '2017-08-25', '', ''),
(2, 1, '/usr/local/biotools/clustalw', '2017-08-26', '', ''),
(2, 2, '/urs/local/biotools/clustalw', '2017-10-22', '', ''),
(2, 3, '/usr/local/biotools/clustalw/clustalw2', '2017-09-13', '', ''),
(3, 1, '/usr/local/biotools/ncbi-blast-2.2.26+/bin', '2017-08-27', '', ''),
(4, 1, '/usr/local/biotools/ncbi-blast-2.2.28+/bin', '2017-08-28', '', ''),
(5, 1, '/usr/local/biotools/paup2/paup4b10-x86-linux', '2017-08-29', '', ''),
(5, 2, '/data/biotools/linux/paup2/paup4b10-x86-linux', '2017-11-09', '', ''),
(6, 1, '/usr/local/biotools/', '2017-08-30', '', ''),
(7, 1, '/usr/local/biotools', '2017-08-31', '', ''),
(8, 1, '/usr/local/biotools', '2017-09-01', '', ''),
(9, 1, '/usr/local/biotools', '2017-09-02', '', ''),
(10, 1, '/usr/local/biotools/puzzle', '2017-09-03', '', ''),
(11, 1, '/usr/local/biotools/tgf10rc4', '2017-09-04', '', ''),
(12, 1, '/usr/local/biotools/tree-puzzle-5.3.rc16-linux', '2017-09-05', '', ''),
(13, 2, '/urs/local/biotools/bcftools-1.1', '2017-10-10', '', ''),
(14, 2, '/urs/local/biotools/beagle-lib', '2017-10-11', '', ''),
(15, 2, '/urs/local/biotools/BEAST2/bin', '2017-10-12', '', ''),
(16, 2, '/data/biotools/linux/BEASTv1.8.2', '2017-10-13', '', ''),
(17, 2, '/urs/local/biotools/BEASTv1.8.4/bin', '2017-10-14', '', ''),
(18, 2, '/data/biotools/linux/BEASTv2.0.2', '2017-10-15', '', ''),
(19, 2, '/data/biotools/linux/', '2017-10-16', '', ''),
(20, 2, '/data/biotools/linux/bedtools2', '2017-10-17', '', ''),
(21, 2, '/data/biotools/linux/BioPerl-1.6.1', '2017-10-18', '', ''),
(22, 2, '/urs/local/biotools/bowtie2-2.2.4', '2017-10-19', '', ''),
(23, 2, '/urs/local/biotools/bwa', '2017-10-20', '', ''),
(23, 3, '/usr/local/biotools/bwa/', '2017-09-21', '', ''),
(24, 2, '/data/biotools/linux/clustal-omega-1.2.1', '2017-10-21', '', ''),
(26, 2, '/urs/local/biotools/', '2017-10-23', '', ''),
(27, 2, '/data/biotools/linux/FastME_2.07', '2017-10-24', '', ''),
(28, 2, '/data/biotools/linux/fastme-2.08', '2017-10-25', '', ''),
(29, 2, '/data/biotools/linux/FastQC', '2017-10-26', '', ''),
(29, 3, '/usr/local/biotools/FastQC/fastqc', '2017-09-18', '', ''),
(30, 2, '/data/biotools/linux/', '2017-10-27', '', ''),
(31, 2, '/data/biotools/linux/hyphy-2.2.4', '2017-10-28', '', ''),
(32, 2, '/urs/local/biotools/iqtree/bin', '2017-10-29', '', ''),
(33, 2, '/urs/local/biotools/iva-0.11.4', '2017-10-30', '', ''),
(34, 2, '/data/biotools/linux/iva-0.11.6', '2017-10-31', '', ''),
(35, 2, '/data/biotools/linux/Jellyfish-1.5.5', '2017-11-01', '', ''),
(36, 2, '/data/biotools/linux/jellyfish-2.2.3', '2017-11-02', '', ''),
(37, 2, '/urs/local/biotools/khmer-master', '2017-11-03', '', ''),
(38, 2, '/data/biotools/linux/kraken-0.10.5-beta', '2017-11-04', '', ''),
(39, 2, '/urs/local/biotools/mosaik/MOSAIK', '2017-11-05', '', ''),
(40, 2, '/data/biotools/linux/mrbayes_3.2.2', '2017-11-06', '', ''),
(41, 2, '/urs/local/biotools/MUMmer3.23', '2017-11-07', '', ''),
(42, 2, '/urs/local/biotools/muscle', '2017-11-08', '', ''),
(44, 2, '/data/biotools/linux/PhyML-3.1', '2017-11-10', '', ''),
(45, 2, '/data/biotools/linux/plink-1.07-x86_64', '2017-11-11', '', ''),
(46, 2, '/urs/local/biotools/plink1.90', '2017-11-12', '', ''),
(47, 2, '/urs/local/biotools/poretools/', '2017-11-13', '', ''),
(48, 2, '/data/biotools/linux/Python-3.3.3', '2017-11-14', '', ''),
(49, 2, '/urs/local/biotools/Python-3.7.0b1', '2017-11-15', '', ''),
(50, 2, '/urs/local/biotools/QUASR_v6.08', '2017-11-16', '', ''),
(51, 2, '/urs/local/biotools/R/library/3.4', '2017-11-17', '', ''),
(52, 2, '/urs/local/biotools/RAxML', '2017-11-18', '', ''),
(53, 2, '/urs/local/biotools/samtools-1.1', '2017-11-19', '', ''),
(54, 2, '/urs/local/biotools/sickle-master', '2017-11-20', '', ''),
(55, 2, '/data/biotools/linux/smalt-0.7.5', '2017-11-21', '', ''),
(56, 2, '/urs/local/biotools/SPAdes-3.10.1-Linux', '2017-11-22', '', ''),
(57, 2, '/data/biotools/linux/standard-RAxML-master', '2017-11-23', '', ''),
(58, 2, '/urs/local/biotools/tn93', '2017-11-24', '', ''),
(59, 2, '/urs/local/biotools/Trimmomatic-0.33', '2017-11-25', '', ''),
(60, 2, '/urs/local/biotools/vicuna/bin', '2017-11-26', '', ''),
(61, 2, '/urs/local/biotools/wise/wise2.4.1', '2017-11-27', '', ''),
(62, 3, '/usr/local/biotools/', '2017-09-12', '', ''),
(64, 3, '/usr/local/biotools/blast-2.5.0/bin/', '2017-09-14', '', ''),
(65, 3, '/usr/local/biotools/puzzle/src/puzzle', '2017-09-15', '', ''),
(66, 3, '/usr/local/biotools/tgf10rc4/source/tgf', '2017-09-16', '', ''),
(67, 3, '/usr/local/biotools/diamond/bin/diamond', '2017-09-17', '', ''),
(69, 3, '/usr/local/biotools/SPAdes-3.10.1-Linux/bin/', '2017-09-19', '', ''),
(70, 3, '/usr/local/biotools/samtools/samtools', '2017-09-20', '', ''),
(72, 3, '/usr/local/biotools/vsearch/bin/vsearch', '2017-09-22', '', '');

-- --------------------------------------------------------

--
-- Table structure for table `b_sw_subcat`
--

CREATE TABLE `b_sw_subcat` (
  `subcat_id` int(3) NOT NULL,
  `subcat_name` varchar(50) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `b_sw_subcat`
--

INSERT INTO `b_sw_subcat` (`subcat_id`, `subcat_name`) VALUES
(1, 'Generic'),
(2, 'Libraries'),
(3, 'Multiple Sequence Alignment'),
(4, 'Languages'),
(5, 'Aligner'),
(6, 'Analysis'),
(7, 'Quality Control'),
(8, 'Assembler');

-- --------------------------------------------------------

--
-- Table structure for table `b_workshops`
--

CREATE TABLE `b_workshops` (
  `id` int(11) DEFAULT NULL,
  `name` mediumtext,
  `city` mediumtext,
  `country` mediumtext,
  `date` tinytext,
  `year` year(4) DEFAULT NULL,
  `venue` mediumtext,
  `type` text,
  `link` mediumtext,
  `newsid` int(11) DEFAULT NULL,
  `feature` char(1) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `b_workshops`
--

INSERT INTO `b_workshops` (`id`, `name`, `city`, `country`, `date`, `year`, `venue`, `type`, `link`, `newsid`, `feature`) VALUES
(1, 'WHO and UNDP Regional Training Course on  Bioinformatics Applied to Tropical Diseases In Africa', 'Cape Town', 'South Africa', '20 January - 2 February', 2002, 'South African National Bioinformatics Institute, University of the Western Cape', 'external', NULL, NULL, NULL),
(2, 'First Brazilian Workshop in Virus Evolution and Molecular Epidemiology', 'Salvador', 'Brazil', ' March 25 - 27', 2002, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(3, 'Eighth European Workshop on Virus Evolution and Molecular Epidemiology', 'Leuven', 'Belgium', 'September 4 - 11', 2002, 'REGA institute, Leuven Catolic University', 'external', NULL, NULL, NULL),
(4, 'The South African HIV/AIDS Treatment Management and Drug Resistance Workshop ', 'Durban', 'South Africa', 'July 6', 2003, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(5, 'The Seminar on Evolution, Phylogenetics and HIV', 'Cape Town', 'South Africa', 'July 11', 2003, 'South African Medical Research Council (MRC)', 'external', NULL, NULL, NULL),
(6, 'First African Workshop on Virus Evolution and Molecular Epidemiology', 'Durban', 'South Africa', 'July 2 - 5', 2003, 'South African Medical Research Council (MRC)', 'external', NULL, NULL, NULL),
(7, 'The Ninth International Workshop on Virus Evolution and Molecular Epidemiology', 'Stanford', 'U.S.A.', 'August 13 - 23', 2003, 'Stanford University', 'external', NULL, NULL, NULL),
(8, 'The Bioinformatics and Viral Evolution Workshop', 'Salvador', 'Brazil', '29 January - 6 February', 2004, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(9, 'Molecular Epidemiology of Enteric Opportunistic Protozoa Workshop', 'Durban', 'South Africa', 'February 16 - 20', 2004, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(10, 'Introduction to HIV Sequencing and Phylogenetic Analysis Workshop', 'Durban', 'South Africa', 'February 9 - 13', 2004, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(11, 'The Advanced Bioinformatics and Viral Evolution Workshop', 'Salvador', 'Brazil', 'June 12 - 19', 2004, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(12, 'The 10th International Workshop on Virus Evolution and Molecular Epidemiology', 'Helsinki', 'Finland', '30 August - 3 September', 2004, 'The Finnish National Public Health Institute', 'external', NULL, NULL, NULL),
(13, 'The Second Brazilian Workshop in Virus Evolution and Molecular Epidemiology', 'Salvador', 'Brazil', 'November 9 - 15', 2004, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(14, 'The HIV Data Management and Data Mining for Antiretroviral Drug Resistance Workshop', 'Durban', 'South Africa', 'December 13 - 17', 2004, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(15, 'The WHO Advanced HIV Sequence Analysis Workshop', 'Ibadan', 'Nigeria', 'April 2 - 8', 2005, 'University of Ibadan', 'external', NULL, NULL, NULL),
(17, 'HIV Databases HIVBase Workshop', 'Salvador', 'Brazil', 'September 13 - 16', 2005, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(16, 'The 11th International Workshop on Virus Evolution and Molecular Epidemiology', 'Petropolis', 'Brazil', 'September 5 - 9', 2005, 'National Laboratory for Scientific Computing', 'external', NULL, NULL, NULL),
(18, 'Stanford-South Africa Biomedical Informatics (SSABMI) Training Program', 'Cape Town', 'South Africa', 'September 19 - 22', 2005, 'University of the Western Cape', 'external', NULL, NULL, NULL),
(19, 'The 12th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Athens', 'Greece', 'September 11 - 15', 2006, 'Univeristy of Athens, National Retrovirus Reference Center', 'external', NULL, NULL, NULL),
(20, 'Bioinformatics of African Pathogens and Disease Vectors Workshop', 'Nairobi', 'Kenya', '27 May to 2 June', 2007, 'ICIPE', 'external', NULL, NULL, NULL),
(21, 'The 13th International Virus Bioinformatics Workshop', 'Lisbon', 'Portugal', 'September 9 - 14', 2007, 'Instituto Nacional de Saude Dr. Ricardo Jorge (INSA)', 'external', NULL, NULL, NULL),
(22, 'Introduction to HIV Phylogenetics Workshop', 'Durban', 'South Africa', 'August 13 - 15', 2007, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(23, 'Advanced Viral Evolutionary Workshop', 'Cape Town', 'South Africa', 'September 17 - 18', 2007, 'South Africa National Bioinformatics Institute, University of the Western Cape', 'external', NULL, NULL, NULL),
(24, 'HIV Drug Resistance in Clinical Practice Workshop', 'Cape Town', 'South Africa', 'September 5', 2008, 'University of the Western Cape', 'external', NULL, NULL, NULL),
(25, '14th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Cape Town', 'South Africa', 'September 1 - 5', 2008, 'South Africa National Bioinformatics Institute, University of the Western Cape', 'external', NULL, NULL, NULL),
(26, 'IRTG 1522 Summer School: From Bioinformatics to Rational Drug Design', 'Wuzburg', 'Germany', 'July 24 - 26', 2009, 'University of Wurzburg', 'external', NULL, NULL, NULL),
(27, '15th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Rotterdam', 'Netherlands', 'September 7 - 11', 2009, 'Erasmus Medical Center', 'external', NULL, NULL, NULL),
(28, '4th South African HIV Drug Resistance and Treatment Monitoring Workshop', 'Bloemfontein', 'South Africa', 'October 28 - 30', 2009, 'University of the Free State', 'external', NULL, NULL, NULL),
(29, 'ISCB-Africa ASBCB Joint Conference on Bioinformatics of Infectious Diseases', 'Bamako', 'Mali', '30 November to 2 December', 2009, 'International Conference Centre', 'external', NULL, NULL, NULL),
(30, 'Oxford Virology Symposium: From Theory to Therapeutics', 'Oxford', 'U.K.', 'April 14 - 16', 2010, 'Christ Church College, University of Oxford', 'external', NULL, NULL, NULL),
(31, '16th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Baltimore', 'U.S.A.', '29 August to 3 September', 2010, 'Johns Hopkins University', 'external', NULL, NULL, NULL),
(32, '5th South African HIV Drug Resistance and Treatment Monitoring Workshop', 'Bloemfontein', 'South Africa', 'October 27 - 29', 2010, 'University of the Free State', 'external', NULL, NULL, NULL),
(33, 'Swiss Prot / South Africa Protein Bioinformatics Workshop', 'Durban', 'South Africa', 'November 17 - 18', 2010, 'South African Medical Research Council (MRC)', 'external', NULL, NULL, NULL),
(34, 'Swiss Prot / South Africa Protein Bioinformatics Workshop II', 'Cape Town', 'South Africa', 'November 23', 2010, 'University of Cape Town (UCT)', 'external', NULL, NULL, NULL),
(35, 'HIV Drug Resistance Satellite Meeting at SA AIDS Conference', 'Durban', 'South Africa', 'June 7', 2011, 'International Conference Centre (ICC)', 'external', NULL, NULL, NULL),
(36, '2nd Brazilian Workshop on HIV & HTLV-1 Bioinformatics and Databases', 'Salvador', 'Brazil', 'September 5 - 7', 2011, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(37, '5th Annual Workshop on Advanced Clinical Care (AWACC)', 'Durban', 'South Africa', 'October 6 - 7', 2011, 'Southern Sun Elangeni Hotel', 'external', NULL, NULL, NULL),
(38, '6th Southern African HIV / TB Drug Resistance & Clinical Management Workshop', 'Gaborone', 'Botswana', 'November 7 - 8', 2011, 'University of Botswana', 'external', NULL, NULL, NULL),
(39, '1st Nurses and Health Care Workers HIV & TB Drug Resistance SATuRN Workshop', 'Mtubatuba', 'South Africa', 'May 22', 2012, 'Africa Centre for Population Health', 'external', NULL, NULL, NULL),
(40, '17th International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Belgrade', 'Servia', 'August 27 - 31', 2012, 'University of Belgrade, Faculty of Medicine', 'external', NULL, NULL, NULL),
(41, '7th South African HIV & TB Drug Resistance and Treatment Monitoring Workshop', 'Cape Town', 'South Africa', 'November 28 - 29', 2012, 'Cape Town International Conference Centre (CTICC)', 'external', NULL, NULL, NULL),
(42, 'HIV/TB Drug Resistance and Clinical Management Workshop & Book Launch', 'Mkuze', 'South Africa', 'March 7 - 8', 2013, 'Ghost Mountain Inn', 'external', NULL, NULL, NULL),
(43, 'Practical Course on Quality Assurance of HIV-1 Drug Resistance Interpretation in Sequence Editing and Data Management Processes', 'Johannesburg', 'South Africa', 'April 22 - 26', 2013, 'National Institute for Communicable Diseases (NICD)', 'external', NULL, NULL, NULL),
(44, 'Bioinformatics in the tropics I: 1st International Bioinformatics & Molecular Viral Evolution Workshop', 'Salvador', 'Brazil', 'July 22 - 26', 2013, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(45, 'SATuRN satelitte workshop at 17th Annual Rural Health Conference', 'Saint Lucia', 'South Africa', 'August 8 - 10', 2013, 'Saint Lucia Conference Centre', 'external', NULL, NULL, NULL),
(46, '18th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Gainesville', 'U.S.A.', 'August 25 - 30', 2013, 'University of Florida - Gainsville', 'external', NULL, NULL, NULL),
(47, 'BROAD/MIT Bioinformatics of Infectious Disease: Comparative Genomics of M. tuberculosis', 'Durban', 'South Africa', 'September 16 - 30', 2013, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(48, 'Bioinformatics in the tropics II: Large data sets analysis workshop: HIV phylogenetics, molecular epidemiology and drug resistance', 'Durban', 'South Africa', 'September 23 - 26', 2013, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(49, 'Annual Workshop on Advanced Clinical Care - AIDS (AWACC)', 'Durban', 'South Africa', 'September 26 - 27', 2013, 'Southern Sun Elangeni Hotel', 'external', NULL, NULL, NULL),
(50, 'Infectious Disease Genomics and Global Health Wellcome Trust Conference', 'Hixton, Cambridge', 'U.K.', 'October 16 - 18', 2013, 'Wellcome Trust Genome Campus', 'external', NULL, NULL, NULL),
(51, '8th Southern African HIV & TB Drug Resistance and Treatment Monitoring Workshop', 'Bloemfontein', 'South Africa', 'November 20 - 22', 2013, 'University of the Free State', 'external', NULL, NULL, NULL),
(52, 'Bioinformatics in the Tropics Uganda 2014', 'Entebbe', 'Uganda', 'April 7 - 10', 2014, 'Uganda Virus Research Institute (UVRI)', 'external', NULL, NULL, NULL),
(53, 'Satellite Workshop on HIV Phylodynamics at 21st HIV Dynamics and Evolution Workshop', 'Tucson', 'U.S.A.', 'May 7 - 10', 2014, 'Univesity of Arizona', 'external', NULL, NULL, NULL),
(54, 'Bioinformatics in the Tropics Brazil 2014: 2nd International Bioinformatics Workshop on Virus evolution and Molecular Epidemiology', 'Salvador', 'Brazil', 'May 26 - 30', 2014, 'Centro de Pesquisas Goncalo Moniz - Fundacao Oswaldo Cruz (FioCruz)', 'external', NULL, NULL, NULL),
(55, '19th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Rome', 'Italy', 'September 7 - 12', 2014, 'National Institute for Infectious Diseases \'L Spallanzani\'', 'external', NULL, NULL, NULL),
(56, 'SATuRN & CAPRISA HIV & TB Advanced Clinical Care Workshop', 'Durban', 'South Africa', 'March 12 - 13', 2015, 'Makaranga Garden Lodge', 'external', NULL, NULL, NULL),
(57, 'Satellite Workshop on HIV Phylodynamics at 22nd HIV Dynamics and Evolution Workshop', 'Budapest', 'Hungary', 'May 13 - 16', 2015, 'artHotel Budapest', 'external', NULL, NULL, NULL),
(58, 'Wellcome Trust Advanced Workshop: Genomic Epidemiology in Africa', 'Durban', 'South Africa', 'June 21 - 26', 2015, 'Nelson R Mandela School of Medicine, UKZN', 'external', NULL, NULL, NULL),
(59, 'Bioinformatics in the tropics Uganda 2015: Introduction to bioinformatics analysis techniques for next generation sequencing data', 'Entebbe', 'Uganda', 'July 6 - 10', 2015, 'Uganda Virus Research Institute (UVRI)', 'external', NULL, NULL, NULL),
(60, '20th International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'St. Augustine', 'Trinidad and Tobago', 'August 9 - 14', 2015, 'The University of the West Indies (UWI)', 'external', NULL, NULL, NULL),
(61, 'Annual Workshop on Advanced Clinical Care - AIDS (AWACC)', 'Durban', 'South Africa', 'November 19 - 20', 2015, 'Southern Sun Elangeni Hotel', 'external', NULL, NULL, NULL),
(62, 'SATuRN & CAPRISA HIV & TB Advanced Clinical Care Workshop', 'Durban', 'South Africa', 'May 5 - 6', 2016, 'Coastlands Hotel', 'external', 'http://bioafrica.net/workshops/SATuRNCAPRISAHIVTBClinicalCareWorkshop2016.html', 150, ''),
(63, '21st International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology', 'Seoul', 'South Korea', 'August 14 - 19', 2016, 'Korea University College of Medicine', 'external', 'https://rega.kuleuven.be/cev/veme-workshop/2016', 149, 'Y'),
(64, '4th Joint Congress of the South African Society for Bioinformatics (SASBi) and the South African Genetics Society (SAGS)', 'Durban', 'South Africa', 'September 20 - 23', 2016, 'Nelson R Mandela School of Medicine, UKZN', 'external', 'http://www.sasbi-sags.co.za/', 158, 'Y'),
(65, '10th Annual Workshop on Advanced Clinical Care - AIDS (AWACC)', 'Durban', 'South Africa', 'October 6 - 7', 2016, 'International Conference Centre (ICC)', 'external', 'http://www.awacc.org', 159, 'Y'),
(66, 'Ethics and Viral Genomics: An Exploration of Ethical Issues Associated with HIV Phylogenetics', 'Durban', 'South Africa', 'December 9', 2016, 'Nelson R Mandela School of Medicine, UKZN', 'external', 'http://bioafrica.net/news.php?id=166', 166, ''),
(67, 'SATuRN & CAPRISA 2017: HIV & TB Drug Resistance and Advanced Care Workshop', 'Drakensberg', 'South Africa', 'March 30 - 31', 2017, 'Drakensberg Gardens Golf and Spa Resort', 'external', 'http://bioafrica.net/workshops/SATuRNCAPRISAHIVTBClinicalCareWorkshop2017.html', 169, 'Y'),
(68, 'Swiss South African Symposium on Pathogen Genomics', 'Cape Town', 'South Africa', 'February 23', 2017, 'University of Cape Town', 'external', 'http://bioafrica.net/news.php?id=171', 171, NULL),
(69, 'SFU-SANTHE Intensive Course: Inter-disciplinary approaches to understanding the global burden of HIV and youth', 'Durban', 'South Africa', 'May 1 - 12', 2017, 'Nelson R Mandela School of Medicine, UKZN', 'external', 'http://www.santheafrica.org/courses/sfu-santhe-intensive-course-inter-disciplinary-approaches-understanding-global-burden-hiv', NULL, NULL),
(70, '22nd International Bioinformatics Workshop on Virus Evolution and Molecular Epidemiology (VEME)', 'Lisbon', 'Portugal', 'August 27 - September 1', 2017, 'Universidade Nova de Lisboa', 'external', 'http://www.krisp.org.za/news.php?id=184', 184, 'Y'),
(71, '11th Annual Workshop on Advanced Clinical Care - AIDS (AWACC)', 'Durban', 'South Africa', 'September 7 - 8', 2017, 'Elangeni Hotel', 'external', 'http://www.krisp.org.za/news.php?id=183', 183, 'Y'),
(72, 'X-meeting - 13th International Conference of the AB3C ', 'Sao Pedro', 'Brazil', 'October 4 - 6', 2017, 'Hotel Fazenda Fonte Colina Verde', 'external', 'http://www.krisp.org.za/news.php?id=185', 185, 'Y');

-- --------------------------------------------------------

--
-- Table structure for table `crflist`
--

CREATE TABLE `crflist` (
  `id` int(11) NOT NULL,
  `name` varchar(10) DEFAULT NULL,
  `RegaV3` binary(1) DEFAULT NULL,
  `description` longtext,
  `losdescription` longtext,
  `loslink` longtext,
  `geographic` varchar(100) DEFAULT NULL,
  `transmission` varchar(50) DEFAULT NULL,
  `epidemiosign` varchar(50) DEFAULT NULL,
  `numberseq` int(10) DEFAULT NULL,
  `lossearch` varchar(10) DEFAULT NULL,
  `firstisolated` year(4) DEFAULT NULL,
  `lastisolated` year(4) DEFAULT NULL,
  `tree` tinytext,
  `REGAV3map` tinytext,
  `losmap` tinytext,
  `REGAV3link` tinytext,
  `exclusion` longtext,
  `phyloV1` binary(1) DEFAULT NULL,
  `numberseqCG` int(10) DEFAULT NULL,
  `firstisolatedCG` year(4) DEFAULT NULL,
  `lastisolatedCG` year(4) DEFAULT NULL,
  `geographicCG` varchar(200) DEFAULT NULL,
  `refstrain` tinytext,
  `REGArefstrain1` tinytext,
  `REGArefstrain2` tinytext,
  `REGArefstrain3` tinytext,
  `Regav3resultCG` tinytext,
  `Regav3result` tinytext,
  `phylotyperesults` longtext
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `crflist`
--

INSERT INTO `crflist` (`id`, `name`, `RegaV3`, `description`, `losdescription`, `loslink`, `geographic`, `transmission`, `epidemiosign`, `numberseq`, `lossearch`, `firstisolated`, `lastisolated`, `tree`, `REGAV3map`, `losmap`, `REGAV3link`, `exclusion`, `phyloV1`, `numberseqCG`, `firstisolatedCG`, `lastisolatedCG`, `geographicCG`, `refstrain`, `REGArefstrain1`, `REGArefstrain2`, `REGArefstrain3`, `Regav3resultCG`, `Regav3result`, `phylotyperesults`) VALUES
(1, '01_AE', 0x79, 'CRF01_AE  represents a putative subtype A/E recombinant form of HIV-1 which is spreading epidemically in Asia, but originated from Central Africa.', 'CRF01_AE (reference strain CM240) represents a putative subtype A/E recombinant form of HIV-1 which is spreading epidemically in Asia, but originated from Central Africa (Murphy et al. 1993; Carr et al. 1996; Gao et al. 1996). In the future, putative recombinants with only one full-length \"parental\" subtype representative would be designated as being comprised of this subtype and unclassified regions (U). Under the new nomenclature system CRF01_AE would be referred to as CRF01_AU because the putative \"parental\" non-recombinant E strain has not been found. But, as the \"E\" designation for the env region of these strains is very commonly used, renaming it would lead to confusion. Thus, the \"E\" designation will be retained.', '01_AE', NULL, NULL, 'high', 2063, NULL, 1990, 2009, NULL, '01_AE', 'CRF01', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/0', NULL, NULL, 152, 1990, 2007, 'AF(1),CF(3),CN(29),HK(1),ID(1),JP(9),TH(71),US(4),VN(33)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 01_AE', 'HIV-1 Subtype A (01_AE)', NULL),
(2, '02_AG', 0x79, 'CRF02_AG is a subtype A/G recombinant form that is one of the most prevalent HIV-1 strains in West and Central Africa.', 'CRF02_AG (Howard and Rasheed 1996) is a subtype A/G recombinant form that is circulating widely in West and Central Africa (Carr et al. 1998), but has also been reported in Taiwan (Lee et al. 1998).', '02_AG', NULL, NULL, 'high', 2055, NULL, 1997, 2008, NULL, '02_AG', 'CRF02', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/1', NULL, 0x79, 60, 1991, 2006, 'CM(31),CY(1),ES(2),FR(2),GH(10),GW(2),LR(1),NG(3),SE(1),SN(2),US(2),UZ(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 02_AG', 'HIV-1 CRF 02_AG', NULL),
(3, '03_AB', 0x79, 'CRF03_AB represents a subtype A/B recombinant form that was first found in Kaliningrad, and was circulating in Russian and Ukrainian cities.', 'CRF03_AB represents a subtype A/B recombinant that was first found in Kaliningrad, and is circulating in Russian and Ukrainian cities, primarily in injecting drug users (Liitsola et al. 1998; Lukashov 1999). Circulation of this strain appears to have been accelerated by intravenous injection of a locally produced opiate contaminated with HIV-infected blood. The recombination breakpoints were discussed in detail by Liitsola et al. 2000.', '03_AB', 'AZ(1), BY(1), RU(3)', NULL, NULL, 5, NULL, 1997, 2002, NULL, '03_AB', 'CRF03', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/2', NULL, NULL, 3, 1997, 2000, 'BY(1),RU(2)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 03_AB', 'HIV-1 CRF 03_AB', NULL),
(4, '04_cpx', 0x79, 'CRF04_cpx  represents a Cypriot/Greek recombinant form that was previously classified as an A/G/I recombinant. ', 'CRF04_cpx (reference strain 94CY032) which represents a Cypriot/Greek recombinant form that was previously classified as an A/G/I recombinant (Gao et al. 1998; Nasioulas et al. 1999). This recombinant has recently been found to be an even more complex mosaic comprised of subtypes A, G, H, K and unclassified regions (Paraskevis et al. 2001). Note that the \"I\" designation has been dropped from the nomenclature.', '04_cpx', 'CY(1), FR(1), GR(6)', NULL, 'medium', 9, NULL, 1991, 2005, NULL, '04_cpx', 'CRF04', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/3', NULL, NULL, 4, 1991, 2005, 'CY(2),GR(2)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 04_CPX', 'HIV-1 CRF 04_CPX', NULL),
(5, '05_DF', 0x79, 'CRF05_DF were first detected in Belgian individuals presumably infected by partners for the Democratic Republic of the Congo (DRC).', 'The CRF05 chimera was described by Laukkanen et al. 2000. Two genomes (VI1310 and VI961) are from Belgian individuals likely infected by partners from the Democratic Republic of the Congo (DRC, former Zaire). A third genome, 99X492(AY227107), was published by Casado et al. 2003.\n\n', '05_DF', 'BE(6), BG(2), CD(3), CG(1), ES(2), TG(1),', NULL, 'medium', 15, NULL, 1987, 2006, NULL, '05_DF', 'CRF05', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/4', NULL, NULL, 3, 1993, 1999, 'BE(2),ES(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 05_DF', 'HIV-1 CRF 05_DF', NULL),
(6, '06_cpx', 0x79, 'CRF06_cpx has been identified in Burkina Faso, Mali, Nigeria and Senegal in Africa. It also causes epidemic in Europe in Estonia, the U.K. and other european countries.', 'The first two full-length sequences of this CRF were BFP90(AF064699) from Burkina Faso (Oelrichs et al. 1998) and 95ML84(AJ245481) from Mali (Montavon et al. 1999). The recombinant was previously named \"CRF06_AGJ\", but the subsequent identification of subtype K (Triques et al. 2000) suggested that some regions of CRF06 are subtype K, so the subtype is now called \"CRF06_cpx\". The recombinant structure of the reference sequence was subsequently analyzed by Montavon et al. 2002.', '06_cpx', 'AR(1),AU(1),BE(4),BF(88),CD(1),CI(4),CN(2),CZ(2),DE(3),DK(1),EE(130),ES(11),FI(2),FR(6),GA(1),GB(34)', NULL, 'high', 371, NULL, 1994, 2008, NULL, '06_cpx', 'CRF06', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/5', NULL, NULL, 8, 1995, 2005, 'AU(1),CD(1),EE(1),GH(1),ML(2),RU(1),SN(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 06_CPX', 'HIV-1 CRF 06_CPX', NULL),
(7, '07_BC', 0x79, 'CRF07_BC was identified in China.', 'A description of this CRF was published by Su, L. et al. 2000 but no sequences were deposited. A patent of the CN54 sequence was recorded with accession numbers AX149771 and AX149647. Two other genomes sequenced by Rodenburg et al. 2001 are available: 97CN001 (AF286226) and 98CN009 (AF286230); however, 97CN001 is reportedly from the same blood sample as CN54.', '07_BC', 'CN(126), TW(60)', NULL, 'high', 186, NULL, 1997, 2009, NULL, '07_BC', 'CRF07', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/6', NULL, NULL, 8, 1997, 2005, 'CN(7),TW(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 07_BC', 'HIV-1 CRF 07_BC', NULL),
(8, '08_BC', 0x79, 'CRF08_BC was identified in China.', 'The CRF was named by McCutchan 2000. Four near-full-length sequences are available: 97CNGX-6F (AY008715), 97CNGX-7F (AY008716) and 97CNGX-9F (AY008717), all published by Piyasirisilp et al. 2000, and 98CN006 (AF286229) published by Rodenburg et al. 2001.', NULL, 'CN(170), IN(1)', NULL, 'high', 171, NULL, 1996, 2008, NULL, '08_BC', 'CRF08', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/7', NULL, NULL, 6, 1997, 2006, 'CN(6)', NULL, NULL, NULL, NULL, 'HIV-1 Subtype C (08_BC)', 'HIV-1 CRF 08_BC', NULL),
(9, '09_cpx', 0x79, 'CRF09_cpx was identified in Central-Western Africa.', 'The CRF09 reference strain was mentioned by McCutchan et al. 2000 and Brodine et al. 2003. The mosaic structure was examined by McCutchan et al. 2004, who provided four complete genomes: 96GH2911(AY093605), 95SN1795(AY093603), 99DE4057(AY093607), and 95SN7808(AY093604). Their phylogenetic analyses found that most regions of CRF09 cluster most closely with strains of subtypes A or G, and may share some breakpoints with CRF02_AG. However, most regions can best be described as A-like or G-like, as they fall outside the crown group for these subtypes. Some regions appear to be most closely related to strain Z321. Because of the difficulty in assigning many of the regions of CRF09 to any of the pure subtypes, we do not provide a diagram. For more information, see McCutchan et al. 2004.\n\nA fifth CRF09 genome was sequenced by Toni et al. 2005: 00IC-10092(AJ866553).', NULL, 'AO(1),BF(2),CI(1),CM(4),CZ(1),GH(3),IT(1),ML(6),NG(1),SN(5),US(1)', NULL, 'medium', 26, NULL, 1995, 2006, NULL, '09_cpx', 'CRF09', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/8', NULL, NULL, 5, 1995, 2000, 'CI(1),GH(1),SN(2),US(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 09_cpx', 'HIV-1 CRF 09_cpx', NULL),
(10, '10_CD', 0x79, 'CRF10_CD was identified in Eastern Africa.', 'This CRF was published by Koulinska et al. 2001. Three representatives have been fully sequenced: TZBF061 (AF289548), TZBF071 (AF289549), and TZBF110 (AF289550). Note that some regions of these genomes labeled as subtype D are nearly equidistant between subtypes B and D.', NULL, 'BI(1),CN(1),ES(2),KE(1),TZ(3)', NULL, 'medium', 8, NULL, 1996, 2008, NULL, '10_CD', 'CRF10', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/9\n', NULL, NULL, 3, 1996, 1996, 'TZ(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 10_CD', 'HIV-1 Subtype D', NULL),
(11, '11_cpx', 0x79, 'CRF11_cpx was discovered in Cameroon and France.', 'Six genomes of this CRF are available: GR17 (AF179368) by Paraskevis et al. 2000; MP818 (AJ291718), MP1298 (AJ291719), and MP1307 (AJ291720) by Montavon et al. 2002; and 96CM4496 (AF492623) and 95CM1816 (AF492624) by Wilbe et al. 2002 . In the nef/LTR region, both the A and E segments appear to be derived from CRF01_AE, while the other A segments are not. The segments labeled U were regions where the sequence was equidistant between G and J.', NULL, 'BE(1),BW(1),CD(3),CM(22),DE(1),ES(9),FR(12),GA(3),GB(1),GR(1),NG(1),NO(1),SE(1)', NULL, 'medium', 57, NULL, 1995, 2007, NULL, '11_cpx', 'CRF11', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/10', NULL, NULL, 10, 1995, 2002, 'CM(7),FR(2),GR(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 11_CPX', 'HIV-1 Subtype J (11_CPX)', NULL),
(12, '12_BF', 0x79, 'CRF12_BF was identified in Argentina and Uruguay. This CRF is widespread in South America.', 'Four representatives of this CRF, two from Argentina and two from Uruguay, were fully sequenced and described by Carr et al. 2001: AY037279, AF385934, AF385935, and AF385936. Two more complete genomes of this CRF, from Argentina, were described by Thomson et al. 2002: AF408629 and AF408630. Thomson et al. 2000 had previously sequenced the pol region of suspected CRF12_BF isolates (see AF308478..AF308539). Other BF recombinant sequences sharing some but not all recombination sites with CRF12 were also described by Thomson et al. 2002.', NULL, 'AR(280),BE(1),BR(4),DE(2),ES(24),IT(3),US(1),UY(4)', NULL, 'high', 319, NULL, 1997, 2007, NULL, NULL, 'CRF12', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/11', NULL, NULL, 7, 1997, 2001, 'AR(3),UY(4)', NULL, NULL, NULL, NULL, 'Recombinant of 12_BF, F1 ', 'HIV-1 Subtype F (12_BF)', NULL),
(13, '13_cpx', 0x79, 'CRF13_cpx was identified in Cameroon and Belgium.', 'Three representatives of this CRF have been fully sequenced as described by Wilbe et al. 2002 and Kijak et al. 2004: AF460972, AF460974, and AY371154. Regions depicted as derived from \"subtype E\" here, are derived from CRF01_AE. The J-like region at the gag-pol overlap and into pol, is more closely related to CRF11_cpx than to pure subtype J sequences, while the vif-vpr subtype J region is more closely related to non-recombinant J than to CRF11_cpx. More analysis of this CRF was described by Zhang et al. 2005', NULL, 'BE(6),CD(1),CG(1),CM(11),DE(1),GL(1),PL(1),US(1)', NULL, 'medium', 23, NULL, 1996, 2009, NULL, NULL, 'CRF13', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/12', NULL, NULL, 6, 1996, 2004, 'CM(6)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 13_CPX', 'HIV-1 Subtype J (13_CPX)', NULL),
(14, '14_BG', 0x79, 'CRF14_BG was identifioed in Spain.', 'Six representatives of this CRF, found in Spain, were sequenced by the group of Rafael Najera and described by Delgado et al. 2002: AF423756, AF423757, AF423758, AF423759, AF450096, and AF450097.', NULL, 'BE(1),ES(20),GB(1)', NULL, 'medium', 22, NULL, 1999, 2007, NULL, NULL, 'CRF14', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/13', NULL, NULL, 8, 1999, 2005, 'ES(8)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 14_BG', 'HIV-1 Subtype G (14_BG)', NULL),
(15, '15_01B', 0x6e, 'CRF15_01B was identified in Thailand.', 'Four representatives of this CRF, found in Thailand, have been sequenced by the group of Francine McCutchan. The sequence with accession number AF516184 was the first reported to be CRF15_01B. Three more complete genomes have been sequenced and described in Tovanabutra et al. 2003: AF516184, AF529572, AF529573, and AF530576. The genomes of this CRF are derived primarily from CRF01_AE with only the env region (roughly bases 5700 to 7800 in AF516184) being derived from subtype B.', NULL, 'TH(5)', NULL, 'low', 5, NULL, 1996, 2002, NULL, NULL, 'CRF15', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/14', 'CRF15_01B is similar to CRF01_AE in most of the genomic regions. It also clusters with CRF01_AE and if used in the Rega V3 do not allow the classification of CRF01_AE as it will compete and break CRF01_AE cluster, specially on the usage of Pol sequences that are normally generated for resistance studies.\n', NULL, 5, 1996, 2002, 'TH(5)', NULL, NULL, NULL, NULL, 'Recombinant of 01_AE, B', 'HIV-1 Subtype A (01_AE)', NULL),
(16, '16_A2D', 0x6e, 'CRF16_A2D was identified in Argentina.', 'CRF16 was described by Gomez-Carrillo et al. 2004. Two representative complete genomes of this CRF, found in Kenya and South Korea, plus 2 partial genomes from Argentina, have been sequenced. The sequences KISII5009(AF457060) and 97KR004(AF286239) are the complete genomes. Note that AF457060 is hypermutated. Additional analysis of CRF16_A2D and CRF21_A2D was published by Visawapoka et al. 2006.', NULL, 'AR(4),KE(1),KR(1)', NULL, 'low', 6, NULL, 1991, 2003, NULL, NULL, 'CRF16', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/15', 'It is a rare A2 strain in Kenya, Argentina and Korea. It also cause cluster problems on a phylogentic tree with 21_A2D (a 16_A2D related recombinant ) and old D sequences from South Africa. Martine - recombination fragment small.', NULL, 2, 1991, 1997, 'KE(1),KR(1)', NULL, NULL, NULL, NULL, 'HIV-1 Subtype A (A2)', 'HIV-1 Subtype A (A2)', NULL),
(17, '17_BF', 0x6e, NULL, 'The structure of ARMA038 (AY037281) was published by Carr et al. 2001. This CRF shares some breakpoints with CRF12_BF.\n\nSeveral related genomes have been sequenced: ARG1139 (EU581825), ARG2233 (EU581826), PSP073 (EU581824), PSP096 (EU581823), BO119 (EU581827), and PCR155 (EU581828)', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'CRF17', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/16', 'CRF17_BF is a B/F recombinant related to CRF12_BF. It causes clustering probem on the phylogenetic tree with CRF12_BF and do not allow others CRF12 sequences to be correctly classified. In addition, there is problem to classify others CRFs that are B and F recombinants. My experience suggest that recombination between B and F is still happening in South America and that most of the CRFs_BF are not epidemiologically important, but a few complete genomes with common origin that have been identified by researchers and complete genome generated.', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Recombinant of 12_BF, F1, B', 'HIV-1 Subtype B', NULL),
(18, '18_cpx', 0x79, 'CRF18_cpx was identified in Cuba.', 'CRF18 was described by Thomson et al. 2005, who provided two genome sequences, CU76(AY586540) and CU14(AY586541). Other genome sequences include CU68(AY894993) and CM53379(AF377959). In the drawing, the ambiguous region around 5280 was rooted between A and G, and the region around 6600 was rooted between G and J.', NULL, 'AO(1),CG(1),CM(4),CU(34),ES(1),GB(2),GE(1),ML(1)', NULL, 'medium', 48, NULL, 1997, 2006, NULL, NULL, 'CRF18', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/17', NULL, NULL, 4, 1997, 1999, 'CM(1),CU(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 18_cpx', 'HIV-1 CRF 18_cpx', NULL),
(19, '19_cpx', 0x79, 'CRF19_cpx was identified in Cuba.', 'CRF19 was described by Casado et al. 2005, who provided three genome sequences, AY894994, AY588970, and AY588971.', NULL, 'CU(81),ES(2),GR(1),NG(1)', NULL, 'medium', 85, NULL, 1999, 2007, NULL, NULL, 'CRF19', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/18', NULL, NULL, 3, 1999, 1999, 'CU(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 19_cpx', 'HIV-1 Subtype D (19_cpx)', NULL),
(20, '20_BG', 0x79, 'CRF20_BG was identified in Cuba.', 'Perez et al. 2006 described 3 clusters of BG recombinant sequences found among HIV patients in Cuba. Sierra et al. 2007 determined the breakpoints of these recombinants and defined them as CRFs 20, 23, and 24. Genome sequences for CRF20 include: Cu103 (AY586545), R77 (AY586544), and CB134 (DQ020274).', NULL, 'CU(23),ES(1)', NULL, 'medium', 24, NULL, 1999, 2003, NULL, NULL, 'CRF20', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/19', NULL, NULL, 3, 1999, 2003, 'CU(2),ES(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 20_BG', 'HIV-1 Subtype G (20_BG)', NULL),
(21, '21_A2D', 0x6e, 'CRF21_A2D was identified in Kenya.', 'CRF21 was described by Dowling et al. 2002. Genome sequences include: AF457051 and AF457072. Additional analysis of CRF16_A2D and CRF21_A2D was published by Visawapoka et al. 2006.', NULL, 'KE(3)', NULL, 'low', 3, NULL, 1991, 1999, NULL, NULL, 'CRF21', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/20', 'It is a rare A2 recombinant strain found in Kenya, which probably is not epidemiologically significant. It also cause cluster problems on a phylogentic tree with 16_A2D and old D sequences from South Africa. ', NULL, 3, 1991, 1999, 'KE(3)', NULL, NULL, NULL, NULL, 'Recombinant of D, A1', 'HIV-1 Subtype D', NULL),
(22, '22_01A1', 0x6e, 'CRF22_01A1 was identified in Cameroon.', 'Carr et al. 2001 published an analysis of a novel URF, CM53122, that was a recombinant of CRF01_AE and segments of subtype A1 that were not derived from CRF01. The authors later defined this as a CRF, based on two additional genome sequences, CM3097 and CM001BBY (AY371159). The original CM53122 genome sequence is available in two segments (AY037284 + AY037285). CM001BBY has been chosen here as the reference strain due to the availability of a contiguous full-length sequence. A complete description of this CRF has not yet been published (as of September 2008).', NULL, 'CM(7)', NULL, 'low', 7, NULL, 1997, 2002, NULL, NULL, 'CRF22', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/21', 'It is a CRF01_AE recombinant with an A1 strain sampled only in Cameroon, which is not comfirmed in bootscanning analysis.', NULL, 2, 2001, 2002, 'CM(2)', NULL, NULL, NULL, NULL, 'Recombinant of A1, G', 'HIV-1 Subtype A (A1)', NULL),
(23, '23_BG', 0x6e, 'CRF23_BG was identified in Cuba and Spain.', 'Perez et al. 2006 described 3 clusters of BG recombinant sequences found among HIV patients in Cuba. Sierra et al. 2007 determined the breakpoints of these recombinants and defined them as CRFs 20, 23, and 24. Genome sequences for CRF23 include CB118 (AY900571) and CB347 (AY900572).', NULL, 'CU(6),ES(4)', NULL, NULL, 10, NULL, 2003, 2005, NULL, NULL, 'CRF23', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/22', 'It is too similar to CRF24_BG and causes clustering problem with CRF24_BG on a phylogenetic tree. When used as a reference strain it not classify correctly on GAG and ENV. Needs reference.', NULL, 2, 2003, 2003, 'CU(2)', NULL, NULL, NULL, NULL, 'Recombinant of G, B', 'HIV-1 Subtype G', NULL),
(24, '24_BG', 0x79, 'CRF24_BG was identified in Cuba.', 'Perez et al. 2006 described 3 clusters of BG recombinant sequences found among HIV patients in Cuba. Sierra et al. 2007 determined the breakpoints of these recombinants and defined them as CRFs 20, 23, and 24. Genome sequences for CRF24 include CB378 (AY900574), CB619 (AY900576), CB471 (AY900575), CB228 (AY900577), and CB219 (AY900581).', NULL, 'CU(22),IT(2)', NULL, 'medium', 24, NULL, 2003, 2005, NULL, NULL, 'CRF24', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/23', NULL, NULL, 3, 2003, 2003, 'CU(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 24_BG', 'HIV-1 CRF 24_BG', NULL),
(25, '25_cpx', 0x79, 'CRF25_cpx was identified in Cameroon and Saudi Arabia.', 'CRF25_cpx was first described in unpublished data by J. Carr: 01CM.101BA (DQ826726). A second complete genome of CRF25 was identified by Kijak et al. 2004: 02CM_1918LE (AY371169). A third genome from Cameroon was identified by Luk et al. 2008: BA040 (EU693240). Two complete genomes from Saudi Arabia were described by Yamaguchi et al. 2008: J11233 (EU697906) and J11451 (EU697908).', NULL, 'CM(3),SA(2)', NULL, 'low', 5, NULL, 2001, 2006, NULL, NULL, 'CRF25', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/24', NULL, NULL, 5, 2001, 2006, 'CM(3),SA(2)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 25_cpx', 'HIV-1 Subtype G (25_cpx)', NULL),
(26, '26_AU', 0x6e, 'CRF26_AU was described in the Democratic Republic of COngo.', 'CRF26_AU was described by Vidal et al. 2009 with 4 complete genomes: 02CD_KS069 (FM877780), 97CD_KTB119 (FM877777), 02CD_LBTB084 (FM877781), and 02CD_MBTB047 (FM877782). The authors showed that the A regions of these genomes cluster separately from other A sub-subtypes, and so defined this novel cluster as A5. Thus the authors refer to the CRF as CRF26_A5U.', NULL, 'CD(4)', NULL, 'low', 4, NULL, 1997, 2002, NULL, NULL, 'CRF26', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/25', 'Sequence recently available, need to be tested.', NULL, 4, 1997, 2002, 'CD(4)', NULL, NULL, NULL, NULL, 'Recombinant of A1, A2', 'HIV-1 Subtype A (A1), potential recombinant', NULL),
(27, '27_cpx', 0x79, 'CRF27_cpx was identified in the Democratic republic of Congo and France.', 'Vidal et al. 2008 defined CRF27 based on 3 epidemiologically unlinked genome sequences, 2 from the Democratic Republic of Congo and 1 from a Congolese patient sampled in France: 97CD-KTB49 (AJ404325), 02CD-LBR024 (AM851090), and 04FR-KZS (AM851091).', NULL, 'CD(2),FR(1)', NULL, 'low', 3, NULL, 1997, 2004, NULL, NULL, 'CRF27', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/26', NULL, NULL, 3, 1997, 2004, 'CD(2),FR(1)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 27_cpx', 'HIV-1 CRF 27_cpx', NULL),
(28, '28_BF', 0x6e, 'CRF28_BF was described in Brazil and Venezuela.', 'CRF28 and CRF29 were described by De Sa Filho et al. 2006 and Sanabani et al. 2006. CRF28 genome sequences include: DQ085873, DQ085874, and DQ085872.\n\n', NULL, 'BR(3),VE(1)', NULL, 'low', 4, NULL, 1999, 1999, NULL, NULL, 'CRF28', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/27', 'CRF28_BF reference sequences are quite diverse and the recombination break points are not exactly the same. It cluster together with CRF29_BF in many regions of the genome. It is possible to use either CRF28 or CRF29, I used CRF29_BF. However, both of CRFs (28 and 29) does not seen to be epidemiologically important and could be excluded.', NULL, 4, 1999, 1999, 'BR(3),VE(1)', NULL, NULL, NULL, NULL, 'Recombinant of 29_BF, B, F1', 'HIV-1 CRF 29_BF', NULL),
(29, '29_BF', 0x79, 'CRF29_BF was described in Brazil.', 'CRF28 and CRF29 were described by De Sa Filho et al. 2006 and Sanabani et al. 2006. CRF29 genome sequences include: DQ085876, AY455778, and DQ085871.', NULL, 'BR(4)', NULL, 'low', 4, NULL, 1999, 2002, NULL, NULL, 'CRF29', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/28', NULL, NULL, 3, 1999, 2001, 'BR(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 29_BF', 'HIV-1 CRF 29_BF', NULL),
(30, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(31, '31_BC', 0x79, 'CRF31_BC was described in Brazil.', 'CRF31 was described by Santos et al. 2006. Complete genomes include 04BR137 (AY727526), 04BR142 (AY727527), and 110PA (EF091932), all from Brazil.', NULL, 'BR(14),ES(1)', NULL, 'medium', 15, NULL, 1998, 2007, NULL, NULL, 'CRF31', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/29', NULL, NULL, 3, 2002, 2004, 'BR(3)', NULL, NULL, NULL, NULL, 'HIV-1 Subtype C (31_BC)', 'HIV-1 Subtype C (31_BC)', NULL),
(32, '32_06A1', 0x6e, 'CRF32_06A1 was described in Estonia.', 'CRF32 was described by Adojaan et al. 2005, who provided reference sequence EE0369 (AY535660) and another CRF06/A1 recombinant EST2002_1169 (DQ167215).', NULL, 'EE(2)', NULL, 'low', 2, NULL, 2001, 2002, NULL, NULL, 'CRF32', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/30', 'CRF32_06A1 cluster with CRF06_cpx. It needs tree to be displayed and reference reviewed.', NULL, 2, 2001, 2002, 'EE(2)', NULL, NULL, NULL, NULL, 'Recombinant of 06_CPX, A1, G', 'HIV-1 CRF 06_CPX', NULL),
(33, '33_01B', 0x6e, 'CRF33_01B was described in Malaysia.', 'CRF33 was described by Tee et al. 2006, who provided 4 genome sequences from Malaysia: 05MYKL007_1 (DQ366659), 05MYKL015_2 (DQ366660), 05MYKL031_1 (DQ366661), and 05MYKL045_1 (DQ366662).', NULL, 'ID(2),MY(13),SG(1)', NULL, 'medium', 16, NULL, 2003, 2007, NULL, NULL, 'CRF33', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/31', 'CRF33_01B is most similar to CRF34_01B, they cluster together in many regions of the genome with CRF01_AE. This do not allow the classification of CRF01_AE complete genomes if CRF34_01B or CRF33_01B are in the reference dataset.', NULL, 6, 2005, 2007, 'ID(2),MY(4)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 33_01A1', 'HIV-1 CRF 33_01A1', NULL),
(34, '34_01B', 0x6e, 'CRF34_01B was described in Thailand and Singapore.', 'CRF34 was described by Tovanabutra et al. 2007 based on 3 genome sequences from Thailand: OUR1969P (EF165539), OUR2275P (EF165540), and OUR2478P (EF165541).\n\n', NULL, 'SG(2),TH(3)', NULL, 'medium', 5, NULL, 1999, 2007, NULL, NULL, 'CRF34', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/32', 'CRF34_01B is most similar to CRF33_01B, they cluster together in many regions of the genome. However if CRF33_01B is excluded, CRF34_01B can be used as a CRF in Rega V3. ', NULL, 3, 1999, 1999, 'TH(3)', NULL, NULL, NULL, NULL, 'Recombinant of A1, G, B, F1', 'HIV-1 Subtype A (A1), potential recombinant', NULL),
(35, '35_AD', 0x79, 'CRF25_AD was described in Afghanistan.', 'CRF35 was described by Sanders-Buell et al. 2007 based on 4 genome sequences from Afghanistan: AF094 (EF158040), AF095 (EF158041), AF104 (EF158042) and AF026 (EF158043).', NULL, 'AF(11)', NULL, 'medium', 11, NULL, 2005, 2007, NULL, NULL, 'CRF35', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/33', NULL, NULL, 11, 2005, 2007, 'AF(11)', NULL, NULL, NULL, NULL, 'HIV-1 Subtype A (35_AD)', 'HIV-1 Subtype A (35_AD)', NULL),
(36, '36_cpx', 0x6e, 'CRF26_cpx was described in Cameroon.', 'CRF36 was described by Powell et al. 2007b based on 2 genome sequences from Cameroon: NYU830 (EF087994) and NYU1162 (EF087995). Two regions of CRF36 were found to cluster significantly with CRF22.', NULL, 'CM(2)', NULL, 'low', 2, NULL, 2000, 2000, NULL, NULL, 'CRF36', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/34', 'CRF36_cpx is to similar to CRF02_AG, they cluster together in many regions of the genome and break the CRF01_AG cluster, which if kept as a reference strain do not allow CRF02_AG sequences to be classified correctly. This CRF was also  identified in Cameroon, according to the authors of the paper yhe ancestral sequences present in CRF36_cpx represent a link to extinct strains, and, potentially, insight into the evolution of HIV-1.', NULL, 2, 2000, 2000, 'CM(2)', NULL, NULL, NULL, NULL, 'Recombinant of 02_AG, A1, G', 'HIV-1 CRF 02_AG', NULL),
(37, '37_cpx', 0x79, 'CRF37_cpx was described in Cameroon.', 'CRF37 was described by Powell et al. 2007a based on 2 genome sequences from Cameroon: NYU926 (EF116594) and CM53392 (AF377957). Parts of CRF37 cluster very closely with CRF19.', NULL, 'CG(1),CM(3)', NULL, 'low', 4, NULL, 1997, 2000, NULL, NULL, 'CRF37', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/35', NULL, NULL, 2, 1997, 2000, 'CM(2)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 37_cpx', 'HIV-1 CRF 37_cpx', NULL),
(38, '38_BF', NULL, NULL, NULL, NULL, NULL, NULL, 'low', 0, NULL, NULL, NULL, NULL, NULL, 'CRF38', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/36', 'There is no sequences in Los Alamos Search Engine for this CRF (August 2010). However, one complete genome can be downloaded from the curated alignments. As more complete genome becomes available, this CRF should be tested using phylotyping analysis.', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'Recombinant of 12_BF, F1, B', 'Recombinant of B, F1', NULL),
(39, '39_BF', 0x79, 'CRF39_BF was described in Brazil.', 'Guimaraes et al. 2008 described two BF1 recombinants in Brazil, CRF39 and CRF40. CRF39 was defined based on 3 genome sequences: 03BRRJ103 (EU735534), 04BRRJ179 (EU735535) and 03BRRJ327 (EU735536).', NULL, 'BR(3)', NULL, 'low', 3, NULL, 2003, 2004, NULL, NULL, 'CRF39', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/37', NULL, NULL, 3, 2003, 2004, 'BR(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 39_BF', 'HIV-1 CRF 39_BF', NULL),
(40, '40_BF', 0x79, 'CRF40_BF was described in Brazil.', 'Guimaraes et al. 2008 described two BF1 recombinants in Brazil, CRF39 and CRF40. CRF40 was defined based on 4 genome sequences: 05BRRJ055 (EU735537), 04BRRJ115 (EU735538), 05BRRJ200 (EU735539) and 04BRSQ46 (EU735540).\n\n', NULL, 'BR(4)', NULL, 'low', 4, NULL, 2004, 2005, NULL, NULL, 'CRF40', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/38', NULL, NULL, 4, 2004, 2005, 'BR(4)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 40_BF', 'HIV-1 CRF 40_BF', NULL),
(41, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(42, '42_BF', 0x79, 'CRF42_BF was described in Luxemburg.', 'CRF42_BF is described by D. Struck et al. in press (August 2008). There were 21 complete genomes sequenced, with accession numbers EU170135-EU170155.', NULL, 'LU(17)', NULL, 'medium', 17, NULL, 2003, 2006, NULL, NULL, 'CRF42', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/39', NULL, NULL, 17, 2003, 2006, 'LU(17)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 42_BF', 'HIV-1 CRF 42_BF', NULL),
(43, '43_02G', 0x79, 'CRF42_02G was described in Saudi Arabia.', 'Yamaguchi et al. 2008 described 4 complete genomes from Saudi Arabia: J11223 (EU697904), J11232 (EU697905), J11243 (EU697907), and J11456 (EU697909).', NULL, 'SA(4)', NULL, 'low', 4, NULL, 2003, 2003, NULL, NULL, 'CRF43', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/40', NULL, NULL, 4, 2003, 2003, 'SA(4)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 43_02G', 'HIV-1 Subtype G (43_02G)', NULL),
(44, '44_BF', 0x6e, 'CRF44_BF is unpublished.', 'CRF44_BF is unpublished.', NULL, 'CL(1)', NULL, 'low', 1, NULL, 2000, 2000, NULL, NULL, 'CRF44', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/41', 'Only one complete genome available. Unpublished manuscript.', NULL, 1, 2000, 2000, 'CL(1)', NULL, NULL, NULL, NULL, 'Recombinant of F1, B', 'Recombinant of F1, B', NULL),
(45, '45_cpx', 0x6e, 'CRF45_cpx was described in the Democratic Republic of Congo.', 'CRF45 was described by Niama et al. 2009. Genome sequences were identified as 04FR.AKU (EU448295) and 4 additional genomes with accession numbers FN392874-FN392877. Some fragments of CRF45 resemble regions of CRF04_cpx or CRF09_cpx. CRF45 may be the ancestral lineage of complex recombinants HIV-MAL and HIV-NOGIL.', NULL, 'CD(2),CM(1),FR(1),GA(1)', NULL, 'medium', 5, NULL, 1997, 2004, NULL, NULL, 'CRF45', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/42', 'This CRF (CRF45_cpx) is supported by clustering using phylotype analysis. However the bootstrap support on the Pol gene is relatively low (83%). In addition, this CRF is found in West-Central Africa and probably part of the early diversity of HIV-1.', NULL, 5, 1997, 2004, 'CD(2),CM(1),FR(1),GA(1)', NULL, NULL, NULL, NULL, 'Recombinant of A1, 09_cpx, K', 'Recombinant of K, F1', NULL),
(46, '46_BF', 0x6e, 'CRF46_BF was described in Brazil.', 'CRF46_BF is list as unpublished in Los Alamos CRF page, however CG sequences can be downloaded from the Los Alamos Search interface.', NULL, 'BR(8),JP(2)', NULL, NULL, 10, NULL, 1999, 2007, NULL, NULL, 'CRF46', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/43', 'CRF46_BF is classified as F1 (no B recombination detected in Rega V3). This CRF is also too diverse and do not cluster together with high bootstrap values on the complete genome and Pol genes. This CRF cluster withing subtype F1 in CG and POL trees.', NULL, 10, 1999, 2007, 'BR(8),JP(2)', NULL, NULL, NULL, NULL, 'HIV-1 Subtype F (F1)', 'HIV-1 Subtype F (F1)', NULL),
(47, '47_BF', 0x79, 'CRF47_BF was described in Spain.', 'CRF47_BF is list as unpublished in Los Alamos CRF page, however CG sequences can be downloaded from the Los Alamos Search interface.', NULL, 'ES(2)', NULL, 'low', 2, NULL, 2008, 2008, NULL, NULL, 'CRF47', 'http://bioafrica.mrc.ac.za:8080/rega-genotype-3.0/hiv/typingtool#/job/CRFs/44', 'This CRF (CRF47_BF) is supported by bootstrap in the complete genome and Pol. It can be used as a reference dataset in Rega V3.', NULL, 3, 2008, 2008, 'ES(3)', NULL, NULL, NULL, NULL, 'HIV-1 CRF 47_BF', 'HIV-1 CRF 47_BF', NULL),
(48, '48_01B', 0x6e, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, 'CRF48', NULL, 'Only one complete genome available. Unpublished manuscript.', NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `manuscripts`
--

CREATE TABLE `manuscripts` (
  `id` int(11) NOT NULL,
  `PMID` int(20) DEFAULT NULL,
  `authors` longtext,
  `journal` longtext,
  `Title` longtext,
  `CRF` int(4) DEFAULT NULL,
  `abstract` longtext
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `manuscripts`
--

INSERT INTO `manuscripts` (`id`, `PMID`, `authors`, `journal`, `Title`, `CRF`, `abstract`) VALUES
(1, NULL, 'Visawapoka U, Tovanabutra S, Currier JR, Cox JH, Mason CJ, Wasunna M, Ponglikitmongkol M, Dowling WE, Robb ML, Birx DL, McCutchan FE.', 'AIDS Res Hum Retroviru	ses. 2006 Jul;22(7):695-702.', 'Circulating and unique recombinant forms of HIV type 1 containing subsubtype A2.', 16, 'HIV-1 strains containing subsubtype A2 are relatively rare in the pandemic but have been repeatedly identified in Kenya, where candidate vaccines based in part on subtype A, but not A2 strains, may be evaluated. Among the most recent is CRF16_A2D, a circulating recombinant form (CRF) whose prototypes are complete or partial HIV-1 sequences from Kenya, Korea, and Argentina. Using samples from blood bank discards in Kenya and complete genome sequencing, this report further documents CRF16_A2D and related recombinants and identifies a second CRF, CRF21_A2D. The two A2-containing CRFs, and two recombinants related to CRF16_A2D, share common structural elements but appear to have been independently derived. Concerted selection may have influenced the emergence and spread of certain A2-containing strains in Kenya. The second complete subtype C sequence from Kenya is also reported here. Monitoring of A2-containing recombinants and subtype C strains, both relatively rare in Kenya, may be informative in the course of cohort development and evaluation of candidate vaccines.'),
(2, NULL, 'Powell RL, Zhao J, Konings FA, Tang S, Nanfack A, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN.', 'AIDS Res Hum Retroviruses. 2007 Aug;23(8):1008-19.', 'Identification of a novel circulating recombinant form (CRF) 36_cpx in Cameroon that combines two CRFs (01_AE and 02_AG) with ancestral lineages of subtypes A and G', 36, 'An array of CRFs have been identified in Cameroon, the most notable being CRF02_AG. HIV-1 in the East Province of Cameroon is particularly diverse: in a recent study, we found a high proportion of unique recombinant forms (URFs). Herein we describe the analysis of the full-length sequences of two of these URFs, which, after preliminary analysis of gag, pol, and env fragments, appeared to be a novel CRF. This novel strain, CRF36_cpx, contains fragments that can be assigned to the CRF01_AE, CRF02_AG, and subtype A and G radiations. Forty percent of the genome can be classified as CRF02_AG, including regions in gag, pol, env, and the accessory genes. Twenty-seven percent is CRF01_AE, comprising the majority of gag, the beginning of env, and the end of env into the 3\' LTR. Twenty percent of the genome can be assigned to subtype A, with segments in pol and env. The remaining 13% of the sequence is classifiable as subtype G, in pol and vpu. The subtype A and G lineages formed by the CRF36_cpx sequences are unique and appear ancestral in nature. CRF36_cpx is both the first to combine more than one CRF and the first to include fragments of CRF02_AG. The ancestral sequences present in CRF36_cpx represent a link to extinct strains, and, potentially, insight into the evolution of HIV-1.'),
(3, NULL, NULL, NULL, NULL, NULL, NULL);

-- --------------------------------------------------------

--
-- Table structure for table `rega`
--

CREATE TABLE `rega` (
  `id` int(11) DEFAULT NULL,
  `Regav3resultCG` tinytext,
  `Regav3resultPOL` tinytext,
  `exclusion reason` longtext
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Table structure for table `strains`
--

CREATE TABLE `strains` (
  `id` int(11) NOT NULL,
  `sequence` longtext,
  `accession` varchar(32) DEFAULT NULL,
  `CRF` int(11) DEFAULT NULL,
  `image` int(20) DEFAULT NULL,
  `seqnames` varchar(32) DEFAULT NULL,
  `regaref` int(11) DEFAULT NULL,
  `treeCG` tinytext,
  `diversityCG` decimal(10,4) DEFAULT NULL,
  `supportCG` decimal(10,4) DEFAULT NULL,
  `SlDvCG` decimal(10,4) DEFAULT NULL,
  `dfCG` decimal(10,4) DEFAULT NULL,
  `sgCG` decimal(10,4) DEFAULT NULL,
  `slCG` decimal(10,4) DEFAULT NULL,
  `tree` decimal(10,4) DEFAULT NULL,
  `diversity` decimal(10,4) DEFAULT NULL,
  `support` decimal(10,4) DEFAULT NULL,
  `SlDv` decimal(10,4) DEFAULT NULL,
  `df` decimal(10,4) DEFAULT NULL,
  `sg` decimal(10,4) DEFAULT NULL,
  `sl` decimal(10,4) DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=latin1;

--
-- Dumping data for table `strains`
--

INSERT INTO `strains` (`id`, `sequence`, `accession`, `CRF`, `image`, `seqnames`, `regaref`, `treeCG`, `diversityCG`, `supportCG`, `SlDvCG`, `dfCG`, `sgCG`, `slCG`, `tree`, `diversity`, `support`, `SlDv`, `df`, `sg`, `sl`) VALUES
(1, NULL, NULL, 1, NULL, '01_AECF19090CF11697', NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(2, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0310', '100.0000', '0.4970', '0.0000', '0.0200', '0.0150', NULL, '0.0200', '99.0000', '0.6370', '1.0000', '0.0140', '0.0130'),
(3, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0070', '100.0000', '6.6540', '0.0000', '0.0520', '0.0490', NULL, '0.0070', '100.0000', '4.5110', '0.0000', '0.0330', '0.0330'),
(4, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0410', '100.0000', '1.0690', '0.0000', '0.0440', '0.0440', NULL, '0.0240', '100.0000', '1.2040', '0.0000', '0.0330', '0.0290'),
(5, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0330', '100.0000', '0.6470', '0.0000', '0.0210', '0.0210', NULL, '0.0280', '97.0000', '0.8530', '0.0000', '0.0250', '0.0240'),
(6, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0260', '96.0000', '0.0810', '0.0000', '0.0180', '0.0020', NULL, '0.0240', '99.0000', '0.8120', '1.0000', '0.0190', '0.0190'),
(7, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0060', '100.0000', '4.3730', '0.0000', '0.0470', '0.0270', NULL, '0.0070', '100.0000', '3.7730', '0.0000', '0.0280', '0.0250'),
(8, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0090', '100.0000', '1.1630', '0.0000', '0.0300', '0.0110', NULL, '0.0100', '100.0000', '2.0780', '0.0000', '0.0250', '0.0220'),
(9, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0340', '100.0000', '0.9420', '0.0000', '0.0330', '0.0320', NULL, '0.0260', '99.0000', '0.4870', '0.0000', '0.0170', '0.0130'),
(10, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0300', '100.0000', '0.8410', '0.0000', '0.0510', '0.0250', NULL, '0.0240', '93.0000', '0.6380', '0.0000', '0.0260', '0.0150'),
(11, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0440', '100.0000', '0.5850', '0.0000', '0.0270', '0.0260', NULL, '0.0390', '78.0000', '0.2240', '0.0000', '0.0140', '0.0090'),
(12, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0240', '100.0000', '0.0770', '0.0000', '0.0080', '0.0020', NULL, '0.0160', '91.0000', '0.4570', '0.0000', '0.0080', '0.0070'),
(13, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0230', '100.0000', '1.7500', '0.0000', '0.0430', '0.0400', NULL, '0.0110', '100.0000', '1.6620', '0.0000', '0.0240', '0.0180'),
(14, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0090', '100.0000', '6.5620', '0.0000', '0.0620', '0.0610', NULL, '0.0050', '100.0000', '6.4270', '0.0000', '0.0340', '0.0330'),
(15, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0260', '100.0000', '0.7040', '0.0000', '0.0240', '0.0180', NULL, '0.0090', '82.0000', '0.4190', '1.0000', '0.0140', '0.0040'),
(16, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(17, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0300', '100.0000', '0.2890', '0.0000', '0.0150', '0.0090', NULL, '0.0190', '70.0000', '0.1280', '0.0000', '0.0030', '0.0020'),
(18, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0350', '100.0000', '0.8670', '0.0000', '0.0310', '0.0300', NULL, '0.0160', '100.0000', '0.8810', '0.0000', '0.0180', '0.0140'),
(19, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0270', '100.0000', '1.4070', '0.0000', '0.0390', '0.0390', NULL, '0.0180', '100.0000', '1.2600', '0.0000', '0.0250', '0.0230'),
(20, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0100', '100.0000', '0.9250', '0.0000', '0.0180', '0.0090', NULL, '0.0120', '96.0000', '0.4220', '0.0000', '0.0110', '0.0050'),
(21, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0300', '100.0000', '0.8360', '0.0000', '0.0280', '0.0250', NULL, '0.0320', '75.0000', '0.1350', '0.0000', '0.0130', '0.0040'),
(22, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0280', '100.0000', '0.7480', '0.0000', '0.0220', '0.0210', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(23, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0200', '100.0000', '0.5800', '0.0000', '0.0190', '0.0110', NULL, '0.0100', '100.0000', '0.5040', '0.0000', '0.0140', '0.0050'),
(24, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0170', '100.0000', '0.4020', '0.0000', '0.0160', '0.0070', NULL, '0.0080', '94.0000', '1.2340', '0.0000', '0.0190', '0.0100'),
(25, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0370', '100.0000', '0.5620', '0.0000', '0.0210', '0.0210', NULL, '0.0230', '100.0000', '0.8240', '0.0000', '0.0210', '0.0190'),
(26, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0390', '100.0000', '0.8510', '0.0000', '0.0330', '0.0330', NULL, '0.0290', '100.0000', '0.9760', '0.0000', '0.0280', '0.0280'),
(27, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0400', '100.0000', '0.5010', '0.0000', '0.0230', '0.0200', NULL, '0.0290', '100.0000', '0.2540', '0.0000', '0.0110', '0.0070'),
(28, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0320', '100.0000', '0.2530', '0.0000', '0.0120', '0.0080', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(29, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0380', '100.0000', '0.2960', '0.0000', '0.0150', '0.0110', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(30, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(31, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0220', '100.0000', '1.0650', '0.0000', '0.0300', '0.0230', NULL, '0.0240', '100.0000', '0.6500', '0.0000', '0.0200', '0.0160'),
(32, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0100', '100.0000', '3.7000', '0.0000', '0.0540', '0.0380', NULL, '0.0220', '100.0000', '0.7540', '0.0000', '0.0390', '0.0160'),
(33, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0260', '100.0000', '0.3410', '0.0000', '0.0180', '0.0090', NULL, '0.0200', '100.0000', '1.1900', '0.0000', '0.0250', '0.0240'),
(34, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0020', '100.0000', '15.2780', '0.0000', '0.0390', '0.0340', NULL, '0.0010', '100.0000', '53.0800', '0.0000', '0.0380', '0.0370'),
(35, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0200', '100.0000', '1.4780', '0.0000', '0.0420', '0.0300', NULL, '0.0100', '100.0000', '2.0950', '0.0000', '0.0410', '0.0210'),
(36, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0240', '100.0000', '1.3770', '0.0000', '0.0380', '0.0330', NULL, '0.0090', '100.0000', '1.0340', '0.0000', '0.0270', '0.0090'),
(37, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0400', '100.0000', '0.5430', '0.0000', '0.0230', '0.0220', NULL, '0.0340', '100.0000', '0.7720', '0.0000', '0.0270', '0.0260'),
(38, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(39, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0310', '100.0000', '1.0280', '0.0000', '0.0320', '0.0320', NULL, '0.0340', '100.0000', '0.9680', '0.0000', '0.0380', '0.0330'),
(40, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0280', '100.0000', '1.0020', '0.0000', '0.0280', '0.0280', NULL, '0.0450', '91.0000', '0.4680', '0.0000', '0.0260', '0.0210'),
(41, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(42, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0040', '100.0000', '9.3310', '0.0000', '0.0430', '0.0420', NULL, '0.0040', '100.0000', '9.8730', '0.0000', '0.0380', '0.0350'),
(43, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0190', '100.0000', '1.7200', '0.0000', '0.0380', '0.0320', NULL, '0.0090', '100.0000', '1.4950', '0.0000', '0.0300', '0.0130'),
(44, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(45, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0390', '100.0000', '0.6610', '0.0000', '0.0270', '0.0260', NULL, '0.0240', '83.0000', '0.2770', '0.0000', '0.0120', '0.0070'),
(46, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0360', '62.0000', '0.0090', '0.0000', '0.0170', '0.0000', NULL, '0.0430', '34.0000', '0.1390', '1.0000', '0.0120', '0.0060'),
(47, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0150', '100.0000', '3.1110', '0.0000', '0.0480', '0.0470', NULL, '0.0090', '100.0000', '3.0560', '0.0000', '0.0310', '0.0290'),
(48, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
(49, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, '0.0200', '92.0000', '0.3440', '0.0000', '0.0070', '0.0070');

--
-- Indexes for dumped tables
--

--
-- Indexes for table `b_blogs`
--
ALTER TABLE `b_blogs`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_casebook`
--
ALTER TABLE `b_casebook`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_cases`
--
ALTER TABLE `b_cases`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_cmds`
--
ALTER TABLE `b_cmds`
  ADD PRIMARY KEY (`cmd_id`);

--
-- Indexes for table `b_expertises`
--
ALTER TABLE `b_expertises`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_grants`
--
ALTER TABLE `b_grants`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_grants_results`
--
ALTER TABLE `b_grants_results`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_installed_sw`
--
ALTER TABLE `b_installed_sw`
  ADD PRIMARY KEY (`sw_id`);

--
-- Indexes for table `b_links`
--
ALTER TABLE `b_links`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_main_orgn_info`
--
ALTER TABLE `b_main_orgn_info`
  ADD PRIMARY KEY (`org_no`);

--
-- Indexes for table `b_news`
--
ALTER TABLE `b_news`
  ADD PRIMARY KEY (`id`),
  ADD KEY `id` (`id`),
  ADD KEY `id_2` (`id`);

--
-- Indexes for table `b_people`
--
ALTER TABLE `b_people`
  ADD PRIMARY KEY (`id`),
  ADD KEY `researcher` (`name`);

--
-- Indexes for table `b_projects`
--
ALTER TABLE `b_projects`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_publications`
--
ALTER TABLE `b_publications`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_reports`
--
ALTER TABLE `b_reports`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_resources_ppt`
--
ALTER TABLE `b_resources_ppt`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_resources_video`
--
ALTER TABLE `b_resources_video`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_server`
--
ALTER TABLE `b_server`
  ADD PRIMARY KEY (`svr_id`);

--
-- Indexes for table `b_software`
--
ALTER TABLE `b_software`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `b_sw`
--
ALTER TABLE `b_sw`
  ADD PRIMARY KEY (`sw_id`);

--
-- Indexes for table `b_sw_cat`
--
ALTER TABLE `b_sw_cat`
  ADD PRIMARY KEY (`cat_id`);

--
-- Indexes for table `b_sw_cat_subcat`
--
ALTER TABLE `b_sw_cat_subcat`
  ADD PRIMARY KEY (`cat_id`,`subcat_id`),
  ADD UNIQUE KEY `ix_ReversePK` (`subcat_id`,`cat_id`);

--
-- Indexes for table `b_sw_cmds`
--
ALTER TABLE `b_sw_cmds`
  ADD PRIMARY KEY (`sw_id`,`cmd_id`),
  ADD UNIQUE KEY `ix_ReversePK` (`cmd_id`,`sw_id`);

--
-- Indexes for table `b_sw_expert`
--
ALTER TABLE `b_sw_expert`
  ADD PRIMARY KEY (`sw_id`,`id`),
  ADD UNIQUE KEY `ix_ReversePK` (`id`,`sw_id`);

--
-- Indexes for table `b_sw_inst_locn`
--
ALTER TABLE `b_sw_inst_locn`
  ADD PRIMARY KEY (`sw_id`,`svr_id`),
  ADD UNIQUE KEY `ix_ReversePK` (`svr_id`,`sw_id`);

--
-- Indexes for table `b_sw_subcat`
--
ALTER TABLE `b_sw_subcat`
  ADD PRIMARY KEY (`subcat_id`);

--
-- Indexes for table `crflist`
--
ALTER TABLE `crflist`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `manuscripts`
--
ALTER TABLE `manuscripts`
  ADD PRIMARY KEY (`id`);

--
-- Indexes for table `strains`
--
ALTER TABLE `strains`
  ADD PRIMARY KEY (`id`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `b_blogs`
--
ALTER TABLE `b_blogs`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=46;

--
-- AUTO_INCREMENT for table `b_casebook`
--
ALTER TABLE `b_casebook`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=14;

--
-- AUTO_INCREMENT for table `b_cases`
--
ALTER TABLE `b_cases`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=106;

--
-- AUTO_INCREMENT for table `b_cmds`
--
ALTER TABLE `b_cmds`
  MODIFY `cmd_id` int(4) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=13;

--
-- AUTO_INCREMENT for table `b_expertises`
--
ALTER TABLE `b_expertises`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT;

--
-- AUTO_INCREMENT for table `b_grants`
--
ALTER TABLE `b_grants`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `b_grants_results`
--
ALTER TABLE `b_grants_results`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=8;

--
-- AUTO_INCREMENT for table `b_installed_sw`
--
ALTER TABLE `b_installed_sw`
  MODIFY `sw_id` int(3) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=73;

--
-- AUTO_INCREMENT for table `b_links`
--
ALTER TABLE `b_links`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=3;

--
-- AUTO_INCREMENT for table `b_news`
--
ALTER TABLE `b_news`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=192;

--
-- AUTO_INCREMENT for table `b_people`
--
ALTER TABLE `b_people`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=30;

--
-- AUTO_INCREMENT for table `b_projects`
--
ALTER TABLE `b_projects`
  MODIFY `id` int(11) UNSIGNED NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=7;

--
-- AUTO_INCREMENT for table `b_publications`
--
ALTER TABLE `b_publications`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=171;

--
-- AUTO_INCREMENT for table `b_reports`
--
ALTER TABLE `b_reports`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=23;

--
-- AUTO_INCREMENT for table `b_resources_ppt`
--
ALTER TABLE `b_resources_ppt`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=11;

--
-- AUTO_INCREMENT for table `b_resources_video`
--
ALTER TABLE `b_resources_video`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=26;

--
-- AUTO_INCREMENT for table `b_server`
--
ALTER TABLE `b_server`
  MODIFY `svr_id` int(2) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `b_software`
--
ALTER TABLE `b_software`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=34;

--
-- AUTO_INCREMENT for table `b_sw`
--
ALTER TABLE `b_sw`
  MODIFY `sw_id` int(4) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=11;

--
-- AUTO_INCREMENT for table `b_sw_cat`
--
ALTER TABLE `b_sw_cat`
  MODIFY `cat_id` int(2) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=9;

--
-- AUTO_INCREMENT for table `b_sw_subcat`
--
ALTER TABLE `b_sw_subcat`
  MODIFY `subcat_id` int(3) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=9;

--
-- AUTO_INCREMENT for table `crflist`
--
ALTER TABLE `crflist`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=49;

--
-- AUTO_INCREMENT for table `manuscripts`
--
ALTER TABLE `manuscripts`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=4;

--
-- AUTO_INCREMENT for table `strains`
--
ALTER TABLE `strains`
  MODIFY `id` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=50;

--
-- Constraints for dumped tables
--

--
-- Constraints for table `b_sw_expert`
--
ALTER TABLE `b_sw_expert`
  ADD CONSTRAINT `b_sw_expert_ibfk_1` FOREIGN KEY (`sw_id`) REFERENCES `b_installed_sw` (`sw_id`) ON DELETE CASCADE ON UPDATE CASCADE;
COMMIT;

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
